<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V. and International Society of Chemotherapy.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32234468
      </article-id>
      <article-id pub-id-type="pmc">
       7138178
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(20)30105-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2020.105955
      </article-id>
      <article-id pub-id-type="publisher-id">
       105955
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The epidemiology, diagnosis and treatment of COVID-19
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Zhai
         </surname>
         <given-names>
          Pan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Ding
         </surname>
         <given-names>
          Yanbing
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Xia
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Long
         </surname>
         <given-names>
          Junke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Zhong
         </surname>
         <given-names>
          Yanjun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0004">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0006">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Yiming
         </given-names>
        </name>
        <email>
         lym-fly@whu.edu.cn
        </email>
        <xref ref-type="aff" rid="aff0005">
         e
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       Department of Neurology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430073, Hubei, China
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       Department of Respiratory Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430073, Hubei, China
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
      </aff>
      <aff id="aff0004">
       <label>
        d
       </label>
       ICU Center, The Second Xiangya Hospital, Central South University, Furong, Changsha, Hunan, 41001, China
      </aff>
      <aff id="aff0005">
       <label>
        e
       </label>
       Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        <bold>
         Corresponding author.
        </bold>
        Yiming Li, Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China.
        <email>
         lym-fly@whu.edu.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        28
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        28
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       105955
      </elocation-id>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0001">
       <title>
        Highlights
       </title>
       <p>
        <list id="celist0001" list-type="simple">
         <list-item id="celistitem0001">
          <label>
           •
          </label>
          <p id="para0001">
           The mean incubation period is 2-14 days, and the basic reproduction number is 2.24-3.58.
          </p>
         </list-item>
         <list-item id="celistitem0002">
          <label>
           •
          </label>
          <p id="para0002">
           COVID-19 infection should be diagnosed clinically with typical respiratory syndromes coupled with recent exposure.
          </p>
         </list-item>
         <list-item id="celistitem0003">
          <label>
           •
          </label>
          <p id="para0003">
           Chest computerized tomography (CT) could facilitate early diagnosis.
          </p>
         </list-item>
         <list-item id="celistitem0004">
          <label>
           •
          </label>
          <p id="para0004">
           Public health measures, such as isolation, quarantine, social distancing and community containment, can curb COVID-19.
          </p>
         </list-item>
         <list-item id="celistitem0005">
          <label>
           •
          </label>
          <p id="para0005">
           Clinical trials assessing antivirals, chloroquine, hydroxychloroquine, glucocorticoids, convalescent plasma transfusion against COVID-19.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0002">
       <p>
        In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. This paper reviews the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, are discussed in this article. In addition, registered trials investigating treatment options for COVID-19 infection are listed.
       </p>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        Diagnosis
       </kwd>
       <kwd>
        Isolation
       </kwd>
       <kwd>
        Remdesivir
       </kwd>
       <kwd>
        Clinical trials
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="misc0001">
       Editor: Jean-Marc Rolain
      </p>
     </notes>
    </front>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="para0006">
      There is a current worldwide outbreak of a new type of coronavirus (COVID-19), which originated from Wuhan, China and has now spread to 140 other countries, including Japan, Korea and Italy. The World Health Organization (WHO) declared that COVID-19 has become a global health concern, causing severe respiratory tract infections in humans. Current evidence indicates that SARS-CoV-2 spread to humans via transmission from wild animals illegally sold in the Huanan Seafood Wholesale Market. Phylogenetic analysis shows that SARS-CoV-2 is a new member of the Coronaviridae family but is distinct from SARS-CoV (identity of approximately 79%) and MERS-CoV (identity of approximately 50%)
      <xref ref-type="bibr" rid="bib0001">
       [1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0002">
       2]
      </xref>
      . Knowing the origin of such a pathogen is critical to developing the means to block further transmission and vaccines
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      . Notably, SARS-CoV-2 shares a high level of genetic similarity (96.3%) with the bat coronavirus RaTG13, which was obtained from bats in Yunnan in 2013; however, bats are not the immediate source of SARS-CoV-2
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      .
     </p>
     <p id="para0007">
      The typical symptoms of COVID-19 are fever, sore throat, fatigue, cough or dyspnea coupled with recent exposure. As of March 16, 2020, the outbreak of COVID-19 generated 168 826 confirmed cases, including 6503 deaths worldwide. In China during the outbreak of the pandemic, 42 000 doctors and nurses from all over the country supported Wuhan. Moreover, the government shared the updated genome sequence of COVID-19 to the public, and scientists from China and overseas are working closely and efficiently on this public health emergency
      <xref ref-type="bibr" rid="bib0005">
       [5
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0006">
       6]
      </xref>
      . Due to interventions and control measures from the government (shutting down public transportation and implementing a treatment strategy) and the change in personal behaviors (wearing masks and reducing contact with others), the number of confirmed and suspected cases in China has started to decrease.
     </p>
     <p id="para0008">
      However, the transmission of pneumonia associated with SARS-CoV-2 has not yet been eliminated. The COVID-19 outbreak is still a major challenge for clinicians. The aim of this article is to describe the epidemiology, diagnosis, isolation, and treatment of COVID-19.
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Epidemiology
     </title>
     <sec id="sec0003">
      <label>
       2.1
      </label>
      <title>
       Incubation period
      </title>
      <p id="para0009">
       A study of early transmission dynamics of COVID-19 revealed that the mean incubation period was 5.2 days (95% confidence interval [CI], 4.1-7.0), with the 95th percentile of the distribution at 12.5 days
       <xref ref-type="bibr" rid="bib0007">
        [7]
       </xref>
       . A later study using the travel history and symptom onset of 88 confirmed cases showed a similar mean incubation period of 6.4 days (95% CI, 5.6-7.7)
       <xref ref-type="bibr" rid="bib0008">
        [8]
       </xref>
       . An unusual case was also reported in which the incubation period was as long as 19 days
       <xref ref-type="bibr" rid="bib0009">
        [9]
       </xref>
       . Notably, a long incubation time means adjustments in screening and control policies
       <xref ref-type="bibr" rid="bib0010">
        [10]
       </xref>
       . The 19-day incubation period is a low probability event, and experts suggest 14 days for quarantine.
      </p>
     </sec>
     <sec id="sec0004">
      <label>
       2.2
      </label>
      <title>
       Basic reproduction number
      </title>
      <p id="para0010">
       The basic reproduction number is model-based, largely depends on the epidemiological setting, and is the most important parameter to determine intrinsic transmissibility. The early outbreak data largely follow exponential growth. Different models based on the clinical progression of the disease were devised to estimate the basic reproduction number. In the early stages of COVID-19, the pandemic doubled in size every 7.4 days, and the basic reproduction number was estimated to be 2.2
       <xref ref-type="bibr" rid="bib0007">
        [7]
       </xref>
       . Another study estimated the basic reproduction number as ranging from 2.24 to 3.58
       <xref ref-type="bibr" rid="bib0011">
        [11]
       </xref>
       . However, a deterministic compartmental model based on the likelihood and a model analysis showed that the control reproduction number may be as high as 6.47
       <xref ref-type="bibr" rid="bib0012">
        [12]
       </xref>
       . The authors noted that this basic reproduction number was higher because the estimate accounts for 3-4 generations of viral transmission and intensive social contacts. The basic reproduction number estimated by the majority of studies ranges from 2.24 to 3.58
       <xref ref-type="bibr" rid="bib0013">
        [13]
       </xref>
       , which is slightly higher than that of SARS.
      </p>
     </sec>
    </sec>
    <sec id="sec0005">
     <label>
      3
     </label>
     <title>
      Diagnosis
     </title>
     <p id="para0011">
      Rapid and accurate detection of COVID-19 is crucial to control outbreaks in the community and in hospitals
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      . Current diagnostic tests for coronavirus include reverse-transcription polymerase chain reaction (RT-PCR), real‐time RT-PCR (rRT‐PCR), and reverse transcription loop‐mediated isothermal amplification (RT‐LAMP)
      <xref ref-type="bibr" rid="bib0015">
       [15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0016">
       16]
      </xref>
      . RT-LAMP has similar sensitivity to rRT-PCR, is highly specific and is used to detect MERS-CoV
      <xref ref-type="bibr" rid="bib0017">
       [17
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0018">
       18]
      </xref>
      . According to current diagnostic criteria founded by the China National Health Commission, laboratory examinations, including nasopharyngeal and oropharyngeal swab tests, have become a standard assessment for diagnosis of COVID-19 infection. To identify patients earlier, two one-step quantitative RT-PCR (qRT-PCR) assays were developed to detect two different regions (ORF1b and N) of the SARS-CoV-2 genome
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
      . Three novel RT-PCR assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 were developed. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro; highly sensitive and specific assays may help to improve the laboratory diagnosis of COVID-19
      <xref ref-type="bibr" rid="bib0020">
       [20]
      </xref>
      . The SARS-CoV E gene assay was more sensitive than the RdRp gene assay combined with the one-step RT-PCR system
      <xref ref-type="bibr" rid="bib0021">
       [21]
      </xref>
      . The E gene PCR was sufficient to diagnose a SARS-CoV-2 infection but the RdRp protocol was recommended to confirm a positive result
      <xref ref-type="bibr" rid="bib0022">
       [22
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0023">
       23]
      </xref>
      . The overall positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan was 38%
      <xref ref-type="bibr" rid="bib0024">
       [24]
      </xref>
      . The positive rate of PCR for oropharyngeal swabs is not very high: only 53.3% of COVID-19-confirmed patients had positive oral swabs tests
      <xref ref-type="bibr" rid="bib0025">
       [25]
      </xref>
      . In a series of 51 patients with confirmed COVID-19 infection, 71% patients were RT-PCR positive at the first time of testing of throat swab or sputum samples
      <xref ref-type="bibr" rid="bib0026">
       [26]
      </xref>
      . The RT-PCR results usually become positive after several days (2-8 days)
      <xref ref-type="bibr" rid="bib0027">
       [27]
      </xref>
      . Automated solutions for molecular diagnostics can handle large numbers of samples and can be scaled to keep pace with fluctuating demand
      <xref ref-type="bibr" rid="bib0028">
       [28]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0029">
       [29]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . The good analytical performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, was observed with minimal hands-on time, while offering fast and reliable results
      <xref ref-type="bibr" rid="bib0031">
       [31
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0032">
       32]
      </xref>
      .
     </p>
     <p id="para0011s">
      The current laboratory test is time-consuming, and a shortage of commercial kits delays diagnosis. For patients suffering from fever, sore throat, fatigue, coughing or dyspnea that is coupled with recent exposure, COVID-19 infection should be diagnosed with typical chest computerized tomography (CT) characteristics despite negative RT-PCR results
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      . Of 1014 patients, 59% had positive RT-PCR results, and 88% had positive chest CT scans
      <xref ref-type="bibr" rid="bib0034">
       [34]
      </xref>
      . COVID-19 belongs to the Coronaviridae family; therefore, it is not surprising that COVID-19 has imaging findings that are similar to those for SARS-CoV and MERS-CoV
      <xref ref-type="bibr" rid="bib0035">
       [35]
      </xref>
      . Typical CT findings included bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, sometimes with a rounded morphology and peripheral lung distribution
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      . Eighty-six percent of patients showed ground-glass opacities or consolidation, and more than one lobe (71%) with bilateral involvement (76%) was affected in the 21 initial chest CT scans
      <xref ref-type="bibr" rid="bib0036">
       [36]
      </xref>
      . Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent
      <xref ref-type="bibr" rid="bib0036">
       [36]
      </xref>
      . Lung abnormalities on chest CT scan were most severe approximately 10 days after the initial onset of symptoms
      <xref ref-type="bibr" rid="bib0037">
       [37]
      </xref>
      . Chest CT scans can be used to assess the severity of COVID-19. COVID-19 also manifests with chest CT imaging abnormalities in asymptomatic patients, with rapid evolution from focal unilateral to diffuse bilateral ground-glass opacities that progressed to or co-existed with consolidations within 1-3 weeks. Combining assessment of imaging features with clinical and laboratory findings could facilitate early diagnosis of COVID-19 pneumonia
      <xref ref-type="bibr" rid="bib0038">
       [38]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0039">
       [39]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0040">
       [40]
      </xref>
      . As the diagnostic criteria expanded from laboratory examination to chest CT imaging, more than 14 000 patients were diagnosed on February 12, 2020.
     </p>
    </sec>
    <sec id="sec0006">
     <label>
      4
     </label>
     <title>
      Isolation
     </title>
     <p id="para0012">
      Classical public health measures, including isolation, quarantine, social distancing and community containment, can be used to curb the pandemic of this respiratory disease
      <xref ref-type="bibr" rid="bib0041">
       [41]
      </xref>
      . China has been preparing since 2003 to contain future pandemics by applying lessons learned from SARS
      <xref ref-type="bibr" rid="bib0042">
       [42]
      </xref>
      . In the COVID-19 pandemic, China issued the largest quarantine in history. All the residents living in mainland China were locked-in, and city public transportation, including buses, trains, ferries, and airports, were shutdown. Given the trajectory of this outbreak, the Chinese government scaled up such efforts to keep pace with the rapid increase in cases and geographical spread. The Wuhan government made full use of the gym and two convention centers and transformed them into makeshift hospitals with 3400 beds in only one night to isolate COVID-19 patients from healthy controls. More makeshift hospitals are under construction. Isolation beds were quickly expanded from only 137 at the beginning of the outbreak of COVID-19 to 56 000 to separate infected patients from non-infected individuals. The swift and decisive response of China contributed to reducing the control reproduction number and transmission risk. Due to the powerful and effective isolation measures taken by the Chinese government, the increase in COVID-19 began to slow down on February 14, 2020, according to the data released by the China National Health Commission.
     </p>
    </sec>
    <sec id="sec0007">
     <label>
      5
     </label>
     <title>
      Treatments
     </title>
     <sec id="sec0008">
      <label>
       5.1
      </label>
      <title>
       Antiviral agents
      </title>
      <p id="para0013">
       There is no current evidence from randomized controlled trials (RCTs) to recommend any specific anti-SARS-CoV-2 treatment for patients with a suspected or confirmed COVID-19 infection. Lopinavir (LPV) inhibits the protease activity of coronavirus in vitro and in animal studies. A retrospective, matched-cohort study including 1052 SARS patients showed that LPV/ritonavir as initial treatment was associated with a reduced death rate (2.3% vs. 11.0%)
       <xref ref-type="bibr" rid="bib0043">
        [43]
       </xref>
       . The protease inhibitor LPV is an effective treatment based on the experience accumulated from the SARS and MERS outbreaks, indicating it is a potential treatment option for COVID‐19
       <xref ref-type="bibr" rid="bib0044">
        [44]
       </xref>
       . Ribavirin, a guanosine analogue, is an antiviral compound used to treat several virus infections, including respiratory syncytial virus, hepatitis C virus, and some viral hemorrhagic fevers. Promising results were obtained with ribavirin in a MERS-CoV rhesus macaque model
       <xref ref-type="bibr" rid="bib0045">
        [45]
       </xref>
       . In addition, SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) model is targeted by ribavirin after sequence analysis, modeling, and docking to build the model. This feature increases its potential as an antiviral against SARS-CoV-2
       <xref ref-type="bibr" rid="bib0046">
        [46]
       </xref>
       .
      </p>
      <p id="para0014">
       The antiviral agent, remdesivir was designed for the Ebola virus disease
       <xref ref-type="bibr" rid="bib0047">
        [47]
       </xref>
       . Remdesivir shows broad-spectrum antiviral activity against several RNA viruses, and it may compete for RdRp
       <xref ref-type="bibr" rid="bib0048">
        [48]
       </xref>
       . Remdesivir and IFNb have superior antiviral activity to LPV and ritonavir in vitro
       <xref ref-type="bibr" rid="bib0049">
        [49]
       </xref>
       . In a mouse model of SARS-CoV pathogenesis, both prophylactic and therapeutic remdesivir improved pulmonary function and reduced lung viral loads and severe lung pathology
       <xref ref-type="bibr" rid="bib0050">
        [50]
       </xref>
       . In a rhesus macaque model of MERS-CoV infection, prophylactic remdesivir treatment was initiated 24 h prior to inoculation, and MERS-CoV did not induce clinical disease and did not replicate in respiratory tissues, thus preventing the formation of lung lesions
       <xref ref-type="bibr" rid="bib0051">
        [51]
       </xref>
       . In cell-based assays, the triphosphate form of remdesivir incorporated at position i, and RNA chain termination was delayed, which explained the high potency of remdesivir against RNA
       <xref ref-type="bibr" rid="bib0052">
        [52]
       </xref>
       . Remdesivir was used to treat the first case of COVID-19 infection in the United States: the patient's clinical condition improved after only one day of remdesivir treatment
       <xref ref-type="bibr" rid="bib0053">
        [53]
       </xref>
       . A phase II clinical trial of remdesivir was performed by the University of Nebraska Medical Center, and a phase III clinical trial was performed by the China-Japan Friendship Hospital. The results of these clinical trials will be revealed in April 2020. Remdesivir improved pulmonary function, reduced lung viral loads, and ameliorated severe lung pathology. In contrast, prophylactic LPV/RTV-IFNb only slightly reduced viral loads and did not impact other disease parameters, and therapeutic LPV/RTV-IFNb improved pulmonary function, but did not reduce virus replication or severe lung pathology [49]. Overall, these results indicated that remdesivir showed more potential than LPV/RTV-IFNb
       <xref ref-type="bibr" rid="bib0054">
        [54]
       </xref>
       . In a case report, lopinavir/ritonavir (Kaletra®) and arbidol were associated with significant improvements in COVID-19 patients
       <xref ref-type="bibr" rid="bib0055">
        [55]
       </xref>
       . The efficacy and safety of these antiviral agents for COVID-19 will be assessed in further clinical trials. Thirty-four trials of antiviral agents in patients with COVID‐19 have been registered up to March 15, 2020 (
       <xref ref-type="table" rid="tbl0001">
        Table 1
       </xref>
       ).
       <table-wrap id="tbl0001" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Clinical trials of antiviral agents in patients with COVID-19.
         </p>
        </caption>
        <alt-text id="alt0001">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Group 3 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000029621
           </td>
           <td valign="top">
            Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Arbidol tablets + basic treatment (190 patients)
           </td>
           <td align="left" valign="top">
            Basic treatment (190 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029308
           </td>
           <td valign="top">
            A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and 50 mg of ritonavir), twice a day, 2 tablets at a time (80 patients)
           </td>
           <td align="left" valign="top">
            Conventional standardized treatment (80 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Clinical improvement time of 28 days after randomization, 7-point scale
           </td>
           <td valign="top">
            Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029387
           </td>
           <td valign="top">
            Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia
           </td>
           <td valign="top">
            Ribavirin + Interferon alpha-1b (36 patients)
           </td>
           <td valign="top">
            Lopinavir / ritonavir + interferon alpha-1b (36 patients)
           </td>
           <td valign="top">
            Ribavirin + LPV/r+Interferon alpha-1b (36 patients)
           </td>
           <td valign="top">
            Time to 2019-nCoV RNA negativity in patients
           </td>
           <td valign="top">
            Chongqing Public Health Medical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029468
           </td>
           <td valign="top">
            A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Lopinavir/ritonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination (60 patients)
           </td>
           <td valign="top">
            LPV/r (60 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Survival rate
           </td>
           <td valign="top">
            Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029539
           </td>
           <td valign="top">
            A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Conventional standardized treatment and Lopinavir-Ritonavir (164 patients)
           </td>
           <td align="left" valign="top">
            Conventional standardized treatment (164 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 ≤94% or respiratory frequency ≥ 24 times/min in the state of resting without oxygen inhalation
           </td>
           <td valign="top">
            Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029541
           </td>
           <td valign="top">
            A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            DRV/c (800 mg/150 mg QD) + conventional treatment containing thymosin (40 patients)
           </td>
           <td align="left" valign="top">
            LPV/r (400 mg/100 mg bid) + conventional treatment containing thymosin (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to conversion of 2019-nCoV RNA result from RI sample
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029548
           </td>
           <td valign="top">
            Randomized, open-label, controlled trial for evaluating the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients
           </td>
           <td valign="top">
            BaloxavirMarboxil: 80 mg on day1, 80 mg on day 4; and 80 mg on day 7 as necessary (10 patients)
           </td>
           <td valign="top">
            Favipiravir: 600 mg tid with 160 0mg first loading dosage for no more than 14 days (10 patients)
           </td>
           <td valign="top">
            Lopinavir-Ritonavir: 2(200mg/50 mg), twice daily, for 14days (10 patients)
           </td>
           <td valign="top">
            Time to viral negativity by RT-PCR,Time to clinical improvement
           </td>
           <td valign="top">
            The First Affiliated Hospital, Zhejiang University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029600
           </td>
           <td valign="top">
            Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Alpha-Interferon atomization (30 patients)
           </td>
           <td valign="top">
            Lopinavir and Ritonavir + alpha-Interferon atomization (30 patients)
           </td>
           <td valign="top">
            Favipiravir + alpha-Interferon atomization(30 patients)
           </td>
           <td valign="top">
            Negative time of novel Coronavirus by PCR, chest imaging, incidence rate of kidney damage
           </td>
           <td valign="top">
            The Third People's Hospital of Shenzhen
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029603
           </td>
           <td valign="top">
            A randomized, open-label, multi-centre clinical trial evaluating and comparing the safety and efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for confirmed cases of novel Coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Conventional standardized treatment and ASC09/Ritonavir (80 patients)
           </td>
           <td align="left" valign="top">
            Conventional standardized treatment and Lopinavir/Ritonavir (80 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            The incidence of composite adverse outcome
           </td>
           <td valign="top">
            The First Affiliated Hospital of Zhejiang University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029853
           </td>
           <td valign="top">
            A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Oral administration of 5 tablets of 1 mg azvudine daily (10 patients)
           </td>
           <td align="left" valign="top">
            Control group (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Temperature, improvement of respiratory symptoms
           </td>
           <td valign="top">
            People's Hospital of Guangshan County
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029996
           </td>
           <td valign="top">
            A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Tablets; 200 mg; oral; twice a day; adult dose is 1600 mg per time on first day (20 patients)
           </td>
           <td valign="top">
            Tablets; 200 mg; orally; twice a day; adult dose is 1800 mg per time on first day (20 patients)
           </td>
           <td valign="top">
            Tablets; 200 mg; oral; twice a day; adult dose is 2400 mg per time on first day (20 patients)
           </td>
           <td valign="top">
            Time to clinical recovery
           </td>
           <td valign="top">
            Beijing Chaoyang Hospital, Capital Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030041
           </td>
           <td valign="top">
            A single-arm, single-center clinical trial for azvudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Azvudine tablets (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            The novel coronavirus nucleic acid negative rate
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030113
           </td>
           <td valign="top">
            Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir
           </td>
           <td valign="top">
            Ritonavir/ritonavir treatment (15 patients)
           </td>
           <td valign="top">
            Favipiravir (15 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination
           </td>
           <td valign="top">
            The Third People's Hospital of Shenzhen
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030254
           </td>
           <td valign="top">
            A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Farpiravir tablets (120 patients)
           </td>
           <td align="left" valign="top">
            Abidole tablets (120 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Pulse oxygen saturation parameters, respiratory support Nucleic acid test of novel coronavirus
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030259
           </td>
           <td valign="top">
            Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial
           </td>
           <td valign="top">
            Danorevir sodium tablets/ritonavir oral (30 patients)
           </td>
           <td valign="top">
            Symptomatic treatment (30 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of composite adverse outcomes: SpO2, PaO2/FiO2, respiratory rate
           </td>
           <td valign="top">
            Shanghai Changzheng Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030424
           </td>
           <td valign="top">
            A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Azvudine Tablet: D1: 10 mg/day,QD
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Negative conversion rate of the new coronavirus nucleic acid
           </td>
           <td valign="top">
            Henan Provincial People's Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030472
           </td>
           <td valign="top">
            An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Ganovo/ritonavir oral + conventional treatment (10 patients)
           </td>
           <td valign="top">
            Conventional treatment (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of composite adverse outcomes: SPO2, PaO2/FiO2 and respiratory rate
           </td>
           <td valign="top">
            Shenyang Sixth People's Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030487
           </td>
           <td valign="top">
            A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Azvudine Tablet: D1: 10 mg/day, QD
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Negative conversion rate of the new coronavirus nucleic acid
           </td>
           <td valign="top">
            The First Affiliated Hospital of Henan University of CM
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04244591
           </td>
           <td valign="top">
            Glucocorticoid therapy for novel Coronavirus critically ill patients with severe acute respiratory failure (Steroids-SARI)
           </td>
           <td valign="top">
            Methylprednisolone therapy and standard care
           </td>
           <td valign="top">
            Standard care
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Lower Murray lung injury score
           </td>
           <td valign="top">
            Peking Union Medical College Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04252274
           </td>
           <td valign="top">
            Efficacy and safety of Darunavir and Cobicistat for treatment of pneumonia caused by 2019-nCoV (DACO-nCoV)
           </td>
           <td valign="top">
            Darunavir, Cobicistat and conventional treatments
           </td>
           <td align="left" valign="top">
            Conventional treatments
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7
           </td>
           <td valign="top">
            Shanghai Public Health Clinical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04252664
           </td>
           <td valign="top">
            A Phase 3 randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate 2019-nCoV respiratory disease
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Remdesivir placebo
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            All cause mortality
           </td>
           <td valign="top">
            Capital Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04254874
           </td>
           <td valign="top">
            A prospective/retrospective, randomized controlled clinical study of interferon atomization in the 2019-nCoV pneumonia
           </td>
           <td valign="top">
            Abidol hydrochloride
           </td>
           <td align="left" valign="top">
            Abidol Hydrochloride combined with Interferon atomization
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of disease remission, Time for lung recovery
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04255017
           </td>
           <td valign="top">
            A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia
           </td>
           <td valign="top">
            Abidol hydrochloride
           </td>
           <td valign="top">
            Oseltamivir
           </td>
           <td valign="top">
            Lopinavir/ritonavir
           </td>
           <td valign="top">
            Rate of disease remission
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04257656
           </td>
           <td valign="top">
            Severe 2019-nCoV Remdesivir randomized controlled trial (RCT)
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Remdesivir placebo
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to Clinical Improvement (TTCI)
           </td>
           <td valign="top">
            Capital Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04260594
           </td>
           <td valign="top">
            Clinical study of arbidol hydrochloride tablets in the treatment of pneumonia caused by novel Coronavirus
           </td>
           <td valign="top">
            Arbidol
           </td>
           <td valign="top">
            Basic treatment
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virus negative conversion rate in the first week
           </td>
           <td valign="top">
            Jieming QU
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261270
           </td>
           <td valign="top">
            A randomized, open, controlled clinical study to evaluate the efficacy of ASC09F and Ritonavir for 2019-nCoV pneumonia
           </td>
           <td valign="top">
            ASC09F + Oseltamivir
           </td>
           <td valign="top">
            Ritonavir + Oseltamivir
           </td>
           <td valign="top">
            Oseltamivir
           </td>
           <td valign="top">
            Rate of comprehensive adverse outcome
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261270
           </td>
           <td valign="top">
            A randomized, open, controlled clinical study to evaluate the efficacy of ASC09F and Ritonavir for 2019-nCoV pneumonia
           </td>
           <td valign="top">
            ASC09F + Oseltamivir
           </td>
           <td align="left" valign="top">
            Ritonavir + Oseltamivir
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of comprehensive adverse outcome
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261517
           </td>
           <td valign="top">
            Efficacy and safety of hydroxychloroquine for treatment of pneumonia caused by 2019-nCoV (HC-nCoV)
           </td>
           <td valign="top">
            Hydroxychloroquine and conventional treatments
           </td>
           <td align="left" valign="top">
            Conventional treatments
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions
           </td>
           <td valign="top">
            Shanghai Public Health Clinical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261907
           </td>
           <td valign="top">
            Evaluating and comparing the safety and efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for novel Coronavirus infection
           </td>
           <td valign="top">
            ASC09/ritonavir
           </td>
           <td valign="top">
            Lopinavir/ritonavir
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            The incidence of composite adverse outcome
           </td>
           <td valign="top">
            First Affiliated Hospital of Zhejiang University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04276688
           </td>
           <td valign="top">
            Lopinavir/ Ritonavir, Ribavirin and IFN-beta combination for nCoV treatment
           </td>
           <td valign="top">
            Lopinavir/ritonavir
           </td>
           <td valign="top">
            Ribavirin
           </td>
           <td valign="top">
            Interferon Beta-1B
           </td>
           <td valign="top">
            Time to negative NPS 2019-n-CoV RT-PCR
           </td>
           <td valign="top">
            The University of Hong Kong
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04292730
           </td>
           <td valign="top">
            Study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with moderate Coronavirus disease (COVID-19) compared to standard of care treatment
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Standard of care
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Proportion of participants discharged by Day 14
           </td>
           <td valign="top">
            Gilead Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04292899
           </td>
           <td valign="top">
            Study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe Coronavirus disease (COVID-19)
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Standard of care
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Proportion of participants With normalization of fever and oxygen saturation through Day 14
           </td>
           <td valign="top">
            Gilead Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04304053
           </td>
           <td valign="top">
            Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID-19 epidemic
           </td>
           <td valign="top">
            Antiviral treatment and prophylaxis
           </td>
           <td align="left" valign="top">
            Standard Public Health measures
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases
           </td>
           <td valign="top">
            Lihir Medical Centre
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04307693
           </td>
           <td valign="top">
            Comparison of Lopinavir/Ritonavir or hydroxychloroquine in patients with mild Coronavirus disease (COVID-19)
           </td>
           <td valign="top">
            Lopinavir / Ritonavir tablet
           </td>
           <td align="left" valign="top">
            Hydroxychloroquine sulfate tablet
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Viral load
           </td>
           <td valign="top">
            Asan Medical Center
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0009">
      <label>
       5.2
      </label>
      <title>
       Chloroquine and hydroxychloroquine
      </title>
      <p id="para0015">
       Chloroquine is a widely-used antimalarial and autoimmune disease drug that has been reported to be a potential broad-spectrum antiviral drug
       <xref ref-type="bibr" rid="bib0056">
        [56]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0057">
        [57]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0058">
        [58]
       </xref>
       . Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV
       <xref ref-type="bibr" rid="bib0059">
        [59]
       </xref>
       . The first results obtained from more than 100 patients showed the apparent efficacy of chloroquine in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance, all in the absence of severe side effects
       <xref ref-type="bibr" rid="bib0060">
        [60]
       </xref>
       . Chloroquine was included in the recommendations for the prevention and treatment of COVID-19 pneumonia
       <xref ref-type="bibr" rid="bib0060">
        [60
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0061">
        61]
       </xref>
       . The optimal dosage of chloroquine for SARS-CoV-2 will need to be assessed in future trials
       <xref ref-type="bibr" rid="bib0062">
        [62]
       </xref>
       .
      </p>
      <p id="para0016">
       Hydroxychloroquine is a chloroquine analog for which there are fewer concerns about drug-drug interactions
       <xref ref-type="bibr" rid="bib0063">
        [63]
       </xref>
       . In the previous SARS outbreak, hydroxychloroquine was reported to have anti-SARS-CoV activity in vitro
       <xref ref-type="bibr" rid="bib0064">
        [64]
       </xref>
       . Using physiologically-based pharmacokinetic (PBPK) models, hydroxychloroquine was found to be more potent than chloroquine in SARS-CoV-2-infected Vero cells
       <xref ref-type="bibr" rid="bib0065">
        [65]
       </xref>
       . Cytokines IL-6 and IL-10 have been reported to be increased in response to SARS-CoV-2 infection
       <xref ref-type="bibr" rid="bib0066">
        [66
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0067">
        67]
       </xref>
       . This may progress to a cytokine storm, followed by multiorgan failure and death. Both chloroquine and hydroxychloroquine have immunomodulatory effects and can suppress the immune response
       <xref ref-type="bibr" rid="bib0068">
        [68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0069">
        69]
       </xref>
       . Therefore, 21 clinical studies were launched by Chinese hospitals and the University of Oxford to evaluate the efficacy of these agents in COVID-19 infection (
       <xref ref-type="table" rid="tbl0002">
        Table 2
       </xref>
       ). It is also necessary to determine whether the benefit of chloroquine therapy depends on the age of the patient and the clinical presentation or stage of the disease
       <xref ref-type="bibr" rid="bib0070">
        [70]
       </xref>
       . If clinical data confirm the biological results, chloroquine and hydroxychloroquine may be used in prophylaxis as well as curative treatment for individuals exposed to SARS-CoV-2
       <xref ref-type="bibr" rid="bib0071">
        [71]
       </xref>
       .
       <table-wrap id="tbl0002" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Clinical trials of chloroquine and hydroxychloroquine in patients with COVID-19.
         </p>
        </caption>
        <alt-text id="alt0002">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Group 3 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000029898
           </td>
           <td valign="top">
            Evaluation of the efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate chloroquine in severe patients with novel Coronavirus pneumonia (COVID-19): a randomized, open-label, parallel, controlled trial
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate Day1: first dose: 6 tablets (0.1 g/tablet) , second dose: 6 tablets (0.1 g/tablet) after 6 h ;Day2~5: 2 tablets (0.1 g/tablet), BID (50 patients)
           </td>
           <td valign="top">
            Phosphate chloroquine Day 1-3:500 mg, BID Day 4-5:250 mg, BID (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            TTCI (Time to Clinical Improvement)
           </td>
           <td valign="top">
            Peking University Third Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029988
           </td>
           <td valign="top">
            Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate (40 patients)
           </td>
           <td valign="top">
            None (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to Clinical Recovery
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029542
           </td>
           <td valign="top">
            Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine (10 patients)
           </td>
           <td align="left" valign="top">
            Conventional management (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Viral-negative transforming time 30-day cause-specific mortality
           </td>
           <td valign="top">
            Sun Yat sen Memorial Hospital of Sun Yat sen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029559
           </td>
           <td valign="top">
            Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Hydroxychloroquine 0.1 oral 2/day (100 patients)
           </td>
           <td valign="top">
            Hydroxychloroquine 0.2 oral 2/day (100 patients)
           </td>
           <td valign="top">
            Starch pill oral 2/day (100 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Renmin Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029609
           </td>
           <td valign="top">
            A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Oral chloroquine phosphate (59 mild-moderate patients and 14 severe patients)
           </td>
           <td valign="top">
            Oral Lopinavir/ritonavir (59 mild-moderate patients and 14 severe patients)
           </td>
           <td valign="top">
            Chloroquine phosphate plus Lopinavir/ritonavir (59 mild-moderate patients)
           </td>
           <td valign="top">
            Virus nucleic acid-negative transforming time
           </td>
           <td valign="top">
            The Fifth Affiliated Hospital of Sun Yat-Sen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029740
           </td>
           <td valign="top">
            Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients (randomized open-label control clinical trial)
           </td>
           <td valign="top">
            Oral intake hydroxycholoroquine 0.2 twice a day (54 patients)
           </td>
           <td valign="top">
            Conventional therapy (24 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Oxygen index, lung radiography, temperature
           </td>
           <td valign="top">
            The First Hospital of Peking University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029741
           </td>
           <td valign="top">
            Compare the efficacy and safety of chloroquine and lopinavir/ritonavir in patients with mild/general CoVID-19 infection, and establish a standardized treatment plan.
           </td>
           <td valign="top">
            Chloroquine phosphate (56 patients)
           </td>
           <td valign="top">
            Control group (56 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Length of stay, oxygenation index during treatment, all-cause mortality in 28 days
           </td>
           <td valign="top">
            The Fifth Affiliated Hospital Sun Yat-Sen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029803
           </td>
           <td valign="top">
            A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)
           </td>
           <td valign="top">
            Hydroxychloroquine, small dose and high dose (80 patients/group)
           </td>
           <td align="left" valign="top">
            Abidol hydrochloride, small dose and high dose (80 patients/group)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus
           </td>
           <td valign="top">
            Renmin Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029826
           </td>
           <td valign="top">
            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            2 tablets phosphoric chloroquine BID (80 patients)
           </td>
           <td align="left" valign="top">
            2 tablets placebo BID (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Mortality rate
           </td>
           <td valign="top">
            Jingzhou Central Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029837
           </td>
           <td valign="top">
            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            2 tablets phosphoric chloroquine BID (80 patients)
           </td>
           <td align="left" valign="top">
            2 tablets placebo BID (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time of conversion to negative novel coronavirus nucleic acid
           </td>
           <td valign="top">
            Jingzhou Central Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029868
           </td>
           <td valign="top">
            Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial
           </td>
           <td valign="top">
            Oral hydroxychloroquine sulfate tablets (100 patients)
           </td>
           <td align="left" valign="top">
            Conventional treatment meeting the Guideline (100 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Viral nucleic acid test
           </td>
           <td valign="top">
            Ruijin Hospital, Shanghai Jiaotong University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029898
           </td>
           <td valign="top">
            Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Common Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate Day1: first dose: 6 tablets (0.1 g/tablet) , second dose: 6 tablets (0.1 g/tablet) after 6 h ;Day 2~5: 2 tablets (0.1 g/tablet), BID (50 patients)
           </td>
           <td valign="top">
            Phosphate chloroquine Day 1-3:500 mg, BID Day 4-5:250 mg, BID (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to Clinical Recovery, TTCR
           </td>
           <td valign="top">
            Peking University Third Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029935
           </td>
           <td valign="top">
            A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)
           </td>
           <td align="left" valign="top">
            Conventional treatment combined with Chloroquine Phosphate (100 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Length of hospital stay
           </td>
           <td valign="top">
            HwaMei Hospital, University of Chinese Academy of Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029939
           </td>
           <td valign="top">
            A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)
           </td>
           <td valign="top">
            Conventional treatment (50 patients)
           </td>
           <td align="left" valign="top">
            conventional treatment combined with Chloroquine Phosphate (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Length of hospital stay
           </td>
           <td valign="top">
            HwaMei Hospital, University of Chinese Academy of Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029988
           </td>
           <td valign="top">
            Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate (40 patients)
           </td>
           <td valign="top">
            None (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to clinical recovery
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029992
           </td>
           <td valign="top">
            A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate 1.0 g x 2 days for the first dose, 0.5 g x 12 days from the third day (40 patients)
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate 0.2 g bid x 14 days (40 patients)
           </td>
           <td valign="top">
            Recommended treatment plan for novel coronavirus pneumonia severe and critical cases (20 patients)
           </td>
           <td valign="top">
            Clinical recovery time, changes in viral load of upper and lower respiratory tract samples compared with the baseline
           </td>
           <td valign="top">
            Zhongshan Hospital Affiliated to Xiamen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030031
           </td>
           <td valign="top">
            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            2 tablets phosphoric chloroquine BID 80 patients)
           </td>
           <td align="left" valign="top">
            2 tablets placebo BID (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time of conversion to negative novel coronavirus nucleic acid
           </td>
           <td valign="top">
            The Sixth Affiliated Hospital of Guangzhou Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030054
           </td>
           <td valign="top">
            A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate 0.2 g bid x 14 days a day (30 patients)
           </td>
           <td valign="top">
            First dose of chloroquine phosphate 1 g x 2 days, and the third day was 0.5 g x 12 days (30 patients)
           </td>
           <td valign="top">
            Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan (20 patients)
           </td>
           <td valign="top">
            Clinical recovery time
           </td>
           <td valign="top">
            Zhongshan Hospital Affiliated to Xiamen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030417
           </td>
           <td valign="top">
            Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate aerosol inhalation solution (15 patients)
           </td>
           <td align="left" valign="top">
            Water for injection atomization inhalation (15 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Temperature, respiratory symptoms
           </td>
           <td valign="top">
            Harbin infectious diseases hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030718
           </td>
           <td valign="top">
            Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate (40 patients)
           </td>
           <td align="left" valign="top">
            Regular treatment (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to clinical recovery
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04303507
           </td>
           <td valign="top">
            Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
           </td>
           <td valign="top">
            Chloroquine
           </td>
           <td valign="top">
            Placebo
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Number of symptomatic COVID-19 infections
           </td>
           <td valign="top">
            University of Oxford
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0010">
      <label>
       5.3
      </label>
      <title>
       Corticosteroids
      </title>
      <p id="para0017">
       In a study of 41 COVID-19 patients, 21% received corticosteroids, which could suppress lung inflammation
       <xref ref-type="bibr" rid="bib0066">
        [66]
       </xref>
       . The administered dose of methylprednisolone varied depending on disease severity. Current interim guidance from the WHO on the clinical management of severe acute respiratory infection when SARS-CoV-2 infection is suspected (released January 28, 2020) advises against the use of corticosteroids unless indicated for another reason. The clinical outcomes of coronavirus and similar outbreaks do not support the use of corticosteroids. In a retrospective observational study of 309 adults who were critically ill with MERS, patients who were given corticosteroids were more likely to require mechanical ventilation, vasopressors, and renal replacement therapy
       <xref ref-type="bibr" rid="bib0072">
        [72]
       </xref>
       . For the management of SARS, corticosteroid treatment was more associated with psychosis, diabetes and avascular necrosis
       <xref ref-type="bibr" rid="bib0073">
        [73
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0074">
        74]
       </xref>
       . Overall, there is no unique reason to expect that patients with COVID-19 infection will benefit from corticosteroids, and such treatment may be harmful
       <xref ref-type="bibr" rid="bib0075">
        [75]
       </xref>
       . However, according to our clinical experience, corticosteroids could be prescribed at the right time for the right patients. The clinical trials involving corticosteroids are shown in
       <xref ref-type="table" rid="tbl0003">
        Table 3
       </xref>
       .
       <table-wrap id="tbl0003" position="float">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Clinical trials of corticosteroids in patients with COVID-19.
         </p>
        </caption>
        <alt-text id="alt0003">
         Table 3
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Group 3 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000029386
           </td>
           <td valign="top">
            Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial
           </td>
           <td valign="top">
            Methylprednisolone, intravenous injection, 1-2 mg/kg·d for 3 days (24 patients)
           </td>
           <td valign="top">
            Without any glucocorticoid therapy (24 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            SOFA score
           </td>
           <td valign="top">
            Chongqing Public Health Medical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029656
           </td>
           <td valign="top">
            A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Standard treatment and methylprednisolone for injection (50 patients)
           </td>
           <td align="left" valign="top">
            Standard treatment (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Chest imaging, complications
           </td>
           <td valign="top">
            Wuhan Pulmonary Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030481
           </td>
           <td valign="top">
            The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
           </td>
           <td valign="top">
            Early corticosteroid intervention (75 patients)
           </td>
           <td valign="top">
            Middle-late corticosteroid intervention (75 patients)
           </td>
           <td valign="top">
            No corticosteroid (50 patients)
           </td>
           <td valign="top">
            Time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens change to negative
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT0424459
           </td>
           <td valign="top">
            The efficacy of different hormone doses in 2019-nCoV severe pneumonia
           </td>
           <td valign="top">
            Methylprednisolone (&lt;40 mg/d intravenous drip for 7 days)
           </td>
           <td valign="top">
            Methylprednisolone (40~80 mg/d intravenous drip for 7 days)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of disease remission, rate and time of entering the critical stage
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0011">
      <label>
       5.4
      </label>
      <title>
       Antibodies
      </title>
      <p id="para0018">
       The development of vaccines and therapeutic antibodies against COVID-19 has important implications. Considering the relatively high identity of the receptor-binding domain (RBD) in SARS-CoV-2 and SARS-CoV, the cross-reactivity of anti-SARS-CoV antibodies with the COVID-19 spike protein was assessed. The spike protein is the major inducer of neutralizing antibodies. Fortunately, the SARS-CoV-specific human monoclonal antibody CR3022 binds potently with the COVID-19 RBD
       <xref ref-type="bibr" rid="bib0076">
        [76]
       </xref>
       . However, other SARS-CoV RBD-directed antibodies 230, m396 and 80R cannot bind to the COVID-19 RBD
       <xref ref-type="bibr" rid="bib0077">
        [77]
       </xref>
       . CR3022 may be a potential therapeutic candidate, alone or in combination with other neutralizing antibodies, for the prevention and treatment of COVID-19 infections. Antibodies MAb114 and REGN-EB3 were designed for treatment of Ebola virus infection and significantly reduce mortality from Ebola virus disease
       <xref ref-type="bibr" rid="bib0047">
        [47]
       </xref>
       . Monoclonal antibodies can only recognize a single antigen epitope, which limits the use of MAb114 and REGN-EB3 in the treatment of COVID-19. However, the development of COVID-19-specific antibodies requires a long time. It is not easy to apply monoclonal antibodies for new pathogens to clinical practice in a short time.
      </p>
     </sec>
     <sec id="sec0012">
      <label>
       5.5
      </label>
      <title>
       Convalescent plasma transfusion
      </title>
      <p id="para0019">
       Convalescent plasma was administered early after symptom onset in the treatment of SARS, and the pooled odds of mortality following treatment was reduced compared with placebo or no therapy (odds ratio, 0.25)
       <xref ref-type="bibr" rid="bib0078">
        [78]
       </xref>
       . However, in Ebola virus disease, the transfusion of up to 500 mL of convalescent plasma in 84 patients was not associated with a significant improvement in survival
       <xref ref-type="bibr" rid="bib0079">
        [79]
       </xref>
       . In a laboratory test, the COVID-19 virus was isolated from the bronchoalveolar lavage fluid of a critically ill patient, and it could be neutralized by sera from several patients
       <xref ref-type="bibr" rid="bib0080">
        [80]
       </xref>
       . Current clinical trials involving convalescent plasma transfusion are shown in
       <xref ref-type="table" rid="tbl0004">
        Table 4
       </xref>
       . The National Health Commission of China appealed to convalescent patients to donate blood for the treatment of COVID-19 infection. Convalescent plasma should be collected within two weeks after recovery to ensure a high neutralization antibody titer. The difficulty in obtaining plasma during convalescence limits its clinical application. Well-designed clinical trials are needed to further evaluate the efficacy and safety of convalescent plasma therapy in patients with COVID-19 infection.
       <table-wrap id="tbl0004" position="float">
        <label>
         Table 4
        </label>
        <caption>
         <p>
          Clinical trials of convalescent plasma transfusion in patients with COVID-19Searched on
          <ext-link ext-link-type="uri" id="interref2a" xlink:href="http://www.chictr.org.cn/">
           http://www.chictr.org.cn/
          </ext-link>
          and
          <ext-link ext-link-type="uri" id="interref2b" xlink:href="https://clinicaltrials.gov/">
           https://clinicaltrials.gov/
          </ext-link>
          . As of March 15, 2020.
         </p>
        </caption>
        <alt-text id="alt0004">
         Table 4
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000030039
           </td>
           <td valign="top">
            Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Conventional therapy with infusion of convalescent plasma: 200-500 mL (30 patients)
           </td>
           <td valign="top">
            Conventional therapy (30 patients)
           </td>
           <td valign="top">
            Viral load, SARS-CoV-2 antibody levels
           </td>
           <td valign="top">
            Affiliated Hospital of Xuzhou Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029757
           </td>
           <td valign="top">
            Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
           </td>
           <td valign="top">
            Conventional treatment and convalescent plasma therapy (100 patients)
           </td>
           <td valign="top">
            Conventional treatment (100 patients)
           </td>
           <td valign="top">
            Number of days between randomized grouping and clinical improvement
           </td>
           <td valign="top">
            China-Japan Friendship Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029850
           </td>
           <td valign="top">
            Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Standardized comprehensive treatment combined with convalescent plasma treatment (10 patients)
           </td>
           <td valign="top">
            Standardized comprehensive treatment (10 patients)
           </td>
           <td valign="top">
            Fatality rate
           </td>
           <td valign="top">
            The First Affiliated Hospital of Zhejiang University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030010
           </td>
           <td valign="top">
            A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)
           </td>
           <td valign="top">
            Anti-SARS-CoV-2 virus-inactivated plasma (50 patients)
           </td>
           <td valign="top">
            Ordinary plasma (50 patients)
           </td>
           <td valign="top">
            Improvement of clinical symptoms
           </td>
           <td valign="top">
            Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030046
           </td>
           <td valign="top">
            A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)
           </td>
           <td valign="top">
            Anti-2019-nCoV virus-inactivated plasma (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Changes to clinical symptoms, laboratory and radiological data
           </td>
           <td valign="top">
            First People's Hospital of Jiangxia District
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030179
           </td>
           <td valign="top">
            Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Routine treatment + plasma treatment (50 patients)
           </td>
           <td valign="top">
            Routine treatment (50 patients)
           </td>
           <td valign="top">
            Cure rate, mortality
           </td>
           <td valign="top">
            The First Affiliated Hospital of Nanchang University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030381
           </td>
           <td valign="top">
            A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2-inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient
           </td>
           <td valign="top">
            Conventional treatment and anti-SARS-CoV-2 virus-inactivated plasma (20 patients)
           </td>
           <td valign="top">
            Conventional treatment and ordinary plasma (20 patients)
           </td>
           <td valign="top">
            Clinical symptom improvement
           </td>
           <td valign="top">
            First People's Hospital of Jiangxi District, Wuhan
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030627
           </td>
           <td valign="top">
            Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases
           </td>
           <td valign="top">
            Convalescent plasma therapy + routine treatment (15 patients)
           </td>
           <td valign="top">
            Routine treatment (15 patients)
           </td>
           <td valign="top">
            Temperature, virus nucleic acid detection
           </td>
           <td valign="top">
            The First Affiliated Hospital of Zhengzhou University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030702
           </td>
           <td valign="top">
            Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial
           </td>
           <td valign="top">
            Conventional treatment and convalescent plasma therapy (25 patients)
           </td>
           <td valign="top">
            Conventional treatment (25 patients)
           </td>
           <td valign="top">
            Time to clinical recovery after randomization
           </td>
           <td valign="top">
            China-Japan Friendship Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04292340
           </td>
           <td valign="top">
            Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19
           </td>
           <td align="left" valign="top">
            Anti-SARS-CoV-2-inactivated convalescent plasma
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions
           </td>
           <td valign="top">
            Shanghai Public Health Clinical Center
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0013">
      <label>
       5.6
      </label>
      <title>
       Vaccines
      </title>
      <p id="para0020">
       The structure of SARS-CoV-2 S protein has been revealed, and this should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis
       <xref ref-type="bibr" rid="bib0077">
        [77]
       </xref>
       . These findings provide the basis for further studies to optimize vaccination strategies for this emerging infection. The majority of the vaccines being developed for coronaviruses target the spike glycoprotein or S protein
       <xref ref-type="bibr" rid="bib0081">
        [81]
       </xref>
       . Vaccine development is a long process, and no vaccines are available at the time of a pandemic outbreak. For example, the Ebola epidemic outbreak occurred in 2013, and three years later, the rVSV Ebola Vaccine was selected for phase I clinical trials for its safety and immunogenicity in Africa and Europe
       <xref ref-type="bibr" rid="bib0082">
        [82]
       </xref>
       . In November 2019, the European Commission granted marketing authorization to Merck Sharp and Dohme B.V. in Europe for their Ebola vaccine, Ervebo. Fortunately, Moderna company announced on February 24, 2020 that the company's experimental mRNA COVID-19 vaccine, known as mRNA-1273, is ready for human testing. It is a remarkably fast development cycle to develop an initial vaccine just weeks after identifying the SARS-CoV-2 genetic sequence. The clinical trial of safety and immunogenicity of mRNA-1273 in the treatment of COVID-19 is under investigation (ClinicalTrials.gov Identifier: NCT04283461). Moreover, a new oral SARS-CoV-2 vaccine has been successfully developed at Tianjin University, which uses food-grade safe
       <italic>
        Saccharomyces cerevisiae
       </italic>
       as a carrier and targets the S protein. There are 18 biotechnology companies and universities in China working on SARS-CoV-2 vaccines. Vaccines for SARS-CoV-2 have been developed much faster than those for Ebola because of the collaborative efforts of scientists around the world and the fast-track approval of SARS-CoV-2 vaccine development efforts by the Chinese health organizations.
      </p>
     </sec>
    </sec>
    <sec id="sec0014">
     <label>
      6
     </label>
     <title>
      Conclusions
     </title>
     <p id="para0021">
      Bats have been recognized as a natural reservoir and vectors of a variety of coronaviruses, and these viruses have crossed species barriers to infect humans and many different kinds of animals, including avians, rodents, and chiropters
      <xref ref-type="bibr" rid="bib0083">
       [83
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0084">
       84]
      </xref>
      . While the origin of COVID-19 is still being investigated, COVID-19 has features typical of the Coronaviridae family and was classified in the beta-coronavirus 2b lineage. COVID-19 can be transmitted between humans. Interventions, including intensive contact tracing followed by quarantine and isolation, can effectively reduce the spread of COVID-19, with the effect of travel restrictions. Wearing masks, washing hands and disinfecting surfaces contribute to reducing the risk of infection. Human coronaviruses can be efficiently inactivated within 1 min using surface disinfection procedures with 62-71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite
      <xref ref-type="bibr" rid="bib0085">
       [85]
      </xref>
      .
     </p>
     <p id="para0022">
      Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, control the pandemic, and reduce the economic impact of COVID-19 on China and the world. In acute respiratory infection, RT-PCR is routinely used to detect causative viruses from respiratory secretions. The positive rate of PCR from oropharyngeal swabs is not very high. In this situation, more swab testing is needed to clarify diagnosis. Typical CT findings can help early screening of suspected cases and diagnosis of COVID-19.
     </p>
     <p id="para0023">
      The COVID-19 infection has a clustering onset and is more likely to affect older males (average age 51 years) with comorbidities
      <xref ref-type="bibr" rid="bib0086">
       [86]
      </xref>
      . No evidence supports adverse birth outcomes, intrauterine infection, or vertical transmission of COVID-19
      <xref ref-type="bibr" rid="bib0087">
       [87]
      </xref>
      . However, viral infections can be acquired when the infant passes through the birth canal during vaginal delivery or through postpartum breastfeeding
      <xref ref-type="bibr" rid="bib0088">
       [88]
      </xref>
      . The most common symptoms were fever, cough, expectoration, headache, myalgia or fatigue, diarrhea, and hemoptysis
      <xref ref-type="bibr" rid="bib0089">
       [89]
      </xref>
      . Some people may experience severe acute respiratory distress syndrome. Histological examination of lung biopsy samples showed bilateral diffuse alveolar damage with cellular fibromyxoid exudates
      <xref ref-type="bibr" rid="bib0090">
       [90]
      </xref>
      . Other organs are also susceptible to COVID-19. The single-cell RNA-seq data was used to analyse receptor ACE2 expression to reveal the potential risk of different human organs to COVID-19 infection
      <xref ref-type="bibr" rid="bib0091">
       [91]
      </xref>
      . COVID-19 uses the same cell entry receptor as SARS-CoV, ACE2, which regulates both cross-species and human-to-human transmissions
      <xref ref-type="bibr" rid="bib0080">
       [80]
      </xref>
      . Proximal tubular cells also express higher levels of the ACE2 receptor, which leads to susceptibility to COVID-19
      <xref ref-type="bibr" rid="bib0091">
       [91]
      </xref>
      and induces kidney injury. Data from 33 patients with a complete clinical course were analysed, and the levels of blood urea and creatinine were higher in non-survivors than in survivors
      <xref ref-type="bibr" rid="bib0092">
       [92]
      </xref>
      .
     </p>
     <p id="para0024">
      All patients with COVID-19-infected pneumonia received antibacterial agents, 90% received antiviral therapy, and 45% received methylprednisolone
      <xref ref-type="bibr" rid="bib0092">
       [92]
      </xref>
      . Clinical trials are underway to investigate the efficacy of new antiviral drugs, convalescent plasma transfusion, and vaccines. Most of the trials were initiated by investigators and the study period is 1 to 11 months. Although the final results of these studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for therapy
      <xref ref-type="bibr" rid="bib0093">
       [93]
      </xref>
      .
     </p>
     <p id="para0025">
      The COVID-19 pandemic is a public health emergency of international concern, and all countries need a coordinated international effort to fight COVID-19. The transmission of pneumonia associated with SARS-CoV-2 has not yet been eliminated. In the absence of vaccines and antivirals, isolation and quarantine are achieving remarkable results. It is necessary to strengthen the monitoring of COVID-19 and to develop drugs and vaccines against the COVID-19 infection as soon as possible.
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         727
        </fpage>
        <lpage>
         733
        </lpage>
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <element-citation id="sbref0003" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         HIV-1 did not contribute to the 2019-nCoV genome
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         378
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="pmid">
         32056509
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paraskevis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kostaki
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Magiorkinis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Panayiotakopoulos
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sourvinos
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event
        </article-title>
        <source>
         Infect Genet Evol
        </source>
        <volume>
         79
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         104212
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harcourt
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Kamili
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sakthivel
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Acute Respiratory Syndrome Coronavirus 2 from patient with 2019 novel Coronavirus disease, United States
        </article-title>
        <source>
         Emerging Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Z.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new coronavirus associated with human respiratory disease in China
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         265
        </fpage>
        <lpage>
         269
        </lpage>
        <pub-id pub-id-type="pmid">
         32015508
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1199
        </fpage>
        <lpage>
         1207
        </lpage>
        <pub-id pub-id-type="pmid">
         31995857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Klinkenberg
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presumed asymptomatic carrier transmission of COVID-19
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Rayner
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does SARS-CoV-2 has a longer incubation period than SARS and MERS?
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         476
        </fpage>
        <lpage>
         478
        </lpage>
        <pub-id pub-id-type="pmid">
         32056235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Ran
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Musa
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         214
        </fpage>
        <lpage>
         217
        </lpage>
        <pub-id pub-id-type="pmid">
         32007643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Bragazzi
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of the transmission risk of the 2019-nCoV and Its implication for public health interventions
        </article-title>
        <source>
         J Clin Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Shih
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105924
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           O.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chik-Yan Yip
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Consistent detection of 2019 novel coronavirus in saliva
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhadra
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ellington
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         10
        </volume>
        <year>
         2015
        </year>
        <object-id pub-id-type="publisher-id">
         e0123126
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tee
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and evaluation of novel real-time reverse transcription-PCR Assays with locked nucleic acid probes targeting leader sequences of human-pathogenic Coronaviruses
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2722
        </fpage>
        <lpage>
         2726
        </lpage>
        <pub-id pub-id-type="pmid">
         26019210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Rapid and Specific Assay for the Detection of MERS-CoV
        </article-title>
        <source>
         Front Microbiol
        </source>
        <volume>
         9
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1101
        </fpage>
        <pub-id pub-id-type="pmid">
         29896174
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Baek
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         One-pot reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) for detecting MERS-CoV
        </article-title>
        <source>
         Front Microbiol
        </source>
        <volume>
         7
        </volume>
        <year>
         2016
        </year>
        <fpage>
         2166
        </fpage>
        <pub-id pub-id-type="pmid">
         28119682
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           S.M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           K.P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Krishnan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular diagnosis of a novel Coronavirus (2019-nCoV) causing an outbreak of pneumonia
        </article-title>
        <source>
         Clin Chem
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0021" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Konrad
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Eberle
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Dangel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Treis
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bengs
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0022" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cordes
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Heim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         125
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         104305
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <element-citation id="sbref0023" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Molenkamp
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Meijer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0024">
       <label>
        24
       </label>
       <element-citation id="sbref0024" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020
        </article-title>
        <source>
         Clin Chim Acta
        </source>
        <volume>
         505
        </volume>
        <year>
         2020
        </year>
        <fpage>
         172
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         32156607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        25
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         386
        </fpage>
        <lpage>
         389
        </lpage>
        <pub-id pub-id-type="pmid">
         32065057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0026">
       <label>
        26
       </label>
       <element-citation id="sbref0026" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensitivity of chest CT for COVID-19: comparison to RT-PCR
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200432
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0027">
       <label>
        27
       </label>
       <element-citation id="sbref0027" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of chest CT in combination with negative RT-PCR assay for the 2019 novel Coronavirus but high clinical suspicion
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200330
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0028">
       <label>
        28
       </label>
       <element-citation id="sbref0028" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cobb
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Simon
          </surname>
          <given-names>
           C.O.
          </given-names>
         </name>
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Body
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
         <name>
          <surname>
           Reisch
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The cobas(R) 6800/8800 system: a new era of automation in molecular diagnostics
        </article-title>
        <source>
         Expert Rev Mol Diagn
        </source>
        <volume>
         17
        </volume>
        <year>
         2017
        </year>
        <fpage>
         167
        </fpage>
        <lpage>
         180
        </lpage>
        <pub-id pub-id-type="pmid">
         28043179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0029">
       <label>
        29
       </label>
       <element-citation id="sbref0029" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marlowe
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hardy
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Krevolin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gohl
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Arcenas
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         High-throughput testing of urogenital and extragenital specimens for detection of Chlamydia trachomatis and Neisseria gonorrhoeae with Cobas((R)) CT/NG
        </article-title>
        <source>
         Eur J Microbiol Immunol (Bp)
        </source>
        <volume>
         7
        </volume>
        <year>
         2017
        </year>
        <fpage>
         176
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="pmid">
         29034107
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        30
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greub
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sahli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Brouillet
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Jaton
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ten years of R&amp;D and full automation in molecular diagnosis
        </article-title>
        <source>
         Future Microbiol
        </source>
        <volume>
         11
        </volume>
        <year>
         2016
        </year>
        <fpage>
         403
        </fpage>
        <lpage>
         425
        </lpage>
        <pub-id pub-id-type="pmid">
         27028061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0031">
       <label>
        31
       </label>
       <element-citation id="sbref0031" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eigner
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Reucher
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hefner
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Staffa-Peichl
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kolb
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Betz
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical evaluation of multiplex RT-PCR assays for the detection of influenza A/B and respiratory syncytial virus using a high throughput system
        </article-title>
        <source>
         J Virol Methods
        </source>
        <volume>
         269
        </volume>
        <year>
         2019
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         30946852
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0032">
       <label>
        32
       </label>
       <element-citation id="sbref0032" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Reucher
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nörz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lütgehetmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0033">
       <label>
        33
       </label>
       <element-citation id="sbref0033" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200343
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0034">
       <label>
        34
       </label>
       <element-citation id="sbref0034" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of chest CT and RT-PCR testing in Coronavirus disease 2019 (COVID-19) in China: A Report of 1014 Cases
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200642
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        35
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           E.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al Jawder
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Enani
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Skakni
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute Middle East Respiratory Syndrome Coronavirus: temporal lung changes observed on the chest radiographs of 55 patients
        </article-title>
        <source>
         AJR Am J Roentgenol
        </source>
        <volume>
         205
        </volume>
        <year>
         2015
        </year>
        <fpage>
         W267
        </fpage>
        <lpage>
         W274
        </lpage>
        <pub-id pub-id-type="pmid">
         26102309
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0036">
       <label>
        36
       </label>
       <element-citation id="sbref0036" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bernheim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CT imaging features of 2019 novel Coronavirus (2019-nCoV)
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200230
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0037">
       <label>
        37
       </label>
       <element-citation id="sbref0037" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Time course of lung changes on chest CT During recovery from 2019 novel Coronavirus (COVID-19) pneumonia
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200370
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0038">
       <label>
        38
       </label>
       <element-citation id="sbref0038" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Alwalid
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         20
        </volume>
        <year>
         2020
        </year>
        <fpage>
         425
        </fpage>
        <lpage>
         434
        </lpage>
        <pub-id pub-id-type="pmid">
         32105637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0039">
       <label>
        39
       </label>
       <element-citation id="sbref0039" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Eur J Nucl Med Mol Imaging
        </source>
        <volume>
         47
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1275
        </fpage>
        <lpage>
         1280
        </lpage>
        <pub-id pub-id-type="pmid">
         32107577
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        40
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0041">
       <label>
        41
       </label>
       <element-citation id="sbref0041" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           D.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         27
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0042">
       <label>
        42
       </label>
       <element-citation id="sbref0042" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G.Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic planning in China: applying lessons from severe acute respiratory syndrome
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         13
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         S33
        </fpage>
        <lpage>
         S35
        </lpage>
        <pub-id pub-id-type="pmid">
         18366527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0043">
       <label>
        43
       </label>
       <element-citation id="sbref0043" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        <volume>
         9
        </volume>
        <year>
         2003
        </year>
        <fpage>
         399
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0044">
       <label>
        44
       </label>
       <element-citation id="sbref0044" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           T.-T.
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           J.-D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           W.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.-Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        45
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1313
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0046">
       <label>
        46
       </label>
       <element-citation id="sbref0046" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elfiky
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
        </article-title>
        <source>
         Life Sci
        </source>
        <volume>
         248
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         117477
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0047">
       <label>
        47
       </label>
       <element-citation id="sbref0047" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mulangu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Davey
          </surname>
          <given-names>
           R.T.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Tshiani Mbaya
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Proschan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mukadi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized, controlled trial of Ebola virus disease therapeutics
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         381
        </volume>
        <year>
         2019
        </year>
        <fpage>
         2293
        </fpage>
        <lpage>
         2303
        </lpage>
        <pub-id pub-id-type="pmid">
         31774950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0048">
       <label>
        48
       </label>
       <element-citation id="sbref0048" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tchesnokov
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gotte
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of inhibition of Ebola virus RNA-dependent RNA Polymerase by remdesivir
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib0049">
       <label>
        49
       </label>
       <element-citation id="sbref0049" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Leist
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Won
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
        </article-title>
        <source>
         Nat Commun
        </source>
        <volume>
         11
        </volume>
        <year>
         2020
        </year>
        <fpage>
         222
        </fpage>
        <pub-id pub-id-type="pmid">
         31924756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        50
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Case
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
        </article-title>
        <source>
         Sci Transl Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib0051">
       <label>
        51
       </label>
       <element-citation id="sbref0051" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Cronin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jordan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         117
        </volume>
        <year>
         2020
        </year>
        <fpage>
         6771
        </fpage>
        <lpage>
         6776
        </lpage>
        <pub-id pub-id-type="pmid">
         32054787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0052">
       <label>
        52
       </label>
       <element-citation id="sbref0052" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tchesnokov
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gotte
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0053">
       <label>
        53
       </label>
       <element-citation id="sbref0053" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First case of 2019 novel Coronavirus in the United States
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         929
        </fpage>
        <lpage>
         936
        </lpage>
        <pub-id pub-id-type="pmid">
         32004427
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0054">
       <label>
        54
       </label>
       <element-citation id="sbref0054" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martinez
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compounds with therapeutic potential against novel respiratory 2019 coronavirus
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        55
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         64
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="pmid">
         32037389
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0056">
       <label>
        56
       </label>
       <element-citation id="sbref0056" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Di Trani
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         16439323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0057">
       <label>
        57
       </label>
       <element-citation id="sbref0057" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         23
        </volume>
        <year>
         2013
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="pmid">
         23208422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0058">
       <label>
        58
       </label>
       <element-citation id="sbref0058" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         30
        </volume>
        <year>
         2007
        </year>
        <fpage>
         297
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         17629679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0059">
       <label>
        59
       </label>
       <element-citation id="sbref0059" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        60
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="pmid">
         32074550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0061">
       <label>
        61
       </label>
       <element-citation id="sbref0061" publication-type="journal">
        <article-title>
         [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <volume>
         43
        </volume>
        <year>
         2020
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         32164085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0062">
       <label>
        62
       </label>
       <element-citation id="sbref0062" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105932
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0063">
       <label>
        63
       </label>
       <element-citation id="sbref0063" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jallouli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Galicier
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zahr
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Aumaitre
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Frances
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Le Guern
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Rheumatol
        </source>
        <volume>
         67
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2176
        </fpage>
        <lpage>
         2184
        </lpage>
        <pub-id pub-id-type="pmid">
         25989906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0064">
       <label>
        64
       </label>
       <element-citation id="sbref0064" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Biot
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Daher
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chavain
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fandeur
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Khalife
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         49
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2845
        </fpage>
        <lpage>
         2849
        </lpage>
        <pub-id pub-id-type="pmid">
         16640347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        65
       </label>
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0066">
       <label>
        66
       </label>
       <element-citation id="sbref0066" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0067">
       <label>
        67
       </label>
       <element-citation id="sbref0067" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <volume>
         43
        </volume>
        <year>
         2020
        </year>
        <fpage>
         203
        </fpage>
        <lpage>
         208
        </lpage>
        <pub-id pub-id-type="pmid">
         32164089
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0068">
       <label>
        68
       </label>
       <element-citation id="sbref0068" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schrezenmeier
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Dorner
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
        </article-title>
        <source>
         Nat Rev Rheumatol
        </source>
        <volume>
         16
        </volume>
        <year>
         2020
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         166
        </lpage>
        <pub-id pub-id-type="pmid">
         32034323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0069">
       <label>
        69
       </label>
       <element-citation id="sbref0069" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today's diseases
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        70
       </label>
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Touret
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Of chloroquine and COVID-19
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         177
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         104762
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0071">
       <label>
        71
       </label>
       <element-citation id="sbref0071" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105923
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0072">
       <label>
        72
       </label>
       <element-citation id="sbref0072" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Sindi
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Almekhlafi
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hussein
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         197
        </volume>
        <year>
         2018
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         767
        </lpage>
        <pub-id pub-id-type="pmid">
         29161116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0073">
       <label>
        73
       </label>
       <element-citation id="sbref0073" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Allen Chan
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         31
        </volume>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         309
        </lpage>
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0074">
       <label>
        74
       </label>
       <element-citation id="sbref0074" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wing
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yiu
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         39
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1247
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="pmid">
         15486852
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        75
       </label>
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         473
        </fpage>
        <lpage>
         475
        </lpage>
        <pub-id pub-id-type="pmid">
         32043983
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0076">
       <label>
        76
       </label>
       <element-citation id="sbref0076" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         382
        </fpage>
        <lpage>
         385
        </lpage>
        <pub-id pub-id-type="pmid">
         32065055
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0077">
       <label>
        77
       </label>
       <element-citation id="sbref0077" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Abiona
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
        </article-title>
        <source>
         Science
        </source>
        <volume>
         367
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1260
        </fpage>
        <lpage>
         1263
        </lpage>
        <pub-id pub-id-type="pmid">
         32075877
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0078">
       <label>
        78
       </label>
       <element-citation id="sbref0078" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mair-Jenkins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Saavedra-Campos
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cleary
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Khaw
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         211
        </volume>
        <year>
         2015
        </year>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         25030060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0079">
       <label>
        79
       </label>
       <element-citation id="sbref0079" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Griensven
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Semple
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gallian
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Baize
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of convalescent plasma for Ebola virus disease in Guinea
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         374
        </volume>
        <year>
         2016
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         26735992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        80
       </label>
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         270
        </fpage>
        <lpage>
         273
        </lpage>
        <pub-id pub-id-type="pmid">
         32015507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0081">
       <label>
        81
       </label>
       <element-citation id="sbref0081" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV–a target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <volume>
         7
        </volume>
        <year>
         2009
        </year>
        <fpage>
         226
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0082">
       <label>
        82
       </label>
       <element-citation id="sbref0082" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnandji
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huttner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zinser
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Njuguna
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Dahlke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandes
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phase 1 Trials of rVSV Ebola vaccine in Africa and Europe
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         374
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1647
        </fpage>
        <lpage>
         1660
        </lpage>
        <pub-id pub-id-type="pmid">
         25830326
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0083">
       <label>
        83
       </label>
       <element-citation id="sbref0083" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in the detection of respiratory virus infection in humans
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         408
        </fpage>
        <lpage>
         417
        </lpage>
        <pub-id pub-id-type="pmid">
         31944312
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0084">
       <label>
        84
       </label>
       <element-citation id="sbref0084" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jeggo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reservoirs and vectors of emerging viruses
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        <volume>
         3
        </volume>
        <year>
         2013
        </year>
        <fpage>
         170
        </fpage>
        <lpage>
         179
        </lpage>
        <pub-id pub-id-type="pmid">
         23491947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        85
       </label>
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Todt
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pfaender
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Steinmann
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         104
        </volume>
        <year>
         2020
        </year>
        <fpage>
         246
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         32035997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0086">
       <label>
        86
       </label>
       <element-citation id="sbref0086" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0087">
       <label>
        87
       </label>
       <element-citation id="sbref0087" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         809
        </fpage>
        <lpage>
         815
        </lpage>
        <pub-id pub-id-type="pmid">
         32151335
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0088">
       <label>
        88
       </label>
       <element-citation id="sbref0088" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting pregnant women: Lessons from SARS, MERS, and other human Coronavirus infections
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0089">
       <label>
        89
       </label>
       <element-citation id="sbref0089" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         368
        </volume>
        <year>
         2020
        </year>
        <fpage>
         m606
        </fpage>
        <pub-id pub-id-type="pmid">
         32075786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        90
       </label>
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathological findings of COVID-19 associated with acute respiratory distress syndrome
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0091">
       <label>
        91
       </label>
       <element-citation id="sbref0091" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
        </article-title>
        <source>
         Front Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0092">
       <label>
        92
       </label>
       <element-citation id="sbref0092" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0093">
       <label>
        93
       </label>
       <element-citation id="sbref0093" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical trial analysis of 2019-nCoV therapy registered in China
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0001">
      <title>
       Declarations
      </title>
      <p>
       <bold>
        Funding:
       </bold>
       This work was supported by the Professional Development Research Project of the National Chinese Medicine Clinical Research Base of the
       <funding-source id="gs00001">
        State Administration of Traditional Chinese Medicine
       </funding-source>
       (No. JDZX2015295) and the
       <funding-source id="gs00002">
        National Natural Science Foundation of China
       </funding-source>
       (No. 81701962).
      </p>
      <p>
       <bold>
        Competing Interests:
       </bold>
       The authors declare no competing interests.
      </p>
      <p>
       <bold>
        Ethical Approval:
       </bold>
       Not required
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Lancet Public Health
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Lancet Public Health
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Lancet. Public Health
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2468-2667
      </issn>
      <publisher>
       <publisher-name>
        The Authors. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32220655
      </article-id>
      <article-id pub-id-type="pmc">
       7158905
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2468-2667(20)30073-6
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S2468-2667(20)30073-6
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Prem
         </surname>
         <given-names>
          Kiesha
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <email>
         kiesha.prem@lshtm.ac.uk
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="fn" rid="fn1">
         *
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Yang
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="fn" rid="fn1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Russell
         </surname>
         <given-names>
          Timothy W
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Kucharski
         </surname>
         <given-names>
          Adam J
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au50">
        <name>
         <surname>
          Eggo
         </surname>
         <given-names>
          Rosalind M
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au60">
        <name>
         <surname>
          Davies
         </surname>
         <given-names>
          Nicholas
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <collab>
         Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group
         <contrib-group>
          <contrib contrib-type="author" id="au70">
           <name>
            <surname>
             Flasche
            </surname>
            <given-names>
             Stefan
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au80">
           <name>
            <surname>
             Clifford
            </surname>
            <given-names>
             Samuel
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au90">
           <name>
            <surname>
             Pearson
            </surname>
            <given-names>
             Carl A B
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au100">
           <name>
            <surname>
             Munday
            </surname>
            <given-names>
             James D
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au110">
           <name>
            <surname>
             Abbott
            </surname>
            <given-names>
             Sam
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au120">
           <name>
            <surname>
             Gibbs
            </surname>
            <given-names>
             Hamish
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au130">
           <name>
            <surname>
             Rosello
            </surname>
            <given-names>
             Alicia
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au140">
           <name>
            <surname>
             Quilty
            </surname>
            <given-names>
             Billy J
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au150">
           <name>
            <surname>
             Jombart
            </surname>
            <given-names>
             Thibaut
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au160">
           <name>
            <surname>
             Sun
            </surname>
            <given-names>
             Fiona
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au170">
           <name>
            <surname>
             Diamond
            </surname>
            <given-names>
             Charlie
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au180">
           <name>
            <surname>
             Gimma
            </surname>
            <given-names>
             Amy
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au190">
           <name>
            <surname>
             van Zandvoort
            </surname>
            <given-names>
             Kevin
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au200">
           <name>
            <surname>
             Funk
            </surname>
            <given-names>
             Sebastian
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au210">
           <name>
            <surname>
             Jarvis
            </surname>
            <given-names>
             Christopher I
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au220">
           <name>
            <surname>
             Edmunds
            </surname>
            <given-names>
             W John
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au230">
           <name>
            <surname>
             Bosse
            </surname>
            <given-names>
             Nikos I
            </given-names>
           </name>
          </contrib>
          <contrib contrib-type="author" id="au240">
           <name>
            <surname>
             Hellewell
            </surname>
            <given-names>
             Joel
            </given-names>
           </name>
          </contrib>
         </contrib-group>
        </collab>
        <xref ref-type="fn" rid="fn2">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au250">
        <name>
         <surname>
          Jit
         </surname>
         <given-names>
          Mark
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au260">
        <name>
         <surname>
          Klepac
         </surname>
         <given-names>
          Petra
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene &amp; Tropical Medicine, London, UK
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Correspondence to: Dr Kiesha Prem, Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene &amp; Tropical Medicine, London WC1E 7HT, UK
        <email>
         kiesha.prem@lshtm.ac.uk
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         *
        </label>
        <p id="cenpara20">
         Contributed equally
        </p>
       </fn>
       <fn id="fn2">
        <label>
         †
        </label>
        <p id="cenpara30">
         Members are listed at the end of the Article
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        25
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <permissions>
       <copyright-statement>
        © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <related-article ext-link-type="doi" id="d32e668" related-article-type="article-reference" xlink:href="10.1016/S2468-2667(20)30072-4">
      </related-article>
      <abstract id="ceab10">
       <title>
        Summary
       </title>
       <sec>
        <title>
         Background
        </title>
        <p>
         In December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, emerged in Wuhan, China. Since then, the city of Wuhan has taken unprecedented measures in response to the outbreak, including extended school and workplace closures. We aimed to estimate the effects of physical distancing measures on the progression of the COVID-19 epidemic, hoping to provide some insights for the rest of the world.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         To examine how changes in population mixing have affected outbreak progression in Wuhan, we used synthetic location-specific contact patterns in Wuhan and adapted these in the presence of school closures, extended workplace closures, and a reduction in mixing in the general community. Using these matrices and the latest estimates of the epidemiological parameters of the Wuhan outbreak, we simulated the ongoing trajectory of an outbreak in Wuhan using an age-structured susceptible-exposed-infected-removed (SEIR) model for several physical distancing measures. We fitted the latest estimates of epidemic parameters from a transmission model to data on local and internationally exported cases from Wuhan in an age-structured epidemic framework and investigated the age distribution of cases. We also simulated lifting of the control measures by allowing people to return to work in a phased-in way and looked at the effects of returning to work at different stages of the underlying outbreak (at the beginning of March or April).
        </p>
       </sec>
       <sec>
        <title>
         Findings
        </title>
        <p>
         Our projections show that physical distancing measures were most effective if the staggered return to work was at the beginning of April; this reduced the median number of infections by more than 92% (IQR 66–97) and 24% (13–90) in mid-2020 and end-2020, respectively. There are benefits to sustaining these measures until April in terms of delaying and reducing the height of the peak, median epidemic size at end-2020, and affording health-care systems more time to expand and respond. However, the modelled effects of physical distancing measures vary by the duration of infectiousness and the role school children have in the epidemic.
        </p>
       </sec>
       <sec>
        <title>
         Interpretation
        </title>
        <p>
         Restrictions on activities in Wuhan, if maintained until April, would probably help to delay the epidemic peak. Our projections suggest that premature and sudden lifting of interventions could lead to an earlier secondary peak, which could be flattened by relaxing the interventions gradually. However, there are limitations to our analysis, including large uncertainties around estimates of
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         and the duration of infectiousness.
        </p>
       </sec>
       <sec>
        <title>
         Funding
        </title>
        <p>
         Bill &amp; Melinda Gates Foundation, National Institute for Health Research, Wellcome Trust, and Health Data Research UK.
        </p>
       </sec>
      </abstract>
     </article-meta>
    </front>
    <sec id="cesec10">
     <title>
      Introduction
     </title>
     <p id="para10">
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, emerged in the city of Wuhan, Hubei, China, in early December, 2019.
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      Since then, the local and national governments have taken unprecedented measures in response to the coronavirus disease 2019 (COVID-19) outbreak caused by SARS-CoV-2.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      Exit screening of passengers was shortly followed by travel restrictions in Wuhan on Jan 23, 2020, halting all means of unauthorised travel into and out of the city. Similar control measures were extended to the entire province of Hubei by Jan 26, 2020.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      Non-pharmaceutical physical distancing interventions, such as extended school closures and workplace distancing, were introduced to reduce the impact of the COVID-19 outbreak in Wuhan.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      Within the city, schools remained closed, Lunar New Year holidays were extended so that people stayed away from their workplaces, and the local government promoted physical distancing and encouraged residents to avoid crowded places. These measures greatly changed age-specific mixing patterns within the population in previous outbreak response efforts for other respiratory infectious diseases.
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      Although travel restrictions undoubtedly had a role in reducing exportations of infections outside Wuhan and delayed the onset of outbreaks in other regions,
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      changes in mixing patterns affected the trajectory of the outbreak within Wuhan itself. To estimate the effects of physical distancing measures on the progression of the COVID-19 epidemic, we look at Wuhan, hoping to provide some insights for the rest of the world.
     </p>
     <p id="para20">
      <boxed-text id="cetextbox10">
       <caption>
        <title>
         Research in context
        </title>
       </caption>
       <p id="para30">
        <bold>
         Evidence before this study
        </bold>
       </p>
       <p id="para40">
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China in late 2019. In mid-January, 2020, schools and workplaces closed as part of the Lunar New Year holidays. These closures were then extended to prevent SARS-CoV-2 spread. The intended effect of such physical distancing measures was to reduce person-to-person contact, which spreads infectious diseases. Epidemic parameters, such as time-dependent reproduction numbers governing SARS-CoV-2 transmission in Wuhan, have been estimated based on local and internationally exported cases. The frequency of contacts in different age groups and locations (schools, workplaces, households, and others) in China has also been previously estimated. We searched PubMed and medRxiv for studies published in English up to March 7, 2020, with the terms “coronavirus AND (school OR work) AND (Wuhan OR Hubei)” and identified 108 and 130 results, respectively. However, to our knowledge, no published article has reported use of location-specific transmission models that consider the impacts of school or workplace closures to study the spread of SARS-CoV-2 in Wuhan.
       </p>
       <p id="para50">
        <bold>
         Added value of this study
        </bold>
       </p>
       <p id="para60">
        We built an age-specific and location-specific transmission model to assess progression of the Wuhan outbreak under different scenarios of school and workplace closure. We found that changes to contact patterns are likely to have substantially delayed the epidemic peak and reduced the number of coronavirus disease 2019 (COVID-19) cases in Wuhan. If these restrictions are lifted in March, 2020, a second peak of cases might occur in late August, 2020. Such a peak could be delayed by 2 months if the restrictions were relaxed a month later, in April, 2020.
       </p>
       <p id="para70">
        <bold>
         Implications of all the available evidence
        </bold>
       </p>
       <p id="para80">
        The measures put in place to reduce contacts in school and work are helping to control the COVID-19 outbreak by affording health-care systems time to expand and respond. Authorities need to carefully consider epidemiological and modelling evidence before lifting these measures to mitigate the impact of a second peak in cases.
       </p>
      </boxed-text>
     </p>
     <p id="para90">
      Person-to-person transmission is mostly driven by who interacts with whom,
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      which can vary by age and location of the contact (ie, school, work, home, and community). Under the context of a large-scale ongoing outbreak, contact patterns would drastically shift from their baseline conditions. In the COVID-19 outbreak in Wuhan, physical distancing measures, including but not limited to school and workplace closures and health promotions that encourage the general public to avoid crowded places, are designed to drastically shift social mixing patterns and are often used in epidemic settings.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      Although contact patterns can be inferred from reported social contact data that include information on which setting the contact took place in, such studies are often focused on high-income countries,
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      or particular high-density areas.
      <xref ref-type="bibr" rid="bib12">
       <sup>
        12
       </sup>
      </xref>
      This limitation can be addressed by quantifying contact patterns in the home, school, work, and other locations across a range of countries based on available information from household-level data and local population demographic structures.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
     </p>
     <p id="para100">
      To examine how these changes in population mixing have affected the outbreak progression, we used synthetic location-specific contact patterns in Wuhan and adapted these in the presence of school closures, extended workplace closures, and reduction in mixing in the general community. Using these matrices and the latest estimates of the epidemiological parameters of the Wuhan outbreak,
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      we simulated the ongoing trajectory of an outbreak in Wuhan using an age-structured susceptible-exposed-infected-removed (SEIR) model
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="bib18">
       18
      </xref>
      for several physical distancing measures.
     </p>
    </sec>
    <sec id="cesec20">
     <title>
      Methods
     </title>
     <sec id="cesec30">
      <title>
       SEIR model
      </title>
      <p id="para110">
       We simulated the outbreak in Wuhan using a deterministic stage-structured SEIR model over a 1 year period, during which the modelled outbreak peters out. An implication of this approach is that all demographic changes in the population (ie, births, deaths, and ageing) are ignored.
      </p>
      <p id="para120">
       We divided the population according to the infection status into susceptible (S), exposed (E), infected (I), and removed (R) individuals, and according to age into 5-year bands until age 70 years and a single category aged 75 and older (resulting in 16 age categories). Susceptible individuals might acquire the infection at a given rate when they come in contact with an infectious person and enter the exposed disease state before they become infectious and later either recover or die. We assumed Wuhan to be a closed system with a constant population size of 11 million (ie, S + E + I + R=11 million) throughout the course of this epidemic. We used the SEIR model presented in
       <xref ref-type="fig" rid="fig1">
        figure 1
       </xref>
       . The age-specific mixing patterns of individuals in age group
       <italic>
        i
       </italic>
       alter their likelihood of being exposed to the virus given a certain number of infectious people in the population. Additionally, we incorporated contributions of asymptomatic and subclinical cases; however, the question of whether such individuals are able to transmit infection remains unresolved at the time of writing, although evidence suggests that they are likely to.
       <xref ref-type="bibr" rid="bib19">
        <sup>
         19
        </sup>
       </xref>
       We also considered a scenario in which we assumed that younger individuals are more likely to be asymptomatic (or subclinical) and less infectious than older individuals.
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       <fig id="fig1">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Age-structured SEIR model and details of the modelled physical distancing interventions
         </p>
         <p>
          According to infection status, we divided the population into susceptible (S), exposed (E), infected (I), and removed (R) individuals. An infected individual in an age group can be clinical (I
          <sup>
           c
          </sup>
          ) or subclinical (I
          <sup>
           sc
          </sup>
          ), and ρ
          <sub>
           i
          </sub>
          refers to the probability that an individual is symptomatic or clinical. The age-specific mixing patterns of individuals in age group
          <italic>
           i
          </italic>
          , C
          <sub>
           i,j
          </sub>
          , alter their likelihood of being exposed to the virus given a certain number of infected individuals in the population. Younger individuals are more likely to be asymptomatic and less infectious, ie, subclinical. When ρ
          <sub>
           i
          </sub>
          =0 for all
          <italic>
           i
          </italic>
          , the model simplifies to a standard SEIR. The force of infection φ
          <sub>
           i,t
          </sub>
          is given by (βΣ
          <sub>
           j
          </sub>
          C
          <sub>
           i,j
          </sub>
          <italic>
           I
          </italic>
          <sup>
           C
          </sup>
          <sub>
           j,t
          </sub>
          +αβΣ
          <sub>
           j
          </sub>
          C
          <sub>
           i,j
          </sub>
          <italic>
           I
          </italic>
          <sup>
           SC
          </sup>
          <sub>
           j,t
          </sub>
          , where β is the transmission rate and α is the proportion of transmission that resulted from a subclinical individual. SEIR= susceptible-exposed-infected-removed.
         </p>
        </caption>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para130">
       For a given age group
       <italic>
        i
       </italic>
       , epidemic transitions can be described by
      </p>
      <p id="para140">
       <disp-formula id="formula10">
        <mml:math altimg="si1.gif" id="M1">
         <mml:mrow>
          <mml:msub>
           <mml:mi>
            S
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           =
          </mml:mo>
          <mml:msub>
           <mml:mi>
            S
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           -
          </mml:mo>
          <mml:mi>
           β
          </mml:mi>
          <mml:msub>
           <mml:mi>
            S
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
          </mml:msub>
          <mml:munderover>
           <mml:mo>
            ∑
           </mml:mo>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             =
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mi>
            n
           </mml:mi>
          </mml:munderover>
          <mml:mrow>
           <mml:msub>
            <mml:mi>
             C
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              j
             </mml:mi>
            </mml:mrow>
           </mml:msub>
           <mml:msubsup>
            <mml:mi>
             I
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              j
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
            <mml:mi>
             c
            </mml:mi>
           </mml:msubsup>
           <mml:mo>
            -
           </mml:mo>
           <mml:mi>
            α
           </mml:mi>
           <mml:msub>
            <mml:mi>
             β
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
           </mml:msub>
          </mml:mrow>
          <mml:munderover>
           <mml:mo>
            ∑
           </mml:mo>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             =
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mi>
            n
           </mml:mi>
          </mml:munderover>
          <mml:mrow>
           <mml:msub>
            <mml:mi>
             C
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              j
             </mml:mi>
            </mml:mrow>
           </mml:msub>
           <mml:msubsup>
            <mml:mi>
             I
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              j
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
            <mml:mrow>
             <mml:mi>
              s
             </mml:mi>
             <mml:mi>
              c
             </mml:mi>
            </mml:mrow>
           </mml:msubsup>
          </mml:mrow>
         </mml:mrow>
        </mml:math>
       </disp-formula>
      </p>
      <p id="para150">
       <disp-formula id="formula20">
        <mml:math altimg="si2.gif" id="M2">
         <mml:mrow>
          <mml:msub>
           <mml:mi>
            E
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           =
          </mml:mo>
          <mml:mi>
           β
          </mml:mi>
          <mml:munderover>
           <mml:mo>
            ∑
           </mml:mo>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             =
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mi>
            n
           </mml:mi>
          </mml:munderover>
          <mml:mrow>
           <mml:msub>
            <mml:mi>
             C
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              j
             </mml:mi>
            </mml:mrow>
           </mml:msub>
           <mml:msubsup>
            <mml:mi>
             I
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              j
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
            <mml:mi>
             c
            </mml:mi>
           </mml:msubsup>
           <mml:mo>
            +
           </mml:mo>
           <mml:mi>
            α
           </mml:mi>
           <mml:msub>
            <mml:mi>
             β
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
           </mml:msub>
          </mml:mrow>
          <mml:munderover>
           <mml:mo>
            ∑
           </mml:mo>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             =
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mi>
            n
           </mml:mi>
          </mml:munderover>
          <mml:mrow>
           <mml:msub>
            <mml:mi>
             C
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              j
             </mml:mi>
            </mml:mrow>
           </mml:msub>
           <mml:msubsup>
            <mml:mi>
             I
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              j
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
            <mml:mrow>
             <mml:mi>
              s
             </mml:mi>
             <mml:mi>
              c
             </mml:mi>
            </mml:mrow>
           </mml:msubsup>
           <mml:mo>
            -
           </mml:mo>
           <mml:mo stretchy="false">
            (
           </mml:mo>
           <mml:mn>
            1
           </mml:mn>
           <mml:mo>
            -
           </mml:mo>
           <mml:mi>
            κ
           </mml:mi>
           <mml:mo stretchy="false">
            )
           </mml:mo>
           <mml:msub>
            <mml:mi>
             E
            </mml:mi>
            <mml:mrow>
             <mml:mi>
              i
             </mml:mi>
             <mml:mo>
              ,
             </mml:mo>
             <mml:mi>
              t
             </mml:mi>
            </mml:mrow>
           </mml:msub>
          </mml:mrow>
         </mml:mrow>
        </mml:math>
       </disp-formula>
      </p>
      <p id="para160">
       <disp-formula id="formula30">
        <mml:math altimg="si3.gif" id="M3">
         <mml:mrow>
          <mml:msub>
           <mml:mi>
            I
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           =
          </mml:mo>
          <mml:msub>
           <mml:mi>
            ρ
           </mml:mi>
           <mml:mi>
            i
           </mml:mi>
          </mml:msub>
          <mml:mi>
           κ
          </mml:mi>
          <mml:msub>
           <mml:mi>
            E
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           +
          </mml:mo>
          <mml:mo stretchy="false">
           (
          </mml:mo>
          <mml:mn>
           1
          </mml:mn>
          <mml:mo>
           -
          </mml:mo>
          <mml:mi>
           γ
          </mml:mi>
          <mml:mo stretchy="false">
           )
          </mml:mo>
          <mml:msubsup>
           <mml:mi>
            I
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
           <mml:mi>
            c
           </mml:mi>
          </mml:msubsup>
         </mml:mrow>
        </mml:math>
       </disp-formula>
      </p>
      <p id="para170">
       <disp-formula id="formula40">
        <mml:math altimg="si4.gif" id="M4">
         <mml:mrow>
          <mml:msub>
           <mml:mi>
            I
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           =
          </mml:mo>
          <mml:mo stretchy="false">
           (
          </mml:mo>
          <mml:mn>
           1
          </mml:mn>
          <mml:mo>
           -
          </mml:mo>
          <mml:msub>
           <mml:mi>
            ρ
           </mml:mi>
           <mml:mi>
            i
           </mml:mi>
          </mml:msub>
          <mml:mo stretchy="false">
           )
          </mml:mo>
          <mml:mi>
           κ
          </mml:mi>
          <mml:msub>
           <mml:mi>
            E
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           +
          </mml:mo>
          <mml:mo stretchy="false">
           (
          </mml:mo>
          <mml:mn>
           1
          </mml:mn>
          <mml:mo>
           -
          </mml:mo>
          <mml:mi>
           γ
          </mml:mi>
          <mml:mo stretchy="false">
           )
          </mml:mo>
          <mml:msubsup>
           <mml:mi>
            I
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
           <mml:mrow>
            <mml:mi>
             s
            </mml:mi>
            <mml:mi>
             c
            </mml:mi>
           </mml:mrow>
          </mml:msubsup>
         </mml:mrow>
        </mml:math>
       </disp-formula>
      </p>
      <p id="para180">
       <disp-formula id="formula50">
        <mml:math altimg="si5.gif" id="M5">
         <mml:mrow>
          <mml:msub>
           <mml:mi>
            R
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           =
          </mml:mo>
          <mml:msub>
           <mml:mi>
            R
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             i
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
           </mml:mrow>
          </mml:msub>
          <mml:mo>
           +
          </mml:mo>
          <mml:mi>
           γ
          </mml:mi>
          <mml:msubsup>
           <mml:mi>
            I
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mi>
            c
           </mml:mi>
          </mml:msubsup>
          <mml:mo>
           +
          </mml:mo>
          <mml:mi>
           γ
          </mml:mi>
          <mml:msubsup>
           <mml:mi>
            I
           </mml:mi>
           <mml:mrow>
            <mml:mi>
             j
            </mml:mi>
            <mml:mo>
             ,
            </mml:mo>
            <mml:mi>
             t
            </mml:mi>
            <mml:mo>
             +
            </mml:mo>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mrow>
            <mml:mi>
             s
            </mml:mi>
            <mml:mi>
             c
            </mml:mi>
           </mml:mrow>
          </mml:msubsup>
         </mml:mrow>
        </mml:math>
       </disp-formula>
      </p>
      <p id="para190">
       Where β is the transmission rate (scaled to the right value of
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       ), C
       <sub>
        i,j
       </sub>
       describe the contacts of age group
       <italic>
        j
       </italic>
       made by age group
       <italic>
        i
       </italic>
       , κ=1-exp(–1/
       <italic>
        d
       </italic>
       <sub>
        L
       </sub>
       ) is the daily probability of an exposed individual becoming infectious (with
       <italic>
        d
       </italic>
       <sub>
        L
       </sub>
       being the average incubation period), and γ=1–exp(–1/
       <italic>
        d
       </italic>
       <sub>
        I
       </sub>
       ) is the daily probability that an infected individual recovers when the average duration of infection is
       <italic>
        d
       </italic>
       <sub>
        I
       </sub>
       . We also incorporated contributions of asymptomatic and subclinical cases, 1–ρ
       <sub>
        i
       </sub>
       denotes the probability of an infected case being asymptomatic or subclinical. We assumed that younger individuals are more likely to be asymptomatic (or subclinical) and less infectious (proportion of infectiousness compared to
       <italic>
        I
       </italic>
       <sup>
        c
       </sup>
       , α).
      </p>
      <p id="para200">
       Using parameters from the literature as presented in the
       <xref ref-type="table" rid="tbl1">
        table
       </xref>
       , we simulated the outbreak. We assumed the mean incubation period and mean infectious period to be 6·4 days
       <xref ref-type="bibr" rid="bib16">
        <sup>
         16
        </sup>
       </xref>
       and 3 days or 7 days,
       <xref ref-type="bibr" rid="bib22">
        <sup>
         22
        </sup>
       </xref>
       respectively. Each simulation started with 200 or 2000 infectious individuals
       <italic>
        I
       </italic>
       <sub>
        0
       </sub>
       ,
       <xref ref-type="bibr" rid="bib15">
        <sup>
         15
        </sup>
       </xref>
       with the rest of the population being in the susceptible state. We explored the uncertainty in the model by drawing
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       values uniformly from the 95% CI from the posterior of the
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       distribution from the semi-mechanistic model by Kucharski and colleagues (
       <xref ref-type="sec" rid="sec1">
        appendix p 2
       </xref>
       ).
       <xref ref-type="bibr" rid="bib14">
        <sup>
         14
        </sup>
       </xref>
       <table-wrap id="tbl1" position="float">
        <label>
         Table
        </label>
        <caption>
         <p>
          Parameters of the susceptible-exposed-infected-removed model
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
           </th>
           <th align="left">
            <bold>
             Values
            </bold>
           </th>
           <th align="left">
            <bold>
             References
            </bold>
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            Basic reproduction number,
            <italic>
             R
            </italic>
            <sub>
             0
            </sub>
           </td>
           <td align="left">
            2·2 (1·6–3·0)
            <xref ref-type="table-fn" rid="tbl1fn1">
             *
            </xref>
           </td>
           <td align="left">
            Kucharski et al
            <xref ref-type="bibr" rid="bib14">
             <sup>
              14
             </sup>
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Average incubation period,
            <italic>
             d
            </italic>
            <sub>
             L
            </sub>
           </td>
           <td align="left">
            6·4 days
           </td>
           <td align="left">
            Backer et al
            <xref ref-type="bibr" rid="bib16">
             <sup>
              16
             </sup>
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Average duration of infection,
            <italic>
             d
            </italic>
            <sub>
             I
            </sub>
           </td>
           <td align="left">
            3 days or 7 days
           </td>
           <td align="left">
            Woelfel et al
            <xref ref-type="bibr" rid="bib22">
             <sup>
              22
             </sup>
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Initial number of infected,
            <italic>
             I
            </italic>
            <sub>
             0
            </sub>
           </td>
           <td align="left">
            200 or 2000
           </td>
           <td align="left">
            Abbott et al
            <xref ref-type="bibr" rid="bib15">
             <sup>
              15
             </sup>
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Pr (infected case is clinical), ρ
            <sub>
             i
            </sub>
           </td>
           <td align="left">
            0 or 0·4, for
            <italic>
             i
            </italic>
            ≤4
           </td>
           <td align="left">
            Bi et al
            <xref ref-type="bibr" rid="bib20">
             <sup>
              20
             </sup>
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Pr (infected case is clinical), ρ
            <sub>
             i
            </sub>
           </td>
           <td align="left">
            0 or 0·8, for
            <italic>
             i
            </italic>
            &gt;4
           </td>
           <td align="left">
            Davies
            <xref ref-type="bibr" rid="bib21">
             <sup>
              21
             </sup>
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Pr (infection acquired from subclinical), α
           </td>
           <td align="left">
            0·25
           </td>
           <td align="left">
            Liu et al
            <xref ref-type="bibr" rid="bib19">
             <sup>
              19
             </sup>
            </xref>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tbl1fn1">
          <label>
           *
          </label>
          <p id="cenpara10">
           Data are median (IQR). Pr represents the probability of an event. The parameters
           <italic>
            d
           </italic>
           <sub>
            L
           </sub>
           and
           <italic>
            d
           </italic>
           <sub>
            I
           </sub>
           represent the mean incubation period and duration of infectiousness, respectively.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="cesec40">
      <title>
       Social mixing and interventions
      </title>
      <p id="para210">
       Social mixing patterns vary across locations, including households, workplaces, schools, and other locations. Therefore, we used the method set out by Prem and colleagues,
       <xref ref-type="bibr" rid="bib13">
        <sup>
         13
        </sup>
       </xref>
       which accounts for these differences and obtains the location-specific contact matrices (C) for different scenarios. In a normal setting, contacts made at all of these locations contribute to the overall mixing pattern in a population, so we summed contacts across the different locations to obtain our baseline contact pattern in the population before the outbreak (
       <xref ref-type="fig" rid="fig2">
        figure 2
       </xref>
       ;
       <xref ref-type="sec" rid="sec1">
        appendix pp 1–2
       </xref>
       ). In an outbreak setting, different intervention strategies are aimed at reducing social mixing in different contexts to lower the overall transmission in the population. To simulate the effects of interventions aimed at reducing social mixing, we created synthetic contact matrices for each intervention scenario from these building block matrices.
       <fig id="fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Synthetic age-specific and location-specific contact matrices for China under various physical distancing scenarios during the intense control period for China
         </p>
         <p>
          Synthetic age-specific contact patterns across all locations, at home, in the workplace, in school, and at other locations during normal circumstances (ie, under no intervention) are presented in panels A to E. Age-specific and location-specific contact matrices under the various physical distancing interventions are presented in panels F to T. Darker colour intensities indicate higher proclivity of making the age-specific contact.
         </p>
        </caption>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para220">
       We considered the following three scenarios: first scenario, theoretical: assumed no change to social mixing patterns at all location types, no school term break, and no Lunar New Year holidays; second scenario, no interventions, winter school break in Wuhan, and Lunar New Year holidays: assumed no physical distancing control measures, school-going individuals did not have any contacts at school because of school holidays from Jan 15, to Feb 10, 2020, and 10% and later 75% of workforce would be working during the holidays from Jan 25, to Jan 31, 2020, and from Feb 1, to Feb 10, 2020, respectively; and third scenario, intense control measures in Wuhan to contain the outbreak: assumed school closure and about 10% of workforce (eg, health-care personnel, police, and other essential government staff) would be working even during the control measures (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       ,
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       ). For the third scenario, we modelled the effect of the intense control measures ending at the beginning of March or April, and we allowed for a staggered return to work while the school remained closed (ie, 25% of the workforce working in weeks one and two, 50% of the workforce working in weeks three and four, and 100% of the workforce working and school resuming (
       <xref ref-type="fig" rid="fig2">
        figure 2
       </xref>
       ).
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
      </p>
      <p id="para230">
       Analyses and model building were done in R version 3.6.2.
      </p>
     </sec>
     <sec id="cesec50">
      <title>
       Role of the funding source
      </title>
      <p id="para240">
       The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
      </p>
     </sec>
    </sec>
    <sec id="cesec60">
     <title>
      Results
     </title>
     <p id="para250">
      Our simulations showed that control measures aimed at reducing social mixing in the population can be effective in reducing the magnitude and delaying the peak of the COVID-19 outbreak. For different control measures among individuals aged 55 to &lt;60 years and 10 to &lt;15 years, the standard school winter break and holidays for the Lunar New Year would have had little effect on progression of the outbreak had schools and workplaces reopened as normal (
      <xref ref-type="fig" rid="fig3">
       figure 3
      </xref>
      ).
      <fig id="fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Effects of different intervention strategies on cumulative incidence and new cases per day among individuals aged 55 to &lt;60 years (A to D) and 10 to &lt;15 years (E to H) from late 2019 to end-2020
        </p>
       </caption>
       <graphic xlink:href="gr3_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para260">
      We present the median cumulative incidence, incident cases per day, and age-specific incidence per day of 200 simulated outbreaks (
      <xref ref-type="fig" rid="fig4">
       figure 4
      </xref>
      ). Intense control measures of prolonged school closure and work holidays reduced the cumulative infections by end-2020 and peak incidence, while also delaying the peak of the outbreak (
      <xref ref-type="fig" rid="fig4">
       figure 4
      </xref>
      ). Our model suggests that the effects of these physical distancing strategies vary across age categories; the reduction in incidence is highest among school children and older individuals and lowest among working-age adults (
      <xref ref-type="fig" rid="fig4">
       figure 4
      </xref>
      ;
      <xref ref-type="fig" rid="fig5">
       figure 5
      </xref>
      ).
      <fig id="fig4">
       <label>
        Figure 4
       </label>
       <caption>
        <p>
         Effects of different physical distancing measures on cumulative incidence (A) and new cases per day (B), and age-specific incidence per day (C to G) from late 2019 to end-2020
        </p>
        <p>
         Results depicted here assume an infectious period of 7 days. Median cumulative incidence, incident cases per day, and age-specific incidence per day are represented as solid lines. Shaded areas around the coloured lines in panel A represent the IQR.
        </p>
       </caption>
       <graphic xlink:href="gr4_lrg">
       </graphic>
      </fig>
      <fig id="fig5">
       <label>
        Figure 5
       </label>
       <caption>
        <p>
         Modelled proportion of number of infections averted by end-2020 by age for different physical distancing measures, assuming the duration of infectiousness to be 3 days (A, B) or 7 days (C, D)
        </p>
        <p>
         The additional proportions of cases averted (compared with no intervention) are presented across age and by the different physical distancing measures.
        </p>
       </caption>
       <graphic xlink:href="gr5_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para270">
      Physical distancing measures were most effective if the staggered return to work was at the beginning of April; this reduced the median number of infections by more than 92% (IQR 66–97) and 24% (13–90) in mid-2020 and end-2020, respectively (
      <xref ref-type="fig" rid="fig5">
       figure 5
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 3
      </xref>
      ), should the disease have a longer duration of infectiousness, and reduced the magnitude and delayed peak incidence across all age categories (
      <xref ref-type="fig" rid="fig4">
       figure 4
      </xref>
      ), which could have had further beneficial impact by relieving the pressure on the health-care system in the immediate few months after the outbreak began. Uncertainty in
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      values has a large effect on the timing of the epidemic peak and final size of the outbreak (
      <xref ref-type="fig" rid="fig4">
       figure 4
      </xref>
      ).
     </p>
     <p id="para280">
      The modelled effects of the intense control measures of prolonged school closure and work holidays vary by the duration of infectiousness. If the disease had a short infectious period (3 days), then our model suggests that relaxing physical distancing interventions in March (
      <xref ref-type="fig" rid="fig5">
       figure 5
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 4
      </xref>
      ) could avert around 30% of cases in school children and older individuals. Fewer cases could be averted by end-2020 should the disease have a longer duration of infectiousness (eg, 7 days;
      <xref ref-type="fig" rid="fig5">
       figure 5
      </xref>
      ); physical distancing interventions would need to be relaxed a month later (in April) to observe a larger effect. If children were less infectious, lifting physical distancing interventions in April instead of March could engender additional health benefits (
      <xref ref-type="fig" rid="fig5">
       figure 5
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix pp 5–6
      </xref>
      ).
     </p>
    </sec>
    <sec id="cesec70">
     <title>
      Discussion
     </title>
     <p id="para290">
      COVID-19, a contact-transmissible infectious disease, is thought to spread through a population via direct contact between individuals.
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      Outbreak control measures aimed at reducing the amount of mixing in the population have the potential to delay the peak and reduce the final size of the epidemic. To evaluate the effect of location-specific physical distancing measures—such as extended school closures and interventions in workplaces—on the timing and magnitude of the peak and the final size of the epidemic, we accounted for these heterogeneities in contact networks in our model. We simulated outbreaks and modelled the interventions by scaling down the appropriate component of the contact mixing matrices for China.
     </p>
     <p id="para300">
      Mathematical models can help us understand how SARS-CoV-2 could spread across the population and inform control measures that might mitigate future transmission.
      <xref ref-type="bibr" rid="bib25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      We simulated the trajectory of the ongoing outbreak of COVID-19 in Wuhan using an age-structured SEIR model.
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="bib18">
       18
      </xref>
      As individuals' mixing patterns are non-random, they influence the transmission dynamics of the disease.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      Models that assess the effectiveness of physical distancing interventions, such as school closure, need to account for social structures and heterogeneities in mixing of individuals.
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="bib29">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="bib31">
       31
      </xref>
      In our model, we incorporated changes to age-specific and location-specific social mixing patterns to estimate the effects of location-specific physical distancing interventions in curtailing the spread of the outbreak. The measures put in place to reduce contacts at schools and workplaces are helping control the outbreak by providing the health-care system with the time and opportunity to expand and respond. Consequently, if these restrictions are lifted prematurely, while there are still enough susceptible people to keep the
      <italic>
       R
      </italic>
      <sub>
       e
      </sub>
      &gt;1 once contacts increase, the number of infections would increase. Realistically, interventions are lifted slowly, partly as an attempt to avoid a sharp increase in infection, but also for logistical and practical reasons. Therefore, we simulated lifting the interventions in a staggered fashion.
     </p>
     <p id="para310">
      Evidence of the effects of various physical distancing measures on containing the outbreak are scarce and little is known about the behavioural changes of individuals over time, either during an outbreak or otherwise. Therefore, to model the effects of the physical distancing measures implemented in Wuhan, we assumed the effect that certain types of physical distancing have on age-specific and location-specific contact rates.
     </p>
     <p id="para320">
      Much is unknown about the true age-specific susceptibility and transmissibility of COVID-19. Therefore, we assumed no heterogeneity in susceptibility between children. Furthermore, for simplicity, we assumed that children and adults were equally transmissible, other than the differences in their contact rates (subclinical children could be more infectious than subclinical adults;
      <xref ref-type="sec" rid="sec1">
       appendix pp 5–6
      </xref>
      ). Similar to an influenza-like pathogen, our model suggests that interactions between school children and older individuals in the population have important public health implications, as children might have high infection rates but the elderly are more vulnerable to severe infections, with potentially fatal outcomes.
      <xref ref-type="bibr" rid="bib32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       33
      </xref>
      However, unlike models built for pandemic or seasonal flu, we accounted for the lack of population immunity to SARS-CoV-2.
     </p>
     <p id="para330">
      This study describes a mathematical model that quantifies the potential impacts of physical distancing policies, relying on Wuhan as a case study. Epidemiological investigations during the WHO-China Joint Mission on COVID-19 found many infections clustered around households.
      <xref ref-type="bibr" rid="bib34">
       <sup>
        34
       </sup>
      </xref>
      Extreme physical distancing measures, including school closures, workplace closures, and avoidance of any public gatherings all at once can push the transmission to households, leading to increased clustering of household cases.
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      As households are not explicitly included in the model, we did not consider heterogeneity and clustering of household transmission. Distinguishing between repeated and new contacts is important for disease propagation in contact network models;
      <xref ref-type="bibr" rid="bib35">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="bib36">
       36
      </xref>
      more sophisticated methods that account for temporal presence within the household
      <xref ref-type="bibr" rid="bib37">
       <sup>
        37
       </sup>
      </xref>
      would be needed to characterise higher degrees of contact. Looking at limitations of our study, our compartmental model does not capture individual-level heterogeneity in contacts, which could be important in super-spreading events, particularly early in an epidemic. Combined with nosocomial infections, the risk of COVID-19 infection is potentially amplified with close contact between confirmed cases and health-care workers. However, the compartmental model we present is not equipped to explicitly consider transmission within health-care institutions and households. More complex models, such as individual-based models with familial and health-care structures, should be explored. Nosocomial infection risk among health-care workers and patients has been identified as a research gap to be prioritised in the next few months by WHO.
     </p>
     <p id="para340">
      A key parameter is the basic reproduction number (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      ), which determines how fast SARS-CoV-2 can spread through the population during the early stages of the outbreak. This is an inherently difficult parameter to estimate, since the true number of cases that can transmit infection at a given time is unknown (reported cases are likely to be just a small fraction of true cases) and probably varies over time (because of different interventions being introduced and population behaviour changing in response to the epidemic). In our analysis, we used an existing model that inferred time-dependent
      <italic>
       R
      </italic>
      <sub>
       e
      </sub>
      based on the growth of reported cases in Wuhan and the number of exported cases outside China originating from Wuhan.
      <xref ref-type="bibr" rid="bib14">
       <sup>
        14
       </sup>
      </xref>
      We acknowledge that the underlying reproduction number in Wuhan could have been larger than that used in our study. However, other studies of early SARS-CoV-2 transmission dynamics in Wuhan, using different methods, arrived at the same estimate with similar ranges.
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
     </p>
     <p id="para350">
      Although the precise effects of interventions might vary by country and different estimates of key parameters, our model highlights the usefulness of physical distancing interventions and the need to carefully calibrate their lifting to avoid second and subsequent waves of a COVID-19 epidemic. Areas of China outside Hubei and other east or southeast Asian regions have managed to avert a major outbreak locally and delayed the peak of the epidemic, without resorting to Hubei's extreme measures.
      <xref ref-type="bibr" rid="bib38">
       <sup>
        38
       </sup>
      </xref>
      Policy makers are advised to reapportion their resources to focus on mitigating the effects of potentially soon-to-be overwhelmed health systems.
      <xref ref-type="bibr" rid="bib39">
       <sup>
        39
       </sup>
      </xref>
     </p>
     <p id="para360">
      Non-physical distancing factors play a part in mitigating potential spikes in cases, especially when physical distancing measures are relaxed. The effects of seasonality on SARS-CoV-2 are difficult to predict without long time series; supporting evidence for the link between climate and COVID-19 has been largely anecdotal and based on spread in different settings and such analyses are subject to confounding.
      <xref ref-type="bibr" rid="bib40">
       40
      </xref>
      ,
      <xref ref-type="bibr" rid="bib41">
       41
      </xref>
      Consequently, we have not incorporated climatic factors into our mathematical model. Future research should be directed towards understanding the potential seasonality of COVID-19 and the climatic factors that could affect its transmission dynamics. Other innovations, such as the rapid expansion of hospital capacity and testing capabilities, would shorten diagnostic and health system delays,
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       39
      </xref>
      thus reducing effective interactions between infectious and susceptible individuals and interrupting transmission. Effective vaccines
      <xref ref-type="bibr" rid="bib42">
       <sup>
        42
       </sup>
      </xref>
      and antivirals
      <xref ref-type="bibr" rid="bib43">
       <sup>
        43
       </sup>
      </xref>
      that are being developed could counteract this global public health threat. The extent to which these strategies can detect cases earlier and isolate infectious individuals from the susceptible pool or protect against infection is less well-understood, hence necessitating further evaluation.
     </p>
     <p id="para370">
      Combined physical distancing and travel restrictions have aided in lowering the transmission of COVID-19 over the course of the ongoing outbreak in Wuhan.
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      Evidence for this drop in transmission can be gleaned from the time-varying estimates of the reproduction number
      <xref ref-type="bibr" rid="bib14">
       <sup>
        14
       </sup>
      </xref>
      or observing that the turnover of the epidemic has occurred far before depletion of susceptible individuals, indicating the effects of the implemented measures. It is difficult to quantify whether physical distancing alone is responsible for the drop in cases, especially during the ongoing epidemic. Therefore, we took a broad view of this question, making assumptions about the results of certain forms of physical distancing and measuring the effects somewhat qualitatively. However, to some extent, physical distancing has resulted in both a shorter epidemic and a lower peak. Given what is known about the transmissibility and (the relatively long 5–6 days) incubation period of COVID-19,
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      the efficacy of physical distancing in reducing these important attributes of any epidemic are no surprise.
     </p>
     <p id="para380">
      In the analysis, we have varied the basic reproduction number, the average duration of infections, the initial proportion of cases infected, the susceptibility of children, and the role of younger individuals in transmission dynamics of COVID-19.
     </p>
     <p id="para390">
      In conclusion, non-pharmaceutical interventions based on sustained physical distancing have a strong potential to reduce the magnitude of the epidemic peak of COVID-19 and lead to a smaller number of overall cases. Lowering and flattening of the epidemic peak is particularly important, as this reduces the acute pressure on the health-care system. Premature and sudden lifting of interventions could lead to an earlier secondary peak, which could be flattened by relaxing the interventions gradually.
     </p>
    </sec>
    <sec id="cesec80" sec-type="data-availability">
     <title>
      Data sharing
     </title>
     <p>
      Access to computer code is provided in the
      <xref ref-type="sec" rid="sec1">
       appendix (p 1)
      </xref>
      . Data used in this study are freely available to the scientific community.
     </p>
    </sec>
    <back>
     <ref-list id="bibl10">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Jan 29.
        </comment>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         published Feb 20.
        </comment>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001017
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bärnighausen
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 control in China during mass population movements at New Year
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         764
        </fpage>
        <lpage>
         766
        </lpage>
        <pub-id pub-id-type="pmid">
         32105609
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings—social distancing measures
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Feb 6.
        </comment>
        <pub-id pub-id-type="doi">
         10.3201/eid2605.190995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hens
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Ayele
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Goeyvaerts
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight European countries
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         9
        </volume>
        <year>
         2009
        </year>
        <fpage>
         187
        </fpage>
        <pub-id pub-id-type="pmid">
         19943919
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zviedrite
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Uzicanin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review
        </article-title>
        <source>
         BMC Public Health
        </source>
        <volume>
         18
        </volume>
        <year>
         2018
        </year>
        <fpage>
         518
        </fpage>
        <pub-id pub-id-type="pmid">
         29669545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quilty
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Clifford
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Flasche
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Eggo
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV)
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         2000080
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sbref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early evaluation of the Wuhan City travel restrictions in response to the 2019 novel coronavirus outbreak
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Jan 30.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.01.30.20019844
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sbref90" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         2000058
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sbref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JFW
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sbref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mossong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hens
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jit
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Social contacts and mixing patterns relevant to the spread of infectious diseases
        </article-title>
        <source>
         PLoS Med
        </source>
        <volume>
         5
        </volume>
        <year>
         2008
        </year>
        <fpage>
         e74
        </fpage>
        <pub-id pub-id-type="pmid">
         18366252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sbref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Klepac
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patterns of human social contact and contact with animals in Shanghai, China
        </article-title>
        <source>
         Sci Rep
        </source>
        <volume>
         9
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         15141
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sbref130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prem
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Jit
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Projecting social contact matrices in 152 countries using contact surveys and demographic data
        </article-title>
        <source>
         PLOS Comput Biol
        </source>
        <volume>
         13
        </volume>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         e1005697
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sbref140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <name>
          <surname>
           Diamond
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early dynamics of transmission and control of COVID-19: a mathematical modelling study
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 11.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(20)30144-4
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abbott
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hellewell
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Munday
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Funk
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The transmissibility of novel Coronavirus in the early stages of the 2019–20 outbreak in Wuhan: exploring initial point-source exposure sizes and durations using scenario analysis
        </article-title>
        <source>
         Wellcome Open Res
        </source>
        <volume>
         5
        </volume>
        <year>
         2020
        </year>
        <fpage>
         17
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Klinkenberg
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         2000062
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sbref170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klepac
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Pomeroy
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <name>
          <surname>
           Bjørnstad
          </surname>
          <given-names>
           ON
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           ADME
          </given-names>
         </name>
         <name>
          <surname>
           Rijks
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stage-structured transmission of phocine distemper virus in the Dutch 2002 outbreak
        </article-title>
        <source>
         Proc Biol Sci
        </source>
        <volume>
         276
        </volume>
        <year>
         2009
        </year>
        <fpage>
         2469
        </fpage>
        <lpage>
         2476
        </lpage>
        <pub-id pub-id-type="pmid">
         19364743
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sbref180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klepac
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Caswell
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         The stage-structured epidemic: linking disease and demography with a multi-state matrix approach model
        </article-title>
        <source>
         Theor Ecol
        </source>
        <volume>
         4
        </volume>
        <year>
         2011
        </year>
        <fpage>
         301
        </fpage>
        <lpage>
         319
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sbref190" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Funk
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Flasche
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The contribution of pre-symptomatic transmission to the COVID-19 outbreak. Centre for Mathematical Modelling of Infectious Disease Repository
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs60" xlink:href="https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html">
         https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sbref200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1286 of their close contacts
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 3.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.03.03.20028423
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sbref210" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         nicholasdavies/ncov-age-dist
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs80" xlink:href="https://github.com/nicholasdavies/ncov-age-dist">
         https://github.com/nicholasdavies/ncov-age-dist
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woelfel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Guggemos
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 5.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.03.05.20030502
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sbref230" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AQ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zhezhou City strategy for resuming work and production among business enterprises
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs100" xlink:href="http://m.xinhuanet.com/ha/2020-02/13/c_1125567288.htm">
         http://m.xinhuanet.com/ha/2020-02/13/c_1125567288.htm
        </ext-link>
        <year>
         Feb 13, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sbref240" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Sohu News
         </collab>
        </person-group>
        <article-title>
         Academic calendar for elementary and middle school in Wuhan
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs110" xlink:href="https://www.sohu.com/a/325806609_500181">
         https://www.sohu.com/a/325806609_500181
        </ext-link>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sbref250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1961
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12766206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sbref260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Keeling
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Planning for smallpox outbreaks
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         425
        </volume>
        <year>
         2003
        </year>
        <fpage>
         681
        </fpage>
        <lpage>
         685
        </lpage>
        <pub-id pub-id-type="pmid">
         14562094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sbref270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Teunis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kretzschmar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        <volume>
         164
        </volume>
        <year>
         2006
        </year>
        <fpage>
         936
        </fpage>
        <lpage>
         944
        </lpage>
        <pub-id pub-id-type="pmid">
         16968863
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sbref280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Keeling
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disease evolution on networks: the role of contact structure
        </article-title>
        <source>
         Proc Biol Sci
        </source>
        <volume>
         270
        </volume>
        <year>
         2003
        </year>
        <fpage>
         699
        </fpage>
        <lpage>
         708
        </lpage>
        <pub-id pub-id-type="pmid">
         12713743
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sbref290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Keeling
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incorporating household structure and demography into models of endemic disease
        </article-title>
        <source>
         J R Soc Interface
        </source>
        <volume>
         16
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         20190317
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sbref300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           WJJ
          </given-names>
         </name>
         <name>
          <surname>
           Kretzschmar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Perspective: human contact patterns and the spread of airborne infectious diseases
        </article-title>
        <source>
         Trends Microbiol
        </source>
        <volume>
         7
        </volume>
        <year>
         1999
        </year>
        <fpage>
         372
        </fpage>
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="pmid">
         10470046
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sbref310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           O'Callaghan
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Nokes
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Who mixes with whom? A method to determine the contact patterns of adults that may lead to the spread of airborne infections
        </article-title>
        <source>
         Proc Biol Sci
        </source>
        <volume>
         264
        </volume>
        <year>
         1997
        </year>
        <fpage>
         949
        </fpage>
        <lpage>
         957
        </lpage>
        <pub-id pub-id-type="pmid">
         9263464
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sbref320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cate
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical manifestations and consequences of influenza
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         82
        </volume>
        <year>
         1987
        </year>
        <fpage>
         15
        </fpage>
        <lpage>
         19
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sbref330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falsey
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Walsh
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human metapneumovirus infections in young and elderly adults
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         187
        </volume>
        <year>
         2003
        </year>
        <fpage>
         785
        </fpage>
        <lpage>
         790
        </lpage>
        <pub-id pub-id-type="pmid">
         12599052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sbref340" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs120" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf">
         https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
        </ext-link>
        <year>
         16–24 Feb, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sbref350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eubank
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Guclu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modelling disease outbreaks in realistic urban social networks
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         429
        </volume>
        <year>
         2004
        </year>
        <fpage>
         180
        </fpage>
        <lpage>
         184
        </lpage>
        <pub-id pub-id-type="pmid">
         15141212
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sbref360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stehlé
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Voirin
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Barrat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Simulation of an SEIR infectious disease model on the dynamic contact network of conference attendees
        </article-title>
        <source>
         BMC Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2011
        </year>
        <fpage>
         87
        </fpage>
        <pub-id pub-id-type="pmid">
         21771290
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sbref370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Potter
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Handcock
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Longini
          </surname>
          <given-names>
           IM
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Halloran
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating within-household contact networks from egocentric data
        </article-title>
        <source>
         Ann Appl Stat
        </source>
        <volume>
         5
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1816
        </fpage>
        <lpage>
         1838
        </lpage>
        <pub-id pub-id-type="pmid">
         22427793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sbref380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
        </person-group>
        <article-title>
         They've contained the coronavirus. Here's how
        </article-title>
        <source>
         New York Times
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="interrefs130" xlink:href="https://www.nytimes.com/2020/03/13/opinion/coronavirus-best-response.html">
         https://www.nytimes.com/2020/03/13/opinion/coronavirus-best-response.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sbref390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chiew
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can we contain the COVID-19 outbreak with the same measures as for SARS?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 5.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(20)30129-8
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sbref400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of absolute humidity on transmission rates of the COVID-19 outbreak
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online February 17.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.02.12.20022467
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sbref410" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lipsitch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seasonality of SARS-CoV-2: Will COVID-19 go away on its own in warmer weather? Center for Communicable Disease Dynamics
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs160" xlink:href="https://ccdd.hsph.harvard.edu/will-covid-19-go-away-on-its-own-in-warmer-weather/">
         https://ccdd.hsph.harvard.edu/will-covid-19-go-away-on-its-own-in-warmer-weather/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sbref420" publication-type="other">
        <ext-link ext-link-type="uri" id="interrefs170" xlink:href="http://ClinicalTrials.gov">
         ClinicalTrials.gov
        </ext-link>
       </element-citation>
       <element-citation id="sbref430" publication-type="other">
        <article-title>
         Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) to prevent SARS-CoV-2 infection
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs180" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04283461">
         https://clinicaltrials.gov/ct2/show/NCT04283461
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sbref440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 9.
        </comment>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciaa237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sbref450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The psychological impact of quarantine and how to reduce it: rapid review of the evidence
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         912
        </fpage>
        <lpage>
         920
        </lpage>
        <pub-id pub-id-type="pmid">
         32112714
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sbref460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         689
        </fpage>
        <lpage>
         697
        </lpage>
        <pub-id pub-id-type="pmid">
         32014114
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="sec1" sec-type="supplementary-material">
      <title>
       Supplementary Material
      </title>
      <p id="para490">
       <supplementary-material content-type="local-data" id="ecomp10">
        <caption>
         <title>
          Supplementary appendix
         </title>
        </caption>
        <media xlink:href="mmc1.pdf">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ceack10">
      <sec>
       <title>
        Acknowledgments
       </title>
       <p>
        KP, YL, MJ, and PK were funded by the Bill &amp; Melinda Gates Foundation (INV-003174). YL and MJ were funded by the National Institute for Health Research (NIHR; 16/137/109). TWR and AJK were funded by the Wellcome Trust (206250/Z/17/Z). RME was funded by Health Data Research UK (MR/S003975/1). ND was funded by NIHR (HPRU-2012-10096). This research was partly funded by the NIHR (16/137/109) using aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. We would like to acknowledge the other members of the London School of Hygiene &amp; Tropical Medicine COVID-19 modelling group, who contributed to this work. Their funding sources are as follows: Stefan Flasche and Sam Clifford (Sir Henry Dale Fellowship 208812/Z/17/Z); Billy J Quilty, Fiona Sun, and Charlie Diamond (NIHR 16/137/109); Joel Hellewell, Sam Abbott, James D Munday, and Sebastian Funk (Wellcome Trust 210758/Z/18/Z); Amy Gimma and Christopher I Jarvis (Global Challenges Research Fund ES/P010873/1); Hamish Gibbs (Department of Health and Social Care ITCRZ 03010); Alicia Rosello (NIHR PR-OD-1017-20002); Thibaut Jombart (Research Public Health Rapid Support Team, NIHR Health Protection Research Unit Modelling Methodology); Kevin van Zandvoort (Elrha's Research for Health in Humanitarian Crises [R2HC] Programme, UK Government [Department for International Development], Wellcome Trust, and NIHR).
       </p>
      </sec>
     </ack>
     <ack>
      <title>
       Contributors
      </title>
      <p>
       PK, YL, MJ, and KP conceived the study. KP, YL, and PK designed and programmed the model, and KP made the figures. TWR, AJK, RME, and ND consulted on the analyses. All authors interpreted the results, contributed to writing the Article, and approved the final version for submission.
      </p>
     </ack>
     <ack>
      <title>
       Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group
      </title>
      <p>
       Stefan Flasche, Samuel Clifford, Carl A B Pearson, James D Munday, Sam Abbott, Hamish Gibbs, Alicia Rosello, Billy J Quilty, Thibaut Jombart, Fiona Sun, Charlie Diamond, Amy Gimma, Kevin van Zandvoort, Sebastian Funk, Christopher I Jarvis, W John Edmunds, Nikos I Bosse, Joel Hellewell
      </p>
     </ack>
     <ack>
      <title>
       Declaration of interests
      </title>
      <p>
       We declare no competing interests.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Lancet Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Lancet Infect Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Lancet. Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1473-3099
      </issn>
      <issn pub-type="epub">
       1474-4457
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32213332
      </article-id>
      <article-id pub-id-type="pmc">
       7158571
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1473-3099(20)30162-6
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S1473-3099(20)30162-6
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Koo
         </surname>
         <given-names>
          Joel R
         </given-names>
        </name>
        <degrees>
         BSc
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          Cook
         </surname>
         <given-names>
          Alex R
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <email>
         alex.richard.cook@gmail.com
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          Minah
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Yinxiaohe
         </given-names>
        </name>
        <degrees>
         MSc
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au50">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Haoyang
         </given-names>
        </name>
        <degrees>
         BSc
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au60">
        <name>
         <surname>
          Lim
         </surname>
         <given-names>
          Jue Tao
         </given-names>
        </name>
        <degrees>
         MSc
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au70">
        <name>
         <surname>
          Tam
         </surname>
         <given-names>
          Clarence
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au80">
        <name>
         <surname>
          Dickens
         </surname>
         <given-names>
          Borame L
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Saw Swee Hock School of Public Health, National University of Singapore, Singapore
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       London School of Hygiene &amp; Tropical Medicine, London, UK
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Correspondence to: Dr Alex R Cook, Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549
        <email>
         alex.richard.cook@gmail.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        23
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        23
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <related-article ext-link-type="doi" id="d32e417" related-article-type="article-reference" xlink:href="10.1016/S1473-3099(20)30190-0">
      </related-article>
      <abstract id="ceab10">
       <title>
        Summary
       </title>
       <sec>
        <title>
         Background
        </title>
        <p>
         Since the coronavirus disease 2019 outbreak began in the Chinese city of Wuhan on Dec 31, 2019, 68 imported cases and 175 locally acquired infections have been reported in Singapore. We aimed to investigate options for early intervention in Singapore should local containment (eg, preventing disease spread through contact tracing efforts) be unsuccessful.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         We adapted an influenza epidemic simulation model to estimate the likelihood of human-to-human transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a simulated Singaporean population. Using this model, we estimated the cumulative number of SARS-CoV-2 infections at 80 days, after detection of 100 cases of community transmission, under three infectivity scenarios (basic reproduction number [
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         ] of 1·5, 2·0, or 2·5) and assuming 7·5% of infections are asymptomatic. We first ran the model assuming no intervention was in place (baseline scenario), and then assessed the effect of four intervention scenarios compared with a baseline scenario on the size and progression of the outbreak for each
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         value. These scenarios included isolation measures for infected individuals and quarantining of family members (hereafter referred to as quarantine); quarantine plus school closure; quarantine plus workplace distancing; and quarantine, school closure, and workplace distancing (hereafter referred to as the combined intervention). We also did sensitivity analyses by altering the asymptomatic fraction of infections (22·7%, 30·0%, 40·0%, and 50·0%) to compare outbreak sizes under the same control measures.
        </p>
       </sec>
       <sec>
        <title>
         Findings
        </title>
        <p>
         For the baseline scenario, when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         was 1·5, the median cumulative number of infections at day 80 was 279 000 (IQR 245 000–320 000), corresponding to 7·4% (IQR 6·5–8·5) of the resident population of Singapore. The median number of infections increased with higher infectivity: 727 000 cases (670 000–776 000) when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         was 2·0, corresponding to 19·3% (17·8–20·6) of the Singaporean population, and 1 207 000 cases (1 164 000–1 249 000) when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         was 2·5, corresponding to 32% (30·9–33·1) of the Singaporean population. Compared with the baseline scenario, the combined intervention was the most effective, reducing the estimated median number of infections by 99·3% (IQR 92·6–99·9) when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         was 1·5, by 93·0% (81·5–99·7) when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         was 2·0, and by 78·2% (59·0 −94·4) when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         was 2·5. Assuming increasing asymptomatic fractions up to 50·0%, up to 277 000 infections were estimated to occur at day 80 with the combined intervention relative to 1800 for the baseline at
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         of 1·5.
        </p>
       </sec>
       <sec>
        <title>
         Interpretation
        </title>
        <p>
         Implementing the combined intervention of quarantining infected individuals and their family members, workplace distancing, and school closure once community transmission has been detected could substantially reduce the number of SARS-CoV-2 infections. We therefore recommend immediate deployment of this strategy if local secondary transmission is confirmed within Singapore. However, quarantine and workplace distancing should be prioritised over school closure because at this early stage, symptomatic children have higher withdrawal rates from school than do symptomatic adults from work. At higher asymptomatic proportions, intervention effectiveness might be substantially reduced requiring the need for effective case management and treatments, and preventive measures such as vaccines.
        </p>
       </sec>
       <sec>
        <title>
         Funding
        </title>
        <p>
         Singapore Ministry of Health, Singapore Population Health Improvement Centre.
        </p>
       </sec>
      </abstract>
     </article-meta>
    </front>
    <sec id="cesec10">
     <title>
      Introduction
     </title>
     <p id="para10">
      In December, 2019, several health facilities in the Chinese city of Wuhan (Hubei province) reported clusters of individuals with pneumonia
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      whose clinical presentations resembled the symptoms of severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 in the nearby Guangdong province and led to outbreaks worldwide.
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      On Jan 7, 2020, a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was isolated, confirming the circulation of a new respiratory illness, coronavirus disease 2019 (COVID-19), with evidence suggesting that the Huanan seafood wholesale market was the initial transmission site.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      On Jan 1, 2020, the market was closed for environmental sanitation and disinfection to prevent further transmission.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      Cases of COVID-19 have since been reported in health-care workers
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      and family clusters in China,
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      with 67 794 cases and 3805 deaths confirmed in Hubei province as of March 15, 2020.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      Older individuals (aged &gt;60 years) and people with chronic underlying health conditions are particularly susceptible to severe disease.
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      Rapid spread of the virus compelled the Chinese Government to restrict movement in affected cities, with the cessation of public transport
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
      and cancellation of flights.
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
      Despite extensive efforts to prevent onward spread, 143 countries and territories outside of mainland China have now reported imported cases.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
     </p>
     <p id="para20">
      <boxed-text id="cetextbox10">
       <caption>
        <title>
         Research in context
        </title>
       </caption>
       <p id="para30">
        <bold>
         Evidence before this study
        </bold>
       </p>
       <p id="para40">
        At present, in Wuhan, the capital of Hubei province in China, an outbreak of coronavirus disease 2019 (COVID-19) is ongoing, caused by the 2019 novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously called 2019-nCoV). Evidence to date has suggested rapid spread of the virus: at the time of writing, imported cases have been reported in 143 countries and territories, including Singapore. 243 confirmed cases have been reported in Singapore; however, this number is expected to increase substantially in the following weeks. In 2003, SARS-CoV, which also originated from mainland China, established locally, causing 33 deaths after 238 cases were confirmed. Therefore, there is considerable concern since 3204 deaths and 81 048 cases of COVID-19 have already been confirmed in mainland China, which surpasses the numbers observed in the SARS-CoV outbreak. 2020 Lunar New Year celebrations have now ended, marking a period of extensive travel between China and Singapore, and a corresponding high risk for case importation. Despite heightened surveillance and isolation of individuals suspected to have COVID-19 and confirmed cases, the risk is ongoing, with the number of cases continuing to increase in Singapore. Immediate deployment of interventions will be required to contain the outbreak in the event that significant secondary local transmission is observed within the community. We searched PubMed from database inception to Feb 26, 2020, for articles using the search terms “Wuhan coronavirus”, “COVID-19”, “SARS-CoV-2”, “2019-nCoV”, and “coronavirus interventions”. Our search yielded three relevant articles. Two articles investigated the effects of travel restrictions in Wuhan during the early stages of the outbreak; one of the articles additionally investigated the effects of quarantine in China, and the other article estimated the effectiveness of airport screening for the detection of infected travellers. We found no articles assessing the efficacy of immediate national control measures outside of China.
       </p>
       <p id="para50">
        <bold>
         Added value of this study
        </bold>
       </p>
       <p id="para60">
        This study is the first to investigate the use of isolation for individuals with COVID-19 and quarantine of family members, school closures, and workplace distancing as interventions for the immediate control of COVID-19 in the event of secondary local transmission using a simulation model. We found that a combined approach (incorporating quarantine, school closures, and workplace distancing) could prevent a national outbreak at low levels of infectivity and reduce the number of total infections considerably at higher levels of infectivity. Such control measures should be deployed in countries outside of China with evidence of imported cases and evidence of local transmission.
       </p>
       <p id="para70">
        <bold>
         Implications of all the available evidence
        </bold>
       </p>
       <p id="para80">
        The results of this study provide policy makers in Singapore and other countries with evidence to begin the implementation of relatively standard outbreak control measures that could mitigate or reduce local transmission rates if deployed effectively and in a timely manner.
       </p>
      </boxed-text>
     </p>
     <p id="para90">
      Internationally, ongoing local transmission of SARS-CoV-2 has been confirmed in 81 countries and territories.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      In Singapore, 243 individuals have tested positive for SARS-CoV-2, 121 have been hospitalised and are stable, 13 are in a critical condition, and 109 have been discharged at the time of writing.
      <xref ref-type="bibr" rid="bib9">
       <sup>
        9
       </sup>
      </xref>
      The first case in Singapore was identified on Jan 23, 2020, and was imported from China;
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      a further 68 cases were imported, with the remaining 175 cases most likely the result of transmission within Singapore.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      All imported cases were travellers who had returned from Wuhan before Feb 4, 2020, with transmission to close contacts recorded within families at a church and shop in three small transmission clusters.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
     </p>
     <p id="para100">
      As of March 16, 2020, inpatients with COVID-19 in Singapore are isolated at the hospital they present to or at the National Centre for Infectious Diseases, a specialised facility designed to facilitate infectious disease outbreak response.
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      A government-wide taskforce has been established to increase surveillance at borders and prepare the public in terms of awareness and education.
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      The Ministry of Health Singapore has implemented contact tracing efforts to identify potential cases among people travelling with, or in close proximity to, individuals with COVID-19.
      <xref ref-type="bibr" rid="bib12">
       <sup>
        12
       </sup>
      </xref>
      Despite these efforts and nationwide precautionary measures, including the dispensing of masks to households and public hospital emergency departments being on high alert for an outbreak response, the number of suspected and imported cases in Singapore is expected to increase due to the high volume of incoming travellers.
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      Preliminary estimates indicate that the ascertainment rate in Wuhan is 5·1% (95% CI 4·8–5·5);
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      however, high levels of under-reporting and misdiagnosis due to difficulties in identifying cases make it challenging for policy makers to prepare a large-scale response. Consequently, following the recommendations made by Wu and colleagues,
      <xref ref-type="bibr" rid="bib14">
       <sup>
        14
       </sup>
      </xref>
      modelling studies are needed to estimate the potential impact of interventions in the early phase of the outbreak when uncertainty is highest, which is crucial should local transmission begin to increase.
     </p>
     <p id="para110">
      In this study, we aimed to develop a national spatial model of COVID-19 transmission in Singapore to estimate the distribution of cases across time and space and to assess the potential impact of interventions on outbreak size should local containment efforts fail.
     </p>
    </sec>
    <sec id="cesec20">
     <title>
      Methods
     </title>
     <sec id="cesec30">
      <title>
       Epidemic simulation model
      </title>
      <p id="para120">
       We used FluTE,
       <xref ref-type="bibr" rid="bib15">
        <sup>
         15
        </sup>
       </xref>
       an agent-based influenza epidemic simulation model, which accounts for demography, host movement, and social contact rates in workplaces, schools, and homes to estimate the likelihood of human-to-human transmission of SARS-CoV-2 should local containment fail. The FluTE simulation model requires a synthetic population to build the contact and transmission network. Therefore, we used the geographical, demographic, and epidemiological model of Singapore (hereafter referred to as GeoDEMOS-R, where R represents respiratory illness),
       <xref ref-type="bibr" rid="bib16">
        <sup>
         16
        </sup>
       </xref>
       a modelling framework that aims to recreate a synthetic but realistic representation of the Singaporean population at the household and individual level. We generated the synthetic population using national 2010 census data
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        18
       </xref>
       to fit multiple attributes of the population at the household and individual level. The generated households contained demographic characteristics, such as age, marital status, religion, and ethnicity, of household members. Individuals were then allocated to workplaces or educational facilities on the basis of local transportation data and home addresses according to 2010 census data.
       <xref ref-type="bibr" rid="bib19">
        <sup>
         19
        </sup>
       </xref>
       The contact behaviour of individuals in the area of their home (ie, between family members and their local community; defined as the home community), workplace, and school, where applicable, were recorded with potential transmission events as a function of infectivity. We ran the models for 80 days to investigate the early stages of an epidemic and seeded 100 local cases randomly among the resident population at 0 days, representing a few generations of local transmission at the time of scenario implementation (ie, when contact tracing has failed to identify cases within the community and unknown local transmission has started). A full description of the model is available in the
       <xref ref-type="sec" rid="sec1">
        appendix (pp 1–5)
       </xref>
       .
      </p>
     </sec>
     <sec id="cesec40">
      <title>
       SARS-CoV-2 infection parameters
      </title>
      <p id="para130">
       Within the FluTE infection model, we assumed that no individual had existing immunity to SARS-CoV-2. Since data (ie, infectiousness, the cumulative distribution function for the incubation period, and the duration of hospital stay) on SARS-CoV-2 were unavailable at the time of designing this study, we used SARS-CoV parameters to estimate the infectivity profile of SARS-CoV-2. These parameters included how infectious an individual is over time,
       <xref ref-type="bibr" rid="bib20">
        <sup>
         20
        </sup>
       </xref>
       the proportion of the population assumed to be asymptomatic (7·5%),
       <xref ref-type="bibr" rid="bib21">
        <sup>
         21
        </sup>
       </xref>
       the cumulative distribution function for the mean incubation period (with SARS-CoV and SARS-CoV-2 having the same mean incubation period of 5·3 days),
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       and the duration of hospital stay after symptom onset (3·5 days).
       <xref ref-type="bibr" rid="bib20">
        <sup>
         20
        </sup>
       </xref>
       Asymptomatic individuals were able to infect at a 50% reduced rate compared with their symptomatic counterparts based on estimates from Nishiura and colleagues.
       <xref ref-type="bibr" rid="bib23">
        <sup>
         23
        </sup>
       </xref>
      </p>
      <p id="para140">
       We also investigated four alternate asymptomatic proportions: 22·7%, as reported by Furuya-Kanamori and colleagues
       <xref ref-type="bibr" rid="bib24">
        <sup>
         24
        </sup>
       </xref>
       for influenza A H1N1 in a pooled prevalence study; and 30·0%, 40·0%, and 50·0%, as potential but theoretical proportions to investigate intervention efficacy with a high fraction of infections that are cryptic and undetectable.
      </p>
      <p id="para150">
       Three values for the basic reproduction number (
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       ) were chosen for the infectiousness factor (1·5, 2·0, and 2·5) on the basis of analyses of Wuhan case data by Wu and colleagues.
       <xref ref-type="bibr" rid="bib14">
        <sup>
         14
        </sup>
       </xref>
      </p>
     </sec>
     <sec id="cesec50">
      <title>
       Intervention scenarios
      </title>
      <p id="para160">
       For the baseline scenario (ie, no interventions), we ran 1000 epidemic simulations to account for the stochasticity in infection contact networks and to calculate CIs across time. Four intervention scenarios were proposed for implementation after failure of local containment, following policy options currently being assessed by the Singaporean Ministry of Health, as standard interventions for respiratory virus control: isolation of infected individuals and quarantine of their family members (hereafter referred to as quarantine); quarantine plus immediate school closure for 2 weeks; quarantine plus immediate workplace distancing, in which 50% of the workforce is encouraged to work from home for 2 weeks; and a combination of quarantine, immediate school closure, and workplace distancing (hereafter referred to as the combined intervention). Quarantine of infected individuals is expected to occur 1 day after symptom onset in a health-care facility that is assumed to have 3000 beds at maximum capacity (during the early stage of the outbreak) and is fully equipped to handle full quarantine measures (ie, negative pressure isolation rooms, full personal protective equipment use by staff) so that the individual is unable to transmit SARS-CoV-2 to other inpatients. At full capacity, the remaining individuals are isolated at home after receiving treatment. Family members of infected individuals are quarantined at home for 14 days and thus are unable to attend work or school or infect the wider community at their residential address. However, transmission within families is possible as a result of the presence of an isolated and infected individual. Each of these intervention scenarios had 1000 simulations in which we additionally recorded the location of infection as the home community, workplace, or school (
       <xref ref-type="sec" rid="sec1">
        appendix pp 3–4
       </xref>
       ).
      </p>
      <p id="para170">
       Each of the 1000 epidemic simulations had a set of parameters, and was run for baseline and the four control strategies. The median simulation was determined as the median cumulative number of cases at day 80. The same set of parameters was used for each 1000 set of simulations for each
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       value. When analysing differences across infectivity scenarios, we compared the outputs of each simulation, which used the same parameters, not the medians of each grouping. We calculated IQRs as the 25th and 75th simulation in terms of cumulative case count at 80 days. We used R statistical software (version 3.6.3) to plot graphs and for all analyses. We chose to present intervention data for the scenario in which
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       is 2·0, because this represents a moderate and likely outbreak for policy planners. The relatively mild (
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       =1·5) and severe (
       <italic>
        R
       </italic>
       <sub>
        0
       </sub>
       =2.5) outbreak scenarios are presented in the
       <xref ref-type="sec" rid="sec1">
        appendix (pp 9–10)
       </xref>
       .
      </p>
     </sec>
     <sec id="cesec60">
      <title>
       Role of the funding source
      </title>
      <p id="para180">
       The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
      </p>
     </sec>
    </sec>
    <sec id="cesec70">
     <title>
      Results
     </title>
     <p id="para190">
      For the baseline scenario, when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5, the median cumulative number of infections on day 80 was 279 000 (IQR 245 000–320 000;
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ,
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ), which corresponds to 7·4% (IQR 6·5–8·5) of the population. For the quarantine intervention, the median cumulative number of infections at day 80 was reduced to 15 000 (800–30 000;
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 9
      </xref>
      ), which is a 94·8% decrease (90·2–99·7) in the number of infected individuals compared with the baseline scenario. School closure and workplace distancing reduced the median cumulative number of infections on day 80 to 10 000 (200–28 000) and 4000 (200–23 000), respectively (
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 9
      </xref>
      ). The combined intervention decreased the median cumulative infection count on day 80 to 1800 (200–23 000;
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 9
      </xref>
      ), representing a 99·3% (IQR 92·6–99·9) reduction from the baseline scenario. The corresponding maximum number of daily infections from day 0 to day 80 was 12 400 (IQR 11 700–12 900) for the baseline scenario, 600 (0–1400) for the quarantine scenario, 500 (0–1300) for the school-closure scenario, 300 (0–900) for the workplace-distancing scenario, and 120 (0–900) for the combined intervention (
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 9
      </xref>
      ).
      <fig id="fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Total daily number and cumulative number of SARS-CoV-2 infections up to 80 days after failure of local containment for the baseline scenario, by infectivity level
        </p>
        <p>
         Total number of daily infections is shown on the left; cumulative number of infections is shown on the right. Dark lines represent the medians in each panel. Shaded areas show all 1000 simulations for each scenario. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         =basic reproduction number.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
      <table-wrap id="tbl1" position="float">
       <label>
        Table
       </label>
       <caption>
        <p>
         Estimated median or cumulative number of SARS-CoV-2 infections on day 80 by location, intervention, and level of infectivity
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th align="left">
           <bold>
            Baseline
           </bold>
          </th>
          <th align="left">
           <bold>
            Quarantine
           </bold>
          </th>
          <th align="left">
           <bold>
            School closure
           </bold>
          </th>
          <th align="left">
           <bold>
            Workplace distancing
           </bold>
          </th>
          <th align="left">
           <bold>
            Combined intervention
           </bold>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="6">
           <bold>
            <italic>
             R
            </italic>
            <sub>
             0
            </sub>
            =1·5
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           Total number of infections
          </td>
          <td align="left">
           279 000 (245 000–320 000)
          </td>
          <td align="left">
           15 000 (800–30 000)
          </td>
          <td align="left">
           10 000 (200–28 000)
          </td>
          <td align="left">
           4000 (200–23 000)
          </td>
          <td align="left">
           1800 (200–23 000)
          </td>
         </tr>
         <tr>
          <td align="left">
           Home community
          </td>
          <td align="left">
           138 000 (116 000–152 000)
          </td>
          <td align="left">
           2200 (300–7800)
          </td>
          <td align="left">
           2000 (117–7200)
          </td>
          <td align="left">
           700 (98–5500)
          </td>
          <td align="left">
           300 (13–5700)
          </td>
         </tr>
         <tr>
          <td align="left">
           School
          </td>
          <td align="left">
           1400 (1100–1500)
          </td>
          <td align="left">
           14 (5–80)
          </td>
          <td align="left">
           16 (2–70)
          </td>
          <td align="left">
           7 (4–51)
          </td>
          <td align="left">
           1 (0–54)
          </td>
         </tr>
         <tr>
          <td align="left">
           Workplace
          </td>
          <td align="left">
           139 000 (128 000–164 000)
          </td>
          <td align="left">
           12 000 (500–21 900)
          </td>
          <td align="left">
           8000 (124–21 000)
          </td>
          <td align="left">
           3500 (102–17 800)
          </td>
          <td align="left">
           1500 (42–18 000)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="6">
           <bold>
            <italic>
             R
            </italic>
            <sub>
             0
            </sub>
            =2·0
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           Total number of infections
          </td>
          <td align="left">
           727 000 (670 000–776 000)
          </td>
          <td align="left">
           130 000 (38 000–244 000)
          </td>
          <td align="left">
           97 000 (14 000–219 000)
          </td>
          <td align="left">
           67 000 (11 000–145 000)
          </td>
          <td align="left">
           50 000 (2000–143 000)
          </td>
         </tr>
         <tr>
          <td align="left">
           Home community
          </td>
          <td align="left">
           372 000 (339 000–411 000)
          </td>
          <td align="left">
           66 000 (23 000–129 000)
          </td>
          <td align="left">
           46 000 (11 000–113 000)
          </td>
          <td align="left">
           28 000 (8000–79 000)
          </td>
          <td align="left">
           21 000 (1200–68 000)
          </td>
         </tr>
         <tr>
          <td align="left">
           School
          </td>
          <td align="left">
           4300 (3700–4300)
          </td>
          <td align="left">
           600 (100–1200)
          </td>
          <td align="left">
           500 (27–1000)
          </td>
          <td align="left">
           300 (33–800)
          </td>
          <td align="left">
           200 (11–800)
          </td>
         </tr>
         <tr>
          <td align="left">
           Workplace
          </td>
          <td align="left">
           351 000 (327 000–361 000)
          </td>
          <td align="left">
           63 000 (15 000–127 000)
          </td>
          <td align="left">
           51 000 (3000–105 000)
          </td>
          <td align="left">
           38 000 (2800–65 000)
          </td>
          <td align="left">
           28 000 (800–67 000)
          </td>
         </tr>
         <tr>
          <td align="left" colspan="6">
           <bold>
            <italic>
             R
            </italic>
            <sub>
             0
            </sub>
            =2·5
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           Total number of infections
          </td>
          <td align="left">
           1 207 000 (1 164 000–1 249 000)
          </td>
          <td align="left">
           520 000 (268 000–754 000)
          </td>
          <td align="left">
           466 000 (175 000–728 000)
          </td>
          <td align="left">
           320 000 (116 000–558 000)
          </td>
          <td align="left">
           258 000 (65 000–508 000)
          </td>
         </tr>
         <tr>
          <td align="left">
           Home community
          </td>
          <td align="left">
           640 000 (623 000–675 000)
          </td>
          <td align="left">
           264 000 (144 000–410 000)
          </td>
          <td align="left">
           235 000 (92 000–366 000)
          </td>
          <td align="left">
           163 000 (66 000–281 000)
          </td>
          <td align="left">
           132 000 (34 000–265 000)
          </td>
         </tr>
         <tr>
          <td align="left">
           School
          </td>
          <td align="left">
           7100 (7200–7900)
          </td>
          <td align="left">
           3000 (1400–4000)
          </td>
          <td align="left">
           2400 (1300–3600)
          </td>
          <td align="left">
           1500 (800–3400)
          </td>
          <td align="left">
           1300 (300–2800)
          </td>
         </tr>
         <tr>
          <td align="left">
           Workplace
          </td>
          <td align="left">
           560 000 (550 000–584 000)
          </td>
          <td align="left">
           253 000 (140 000–390 000)
          </td>
          <td align="left">
           228 000 (82 000–358 000)
          </td>
          <td align="left">
           156 000 (49 000–274 000)
          </td>
          <td align="left">
           124 000 (31 000–241 000)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Data are median (IQR). All numbers up to 10 000 have been rounded to the nearest hundred, and numbers higher than 10 000 have been rounded to the nearest thousand, therefore, some discrepancies will exist in the summations. Due to the stochasticity within each simulation, numbers less than 20 indicate nearly complete suppression and should not be compared to assess effectiveness. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
          <italic>
           R
          </italic>
          <sub>
           0
          </sub>
          =basic reproduction number.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="para200">
      When
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·0, the proportion of the Singaporean population infected under the baseline scenario increased to 19·3% (IQR 17·8–20·6), with a median cumulative number of infections on day 80 of 727 000 (IQR 670 000–776 000;
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ,
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ). On day 80, quarantine resulted in a cumulative median of 130 000 cases (38 000–244 000), school closure 97 000 cases (14 000–219 000), workplace distancing 67 000 cases (11 000–145 000), and the combined intervention 50 000 cases (2000–143 000;
      <xref ref-type="fig" rid="fig2">
       figure 2
      </xref>
      ,
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ). The maximum number of daily infections was 27 800 (IQR 27 300–28 000) for the baseline scenario, 11 000 (4100–18 600) for the quarantine scenario, 8400 (1900–17 000) for the school-closure scenario, 6100 (1500–12 000) for the workplace-distancing scenario, and 4900 (100–11 700) for the combined intervention (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ,
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      ). The combined approach resulted in the largest reduction in cases from baseline (93·0% reduction [IQR 81·5–99·7]).
      <fig id="fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Total daily number and cumulative number of SARS-CoV-2 infections up to 80 days under different intervention scenarios when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         is 2·0
        </p>
        <p>
         Total number of daily infections is shown on the left; cumulative number of infections is shown on the right. Dark blue lines represent the corresponding baseline median when
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         is 2·0 with no interventions. Shaded areas around the dark blue lines show the IQRs for all simulations. Dark orange, green, light orange, and purple shading represent all simulation runs for each scenario, with darker lines in corresponding colours representing medians. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         =basic reproduction number.
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para210">
      For the baseline scenario, when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·5, 32% (IQR 30·9–33·1) of the Singaporean population were infected, with a cumulative median of 1 207 000 cases (IQR 1 164 000–1 249 000) on day 80 (
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ,
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ). At this level of transmission, quarantine resulted in a median of 520 000 cases (268 000–754 000), school closure 466 000 cases (175 000–728 000), workplace distancing 320 000 cas
      <bold>
       e
      </bold>
      s (116 000–558 000), and the combined intervention 258 000 cases (65 000–508 000;
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 10
      </xref>
      ). The maximum number of daily infections was 42 800 (IQR 41 400–43 500) for the baseline scenario, 37 900 (25 900–41 800) for the quarantine scenario, 36 400 (18 100–41 400) for the school-closure scenario, 29 800 (12 500–40 500) for the workplace-distancing scenario, and 25 200 (7700–39 200) for the combined intervention (
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 10
      </xref>
      ). Compared with baseline, the combined approach resulted in the greatest reduction in cases (78·2% [IQR 59·0–94·4]).
     </p>
     <p id="para220">
      For all simulations, the median age of infection was 37 years (IQR 26–49). The location of infection (school, workplace, or home community) was determined according to the site where individuals were exposed to the virus (
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ). Owing to behaviours of school absenteeism and work-distancing presenteeism, the number of infections acquired at work consistently exceeded those at school, although students could be transmitting the virus within the home community (
      <xref ref-type="table" rid="tbl1">
       table
      </xref>
      ). Such patterns of transmission are particularly evident for the combined intervention at higher levels of infectivity (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      =2·5), with a median of 1300 infections acquired at school (IQR 300–2800), 124 000 at the workplace (31 000–241 000), and 132 000 (34 000–265 000) in the home community.
     </p>
     <p id="para230">
      The median number of daily infections across time showed that when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5 or 2·0, the epidemic peak was unlikely to occur during the 80-day timeframe, whereas when R
      <sub>
       0
      </sub>
      was 2·5, a peak in cases was observed approximately 9 weeks after reaching 100 community infections (
      <xref ref-type="fig" rid="fig1">
       figure 1
      </xref>
      ). When
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·5, the interventions had a suppressive effect on the number of new cases each day, although the number of cases continued to increase at day 80, indicating a delayed intervention effect rather than a preventive effect as observed when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5 (
      <xref ref-type="fig" rid="fig2">
       figure 2
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix pp 9–10
      </xref>
      ). Geospatially, the number of cases across Singapore at day 80 show a high number of home community infections in highly residential areas and considerable infection-source mixing (
      <xref ref-type="fig" rid="fig3">
       figure 3
      </xref>
      ;
      <xref ref-type="sec" rid="sec1">
       appendix p 11
      </xref>
      ). The combined intervention had the greatest effect on the number of infections, with a universal reduction across Singapore when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5 (
      <xref ref-type="fig" rid="fig3">
       figure 3
      </xref>
      ). The combined intervention had a smaller effect when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·0 or 2·5, with a relatively homogeneous distribution nationwide, although dense residential clusters in the north of Singapore, in areas near the Malaysia border, indicate strong comparative persistence of the virus despite the use of the combined approach (
      <xref ref-type="fig" rid="fig3">
       figure 3
      </xref>
      ).
      <fig id="fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Geospatial distribution of coronavirus disease 2019 cases at the time of infection at 80 days in Singapore
        </p>
        <p>
         Red dots show infections acquired in the home community, orange dots show infections acquired in the workplace, and blue dots show infections acquired at school. A central water catchment is located in the centre of the map, where population density is low. The combined intervention involved quarantine, workplace distancing, and school closure.
         <italic>
          R
         </italic>
         <sub>
          0
         </sub>
         =basic reproduction number.
        </p>
       </caption>
       <graphic xlink:href="gr3_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para240">
      Our models assumed that 7·5% of cases were asymptomatic. Considering a higher asymptomatic proportion of the total infected population of 22·7%, owing to isolation of fewer infected individuals and quarantine of fewer family members, for the quarantine scenario when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5, an additional 100 000 cases (IQR 41 800–152 000) would be observed at 80 days (
      <xref ref-type="sec" rid="sec1">
       appendix p 7
      </xref>
      ). Similarly, a higher asymptomatic proportion resulted in a higher median cumulative number of cases for the school-closure, work-distancing, and combined intervention scenarios: an additional 97 000 (IQR 31 200–151 000), 64 800 (10 500–110 000), and 51 000 cases (1500–107 000), respectively, when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5 (
      <xref ref-type="sec" rid="sec1">
       appendix p 12
      </xref>
      ). When
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·0, assuming an asymptomatic proportion of 22·7%, an additional 381 000 cases (IQR 250 000–474 000) were observed for the quarantine scenario, 400 000 cases (275 000–509 000) for the school-closure scenario, 316 000 cases (175 000–433 000) for the workplace-distancing scenario, and 294 000 cases (162 000–430 000) for the combined interventions scenario (
      <xref ref-type="sec" rid="sec1">
       appendix p 13
      </xref>
      ). When
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·5, an additional 577 000 cases (IQR 382 000–777 000), 557 000 cases (372 000–785000), 567 000 cases (379 000–775 000), and 599 000 cases (394 000–804 000) were observed for the quarantine, school-closure, workplace-distancing, and combined intervention scenarios, respectively (
      <xref ref-type="sec" rid="sec1">
       appendix p 14
      </xref>
      ). The medians of the number of infections and location of infection for the 22·7% asymptomatic fraction is presented in the
      <xref ref-type="sec" rid="sec1">
       appendix (p 7)
      </xref>
      .
     </p>
     <p id="para250">
      The median number of infections and location of infection for the higher theoretical asymptomatic proportions are presented in the
      <xref ref-type="sec" rid="sec1">
       appendix (p 8)
      </xref>
      . At higher asymptomatic proportions of 30·0%, 40·0%, and 50·0%, further increases were observed (
      <xref ref-type="sec" rid="sec1">
       appendix pp 8, 15–19
      </xref>
      ). We only ran the analysis at higher asymptomatic rates at the lower level of infectivity (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      =1·5), because we observed substantial increases in the number of cases observed, reflecting poor case control that would otherwise be exacerbated and lead to containment failure at higher infectivity. When
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5, interventions caused substantial reductions in the number of infections at asymptomatic fractions of 7·5% and 22·7%. For quarantine, by comparison with the number of cases observed for the 7·5% asymptomatic proportion assumption when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5, the median number of cases increased by 172 000 (IQR 113 000–221 000) for a 30·0% asymptomatic proportion. This number increased to 253 000 (209 000–294 000) for a 40·0% asymptomatic fraction, and to 314 000 (276 000–343 000) for a 50·0% asymptomatic fraction (
      <xref ref-type="sec" rid="sec1">
       appendix pp 15–17
      </xref>
      ). At an asymptomatic proportion of 30·0%, increases compared with a 7·5% asymptomatic proportion of 172 000 (IQR 104 000–221 000), 124 000 (53 100–170 000), and 114 000 cases (36 300–172 000) were observed for school closure, workplace distancing, and the combined interventions, respectively (
      <xref ref-type="sec" rid="sec1">
       appendix pp 15–17
      </xref>
      ). Increases for school closure, workplace distancing, and combined interventions were 253 000 (IQR 206 000–287 000), 203 000 (153 000–251 000), and 196 000 cases (134 000–244 000), respectively, for an asymptomatic proportion of 40·0% and 312 000 (278 000–340 000), 269 000 (215 000–308 000), and 267 000 cases (216 000–307 000), respectively, for an asymptomatic proportion of 50·0% (
      <xref ref-type="sec" rid="sec1">
       appendix pp 16–17
      </xref>
      ).
     </p>
    </sec>
    <sec id="cesec80">
     <title>
      Discussion
     </title>
     <p id="para260">
      Concerns about COVID-19 becoming a global epidemic are increasing on the basis of previous epidemics, such as SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic influenza. The introduction of cases into new countries, regions and cities is likely to continue in areas where local establishment could form, depending on the ongoing level of control measures. In the event that local containment is unsuccessful, our findings suggest that national outbreak control is feasible provided that
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      is low (≤1·5), with a combination of the proposed intervention measures (quarantine, school closure, and workplace distancing) being most effective. Under this scenario (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      =1·5
      <bold>
       )
      </bold>
      , workplace distancing reduced the median number of cases from 279 000 (IQR 245 000– 320 000) to 4000 (200–23 000), as a result of the high employment rates (around 98%) among individuals of working age in Singapore.
      <xref ref-type="bibr" rid="bib25">
       <sup>
        25
       </sup>
      </xref>
      This observation is consistent with the conclusions of a review of 15 studies that found a median reduction of 23% (range 12–82) in the cumulative influenza A H1N1 attack rate with workplace distancing alone.
      <xref ref-type="bibr" rid="bib26">
       <sup>
        26
       </sup>
      </xref>
      The implementation of such a control measure, however, is likely to have an acute societal economic effect on individuals who must work from home or take leave, especially if reimbursement is not possible. Thus, decision making becomes a function of risk as to whether the imported cases have or will infect the local population and cause a local outbreak. An
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      value of 1·5 is not consistent with the evidence from China,
      <xref ref-type="bibr" rid="bib14">
       <sup>
        14
       </sup>
      </xref>
      and thus prevention of community transmission might not be possible using interventions that would be widely supported by the population.
     </p>
     <p id="para270">
      At the start of the outbreak, the risk of repeated importation of SARS-CoV-2 into Singapore was deemed to be considerable given that around 3·4 million people travel from Wuhan to Singapore annually.
      <xref ref-type="bibr" rid="bib27">
       <sup>
        27
       </sup>
      </xref>
      Furthermore, the start of the epidemic coincided with the 2020 Chinese Lunar New Year holiday, with the expectation that the number of individuals arriving from China would be similar to that for the 2018 celebrations (around 800 000 tourists from China).
      <xref ref-type="bibr" rid="bib27">
       <sup>
        27
       </sup>
      </xref>
      The high influx of incoming travellers exacerbated the risk of local disease establishment, bringing at least 18 initial confirmed imported cases into Singapore before Feb 4, 2020, when the first four local transmission cases were confirmed.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      These four cases had contact with at least two infected tourists at a shop, who were identified through intensive contact tracing efforts. Although travel is now reduced, at least 175 subsequent locally-acquired infections have been reported at the time of writing across a diverse range of residential and commercial sites despite efforts by the Singaporean Government to quarantine and isolate infected individuals. On March 16, 2020, 11 of the 17 confirmed cases were imported with travel histories including the UK, Indonesia, Portugal, Spain, the USA, France, Germany, Switzerland, and Belgium.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      On March 17, 2020, a further 17 of 23 cases were reported to be imported.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      With the risk of disease establishment remaining high from the continued importation of cases, workplace distancing and school closure remain as critical interventions that can avert a significant number of cases.
     </p>
     <p id="para280">
      We found that these two interventions, when used in combination with quarantine, would be highly effective at low infection rates (ie,
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      of 1·5), with median of 10 000 cases (IQR 200–28 000) observed for school closures and 4000 cases (200–23 000) for workplace distancing compared with 279 000 cases (245 000–320 000) at the baseline. At the highest level of infectivity (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      =2·5), substantial reductions were observed with a median of 466 000 cases (IQR 175 000–728 000) observed when school closure was used and 320 000 (116 000–558 000) for workplace distancing compared with 1 207 000 cases (1 164 000–1 249 000) at baseline. However, if the preventive effect of these interventions reduces considerably due to higher asymptomatic proportions, more pressure will be placed on the quarantining and treatment of infected individuals, which could become unfeasible when the number of infected individuals exceeds the capacity of health-care facilities.
     </p>
     <p id="para290">
      Scale-up of ongoing surveillance programmes and rigorous contract tracing
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       28
      </xref>
      are thus required to assist in the maintenance of a low number of unidentified infections at this time, with school closure and workplace distancing being potentially effective strategies for deployment nationwide should local transmission, with multiple transmission events recorded between individuals in the resident population, begin. Our simulation model, which examined hypothetical infection spread with 100 unidentified Singaporean cases as a seed population, showed that for the baseline scenario (ie, no control interventions) by day 80, when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5, around 279 000 individuals would be infected, when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·0, around 727 000 individuals would be infected, and when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 2·5, around 1 207 000 individuals would be infected. In the event that suppression of transmission through quarantine is unsuccessful and local transmission begins, which has currently been observed in other countries on a small scale,
      <xref ref-type="bibr" rid="bib29">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       30
      </xref>
      policy makers in Singapore should deploy alternate measures, such as school closure and workplace distancing, in a timely manner. School closure has been used in the past in Singapore to limit the spread of hand, foot, and mouth disease, and was associated with a decrease of up to 53% in secondary cases,
      <xref ref-type="bibr" rid="bib31">
       <sup>
        31
       </sup>
      </xref>
      probably because children generally have high contact rates with their peers in the school environment. Given this historical experience, a similar programme for COVID-19 could be established reasonably quickly. However, at present, data on the susceptibility of children to SARS-CoV-2 infection, the number of infected children in Singapore, and the probability of children becoming symptomatic are limited, making school closure less desirable than workplace distancing.
     </p>
     <p id="para300">
      The continually high percentage contribution of work-related infections despite work distancing being effective suggests that the workplace is a key infection site in Singapore, whereby reductions in workplace transmission averts cases at all other sites. The effects of school closure and quarantine were comparable, since the displacement of students to the home community will then rely on quarantine as a measure of preventing infection. However, asymptomatic cases, assumed to account for 7·5% of the infected population, would continue to contribute to transmission, and the identification of these individuals presents a challenge.
     </p>
     <p id="para310">
      Increasing the asymptomatic proportion in our model from 7·5% to 22·7%, which is reflective of influenza A H1N1,
      <xref ref-type="bibr" rid="bib24">
       <sup>
        24
       </sup>
      </xref>
      resulted in limited infection control with considerable stochasticity, whereby the failure of early quarantine led to outbreaks similar in size to those observed for the baseline scenario, even when
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      was 1·5. Under this assumption, the median number of cases averted compared with baseline ranged from 219 000 to 282 000 cases (64·4–82·9% reduction) depending on the intervention scenario. For the quarantine, school-closure, work-distancing, and combined intervention scenarios, assuming an asymptomatic proportion of 7·5% and an
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      of 1·5, a median of 264 000–277 200 cases (94·6–99·4% reduction) would be averted compared with the baseline scenario. Thus, considering the differences in number of cases averted by proportion of asymptomatic individuals in the population, additional interventions, such as vaccination (where research is rapidly ongoing) or the prescribing of existing antiviral drugs that are effective for the treatment of related viral infections, should be considered. Contact inhibition remains important, but the high proportion of asymptomatic and undocumented infections and missed opportunities to quarantine will make control challenging. Even at a low infectivity (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      ≤1·5), a high asymptomatic proportion is problematic, with 58 000 infections (IQR 5400–123 000) occurring at an asymptomatic proportion of 22·7% compared with 1800 infections (200–23 000) at a 7·5% asymptomatic proportion with the combined intervention'. These effects were exacerbated further at higher asymptomatic proportions of 30·0–50·0%. With fewer cases averted and larger outbreak sizes from undocumented spread due to asymptomatic individuals, the dialogue partly shifts from containment to case management to reduce mortality from complications.
     </p>
     <p id="para320">
      Regardless of the proportion of individuals in the population with asymptomatic infection, all the proposed interventions should be used in addition to other measures, such as rapid diagnosis and appropriate case management, if local containment fails. Current government-led outbreak control measures will only be successful with public cooperation through exercising good hygiene, infection prevention in shared spaces, and adequate education to understand when symptoms might be indicative of a potential SARS-CoV-2 infection. Public complicity is particularly crucial for older individuals (&gt;60 years), individuals who are immunocompromised, and people with comorbidities who are at high risk of severe complications.
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      During the 2003 SARS outbreak, 238 probable SARS cases were reported and 33 individuals died in Singapore, with the highest proportion of deaths (45%) reported among people aged 65 years and older.
      <xref ref-type="bibr" rid="bib32">
       <sup>
        32
       </sup>
      </xref>
      The same observation is thus expected for COVID-19 should local transmission occur since the median age of infection in our models was 37 years (IQR 26–49), with comparatively few children becoming infected because of school closure and awareness among parents to quarantine children with fever. Singapore has one of the highest employment rates among older individuals (aged ≥65 years) of all countries within the Organisation for Economic Co-operation and Development (OECD)
      <xref ref-type="bibr" rid="bib33">
       <sup>
        33
       </sup>
      </xref>
      and a culture of eating at so-called hawker centres (ie, food courts), with around 75% of people visiting a hawker centre at least once a week.
      <xref ref-type="bibr" rid="bib34">
       <sup>
        34
       </sup>
      </xref>
      Consequently, many older people are expected to be exposed to infection at work or within their home communities, which could be mitigated in part by implementation of workplace distancing and, if possible, incentivisation to remain at home and practise workplace distancing, specifically for older individuals.
     </p>
     <p id="para330">
      At present, the quarantining of family and close contacts of confirmed cases is crucial, as shown by the substantial increase in infection rates among individuals who shared living spaces and bathrooms during the 2009 H1N1 influenza pandemic in China, despite the regular disinfection of these areas.
      <xref ref-type="bibr" rid="bib35">
       <sup>
        35
       </sup>
      </xref>
      The protocols in place at present, including the use of specialist ambulances, negative pressure isolation rooms, and ultraviolet disinfection, will assist in isolating the infection and preventing transmission events at health-care facilities, as was seen during the 2003 SARS outbreak.
      <xref ref-type="bibr" rid="bib21">
       <sup>
        21
       </sup>
      </xref>
      Since at least 15 medical staff in Wuhan have contracted the virus,
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      Singapore has provided full personal protective equipment for health-care workers; however, the results of our study suggest that community transmission will substantially contribute to transmission should local containment fail despite these measures. The main control measures at this time are surveillance, standard testing procedures,
      <xref ref-type="bibr" rid="bib36">
       <sup>
        36
       </sup>
      </xref>
      and quarantine of individuals who are confirmed positive for the virus. Such measures have been used in the past for suspected cases of MERS-CoV, which has a 34·4% case-fatality rate,
      <xref ref-type="bibr" rid="bib37">
       <sup>
        37
       </sup>
      </xref>
      with no cases of MERS-CoV reported in Singapore to date, and for Zika virus, which established locally in 2016, with only ten cases reported in 2019.
      <xref ref-type="bibr" rid="bib38">
       <sup>
        38
       </sup>
      </xref>
      Such successes in preventing local outbreaks are attributed to robust disease surveillance in Singapore. Nevertheless, dengue outbreaks are ongoing in Singapore,
      <xref ref-type="bibr" rid="bib39">
       <sup>
        39
       </sup>
      </xref>
      which highlights the difficulties in disease control that are in part due to undocumented spread and individuals who are asymptomatic; these issues are likely to affect the control of the ongoing COVID-19 epidemic since many imported cases worldwide have been asymptomatic on entry to countries.
      <xref ref-type="bibr" rid="bib9">
       <sup>
        9
       </sup>
      </xref>
      The implementation of school closure and workplace distancing can therefore be considered as a potential secondary control response in the event of infection quarantine failure and the establishment of community transmission.
     </p>
     <p id="para340">
      Our study has several limitations. First, since GeoDEMOS-R is validated against census data, errors exist in our estimations of population features that are based on data that have been sample enumerated. Second, a large population of migrant workers who travel from Malaysia to Singapore each day, visiting tourists, and long-term visa owners were not accounted for in our infection dynamics. Third, the epidemiological characteristics of COVID-19 remain uncertain in terms of the transmission and infectivity profile of the virus; therefore, estimates of the time between symptom onset and admission to hospital, how infectious an individual is over time, and the asymptomatic rate were based on SARS-CoV. Once this information becomes available for COVID-19, a full sensitivity analysis should be done. Fourth, the contact patterns between individuals are highly dynamic and heterogeneous across the population; therefore, our simulated work, school, and home populations serve as a general estimation of infection spread. Fifth, effectiveness of the interventions might vary depending on the ongoing seeding of imported cases, which we did not account for, and will also rely on intervention compliance. Sixth, multiple indirect effects from the interventions and modifications to human behaviour are likely, which are difficult to quantify and measure. The optimum times to implement each intervention and how long they should be run for to achieve long-term epidemic control should be explored. Finally, there are multiple unforeseen factors that remain challenging to assess at this time, such as increased infection rates at mass gatherings, delays in quarantining as a result of individuals not seeking health care at symptom onset, alternate contact events in locations such as public transport, potential transmission events in the health-care setting, and the effects of community-wide behavioural shifts in response to knowledge of the outbreak.
     </p>
     <p id="para350">
      Pandemic planning is crucial at the early stages to avert a nationwide outbreak. In this study, we investigated the use of interventions that aim to restrict contact between individuals at important mixing sites
      <bold>
       :
      </bold>
      schools, workplaces, and at home. We found that, especially for lower infection scenarios (
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      of 1·5), a combined approach comprising quarantine (for infected individuals and their families), school closure, and workplace distancing is effective and could prevent 99·3% of infections (IQR 92·6–99·9) when compared with the baseline scenario. At higher infectivity scenarios, outbreak prevention becomes considerably more challenging because although effective, transmission events still occur: for the combined approach scenario, a median of 50 000 cases were estimated at
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      of 2·0 and 258 000 cases at
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      of 2·5. These combined interventions should therefore be implemented rapidly upon confirmation of second-generation local transmission occurring within the resident population to suppress increases in the national
      <italic>
       R
      </italic>
      <sub>
       0
      </sub>
      . At higher asymptomatic rates, public education and case management become increasingly important, with a need to develop vaccines and existing drug therapies.
     </p>
     <p id="para51">
      <boxed-text id="cetextbox11">
       <p id="para52">
        <bold>
         This online publication has been corrected. The corrected version first appeared at thelancet.com/infection on March 27, 2020
        </bold>
       </p>
      </boxed-text>
     </p>
    </sec>
    <back>
     <ref-list id="bibl10">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JSM
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         10
        </volume>
        <issue>
         suppl 12
        </issue>
        <year>
         2004
        </year>
        <fpage>
         S88
        </fpage>
        <lpage>
         S97
        </lpage>
        <pub-id pub-id-type="pmid">
         15577937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Jan 29.
        </comment>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref40" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Pneumonia of unknown cause–China
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs20" xlink:href="https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/">
         https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/
        </ext-link>
        <year>
         Jan 5, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref50" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Novel coronavirus (2019-nCoV) situation report–3
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs30" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200123-sitrep-3-2019-ncov.pdf">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200123-sitrep-3-2019-ncov.pdf
        </ext-link>
        <year>
         Jan 23, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref60" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Coronavirus disease 2019 (COVID-19) situation report–55
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs40" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200315-sitrep-55-covid-19.pdf?sfvrsn=33daa5cb_8">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200315-sitrep-55-covid-19.pdf?sfvrsn=33daa5cb_8
        </ext-link>
        <year>
         March 15, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref70" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          BBC
         </collab>
        </person-group>
        <article-title>
         Coronavirus: Wuhan shuts public transport over outbreak
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs50" xlink:href="https://www.bbc.com/news/world-asia-china-51215348">
         https://www.bbc.com/news/world-asia-china-51215348
        </ext-link>
        <year>
         Jan 23, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sbref80" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          BBC
         </collab>
        </person-group>
        <article-title>
         China's travel industry counts cost of coronavirus
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs60" xlink:href="https://www.bbc.com/news/business-51232374">
         https://www.bbc.com/news/business-51232374
        </ext-link>
        <year>
         Jan 24, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sbref90" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ministry of Health Singapore
         </collab>
        </person-group>
        <article-title>
         Updates on COVID-19 (coronavirus disease 2019) local situation
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs70" xlink:href="https://www.moh.gov.sg/covid-19">
         https://www.moh.gov.sg/covid-19
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sbref100" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ministry of Health Singapore
         </collab>
        </person-group>
        <article-title>
         Confirmed imported case of novel coronavirus infection in Singapore; multi-ministry taskforce ramps up precautionary measures
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs80" xlink:href="https://www.moh.gov.sg/news-highlights/details/confirmed-imported-case-of-novel-coronavirus-infection-in-singapore-multi-ministry-taskforce-ramps-up-precautionary-measures">
         https://www.moh.gov.sg/news-highlights/details/confirmed-imported-case-of-novel-coronavirus-infection-in-singapore-multi-ministry-taskforce-ramps-up-precautionary-measures
        </ext-link>
        <year>
         Jan 23, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sbref110" publication-type="other">
        <ext-link ext-link-type="uri" id="interrefs90" xlink:href="http://Gov.sg">
         Gov.sg
        </ext-link>
       </element-citation>
       <element-citation id="sbref120" publication-type="other">
        <article-title>
         Coronavirus disease 2019: cases in Singapore
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs100" xlink:href="https://www.gov.sg/article/covid-19-cases-in-singapore">
         https://www.gov.sg/article/covid-19-cases-in-singapore
        </ext-link>
        <year>
         Feb 25, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sbref130" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ministry of Health Singapore
         </collab>
        </person-group>
        <article-title>
         Two more cases of confirmed imported case of novel coronavirus infection in Singapore
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs110" xlink:href="https://www.moh.gov.sg/news-highlights/details/two-more-cases-of-confirmed-imported-case-of-novel-coronavirus-infection-in-singapore">
         https://www.moh.gov.sg/news-highlights/details/two-more-cases-of-confirmed-imported-case-of-novel-coronavirus-infection-in-singapore
        </ext-link>
        <year>
         Jan 24, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sbref140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Bridgen
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jewell
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Jan 28.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.01.23.20018549
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         689
        </fpage>
        <lpage>
         697
        </lpage>
        <pub-id pub-id-type="pmid">
         32014114
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Halloran
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Obenchain
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Longini
          </surname>
          <given-names>
           IM
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <article-title>
         FluTE, a publicly available stochastic influenza epidemic simulation model
        </article-title>
        <source>
         PLOS Comput Biol
        </source>
        <volume>
         6
        </volume>
        <year>
         2010
        </year>
        <object-id pub-id-type="publisher-id">
         e1000656
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sbref170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Alkema
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
        </person-group>
        <article-title>
         Forecasting the burden of type 2 diabetes in Singapore using a demographic epidemiological model of Singapore
        </article-title>
        <source>
         BMJ Open Diabetes Res Care
        </source>
        <volume>
         2
        </volume>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e000012
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sbref180" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Department of Statistics Singapore
         </collab>
        </person-group>
        <article-title>
         Singapore census of population 2010, statistical release 1: demographic characteristics, education, language and religion
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs130" xlink:href="https://www.singstat.gov.sg/publications/cop2010/cop2010-sr1">
         https://www.singstat.gov.sg/publications/cop2010/cop2010-sr1
        </ext-link>
        <year>
         2011
        </year>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sbref190" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Department of Statistics Singapore
         </collab>
        </person-group>
        <article-title>
         Singapore census of population 2010, statistical release 2: households and housing
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs140" xlink:href="https://www.singstat.gov.sg/publications/cop2010/census10_stat_release2">
         https://www.singstat.gov.sg/publications/cop2010/census10_stat_release2
        </ext-link>
        <year>
         2011
        </year>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sbref200" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Department of Statistics Singapore
         </collab>
        </person-group>
        <article-title>
         Singapore census of population 2010, statistical release 3: geographic distribution and transport
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs150" xlink:href="https://www.singstat.gov.sg/publications/cop2010/cop2010-sr3">
         https://www.singstat.gov.sg/publications/cop2010/cop2010-sr3
        </ext-link>
        <year>
         2011
        </year>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sbref210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McBryde
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Gibson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pettitt
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           McElwain
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bayesian modelling of an epidemic of severe acute respiratory syndrome
        </article-title>
        <source>
         Bull Math Biol
        </source>
        <volume>
         68
        </volume>
        <year>
         2006
        </year>
        <fpage>
         889
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="pmid">
         16802088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Teleman
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Heng
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name>
          <surname>
           Earnest
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Leo
          </surname>
          <given-names>
           YS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic SARS coronavirus infection among healthcare workers, Singapore
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1142
        </fpage>
        <lpage>
         1145
        </lpage>
        <pub-id pub-id-type="pmid">
         16022801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sbref230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meltzer
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple contact dates and SARS incubation periods
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         207
        </fpage>
        <lpage>
         209
        </lpage>
        <pub-id pub-id-type="pmid">
         15030684
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sbref240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of the asymptomatic ratio of novel coronavirus (2019-nCoV) infections
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Feb 17.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.02.03.20020248
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sbref250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Furuya-Kanamori
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Milinovich
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Magalhaes
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Mackay
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name>
          <surname>
           Yakob
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heterogeneous and dynamic prevalence of asymptomatic influenza virus infections
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1052
        </fpage>
        <lpage>
         1056
        </lpage>
        <pub-id pub-id-type="pmid">
         27191967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sbref260" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ministry of Manpower Singapore
         </collab>
        </person-group>
        <article-title>
         Summary table: unemployment
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs170" xlink:href="https://stats.mom.gov.sg/Pages/Unemployment-Summary-Table.aspx">
         https://stats.mom.gov.sg/Pages/Unemployment-Summary-Table.aspx
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sbref270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zviedrite
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Uzicanin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review
        </article-title>
        <source>
         BMC Public Health
        </source>
        <volume>
         18
        </volume>
        <year>
         2018
        </year>
        <fpage>
         518
        </fpage>
        <pub-id pub-id-type="pmid">
         29669545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sbref280" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Singapore Tourism Board
         </collab>
        </person-group>
        <article-title>
         Capturing quality growth amidst uncertainty
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs180" xlink:href="https://www.stb.gov.sg/content/dam/stb/documents/TIC2019/China-%20Capturing%20Quality%20Growth%20amidst%20Uncertainty.pdf">
         https://www.stb.gov.sg/content/dam/stb/documents/TIC2019/China-%20Capturing%20Quality%20Growth%20amidst%20Uncertainty.pdf
        </ext-link>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sbref290" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          The Strait Times
         </collab>
        </person-group>
        <article-title>
         Temperature screening to cover all flights
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs190" xlink:href="https://www.straitstimes.com/singapore/health/temperature-screening-to-cover-all-flights">
         https://www.straitstimes.com/singapore/health/temperature-screening-to-cover-all-flights
        </ext-link>
        <year>
         Jan 28, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sbref300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           LT
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           TV
          </given-names>
         </name>
         <name>
          <surname>
           Luong
          </surname>
          <given-names>
           QC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Importation and human-to-human transmission of a novel coronavirus in Vietnam
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         872
        </fpage>
        <lpage>
         874
        </lpage>
        <pub-id pub-id-type="pmid">
         31991079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sbref310" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          The Japan Times
         </collab>
        </person-group>
        <article-title>
         Japan reports first domestic transmission of coronavirus
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs200" xlink:href="https://www.japantimes.co.jp/news/2020/01/28/national/japan-first-domestic-transmission-coronavirus/#.XjL3T2gzaCo">
         https://www.japantimes.co.jp/news/2020/01/28/national/japan-first-domestic-transmission-coronavirus/#.XjL3T2gzaCo
        </ext-link>
        <year>
         Jan 28, 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sbref320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Badaruddin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Cutter
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of school closure on hand, foot, and mouth disease transmission in Singapore: a modeling approach
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         99
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1625
        </fpage>
        <lpage>
         1632
        </lpage>
        <pub-id pub-id-type="pmid">
         30350767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sbref330" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ministry of Health Singapore
         </collab>
        </person-group>
        <article-title>
         Special feature: severe acute respiratory syndrome (SARS)
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs210" xlink:href="https://www.moh.gov.sg/docs/librariesprovider5/resources-statistics/reports/special_feature_sars.pdf">
         https://www.moh.gov.sg/docs/librariesprovider5/resources-statistics/reports/special_feature_sars.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sbref340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rogerson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Stacey
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Successful ageing in Singapore
        </article-title>
        <source>
         Geriatrics (Basel)
        </source>
        <volume>
         3
        </volume>
        <year>
         2018
        </year>
        <fpage>
         81
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sbref350" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ministry of the Environment and Water Resources Singapore
         </collab>
        </person-group>
        <article-title>
         Hawker Centre 3.0 Committee Report
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs220" xlink:href="https://www.mewr.gov.sg/Data/Editor/Documents/HC%203.0%20Report.pdf">
         https://www.mewr.gov.sg/Data/Editor/Documents/HC%203.0%20Report.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sbref360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C-Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quarantine methods and prevention of secondary outbreak of pandemic (H1N1) 2009
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         16
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1300
        </fpage>
        <lpage>
         1302
        </lpage>
        <pub-id pub-id-type="pmid">
         20678330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sbref370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         2000045
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sbref380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Elkholy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Worldwide reduction in MERS cases and deaths since 2016
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         25
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1758
        </fpage>
        <lpage>
         1760
        </lpage>
        <pub-id pub-id-type="pmid">
         31264567
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sbref390" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          National Environment Agency
         </collab>
        </person-group>
        <article-title>
         Zika cases and clusters
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs230" xlink:href="https://www.nea.gov.sg/dengue-zika/zika/zika-cases-and-clusters">
         https://www.nea.gov.sg/dengue-zika/zika/zika-cases-and-clusters
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sbref400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E-E
          </given-names>
         </name>
         <name>
          <surname>
           Goh
          </surname>
          <given-names>
           K-T
          </given-names>
         </name>
         <name>
          <surname>
           Gubler
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dengue prevention and 35 years of vector control in Singapore
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         887
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16707042
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="sec1" sec-type="supplementary-material">
      <title>
       Supplementary Material
      </title>
      <p id="para420">
       <supplementary-material content-type="local-data" id="ecomp10">
        <caption>
         <title>
          Supplementary appendix
         </title>
        </caption>
        <media xlink:href="mmc1.pdf">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ceack10">
      <sec>
       <title>
        Acknowledgments
       </title>
       <p>
        This study was supported by the
        <funding-source id="GS1">
         Singapore Population Health Improvement Centre
        </funding-source>
        (NMRC/CG/C026/2017_NUHS).
       </p>
      </sec>
     </ack>
     <ack>
      <title>
       Contributors
      </title>
      <p>
       JRK, BLD, and ARC designed the experiments. JRK and BLD created the models. JRK ran the simulations. BLD interpreted the results and wrote the manuscript. MP, YS, HS, JTL, and CT collected data for the models.
      </p>
     </ack>
     <ack>
      <title>
       Declaration of interests
      </title>
      <p>
       We declare no competing interests.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Lancet Psychiatry
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Lancet Psychiatry
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Lancet. Psychiatry
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2215-0366
      </issn>
      <issn pub-type="epub">
       2215-0374
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32304649
      </article-id>
      <article-id pub-id-type="pmc">
       7159850
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2215-0366(20)30168-1
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S2215-0366(20)30168-1
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Holmes
         </surname>
         <given-names>
          Emily A
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="fn" rid="fn1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          O'Connor
         </surname>
         <given-names>
          Rory C
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="fn" rid="fn1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Perry
         </surname>
         <given-names>
          V Hugh
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Tracey
         </surname>
         <given-names>
          Irene
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au50">
        <name>
         <surname>
          Wessely
         </surname>
         <given-names>
          Simon
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff9">
         i
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au60">
        <name>
         <surname>
          Arseneault
         </surname>
         <given-names>
          Louise
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff9">
         i
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au70">
        <name>
         <surname>
          Ballard
         </surname>
         <given-names>
          Clive
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff11">
         k
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au80">
        <name>
         <surname>
          Christensen
         </surname>
         <given-names>
          Helen
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff12">
         l
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au90">
        <name>
         <surname>
          Cohen Silver
         </surname>
         <given-names>
          Roxane
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff13">
         m
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au100">
        <name>
         <surname>
          Everall
         </surname>
         <given-names>
          Ian
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff9">
         i
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au110">
        <name>
         <surname>
          Ford
         </surname>
         <given-names>
          Tamsin
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff14">
         n
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au120">
        <name>
         <surname>
          John
         </surname>
         <given-names>
          Ann
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff16">
         p
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au130">
        <name>
         <surname>
          Kabir
         </surname>
         <given-names>
          Thomas
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff17">
         q
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au140">
        <name>
         <surname>
          King
         </surname>
         <given-names>
          Kate
         </given-names>
        </name>
        <degrees>
         BSc
        </degrees>
        <xref ref-type="aff" rid="aff18">
         r
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au150">
        <name>
         <surname>
          Madan
         </surname>
         <given-names>
          Ira
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff19">
         s
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au160">
        <name>
         <surname>
          Michie
         </surname>
         <given-names>
          Susan
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au170">
        <name>
         <surname>
          Przybylski
         </surname>
         <given-names>
          Andrew K
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff8">
         h
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au180">
        <name>
         <surname>
          Shafran
         </surname>
         <given-names>
          Roz
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au190">
        <name>
         <surname>
          Sweeney
         </surname>
         <given-names>
          Angela
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff20">
         t
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au200">
        <name>
         <surname>
          Worthman
         </surname>
         <given-names>
          Carol M
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff21">
         u
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au210">
        <name>
         <surname>
          Yardley
         </surname>
         <given-names>
          Lucy
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff22">
         v
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au220">
        <name>
         <surname>
          Cowan
         </surname>
         <given-names>
          Katherine
         </given-names>
        </name>
        <degrees>
         MA
        </degrees>
        <xref ref-type="aff" rid="aff23">
         w
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au230">
        <name>
         <surname>
          Cope
         </surname>
         <given-names>
          Claire
         </given-names>
        </name>
        <degrees>
         PhD
        </degrees>
        <email>
         claire.cope@acmedsci.ac.uk
        </email>
        <xref ref-type="aff" rid="aff24">
         x
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au240">
        <name>
         <surname>
          Hotopf
         </surname>
         <given-names>
          Matthew
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff9">
         i
        </xref>
        <xref ref-type="aff" rid="aff10">
         j
        </xref>
        <xref ref-type="fn" rid="fn2">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au250">
        <name>
         <surname>
          Bullmore
         </surname>
         <given-names>
          Ed
         </given-names>
        </name>
        <degrees>
         Prof
        </degrees>
        <degrees>
         PhD
        </degrees>
        <xref ref-type="aff" rid="aff14">
         n
        </xref>
        <xref ref-type="aff" rid="aff15">
         o
        </xref>
        <xref ref-type="fn" rid="fn2">
         †
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Psychology, Uppsala University, Uppsala, Sweden
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Suicidal Behaviour Research Laboratory, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       UK Dementia Research Institute, University College London, London, UK
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       UCL Centre for Behaviour Change, University College London, London, UK
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       UCL Great Ormond Street Institute of Child Health, University College London, London, UK
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
      </aff>
      <aff id="aff8">
       <label>
        h
       </label>
       Oxford Internet Institute, University of Oxford, Oxford, UK
      </aff>
      <aff id="aff9">
       <label>
        i
       </label>
       Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
      </aff>
      <aff id="aff10">
       <label>
        j
       </label>
       NIHR Biomedical Research Centre at the Maudsley, Maudsley Hospital, London, UK
      </aff>
      <aff id="aff11">
       <label>
        k
       </label>
       University of Exeter Medical School, University of Exeter, Exeter, UK
      </aff>
      <aff id="aff12">
       <label>
        l
       </label>
       Black Dog Institute, Sydney, Australia
      </aff>
      <aff id="aff13">
       <label>
        m
       </label>
       Department of Psychological Science, Department of Medicine, and Program in Public Health, University of California, Irvine, USA
      </aff>
      <aff id="aff14">
       <label>
        n
       </label>
       Department of Psychiatry, University of Cambridge, Cambridge, UK
      </aff>
      <aff id="aff15">
       <label>
        o
       </label>
       Department of Research and Development, Cambridgeshire &amp; Peterborough NHS Foundation Trust, Cambridge, UK
      </aff>
      <aff id="aff16">
       <label>
        p
       </label>
       Swansea University Medical School, Swansea University, Swansea, UK
      </aff>
      <aff id="aff17">
       <label>
        q
       </label>
       The McPin Foundation, London, UK
      </aff>
      <aff id="aff18">
       <label>
        r
       </label>
       Independent, Cambridge, UK
      </aff>
      <aff id="aff19">
       <label>
        s
       </label>
       Department of Occupational Health, Guy's and St Thomas' NHS Foundation Trust, London, UK
      </aff>
      <aff id="aff20">
       <label>
        t
       </label>
       Population Health Research Institute, St George's University of London, London, UK
      </aff>
      <aff id="aff21">
       <label>
        u
       </label>
       Anthropology Faculty, Emory University, Atlanta, USA
      </aff>
      <aff id="aff22">
       <label>
        v
       </label>
       School of Psychological Science, University of Bristol, Bristol, UK
      </aff>
      <aff id="aff23">
       <label>
        w
       </label>
       Katherine Cowan Consulting Ltd, St Leonards-on-Sea, UK
      </aff>
      <aff id="aff24">
       <label>
        x
       </label>
       Academy of Medical Sciences, London, UK
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Correspondence to: Dr Claire Cope, Academy of Medical Sciences, London W1B 1QH, UK
        <email>
         claire.cope@acmedsci.ac.uk
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         *
        </label>
        <p id="cenpara10">
         Joint first authors
        </p>
       </fn>
       <fn id="fn2">
        <label>
         †
        </label>
        <p id="cenpara20">
         Joint last authors
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        15
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ceab10">
       <title>
        Summary
       </title>
       <p>
        The coronavirus disease 2019 (COVID-19) pandemic is having a profound effect on all aspects of society, including mental health and physical health. We explore the psychological, social, and neuroscientific effects of COVID-19 and set out the immediate priorities and longer-term strategies for mental health science research. These priorities were informed by surveys of the public and an expert panel convened by the UK Academy of Medical Sciences and the mental health research charity, MQ: Transforming Mental Health, in the first weeks of the pandemic in the UK in March, 2020. We urge UK research funding agencies to work with researchers, people with lived experience, and others to establish a high level coordination group to ensure that these research priorities are addressed, and to allow new ones to be identified over time. The need to maintain high-quality research standards is imperative. International collaboration and a global perspective will be beneficial. An immediate priority is collecting high-quality data on the mental health effects of the COVID-19 pandemic across the whole population and vulnerable groups, and on brain function, cognition, and mental health of patients with COVID-19. There is an urgent need for research to address how mental health consequences for vulnerable groups can be mitigated under pandemic conditions, and on the impact of repeated media consumption and health messaging around COVID-19. Discovery, evaluation, and refinement of mechanistically driven interventions to address the psychological, social, and neuroscientific aspects of the pandemic are required. Rising to this challenge will require integration across disciplines and sectors, and should be done together with people with lived experience. New funding will be required to meet these priorities, and it can be efficiently leveraged by the UK's world-leading infrastructure. This Position Paper provides a strategy that may be both adapted for, and integrated with, research efforts in other countries.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec id="cesec10">
     <title>
      Introduction
     </title>
     <p id="para430">
      It is already evident that the direct and indirect psychological and social effects of the coronavirus disease 2019 (COVID-19) pandemic are pervasive and could affect mental health now and in the future. The pandemic is occurring against the backdrop of increased prevalence of mental health issues in the UK in recent years in some groups.
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      Furthermore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, might infect the brain or trigger immune responses that have additional adverse effects on brain function and mental health in patients with COVID-19.
     </p>
     <p id="para440">
      Research funders and researchers must deploy resources to understand the psychological, social, and neuroscientific effects of the COVID-19 pandemic. Mobilisation now will allow us to apply the learnings gained to any future periods of increased infection and lockdown, which will be particularly important for front-line workers and for vulnerable groups, and to future pandemics. We propose a framework for the prioritisation and coordination of essential, policy-relevant psychological, social, and neuroscientific research, to ensure that any investment is efficiently targeted to the crucial mental health science questions as the pandemic unfolds. We use the term mental health sciences to reflect the many different disciplines, including, but not limited to, psychology, psychiatry, clinical medicine, behavioural and social sciences, and neuroscience, that will need to work together in a multidisciplinary fashion together with people with lived experience of mental health issues or COVID-19 to address these research priorities.
     </p>
     <p id="para450">
      The UK has powerful advantages in mounting a successful response to the pandemic, including strong existing research infrastructure and expertise, but the research community must act rapidly and collaboratively if it is to deal with the growing threats to mental health. A fragmented research response, characterised by small-scale and localised initiatives, will not yield the clear insights necessary to guide policy makers or the public. Rigorous scientific and ethical review of protocols and results remains the cornerstone of safeguarding patients and upholding research standards. Deploying a mental health science perspective
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      to the pandemic will also inform population-level behaviour change initiatives aimed at reducing the spread of the virus. International comparisons will be especially helpful in this regard. In this Position Paper, we explore the psychological, social, and neuroscientific effects of COVID-19 and set out clear immediate priorities and longer-term strategies for each of these aspects.
     </p>
     <p id="para460">
      We also surveyed the public and people with lived experience of mental ill-health (
      <xref ref-type="boxed-text" rid="box1">
       panel 1
      </xref>
      ). The general population survey, done by Ipsos MORI,
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      revealed widespread concerns about the effect of social isolation or social distancing on wellbeing; increased anxiety, depression, stress, and other negative feelings; and concern about the practical implications of the pandemic response, including financial difficulties. The prospect of becoming physically unwell with COVID-19 ranked lower than these issues related to the social and psychological response to the pandemic. The MQ: Transforming Mental Health stakeholder survey of people with lived experience of a mental health issue likewise highlighted general concerns about social isolation and increased feelings of anxiety and depression. More specifically, stakeholders frequently expressed concerns about exacerbation of pre-existing mental health issues, greater difficulty in accessing mental health support and services under pandemic conditions, and the effect of COVID-19 on the mental health of family members, especially children and older people. Both surveys are reported online.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      These findings, combined with the published scientific literature, informed the development of our research priorities. The surveys represent a snapshot of the current situation, but they will need to be repeated more rigorously over the course of the pandemic, and the research priorities reviewed.
      <boxed-text id="box1">
       <label>
        Panel 1
       </label>
       <caption>
        <title>
         Methodology
        </title>
       </caption>
       <p id="para10">
        This Position Paper summarises the priorities put forward by an interdisciplinary group of 24 world-leading experts, including people with lived experience of a mental health issue, from across the bio-psycho-social spectrum of expertise in mental health science in March and April, 2020. The experts were convened by the UK Academy of Medical Sciences and the mental health research charity, MQ: Transforming Mental Health. Members participated in an individual capacity, not as representatives of their organisations. A coordinating group of seven experts met daily over a period of two weeks to develop the research priorities, informed by input from the expert advisory group. Given the need to develop the research priorities rapidly to inform immediate funding priorities, extended evidence gathering and consultation was not possible. However, we are confident that the wide breadth of expertise on the expert group and their leading roles in their respective fields provide a wide-ranging and comprehensive view of the mental health and neuroscience research priorities now; priorities which should be reviewed and should evolve with the pandemic.
       </p>
       <p id="para20">
        Lived experience of a mental health issue was incorporated by four mechanisms. First, three representatives with lived experience provided input as part of the expert advisory group. Second, an online survey collected data on people's two biggest concerns about the mental health and wellbeing implications of the coronavirus disease 2019 (COVID-19) pandemic and the coping strategies used by patients. The survey was promoted via email to MQ's supporter network and via social media. In total, 2198 people completed the survey, submitting 4350 concerns about the mental health effects of the COVID-19 pandemic and 1987 responses about what has helped to maintain mental health and wellbeing during the pandemic. A thematic analysis of the full dataset was done. Third, two questions were asked on Ipsos MORI's online Omnibus survey to collect data on people's concerns about the effect of COVID-19 on mental wellbeing and what is helping people's mental wellbeing at this time. In total, 1099 interviews were completed with adults aged between 16 and 75 years from across England, Wales, and Scotland. Quotas were set and data were weighted to the offline population to ensure a nationally representative sample by gender, age, and region. Statistical analysis was done and any subgroup differences included are statistically significant at a 95% confidence interval unless stated otherwise. A summary report of the findings of both surveys and further methodological details can be found online.
        <xref ref-type="bibr" rid="bib4">
         <sup>
          4
         </sup>
        </xref>
        The Ipsos MORI tabular data can be found on its website.
        <xref ref-type="bibr" rid="bib5">
         <sup>
          5
         </sup>
        </xref>
        Finally, the manuscript was peer-reviewed by a reviewer with lived experience of a mental health issue. We acknowledge the limitations of our surveys, including the representativeness of the MQ sample, the short timescale for input, and the representativeness of online populations. We also acknowledge the restricted evidence gathering and opportunity for wider consultation of people with lived experience. However, combined, these four mechanisms of collecting input from people with lived experience provide important insight into people's concerns about the effect of COVID-19 on mental health and coping strategies within the very short timeframe.
       </p>
       <p id="para30">
        A living systematic map
        <xref ref-type="bibr" rid="bib6">
         <sup>
          6
         </sup>
        </xref>
        is tracking emerging empirical studies, systematic reviews, and modelling on COVID-19. As of April 1, 2020, 643 records were identified in the databases MEDLINE and Embase. Only ten of these were on mental health effects of the pandemic.
        <xref ref-type="bibr" rid="bib7">
         7
        </xref>
        ,
        <xref ref-type="bibr" rid="bib8">
         8
        </xref>
        ,
        <xref ref-type="bibr" rid="bib9">
         9
        </xref>
        ,
        <xref ref-type="bibr" rid="bib10">
         10
        </xref>
        ,
        <xref ref-type="bibr" rid="bib11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="bib12">
         12
        </xref>
        ,
        <xref ref-type="bibr" rid="bib13">
         13
        </xref>
        ,
        <xref ref-type="bibr" rid="bib14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="bib15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="bib16">
         16
        </xref>
       </p>
      </boxed-text>
     </p>
    </sec>
    <sec id="cesec20">
     <title>
      Psychology and individual factors: researching the effect of COVID-19 on mental health
     </title>
     <p id="para470">
      In this section, we focus on the psychological processes and effects in individual people related to COVID-19, such as cognition, emotion, and behaviour, that affect mental health (
      <xref ref-type="table" rid="tbl1">
       table 1
      </xref>
      ).
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Psychology and individual factors: the effect of COVID-19 on mental health
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th align="left">
           <bold>
            Immediate actions
           </bold>
          </th>
          <th align="left">
           <bold>
            Longer-term strategic programmes
           </bold>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           What is the effect of COVID-19 on risk of anxiety, depression, and other outcomes, such as self-harm and suicide?
          </td>
          <td align="left">
           Improve monitoring and reporting of the rates of anxiety, depression, self-harm, suicide, and other mental health issues; determine the efficacy of mechanistically based digital and non-digital interventions and evaluate optimal model(s) of implementation
          </td>
          <td align="left">
           Determine the mechanisms (eg, entrapment and loneliness) that explain the rates of anxiety, depression, self-harm, and suicide; understand the role of psychological factors in buffering the effect of social context on mental health issues; ascertain the longer-term consequences on wellbeing of COVID-19 for the young and older generations (and vulnerable groups)
          </td>
         </tr>
         <tr>
          <td align="left">
           What is the optimal structure for a mentally healthy life in the wake of COVID-19 and social or physical distancing?
          </td>
          <td align="left">
           Determine what psychological support is available to help front-line medical and health-care staff and their families; understand the psychological (eg, coping), physiological (eg, sleep and nutrition), and structural (eg, work rotas and daily routines) factors that protect or adversely affect mental health
          </td>
          <td align="left">
           Develop novel interventions to protect mental wellbeing, including those based on positive mechanistically based components, such as altruism and prosocial behaviour and understanding of online life; understand how we optimise positive social resources and enhance resilience in the face of stress; establish the effects of altruism on mental health and wellbeing in the wake of COVID-19
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          COVID-19=coronavirus disease 2019.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="cesec30">
      <title>
       What is the effect of COVID-19 on risk of anxiety, depression, and other outcomes, such as self-harm and suicide?
      </title>
      <p id="para480">
       Although a rise in symptoms of anxiety and coping responses to stress are expected during these extraordinary circumstances, there is a risk that prevalence of clinically relevant numbers of people with anxiety, depression, and engaging in harmful behaviours (such as suicide and self-harm) will increase. Of note, however, is that a rise in suicide is not inevitable, especially with national mitigation efforts.
       <xref ref-type="bibr" rid="bib17">
        <sup>
         17
        </sup>
       </xref>
      </p>
      <p id="para490">
       The potential fallout of an economic downturn on mental health is likely to be profound on those directly affected and their caregivers. The severe acute respiratory syndrome epidemic in 2003 was associated with a 30% increase in suicide in those aged 65 years and older; around 50% of recovered patients remained anxious; and 29% of health-care workers experienced probable emotional distress.
       <xref ref-type="bibr" rid="bib18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       Patients who survived severe and life-threatening illness were at risk of post-traumatic stress disorder and depression.
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       Many of the anticipated consequences of quarantine
       <xref ref-type="bibr" rid="bib14">
        <sup>
         14
        </sup>
       </xref>
       and associated social and physical distancing measures are themselves key risk factors for mental health issues. These include suicide and self-harm, alcohol and substance misuse, gambling, domestic and child abuse, and psychosocial risks (such as social disconnection, lack of meaning or anomie, entrapment, cyberbullying, feeling a burden, financial stress, bereavement, loss, unemployment, homelessness, and relationship breakdown).
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
      </p>
      <p id="para500">
       A major adverse consequence of the COVID-19 pandemic is likely to be increased social isolation and loneliness (as reflected in our surveys),
       <xref ref-type="bibr" rid="bib4">
        <sup>
         4
        </sup>
       </xref>
       which are strongly associated with anxiety, depression, self-harm, and suicide attempts across the lifespan.
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       Tracking loneliness and intervening early are important priorities. Crucially, reducing sustained feelings of loneliness and promoting belongingness are candidate mechanisms to protect against suicide, self-harm, and emotional problems.
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       Social isolation and loneliness are distinct and might represent different risk pathways.
      </p>
      <p id="para510">
       To inform management of COVID-19, it is vital to understand the socioeconomic effect of the policies used to manage the pandemic, which will inevitably have serious effects on mental health by increasing unemployment, financial insecurity, and poverty.
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="bib29">
        29
       </xref>
       Involvement of people with lived experience and rapid qualitative research with diverse people and communities will help to identify ways in which this negative effect might be alleviated. Achieving the right balance between infection control and mitigation of these negative socioeconomic effects must be considered.
       <xref ref-type="bibr" rid="bib30">
        <sup>
         30
        </sup>
       </xref>
      </p>
      <p id="para520">
       The immediate research priorities are to monitor and report rates of anxiety, depression, self-harm, suicide, and other mental health issues both to understand mechanisms and crucially to inform interventions. This should be adopted across the general population and vulnerable groups, including front-line workers. Monitoring must go beyond NHS record linkage to capture the real incidence in the community, because self-harm might become more hidden. We must harness existing datasets and ongoing longitudinal studies, and establish new cohorts with new ways of recording including detailed psychological factors.
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       Techniques assessing moment to moment changes in psychological risk factors should be embraced.
      </p>
      <p id="para530">
       Given the unique circumstances of COVID-19, data will be vital to determine causal mechanisms associated with poor mental health,
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       including loneliness and entrapment. To optimise effectiveness of psychological treatments, they need to be mechanistically informed—that is, targeting factors which are both causally associated with poor mental health and modifiable by an intervention.
       <xref ref-type="bibr" rid="bib31">
        <sup>
         31
        </sup>
       </xref>
       A one-size-fits-all response will not suffice because the effectiveness of interventions can vary across groups.
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       Digital psychological interventions that are mechanistically informed, alongside better understanding of the buffering effects of social relationships during stressful events, are required in the long term. The digital response is crucial,
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       not only because of social isolation measures but also because less than a third of people who die by suicide have been in contact with mental health services in the 12 months before death.
       <xref ref-type="bibr" rid="bib40">
        <sup>
         40
        </sup>
       </xref>
       Digital interventions for anxiety, depression, self-harm, and suicide include information provision, connectivity and triage, automated and blended therapeutic interventions (such as apps and online programmes), telephone calls and messages to reach those with poorer digital resources (digital poverty),
       <xref ref-type="bibr" rid="bib41">
        <sup>
         41
        </sup>
       </xref>
       suicide risk assessments, chatlines and forums, and technologies that can be used to monitor risk either passively or actively. The digital landscape extends beyond apps and requires an evidence base. Artificial intelligence-driven adaptive trials could help to evaluate effectiveness, while digital phenotyping could be helpful to ascertain early warning signs for mental ill-health.
       <xref ref-type="bibr" rid="bib42">
        <sup>
         42
        </sup>
       </xref>
      </p>
      <p id="para540">
       Looking beyond digital interventions (as not everyone has access to them), and ascertaining what other mechanistically based psychological interventions are effective and for whom is important.
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="bib43">
        43
       </xref>
       Risks and buffers for loneliness should be a focal target in interventions to protect wellbeing. The longer-term consequences of COVID-19 for the younger and older generations (and other groups at high risk, including workers, those with existing mental health conditions, and caregivers) are also unknown and must be a priority.
      </p>
     </sec>
     <sec id="cesec40">
      <title>
       How do individuals build optimal structures for a mentally healthy life that works for them in the wake of COVID-19 and social and physical distancing?
      </title>
      <p id="para550">
       The optimal structure of a mentally healthy life for individuals in the wake of COVID-19 needs to be mapped out. Structure will vary as a function of background and individual circumstances. Changes in sleep and lifestyle behaviours influence our mental health and stress response. Understanding the effective, individualised ways of coping in such a situation is of paramount importance.
       <xref ref-type="bibr" rid="bib44">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="bib45">
        45
       </xref>
       ,
       <xref ref-type="bibr" rid="bib46">
        46
       </xref>
       The social and personal resources (eg, seeing family and getting sufficient sleep) available to individuals can be important resilience-related factors for mitigating mental health difficulties under particularly stressful circumstances.
       <xref ref-type="bibr" rid="bib47">
        <sup>
         47
        </sup>
       </xref>
       We need research to foster positive social resources, resilience, and altruism.
      </p>
      <p id="para560">
       The immediate research priorities are to understand how front-line health and social care staff and their families can be supported to optimise coping strategies to mitigate symptoms of stress, and facilitate the implementation of preventive interventions in the future.
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib48">
        48
       </xref>
       During the COVID-19 pandemic, it is important that health and social care workers are supported to stay in work, the health, personal, social, and economic benefits of which are vast. Personalised psychological approaches are likely to be a key component to address complex mental health conditions, coping mechanisms, and prevention.
       <xref ref-type="bibr" rid="bib31">
        <sup>
         31
        </sup>
       </xref>
       Given the association between sleep disturbance and mental health,
       <xref ref-type="bibr" rid="bib49">
        <sup>
         49
        </sup>
       </xref>
       and the effect of sleep disturbance on the risk of suicide,
       <xref ref-type="bibr" rid="bib50">
        <sup>
         50
        </sup>
       </xref>
       research on mitigating the effect of such changes on mental health and stress response is required.
      </p>
      <p id="para570">
       The longer-term strategic research programmes are to develop novel interventions to protect mental wellbeing, including those based on positive mechanistically based components (ie, causal, modifiable factors), such as altruism and prosocial behaviour. This could include increased opportunities to elicit community support,
       <xref ref-type="bibr" rid="bib51">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="bib52">
        52
       </xref>
       exercise,
       <xref ref-type="bibr" rid="bib53">
        <sup>
         53
        </sup>
       </xref>
       social activities,
       <xref ref-type="bibr" rid="bib54">
        <sup>
         54
        </sup>
       </xref>
       training in assertiveness and conflict resolution,
       <xref ref-type="bibr" rid="bib55">
        <sup>
         55
        </sup>
       </xref>
       and group interventions that provide support through peers.
       <xref ref-type="bibr" rid="bib56">
        <sup>
         56
        </sup>
       </xref>
      </p>
      <p id="para580">
       The inclusion of altruism in UK Government health messages has likely had a positive effect on wellbeing compared with compulsory orders to stay at home.
       <xref ref-type="bibr" rid="bib14">
        <sup>
         14
        </sup>
       </xref>
       Key research questions include “What positive mechanistically based psychological interventions can be developed for mental wellbeing derived from theories of altruism and prosocial behaviour?” and “What can be learned from the large-scale roll-out of volunteer-based psychological interventions that will optimise the benefits to individuals and society?”
      </p>
      <p id="para590">
       Working from home, loss of employment, and social and physical distancing have abruptly interrupted many social opportunities important to physical and psychological health. It is important to research the mental health dimension of online life and investigate how changes in engagement with gaming and online platforms might inform interventions aimed at improving mental health. We must rapidly learn from successful existing strategies to maintain and build social resources and resilience and promote good mental health in specific populations moving forward.
      </p>
     </sec>
    </sec>
    <sec id="cesec50">
     <title>
      Social and population factors: the effect of COVID-19 on mental health
     </title>
     <p id="para600">
      Population-level factors, such as the effect of social distancing measures (more recently being redescribed as physical distancing)
      <xref ref-type="bibr" rid="bib57">
       <sup>
        57
       </sup>
      </xref>
      and other necessary public health measures, affect mental health within a syndemics approach (
      <xref ref-type="table" rid="tbl2">
       table 2
      </xref>
      ). By syndemics we mean intersecting global trends among demographics (eg, ageing, rising inequality) and health conditions (eg, chronic diseases and obesity) that yield resultant comorbidities. These interacting health effects and societal forces that fuel them combine to form syndemics, or complex knots of health determinants.
      <xref ref-type="bibr" rid="bib58">
       <sup>
        58
       </sup>
      </xref>
      Research priorities around COVID-19 require us to embrace complexity by deploying multidimensional perspectives.
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Social and population factors: the effect of COVID-19 on mental health
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th align="left">
           <bold>
            Immediate actions
           </bold>
          </th>
          <th align="left">
           <bold>
            Longer-term strategic programmes
           </bold>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           What are the mental health consequences of the COVID-19 lockdown and social isolation for vulnerable groups, and how can these be mitigated under pandemic conditions?
          </td>
          <td align="left">
           Determine the best ways of signposting and delivering mental health services for vulnerable groups, including online clinics and community support; identify and evaluate outreach methods to support those at risk of abuse within the home; ascertain which evidence-based interventions can be rapidly repurposed at scale for the COVID-19 pandemic, and identify intervention gaps requiring bespoke remotely delivered interventions to boost wellbeing and reduce mental health issues; swiftly provide interventions to promote mental wellbeing in front-line health-care workers exposed to stress and trauma that can be delivered now and at scale
          </td>
          <td align="left">
           On the basis of the intervention gaps identified, design bespoke approaches for population-level interventions targeted at the prevention and treatment of mental health symptoms (eg, anxiety) and at boosting coping and resilience (eg, exercise); develop innovative novel universal interventions on new mechanistically based targets from experimental and social sciences (eg, for loneliness consider befriending) that can help mental health; assess the effectiveness of arts-based and life-skills based interventions and other generative activities including exercise outdoors
          </td>
         </tr>
         <tr>
          <td align="left">
           What is the effect of repeated media consumption about COVID-19 in traditional and social media on mental health, and how can wellbeing be promoted?
          </td>
          <td align="left">
           Understand the role of repeated media consumption in amplifying distress and anxiety, and optimal patterns of consumption for wellbeing; develop strategies to prevent over-exposure to anxiety-provoking media, including how to encourage diverse populations to stay informed by authoritative sources they trust; mitigate and manage the effect of viewing distressing footage
          </td>
          <td align="left">
           Inform evidence-based media policy around pandemic reporting (eg, clearly identify authoritative sources, encourage companies to correct disinformation, and policies on traumatic footage); mitigate individuals' risk of misinformation (eg, improve health literacy and critical thinking skills and minimise sharing of misinformation); understand and harness positive uses of traditional media, online gaming, and social media platforms
          </td>
         </tr>
         <tr>
          <td align="left">
           What are the best methods for promoting successful adherence to behavioural advice about COVID-19 while enabling mental wellbeing and minimising distress?
          </td>
          <td align="left">
           Understand how health messaging can optimise behaviour change, and reduce unintended mental health issues; track perceptions of and responses to public health messages to allow iterative improvements, informed by mental health science
          </td>
          <td align="left">
           Synthesise evidence base of lessons learned for future pandemics, tailored to specific groups as required; motivate and enable people to prepare psychologically and plan practically for possible future scenarios; understand the facilitators and barriers for activities that promote good mental health, such as exercise; promote people's care and concern for others, fostering collective solidarity and altruism
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          COVID-19=coronavirus disease 2019.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="cesec60">
      <title>
       What are the mental health consequences of the COVID-19 lockdown and social isolation for vulnerable groups, and how can these be mitigated under pandemic conditions?
      </title>
      <p id="para610">
       We do not yet know the acute or long-term consequences of the COVID-19 lockdown and social isolation on mental health. Although worries and uncertainties about a pandemic are common, for some they can cause undue distress and impairment to social and occupational functioning.
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       Across society, a sense of loss can stem from losing direct social contacts, and also range from loss of loved ones, to loss of employment, educational opportunities, recreation, freedoms, and supports. Existing evidence suggests some measures taken to control the pandemic might have a disproportionate effect on those most vulnerable (
       <xref ref-type="boxed-text" rid="box2">
        panel 2
       </xref>
       ).
       <boxed-text id="box2">
        <label>
         Panel 2
        </label>
        <caption>
         <title>
          Populations of interest, including vulnerable groups
         </title>
        </caption>
        <p id="para40">
         Although the whole population is affected by the coronavirus disease 2019 pandemic, specific sections of the population will experience it differently.
        </p>
        <p id="para50">
         Children, young people, and families will be affected by school closures. They might also be affected by exposure to substance misuse, gambling, domestic violence and child maltreatment, absence of free school meals, accommodation issues and overcrowding, parental employment, and change and disruption of social networks.
        </p>
        <p id="para60">
         Older adults and those with multimorbidities might be particularly affected by issues including isolation, loneliness, end of life care, and bereavement, which may be exacerbated by the so-called digital divide.
        </p>
        <p id="para70">
         People with existing mental health issues, including those with severe mental illnesses, might be particularly affected by relapse, disruptions to services, isolation, the possible exacerbation of symptoms in response to pandemic-related information and behaviours, and changes in mental health law.
        </p>
        <p id="para80">
         Front-line health-care workers might be affected by fears of contamination, moral injury, disruption of normal supportive structures, work stress, and retention issues.
        </p>
        <p id="para90">
         People with learning difficulties and neurodevelopmental disorders might be affected by changes and disruption to support and routines, isolation, and loneliness.
        </p>
        <p id="para100">
         Society might experience increased social cohesion and communitarianism, but also be negatively affected by increased health inequalities, increased food bank use, increased race-based attacks, and other trauma. Rural communities might also be affected differently to urban communities.
        </p>
        <p id="para110">
         Socially excluded groups, including prisoners, the homeless, and refugees, might require a tailored response.
        </p>
        <p id="para120">
         People on low incomes face job and financial insecurity, cramped housing, and poor access to the internet and technology.
        </p>
       </boxed-text>
      </p>
      <p id="para620">
       Vulnerable groups include those with pre-existing mental or physical health issues (including those with severe mental illnesses), recovered individuals, and those who become mentally unwell (eg, in response to anxiety and loneliness surrounding the pandemic;
       <xref ref-type="boxed-text" rid="box2">
        panel 2
       </xref>
       ).
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       Therefore, loss of access to mental health support, alongside loss of positive activities, might increase vulnerability during COVID-19 lockdown. Increased feelings of anxiety and depression in response to the outbreak have been highlighted already.
       <xref ref-type="bibr" rid="bib63">
        <sup>
         63
        </sup>
       </xref>
       Health workers who come in close contact with the virus and are exposed to traumatic events, such as death and dying, while making highly challenging decisions, are particularly at risk of stress responses.
       <xref ref-type="bibr" rid="bib15">
        <sup>
         15
        </sup>
       </xref>
      </p>
      <p id="para630">
       The pandemic intersects with rising mental health issues in childhood and adolescence.
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       Ascertaining and mitigating the effects of school closures for youth seeking care is urgent and essential, given that school is often the first place children and adolescents seek help,
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       as is considering vulnerabilities, such as special educational needs and developmental disorders, and finding therapeutic levers.
       <xref ref-type="bibr" rid="bib67">
        <sup>
         67
        </sup>
       </xref>
       For the older population, promoting good mental health is important during self-isolation, which can be compounded by lifestyle restrictions, exacerbated loneliness, comorbidities (such as dementia), and feelings of worry and guilt for using resources.
       <xref ref-type="bibr" rid="bib68">
        <sup>
         68
        </sup>
       </xref>
       There is an acute need to identify, in consultation with people with lived experience, remotely delivered interventions that support those at risk of abuse.
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
      </p>
      <p id="para640">
       The immediate research priorities are to reduce mental health issues and support wellbeing in vulnerable groups in particular. A coordinating mechanism for pandemic mental health interventions is required for the agile identification of interventions that can be repurposed, alongside the identification of intervention gaps that will require bespoke de novo design, and the evaluation and roll-out of remotely delivered interventions. By the term intervention, we mean interventions of all sorts that make a difference to mental health, including population-level policy, occupational guidelines, and psychological interventions.
      </p>
      <p id="para650">
       We need to gather high-quality data rapidly to ascertain the effects of lockdown and social isolation over time. Innovative research is needed to establish ways to mitigate and manage mental health risks and inform interventions under pandemic conditions.
      </p>
      <p id="para660">
       Research to support vulnerable groups needs to consider cross-cutting themes (such as the physical absence of schools and clinics) to create methods to provide connectivity and support; promote rapid innovation in mental health services that can be remotely signposted and delivered (including online clinics and community support); identify and evaluate means to support those at risk of abuse within the home (eg, online outreach); and swiftly provide interventions to promote mental wellbeing in front-line health workers. By identifying cross-cutting research themes, interventions to help specific vulnerable populations should be leveraged to help other vulnerable groups.
      </p>
      <p id="para670">
       With regard to the longer-term priorities, health services research must reliably and iteratively inform remotely delivered mental health resources, such as digital clinics, to efficiently manage mental health issues in an adaptive and flexible manner.
       <xref ref-type="bibr" rid="bib71">
        <sup>
         71
        </sup>
       </xref>
       This requires a coordinating mechanism to prioritise and streamline efforts, working with service users to optimise signposting and delivery and define therapeutic targets that matter from a user perspective (eg, loss, loneliness). Such a mechanism requires a range of disciplines, including psychology, digital science, and social sciences.
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="bib72">
        72
       </xref>
       International collaboration will ensure the necessary research skills and expertise. Research should harness internet-based social media and gaming using existing platforms and be cognisant of the so-called digital divide, which leaves 15% of Britons without internet access.
       <xref ref-type="bibr" rid="bib73">
        <sup>
         73
        </sup>
       </xref>
      </p>
      <p id="para680">
       Research for population-level interventions will require rapid evolution of approaches, starting with testing whether existing digital interventions can be repurposed, such as physical activity, sleep, and stress management programmes, as well as targeted approaches for the prevention and treatment of established mental health symptoms (eg, anxiety and worry).
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="bib74">
        74
       </xref>
       Tailoring of such universal interventions will need to be informed by experimental and social science (eg, for loneliness, befriending, and physical activity).
       <xref ref-type="bibr" rid="bib75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="bib76">
        76
       </xref>
       The effectiveness of arts-based interventions also needs to be assessed
       <xref ref-type="bibr" rid="bib77">
        <sup>
         77
        </sup>
       </xref>
       as do other generative activities that boost positive coping and resilience throughout society, from community-based activities, to life-skills classes, to exercising outdoors.
       <xref ref-type="bibr" rid="bib4">
        <sup>
         4
        </sup>
       </xref>
       The effectiveness of all interventions requires rigorous evaluation and implementation to avoid recommending a plethora of apps with no evidence base.
       <xref ref-type="bibr" rid="bib78">
        <sup>
         78
        </sup>
       </xref>
       Interventions at the population level should be repurposed, developed, and tested in a virtuous loop to create the necessary evidence base.
      </p>
     </sec>
     <sec id="cesec70">
      <title>
       What is the effect of repeated media consumption about COVID-19 through traditional media and social media on mental health, and how can wellbeing be promoted?
      </title>
      <p id="para690">
       People seek trusted information via the media, which can provide swift, critical guidance regarding the pandemic. Media consumption can be adaptive and positive for mental health. However, reports of infectious diseases often use risk-elevating messages, which can amplify public anxiety.
       <xref ref-type="bibr" rid="bib79">
        <sup>
         79
        </sup>
       </xref>
       Social media can be a source of rapidly disseminated misinformation,
       <xref ref-type="bibr" rid="bib80">
        <sup>
         80
        </sup>
       </xref>
       amplifying perceptions of risk.
       <xref ref-type="bibr" rid="bib81">
        <sup>
         81
        </sup>
       </xref>
       Repeated media exposure to information about an infectious disease particularly can exacerbate stress responses, amplify worry, and impair functioning.
       <xref ref-type="bibr" rid="bib82">
        <sup>
         82
        </sup>
       </xref>
       Anxiety and uncertainty can drive additional media consumption and further distress, creating a cycle that can be difficult to break.
       <xref ref-type="bibr" rid="bib83">
        <sup>
         83
        </sup>
       </xref>
       Media-fuelled distress can promote behaviours that negatively affect the health-care system (eg, visits to emergency departments and hoarding of face masks), with downstream mental and physical health consequences.
       <xref ref-type="bibr" rid="bib84">
        <sup>
         84
        </sup>
       </xref>
      </p>
      <p id="para700">
       The immediate research priority is to better understand the role of repeated media consumption around COVID-19 in amplifying distress and mental ill-health in various groups, and the optimal patterns of consumption to promote wellbeing. Research is needed to inform future approaches, including strategies to help individuals to stay informed by authoritative sources, prevent over-exposure to media, and mitigate and help manage the effect of viewing images with traumatic content.
      </p>
      <p id="para710">
       Longer-term research priorities should inform evidence-based guidelines for media around pandemic reporting (eg, clearly identifying authoritative sources, limiting graphic footage, and encouraging social media companies to flag or correct disinformation and rumours). Research should also help to develop strategies to mitigate an individual's risk of exposure to misinformation and amplification of anxiety by minimising sharing of misinformation, and promoting strategies for managing the emotional consequences. Adaptive and positive uses of traditional media and social media, such as influencers, should be understood and harnessed. Understanding the effect of pandemic media on various vulnerable groups is essential.
      </p>
     </sec>
     <sec id="cesec80">
      <title>
       What are the best methods for promoting successful adherence to behavioural advice about COVID-19 while enabling mental wellbeing and minimising distress?
      </title>
      <p id="para720">
       Behavioural change—such as the three personal protective behaviours of handwashing, not touching the T-zone of the face, and tissue use, and social or physical distancing required to control the pandemic—necessitates ensuring people know what to do, are motivated to do it, and have the skills and opportunity to enact the changed behaviours.
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ,
       <xref ref-type="bibr" rid="bib86">
        86
       </xref>
       Messaging is key for good knowledge,
       <xref ref-type="bibr" rid="bib86">
        <sup>
         86
        </sup>
       </xref>
       but public health messaging needs to draw on behavioural science if it is to be effective and avoid unintended consequences. We know that the more concerned people are in pandemics, the more likely they are to adhere to advice.
       <xref ref-type="bibr" rid="bib59">
        <sup>
         59
        </sup>
       </xref>
       However, increasing concern experienced by the public might heighten distress, which could undermine adherence or exacerbate existing mental health issues. Anxiety can be fuelled by uncertainty and by fears of risk of harm to self or others. For example, feelings of paranoia
       <xref ref-type="bibr" rid="bib87">
        <sup>
         87
        </sup>
       </xref>
       can be heavily influenced by anxiety, and symptoms of obsessive compulsive disorder
       <xref ref-type="bibr" rid="bib88">
        <sup>
         88
        </sup>
       </xref>
       can be associated with fear of contagion and rigid handwashing.
       <xref ref-type="bibr" rid="bib89">
        <sup>
         89
        </sup>
       </xref>
       Increasing people's confidence and clarity in what they need to do fosters adherence to health behaviours,
       <xref ref-type="bibr" rid="bib90">
        <sup>
         90
        </sup>
       </xref>
       and can help people to manage psychological distress.
      </p>
      <p id="para730">
       Immediate research on COVID-19 health messaging is urgently required to both optimise health behaviour change and to reduce unintended mental health issues, which will be required in the event of a second wave of infection. Research should prioritise message content, format, and delivery modes and behavioural change alongside risk communication, and consider how this might need to vary for diverse groups. A virtuous cycle that tracks perceptions of and responses to public health messages during this pandemic will enable iterative improvements. It must be informed by mental health science
       <xref ref-type="bibr" rid="bib3">
        <sup>
         3
        </sup>
       </xref>
       to close the knowledge-to-implementation gap (eg, between effective behaviour messages and maladaptive consequences).
      </p>
      <p id="para740">
       Longer-term research priorities are to create an evidence base of lessons learned to plan for future pandemics—that is, detailing how to foster a rapid and coordinated response regarding health messaging from governments
       <xref ref-type="bibr" rid="bib91">
        <sup>
         91
        </sup>
       </xref>
       and simultaneously to develop effective systems embedded in communities to reach out and access the most vulnerable groups in our society, including how to motivate and enable people to prepare psychologically and plan practically for possible future scenarios, and how to promote people's care and concern for others, fostering a sense of collective solidarity and altruism. The optimal messaging should be tailored (including digitally) to different social groups to connect diverse segments of the population to appropriate mental health information resources.
      </p>
     </sec>
    </sec>
    <sec id="cesec90">
     <title>
      Neuroscience: effects of the virus on brain health and mental health
     </title>
     <p id="para750">
      Almost nothing is known with certainty about the effect of SARS-CoV-2 infection on the human nervous system. SARS-CoV-2 is a zoonotic virus and a review from 2005 suggested that about half of zoonotic virus epidemics have been caused by neurotropic viruses that invade the CNS.
      <xref ref-type="bibr" rid="bib92">
       <sup>
        92
       </sup>
      </xref>
      The closely related coronaviruses responsible for the severe acute respiratory syndrome epidemic in 2003 and the so-called Middle East respiratory syndrome in 2012 are biologically neurotropic and clinically neurotoxic, causing mental health and neurological disorders.
      <xref ref-type="bibr" rid="bib93">
       93
      </xref>
      ,
      <xref ref-type="bibr" rid="bib94">
       94
      </xref>
      ,
      <xref ref-type="bibr" rid="bib95">
       95
      </xref>
      SARS-Cov-2 has a similar receptor-binding domain structure to SARS-CoV and probably shares its neurotropism and neurotoxicity (
      <xref ref-type="boxed-text" rid="box3">
       panel 3
      </xref>
      ).
      <xref ref-type="bibr" rid="bib96">
       <sup>
        96
       </sup>
      </xref>
      <boxed-text id="box3">
       <label>
        Panel 3
       </label>
       <caption>
        <title>
         Neuroscience: effects of the virus on brain health and mental health
        </title>
       </caption>
       <p id="para130">
        <bold>
         Immediate actions
        </bold>
       </p>
       <p id="para140">
        <list id="celist10" list-type="simple">
         <list-item id="celistitem10">
          <label>
           •
          </label>
          <p id="para150">
           Build a neuropsychological database of UK coronavirus disease 2019 cases (standardised, longitudinally repeated, data at scale) which is clinically and geographically inclusive
          </p>
         </list-item>
         <list-item id="celistitem20">
          <label>
           •
          </label>
          <p id="para160">
           Expand facilities for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected tissue handling
          </p>
         </list-item>
        </list>
       </p>
       <p id="para170">
        <bold>
         Longer-term strategic research programmes
        </bold>
       </p>
       <p id="para180">
        <list id="celist20" list-type="simple">
         <list-item id="celistitem30">
          <label>
           •
          </label>
          <p id="para190">
           Understand how SARS-CoV-2 might enter and propagate through the brain and how the immune response to SARS-CoV-2 infection contributes to mental health and neurological symptoms
          </p>
         </list-item>
         <list-item id="celistitem40">
          <label>
           •
          </label>
          <p id="para200">
           Investigate the long-term relationship between SARS-CoV-2 infection and post-infective fatigue or depressive syndromes
          </p>
         </list-item>
         <list-item id="celistitem50">
          <label>
           •
          </label>
          <p id="para210">
           Validate clinical biomarkers of SARS-CoV-2 brain infection using MRI and other methods
          </p>
         </list-item>
         <list-item id="celistitem60">
          <label>
           •
          </label>
          <p id="para220">
           Develop interventions to interrupt or prevent the adverse biological effects of SARS-CoV-2 on brain function and mental health, including repurposed drugs
          </p>
         </list-item>
        </list>
       </p>
      </boxed-text>
     </p>
     <p id="para760">
      Neurological symptoms of COVID-19 infection are common, diverse, and often severe. In a retrospective study of 214 patients in Wuhan, China 36% had CNS symptoms or disorders and the subgroup of 88 patients with severe respiratory disease had significantly increased frequency of CNS problems (45%).
      <xref ref-type="bibr" rid="bib97">
       <sup>
        97
       </sup>
      </xref>
      The problems reported include dizziness, headache, loss of smell (anosmia), loss of taste (ageusia), muscle pain and weakness, impaired consciousness, and cerebrovascular complications. Similar reports have begun to emerge from Italy.
      <xref ref-type="bibr" rid="bib98">
       <sup>
        98
       </sup>
      </xref>
      Some of these acute neurological presentations could reflect systemic aspects of infection, such as disseminated intravascular coagulation causing strokes or intense inflammation and hypoxia causing delirium.
     </p>
     <p id="para770">
      SARS-CoV-2 infection of the brain could be a contributor to the core medical syndrome of respiratory distress and failure in patients with COVID-19.
      <xref ref-type="bibr" rid="bib99">
       <sup>
        99
       </sup>
      </xref>
      Viral infection of the lung alveoli is the immediate cause of severe acute respiratory syndrome; but viral infection of key brainstem nuclei could disrupt the normal rhythms and homoeostatic control of respiration. This idea needs to be tested rapidly
      <xref ref-type="bibr" rid="bib99">
       <sup>
        99
       </sup>
      </xref>
      because if brainstem infection does contribute to the severity of SARS and the need for treatment in an intensive care unit, it could be directly relevant to the immediate COVID-19 crisis in the NHS and other health-care systems.
     </p>
     <p id="para780">
      In the longer term, it is possible that SARS-CoV-2 will have persistent direct neurotoxic effects and immune-mediated neurotoxic effects on the brain. The Spanish flu epidemic of 1918–19 was linked to a spike in incidence of post-encephalitic Parkinsonism.
      <xref ref-type="bibr" rid="bib100">
       <sup>
        100
       </sup>
      </xref>
      Currently, it is not known if SARS-CoV-2 infection could cause mental health or neurodegenerative disorders immediately or years after the acute respiratory phase of COVID-19 has passed, but action is needed now to build the research capacity to test these potentially important biological causes of COVID-19-related mental illness.
     </p>
     <p id="para790">
      Immediate actions include the development of a neuropsychological database of COVID-19 cases to bring together standardised, longitudinally repeated data at scale both from the clinic for those needing hospital treatment and by online assessments for patients in isolation at home. Following the progression of clinical symptoms over time will be key to understanding and predicting the effects of infection on the CNS.
     </p>
     <p id="para800">
      Facilities for SARS-CoV-2-infected tissue handling need to be expanded to examine human brain tissue post mortem, which is crucial to understanding the neurotropic and neurotoxic properties of the virus. Facilities equipped to safely handle human (or animal) brain tissue infected with SARS-CoV-2 are currently very few in number. We recommend building pathology and molecular neuroscience networks to enable brain and other tissue to be collected at autopsy and examined for viral infection and damage. This will require protocols for tissue collection and examination in appropriate laboratory facilities to protect researchers and other staff at all times.
     </p>
     <p id="para810">
      The longer-term research priorities are to understand the mechanisms by which SARS-CoV-2 might enter the brain. There are two conceivable pathways: neuronal or vascular.
      <xref ref-type="bibr" rid="bib101">
       <sup>
        101
       </sup>
      </xref>
      The neuronal pathway, used by other coronaviruses,
      <xref ref-type="bibr" rid="bib102">
       102
      </xref>
      ,
      <xref ref-type="bibr" rid="bib103">
       103
      </xref>
      is to invade a specialist sensory receptor in peripheral tissue, travel by the axonal transport systems to the brainstem, and propagate between neurons by trans-synaptic mechanisms. It is not known whether SARS-CoV-2 can follow the same path to infect the human brain or whether it invades nerve cells by hijacking angiotensin converting enzyme 2 (ACE2),
      <xref ref-type="bibr" rid="bib104">
       104
      </xref>
      ,
      <xref ref-type="bibr" rid="bib105">
       105
      </xref>
      ,
      <xref ref-type="bibr" rid="bib106">
       106
      </xref>
      despite neurons expressing low amounts of the protein, as described in a preprint
      <xref ref-type="bibr" rid="bib107">
       <sup>
        107
       </sup>
      </xref>
      and two other published studies.
      <xref ref-type="bibr" rid="bib108">
       108
      </xref>
      ,
      <xref ref-type="bibr" rid="bib109">
       109
      </xref>
      Alternatively, SARS-CoV-2 might invade the brain from the blood, if circulating particles of the virus were transported across the blood–brain barrier by binding to ACE2 receptors expressed by endothelial cells,
      <xref ref-type="bibr" rid="bib109">
       <sup>
        109
       </sup>
      </xref>
      or if infected leucocytes could carry the virus with them as they migrate into the tissues as part of the immune response to infection.
      <xref ref-type="bibr" rid="bib110">
       <sup>
        110
       </sup>
      </xref>
      Better understanding of how the intense systemic immune response to SARS-CoV-2 infection affects mental health and neurological symptoms,
      <xref ref-type="bibr" rid="bib97">
       97
      </xref>
      ,
      <xref ref-type="bibr" rid="bib111">
       111
      </xref>
      ,
      <xref ref-type="bibr" rid="bib112">
       112
      </xref>
      and of the mechanisms of immune clearance of SARS-CoV-2, is also needed.
      <xref ref-type="bibr" rid="bib113">
       113
      </xref>
      ,
      <xref ref-type="bibr" rid="bib114">
       114
      </xref>
     </p>
     <p id="para820">
      Post-infectious fatigue and depressive syndromes have been associated with other epidemics, and it seems possible that the same will be true of the COVID-19 pandemic. Longitudinal studies, especially if commenced before or soon after the start of the current pandemic, will be crucial in establishing the often complex biological pathways between infection and mental health outcomes.
      <xref ref-type="bibr" rid="bib115">
       115
      </xref>
      ,
      <xref ref-type="bibr" rid="bib116">
       116
      </xref>
      ,
      <xref ref-type="bibr" rid="bib117">
       117
      </xref>
     </p>
     <p id="para830">
      Candidate biomarkers need to be evaluated to measure the effects of SARS-CoV-2 infection on the human brain and brainstem in living patients, including structural and functional MRI, diffusion-weighted MRI, quantitative cerebral blood flow imaging, and magnetic resonance spectroscopy. The 7 Tesla MRI technique has sufficient spatial resolution to measure functional connectivity between subcortical structures that constitute networks for respiratory control and distress.
      <xref ref-type="bibr" rid="bib118">
       <sup>
        118
       </sup>
      </xref>
      Other methods could include sampling cerebrospinal fluid or use of PET to measure brain inflammation; patient self-reporting or behavioural testing of smell, taste, and other cranial or vagal sensory functions; electrophysiological methods to measure brainstem function; and computerised tests of cognitive and emotional processing.
     </p>
     <p id="para840">
      Informed by greater understanding of the effects of viral infection on the nervous system and by more accurate biomarkers of brain function in patients with COVID-19, interventions need to be developed to interrupt or prevent the adverse biological effects of SARS-CoV-2 on brain function and mental health. Potential drug targets include putative mechanisms for neuronal invasion, interneuronal propagation, and immune clearance of SARS-CoV-2. Biological and clinical validation of these or other targets would enable experimental medicine studies or early clinical trials of repurposed drugs. For example, the ACE2 inhibitors already licensed for treatment of hypertension, and a licensed drug for reflux oesophagitis, camostat mesylate, that blocks the serine protease TMPRSS2
      <xref ref-type="bibr" rid="bib119">
       <sup>
        119
       </sup>
      </xref>
      (which operates with ACE2 to facilitate viral entry into cells) have already been advocated as repurposable drugs. There are many other potential candidates for drug repurposing described in a preprint,
      <xref ref-type="bibr" rid="bib120">
       <sup>
        120
       </sup>
      </xref>
      which could be a faster route to effective treatment for CNS infection than development of entirely new drugs or vaccines. Partnerships between researchers in academia and industry will be vital.
     </p>
    </sec>
    <sec id="cesec100">
     <title>
      Infrastructure and opportunities
     </title>
     <p id="para850">
      Many of the immediate priorities are for surveillance of general and specific populations for effects of SARS-CoV-2 infection on health, ranging from health behaviours, psychological symptoms, neuropsychiatric disorders, and mortality, including, but not limited to, suicide. The other immediate priority is to assemble cohorts to determine longer-term outcomes and provide a resource for nesting intervention studies, and a resource of interventions to monitor their effectiveness. We recommend three main routes. For each of these routes, there is a need to coordinate existing research infrastructure through shared protocols, research measures, and data assets, and to uphold the highest standards of scientific and ethical review. We urge the mental health science community to combine agility in initiating new or adapting existing research with collective scrutiny and collaboration.
     </p>
     <p id="para860">
      First, administrative data assets principally derived from existing electronic health records, with systems in place to interrogate these for research purposes, provide a means of identifying health effects at scale. Health Data Research UK is coordinating national efforts. Examples include the Clinical Practice Research Database
      <xref ref-type="bibr" rid="bib121">
       <sup>
        121
       </sup>
      </xref>
      and similar primary care databases; the Clinical Record Interactive Search
      <xref ref-type="bibr" rid="bib122">
       <sup>
        122
       </sup>
      </xref>
      and other related systems for the interrogation of mental health records; and CogStack
      <xref ref-type="bibr" rid="bib123">
       <sup>
        123
       </sup>
      </xref>
      for general hospital settings, which provides near real-time information from health records (eg, to provide feedback on neurological consequences of severe COVID-19). These systems should be linked between mental health services, acute medical services, and community health services to identify patterns and trends both in clinical populations and in individuals with confirmed or suspected COVID-19.
     </p>
     <p id="para870">
      Second, surveillance through recruitment platforms and existing cohorts has the benefit of embedding research on COVID-19 into studies where participants' mental or cognitive health has previously been ascertained. Existing cohorts or data platforms that can be rapidly deployed for COVID-19 research are likely to be particularly valuable. Examples include the National Institute for Health Research National Bioresource, a platform that already includes clinical and genetic data on participants, and could be deployed for rapid characterisation of mental health and neurological symptoms. UK Biobank has successfully done a web-based mental health survey of 160 000 individuals, and the ongoing neuroimaging studies of 100 000 individuals with some repeat imaging, provide an ideal opportunity to image the effect of SARS-CoV-2 infection on the brain and the brainstem via a before-and-after imaging comparison.
     </p>
     <p id="para880">
      Third, novel population-based studies on mental health and COVID-19 should be established, using appropriate epidemiologically robust survey methodology for both the whole population and specific groups of particular interest (eg, children and young people, front-line staff in health and social care, and people who have survived severe COVID-19). Priority should be given to assembling representive populations using explicit sampling frames. Finally, many other disciplines will be establishing similar studies and it is vital that the ascertainment of mental health should be embedded wherever possible.
     </p>
     <p id="para890">
      Whether using established or new cohorts, priority should be given to methods that can ascertain COVID-19 status, symptoms, and behaviours in as close to real-time as possible, providing a dynamic picture of change in illness status, social circumstances, and behaviours. Questions regarding COVID-19 and mental health symptoms and social stressors can readily be disseminated through smartphones. Passive data from smartphones can also give high temporal resolution to behaviours related to the pandemic. Cohorts should gain permissions for the linkage of records, including serological status, when mass testing becomes available, and consent for recruitment into nested substudies, including randomised trials of interventions.
     </p>
     <p id="para900">
      Patient and public involvement in research is a critical underpinning component to research. Given that the entire population has lived experience of the COVID-19 pandemic, researchers will need to be particularly mindful of consulting and collaborating with patient and public groups that reflect the diverse groups being studied when developing protocols, conducting research, and interpreting results (
      <xref ref-type="boxed-text" rid="box4">
       panel 4
      </xref>
      ).
      <boxed-text id="box4">
       <label>
        Panel 4
       </label>
       <caption>
        <title>
         Principles of good research practice in COVID-19 research
        </title>
       </caption>
       <p id="para230">
        <bold>
         Study design
        </bold>
       </p>
       <p id="para240">
        Researchers must continue to describe the patient group or population and the research question under study. A priori research questions are crucial. Sample size, sources of bias, participant characteristics (including sex, age, and ethnicity), and study design need to be carefully considered and must be appropriate to the research questions.
       </p>
       <p id="para250">
        <bold>
         Ethics
        </bold>
       </p>
       <p id="para260">
        Research on human participants should maintain high standards of ethical practice, including seeking research ethics committee approval.
        <xref ref-type="bibr" rid="bib124">
         <sup>
          124
         </sup>
        </xref>
        Committees now have fast-track procedures to expedite study start up. Ethical considerations for doing coronavirus disease 2019 (COVID-19)-related research have been published.
        <xref ref-type="bibr" rid="bib125">
         125
        </xref>
        ,
        <xref ref-type="bibr" rid="bib126">
         126
        </xref>
       </p>
       <p id="para270">
        <bold>
         Vulnerable groups
        </bold>
       </p>
       <p id="para280">
        Researchers should recognise the capacity of the pandemic to exacerbate health inequalities within populations, particularly affecting people with established mental health issues (including severe mental illnesses) and physical disability. Those with precarious or no employment or housing, or other forms of social inequality, such as digital poverty,
        <xref ref-type="bibr" rid="bib41">
         <sup>
          41
         </sup>
        </xref>
        should also be considered.
       </p>
       <p id="para290">
        <bold>
         Involvement of patients, people with lived experience, and the public
        </bold>
       </p>
       <p id="para300">
        Researchers should continue to engage and involve patients, people with lived experience, the public, and service providers in their work by mutually setting research questions, testing the acceptability of protocols and questionnaires, and interpreting results. Researchers should ensure that they discuss their research findings with participants.
       </p>
       <p id="para310">
        <bold>
         Harmonised data and measures
        </bold>
       </p>
       <p id="para320">
        There is an obvious need for researchers to use and share full study protocols and measures, where possible. This will facilitate comparisons between data and projects. The urgency of the research effort should be a strong driver for the principles of open science, reproducibility, and data sharing. The ready availability of analysis code and data is essential to verifying findings. Broad adoption of the registered reports publication model,
        <xref ref-type="bibr" rid="bib127">
         <sup>
          127
         </sup>
        </xref>
        including rapid peer review of study protocols before data collection, will help to minimise waste and ensure conclusions are empirically sound.
       </p>
       <p id="para330">
        <bold>
         Interdisciplinary working
        </bold>
       </p>
       <p id="para340">
        The challenge of the COVID-19 pandemic requires imaginative collaborations between disciplines, including, but not limited to, psychology, psychiatry, neuroscience, virology, intensive care medicine, and respiratory medicine. Previous experience with epidemics has shown the “essential role that the humanities and social sciences play in information, reduction of fear and stigma, prevention, screening, treatment adherence, and control policies”.
        <xref ref-type="bibr" rid="bib128">
         <sup>
          128
         </sup>
        </xref>
       </p>
       <p id="para350">
        <bold>
         Collaboration and coordination
        </bold>
       </p>
       <p id="para360">
        Where possible, research protocols should be deployed at scale harnessing existing research infrastructures, including the Clinical Research Networks, Biomedical Research Centres, Mental Health Translational Research Collaboration, MQ Data Science group, charities, service user groups, and professional bodies. To avoid waste and protect against participant fatigue, it is essential that there is national coordination across research groups. International collaboration and a global perspective would also be beneficial.
       </p>
      </boxed-text>
     </p>
    </sec>
    <sec id="cesec110">
     <title>
      Call for action
     </title>
     <p id="para910">
      Multidisciplinary mental health science research must be central to the international response to the COVID-19 pandemic, given the potential effects on individual and population mental health, and its potential effect on the brain function of some of those affected by the disease. There are important immediate insights to be gained, which could provide evidence-based guidance on responding to this pandemic and on how to promote mental health and wellbeing, and safeguard the brain, should future waves of infection emerge (
      <xref ref-type="boxed-text" rid="box5">
       panel 5
      </xref>
      ).
      <boxed-text id="box5">
       <label>
        Panel 5
       </label>
       <caption>
        <title>
         Rapid learnings to apply to future infection waves or pandemics
        </title>
       </caption>
       <p id="para370">
        <bold>
         The outputs of immediate research could help to inform responses to future infection waves or pandemics by identifying:
        </bold>
       </p>
       <p id="para380">
        <list id="celist30" list-type="simple">
         <list-item id="celistitem70">
          <label>
           •
          </label>
          <p id="para390">
           Mechanisms (eg, coping strategies and preventive interventions) to support vulnerable groups under pandemic conditions, such as front-line health and social care staff, those with pre-existing mental health issues, young people (aged ≤18 years), and older adults (aged ≥65 years)
          </p>
         </list-item>
         <list-item id="celistitem80">
          <label>
           •
          </label>
          <p id="para400">
           Interventions that can be delivered under pandemic conditions to reduce mental health issues and boost wellbeing, including those that can be repurposed
          </p>
         </list-item>
         <list-item id="celistitem90">
          <label>
           •
          </label>
          <p id="para410">
           Solutions to the effect of repeated media consumption about coronavirus disease 2019 (COVID-19) on the mental wellbeing of the population, to help individuals stay informed by authoritative sources while also preventing over-exposure and mitigating the effect of viewing traumatic content
          </p>
         </list-item>
         <list-item id="celistitem100">
          <label>
           •
          </label>
          <p id="para420">
           Methods for promoting more successful adherence to behavioural advice about COVID-19 while enabling mental wellbeing and minimising distress
          </p>
         </list-item>
        </list>
       </p>
      </boxed-text>
     </p>
     <p id="para920">
      The research priorities across the social, psychological, and neuroscientific aspects of this pandemic should be coordinated at a national and international level. We urge UK research funding agencies to work with researchers, people with lived experience, and others to establish a high-level coordination group to ensure that the mental health science research priorities are addressed swiftly, and that a firm evidence base is established for long-term studies. We need rigorous, peer-reviewed, ethically approved research codeveloped with people with lived experience that can be translated into effective interventions, rather than the current uncoordinated approach with a plethora of underpowered studies and surveys.
     </p>
     <p id="para930">
      The immediate priority is the collection of high-quality data on the mental health and psychological effects of the COVID-19 pandemic across the whole population and in specific vulnerable groups, and on brain function, cognition, and mental health for patients with COVID-19 at all clinical stages of infection and illness. These datasets must be brought together under a national data portal for rapid access and use.
     </p>
     <p id="para940">
      There is an urgent need for the discovery, evaluation, and refinement of mechanistically driven interventions to address the psychological, social, and neuroscientific aspects of this pandemic. This includes bespoke psychological interventions to boost wellbeing and minimise mental health risks across society, including in vulnerable groups, and experimental medicine studies to validate clinical biomarkers and repurpose new treatments for the potentially neurotoxic effects of the virus. There is an urgent need for research to address the effect of repeated pandemic-related media consumption and to optimise health messaging around COVID-19. Rising to this challenge will require integration across disciplines and sectors, including industry and health and social care.
     </p>
     <p id="para950">
      New funding will be required to meet these priorities, and it can be efficiently leveraged by the UK's world-leading neuroscience and mental health research infrastructure. The UK must connect with international funders and researchers to support a global response to the mental health and neurological challenges of this pandemic. In these challenging times, mental health science should be harnessed to serve society and benefit both mental and physical health in the long term.
     </p>
    </sec>
    <back>
     <ref-list id="bibl10">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref10" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           McManus
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bebbington
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Jenkins
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Brugha
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mental health and wellbeing in England: Adult Psychiatric Morbidity Survey 2014
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs10" xlink:href="https://files.digital.nhs.uk/pdf/q/3/mental_health_and_wellbeing_in_england_full_report.pdf">
         https://files.digital.nhs.uk/pdf/q/3/mental_health_and_wellbeing_in_england_full_report.pdf
        </ext-link>
        <year>
         2016
        </year>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ford
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Vizard
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Sadler
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Data resource profile: the mental health of children and young people surveys (MHCYP)
        </article-title>
        <source>
         Int J Epidemiol
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Jan 18.
        </comment>
        <pub-id pub-id-type="doi">
         10.1093/ije/dyz259
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Craske
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Graybiel
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological treatments: a call for mental-health science
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         511
        </volume>
        <year>
         2014
        </year>
        <fpage>
         287
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="pmid">
         25030152
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref40" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          The Academy of Medical Sciences
         </collab>
        </person-group>
        <ext-link ext-link-type="uri" id="interrefs30" xlink:href="http://www.acmedsci.ac.uk/COVIDmentalhealthsurveys">
         http://www.acmedsci.ac.uk/COVIDmentalhealthsurveys
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref50" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ipsos
          </surname>
          <given-names>
           MORI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19 and mental wellbeing
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs40" xlink:href="https://www.ipsos.com/ipsos-mori/en-uk/Covid-19-and-mental-wellbeing">
         https://www.ipsos.com/ipsos-mori/en-uk/Covid-19-and-mental-wellbeing
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref60" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lorenc
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Khouja
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Raine
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19: a living systematic map of the evidence
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs50" xlink:href="http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingsystematicmapoftheevidence/tabid/3765/Default.aspx">
         http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingsystematicmapoftheevidence/tabid/3765/Default.aspx
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations
        </article-title>
        <source>
         Gen Psychiatry
        </source>
        <volume>
         33
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         e100213
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sbref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019
        </article-title>
        <source>
         JAMA Netw Open
        </source>
        <volume>
         3
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         e203976
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sbref90" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China
        </article-title>
        <source>
         Int J Environ Res Public Health
        </source>
        <volume>
         17
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sbref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Online mental health services in China during the COVID-19 outbreak
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         7
        </volume>
        <year>
         2020
        </year>
        <fpage>
         e17
        </fpage>
        <lpage>
         e18
        </lpage>
        <pub-id pub-id-type="pmid">
         32085841
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sbref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bo
          </surname>
          <given-names>
           H-X
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China
        </article-title>
        <source>
         Psychol Med
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 27.
        </comment>
        <pub-id pub-id-type="doi">
         10.1017/S0033291720000999
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sbref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China
        </article-title>
        <source>
         Med Sci Monit
        </source>
        <volume>
         26
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         e923549
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sbref130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of COVID-19 epidemic declaration on psychological consequences: a study on active Weibo users
        </article-title>
        <source>
         Int J Environ Res Public Health
        </source>
        <volume>
         17
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         2032
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sbref140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The psychological impact of quarantine and how to reduce it: rapid review of the evidence
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         912
        </fpage>
        <lpage>
         920
        </lpage>
        <pub-id pub-id-type="pmid">
         32112714
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control
        </article-title>
        <source>
         Brain Behav Immun
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 10.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.bbi.2020.03.007
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           JZ
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           XP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mental health survey of 230 medical staff in a tertiary infectious disease hospital for COVID-19
        </article-title>
        <source>
         Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
        </source>
        <volume>
         38
        </volume>
        <year>
         2020
        </year>
        <fpage>
         e001
        </fpage>
        <pub-id pub-id-type="pmid">
         32131151
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <mixed-citation id="oref10" publication-type="other">
        Gunnell D, Appleby L, Arensman E, et al. Suicide risk and prevention during the COVID-19 pandemic.
        <italic>
         Lancet Psychiatry
        </italic>
        (in press).
       </mixed-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sbref170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           YT
          </given-names>
         </name>
         <name>
          <surname>
           Chau
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of epidemic outbreak: the case of severe acute respiratory syndrome (SARS) and suicide among older adults in Hong Kong
        </article-title>
        <source>
         Crisis
        </source>
        <volume>
         31
        </volume>
        <year>
         2010
        </year>
        <fpage>
         86
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         20418214
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sbref180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Scudds
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychosocial impact of SARS
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1326
        </fpage>
        <lpage>
         1327
        </lpage>
        <pub-id pub-id-type="pmid">
         15338536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sbref190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nickell
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Crighton
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Tracy
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychosocial effects of SARS on hospital staff: survey of a large tertiary care institution
        </article-title>
        <source>
         CMAJ
        </source>
        <volume>
         170
        </volume>
        <year>
         2004
        </year>
        <fpage>
         793
        </fpage>
        <lpage>
         798
        </lpage>
        <pub-id pub-id-type="pmid">
         14993174
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sbref200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Connor
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Nock
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The psychology of suicidal behaviour
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         1
        </volume>
        <year>
         2014
        </year>
        <fpage>
         73
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         26360404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sbref210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           John
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Glendenning
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Marchant
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Self-harm, suicidal behaviours, and cyberbullying in children and young people: systematic review
        </article-title>
        <source>
         J Med Internet Res
        </source>
        <volume>
         20
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e129
        </fpage>
        <pub-id pub-id-type="pmid">
         29674305
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turecki
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Brent
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Gunnell
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suicide and suicide risk
        </article-title>
        <source>
         Nat Rev Dis Primers
        </source>
        <volume>
         5
        </volume>
        <year>
         2019
        </year>
        <fpage>
         74
        </fpage>
        <pub-id pub-id-type="pmid">
         31649257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sbref230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elovainio
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hakulinen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pulkki-Råback
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contribution of risk factors to excess mortality in isolated and lonely individuals: an analysis of data from the UK Biobank cohort study
        </article-title>
        <source>
         Lancet Public Health
        </source>
        <volume>
         2
        </volume>
        <year>
         2017
        </year>
        <fpage>
         e260
        </fpage>
        <lpage>
         e266
        </lpage>
        <pub-id pub-id-type="pmid">
         28626828
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sbref240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Danese
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Caspi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lonely young adults in modern Britain: findings from an epidemiological cohort study
        </article-title>
        <source>
         Psychol Med
        </source>
        <volume>
         49
        </volume>
        <year>
         2019
        </year>
        <fpage>
         268
        </fpage>
        <lpage>
         277
        </lpage>
        <pub-id pub-id-type="pmid">
         29684289
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sbref250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Connor
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Kirtley
          </surname>
          <given-names>
           OJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The integrated motivational-volitional model of suicidal behaviour
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        <volume>
         373
        </volume>
        <year>
         2018
        </year>
        <object-id pub-id-type="publisher-id">
         20170268
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sbref260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stack
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suicide: media impacts in war and peace, 1910–1920
        </article-title>
        <source>
         Suicide Life Threat Behav
        </source>
        <volume>
         18
        </volume>
        <year>
         1988
        </year>
        <fpage>
         342
        </fpage>
        <lpage>
         357
        </lpage>
        <pub-id pub-id-type="pmid">
         3217963
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sbref270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barr
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Taylor-Robinson
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Scott-Samuel
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           McKee
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Stuckler
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suicides associated with the 2008-10 economic recession in England: time trend analysis
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         345
        </volume>
        <year>
         2012
        </year>
        <object-id pub-id-type="publisher-id">
         e5142
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sbref280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frasquilho
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Matos
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Salonna
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mental health outcomes in times of economic recession: a systematic literature review
        </article-title>
        <source>
         BMC Public Health
        </source>
        <volume>
         16
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         26728978
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sbref290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prieto
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Sacristán
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Problems and solutions in calculating quality-adjusted life years (QALYs)
        </article-title>
        <source>
         Health Qual Life Outcomes
        </source>
        <volume>
         1
        </volume>
        <year>
         2003
        </year>
        <fpage>
         80
        </fpage>
        <pub-id pub-id-type="pmid">
         14687421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sbref300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Ghaderi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Harmer
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The
         <italic>
          Lancet Psychiatry
         </italic>
         Commission on psychological treatments research in tomorrow's science
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         5
        </volume>
        <year>
         2018
        </year>
        <fpage>
         237
        </fpage>
        <lpage>
         286
        </lpage>
        <pub-id pub-id-type="pmid">
         29482764
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sbref310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kazdin
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mediators and mechanisms of change in psychotherapy research
        </article-title>
        <source>
         Annu Rev Clin Psychol
        </source>
        <volume>
         3
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         27
        </lpage>
        <pub-id pub-id-type="pmid">
         17716046
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sbref320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carl
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Witcraft
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Kauffman
          </surname>
          <given-names>
           BY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials
        </article-title>
        <source>
         Cogn Behav Ther
        </source>
        <volume>
         49
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         30760112
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sbref330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hawton
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Witt
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Salisbury
          </surname>
          <given-names>
           TLT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychosocial interventions following self-harm in adults: a systematic review and meta-analysis
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         3
        </volume>
        <year>
         2016
        </year>
        <fpage>
         740
        </fpage>
        <lpage>
         750
        </lpage>
        <pub-id pub-id-type="pmid">
         27422028
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sbref340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cuijpers
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cristea
          </surname>
          <given-names>
           IA
          </given-names>
         </name>
         <name>
          <surname>
           Karyotaki
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Reijnders
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hollon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Component studies of psychological treatments of adult depression: a systematic review and meta-analysis
        </article-title>
        <source>
         Psychother Res
        </source>
        <volume>
         29
        </volume>
        <year>
         2019
        </year>
        <fpage>
         15
        </fpage>
        <lpage>
         29
        </lpage>
        <pub-id pub-id-type="pmid">
         29115185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sbref350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spinhoven
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cuijpers
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Hollon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cognitive-behavioural therapy and personalized treatment: an introduction to the special issue
        </article-title>
        <source>
         Behav Res Ther
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 29.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.brat.2020.103595
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sbref360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Torok
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suicide prevention using self-guided digital interventions: a systematic review and meta-analysis of randomised controlled trials
        </article-title>
        <source>
         Lancet Digital Health
        </source>
        <volume>
         2
        </volume>
        <year>
         2020
        </year>
        <fpage>
         e25
        </fpage>
        <lpage>
         e36
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sbref370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garrido
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Millington
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Cheers
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         What works and what doesn't work? A systematic review of digital mental health interventions for depression and anxiety in young people
        </article-title>
        <source>
         Front Psychiatry
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <fpage>
         759
        </fpage>
        <pub-id pub-id-type="pmid">
         31798468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sbref380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lattie
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
         <name>
          <surname>
           Adkins
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Winquist
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Stiles-Shields
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wafford
          </surname>
          <given-names>
           QE
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Digital mental health interventions for depression, anxiety and enhancement of psychological well-being among college students: systematic review
        </article-title>
        <source>
         J Med Internet Res
        </source>
        <volume>
         21
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         e12869
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sbref390" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Healthcare quality improvement partnership
         </collab>
        </person-group>
        <article-title>
         National confidential inquiry into suicide and homicide by people with mental illness
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs90" xlink:href="http://www.hqip.org.www.bbmh.manchester.ac.uk/cmhs">
         www.hqip.org.www.bbmh.manchester.ac.uk/cmhs
        </ext-link>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sbref400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Robotham
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Simblett
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Curtis
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wykes
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Digital exclusion among mental health service users: qualitative investigation
        </article-title>
        <source>
         J Med Internet Res
        </source>
        <volume>
         21
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         e11696
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sbref410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huckvale
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Venkatesh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Christensen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety
        </article-title>
        <source>
         NPJ Digit Med
        </source>
        <volume>
         2
        </volume>
        <year>
         2019
        </year>
        <fpage>
         88
        </fpage>
        <pub-id pub-id-type="pmid">
         31508498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sbref420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Connor
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Portzky
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Looking to the future: a synthesis of new developments and challenges in suicide research and prevention
        </article-title>
        <source>
         Front Psychol
        </source>
        <volume>
         9
        </volume>
        <year>
         2018
        </year>
        <object-id pub-id-type="publisher-id">
         2139
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sbref430" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lazarus
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Folkman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Stress, appraisal, and coping
        </chapter-title>
        <year>
         1984
        </year>
        <publisher-name>
         Springer Publishing Company
        </publisher-name>
        <publisher-loc>
         Berlin
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sbref440" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folkman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Stress, health, and coping: synthesis, commentary, and future directions
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Folkman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <source>
         The Oxford Handbook of stress, health, and coping
        </source>
        <year>
         2010
        </year>
        <publisher-name>
         Oxford University Press
        </publisher-name>
        <publisher-loc>
         Oxford
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sbref450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folkman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Moskowitz
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coping: pitfalls and promise
        </article-title>
        <source>
         Annu Rev Psychol
        </source>
        <volume>
         55
        </volume>
        <year>
         2004
        </year>
        <fpage>
         745
        </fpage>
        <lpage>
         774
        </lpage>
        <pub-id pub-id-type="pmid">
         14744233
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sbref460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sehmi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Maughan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Arseneault
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         No man is an island: social resources, stress and mental health at mid-life
        </article-title>
        <source>
         Br J Psychiatry
        </source>
        <volume>
         4
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sbref470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Duan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological interventions for people affected by the COVID-19 epidemic
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         7
        </volume>
        <year>
         2020
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="pmid">
         32085840
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sbref480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alvaro
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression
        </article-title>
        <source>
         Sleep (Basel)
        </source>
        <volume>
         36
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1059
        </fpage>
        <lpage>
         1068
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sbref490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Connor
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Gartland
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           O'Connor
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stress, cortisol and suicide risk
        </article-title>
        <source>
         Int Rev Neurobiol
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Jan 27.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/bs.irn.2019.11.006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sbref500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dawson
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Bryant
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Harper
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Problem Management Plus (PM+): a WHO transdiagnostic psychological intervention for common mental health problems
        </article-title>
        <source>
         World Psychiatry
        </source>
        <volume>
         14
        </volume>
        <year>
         2015
        </year>
        <fpage>
         354
        </fpage>
        <lpage>
         357
        </lpage>
        <pub-id pub-id-type="pmid">
         26407793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sbref510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           BE
          </given-names>
         </name>
         <name>
          <surname>
           Linden
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Najarian
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Social support interventions: do they work?
        </article-title>
        <source>
         Clin Psychol Rev
        </source>
        <volume>
         22
        </volume>
        <year>
         2002
        </year>
        <fpage>
         383
        </fpage>
        <lpage>
         442
        </lpage>
        <pub-id pub-id-type="pmid">
         17201192
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sbref520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ashdown-Franks
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Firth
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Carney
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exercise as medicine for mental and substance use disorders: a meta-review of the benefits for neuropsychiatric and cognitive outcomes
        </article-title>
        <source>
         Sports Med
        </source>
        <volume>
         50
        </volume>
        <year>
         2020
        </year>
        <fpage>
         151
        </fpage>
        <lpage>
         170
        </lpage>
        <pub-id pub-id-type="pmid">
         31541410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sbref530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Solomonov
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Bress
          </surname>
          <given-names>
           JN
          </given-names>
         </name>
         <name>
          <surname>
           Sirey
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engagement in socially and interpersonally rewarding activities as a predictor of outcome in “Engage” behavioral activation therapy for late-life depression
        </article-title>
        <source>
         Am J Geriatr Psychiatry
        </source>
        <volume>
         27
        </volume>
        <year>
         2019
        </year>
        <fpage>
         571
        </fpage>
        <lpage>
         578
        </lpage>
        <pub-id pub-id-type="pmid">
         30797650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sbref540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meunier
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Roberge
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Coulombe
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Houle
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feeling better at work! Mental health self-management strategies for workers with depressive and anxiety symptoms
        </article-title>
        <source>
         J Affect Disord
        </source>
        <volume>
         254
        </volume>
        <year>
         2019
        </year>
        <fpage>
         7
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         31082629
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sbref550" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taubman
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Parikh
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
         <name>
          <surname>
           Christensen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Using school-based interventions for depression education and prevention
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Javed
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Fountoulakis
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <source>
         Advances in psychiatry
        </source>
        <year>
         2019
        </year>
        <publisher-name>
         Springer
        </publisher-name>
        <publisher-loc>
         Berlin
        </publisher-loc>
        <fpage>
         1
        </fpage>
        <lpage>
         32
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sbref560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wasserman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Rutger van der
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Wise
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Terms ‘physical distancing’ and ‘emotional closeness’ should be used and not ‘social distancing’ when defeating the Covid-19 pandemic
        </article-title>
        <source>
         Science
        </source>
        <volume>
         367
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         1282
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sbref570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Swinburn
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Kraak
          </surname>
          <given-names>
           VI
          </given-names>
         </name>
         <name>
          <surname>
           Allender
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The global syndemic of obesity, undernutrition, and climate change: The
         <italic>
          Lancet
         </italic>
         Commission report
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         393
        </volume>
        <year>
         2019
        </year>
        <fpage>
         791
        </fpage>
        <lpage>
         846
        </lpage>
        <pub-id pub-id-type="pmid">
         30700377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sbref580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Potts
          </surname>
          <given-names>
           HWW
          </given-names>
         </name>
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK
        </article-title>
        <source>
         Health Technol Assess
        </source>
        <volume>
         14
        </volume>
        <year>
         2010
        </year>
        <fpage>
         183
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="pmid">
         20630124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sbref590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           JTF
          </given-names>
         </name>
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Avoidance behaviors and negative psychological responses in the general population in the initial stage of the H1N1 pandemic in Hong Kong
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         2010
        </year>
        <fpage>
         139
        </fpage>
        <pub-id pub-id-type="pmid">
         20509887
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sbref600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Lloyd-Evans
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Giacco
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Social isolation in mental health: a conceptual and methodological review
        </article-title>
        <source>
         Soc Psychiatry Psychiatr Epidemiol
        </source>
        <volume>
         52
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1451
        </fpage>
        <lpage>
         1461
        </lpage>
        <pub-id pub-id-type="pmid">
         29080941
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sbref610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cacioppo
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Waite
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Hawkley
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name>
          <surname>
           Thisted
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses
        </article-title>
        <source>
         Psychol Aging
        </source>
        <volume>
         21
        </volume>
        <year>
         2006
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="pmid">
         16594799
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sbref620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J-H
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y-F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patients with mental health disorders in the COVID-19 epidemic
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         7
        </volume>
        <year>
         2020
        </year>
        <fpage>
         e21
        </fpage>
        <pub-id pub-id-type="pmid">
         32199510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sbref630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Collishaw
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Annual research review: secular trends in child and adolescent mental health
        </article-title>
        <source>
         J Child Psychol Psychiatry
        </source>
        <volume>
         56
        </volume>
        <year>
         2015
        </year>
        <fpage>
         370
        </fpage>
        <lpage>
         393
        </lpage>
        <pub-id pub-id-type="pmid">
         25496340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sbref640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sellers
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Warne
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Pickles
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Maughan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Thapar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Collishaw
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-cohort change in adolescent outcomes for children with mental health problems
        </article-title>
        <source>
         J Child Psychol Psychiatry
        </source>
        <volume>
         60
        </volume>
        <year>
         2019
        </year>
        <fpage>
         813
        </fpage>
        <lpage>
         821
        </lpage>
        <pub-id pub-id-type="pmid">
         30989670
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sbref650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fazel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hoagwood
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Stephan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ford
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mental health interventions in schools in high-income countries
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         1
        </volume>
        <year>
         2014
        </year>
        <fpage>
         377
        </fpage>
        <lpage>
         387
        </lpage>
        <pub-id pub-id-type="pmid">
         26114092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sbref660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schoneveld
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Lichtwarck-Aschoff
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Granic
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing childhood anxiety disorders: is an applied game as effective as a cognitive behavioral therapy-based program?
        </article-title>
        <source>
         Prev Sci
        </source>
        <volume>
         19
        </volume>
        <year>
         2018
        </year>
        <fpage>
         220
        </fpage>
        <lpage>
         232
        </lpage>
        <pub-id pub-id-type="pmid">
         28956222
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sbref670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Armitage
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Nellums
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 and the consequences of isolating the elderly
        </article-title>
        <source>
         Lancet Public Health
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 19.
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/S2468-2667(20)30061-X
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sbref680" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Robotham
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Sweeney
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Perôt
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survivors' priority themes and questions for research
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs120" xlink:href="https://www.vamhn.co.uk/uploads/1/2/2/7/122741688/consultation_report_on_website.pdf">
         https://www.vamhn.co.uk/uploads/1/2/2/7/122741688/consultation_report_on_website.pdf
        </ext-link>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sbref690" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sweeney
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Beresford
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Nettle
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Faulkner
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         This is survivor research
        </chapter-title>
        <year>
         2009
        </year>
        <publisher-name>
         PCCS Books
        </publisher-name>
        <ext-link ext-link-type="uri" id="interrefs130" xlink:href="https://www.researchgate.net/publication/257606229_This_Is_Survivor_Research">
         https://www.researchgate.net/publication/257606229_This_Is_Survivor_Research
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sbref700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wind
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name>
          <surname>
           Rijkeboer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Riper
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         The COVID-19 pandemic: the ‘black swan’ for mental health care and a turning point for e-health
        </article-title>
        <source>
         Internet Interv
        </source>
        <volume>
         20
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         100317
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sbref710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milton
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Of mice and mental health: facilitating dialogue and seeing further
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        <volume>
         373
        </volume>
        <year>
         2018
        </year>
        <object-id pub-id-type="publisher-id">
         20170022
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sbref720" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blank
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Dutton
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         OxIS 2019: Digital divides in Britain are narrowing but deepening
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs140" xlink:href="https://ssrn.com/abstract=3522083">
         https://ssrn.com/abstract=3522083
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sbref730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hirsch
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Krahé
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Whyte
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interpretation training to target repetitive negative thinking in generalized anxiety disorder and depression
        </article-title>
        <source>
         J Consult Clin Psychol
        </source>
        <volume>
         86
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1017
        </fpage>
        <lpage>
         1030
        </lpage>
        <pub-id pub-id-type="pmid">
         30507227
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sbref740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holt-Lunstad
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Robles
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Sbarra
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Julianne Holt-Lunstad
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advancing social connection as a public health priority in the United States
        </article-title>
        <source>
         Am Psychol
        </source>
        <volume>
         72
        </volume>
        <year>
         2017
        </year>
        <fpage>
         517
        </fpage>
        <lpage>
         530
        </lpage>
        <pub-id pub-id-type="pmid">
         28880099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sbref750" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Agency for Healthcare Research and Quality
         </collab>
        </person-group>
        <article-title>
         Addressing social isolation to improve the health of older adults: a rapid review
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs150" xlink:href="https://effectivehealthcare.ahrq.gov/products/social-isolation/rapid-product">
         https://effectivehealthcare.ahrq.gov/products/social-isolation/rapid-product
        </ext-link>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sbref760" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fancourt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Finn
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         What is the evidence on the role of the arts in improving health and well-being? A scoping review
        </chapter-title>
        <year>
         2019
        </year>
        <publisher-name>
         WHO Regional Office for Europe
        </publisher-name>
        <publisher-loc>
         Copenhagen
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <element-citation id="sbref770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anthes
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pocket psychiatry: mobile mental-health apps have exploded onto the market, but few have been thoroughly tested
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         532
        </volume>
        <year>
         2016
        </year>
        <fpage>
         20
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         27078548
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sbref780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sell
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Boddie
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           McGinty
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Media messages and perception of risk for Ebola virus infection, United States
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         23
        </volume>
        <year>
         2017
        </year>
        <fpage>
         108
        </fpage>
        <lpage>
         111
        </lpage>
        <pub-id pub-id-type="pmid">
         27983495
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sbref790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           McKee
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Torbica
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Stuckler
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic literature review on the spread of health-related misinformation on social media
        </article-title>
        <source>
         Soc Sci Med
        </source>
        <volume>
         240
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         112552
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sbref800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           ZJ
          </given-names>
         </name>
         <name>
          <surname>
           Vishwanath
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         To fear or not to fear? Applying the social amplification of risk framework on two environmental health risks in Singapore
        </article-title>
        <source>
         J Risk Res
        </source>
        <volume>
         21
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1487
        </fpage>
        <lpage>
         1501
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sbref810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Garfin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Holman
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Silver
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Distress, worry, and functioning following a global health crisis: a national study of Americans' responses to Ebola
        </article-title>
        <source>
         Clin Psychol Sci
        </source>
        <volume>
         5
        </volume>
        <year>
         2017
        </year>
        <fpage>
         513
        </fpage>
        <lpage>
         521
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation id="sbref820" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Holman
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Silver
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Media exposure to mass violence events can fuel a cycle of distress
        </article-title>
        <source>
         Sci Adv
        </source>
        <volume>
         5
        </volume>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         eaav3502
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation id="sbref830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garfin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Silver
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Holman
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel coronavirus (COVID-2019) outbreak: amplification of public health consequences by media exposure
        </article-title>
        <source>
         Health Psychol
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 23.
        </comment>
        <pub-id pub-id-type="doi">
         10.1037/hea0000875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation id="sbref840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           West
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Amlot
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Slowing down the COVID-19 outbreak: changing behaviour by understanding it
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="interrefs170" xlink:href="https://blogs.bmj.com/bmj/2020/03/11/slowing-down-the-covid-19-outbreak-changing-behaviour-by-understanding-it/">
         https://blogs.bmj.com/bmj/2020/03/11/slowing-down-the-covid-19-outbreak-changing-behaviour-by-understanding-it/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation id="sbref850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           van Stralen
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           West
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         The behaviour change wheel: a new method for characterising and designing behaviour change interventions
        </article-title>
        <source>
         Implement Sci
        </source>
        <volume>
         6
        </volume>
        <year>
         2011
        </year>
        <fpage>
         42
        </fpage>
        <pub-id pub-id-type="pmid">
         21513547
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation id="sbref860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Garety
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name>
          <surname>
           Bebbington
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological investigation of the structure of paranoia in a non-clinical population
        </article-title>
        <source>
         Br J Psychiatry
        </source>
        <volume>
         186
        </volume>
        <year>
         2005
        </year>
        <fpage>
         427
        </fpage>
        <lpage>
         435
        </lpage>
        <pub-id pub-id-type="pmid">
         15863749
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation id="sbref870" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Fontenelle
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <name>
          <surname>
           Shavitt
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name>
          <surname>
           Hoexter
          </surname>
          <given-names>
           MQ
          </given-names>
         </name>
         <name>
          <surname>
           Pittenger
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Miguel
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Epidemiology, comorbidity, and burden of OCD
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Pittenger
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <source>
         Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment
        </source>
        <year>
         2017
        </year>
        <publisher-name>
         Oxford University Press
        </publisher-name>
        <publisher-loc>
         Oxford
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation id="sbref880" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abramowitz
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           McKay
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Storch
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Wiley handbook of obsessive compulsive disorders
        </chapter-title>
        <year>
         2017
        </year>
        <publisher-name>
         John Wiley &amp; Sons
        </publisher-name>
        <publisher-loc>
         Chichester
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation id="sbref890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           GJY
          </given-names>
         </name>
         <name>
          <surname>
           Ruiter
          </surname>
          <given-names>
           RAC
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Threatening communication: a critical re-analysis and a revised meta-analytic test of fear appeal theory
        </article-title>
        <source>
         Health Psychol Rev
        </source>
        <volume>
         7
        </volume>
        <issue>
         suppl 1
        </issue>
        <year>
         2013
        </year>
        <fpage>
         S8
        </fpage>
        <lpage>
         S31
        </lpage>
        <pub-id pub-id-type="pmid">
         23772231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation id="sbref900" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Public Health England
         </collab>
        </person-group>
        <article-title>
         A Century of public health marketing: enduring public health challenges and revolutions in communication
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs180" xlink:href="https://publichealthengland.exposure.co/100-years-of-public-health-marketing">
         https://publichealthengland.exposure.co/100-years-of-public-health-marketing
        </ext-link>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation id="sbref910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ecology of emerging neurotropic viruses
        </article-title>
        <source>
         J Neurovirol
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         441
        </fpage>
        <lpage>
         446
        </lpage>
        <pub-id pub-id-type="pmid">
         16287685
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation id="sbref920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YC
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           WZ
          </given-names>
         </name>
         <name>
          <surname>
           Hirano
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Hayashida
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hashikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells
        </article-title>
        <source>
         Virus Res
        </source>
        <volume>
         163
        </volume>
        <year>
         2012
        </year>
        <fpage>
         628
        </fpage>
        <lpage>
         635
        </lpage>
        <pub-id pub-id-type="pmid">
         22248641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation id="sbref930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         41
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1089
        </fpage>
        <lpage>
         1096
        </lpage>
        <pub-id pub-id-type="pmid">
         16163626
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation id="sbref940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         213
        </volume>
        <year>
         2016
        </year>
        <fpage>
         712
        </fpage>
        <lpage>
         722
        </lpage>
        <pub-id pub-id-type="pmid">
         26486634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation id="sbref950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation id="sbref960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neurological manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
        </article-title>
        <source>
         JAMA Neurol
        </source>
        <year>
         2020
        </year>
        <comment>
         published online April 10.
        </comment>
        <pub-id pub-id-type="doi">
         10.1001/jamaneurol.2020.1127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation id="sbref970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19: Neurologists in Italy to colleagues in US: look for poorly-defined neurologic conditions in patients with the coronavirus
        </article-title>
        <source>
         Neurology Today
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="interrefs200" xlink:href="https://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=920">
         https://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=920
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation id="sbref980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YC
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           WZ
          </given-names>
         </name>
         <name>
          <surname>
           Hashikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <comment>
         published online Feb 27.
        </comment>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation id="sbref990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCall
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vilensky
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Taubenberger
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The relationship between encephalitis lethargica and influenza: a critical analysis
        </article-title>
        <source>
         J Neurovirol
        </source>
        <volume>
         14
        </volume>
        <year>
         2008
        </year>
        <fpage>
         177
        </fpage>
        <lpage>
         185
        </lpage>
        <pub-id pub-id-type="pmid">
         18569452
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation id="sbref1000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Le Coupanec
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dubeau
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         28
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation id="sbref1010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dubé
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Le Coupanec
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           AHM
          </given-names>
         </name>
         <name>
          <surname>
           Rini
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e00404
        </fpage>
        <lpage>
         e00418
        </lpage>
        <pub-id pub-id-type="pmid">
         29925652
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation id="sbref1020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andries
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation
        </article-title>
        <source>
         Am J Vet Res
        </source>
        <volume>
         41
        </volume>
        <year>
         1980
        </year>
        <fpage>
         1372
        </fpage>
        <lpage>
         1378
        </lpage>
        <pub-id pub-id-type="pmid">
         6255837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation id="sbref1030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
        </article-title>
        <source>
         Science
        </source>
        <volume>
         367
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1260
        </fpage>
        <lpage>
         1263
        </lpage>
        <pub-id pub-id-type="pmid">
         32075877
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation id="sbref1040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Slutsky
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <volume>
         46
        </volume>
        <year>
         2020
        </year>
        <fpage>
         586
        </fpage>
        <lpage>
         590
        </lpage>
        <pub-id pub-id-type="pmid">
         32125455
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation id="sbref1050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Cassell
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         82
        </volume>
        <year>
         2008
        </year>
        <fpage>
         7264
        </fpage>
        <lpage>
         7275
        </lpage>
        <pub-id pub-id-type="pmid">
         18495771
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation id="sbref1060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brann
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Tsukahara
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Weinreb
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Logan
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Datta
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients
        </article-title>
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 28.
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.03.25.009084
        </pub-id>
        <comment>
         (preprint).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation id="sbref1070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Khaleeq
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Syeda
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms
        </article-title>
        <source>
         ACS Chem Neurosci
        </source>
        <volume>
         11
        </volume>
        <year>
         2020
        </year>
        <fpage>
         995
        </fpage>
        <lpage>
         998
        </lpage>
        <pub-id pub-id-type="pmid">
         32167747
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation id="sbref1080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           MLC
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J Pathol
        </source>
        <volume>
         203
        </volume>
        <year>
         2004
        </year>
        <fpage>
         631
        </fpage>
        <lpage>
         637
        </lpage>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation id="sbref1090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Miletti
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <name>
          <surname>
           Gagnon
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of human monocytes after infection by human coronavirus 229E
        </article-title>
        <source>
         Virus Res
        </source>
        <volume>
         130
        </volume>
        <year>
         2007
        </year>
        <fpage>
         228
        </fpage>
        <lpage>
         240
        </lpage>
        <pub-id pub-id-type="pmid">
         17669539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation id="sbref1100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical and immunologic features in severe and moderate coronavirus disease 2019
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 27.
        </comment>
        <pub-id pub-id-type="doi">
         10.1172/JCI137244
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation id="sbref1110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dantzer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           O'Connor
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Freund
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Kelley
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
        </person-group>
        <article-title>
         From inflammation to sickness and depression: when the immune system subjugates the brain
        </article-title>
        <source>
         Nat Rev Neurosci
        </source>
        <volume>
         9
        </volume>
        <year>
         2008
        </year>
        <fpage>
         46
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         18073775
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation id="sbref1120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Harthi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hussein
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)
        </article-title>
        <source>
         Infection
        </source>
        <volume>
         43
        </volume>
        <year>
         2015
        </year>
        <fpage>
         495
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="pmid">
         25600929
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation id="sbref1130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bender
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of murine coronavirus in the central nervous system
        </article-title>
        <source>
         J Neuroimmune Pharmacol
        </source>
        <volume>
         5
        </volume>
        <year>
         2010
        </year>
        <fpage>
         336
        </fpage>
        <lpage>
         354
        </lpage>
        <pub-id pub-id-type="pmid">
         20369302
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation id="sbref1140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wessely
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         History of postviral fatigue syndrome
        </article-title>
        <source>
         Br Med Bull
        </source>
        <volume>
         47
        </volume>
        <year>
         1991
        </year>
        <fpage>
         919
        </fpage>
        <lpage>
         941
        </lpage>
        <pub-id pub-id-type="pmid">
         1794091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation id="sbref1150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           White
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Amess
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever
        </article-title>
        <source>
         Br J Psychiatry
        </source>
        <volume>
         173
        </volume>
        <year>
         1998
        </year>
        <fpage>
         475
        </fpage>
        <lpage>
         481
        </lpage>
        <pub-id pub-id-type="pmid">
         9926075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation id="sbref1160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wessely
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chalder
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hirsch
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Pawlikowska
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Wright
          </surname>
          <given-names>
           DJM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Postinfectious fatigue: prospective cohort study in primary care
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         345
        </volume>
        <year>
         1995
        </year>
        <fpage>
         1333
        </fpage>
        <lpage>
         1338
        </lpage>
        <pub-id pub-id-type="pmid">
         7752755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation id="sbref1170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faull
          </surname>
          <given-names>
           OK
          </given-names>
         </name>
         <name>
          <surname>
           Jenkinson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Clare
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Pattinson
          </surname>
          <given-names>
           KTS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional subdivision of the human periaqueductal grey in respiratory control using 7 tesla fMRI
        </article-title>
        <source>
         Neuroimage
        </source>
        <volume>
         113
        </volume>
        <year>
         2015
        </year>
        <fpage>
         356
        </fpage>
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="pmid">
         25703831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation id="sbref1180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
        </article-title>
        <source>
         Cell
        </source>
        <volume>
         181
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="pmid">
         32243785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation id="sbref1190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nabirotchkin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Peluffo
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Bouaziz
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19
        </article-title>
        <source>
         Preprints
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 20.
        </comment>
        <pub-id pub-id-type="doi">
         10.20944/preprints202003.0302.v1
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation id="sbref1200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herrett
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Bhaskaran
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Data resource profile: clinical practice research datalink (CPRD)
        </article-title>
        <source>
         Int J Epidemiol
        </source>
        <volume>
         44
        </volume>
        <year>
         2015
        </year>
        <fpage>
         827
        </fpage>
        <lpage>
         836
        </lpage>
        <pub-id pub-id-type="pmid">
         26050254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation id="sbref1210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Soremekun
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data
        </article-title>
        <source>
         BMC Psychiatry
        </source>
        <volume>
         9
        </volume>
        <year>
         2009
        </year>
        <fpage>
         51
        </fpage>
        <pub-id pub-id-type="pmid">
         19674459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation id="sbref1220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Kartoglu
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Stringer
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         CogStack - experiences of deploying integrated information retrieval and extraction services in a large National Health Service Foundation Trust hospital
        </article-title>
        <source>
         BMC Med Inform Decis Mak
        </source>
        <volume>
         18
        </volume>
        <year>
         2018
        </year>
        <fpage>
         47
        </fpage>
        <pub-id pub-id-type="pmid">
         29941004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation id="sbref1230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gostin
          </surname>
          <given-names>
           LO
          </given-names>
         </name>
         <name>
          <surname>
           Bayer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fairchild
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ethical and legal challenges posed by severe acute respiratory syndrome: implications for the control of severe infectious disease threats
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         290
        </volume>
        <year>
         2003
        </year>
        <fpage>
         3229
        </fpage>
        <lpage>
         3237
        </lpage>
        <pub-id pub-id-type="pmid">
         14693876
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation id="sbref1240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Townsend
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Nielsen
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Allister
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Cassidy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Key ethical questions for research during the COVID-19 pandemic
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <volume>
         7
        </volume>
        <year>
         2020
        </year>
        <fpage>
         381
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation id="sbref1250" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Nuffield Council on Bioethics
         </collab>
        </person-group>
        <article-title>
         Rapid policy briefing: ethical considerations in responding to the COVID-19 pandemic
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs250" xlink:href="https://www.nuffieldbioethics.org/publications/covid-19">
         https://www.nuffieldbioethics.org/publications/covid-19
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation id="sbref1260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chambers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         What's next for registered reports?
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         573
        </volume>
        <year>
         2019
        </year>
        <fpage>
         187
        </fpage>
        <lpage>
         189
        </lpage>
        <pub-id pub-id-type="pmid">
         31506624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation id="sbref1270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raguin
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Girard
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toward a global health approach: lessons from the HIV and Ebola epidemics
        </article-title>
        <source>
         Global Health
        </source>
        <volume>
         14
        </volume>
        <year>
         2018
        </year>
        <fpage>
         114
        </fpage>
        <pub-id pub-id-type="pmid">
         30466457
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ceack10">
      <sec>
       <title>
        Acknowledgments
       </title>
       <p>
        We are grateful to all staff at the Academy of Medical Sciences and MQ: Transforming Mental Health for their work in coordinating and supporting this project's secretariat and communications. Special thanks to Rachel Quinn, Nick Hillier, Helen Munn, Neil Balmer, Angeliki Yiangou, Fern Brookes, Holly Rogers, Claire Bithell, Naomi Clarke, Melanie Etherton, Tom Livermore, Dylan Williams, and Daisy Armitage. We also extend our sincere thanks to Katie White, Carolin Oetzmann, Valeria de Angel, and Sumithra Velupillai at King's College London, and Norman Freshney from Norman Freshney Consulting, for their tremendous efforts in data analysis, and Beau Gamble at Uppsala University and Seonaid Cleare at University of Glasgow for their support with referencing. We are also grateful to the team at Ipsos MORI for their work on the online omnibus. Special thanks also to everyone who participated in the MQ: Transforming Mental Health and Ipsos MORI surveys for sharing their views and personal experiences during challenging times—we are hugely grateful to them for their openness and honesty about mental health and wellbeing. We are grateful to Peter Jones from the University of Cambridge and a member of the MQ: Transforming Mental Health Board of Trustees for comments on an earlier draft.
       </p>
      </sec>
     </ack>
     <ack>
      <title>
       Contributors
      </title>
      <p>
       EB, EAH, MH, RCO'C, VHP, IT, and SW contributed to the literature review, conceptualisation, design and interpretation of surveys, and writing and editing of the manuscript as part of the core advisory group. CC contributed to and coordinated the writing and editing of the manuscript. KC analysed the qualitative data gathered via the stakeholder survey. LA, CB, HC, RCS, IE, TF, AJ, IM, SM, AKP, RS, CMW, and LY contributed to the drafting and formulation of the manuscript as part of the expert advisory group. TK, KK, and AS contributed to the drafting and formulation of the manuscript as part of the expert advisory group and by including lived-experience expertise. All authors approved the final version for submission.
      </p>
     </ack>
     <ack>
      <title>
       Declaration of interests
      </title>
      <p>
       CB reports grants and personal fees from Acadia and Lundbeck; personal fees from Roche, Otsuka, Biogen, Eli Lilly, Novo Nordisk, AARP, and Exciva; and grants from Synexus, outside the submitted work. EAH reports serving on the board of trustees of the charity MQ: Transforming Mental Health and as chair of the research committee, but receives no remuneration for these roles. EAH receives royalties from books and occasional fees for workshops and invited addresses; receives occasional consultancy fees from the Swedish agency for health technology assessment and assessment of social services; and reports grants from The OAK Foundation, the Lupina Foundation, and the Swedish Research Council. RCO'C is a member of the National Institute of Health and Care Excellence's guideline development group for the management of self-harm; is co-chair of the Academic Advisory Group to the Scottish Government's National Suicide Prevention Leadership Group; receives royalties from books, and occasional fees for workshops and invited addresses; and reports grants from Medical Research Foundation, the Mindstep Foundation, Chief Scientist Office, Medical Research Council, NHS Health Scotland, Scottish Government, and National Institute for Health Research (NIHR). KK has received meeting attendance payments from the Department of Health and Social Care, NHS England and NHS Improvement, and the Royal College of Psychiatry (RCPsych) over the last year for service user representative work, and payment for a training session she facilitated for RCPsych; and received a pass and accommodation for the RCPsych annual conference in 2019. AKP reports financial support from UK taxpayers, the UK's Economic and Social Research Council, the British Academy, the Diana Award, the John Fell Fund, the Leverhulme Trust, Barnardo's UK, and the Huo Family Foundation in the past five years. As part of science communication and policy outreach activities; and served in an unpaid advisory capacity to the Organization for Economic Co-operation and Development, Facebook, Google, and the ParentZone. IT is a Trustee of MQ: Transforming Mental Health and is on the Council for the Medical Research Council of the UK. MH reports grants from Innovative Medicines Intiative, outside the submitted work. MH and SW are funded by the NIHR Biomedical Research Centre at the Maudsley and a NIHR Senior Investigator Award. NIHR were not involved in any aspect of the publication and had no role in the decision to submit. RCS received funding from the US National Science Foundation, grant SES-2026337. CC reported that Academy of Medical Sciences staff, including herself, and activity costs for this work were partly supported by a core grant the Academy of Medical Sciences receives annually from the Government Department for Business, Energy &amp; Industrial Strategy for policy, communications and public engagement; and reports that her husband is an employee of Otsuka Pharmaceutical Europe and is a trustee of The McPin Foundation. KC was funded by MQ: Transforming Mental Health to carry out the qualitative data analysis of the stakeholder survey. LA is the Mental Health Leadership Fellow for the Economic and Social Research Council. EB is a NIHR Senior Investigator. This Position Paper represents independent research part-funded by the NIHR Biomedical Research Centre at Cambridge University Hospital NHS Trust and the University of Cambridge and South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. RS reports that all research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. LY is an NIHR Senior Investigator and her research programme is partly supported by NIHR Applied Research Collaboration-West, NIHR Health Protection Research Unit for Behavioural Science and Evaluation, and the NIHR Southampton Biomedical Research Centre. The funding for TK's salary came solely from The McPin Foundation. All other authors declare no competing interests.
      </p>
     </ack>
     <ack>
      <title>
       Funding source
      </title>
      <p>
       The stakeholder survey was funded by MQ: Transforming Mental Health. Activity costs for this work, including the Ipsos MORI survey, were partly supported by a core grant the Academy of Medical Sciences receives annually from the Government Department for Business, Energy &amp; Industrial Strategy for policy, communications and public engagement. The views expressed are the views of the authors alone and do not necessarily represent the views of their organisations or funding sources.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Allergy Clin Immunol Pract
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J Allergy Clin Immunol Pract
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of Allergy and Clinical Immunology. in Practice
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2213-2198
      </issn>
      <issn pub-type="epub">
       2213-2201
      </issn>
      <publisher>
       <publisher-name>
        American Academy of Allergy, Asthma &amp; Immunology
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32259628
      </article-id>
      <article-id pub-id-type="pmc">
       7129776
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2213-2198(20)30327-5
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jaip.2020.04.001
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Bansal
         </surname>
         <given-names>
          Priya
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Bingemann
         </surname>
         <given-names>
          Theresa A.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Greenhawt
         </surname>
         <given-names>
          Matthew
         </given-names>
        </name>
        <degrees>
         MD, MBA, MSc
        </degrees>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Mosnaim
         </surname>
         <given-names>
          Giselle
         </given-names>
        </name>
        <degrees>
         MD, MS
        </degrees>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Nanda
         </surname>
         <given-names>
          Anil
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Oppenheimer
         </surname>
         <given-names>
          John
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Sharma
         </surname>
         <given-names>
          Hemant
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff8">
         h
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Stukus
         </surname>
         <given-names>
          David
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff9">
         i
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au9">
        <name>
         <surname>
          Shaker
         </surname>
         <given-names>
          Marcus
         </given-names>
        </name>
        <degrees>
         MD, MSc
        </degrees>
        <email>
         marcus.shaker@dartmouth.edu
        </email>
        <xref ref-type="aff" rid="aff10">
         j
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Asthma and Allergy Wellness Center, St Charles, Ill
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       University of Rochester Division of Allergy, Immunology and Rheumatology, Rochester, NY
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Section of Allergy/Immunology, Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colo
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Division of Pulmonary, Allergy and Critical Care, Department of Medicine, NorthShore University HealthSystem, Evanston, Ill
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       Asthma and Allergy Center, Lewisville and Flower Mound, Texas
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       UMDMJ Rutgers University School of Medicine, Newark, NJ
      </aff>
      <aff id="aff8">
       <label>
        h
       </label>
       Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC
      </aff>
      <aff id="aff9">
       <label>
        i
       </label>
       Division of Allergy and Immunology, Nationwide Children's Hospital, The Ohio State University School of Medicine, Columbus, Ohio
      </aff>
      <aff id="aff10">
       <label>
        j
       </label>
       Geisel School of Medicine and Dartmouth-Hitchcock Medical Center, Lebanon, NH
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author: Marcus Shaker, MD, MSc, Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Dartmouth Geisel School of Medicine, 1 Medical Center Dr, Lebanon, NH 03756.
        <email>
         marcus.shaker@dartmouth.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        4
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        4
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <history>
       <date date-type="received">
        <day>
         1
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         1
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 American Academy of Allergy, Asthma &amp; Immunology.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        American Academy of Allergy, Asthma &amp; Immunology
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The global spread of coronavirus disease 2019 (COVID-19) has caused sudden and dramatic societal changes. The allergy/immunology community has quickly responded by mobilizing practice adjustments and embracing new paradigms of care to protect patients and staff from severe acute respiratory syndrome coronavirus 2 exposure. Social distancing is key to slowing contagion but adds to complexity of care and increases isolation and anxiety. Uncertainty exists across a new COVID-19 reality, and clinician well-being may be an underappreciated priority. Wellness incorporates mental, physical, and spiritual health to protect against burnout, which impairs both coping and caregiving abilities. Understanding the stressors that COVID-19 is placing on clinicians can assist in recognizing what is needed to return to a point of wellness. Clinicians can leverage easily accessible tools, including the Strength-Focused and Meaning-Oriented Approach to Resilience and Transformation approach, wellness apps, mindfulness, and gratitude. Realizing early warning signs of anxiety, depression, substance abuse, and posttraumatic stress disorder is important to access safe and confidential resources. Implementing wellness strategies can improve flexibility, resilience, and outlook. Historical parallels demonstrate that perseverance is as inevitable as pandemics and that we need not navigate this unprecedented time alone.
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Key words
       </title>
       <kwd>
        Wellness
       </kwd>
       <kwd>
        Physician wellness
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        Social distancing
       </kwd>
       <kwd>
        Burnout
       </kwd>
       <kwd>
        Depression
       </kwd>
       <kwd>
        Grief
       </kwd>
       <kwd>
        Mindfulness
       </kwd>
      </kwd-group>
      <kwd-group id="kwrds0015">
       <title>
        Abbreviations used
       </title>
       <kwd>
        CFR, Case-fatality rate
       </kwd>
       <kwd>
        COVID-19, Coronavirus disease 2019
       </kwd>
       <kwd>
        PPE, Personal protective equipment
       </kwd>
       <kwd>
        SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
       </kwd>
       <kwd>
        TB, Tuberculosis
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <title>
      Introduction
     </title>
     <p id="p0010">
      Despite global awareness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since December 2019, coronavirus disease 2019 (COVID-19) has become a global pandemic that caught the world unprepared in the early months of 2020.
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      It is now clear that SARS-CoV-2 is highly contagious, capable of causing severe pneumonia, acute respiratory distress syndrome, and death, particularly in vulnerable populations such as older adults and those with chronic medical conditions, such as cardiovascular disease, diabetes, respiratory disease, hypertension, and malignancy.
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      Strategies are being implemented to “flatten the curve” of the pandemic to preserve capacity and not outpace the availability of precious health care resources. The current supply of personal protective equipment (PPE), intensive care unit beds, and ventilators may not be able to keep up with projected demands.
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      This nightmare scenario has been experienced internationally, with countries such as Italy and Spain overwhelmed, and looming concerns that this may occur in certain parts of the United States.
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      For example, the percentage of symptomatic patients with COVID-19 requiring intensive care unit care has been between 9% and 11%.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      Demonstrating the rapidity of spread, the first recognized case of the pandemic in Italy appears to have been a young man admitted in the Lombardy region with atypical pneumonia on February 20, 2020, and health care resources were overwhelmed within a few weeks.
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      The timeline of the Italian experience illustrates a major reason for COVID-19–induced anxiety around the world (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ).
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      <fig id="fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         The coronavirus pandemic in Italy. Reproduced from Livingston and Bucher.
         <xref ref-type="bibr" rid="bib5">
          <sup>
           5
          </sup>
         </xref>
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0015">
      Attempts to mitigate the impact of COVID-19 have disrupted core aspects of society. Social distancing is central to efforts to control the pandemic.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      However, to be effective, social distancing must be rapidly and universally adopted across a society, which sadly has occurred to varying degrees across the globe. Risk perception is likely a significant lever on the degree to which populations embrace a social distancing approach.
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
     </p>
     <p id="p0020">
      During a pandemic, both medical experts and governmental authorities require a high degree of accurate knowledge and trust to execute effective policies.
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
      Tragically, there has been a vacuum of unified societal knowledge and trust throughout this pandemic. For example, a recent cross-sectional survey of the general public in the United States and the United Kingdom found that, of 2986 US and 2988 UK adults, 23.9% and 18.4%, respectively, believed SARS-CoV-2 to be a bioterrorist weapon.
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
      When asked between February 23 and March 2, 2020, 61% of US and 72% of UK respondents thought the number of people who would die of COVID-19 in their respective country would be fewer than 500 persons.
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
     </p>
     <p id="p0025">
      In response to the medical community, local government, and concerned citizen frustrations with currently available policies and demands for detailed accurate information, our knowledge of COVID-19 is rapidly expanding.
      <xref ref-type="bibr" rid="bib9">
       <sup>
        9
       </sup>
      </xref>
      Unfortunately, the spread of the virus also continues to rapidly increase, with the Johns Hopkins Coronavirus Resource Center listing 607,965 total confirmed cases and 28,124 deaths as of March 27, 2020.
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      The case-fatality rate (CFR) of COVID-19 is being scrutinized.
      <xref ref-type="bibr" rid="bib11">
       <sup>
        11
       </sup>
      </xref>
      Early data from China estimated the CFR to be 2.3% of symptomatic patients presenting for medical evaluation, with rates as high as 15% in vulnerable elderly populations.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      In patients with critical illness, CFR has been reported to be as high as 49%.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      Although CFRs may actually be much lower when mild and asymptomatic cases are considered, the Italian CFR is 7.2%
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ). Much of these data are hindered by lack of knowledge regarding the total number of cases. Health care worker fatalities were noted early and continue to rise in the United States.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      In an early report from China, 3.8% of cases occurred in health care workers, and 14.8% of these were classified as severe, with a CFR of 0.3%.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      In Italy, more than 50 physicians have died of COVID-19 as of March 27, 2020.
      <xref ref-type="bibr" rid="bib12">
       <sup>
        12
       </sup>
      </xref>
     </p>
     <p id="p0030">
      Despite this rising tide of illness, there is room for hope. Although the pace of change demanded in our response to COVID-19 is disorienting, it is important to note that, globally, 145,625 patients with confirmed cases have recovered as of March 29, 2020.
      <xref ref-type="bibr" rid="bib10">
       <sup>
        10
       </sup>
      </xref>
      There is a growing awareness of the need to protect health care workers from SARS-CoV-2 infection.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      However, in addition to an urgent need to prevent infections related to patient care, there is also a growing need to address broader aspects of wellness among health care workers.
     </p>
     <p id="p0035">
      The COVID-19 pandemic has created sudden stressors across many domains of our lives that become apparent when viewed through different lenses, including the theory of knowledge (“you don't know what you don't know,” information vs misinformation), appreciation of system capacity (both health and economic), understanding warranted and unwarranted variation, and human psychology.
      <xref ref-type="bibr" rid="bib14">
       <sup>
        14
       </sup>
      </xref>
      To survive COVID-19 and its aftermath requires care directed toward our patients as well as ourselves and our families. Although tending to personal wellness is always important, it has become even more crucial during these extraordinary times. Understanding risks and consequences of burnout magnified by COVID-19; identifying historical parallels of the pandemic while appreciating new challenges of social media; leveraging new technologies to care for patients, staff, colleagues, and ourselves while managing responsibilities at home; and using wellness resources at the American Academy of Allergy, Asthma &amp; Immunology, the American College of Allergy, Asthma &amp; Immunology, the Canadian Society of Allergy and Clinical Immunology, and state physician health programs as needed can help each of us navigate uncharted waters together, even while practicing social distancing.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Clinician Wellness
     </title>
     <p id="p0040">
      Clinician wellness involves a number of factors including stress and burnout.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      These factors can impact negatively on patient care and lead to increased medical errors, malpractice risk, and early retirement.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Greater clinician stress may lead to higher rates of drug and alcohol addiction, divorce, and suicide.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Clinicians are more likely to have burnout symptoms than the general US workforce and are more likely to be dissatisfied with work-life balance.
      <xref ref-type="bibr" rid="bib16">
       <sup>
        16
       </sup>
      </xref>
      Even before this pandemic, burnout rates among US physicians overall were estimated to be at around 46%.
      <xref ref-type="bibr" rid="bib16">
       <sup>
        16
       </sup>
      </xref>
      Female physicians have higher rates of burnout.
      <xref ref-type="bibr" rid="bib17">
       <sup>
        17
       </sup>
      </xref>
      A recent survey revealed a burnout rate of 35% among US allergy and immunology physicians in the United Ststes.
      <xref ref-type="bibr" rid="bib18">
       <sup>
        18
       </sup>
      </xref>
     </p>
     <p id="p0045">
      Higher rates of burnout may be associated with certain clinician attributes, including belief in service and sense of duty, perfectionism, and personal internalization of patient outcomes.
      <xref ref-type="bibr" rid="bib19">
       <sup>
        19
       </sup>
      </xref>
      Day-to-day office-based stressors include clerical burden (eg, electronic medical record documentation), excessive nonclinical and clinical workloads, and practice inefficiencies.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib20">
       <sup>
        20
       </sup>
      </xref>
      Although medical practice demands may contribute to burnout most significantly, personal and family stressors may add additional pressures.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      The current COVID-19 pandemic has disrupted the health care system worldwide. A prolonged response to the pandemic will lead to additional stress for clinicians and their support staff and further permeate throughout the health care system.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      Consequences of burnout are shown in
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      .
      <fig id="fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Health state transition and outcomes of burnout. A listing of state physician health programs is available at the Web site of the Federation of State Physician Health Programs.
         <xref ref-type="bibr" rid="bib21">
          <sup>
           21
          </sup>
         </xref>
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="sec3">
     <title>
      COVID-19 Challenges to Wellness
     </title>
     <p id="p0050">
      In the setting of a global pandemic it is normal to be frightened for one's own personal safety (and potential mortality), particularly with data emerging about airborne and fomite transmission, exposure risk from asymptomatic carriers, limited testing, and well-publicized issues regarding conflicting advice about what level of PPE is necessary or available. Finding evidenced-based PPE recommendations is difficult; however, over a 2-week span, the Centers for Disease Control and Prevention downgraded the COVID-19 risk from airborne to droplet (outside of an aerosol-generating procedure).
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      Changing recommendations have been a cause of anxiety for clinicians, compounded by employment termination concerns in some instances for wearing precautionary PPE.
     </p>
     <p id="p0055">
      In a crisis, physicians may feel their medical oaths tested when confronted with ethical dilemmas that are intrinsic in rationed care due to equipment shortage or institutional policy of universal do not resuscitate status for COVID-19–positive patients. As the psychological stressors are evolving day by day, non–intensive care unit/emergency department physicians may be redeployed to less familiar (and critical) clinical areas. Questions regarding the ethics of providing care outside of one's scope of practice, and the associated liability, are evolving. The American Medical Association released an update to its code of medical ethics on March 20, 2020, specifically addressing these issues in Opinion 8.3 and Opinions 11.1.2 and 11.1.3.
      <xref ref-type="bibr" rid="bib22">
       <sup>
        22
       </sup>
      </xref>
      These may help provide an ethical backdrop on how to approach such situations, though this still may not do much to leverage preserving one's own wellness and ability to persevere in such circumstances. In New York state, Governor Cuomo has introduced legislation limiting any malpractice liability to physicians practicing outside of their scope, except in cases of gross negligence (which remains nebulously defined).
      <xref ref-type="bibr" rid="bib23">
       <sup>
        23
       </sup>
      </xref>
      However, outside of New York, such liability protection is unclear and may cause justifiable concern.
     </p>
     <p id="p0060">
      Many hospitals and health care systems are recognizing the stress and strain on their clinicians. Some have made counselors available and have been offering free access to online tools for meditation and relaxation. A plethora of such online tools exist, and sometimes a quick breather may serve as a way to recharge and regain some wellness, at least momentarily, when under stress. Multiple businesses have recognized the heroic efforts of the medical community and are offering free services—sometimes just a free coffee and donut may be enough to show that one's efforts are being appreciated. The real concern is that in stressful times, there is a temptation to self-medicate or resort to less productive and more self-harmful solutions—drugs and alcohol in particular, which may increase the risk for suicide and domestic violence. Physicians at baseline work high-stress jobs and are already prone toward issues, including marital problems, and substance abuse, that may become magnified in this particular crisis.
     </p>
    </sec>
    <sec id="sec4">
     <title>
      Change, Loss, Guilt, and Grieving
     </title>
     <p id="p0065">
      Change is difficult, and during COVID-19 change has been rapid and associated with both uncertainty and with varying degrees of loss. Guilt and grieving are also major considerations for our wellness. Elizabeth Kubler Ross defined 5 stages of grieving: denial, anger, bargaining, sadness, and acceptance.
      <xref ref-type="bibr" rid="bib24">
       <sup>
        24
       </sup>
      </xref>
      More recently, these stages have been updated to disbelief, yearning, anger, depression, and acceptance, with the depression peaking at approximately 6 months postloss, and acceptance not until 24 months postloss
      <xref ref-type="bibr" rid="bib25">
       <sup>
        25
       </sup>
      </xref>
      (
      <xref ref-type="fig" rid="fig3">
       Figure 3
      </xref>
      ). Some of these stages may be more identifiable, though loss in the midst of this crisis may be harder to define, and may vary considerably on the basis of personal experiences. When the disease was abroad, there may have been denial/disbelief as to the severity and yearning for limited effects on our society. As testing kits and PPE have been deficient, anger at the government and administration is being felt. Physicians may find themselves bargaining for any way out as they are called to make life or death decisions.
      <fig id="fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Stages of grief. Elizabeth Kubler Ross defined 5 stages of grieving: denial, anger, bargaining, sadness, and acceptance. More recently, these stages have been updated to disbelief, yearning, anger, depression, and acceptance, with the depression peaking at approximately 6 months postloss and acceptance not until 24 months postloss. Reproduced from Maciejewski et al.
         <xref ref-type="bibr" rid="bib25">
          <sup>
           25
          </sup>
         </xref>
        </p>
       </caption>
       <graphic xlink:href="gr3_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0070">
      Undoubtedly, how we practice allergy has already changed, and in addition to health risks physicians face the looming reality of economic loss and associated anxiety. As COVID-19 becomes pervasive around us, there is a need to appreciate the potential for our own countertransference in considering our own personal and familial needs versus the needs of our patients and colleagues. This may be more difficult for some than for others. Naturally, we will all likely experience some degree of guilt and grieving for a number of potential reasons. However, as we may all cycle through these aforementioned stages, there is the final stage of acceptance as we find our way forward. Remind yourself this is a normal, healthy part of wellness, and things will hopefully change for the better.
     </p>
    </sec>
    <sec id="sec5">
     <title>
      A Historical Perspective
     </title>
     <p id="p0075">
      Historically, one can draw an analogy to tuberculosis (TB). In the 19th century, tuberculosis was responsible for 1 in 7 deaths. Like COVID-19, TB mortality also significantly impacted physicians. It was not until 1882 that Dr Edward L. Trudeau discovered the TB bacterium that caused the disease, and in 1896, when he opened the first sanatorium at Saranac Lake, NY, patients sat outdoors on the wide sun porches to take the “fresh air cure” and receive state-of-the art management of that era.
      <xref ref-type="bibr" rid="bib26">
       <sup>
        26
       </sup>
      </xref>
      Unfortunately, fresh air did not cure TB, and it was not until simple public health social distancing that TB declined sharply in the 1920s and 1930s. The societal struggle with TB demonstrates several parallels with the COVID-19 pandemic. Foremost is the clear and present danger posed by an infectious agent for which curative therapy is currently unavailable and for which only symptomatic management can be provided. This creates challenges to both health and wellness, because fear, anxiety, and frustration can threaten to overtake a rational approach to managing the situation of the moment.
     </p>
     <p id="p0080">
      A second parallel with TB is the temptation to embrace unproven therapies. For example, in the early 1880s, interventions used to treat TB included “collapse therapies,” in which physicians performed an elective pneumothorax, with the rationale for this procedure being to deprive the aerobic Mycobacteria of oxygen, in an attempt to kill them.
      <xref ref-type="bibr" rid="bib27">
       <sup>
        27
       </sup>
      </xref>
      This procedure involved injecting oxygen or nitrogen into the chest cavity with increasing pressure until the lung collapsed. However, this collapse was not permanent, and it required repeating the procedure every few weeks. It has been estimated that more than 100,000 patients underwent this procedure in the 25 years after this technique was developed, despite the fact that there were no rigorous studies conducted at the time to confirm its effectiveness.
      <xref ref-type="bibr" rid="bib28">
       <sup>
        28
       </sup>
      </xref>
      It was not until 1943 that Albert Schatz discovered streptomycin, which initially proved successful as TB monotherapy, but, over time, combination therapy was required.
      <xref ref-type="bibr" rid="bib29">
       <sup>
        29
       </sup>
      </xref>
      Similarly, trials are actively ongoing to treat COVID-19, including new antivirals, the use of hydroxychloroquine with azithromycin, anti–IL-6 agents, and the development of vaccines to name just a few.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
     </p>
     <p id="p0085">
      We can learn from our past and realize that, even in the darkest times, there will be a bright future someday. As physicians our calling is to care for those in need. Ultimately, validation of effective treatments will lead to greater physician empowerment. In the meantime, wellness tools and strategies can help to manage our fears and anxiety while we practice medicine with the tools we have in the moment.
     </p>
    </sec>
    <sec id="sec6">
     <title>
      Social Media During a Global Pandemic: The Good, the Bad, and the Ugly
     </title>
     <p id="p0090">
      With billions of active users across various social media platforms such as Facebook, Twitter, and Instagram, the manner in which we communicate and receive information has fundamentally changed. We have unprecedented instant access to information on a scale the world has never seen before.
      <xref ref-type="bibr" rid="bib30">
       <sup>
        30
       </sup>
      </xref>
      Before the introduction of Facebook in 2006, including during the early stages of the internet, we relied on a limited number of vetted resources for information, namely major media outlets or the daily newspaper. In 2020, however, we live in the age of “FakeNews,” and internet users need savviness and knowledge to identify factual information and ignore misinformation.
      <xref ref-type="bibr" rid="bib31">
       <sup>
        31
       </sup>
      </xref>
      The opinions of celebrities, accounts with large numbers of followers, and online influencers are artificially equated with those of actual medical experts. This constant stream of information (and misinformation) can be overwhelming for anyone, let alone clinicians already facing stressful challenges in their professional and personal lives. Before COVID-19, internet addiction was already recognized as a growing problem contributing to social anxiety, attention deficit/hyperactivity disorder, and other aspects of wellness, which may only intensify during these trying times that are constantly reminding us of the stakes we face.
      <xref ref-type="bibr" rid="bib32">
       <sup>
        32
       </sup>
      </xref>
      During a global pandemic, social media utilization can be beneficial for updates of important information related to current precautions and best practices and provide connections to needed resources. It can also help to connect physicians with loved ones across the globe who are having similar fears and are socially distanced. There are simple, yet effective, strategies that merit review for all medical professionals who use social media in order to maximize benefit and mitigate risk (
      <xref ref-type="table" rid="tbl1">
       Table I
      </xref>
      ). More information on managing social media during the pandemic is included in this article's Online Repository at
      <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://www.jaci-inpractice.org">
       www.jaci-inpractice.org
      </ext-link>
      .
      <table-wrap id="tbl1" position="float">
       <label>
        Table I
       </label>
       <caption>
        <p>
         Tips to maximize the benefits of social media as a medical professional
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td>
           Mindfulness
          </td>
          <td>
           <list id="ulist0015" list-type="simple">
            <list-item id="u0070">
             <label>
              •
             </label>
             <p id="p0300">
              Turn off all social media notifications—do not let your device dictate your life
             </p>
            </list-item>
            <list-item id="u0075">
             <label>
              •
             </label>
             <p id="p0305">
              Schedule time each day to interact with social media at a time when you are engaged and not distracted
             </p>
            </list-item>
            <list-item id="u0080">
             <label>
              •
             </label>
             <p id="p0310">
              Recognize when you are forming an emotional response and take time away when necessary
             </p>
            </list-item>
            <list-item id="u0085">
             <label>
              •
             </label>
             <p id="p0315">
              Develop habits to reinforce not interacting with electronics first thing in the morning or before sleep
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Productivity
          </td>
          <td>
           <list id="ulist0020" list-type="simple">
            <list-item id="u0090">
             <label>
              •
             </label>
             <p id="p0320">
              Follow professional organizations to receive up-to-date vetted information
             </p>
            </list-item>
            <list-item id="u0095">
             <label>
              •
             </label>
             <p id="p0325">
              Follow journals of interest for the latest publications
             </p>
            </list-item>
            <list-item id="u0100">
             <label>
              •
             </label>
             <p id="p0330">
              Follow leaders and mentors in the field
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Reaching a target audience
          </td>
          <td>
           <list id="ulist0025" list-type="simple">
            <list-item id="u0105">
             <label>
              •
             </label>
             <p id="p0335">
              Provide valuable content
             </p>
            </list-item>
            <list-item id="u0110">
             <label>
              •
             </label>
             <p id="p0340">
              Use common hashtags when posting information
             </p>
            </list-item>
            <list-item id="u0115">
             <label>
              •
             </label>
             <p id="p0345">
              Incorporate links to longer format articles or online resources
             </p>
            </list-item>
            <list-item id="u0120">
             <label>
              •
             </label>
             <p id="p0350">
              Use pictures, videos, gifs to increase engagement
             </p>
            </list-item>
            <list-item id="u0125">
             <label>
              •
             </label>
             <p id="p0355">
              Comment on posts from other accounts
             </p>
            </list-item>
            <list-item id="u0130">
             <label>
              •
             </label>
             <p id="p0360">
              Repost interesting or important information from other accounts
             </p>
            </list-item>
            <list-item id="u0135">
             <label>
              •
             </label>
             <p id="p0365">
              Answer questions when posed
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Professionalism
          </td>
          <td>
           <list id="ulist0030" list-type="simple">
            <list-item id="u0140">
             <label>
              •
             </label>
             <p id="p0370">
              Maintain patient privacy at all times
             </p>
            </list-item>
            <list-item id="u0145">
             <label>
              •
             </label>
             <p id="p0375">
              Never provide individual medical advice; can direct toward general information or recommend contacting one's personal physician
             </p>
            </list-item>
            <list-item id="u0150">
             <label>
              •
             </label>
             <p id="p0380">
              Avoid cursing, strong political statements, or religious affirmations
             </p>
            </list-item>
            <list-item id="u0155">
             <label>
              •
             </label>
             <p id="p0385">
              Think twice before posting—once you hit send, it can never be completely deleted
             </p>
            </list-item>
            <list-item id="u0160">
             <label>
              •
             </label>
             <p id="p0390">
              Your opinions DO reflect your employer, even if stated otherwise; be aware of existing social media policies at your workplace
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Balancing clinician wellness during COVID-19
          </td>
          <td>
           <list id="ulist0035" list-type="simple">
            <list-item id="u0165">
             <label>
              •
             </label>
             <p id="p0395">
              Engage in non–professional-related online endeavors, ie, podcasts pertaining to areas of interest
             </p>
            </list-item>
            <list-item id="u0170">
             <label>
              •
             </label>
             <p id="p0400">
              Find social groups of similar interests to your own and engage or simply follow
             </p>
            </list-item>
            <list-item id="u0175">
             <label>
              •
             </label>
             <p id="p0405">
              Seek out groups and friends with positive, uplifting messaging
             </p>
            </list-item>
            <list-item id="u0180">
             <label>
              •
             </label>
             <p id="p0410">
              Implement social media to share resources, such as PPE access
             </p>
            </list-item>
            <list-item id="u0185">
             <label>
              •
             </label>
             <p id="p0415">
              Use social media to promote kindness to others and connect with those who are socially distanced
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="sec7">
     <title>
      Depression, Substance Abuse, and Suicide
     </title>
     <p id="p0095">
      There is a relative paucity of data and unknown prevalence regarding physician depression.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Systematic reviews of medical students and residents showed depression prevalence at 27% and 29%, respectively.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib33">
       <sup>
        33
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib34">
       <sup>
        34
       </sup>
      </xref>
      A 2020 Medscape survey of approximately 15,000 physicians revealed a rate of depression of 15% to 18%.
      <xref ref-type="bibr" rid="bib35">
       <sup>
        35
       </sup>
      </xref>
      Unfortunately, clinicians likely have incentive to conceal symptoms of depression for fear of putting hospital privileges or medical licenses in peril.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Thus, the prevalence is likely to be underestimated.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
     </p>
     <p id="p0100">
      Suicide rates for physicians are estimated to be higher than for the general public, and higher in female versus male physicians.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib36">
       <sup>
        36
       </sup>
      </xref>
      Physicians are more likely than nonphysicians to succeed in suicide attempts.
      <xref ref-type="bibr" rid="bib36">
       <sup>
        36
       </sup>
      </xref>
      The 2020 Medscape survey revealed that 21% to 22% of physicians had suicidal ideations and 1% to 2% had attempted suicide.
      <xref ref-type="bibr" rid="bib35">
       <sup>
        35
       </sup>
      </xref>
      Risk factors for suicide include depression, being single, not having children, substance abuse, access to drugs, and associated stress and burnout.
      <xref ref-type="bibr" rid="bib36">
       <sup>
        36
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib37">
       <sup>
        37
       </sup>
      </xref>
      This has unfortunately also affected our field of allergy and immunology.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
     </p>
     <p id="p0105">
      Although the exact prevalence of alcohol and drug addiction among clinicians is not known,
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      physicians are not immune to substance abuse or exempt from personal tragedy of the current opioid epidemic.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Unfortunately, stigma remains among clinicians reporting depression, substance abuse, addiction, and those attempting suicide.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
     </p>
     <p id="p0110">
      With the increasing stresses and uncertainty regarding COVID-19, the clinician may be at an even greater risk. In fact, more than 70% of health care workers in China during this current pandemic reported psychological distress including insomnia, anxiety, and depression.
      <xref ref-type="bibr" rid="bib38">
       <sup>
        38
       </sup>
      </xref>
      Addressing these issues with a mental health care professional may be needed, and it is important to understand warning signs of depression, anxiety, posttraumatic stress disorder, alcoholism, and substance abuse. Besides detection, understanding how to access safe and confidential resources to get help is key. In fact, most states have resources for clinicians seeking help through self-referral for depression, alcoholism, and/or substance abuse, and accessing these resources is confidential and does not need to interfere with licensure or medical practice. A listing of state physician health programs is available at the Web site of the Federation of State Physician Health Programs.
      <xref ref-type="bibr" rid="bib21">
       <sup>
        21
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="sec8">
     <title>
      Promoting Wellness While Maintaing Oupatient Practice During COVID-19
     </title>
     <p id="p0115">
      COVID-19 is adding to nonpandemic stresses of allergy and immunology physicians in practice, regardless of the clinical setting. For example, allergic conditions and COVID-19 symptoms have some overlap.
      <xref ref-type="bibr" rid="bib39">
       <sup>
        39
       </sup>
      </xref>
      Lack of information regarding COVID-19 testing also can increase anxiety of both clinician and patient. Allergy and immunology services such as biologic therapy and immunoglobulin replacement therapy are medically necessary and keep patients out of the emergency department and hospital, potentially saving resources for the care of the COVID-19 patient.
      <xref ref-type="bibr" rid="bib40">
       <sup>
        40
       </sup>
      </xref>
      However, recent guidance has suggested approaches such as telehealth when service reductions are required.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      Appropriate triage during the pandemic allows for effective social distancing; however, economic realities of service adjustments are inescapable, and the consequences of managing reduced revenue will create challenges to staff retention and maintaining a practice. Federal stimulus legislation may provide some relief of economic pressures during the pandemic. Advice to improve resilience during this time is outlined in
      <xref ref-type="table" rid="tbl2">
       Table II
      </xref>
      .
      <xref ref-type="bibr" rid="bib41">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="bib42">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="bib43">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      More information on wellness at work and cost-effectiveness of physician wellness is included in this article's Online Repository at
      <ext-link ext-link-type="uri" id="intref0015" xlink:href="http://www.jaci-inpractice.org">
       www.jaci-inpractice.org
      </ext-link>
      .
      <table-wrap id="tbl2" position="float">
       <label>
        Table II
       </label>
       <caption>
        <p>
         Tips for allergy and immunology practice resilience during the COVID-19 pandemic
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Use telehealth
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Postpone nonessential patient visits and procedures
          </td>
         </tr>
         <tr>
          <td>
           Create a practice task force for addressing and implementing changes
          </td>
         </tr>
         <tr>
          <td>
           Train staff on implemented changes
          </td>
         </tr>
         <tr>
          <td>
           Collaborate with other allergy and immunology colleagues
          </td>
         </tr>
         <tr>
          <td>
           Review practice finances and plan for income changes
          </td>
         </tr>
         <tr>
          <td>
           Overcommunicate with patients
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="sec9">
     <title>
      Working at Home with Children
     </title>
     <p id="p0120">
      During the pandemic, school closures add a layer of complexity to finding a work-life balance. In addition, there are different family units, including single physician parent households, with various custody arrangements. Parents of older children are coping with a unique set of stressors trying to help them navigate an uncertain landscape. High-schoolers currently applying to college are concerned because standardized college admissions tests and advanced placement examinations are being canceled, and they are unsure as to how this will affect their college admissions process. Many college students are anxious about whether their summer internships will be canceled, whether graduate degree programs will understand and accept that many colleges and universities are only providing pass/fail grades this semester, and how they will complete courses that depend on face-to-face interactions, which range from the performing arts to chemistry labs. Many seniors are grieving the loss of graduation ceremonies or are worried that their postcollege full-time job offers will be rescinded. Across the spectrum of pediatrics, children with special needs require increased supervision, and parents may need to work in shifts to provide one-on-one attention. All these factors translate to added stress on clinicians and patients alike.
     </p>
     <p id="p0125">
      Working from home while supervising clinical and/or research activities is challenging and requires new workflows. In this setting, clinicians must balance electronic medical record communication and respond to urgent and routine messages. First, it is important to establish frequent, consistent video and/or phone communication with staff and assign bite-sized tasks. Breaking larger assignments into smaller concrete blocks can prevent overwhelming colleagues, increase empowerment, and nurture a sense of accomplishment and satisfaction. Second, it is important to realize that everyone is adjusting to new pandemic realities. Additional advice on working with kids at home is depicted in
      <xref ref-type="table" rid="tbl3">
       Table III
      </xref>
      .
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       46
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       47
      </xref>
      <table-wrap id="tbl3" position="float">
       <label>
        Table III
       </label>
       <caption>
        <p>
         Suggested strategies for being productive at home with children of different ages
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td>
           <list id="ulist0010" list-type="simple">
            <list-item id="u0010">
             <label>
              •
             </label>
             <p id="p0240">
              Have a daily schedule and stick to it. Kids do better when they know what to expect
             </p>
            </list-item>
            <list-item id="u0015">
             <label>
              •
             </label>
             <p id="p0245">
              Post this schedule where everyone can see it. You can use pictures instead of words for younger children
             </p>
            </list-item>
            <list-item id="u0020">
             <label>
              •
             </label>
             <p id="p0250">
              If you have another adult at home, one method would be to alternate work and childcare hours for each of you
             </p>
            </list-item>
            <list-item id="u0025">
             <label>
              •
             </label>
             <p id="p0255">
              Older children can do their school work if they have it while you are “seeing” patients. Older children could also supervise younger children and help with educational activities
             </p>
            </list-item>
            <list-item id="u0030">
             <label>
              •
             </label>
             <p id="p0260">
              If you do not have help at home, another approach would be to work when the children are sleeping or safely engaged in a quiet activity. Schedule meetings if possible during nap time
             </p>
            </list-item>
            <list-item id="u0035">
             <label>
              •
             </label>
             <p id="p0265">
              For younger kids, bringing new or special toys can help keep them engaged for longer periods of time. Movies are another enjoyable option
             </p>
            </list-item>
            <list-item id="u0040">
             <label>
              •
             </label>
             <p id="p0270">
              Allow kids to socialize remotely with friends and family via FaceTime, Skype, etc
             </p>
            </list-item>
            <list-item id="u0045">
             <label>
              •
             </label>
             <p id="p0275">
              For older children, set daily goals and reward them. Allow them to play outside with siblings while maintaining social distancing
             </p>
            </list-item>
            <list-item id="u0050">
             <label>
              •
             </label>
             <p id="p0280">
              Have children do chores and help out around the house
             </p>
            </list-item>
            <list-item id="u0055">
             <label>
              •
             </label>
             <p id="p0285">
              Use the mute button during conference calls and have a silent do not disturb signal for when you are on important calls. You can also post a sign that signals that you are working
             </p>
            </list-item>
            <list-item id="u0060">
             <label>
              •
             </label>
             <p id="p0290">
              Being proactive and spending quality time with kids, during which you provide undivided attention, will also give you more uninterrupted time to work
             </p>
            </list-item>
            <list-item id="u0065">
             <label>
              •
             </label>
             <p id="p0295">
              Schedule times to get physical activity for you and the children, ideally together
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="sec10">
     <title>
      Coping and Wellness Tools
     </title>
     <p id="p0130">
      Now more than ever, health care providers need to practice self-care. Coping with rapidly changing recommendations can become overwhelming, while stress and anxiety can become insidious bedfellows escalating a cycle of tension both at home and at work. Paradoxically, at a time when social distance is strongly encouraged, we can all find ourselves more interwoven with one another in a common struggle to persevere against an unimaginable global challenge. While we face the defining moment of our time, resilience, compassion, and serenity may be great assets.
     </p>
     <p id="p0135">
      Many of us are filled with a mix of complicated emotions at this time. Strategies that have worked for us in the past, like getting together in person with friends, family, or colleagues, are not available while practicing social distancing. This loss of personal connectivity leads to further struggles for many. At this time, we need to look for ways to connect virtually and ensure we are attending to clinician wellness. This pandemic is unlike anything most have experienced before; however, we are able to draw from our collective experience with previous tragedies and struggles, including September 11, 2001, Hurricane Katrina, severe acute respiratory syndrome, and H1N1 flu epidemics.
     </p>
     <p id="p0140">
      The Strength-Focused and Meaning-Oriented Approach to Resilience and Transformation, which is typically used by social workers after a crisis to help survivors develop resilience to get through and transform and grow in the process, can be used today in our present crisis.
      <xref ref-type="bibr" rid="bib48">
       <sup>
        48
       </sup>
      </xref>
      The framework uses mind, body, and spirit approaches to foster awareness, develop strength, and discover meaning. It addresses this through “emphasizing growth through pain” by focusing on what personal strengths may develop through the experience. It “teaches the mind-body-spirit connection” in recognizing that by taking care of our physical needs we can boost our mood and mental strength. Furthermore, “developing an appreciation of nature,” we are encouraged to appreciate the small things in life, appreciate our own life, and those of loved ones around us. By “facilitating cognitive reappraisal” we can develop new perspectives and remember resilient experiences during other crisis and past successes. “Nourishing social support” allows us to improve and enhance our development and resilience while simultaneously having a sense of acceptance and connectedness while learning to recognize and appreciate the support offered from those around us. The final tenet of this approach includes “promoting the compassionate helper principle” in which we learn from traumatic experiences by extending compassion to ourselves and others.
     </p>
     <p id="p0145">
      Even in the best of times, health care professionals often do not seek assistance when they are experiencing stress, burnout, depression, and suicidality because of concerns regarding confidentiality, cost, time, licensing and career concerns, and stigma. Pospos et al
      <xref ref-type="bibr" rid="bib49">
       <sup>
        49
       </sup>
      </xref>
      selected and evaluated several Web-based resources according to the American Psychiatric Association “app evaluation framework”
      <xref ref-type="bibr" rid="bib50">
       <sup>
        50
       </sup>
      </xref>
      to be used as a starting point to address depression, stress, and suicidal ideation, noting that ideal interventions would be effective, “convenient, accessible, affordable, and confidential” and ideally would be used in conjunction with direct professional care. The resources chosen would inocorporate the treatment approaches used to address burnout among health care professionals: meditation, breath work, relaxation techniques, mindfulness training, cognitive-behavioral therapy, and suicide prevention. The applications it recommended include Breath2Relax, Headspace, MoodGYM, Stress Gym, Stay Alive, and Virtual Hope Box. Of note, the only one that has been assessed for efficacy in health care professionals was MoodGYM, which was shown to reduce suicidal ideation among medical interns.
      <xref ref-type="bibr" rid="bib51">
       <sup>
        51
       </sup>
      </xref>
      Mindfulness-based therapy platforms can allow for a sense of community, connectedness, and a platform to share successes and promote resilience.
      <xref ref-type="bibr" rid="bib52">
       <sup>
        52
       </sup>
      </xref>
      Additional wellness resources are outlined in
      <xref ref-type="table" rid="tbl4">
       Table IV
      </xref>
      .
      <table-wrap id="tbl4" position="float">
       <label>
        Table IV
       </label>
       <caption>
        <p>
         Physician wellness resources
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Online resources
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           AAAAI Physician Wellness Toolkit
           <xref ref-type="bibr" rid="bib53">
            <sup>
             53
            </sup>
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           AMA steps forward
           <xref ref-type="bibr" rid="bib54">
            <sup>
             54
            </sup>
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Stanford WellMD
           <xref ref-type="bibr" rid="bib55">
            <sup>
             55
            </sup>
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Institute for Healthcare Improvement
           <xref ref-type="bibr" rid="bib56">
            <sup>
             56
            </sup>
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Alliance for Academic Internal Medicine (AAIM), Collaborative for Healing and Renewal in Medicine (CHARM)
           <xref ref-type="bibr" rid="bib57">
            <sup>
             57
            </sup>
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Meditation and mindfulness apps
          </td>
         </tr>
         <tr>
          <td>
           Art of Living - Online Happiness
           <xref ref-type="bibr" rid="bib58">
            <sup>
             58
            </sup>
           </xref>
           Program for Healthcare Workers (no charge during COVID-19)
          </td>
         </tr>
         <tr>
          <td>
           Headspace
           <xref ref-type="bibr" rid="bib59">
            <sup>
             59
            </sup>
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Ten percent happier
           <xref ref-type="bibr" rid="bib60">
            <sup>
             60
            </sup>
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          <italic>
           AAAAI
          </italic>
          , American Academy of Allergy, Asthma &amp; Immunology;
          <italic>
           AMA
          </italic>
          , American Medical Association.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="p0150">
      At this time of social distancing it is important to maintain a schedule and your morning routine even if you do not have to leave the house. Enjoy nature while maintaining social distances. Take the time to connect with others virtually if you are feeling lonely via phone, email, and video platforms.
      <xref ref-type="bibr" rid="bib61">
       <sup>
        61
       </sup>
      </xref>
      When feeling overwhelmed by the number of people in the house, take some time for yourself in another room or go outside. Use the resources mentioned in this article to get support digitally. If this does not suffice, please reach out for professional help. Supports may be in place from local universities, the American Medical Association, and state and local professional societies. Limiting your news and social media consumption that you find upsetting may also reduce stress. Avoid using alcohol and other drugs to deal with your emotions—instead, use the skills that have enabled you to get through difficult situations in the past.
      <xref ref-type="bibr" rid="bib62">
       <sup>
        62
       </sup>
      </xref>
      Practicing compassion with yourself and others is also helpful.
      <xref ref-type="bibr" rid="bib63">
       <sup>
        63
       </sup>
      </xref>
      Initiating a gratitude practice has been shown to improve a sense of connection, quality, and amount of sleep and has improved well-being.
      <xref ref-type="bibr" rid="bib64">
       <sup>
        64
       </sup>
      </xref>
      This can be achieved through a gratitude journal in which you write daily entries about someone or something you are grateful for or listing 3 good things daily, which has been shown to reduce symptoms of depression and improve well-being.
      <xref ref-type="bibr" rid="bib65">
       <sup>
        65
       </sup>
      </xref>
      Engaging in a religious or spirituality practice has been associated with improved coping, strategies of acceptance, and less burnout in internal medicine and pediatric interns.
      <xref ref-type="bibr" rid="bib66">
       <sup>
        66
       </sup>
      </xref>
      Finally, allowing time to debrief, meditate, or discuss challenging situations and grief can be helpful to prevent burnout.
      <xref ref-type="bibr" rid="bib67">
       <sup>
        67
       </sup>
      </xref>
     </p>
     <p id="p0155">
      Governmental and health care agencies, institutions, and professional societies can help by sharing and continually updating information and resources. Communication that is concise, clear, transparent, timely, and thoughtful will help build a sense of control in health care providers.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
      Data from the H1N1 pandemic revealed that sufficiency of information was associated with reduced worry.
      <xref ref-type="bibr" rid="bib68">
       <sup>
        68
       </sup>
      </xref>
      Freeing providers from administrative tasks will allow peak performance for longer periods of time. Leadership should encourage all providers to strive to live the tenets of physician wellness.
      <xref ref-type="bibr" rid="bib13">
       <sup>
        13
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="sec11">
     <title>
      Conclusions
     </title>
     <p id="p0160">
      “World War V” is clearly upon us, with all the attendant anxieties and disruptions one might imagine when fighting an invisible enemy on home turf.
      <xref ref-type="bibr" rid="bib69">
       <sup>
        69
       </sup>
      </xref>
      We are faced with a new reality that has changed our culture, implicit assumptions, and basic underpinnings of our daily work. Mandated “stay-at-home” orders and self-quarantine social norms seem to have arrived overnight in some areas of the country, but a patchwork of inconsistency adds to a dizzying assessment of risk—and if we as medical experts find ourselves occasionally off balance, it is certain that our patients likely feel the same.
     </p>
     <p id="p0165">
      Clinician wellness can be an overlooked and marginalized aspect of our lives. In the daily hustle, self-care may often be a last priority as we continue to practice in a field of self-sacrifice and service to others. But if we do not realize it in the beginning, we will certainly realize it in the end that without self-care we will have nothing left to offer to anyone. The caregiver must take care of himself or herself if they want to do a good job taking care of others.
     </p>
     <p id="p0170">
      COVID-19 has arrived, and life is different. As we realize that we are in a seminal moment, that future generations may refer to “pre-COVID” and “post-COVID,”
      <xref ref-type="bibr" rid="bib69">
       <sup>
        69
       </sup>
      </xref>
      we must also pause to reflect, to breathe, and to care for ourselves and our loved ones. This COVID-19 pandemic will pass, and although SARS-CoV-2 may see a slow burn with seasonal encores in the next several years, the practice of allergy and immunology will continue to provide critical services, even as our infrastructure is temporarily reorganized during social distancing. As a specialty, allergy and immunology will continue to lead, and as our community comes together, we will persevere. Take care of yourself.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Del Rio
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Malani
          </surname>
          <given-names>
           P.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19—new insights on a rapidly changing epidemic [published online ahead of print February 28, 2020]
        </article-title>
        <comment>
         JAMA
        </comment>
        <ext-link ext-link-type="doi" id="intref0020" xlink:href="10.1001/jama.2020.3072">
         https://doi.org/10.1001/jama.2020.3072
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Coronavirus disease 2019 (COVID-19) situation summary
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/index.html">
         https://www.cdc.gov/coronavirus/2019-ncov/index.html
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print February 24, 2020]
        </article-title>
        <comment>
         JAMA
        </comment>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.2648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Oppenheimer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Grayson
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stukus
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hartog
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19: pandemic contingency planning for the allergy and immunology clinic [published online ahead of print March 26, 2020]
        </article-title>
        <comment>
         J Allergy Clin Immunol Pract
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.jaip.2020.03.012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Livingston
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bucher
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus disease 2019 (COVID-19) in Italy [published online ahead of print March 17, 2020]
        </article-title>
        <comment>
         JAMA
        </comment>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.4344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Remuzzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Remuzzi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 and Italy: what next? [published online ahead of print March 13, 2020]
        </article-title>
        <comment>
         Lancet
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30627-9
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu-Blatman
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Abrams
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         E. Engaging patient partners in state of the art allergy care: finding balance when discussing risk [published online ahead of print February 7, 2020]
        </article-title>
        <comment>
         Ann Allergy Asthma Immunol
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.anai.2020.01.029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geldsetzer
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Knowledge and perceptions of COVID-19 among the general public in the United States and the United Kingdom: a cross-sectional online survey [published online ahead of print March 20, 2020]
        </article-title>
        <comment>
         Ann Intern Med
        </comment>
        <pub-id pub-id-type="doi">
         10.7326/M20-0912
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="other">
        <article-title>
         PubMed. COVID-19 search results
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/?term=COVID-19">
         https://www.ncbi.nlm.nih.gov/pubmed/?term&amp;equals;COVID-19
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="other">
        <article-title>
         Johns Hopkins University &amp; Medicine. Coronavirus Resource Center
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://coronavirus.jhu.edu">
         https://coronavirus.jhu.edu
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="other">
        <article-title>
         A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/">
         https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Slisco
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         More than 50 doctors in Italy have now died from coronavirus. Newsweek. March 27, 2020
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0075" xlink:href="https://www.newsweek.com/more-50-doctors-italy-have-now-died-coronavirus-1494781">
         https://www.newsweek.com/more-50-doctors-italy-have-now-died-coronavirus-1494781
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Supporting the health care workforce during the COVID-19 global epidemic [published online ahead of print March 12, 2020]
        </article-title>
        <comment>
         JAMA
        </comment>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.3972
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          NHS Improvement
         </collab>
        </person-group>
        <article-title>
         Online library of quality improvement and redesign tools. Sense of profound knowledge (of W Edwards Deming, 1993)
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0085" xlink:href="https://improvement.nhs.uk/documents/2127/lens-profound-knowledge.pdf">
         https://improvement.nhs.uk/documents/2127/lens-profound-knowledge.pdf
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wasan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sussman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Provider health and wellness
        </article-title>
        <source>
         J Allergy Clin Immunol Pract
        </source>
        <volume>
         56
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1543
        </fpage>
        <lpage>
         1548
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shanafelt
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Boone
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dyrbye
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Sotile
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Satele
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Burnout and satisfaction with work-life balance among US physicians relative to the general US population
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         172
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1377
        </fpage>
        <lpage>
         1385
        </lpage>
        <pub-id pub-id-type="pmid">
         22911330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gabbe
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Melville
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mandel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Walker
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Burnout in chairs of obstetrics and gynecology: diagnosis, treatment, and prevention
        </article-title>
        <source>
         Am J Obstet Gynecol
        </source>
        <volume>
         186
        </volume>
        <year>
         2002
        </year>
        <fpage>
         601
        </fpage>
        <lpage>
         612
        </lpage>
        <pub-id pub-id-type="pmid">
         11967480
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bingemann
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Markovics
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sussman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         AAAAI Work Group Report: Physician Wellness in Allergy and Immunology [published online ahead of print February 14, 2020]
        </article-title>
        <comment>
         J Allergy Clin Immunol Pract
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.jaip.2020.01.023
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nedrow
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Steckler
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hardman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physician resilience and burnout: can you make the switch?
        </article-title>
        <source>
         Fam Pract Manag
        </source>
        <volume>
         20
        </volume>
        <year>
         2013
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         30
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shanafelt
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Dyrbye
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           West
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Addressing physician burnout: the way forward
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         317
        </volume>
        <year>
         2017
        </year>
        <fpage>
         901
        </fpage>
        <lpage>
         902
        </lpage>
        <pub-id pub-id-type="pmid">
         28196201
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="other">
        <article-title>
         Federation of State Physician Health Programs. State programs
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0095" xlink:href="https://www.fsphp.org/state-programs">
         https://www.fsphp.org/state-programs
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Medical Association
         </collab>
        </person-group>
        <article-title>
         AMA code of medical ethics: guidance in a pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0100" xlink:href="https://www.ama-assn.org/delivering-care/ethics/ama-code-medical-ethics-guidance-pandemic">
         https://www.ama-assn.org/delivering-care/ethics/ama-code-medical-ethics-guidance-pandemic
        </ext-link>
        <comment>
         Accessed March 30, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          State of New York Executive Order
         </collab>
        </person-group>
        <article-title>
         Continuing temporary suspension and modification of laws relating to the disaster emergency
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0105" xlink:href="https://www.governor.ny.gov/sites/governor.ny.gov/files/atoms/files/EO_202.12.pdf">
         https://www.governor.ny.gov/sites/governor.ny.gov/files/atoms/files/EO_202.12.pdf
        </ext-link>
        <comment>
         Accessed March 30, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kübler-Ross
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         On death and dying
        </chapter-title>
        <year>
         1969
        </year>
        <publisher-name>
         MacMillian
        </publisher-name>
        <publisher-loc>
         New York, NY
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maciejewski
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Block
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Prigerson
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An empirical examination of the stage theory of grief
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         297
        </volume>
        <year>
         2007
        </year>
        <fpage>
         716
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         17312291
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shampo
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kyle
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Steensma
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         L. E. Trudeau—founder of a sanatorium for treatment of tuberculosis
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        <volume>
         85
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e48
        </fpage>
        <pub-id pub-id-type="pmid">
         20592164
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hawes
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Stone
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Collapse therapy of pulmonary tuberculosis in New England States
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         98
        </volume>
        <year>
         1932
        </year>
        <fpage>
         2048
        </fpage>
        <lpage>
         2051
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corbetta
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tofani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Montinaro
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lobar collapse therapy using endobronchial valves as a new complementary approach to treat cavities in multidrug-resistant tuberculosis and difficult-to-treat tuberculosis: a case series
        </article-title>
        <source>
         Respiration
        </source>
        <volume>
         92
        </volume>
        <year>
         2016
        </year>
        <fpage>
         316
        </fpage>
        <lpage>
         328
        </lpage>
        <pub-id pub-id-type="pmid">
         27728916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schatz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bugie
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Waksman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Streptomycin, a substance exhibiting antibiotic activity against Gram positive and Gram negative bacteria
        </article-title>
        <source>
         Proc Soc Exp Biol Med
        </source>
        <volume>
         55
        </volume>
        <year>
         1944
        </year>
        <fpage>
         66
        </fpage>
        <lpage>
         69
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mathieu
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Internet and medical decision making: can it replace the role of health care providers?
        </article-title>
        <source>
         Med Decis Making
        </source>
        <volume>
         30
        </volume>
        <year>
         2010
        </year>
        <fpage>
         14S
        </fpage>
        <lpage>
         16S
        </lpage>
        <pub-id pub-id-type="pmid">
         20881151
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lazer
          </surname>
          <given-names>
           D.M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baum
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Benkler
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Berinsky
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Greenhill
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Menczer
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The science of fake news
        </article-title>
        <source>
         Science
        </source>
        <volume>
         359
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1094
        </fpage>
        <lpage>
         1096
        </lpage>
        <pub-id pub-id-type="pmid">
         29590025
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weinstein
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lejoyeux
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Internet addiction or excessive internet use
        </article-title>
        <source>
         Am J Drug Alcohol Abuse
        </source>
        <volume>
         36
        </volume>
        <year>
         2010
        </year>
        <fpage>
         277
        </fpage>
        <lpage>
         283
        </lpage>
        <pub-id pub-id-type="pmid">
         20545603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rotenstein
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ramos
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Torre
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Segal
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Peluso
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guille
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of depression, depressive symptoms, and suicidal ideation among medical students: a systematic review and meta-analysis
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         316
        </volume>
        <year>
         2016
        </year>
        <fpage>
         2214
        </fpage>
        <lpage>
         2236
        </lpage>
        <pub-id pub-id-type="pmid">
         27923088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mata
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ramos
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bansal
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Guille
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Di Angelantonio
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of depression and depressive symptoms among resident physicians: a systematic review and meta-analysis
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         314
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2373
        </fpage>
        <lpage>
         2383
        </lpage>
        <pub-id pub-id-type="pmid">
         26647259
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="other">
        <article-title>
         Medscape national physician burnout and suicide report 2020
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0110" xlink:href="https://www.medscape.com">
         https://www.medscape.com
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schernhammer
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Taking their own lives -- the high rate of physician suicide
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         352
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2473
        </fpage>
        <lpage>
         2476
        </lpage>
        <pub-id pub-id-type="pmid">
         15958803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hampton
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experts address risk of physician suicide
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         294
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1189
        </fpage>
        <lpage>
         1191
        </lpage>
        <pub-id pub-id-type="pmid">
         16160124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019
        </article-title>
        <source>
         JAMA Netw Open
        </source>
        <volume>
         3
        </volume>
        <year>
         2020
        </year>
        <fpage>
         e203976
        </fpage>
        <pub-id pub-id-type="pmid">
         32202646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus disease 2019 (COVID-19) with a focus on older adults: a guide for allergists and immunologists and patients. Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0115" xlink:href="http://www.aaaai.org">
         www.aaaai.org
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lumry
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Texas Allergy, Asthma, and Immunology Society statement
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0120" xlink:href="http://www.taais.org">
         www.taais.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="other">
        <article-title>
         Use of telemedicine during the COVID-19 pandemic. Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0125" xlink:href="http://www.aaaai.org">
         www.aaaai.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="other">
        <article-title>
         AAAAI telemedicine toolkit
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0130" xlink:href="http://www.aaaai.org">
         www.aaaai.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shute
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seven tips for running your practice in the coronavirus crisis
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0135" xlink:href="http://www.medscape.com">
         www.medscape.com
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="other">
        <article-title>
         COVID-19: pandemic. Small business resources. Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0140" xlink:href="http://www.aaaai.org">
         www.aaaai.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Parents
         </collab>
        </person-group>
        <article-title>
         How to master working from home—while under quarantine with kids
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0145" xlink:href="https://www.parents.com/parenting/work/life-balance/how-to-master-being-a-work-at-home-mom/">
         https://www.parents.com/parenting/work/life-balance/how-to-master-being-a-work-at-home-mom/
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sref46" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Poytner
         </collab>
        </person-group>
        <article-title>
         How to work from home with kids around
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0150" xlink:href="https://www.poynter.org/business-work/2020/how-to-work-from-home-with-kids-around">
         https://www.poynter.org/business-work/2020/how-to-work-from-home-with-kids-around
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          CNN Business
         </collab>
        </person-group>
        <article-title>
         How to work from home with kids (without losing it)
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0155" xlink:href="https://www.cnn.com/2020/03/16/success/working-from-home-with-kids-coronavirus/index.html">
         https://www.cnn.com/2020/03/16/success/working-from-home-with-kids-coronavirus/index.html
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Strength-Focused and Meaning-Oriented Approach to Resilience and Transformation (SMART): a body-mind-spirit approach to trauma management
        </article-title>
        <source>
         Soc Work Health Care
        </source>
        <volume>
         43
        </volume>
        <year>
         2006
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="pmid">
         16956851
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pospos
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           I.T.
          </given-names>
         </name>
         <name>
          <surname>
           Downs
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Iglewicz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Depp
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Web-based tools and mobile applications to mitigate burnout, depression, and suicidality among healthcare students and professionals: a systematic review
        </article-title>
        <source>
         Acad Psychiatry
        </source>
        <volume>
         421
        </volume>
        <year>
         2018
        </year>
        <fpage>
         109
        </fpage>
        <lpage>
         120
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Psychiatric Association
         </collab>
        </person-group>
        <article-title>
         App evaluation model
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0160" xlink:href="https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/app-evaluation-model">
         https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/app-evaluation-model
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guille
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Krystal
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nichols
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Brady
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Web-based cognitive behavioral therapy intervention for the prevention of suicidal ideation in medical interns: a randomized clinical trial
        </article-title>
        <source>
         JAMA Psychiatry
        </source>
        <volume>
         72
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1192
        </fpage>
        <lpage>
         1198
        </lpage>
        <pub-id pub-id-type="pmid">
         26535958
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chee
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic
        </article-title>
        <source>
         Ann Acad Med Singapore
        </source>
        <volume>
         49
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sref53" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Academy of Allergy, Asthma &amp; Immunology
         </collab>
        </person-group>
        <article-title>
         Physician wellness toolkit
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0165" xlink:href="https://www.aaaai.org/practice-resources/running-your-practice/practice-management-resources/wellness">
         https://www.aaaai.org/practice-resources/running-your-practice/practice-management-resources/wellness
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sref54" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Medical Association
         </collab>
        </person-group>
        <article-title>
         AMA steps forward
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0170" xlink:href="https://edhub.ama-assn.org/steps-forward">
         https://edhub.ama-assn.org/steps-forward
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sref55" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Satnford Medicine
         </collab>
        </person-group>
        <article-title>
         WellMD
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0175" xlink:href="https://wellmd.stanford.edu">
         https://wellmd.stanford.edu
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sref56" publication-type="other">
        <article-title>
         Institute of Healthcare Improvement. Improving Health and Health Care Worldwide
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0180" xlink:href="http://www.ihi.org">
         www.ihi.org
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sref57" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Alliance for Academic Internal Medicine
         </collab>
        </person-group>
        <article-title>
         Wellness and resiliency. CHARM
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0185" xlink:href="https://www.im.org/resources/wellness-resiliency/charm">
         https://www.im.org/resources/wellness-resiliency/charm
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sref58" publication-type="other">
        <article-title>
         The Art of Living. Online wellness program
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="interref0015" xlink:href="https://event.us.artofliving.org/us-en/hcp-online-wellness-program/">
         https://event.us.artofliving.org/us-en/hcp-online-wellness-program/
        </ext-link>
        <comment>
         Accessed April 14, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sref59" publication-type="other">
        <article-title>
         Headspace. We're here for you
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0195" xlink:href="https://www.headspace.com/covid-19">
         https://www.headspace.com/covid-19
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sref60" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Ten Percent Happier
         </collab>
        </person-group>
        <article-title>
         Coronavirus sanity guide
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0200" xlink:href="https://www.tenpercent.com/coronavirussanityguide">
         https://www.tenpercent.com/coronavirussanityguide
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sref61" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Rochester University
         </collab>
        </person-group>
        <article-title>
         Make every effort to connect digitally with other people
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0205" xlink:href="https://www.rochester.edu/newscenter/how-to-cope-with-psychology-of-social-distancing-420922/">
         https://www.rochester.edu/newscenter/how-to-cope-with-psychology-of-social-distancing-420922/
        </ext-link>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sref62" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Coping with stress during the 2019-nCoV outbreak
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0210" xlink:href="https://www.who.int/docs/default-source/coronaviruse/coping-with-stress.pdf?sfvrsn=9845bc3a_2">
         https://www.who.int/docs/default-source/coronaviruse/coping-with-stress.pdf?sfvrsn&amp;equals;9845bc3a_2
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sref63" publication-type="other">
        <article-title>
         The Schwartz Center. Resources for healthcare professionals coping with the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0215" xlink:href="https://www.theschwartzcenter.org/covid-19">
         https://www.theschwartzcenter.org/covid-19
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 28, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sref64" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Emmons
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           McCullough
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Counting blessings versus burdens: an experimental investigation of gratitude and subjective well-being in daily life
        </article-title>
        <source>
         J Pers Soc Psychol
        </source>
        <volume>
         84
        </volume>
        <year>
         2003
        </year>
        <fpage>
         377
        </fpage>
        <lpage>
         389
        </lpage>
        <pub-id pub-id-type="pmid">
         12585811
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rippstein-Leuenberger
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mauthner
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Bryan Sexton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Schwendimann
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A qualitative analysis of the Three Good Things intervention in healthcare workers
        </article-title>
        <source>
         BMJ Open
        </source>
        <volume>
         7
        </volume>
        <year>
         2017
        </year>
        <fpage>
         e015826
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Doolittle
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Windish
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of burnout syndrome with specific coping strategies, behaviors, and spiritual attitudes among interns at Yale University, New Haven, USA
        </article-title>
        <source>
         J Educ Eval Health Prof
        </source>
        <volume>
         12
        </volume>
        <year>
         2015
        </year>
        <fpage>
         41
        </fpage>
        <pub-id pub-id-type="pmid">
         26201403
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gogo
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Osta
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McClafferty
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Rana
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cultivating a way of being and doing: individual strategies for physician well-being and resilience
        </article-title>
        <source>
         Curr Probl Pediatr Adolesc Health Care
        </source>
        <volume>
         49
        </volume>
        <year>
         2019
        </year>
        <fpage>
         100663
        </fpage>
        <pub-id pub-id-type="pmid">
         31564630
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sref68" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goulia
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mantas
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitroula
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Mantis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hyphantis
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         General hospital staff worries, perceived sufficiency of information and associated psychological distress during the A/H1N1 influenza pandemic
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         2010
        </year>
        <fpage>
         322
        </fpage>
        <pub-id pub-id-type="pmid">
         21062471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sref69" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           McLuhan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         World War “V”. The American Mind. March 16, 2020
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0220" xlink:href="https://americanmind.org/features/the-coronacrisis-and-our-future-discontents/world-war-v/">
         https://americanmind.org/features/the-coronacrisis-and-our-future-discontents/world-war-v/
        </ext-link>
        <comment>
         Accessed March 29, 2020
        </comment>
       </element-citation>
      </ref>
     </ref-list>
     <ref-list id="fread0010">
      <title>
       References
      </title>
      <ref id="bibE1">
       <element-citation id="sref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stukus
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         How Dr Google is impacting parental medical decision making
        </article-title>
        <source>
         Immunol Allergy Clin North Am
        </source>
        <volume>
         39
        </volume>
        <year>
         2019
        </year>
        <fpage>
         583
        </fpage>
        <lpage>
         591
        </lpage>
        <pub-id pub-id-type="pmid">
         31563191
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE2">
       <element-citation id="sref71" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kind
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Greysen
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Chretien
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advantages and challenges of social media in pediatrics
        </article-title>
        <source>
         Pediatr Ann
        </source>
        <volume>
         40
        </volume>
        <year>
         2011
        </year>
        <fpage>
         430
        </fpage>
        <lpage>
         434
        </lpage>
        <pub-id pub-id-type="pmid">
         21902119
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE3">
       <element-citation id="sref72" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           A.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of social network sites for communication among health professionals: systematic review
        </article-title>
        <source>
         J Med Internet Res
        </source>
        <volume>
         20
        </volume>
        <year>
         2018
        </year>
        <fpage>
         e117
        </fpage>
        <pub-id pub-id-type="pmid">
         29592845
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE4">
       <element-citation id="sref73" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolls
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hansen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         How health care professionals use social media to create virtual communities: an integrative review
        </article-title>
        <source>
         J Med Internet Res
        </source>
        <volume>
         18
        </volume>
        <year>
         2016
        </year>
        <fpage>
         e166
        </fpage>
        <pub-id pub-id-type="pmid">
         27328967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE5">
       <element-citation id="sref74" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Academy of Allergy, Asthma, and Immunology
         </collab>
        </person-group>
        <article-title>
         AAAAI telemedicine toolkit
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="interref0010" xlink:href="https://www.aaaai.org/practice-resources/running-your-practice/practice-management-resources/telemedicine">
         https://www.aaaai.org/practice-resources/running-your-practice/practice-management-resources/telemedicine
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE6">
       <element-citation id="sref75" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Academy of Allergy, Asthma, and Immunology
         </collab>
        </person-group>
        <article-title>
         Use of telemedicine during the COVID-19 pandemic. Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="interref0020" xlink:href="https://education.aaaai.org/resources-for-a-i-clinicians/covid-19">
         https://education.aaaai.org/resources-for-a-i-clinicians/covid-19
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE7">
       <element-citation id="sref76" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Portnoy
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Waller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Elliot
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Telemedicine in the era of COVID-19 [published online ahead of print March 24, 2020]
        </article-title>
        <comment>
         J Allergy Clin Immunol Pract
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.jaip.2020.03.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE8">
       <element-citation id="sref77" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shute
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seven tips for running your practice in the coronavirus crisis
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0240" xlink:href="http://www.medscape.com">
         www.medscape.com
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE9">
       <element-citation id="sref78" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wasan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sussman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Provider health and wellness
        </article-title>
        <source>
         J Allergy Clin Immunol Pract
        </source>
        <volume>
         5
        </volume>
        <year>
         2017
        </year>
        <fpage>
         1543
        </fpage>
        <lpage>
         1548
        </lpage>
        <pub-id pub-id-type="pmid">
         28734859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE10">
       <element-citation id="sref79" publication-type="other">
        <article-title>
         COVID-19: pandemic. Small business resources. Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0245" xlink:href="http://www.aaaai.org">
         www.aaaai.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE11">
       <element-citation id="sref80" publication-type="other">
        <article-title>
         Current economic relief opportunities for US small business impacted by the COVID-19 outbreak in the CARES Act. Natl Law Rev
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0250" xlink:href="https://www.natlawreview.com/article/current-economic-relief-opportunities-us-small-businesses-impacted-covid-19-outbreak">
         https://www.natlawreview.com/article/current-economic-relief-opportunities-us-small-businesses-impacted-covid-19-outbreak
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE12">
       <element-citation id="sref81" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lumry
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Texas Allergy, Asthma, and Immunology Society statement
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0255" xlink:href="http://www.taais.org">
         www.taais.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE13">
       <element-citation id="sref82" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Stigma and resilience
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0260" xlink:href="https://www.cdc.org">
         https://www.cdc.org
        </ext-link>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE14">
       <element-citation id="sref83" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus disease 2019 (COVID-19) with a focus on older adults: a guide for allergists and immunologists and patients. Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0265" xlink:href="http://www.aaaai.org">
         www.aaaai.org
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE15">
       <element-citation id="sref84" publication-type="other">
        <article-title>
         Medscape physician compensation report
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0270" xlink:href="https://www.medscape.com/slideshow/2019-compensation-overview-6011286#2">
         https://www.medscape.com/slideshow/2019-compensation-overview-6011286#2
        </ext-link>
        <year>
         2019
        </year>
        <comment>
         Accessed March 27, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE16">
       <element-citation id="sref85" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Greenhawt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A primer on cost-effectiveness in the allergy clinic
        </article-title>
        <source>
         Ann Allergy Asthma Immunol
        </source>
        <volume>
         123
        </volume>
        <year>
         2019
        </year>
        <fpage>
         120
        </fpage>
        <lpage>
         128.e1
        </lpage>
        <pub-id pub-id-type="pmid">
         31128234
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE17">
       <element-citation id="sref86" publication-type="other">
        <article-title>
         US Department of Labor, Bureau of Labor Statistics. March 22, 2020
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0275" xlink:href="http://www.bls/gov">
         www.bls/gov
        </ext-link>
        <comment>
         Accessed March 22, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE18">
       <element-citation id="sref87" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arias
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         United States Life Tables, 2015
        </article-title>
        <source>
         Natl Vital Stat Rep
        </source>
        <volume>
         67
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         63
        </lpage>
       </element-citation>
      </ref>
      <ref id="bibE19">
       <element-citation id="sref88" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Oppenheimer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Grayson
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stukus
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hartog
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19: pandemic contingency planning for the allergy and immunology clinic [March 26, 2020]
        </article-title>
        <comment>
         J Allergy Clin Immunol Pract
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.jaip.2020.03.012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE20">
       <element-citation id="sref89" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American Academy of Allergy, Asthma, &amp; Immunology
         </collab>
        </person-group>
        <article-title>
         Resources for A/I clinicians during the COVID-19 pandemic
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0285" xlink:href="https://education.aaaai.org/resources-for-a-i-clinicians/covid-19">
         https://education.aaaai.org/resources-for-a-i-clinicians/covid-19
        </ext-link>
        <comment>
         Accessed March 29, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE21">
       <element-citation id="sref90" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          American College of Allergy, Asthma, &amp; Immunology
         </collab>
        </person-group>
        <article-title>
         Coronavirus (COVID-19) resources
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0290" xlink:href="https://education.acaai.org/coronavirus">
         https://education.acaai.org/coronavirus
        </ext-link>
        <comment>
         Accessed March 29, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE22">
       <element-citation id="sref91" publication-type="other">
        <article-title>
         Canadian Society for Allergy and Clinical Immunology
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0295" xlink:href="https://csaci.ca">
         https://csaci.ca
        </ext-link>
        <comment>
         Accessed March 29, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE23">
       <element-citation id="sref92" publication-type="other">
        <article-title>
         American College of Allergy, Asthma, &amp; Immunology. Telehealth toolkit
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0300" xlink:href="https://college.acaai.org/practice-management/telehealth-toolkit">
         https://college.acaai.org/practice-management/telehealth-toolkit
        </ext-link>
        <comment>
         Accessed March 29, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bibE24">
       <element-citation id="sref93" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Portnoy
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Waller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           De Lurgio
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dinakar
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Telemedicine is as effective as in-person visits for patients with asthma
        </article-title>
        <source>
         Ann Allergy Asthma Immunol
        </source>
        <volume>
         117
        </volume>
        <year>
         2016
        </year>
        <fpage>
         241
        </fpage>
        <lpage>
         245
        </lpage>
        <pub-id pub-id-type="pmid">
         27613456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE25">
       <element-citation id="sref94" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Portnoy
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pandya
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Waller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Telemedicine and emerging technologies for health care in allergy/immunology
        </article-title>
        <source>
         J Allergy Clin Immunol
        </source>
        <volume>
         145
        </volume>
        <year>
         2020
        </year>
        <fpage>
         445
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         32035604
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE26">
       <element-citation id="sref95" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Briggs
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dbouk
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dutille
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Oppenheimer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Greenhawt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab
        </article-title>
        <source>
         J Allergy Clin Immunol Pract
        </source>
        <volume>
         8
        </volume>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         572
        </lpage>
        <pub-id pub-id-type="pmid">
         31626991
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE27">
       <element-citation id="sref96" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kanaoka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Feenan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Greenhawt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An economic evaluation of immediate vs non-immediate activation of emergency medical services after epinephrine use for peanut-induced anaphylaxis
        </article-title>
        <source>
         Ann Allergy Asthma Immunol
        </source>
        <volume>
         1221
        </volume>
        <year>
         2019
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         85
        </lpage>
       </element-citation>
      </ref>
      <ref id="bibE28">
       <element-citation id="sref97" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stukus
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fleischer
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Spergel
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Greenhawt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         “To screen or not to screen”: comparing the health and economic benefits of early peanut introduction strategies in five countries
        </article-title>
        <source>
         Allergy
        </source>
        <volume>
         73
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1707
        </fpage>
        <lpage>
         1714
        </lpage>
        <pub-id pub-id-type="pmid">
         29601091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE29">
       <element-citation id="sref98" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenhawt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction
        </article-title>
        <source>
         JAMA Netw Open
        </source>
        <volume>
         2
        </volume>
        <year>
         2019
        </year>
        <fpage>
         e1918041
        </fpage>
        <pub-id pub-id-type="pmid">
         31860109
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bibE30">
       <element-citation id="sref99" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenhawt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shaker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Winders
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bukstein
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Oppenheimer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies [published online ahead of print February 11, 2020]
        </article-title>
        <comment>
         Ann Allergy Asthma Immunol
        </comment>
        <pub-id pub-id-type="doi">
         10.1016/j.anai.2020.01.030
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="appsec1">
      <label>
       Online Repository
      </label>
      <title>
       Pandemic Social Media and the Allergist/Immunologist
      </title>
      <p id="p0175">
       During these stressful times, medical professionals can use social media to benefit themselves as well as their patients. In addition to the Centers for Disease Control and Prevention, trusted medical organizations such as the American Academy of Allergy, Asthma &amp; Immunology (AAAAI), the National Institute of Allergy and Infectious Diseases, and the World Health Organization can be accessed for resources to help clinicians prepare but can also be used to curate and share information with others as well. Clinicians should embrace the trusted relationships they have developed with their own patients as well as the desire of the general public and media to hear from experts.
       <xref ref-type="bibr" rid="bibE1">
        <sup>
         E1
        </sup>
       </xref>
       Those already active on social media can serve as a valuable resource to provide perspective, general information, and address misinformation. One example of conflicting reports from mainstream media that have circulated on social media during the COVID-19 pandemic involves confusion regarding the risk of using corticosteroids during active infection, a topic that is pertinent to patients with asthma. In this example, professionals can use their role on social media to provide anticipatory guidance to patients with asthma by reinforcing the need to maintain inhaled corticosteroid controller medications to try and prevent exacerbations, and highlighting the importance of understanding when and how to start treatment should symptoms occur. In an online world filled with misinformation and fear mongering, clinicians can use their social media presence to promote preparedness, encourage positive behavior change, and spread accurate information instead of panic.
       <xref ref-type="bibr" rid="bibE2">
        <sup>
         E2
        </sup>
       </xref>
       Medical professionals who are not active on social media can still use these platforms to better understand the common questions or points of confusion being discussed. This can aid anticipatory guidance with individual patients who may not raise these concerns on their own during clinical encounters, or provide resources on practice Web sites addressing frequently asked questions.
      </p>
      <p id="p0180">
       It is also important for clinicians to recognize how their use of social media may impact their well-being. In addition, clinicians can seek out social media groups that provide professional and emotional support.
       <xref ref-type="bibr" rid="bibE3">
        E3
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE4">
        E4
       </xref>
       There are countless examples of online groups that provide comfort and collegiality, which can be extremely important for those in community-based outpatient practices who may have limited interactions with colleagues and those who may have temporarily closed their practices because of the current social distancing guidelines. The Physicians Moms Group on Facebook is one of the more prominent examples, where more than 70,000 women share personal and professional stories with one another in a closed forum. Now more than ever, it is important for all of us to be mindful of our social media habits, recognize when our online interactions encroach upon our well-being, and use social media in a positive manner.
      </p>
     </sec>
     <sec id="appsec2">
      <title>
       Wellness at Work
      </title>
      <p id="p0185">
       Telehealth can minimize risk and promote safety, and newly developed AAAAI resources exist to help the clinician get started.
       <xref ref-type="bibr" rid="bibE5">
        E5
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE6">
        E6
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE7">
        E7
       </xref>
       Creating a practice task force to assess recommendations from local, state, and federal governments, as well as medical societies, can be helpful at the onset.
       <xref ref-type="bibr" rid="bibE8">
        <sup>
         E8
        </sup>
       </xref>
       Obtaining PPE is essential, although challenging in the current rationed environment. In addition, collaborating with other local allergists and immunologists can facilitate idea exchange and highlight the reality that, even at a social distance, we are not alone.
       <xref ref-type="bibr" rid="bibE8">
        <sup>
         E8
        </sup>
       </xref>
       Engaging the health care team at the beginning of a workday will help to prevent many stressful situations and also help to lay a scaffold to quickly resolve problems that do arise.
       <xref ref-type="bibr" rid="bibE9">
        <sup>
         E9
        </sup>
       </xref>
       At this time, social distancing is critical to mitigating COVID-19, as is routine and increased office and equipment cleaning.
       <xref ref-type="bibr" rid="bibE10">
        <sup>
         E10
        </sup>
       </xref>
      </p>
      <p id="p0190">
       From the business standpoint, cross-training employees and preparing for increased absenteeism is necessary.
       <xref ref-type="bibr" rid="bibE10">
        <sup>
         E10
        </sup>
       </xref>
       Reviewing practice finances including cash flow and having a plan for decreased income due to potentially less numbers of patients and procedures is necessary, and it is hoped that recent federal legislation will provide some respite.
       <xref ref-type="bibr" rid="bibE10">
        <sup>
         E10
        </sup>
       </xref>
       Specifically, the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020, passed in the Senate with bipartisan support on March 25, 2020, may provide more than $2 trillion in total relief and $350 billion in support for small businesses.
       <xref ref-type="bibr" rid="bibE11">
        <sup>
         E11
        </sup>
       </xref>
       It is important to remember that some allergists and immunologists may temporarily suspend in-office operations or provide care almost exclusively by telehealth, depending on various individual factors, including personal and professional. Preparing for this possibility is advisable.
       <xref ref-type="bibr" rid="bibE8">
        <sup>
         E8
        </sup>
       </xref>
      </p>
      <p id="p0195">
       Regarding patient care, overcommunication is preferred.
       <xref ref-type="bibr" rid="bibE8">
        <sup>
         E8
        </sup>
       </xref>
       Postponing nonessential appointments or procedures is recommended and necessary for social distancing to be effective; however, patient-specific decisions should still be determined by the individual clinician's clinical judgment.
       <xref ref-type="bibr" rid="bibE8">
        E8
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE12">
        E12
       </xref>
       Patients may be more or less concerned about the COVID-19 pandemic than their clinicians, and may be receiving information (and misinformation) from various sources. Reinforcing the concept of social distancing as well as the importance of adequate sleep, exercise (with social distance in mind), and diet is sound advice. Discussing the ways in which the practice is adapting care in the COVID-19 pandemic era includes active communication methods such as Health Insurance Portability and Accountability Act secure text messaging and email software; social media updates via platforms such as Facebook, Twitter, and Instagram; consistently updating the practice website; and placing well-marked educational signage. These interventions can help alleviate patient concerns. Of note, avoidance of stigmatizing groups of people due to suspected or actual infection is fundamental.
       <xref ref-type="bibr" rid="bibE13">
        <sup>
         E13
        </sup>
       </xref>
       <sup>
        ,
       </sup>
       <xref ref-type="bibr" rid="bibE14">
        <sup>
         E14
        </sup>
       </xref>
      </p>
     </sec>
     <sec id="appsec3">
      <title>
       Cost-Effectiveness of Clinician Wellness
      </title>
      <p id="p0200">
       The effect of clinician wellness and wellness programs may be life-changing and life-saving. Unfortunately, even outside of a pandemic the risk of burnout and consequences of ignoring aspects of wellness are underappreciated and often undervalued. Although cost-effectiveness analyses can be a useful analytical tool to understand whether financial trade-offs are worth gains in quality of life, the health and economic consequences of ignoring personal wellness in the practice of medicine have not been well studied.
      </p>
      <p id="p0205">
       In the Medscape 2019 physician compensation report, primary care providers earned an average of $237K per year and average annual specialist compensation was $341K.
       <xref ref-type="bibr" rid="bibE15">
        <sup>
         E15
        </sup>
       </xref>
       In this report of 19,328 respondents across 30+ specialties, annual compensation for allergy and immunology was $274K. Although physicians spent an average of 37 to 40 hours in patient care, 36% of respondents spent 20 hours or more on paperwork and administration per week.
       <xref ref-type="bibr" rid="bibE15">
        <sup>
         E15
        </sup>
       </xref>
       This represents a dramatic increase from 2012, where 53% of physicians spent about 1 to 4 hours on paperwork.
       <xref ref-type="bibr" rid="bibE15">
        <sup>
         E15
        </sup>
       </xref>
       Although most felt rewarded by either patient relationships, problem solving, or making the world a better place, 2% of physicians reported that nothing about their job was rewarding.
       <xref ref-type="bibr" rid="bibE15">
        <sup>
         E15
        </sup>
       </xref>
       Seventy-three percent of allergy and immunology physicians would choose medicine again, with 82% of those preferring to remain in their chosen field of practice.
       <xref ref-type="bibr" rid="bibE15">
        <sup>
         E15
        </sup>
       </xref>
      </p>
      <p id="p0210">
       To illustrate the potential cost-effectiveness of clinician wellness, we constructed a simple Markov model evaluating a cohort of physicians earning the mean salary for allergy and immunology, working 40 hours per week in direct patient care, with 10 hours per week spent on administrative tasks.
       <xref ref-type="bibr" rid="bibE16">
        <sup>
         E16
        </sup>
       </xref>
       Although the health state utility of wellness is unknown, we explored plausible disutility (eg, negative health detriment from an action) ranges of 1% to 5% compared with an idealized practice of work-life balance over a 30-year model horizon, starting practice at age 30 years. Future costs and utilities were uniformly discounted at 3% per annum, with all-cause age-adjusted mortality incorporated into the model and 1-year cycle length.
       <xref ref-type="bibr" rid="bibE17">
        E17
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE18">
        E18
       </xref>
      </p>
      <p id="p0215">
       When considering medical practice, cost-effective care is defined as care costing less than $100,000/quality-adjusted life-year (QALY), with a QALY measured by the relative trade-off between a perfect year of wellness and challenges associated with burnout resulting from inattention to personal wellness.
       <xref ref-type="bibr" rid="bibE16">
        <sup>
         E16
        </sup>
       </xref>
       In this wellness model, a 1% equal reduction in health state utility and compensation demonstrated cost-effectiveness of wellness of $269,440 per QALY, a 10% disutilty with 5% compensation reduction cost $137,469 per QALY, whereas a 15% health disutility with 5% compensation reduction cost $91,646 per QALY. At a 20% relative disutility of wellness, a 5% reduction in compensation cost $68,735 per QALY. Findings from the physician cost-effectiveness wellness model confirmed that attention to wellness can be a cost-effective prospect, even if requiring a reduction in compensation.
      </p>
     </sec>
     <sec id="appsec4">
      <title>
       COVID-19 Allergy Society Supports
      </title>
      <p id="p0220">
       The North American allergy and immunology professional societies—the AAAAI, the American College of Allergy, Asthma &amp; Immunology, and the Canadian Society of Allergy and Clinical Immunology—are providing real-time resources to help on-the-ground clinicians navigate the COVID-19 pandemic. Although challenges to allergists/immunologists vary contextually by private, hospital, or academic practice, societal leadership and collegial support is crucial. These organizations are uniquely positioned to provide resources for contingency planning, advocacy, education, and research priorities during these challenging times. Recently, the AAAAI, the American College of Allergy, Asthma &amp; Immunology, and the Canadian Society of Allergy and Clinical Immunology endorsed a framework for COVID-19 contingency planning in the allergy and immunology clinics in addition to distributing and/or promoting videos, podcasts, social media outreach, community forums, and virtual journal club.
       <xref ref-type="bibr" rid="bibE19">
        <sup>
         E19
        </sup>
       </xref>
       Through leveraging global health expertise, these allergy societies have taken action, such as mobilizing a COVID-19 Task Force charged with real-time monitoring of a fluid and ever-changing pandemic and initiating rapid response communication of critical information. During this time, coordinated messaging from North American allergy and immunology societies can play a pivotal role in advocacy at the federal and state levels to address issues such as expanding coverage for telehealth services nationwide and mitigating the financial impact of the pandemic on private practices.
       <xref ref-type="bibr" rid="bibE20">
        E20
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE21">
        E21
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE22">
        E22
       </xref>
      </p>
     </sec>
     <sec id="appsec5">
      <title>
       How New Strategies and Novel Paradigms of Care Delivery Can Help
      </title>
      <p id="p0225">
       Allergy/Immunology clinic contingency planning can allow for compliance with local and state regulations being increasingly required to defer nonessential medical services during shelter-in-place mandates.
       <xref ref-type="bibr" rid="bibE19">
        <sup>
         E19
        </sup>
       </xref>
       Through this pandemic the ability to persevere will both require and nourish resilience—a key wellness tool.
      </p>
      <p id="p0230">
       The rapid adoption of telehealth is a critical component of COVID-19 care. Without a doubt, the advent of telehealth in the past few years will be a saving grace, and the rapid incorporation of this service into daily practice will no doubt be a lasting legacy of COVID-19. Although it is not always a perfect surrogate for an in-office visit, when viewing the current situation as temporary, it may allow most care to resume without too much interruption outside of certain parts of the physical examination and certain procedures. Many regulations regarding telehealth have been relaxed during the pandemic, allowing for practice across state lines without having to have a license in that state, with use of less HIPPA-compliant vehicles for communication, and ensuring that video visits can be reimbursed at the same level as an in-office visit for the same issue.
       <xref ref-type="bibr" rid="bibE6">
        E6
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE7">
        E7
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE23">
        E23
       </xref>
       Telehealth services can also provide access to aspects of care unavailable with in-person visits, such as creating the avenue for virtual home-visits and, despite social distancing, providing a different view into patient and family needs in the more personal context of their own home. Telehealth may also create conversations with multiple family members to better inform practice—individuals who can inform care and help to promote adherence in ways that may not happen with conventional visits.
       <xref ref-type="bibr" rid="bibE7">
        <sup>
         E7
        </sup>
       </xref>
      </p>
      <p id="p0235">
       An added telehealth benefit may also be improved overall productivity from individual clinicians as well.
       <xref ref-type="bibr" rid="bibE24">
        <sup>
         E24
        </sup>
       </xref>
       Following the pandemic, the ability to conserve some of the more relaxed telehealth standards could be of significant benefit to expanding the reach of a practice into lesser served areas as well.
       <xref ref-type="bibr" rid="bibE25">
        <sup>
         E25
        </sup>
       </xref>
       This crisis will certainly foster creativity in rethinking the way that we deliver care and provide an opportunity to do things better for our patients. There are a few practical examples of this. Economic models have been previously published that have noted the safety of home biologic agent administration,
       <xref ref-type="bibr" rid="bibE26">
        <sup>
         E26
        </sup>
       </xref>
       lack of necessity to activate emergency medical services and seek emergency care after using epinephrine if the patient stabilizes,
       <xref ref-type="bibr" rid="bibE27">
        <sup>
         E27
        </sup>
       </xref>
       and the necessity for screening even high-risk infants for early peanut introduction under the National Institute of Allergy and Immunological Diseases guidelines.
       <xref ref-type="bibr" rid="bibE28">
        E28
       </xref>
       ,
       <xref ref-type="bibr" rid="bibE29">
        E29
       </xref>
       A better understanding of what services prove essential, where patient preferences may leverage shared decision making,
       <xref ref-type="bibr" rid="bibE30">
        <sup>
         E30
        </sup>
       </xref>
       and what aspects of care can be reduced or shifted from an in-office to a telehealth or at-home platform will maximize health and economic outcomes of care during the pandemic. These approaches will allow our specialty to better focus on increasing the value of the care we provide and expand the access to that care.
      </p>
     </sec>
     <fn-group>
      <fn id="d32e1056">
       <p id="ntpara0010">
        M.G. is supported by the
        <funding-source id="gs1">
         Agency for Healthcare Research and Quality
        </funding-source>
        (grant no. 5K08HS024599-02).
       </p>
      </fn>
      <fn id="d32e1065">
       <p id="ntpara0015">
        Conflicts of interest: P. Bansal has served on the advisory boards for Genentech, Regeneron, Kaleo, AstraZeneca, ALK, Shire, Takeda, Pharming, CSL Behring, and Teva; has served as a speaker for AstraZeneca, Regeneron, ALK, Takeda, Shire, CSL Behring, Takeda, and Pharming; and has served as an independent consultant for ALK, AstraZeneca, and Exhale. M. Greenhawt is supported by the
        <funding-source id="gs2">
         Agency for Healthcare Research and Quality
        </funding-source>
        (grant no. 5K08HS024599-02); is an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases–sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, GlaxoSmithKline, Merck, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Allergenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma &amp; Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for
        <italic>
         the Annals of Allergy, Asthma, and Immunology
        </italic>
        ; and is a member of the Joint Taskforce on Allergy Practice Parameters. G. Mosnaim has received research grant support from
        <funding-source id="gs11">
         AstraZeneca
        </funding-source>
        and
        <funding-source id="gs10">
         GlaxoSmithKline
        </funding-source>
        ; currently receives research grant support from
        <funding-source id="gs12">
         Propeller Health
        </funding-source>
        ; owned stock in Electrocore; and served as a consultant and/or member of a scientific advisory board for GlaxoSmithKline, Sanofi-Regeneron, Teva, Novartis, AstraZeneca, Boehringer Ingelheim, and Propeller Health. J. Oppenheimer has served as a consultant for AstraZeneca, GlaxoSmithKline, Sanofi, and Novartis; is a consultant for GlaxoSmithKline, AstraZeneca, and Sanofi; is Associate Editor for
        <italic>
         Annals of Allergy, Asthma &amp; Immunology
        </italic>
        and
        <italic>
         AllergyWatch
        </italic>
        ; is Section Editor of
        <italic>
         Current Opinion of Allergy
        </italic>
        ; receives royalties from Up to Date; is Board Liaison American Board of Internal Medicine for American Board of Allergy and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. D. Stukus is a consultant for DBV Therapeutics, Before Brands, and Abbott Nutrition. M. Shaker has a brother who is CEO of Altrix Medical; is a member of the Joint Task force on Practice Parameters; and serves on the editorial boards of
        <italic>
         the Journal of Allergy and Clinical Immunology: In Practice
        </italic>
        ,
        <italic>
         Annals of Allergy, Asthma, &amp; Immunology
        </italic>
        , and
        <italic>
         the Journal of Food Allergy
        </italic>
        . The rest of the authors declare that they have no relevant conflicts of interest.
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Am Coll Surg
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Am. Coll. Surg
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of the American College of Surgeons
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1072-7515
      </issn>
      <issn pub-type="epub">
       1879-1190
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier Inc. on behalf of the American College of Surgeons.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32240770
      </article-id>
      <article-id pub-id-type="pmc">
       7128345
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1072-7515(20)30263-5
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jamcollsurg.2020.03.019
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Maximizing the Calm Before the Storm: Tiered Surgical Response Plan for Novel Coronavirus (COVID-19)
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Ross
         </surname>
         <given-names>
          Samuel Wade
         </given-names>
        </name>
        <degrees>
         MD, MPH
        </degrees>
        <email>
         Samuel.Ross@atriumhealth.org
        </email>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Lauer
         </surname>
         <given-names>
          Cynthia W.
         </given-names>
        </name>
        <degrees>
         MD, FACS
        </degrees>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Miles
         </surname>
         <given-names>
          William S.
         </given-names>
        </name>
        <degrees>
         MD, FACS, FCCM
        </degrees>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Green
         </surname>
         <given-names>
          John M.
         </given-names>
        </name>
        <degrees>
         MD, FACS
        </degrees>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Christmas
         </surname>
         <given-names>
          A Britton
         </given-names>
        </name>
        <degrees>
         MD, FACS
        </degrees>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          May
         </surname>
         <given-names>
          Addison K.
         </given-names>
        </name>
        <degrees>
         MD, MBA, FACS
        </degrees>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Matthews
         </surname>
         <given-names>
          Brent D.
         </given-names>
        </name>
        <degrees>
         MD, FACS
        </degrees>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       Division of Acute Care Surgery, Department of Surgery, Atrium Health Carolinas Medical Center, Charlotte, NC
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding Author Samuel Wade Ross, MD, MPH Assistant Professor of Surgery Carolinas Medical Center, Charlotte NC 1000 Blythe Blvd, Suite 601 MEB Charlotte, NC 28203 Cell: 704-254-7012
        <email>
         Samuel.Ross@atriumhealth.org
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        30
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        30
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         19
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         19
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Published by Elsevier Inc. on behalf of the American College of Surgeons.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The novel coronavirus (COVID-19) was first diagnosed in Wuhan, China in December 2019 and has now spread throughout the world, being verified by the World Health Organization as a Pandemic on March 11
        <sup>
         th
        </sup>
        . This had led to the calling of a national emergency on March 13
        <sup>
         th
        </sup>
        in the United States. Many hospitals, healthcare networks, and specifically Departments of Surgery are asking the same questions of how to cope and plan for surge capacity, personnel attrition, novel infrastructure utilization, and resource exhaustion. Herein, we present a tiered plan for surgical department planning based on incident command levels. This includes Acute Care Surgeon deployment (given their critical care training and vertically integrated position in the hospital), recommended infrastructure and transfer utilization, triage principles, and faculty, resident and advanced care practitioner deployment.
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        disaster planning
       </kwd>
       <kwd>
        surgery department
       </kwd>
       <kwd>
        resource management
       </kwd>
       <kwd>
        triage
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <title>
      Introduction
     </title>
     <p id="p0010">
      The novel coronavirus that began in Wuhan, China in December 2019, now termed SARS-CoV-2, has caused a global impact on the health, politics, and economy in 3-short months. The clinical syndrome from the virus, now termed COVID-19, can consist of mild respiratory symptoms and fever, to ARDS and death in severe cases. This has led to the disease being officially classified as a pandemic on March 11, 2020 and The Unites States Declared a State of Emergency on March 13, 2020.
      <xref ref-type="bibr" rid="bib1">
       <sup>
        1
       </sup>
      </xref>
      At the time of this writing (March 19
      <sup>
       th
      </sup>
      ), there are over 220,000 confirmed cases worldwide, 9,415 cases in the US with 150 deaths.
      <xref ref-type="bibr" rid="bib2">
       <sup>
        2
       </sup>
      </xref>
      Many countries states and cities have instituted school, gathering, restaurant, and travel bans to mitigate its spread. Patients at older age and with medical comorbidities are at the most risk of requiring hospitalization, ICU care, and at risk for death. In one of the largest epidemiologic studies to date from China with widescale testing, 81% of all infected may have mild symptoms (fever, cough, malaise), 19% required hospitalization, and 5% required critical care; with an overall case-mortality rate of 2.3%. However, age ≥80 years was associated with a 14.9% case-fatality rate, 8% in 70-79 decade, and 49.0% in critically ill patients.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
     </p>
     <p id="p0015">
      As surgeons watching this even unfold in the US, we urge everyone to be prepared and to create a surgical department action plan in conjunction with key stakeholders and content experts vital to institutional response such as: Emergency Medicine, Anesthesia, Pulmonary Critical Care, Infectious Disease, Internal Medicine, facility and nursing management, and ultimately coordinated under the Incident Command System.
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      Implementing screening by symptoms and exposure risk and mitigating healthcare personnel exposure to COVID-19 patients who require surgery is a key first step. Experience out of China
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      and Singapore
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      have demonstrated that screening by symptoms and routine testing, use of appropriate personal protective equipment (PPE), as well as a coordinated plan involving all aspects of peri-operative care is essential. However, the early and continued experience in Italy
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
      and Iran have demonstrated that when measures to mitigate the spread of COVID-19 are not implemented early enough, catastrophic scenarios requiring advanced triage criteria, resource management, and extreme flexibility within the healthcare system is required to save as many lives as possible. A review of crisis management principles relevant to healthcare in this Pandemic and a tiered plan to take these factors into account was developed at our facility and presented herein. Key to understanding these concepts is the fact that patient surge is unlike typical mass casualty plans that we have become accustom with an acute event (minutes to hours) followed by an acute and relatively short response (hours to days), but instead a prolonged course of resource and personal exhaustion (weeks to months).
     </p>
     <sec id="sec1.1">
      <title>
       Our Center
      </title>
      <p id="p0020">
       Atrium Health is one of the largest, integrated, public, not-for-profit health care systems in the United States compromising more than 7,500 licensed beds, employing nearly 70,000 people and accounting for more than 12 million patient encounters including 230,000 procedures on an annual basis across acute care and ambulatory facilities in North Carolina, South Carolina and Georgia. Atrium Health Carolinas Medical Center, Atrium Health Mercy Hospital and Levine Children’s Hospital comprise the Central Division Campus in Charlotte. Carolinas Medical Center is an 874 bed, quaternary care hospital, ACS-verified Level I Adult and Pediatric trauma center. It serves as the University of North Carolina School of Medicine-Charlotte Campus and is the lead institution for the regional Metrolina Trauma Advisory Committee (MTAC). Carolinas Medical Center features a 29-bed dedicated Surgical/Trauma ICU, a separate 29-bed Neurosurgical ICU, 40-bed Medical ICU, 14-bed Cardiac ICU and virtual critical care services for Atrium Health. Over 300 ICU beds in Atrium Health are monitored virtually. Based on lessons from history, those already learned in the COVID-19 Pandemic, and the following principles were used to create a tiered response plan for use in Surgery Departments throughout the United States. Led by our Division of Acute Care Surgery (ACS) in Coordination with Emergency Management and other stakeholders, this plan has been developed for and is being disseminated through our Department of Surgery and throughout all surgical subspecialties at all our facilities.
      </p>
     </sec>
     <sec id="sec1.2">
      <title>
       Social Distancing
      </title>
      <p id="p0025">
       In the earliest weeks of the epidemic in Wuhan, isolation of patients, and then eventual quarantine of family, communities, and then whole cities was seen. While these concepts may be familiar to many, in the past weeks, an old concept, but new to many, has been disseminated to the country to decrease the spread of COVID-19: social distancing. This term includes measures from simply limiting unnecessary activities like in large gatherings such as concerts, marathons, and sports games, to more drastic measures like banning all gatherings more than 50 people, closing schools city-wide and in some cases state-wide, and furloughing non-essential personnel from businesses.
       <xref ref-type="bibr" rid="bib8">
        <sup>
         8
        </sup>
       </xref>
       The goal of these measures is to reduce the spread of the virus so that the doubling time of the virus is increased, the purpose being to have fewer patients present in a shorter time period to hospitals.
      </p>
      <p id="p0030">
       This has gone viral in the #flattenthecurve movement, with the publication of Carl Bergstrom’s graph illustrating the surge in patients on an exponential scale in relationship to the healthcare capacity as a flat line (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       .) Measures such as social distancing would act to slow the spread and prolong the time frame of patients presenting to hospitals. As we have seen in Italy, when the steeper rise occurs, a higher number of deaths occur as patients who need intensive care and ventilators have long out-paced the available resources, and a rationing and triage of patients is required.
       <xref ref-type="bibr" rid="bib7">
        <sup>
         7
        </sup>
       </xref>
       However, with increased testing, meticulous contact tracing, and measured social distancing, South Korea has been able to decrease the rate of spread, and healthcare facilities have not become overburdened.
       <xref ref-type="bibr" rid="bib9">
        <sup>
         9
        </sup>
       </xref>
       <fig id="fig1">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Principle of social distancing to reduce the curve of uncontrolled transmission to levels more sustainable to the healthcare system capacity. (Represented with permission from Carl T Bergstrom)
         </p>
        </caption>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec1.3">
      <title>
       Resource Management
      </title>
      <p id="p0035">
       Optimal disaster response necessitates knowledge, preparedness and coordination to ensure adequate resource availability and allocation. This often requires difficult capacity and financial decisions during a preparation phase to make room for the anticipated influx of patients. Inherent in this, is assessing the number of currently occupied beds, planned procedures and admissions, and the maximum capacity for floor and ICU beds. More novel is what beds could be created in austere conditions by double bedding hospital and ICU rooms, conversion of PACU, operating rooms, and even hallways into ICU beds. A typical OR could house 3-6 patients depending on its size and could be staffed by CRNA’s and Anesthesiologist as elective and even urgent cases are cancelled. Early and proactive bed management is key, as reports from Italy indicate that all non-critical and non-emergent care has ceased as the hospitals are now at 200% capacity.
       <xref ref-type="bibr" rid="bib7">
        <sup>
         7
        </sup>
       </xref>
       Given these capacity issues, systems are unable to provide adequate care for patients with everyday emergencies like stroke, myocardial infarction, and trauma. Thus, the early COVID-19 mortality numbers fail to account for many patients who will have a concurrent preventable mortality from other causes as the result of this unanticipated surge and subsequent resource exhaustion.
      </p>
      <p id="p0040">
       Oxygen delivery and mechanical ventilation will no doubt be the highest value resource given the presence in critically ill COVID-19 patients of respiratory failure (54%) and ARDS (31%).
       <xref ref-type="bibr" rid="bib10">
        <sup>
         10
        </sup>
       </xref>
       In general, the experience has been that non-invasive oxygenation modalities such as nasal cannula and BiPAP are ineffective and patients at this stage will need mechanical ventilation. Ingenuity with methods to create new ventilators from spare parts and retrofit old machines such as IPPB into working ventilators will be required. Additionally, if all patients are COVID-19+ as many as 4-patients could be linked in parallel on pressure control settings to attain reasonable minute ventilation and tidal volumes if required.
       <xref ref-type="bibr" rid="bib11">
        <sup>
         11
        </sup>
       </xref>
       Finally, while ventilators will be in high demand, endotracheal tubes are copious, and if family members are willing, bagging of patients by family members when no ventilator is available may be required.
      </p>
     </sec>
     <sec id="sec1.4">
      <title>
       Personnel Attrition
      </title>
      <p id="p0045">
       First and foremost, a proactive response is needed to limit the unnecessary interactions and contact of all personnel in an effort to minimize exposure risk as early as possible. As the situation evolves staffing will become dynamic requiring a coordinated effort among physicians, advanced practice providers, and residents. Clear and definitive leadership will be required to best determine staffing and provider labor allocation for each facility. Buy-in from all respective division chiefs and departmental coordination will define and facilitate staffing levels. Situational flexibility will be paramount in conjunction with clear and efficient communication and multidisciplinary collaboration. All staffing plans must inherently assume attrition and furloughs required not only as the result of iatrogenic and community exposures, but also due to social instability, and/or resource consumption. As such, agreements should be in place to allow emergency credentialing and expansion of scope of practice to other facilities as necessitated by the needs of the community. In large health systems, or even regional cooperatives, a pool of surgeons can be mobilized to start covering cases at satellite hospitals as surgeons at these facilities are furloughed. Consideration should also be taken to minimize the risk to more senior partners to lower risk roles outside the hospital. Quarantined and senior surgeons can participate in telemedicine and even virtual critical care to increase the capacity to triage patients and care for the critically ill. Additionally, since this will be a prolonged surge if measures of social distancing are successful, consideration to weekly rotating teams off service of faculty, APP’s, and residents to not deplete or expose all providers at once.
      </p>
      <p id="p0050">
       Principles of the crisis standard of care should be used in disaster response when health care needs overwhelm available resources.
       <xref ref-type="bibr" rid="bib12">
        <sup>
         12
        </sup>
       </xref>
       At the highest response levels, plans for the advancement of senior residents and fellows to attending status may be required. Given the increased need for critical care expertise at this highest level, emergency general surgery (EGS) and trauma coverage should be transitioned to general surgery trained elective surgeons to allow deployment of any surgical critical care (SCC) trained physicians solely to the intensive care setting. We recommend a tiered reallocation of Acute Care Surgeons (ACS) faculty as appropriate for each respective facility. At severe manpower shortage levels, non-ACS familiar with high-acuity priorities and hemorrhage control, like vascular, transplant, and hepatobiliary surgeons may be required to take trauma call. Additionally, when supra-maximum patient capacity, with decreasing providers in Critical Care and Internal Medicine, subspecialized surgeons will likely be called to become general physicians to treat the non-critical patients with COVID-19. However, every nurse, therapists, ancillary staff, and physician regardless of specialty should have some basic training of ventilator management given the possibility of provider depletion and expansion of ICU’s.
      </p>
     </sec>
     <sec id="sec1.5">
      <title>
       Trainee Allocation
      </title>
      <p id="p0055">
       Learners inevitably play a role in large-scale responses, and preparations must strike a balance between patient safety and residents’ personal safety. While an emergency plan is focused on patient care, it must also support workforce sustainability in the event of quarantine, illness or injury. Resident participation in emergency preparedness plans is essential in hospitals with training programs. Planning for trainee allocation or quarantine has not been extensively studied. A hospital and graduate medical education department must decide the role trainees will play before their deployment is required, which will likely involve graduated promotion at the highest response level. The role of medical students should be carefully considered with the default response being for them to be dismissed to isolation with the general public. The benefit provided to the affected population by students would be minimal compared to the risk of their exposure.
      </p>
      <p id="p0060">
       Evaluations and planning has focused on mass casualty incidents isolated to specific communities.
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       There has been no published and distributed plan instituted for residents in such a population health scenario as presented by COVID-19. For example, residents’ roles in the disaster response to the Boston Marathon bombing was unclear. There was no understanding if residents would be expected to provide surge staffing or if they would be stratified by experience.
       <xref ref-type="bibr" rid="bib13">
        <sup>
         13
        </sup>
       </xref>
       Though most hospitals train nurses and attendings for mass-casualty events, fewer than half train residents.
       <xref ref-type="bibr" rid="bib14">
        <sup>
         14
        </sup>
       </xref>
       <sup>
        ,
       </sup>
       <xref ref-type="bibr" rid="bib15">
        <sup>
         15
        </sup>
       </xref>
       This is a gap in medical education that should be addressed as these incidences are unfortunately becoming more frequent. Most resident staffing during crises is managed ad hoc by chief residents or program directors. Communications should be in place, whether by group text, online meeting applications or other local mechanism, so that chief residents act as a liaison between institutional command, attending physicians and resident teams. It is likely that trainees could be asked to work beyond scheduled duty hours. Local graduate medical education leadership should be involved in preparations, and knowledge of ACGME program requirements is essential. It is possible residents will be asked to work beyond accepted duty hours, and these exceptions should be made known to the ACGME, but exemptions should be provided given the national emergency. Graduated autonomy and extension of attending physicians by senior residents as well as battlefield promotions of fellows and Chief Residents will be the most logical progression as the response to the crisis escalates and personnel are furloughed or quarantined.
      </p>
     </sec>
     <sec id="sec1.6">
      <title>
       Advanced Triage Criteria
      </title>
      <p id="p0065">
       Unfortunately, in a resource exhaustion and surge capacity, difficult ethical decisions will have to be made on which patients merit the use of a scarce resource. These types of discussions are usually reserved for organ allocation and in cases that require ECMO. Even in a normal situation where your hospital only has one ICU bed, one ventilator, or one ECMO circuit left, the default is to still give it to the first patient that needs that resource. However, more complex in our current Pandemic scenario, is that the ventilator you are allocating today to the person with a poor chance of survival may deprive that resource tomorrow to the patient with a moderate chance of survival. Several schemas have been created in the past to rationalize the choices that are now in front of many healthcare providers, some of which are to maximize number of life years (favors the young), social value (favors occupations that are deemed valuable in preserving society infrastructure and culture), and instrumental value (those that would have impact on the current outbreak like physicians and nurses).
       <xref ref-type="bibr" rid="bib16">
        <sup>
         16
        </sup>
       </xref>
      </p>
      <p id="p0070">
       Currently in Italy, reports in over capacity facilities describe making hard decisions to not intubate patients over 65, and no ICU care to patients over 80.
       <xref ref-type="bibr" rid="bib17">
        <sup>
         17
        </sup>
       </xref>
       This type of rationing is un-thinkable to most Americans with the perception that all aspects of healthcare are an inherent right up to and escalating towards death. While many practitioners in the US will rightly not want to set hard limits like this, the withholding of surgery with recognition of futility is readily decided upon. Surgeons inherently understand futility in end-stage cancer, overwhelming sepsis, and advanced age and comorbidities. COVID-19 patients, with progression to ARDS and multiple risk factors, will have similarly dismal potential for survival. Therefore, in the vein of justice and maximizing benefit to all of society, advanced triage criteria based on individual risk factors should be performed before resources become exhausted to ensure that the next salvageable patient has the opportunity to benefit where the current patient likely will not.
      </p>
     </sec>
     <sec id="sec1.7">
      <title>
       Clinic Triage and Telemedicine
      </title>
      <p id="p0075">
       Given the rapid changes in technology as well as societal healthcare pressures due to the global pandemic, telemedicine should be the frontline triage for specialty surgery clinics.
       <xref ref-type="bibr" rid="bib18">
        <sup>
         18
        </sup>
       </xref>
      </p>
      <p id="p0080">
       The limitations for use, such as costs, training, or HIPPA related concerns, may limit the ability to rapidly upload and utilize these platforms for virtual visits, especially when faced with a rapidly progressing pandemic.
       <xref ref-type="bibr" rid="bib19">
        <sup>
         19
        </sup>
       </xref>
       However, many of these can be circumvented or expedited in the current state of emergency. For example, during the H1N1 Pandemic, North et al. were able to use telephone screening triage to reduce unnecessary clinic visits yet preserve medical access.
       <xref ref-type="bibr" rid="bib20">
        <sup>
         20
        </sup>
       </xref>
       In our specific ACS clinics pre-operative visits were stopped when the Pandemic was declared and the US was seeing increasing numbers. Post-operative patients still need to be evaluated and managed for many issues, such as drains, wounds, and suture removal.
      </p>
      <p id="p0085">
       Due to the time constraints given the increasing community spread, we rapidly developed an ACS clinic patient screening process (eDocument1) that started with already scheduled patients for return to our trauma and EGS clinics. If a patient was determined not to need a virtual or physical visit, a telephone call was used to discuss the appointment and manage patient expectations. This tool evaluated not only if they had medical issues requiring evaluation, but also screened for potential COVID infections, utilizing the institutional infectious disease risk screening questions, embedded within the screening tool (eDocument 2). Utilizing this risk tool allowed a patient that was high risk to be directed to a COVID-19 testing site. All patients designated for upcoming clinics are assessed the week prior to the clinic appointment and determined to: 1. Not need to be seen physically nor virtually and their situation is evaluated by a clinic nurse phone conversation. 2. Be an ideal candidate for a virtual clinic visit or 3. In need of objective data, such as a radiograph or laboratory blood work prior to clinic so the type of clinic visit can be determined. Due to the limited socio-economic resource of most of our patients, many of our patients only have access to Android or Apple smart telephones, if any, so a computer video platform is not always viable.
      </p>
      <p id="p0090">
       We outfitted our clinic with 2 computers with video capability for patients calling into a virtual communication app (TEAMS
       <sub>
        ®
       </sub>
       ) so these patients can connect with a computer, or Android or i-Phone device. We elected to use these technology methods for more rapid preparations for virtual evaluations in the clinics and due to the time constraints of the forced social distancing mandates of the community. After reviewing the previously completed screening tool on a patient, an ACS physician or APP perform the virtual visit utilizing a standard virtual exam template (eDocument 3). With the information gleaned from the screening tool and the virtual exam, a management plan is individualized for each patient and the forms are scanned into patients’ electronic medical records along with a documented clinic note.
      </p>
      <p id="p0095">
       If a patient requires a physical appointment in our ACS clinic, they are screened again on arrival for symptoms of a potential COVID-19 infection. Only 1 additional care giver or family member can accompany the patient. In order to improve social distancing in the waiting rooms all chairs are kept 6 feet apart. On arrival to the clinic if a patient has any active symptoms of a COVID-19 infection, they are directed to a testing site appropriate for their symptoms per institution protocols. Only 1 nurse and 1 attending can evaluate the patient. Utilizing these methods, in the first week of implementation, out of 21 scheduled ACS clinic patients, we have already identified 19 patients able to be managed by virtual or telephone visits (91% reduction in clinic visit exposure). Contact has been completed and they are being managed virtually revealing a potential 91% reduction in clinic visits. Objective data is being obtained for 2 patients (chest radiographs and laboratory values) in order to determine whether they will require a physical clinic visit. One of these 2 patient has staples that will be removed via a nurse visit or at their primary care provider’s office, since they live over 1 hour away from our clinic office. While we are early in the process, transitioning our ACS clinics to a Virtual/Telemedicine Process, with appropriate resources, will continue to allow us to keep patients safe from exposure, preventing potential exposure risk to healthcare staff, as well as maintaining patient safety and perioperative surgical expectations.
      </p>
     </sec>
     <sec id="sec1.8">
      <title>
       Tiered Response
      </title>
      <p id="p0100">
       In reflection of the above principles, led by Acute Care Surgeons with familiarity in Disaster Preparedness and Public Health, in conjunction with the incident command structure, and in an effort to keep in mind a prolonged surge of COVID-19 patients, the following Surgery Department COVID-19 Response Plan was created (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). This has now been disseminated and adapted to each facility, subspecialty surgical service, and is being pivoted to other specialties such as Pulmonary Critical Care and Internal Medicine within Atrium Health. Key in understanding the response level is your individual facilities incident command response level which follows similar structure set by the Federal Emergency Management Agency (FEMA).
       <xref ref-type="bibr" rid="bib4">
        <sup>
         4
        </sup>
       </xref>
       <sup>
        ,
       </sup>
       <xref ref-type="bibr" rid="bib12">
        <sup>
         12
        </sup>
       </xref>
       However, new to this schema is ConditionZero which indicates patient surge and acuity beyond the capacity of the infrastructure and manpower available, a scenario currently being experienced in Italy, Iran, and progressively around the world. Advancement to higher tiers should follow incident command structure, but may also be required within individual specialties, departments, or divisions plans given manpower and resource depletion.
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Surgery COVID-19 Activation and Response Plan
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td>
            Activation, threshold for activation/possible ACS impact
           </td>
           <td>
            Surgery department response
           </td>
           <td>
            Recommended facility response
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            Department
           </td>
           <td>
            ACS
           </td>
           <td>
            Facility
           </td>
           <td>
            Transfer criteria
           </td>
           <td>
            Operating room
           </td>
           <td>
            NORA
           </td>
          </tr>
          <tr>
           <td>
            Alert
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Pandemic level, increasing prevalence throughout the country; potential impact to facility and system; full surgery compliment; peri-operative staffing normal; school closing in community with impact on staff availability
           </td>
           <td>
            Contact patients prior to visit to clinic and/or OR to delay surgery if elective and have COVID-19 high risk features; Minimize clinic visits by screening of patients by nursing for urgent visits to present to clinic, all other managed with calls or telehealth evaluation; stay home if sick; all personnel in QI, research, etc without direct patient care to start working from home; prioritize cases for CV, cancer, urgent and emergent status; APP with no change in role
           </td>
           <td>
            Maintain current staffing model; replace and/or trade to maintain core service lines as faculty become infected and require quarantine; ACS obtain faculty privileging at other system facilities; Services: EGS service, ICU coverage, trauma service
           </td>
           <td>
            Focus on avoiding patient presentation to hospital for testing; minimize routine, non-urgent clinic appointments; focus on virtual visits; restriction of visitors to immediate families
           </td>
           <td>
            Limit non-emergent transfers
           </td>
           <td>
            Normal operations
           </td>
           <td>
            Limit to emergent cases only when COVID-19 positive or expected; All procedures done at patient bedside or in OR when at all possible
           </td>
          </tr>
          <tr>
           <td>
            Level 2
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            First confirmed case at facility; potential impact on facility and system; &lt;10% acute surgical faculty depletion; &lt;20% hospital bed availability; &lt;25% ICU bed availability; reduction in peri-operative staff by 10% due to illness; decreased blood bank supply due to social distancing
           </td>
           <td>
            Reduce elective case volume by 50% with non-time sensitive cases eliminated (focus on required cancer and CV cases); high risk patients (age &gt; 60 y, DM, HTN, smoking history, COPD, CHF, CAD) cancel if not urgent; Reallocation surgical residents, research residents, to ICU and trauma rotations as drawdown on elective cases proceeds; non-ACS APP’s to flex to ACS or medical service lines; All CC credentialed APP to flex to ICU services
           </td>
           <td>
            Maintain current weekday staffing model; ACS Services: EGS service, ICU Services, and trauma services
           </td>
           <td>
            Daily sitrep huddles with departmental stakeholders and facility leadership; subsequent daily sitrep (may be via email) by department leaders to disseminate information; nursing reassignment, expanded patient ratio; expanded patient cohorting; start aggressive discharge of all non-critical patients to ANY discharge destination; wean all patients as able from ventilation; consider early tracheostomy to allow decreased ventilator time and use; triage criteria initiated for ECMO cannulation; institute virtual clinic visits for all surgical clinics unless urgent problem; limit visitors to 1 per patient, appropriately screened on entry
           </td>
           <td>
            Limit non-emergent transfers to the facility (or within the system); institution of an ACS quarterback with knowledge of sitrep, intensive care level, and resource availability for all surgical/SCC/trauma consults, vets all transfer requests prior to connection with requesting service; urgent/emergency cases with surgeon capability at outlying facility should be triaged to stay at the sending facility; emergent cases with critical care needs prioritized to tertiary care facility; only urgent/emergent trauma transfers will be accepted with needs for specialized care; ECMO needs patients prioritized with consultation of ECMO team given scarce resources
           </td>
           <td>
            Per service line decrease number of elective cases by 50%, prioritizing surgical urgency and canceling high risk patients
           </td>
           <td>
            As per alert status
           </td>
          </tr>
          <tr>
           <td>
            Level 1
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Facility at ≥100% capacity; ICU capacity ≥90%; 5 to 20 confirmed admitted cases; decreasing resources of facility; potential impact on the system; denial of discharges from skilled nursing facility, rehab, or other discharge dispositions; 10% to 25% acute care surgical faculty depleted; reduction in perioperative staff by 25% due to illness; severely decreased blood bank supply due to social distancing
           </td>
           <td>
            All elective surgery cancelled and no further booking of cancer cases, consider cancelling all invasive CV and cancer if high risk factors (age &gt;60 y, DM, HTN, smoking hx, COPD CHF, CAD); permission to perform any non-urgent case requires additional facility approval; efforts should be made to temporize urgent cases using nonoperative means and discharge patients home at increasing rates for non-COVID-19 diagnoses; general surgery trained faculty are employed to consult and manage EGS cases; tier 1: general surgery; if available transplant, hepatobiliary, vascular, ACS Fellows (trauma coverage); tier 2: If available MIS, colorectal, GI oncology, PGY5 residents, (EGS coverage); tier 3: all other general surgery trained attendings (as needed coverage or backup); all residents redistributed to ICU, EGS, trauma rotations; all CC trained APP flex to cover ICU
           </td>
           <td>
            Increase proportion of available surgical critical care intensivist to care for COVID-19 ICU patients; ACS faculty responsible for SCC and trauma; older faculty focused toward trauma population and virtual care (virtual clinic or virtual ICU) rather than ICU; EGS transitioned to elective general surgeons; SCC fellow to function as junior faculty for ICU and trauma coverage;
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            ACS services: ICU services, trauma services, virtual critical care, 12 to 24-hour trauma call.
           </td>
           <td>
            Daily sitrep huddles with departmental stakeholders and facility leadership; Subsequent daily sitrep (may be via email) by department leaders to disseminate information; ICU Expansion: Progressive care, monitored beds, PACU overflow; 2 ICU beds per ICU room, if needed; 2 floor beds per hospital room, if needed; no patient visitation
           </td>
           <td>
            No non-emergent transfers; ACS quarterback with knowledge of sitrep, IC level, and resource availability for all surgical/SCC/trauma consults, vets all transfer requests prior to connection with requesting service; urgent surgical cases to stay at the transferring facility with surgical capability and every effort to discharge them with non-operative means; emergency cases at facilities with surgeon capability will stay at that facility; emergent cases with critical care needs prioritized to nearest available facility with an ICU and surgeon; exhaust nonoperative interventions; ECMO needs patients prioritized with consultation of ECMO team given scarce resources; all trauma transfer requests must be vetted through and ACS staff, only emergent or acute specialized care needs will be transferred; Virtual and telephone management of urgent needs
           </td>
           <td>
            Reduce rooms running by 50%; urgent and emergent surgical cases only
           </td>
           <td>
            No NORA cases
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Condition Zero
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Facility at &gt;125% capacity ; ICU capacity ≥100% ; &gt;20 confirmed admitted cases; expected exponential increase in admissions; detrimental impact to the system; catastrophic exhaustion of facility and system/regional resources; &gt;40% perioperative staff depleted; &gt;25% acute care surgical faculty depleted; little or no blood availability
           </td>
           <td>
            All non-emergent cases cancelled; urgent cases transfer to outlying facilities. pursue all nonoperative options for emergent and urgent patients; general surgeons to assist with trauma and EGS coverage; tier 1: general surgery; if available transplant, hepatobiliary, vascular, ACS Fellows (trauma coverage); tier 2: if available MIS, colorectal, GI oncology, PGY5 residents (EGS Coverage); tier 3: all other general surgery trained attendings (as needed coverage or backup); tier 2,3 to cover medical patients when needed; all additional staff, residents, fellows, and APP flex as needed to cover non-surgical COVID-19 patients; advancement of PGY 5 and fellows to junior attending status. creation of PGY5 service for COVID/trauma/EGS, able to take trauma call in attending role with ACS faculty backup; run floor, consults, and if needed ICU level of care; PGY-4 to take position as acting fellow for EGS, trauma, ICU, able to act independently for extension of attending run services for COVID-19 patients all subspecialty fellows promoted to junior attending status for running of own floor COVID-19 medical service; Triage criteria for emergency operations and trauma patients; triage criteria for mechanical ventilation; futility policy for Code Blue Activation in COVID patients; futility policy for trauma activations and admissions
           </td>
           <td>
            Remaining ACS Faculty transition to focus on ICU solely; complete ACS allocation toward ICU patients; (trauma volume expected to decrease and transition to general surgery trained faculty); ACS services: ICU Services, flex ICU/OR ICU, 24-hour trauma call for general surgery staff
           </td>
           <td>
            Daily sitrep huddles with departmental stakeholders and facility leadership; subsequent daily sitrep (may be via email) by department leaders to disseminate information; ICU expansion: OR conversion to 4 ICU beds; anesthesia reassigned to critical care; physicians assigned to areas outside of expertise for patient care; tandem ventilator and/or novel ventilators; possible intubation with family manual ventilation (bag valve mask) on case by case basis; need for increased cohorting of COVID+ providers in hospital still on duty; creation of morgue overflow areas for expected increase in fatalities
           </td>
           <td>
            ACS Quarterback with knowledge of sitrep, IC level, and resource availability for all surgical/SCC/trauma consults, vets all transfer requests prior to connection with requesting service; urgent cases to stay at transferring facility and every effort to discharge; urgent cases to transfer to other facilities to prioritize the care of severely ill, severe trauma, critical care needs of remaining patients emergency cases at facilities with surgeon capability will stay at that facility; emergent cases with critical care needs with advanced triage criteria; exhaust nonoperative interventions; ECMO advanced triage criteria; trauma transfers with advanced triage criteria; virtual and telephone management of urgent needs
           </td>
           <td>
            Only urgent/emergent surgical cases only
           </td>
           <td>
            No NORA cases
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           ACS, acute care surgery; APP, advanced practice provider; CAD, coronary artery disease; CC, critical care; CV, cardiovascular; DM, diabetes mellitus; ECMO, extracorporeal membrane oxygenation; EGS, emergency general surgery; GI, gastrointestinal; HTN, hypertension; IC, incident command; MIS, minimally invasive surgery; NORA, non-operating room anesthesia; OR, operating room; PACU, post-anesthesia care unit; QI, quality improvement; SCC, surgical critical care
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="p0105">
       At Alert level, which many facilities in the US have already surpassed, disaster preparedness must begin in earnest and non-time sensitive elective cases, or many cases in high risk patients, should be delayed, cancelled, and rescheduled for no sooner than 3 months in the future. Limitations on non-emergent transfers, non-operating room anesthesia (NORA) cases, and furlough of non-essential non-clinical staff should occur. Clinic triage and telemedicine should be performed whenever able. Prioritization to develop plans for further Tiers and organization of surgeons into potential call back-up pools should be performed. Additionally, in large health systems and regional collaboratives, efforts to back-up community facilities from larger tertiary departments should be performed to limit transfers required due to quarantined or furloughed surgeons at these sites.
      </p>
      <p id="p0110">
       In progression to further tiers, great focus is given the Acute Care Surgeon ability to staff trauma, SCC, and EGS services, given their true vertical integration in the hospital from the ED, OR, floor, and ICU. Given their flexibility, and critical care training, it will be key to support these ACS faculty with non-ACS surgeons to manage EGS and eventually even trauma. This will allow the ACS Surgeons to support expanded ICU’s, OR ICU conversion, and ECMO patients. At non-trauma centers, in the community, or with no ACS faculty, General Surgeon coverage and adaptation of this plan will be paramount to cover all surgical and COVID-19 patients. At Level 2, healthcare providers will begin to be furloughed, and decreased resources like blood, ventilators, and PPE will be available. Subsequently, a 50% drawdown of all elective cases should be performed with focus on completing necessary cardiovascular and cancer cases, but patients with high risk factors should be deferred (age &gt;60, DM, HTN, smoking hx, COPD CHF, CAD). A good resource for deciding on the necessity is the Elective Surgery Acuity Scale just released by the American College of Surgeons.
       <xref ref-type="bibr" rid="bib21">
        <sup>
         21
        </sup>
       </xref>
       Rearrangements of schedule and service coverage responsibility for residents, APP, and faculty should begin, and cycling of on call teams by several days or a week should be encouraged.
      </p>
      <p id="p0115">
       Response Level 1 will have accumulating provider and staff attrition due to quarantine and illness. Additionally, stocks of PPE, blood, ventilators and other essential infrastructure will be diminished by increasing numbers of COVID-19 patients. Therefore, all non-emergent cases should be cancelled, and transfer requests managed at the requesting facility. All surgical transfers should be vetted by an ACS surgeon with situational awareness to assess its acuity, available resources and beds, and if care may be futile. Expanded ICU beds and staffing by the ACS faculty will be required and non-ACS surgeons required to flex to cover EGS. Teams of younger ACS faculty can be deployed to cover medical ICU’s if needed, and expect SCC fellows to have battlefield promotions to junior ICU attending status. ECMO should be reserved for young, non-comorbid patients, with single organ dysfunction and acceptable prognosis. Expect decreasing staff and blood availability as quarantine and social distancing impact the community. Graduated resident autonomy and Chief Resident run floor services will be expected.
      </p>
      <p id="p0120">
       Finally, if the surge in patients comes as a tsunami as it did in Italy and Wuhan, Condition Zero will require stretching the infrastructure and manpower beyond the breaking point. In this scenario, ACS surgeons should focus on just ICU patient care, and non-ACS surgeons cover trauma and EGS in a tiered response. Non-emergent cases should not be performed, and non-operative modalities should be pursued if possible for all urgent disease processes. The export of urgent EGS cases may be required to other centers Advanced triage criteria with consideration of available resources, expected increase in surge volume, patient risk factors, and principles of justice and value unfortunately must be considered for the continuation and betterment of our society. Novel ventilation strategies should be pursued whenever able, and even emergent non-COVID care may need to be triaged or suspended for certain disease processes if the system, facility, and providers are over-leveraged. At this level COVID-19+ healthcare workers may need to continue treating COVID-19 patients given the extreme attrition of personnel at this level.
      </p>
     </sec>
     <sec id="sec1.9">
      <title>
       Principles to Success
      </title>
      <p id="p0125">
       Do not lose hope. As Wuhan has taught us with social distancing, strict quarantine and abundant testing, we can beat back this disease and mitigate its effect on our communities. In any rapidly evolving crisis, certain principles remain key to combating a constantly evolving and austere situation. Act with speed of the plan above perfection of the plan. Flexibility in the face of adversity is required, and those that are not able to deftly change strategies with new information will be battling the past and not preparing for the future. Even in this response plan, adaptation and integration of individual situations will be required. Communication with an assigned structure is vital to ensuring the entire team, service, facility, and system are working on the same page and criteria. Situation reports within each of these strata is vital to understand the situation on the ground as well as the plan for the institution. However, succinctness is required so that worried and overwhelmed providers can quickly process and implement new information and protocols. Most of all, a sense of community, purpose and legacy is paramount to keep us mission focused on the health of our patients and community; support and acknowledgement of our risk and sacrifice as physicians, providers…as healers, are not in vain.
      </p>
     </sec>
    </sec>
    <sec id="sec2">
     <title>
      Conclusion
     </title>
     <p id="p0130">
      The current COVID-19 Pandemic is causing a paradigm shift for our globalized world in every sector: economic, social, cultural, and even a religious impact. The brunt of the initial surge of patients was weathered in China and has now expanded to almost every country on Earth. All estimates point that the US is on track to have a similar surge of patients like Italy, and therefore now is the time to prepare, coordinate among key stakeholders, set up incident command, and plan for every conceivable contingency. The authors desperately hope that social distancing measures will prevail and that our tiered response plan will not be required at its highest level. However, failure to plan for these eventualities, would make the outcome all the worse if or when they are needed; please use, adapt, share and disseminate for the good of all our patients. This is the defining moment of our generation, leave a legacy worthy of remembrance. Godspeed.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <mixed-citation id="sref1" publication-type="other">
        Control CFD. Coronavirus Disease 2019 (COVID-19). CDC. Situation Summary Web site.
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/summary.html">
         https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/summary.html
        </ext-link>
        . Published 2020. Accessed 3/16/2020, 2020.
       </mixed-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <mixed-citation id="sref2" publication-type="other">
        COVID-19 Map Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2020.
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="https://coronavirus.jhu.edu/map.html">
         https://coronavirus.jhu.edu/map.html
        </ext-link>
        . Accessed March 16, 2020.
       </mixed-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Arnold
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chuang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Implementation of the Hospital Emergency Incident Command System during an outbreak of severe acute respiratory syndrome (SARS) at a hospital in Taiwan, ROC
        </article-title>
        <source>
         J Emerg Med
        </source>
        <volume>
         28
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         196
        </lpage>
        <pub-id pub-id-type="pmid">
         15707815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <mixed-citation id="sref5" publication-type="other">
        Wen X, Li Y. Anesthesia Procedure of Emergency Operation for Patients with Suspected or Confirmed COVID-19. Surgical infections. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ti
          </surname>
          <given-names>
           L.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ang
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Foong
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           B.S.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         What we do when a COVID-19 patient needs an operation: operating room preparation and guidance
        </article-title>
        <source>
         Can J Anaesth
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grasselli
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pesenti
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cecconi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           D.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak
        </article-title>
        <source>
         J Travel Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Covid-19 National Emergency Response Center E, Case Management Team KCfDC, Prevention
         </collab>
        </person-group>
        <article-title>
         Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts
        </article-title>
        <source>
         Osong Public Health Res Perspect
        </source>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         60
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         32149043
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neyman
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Irvin
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A single ventilator for multiple simulated patients to meet disaster surge
        </article-title>
        <source>
         Acad Emerg Med
        </source>
        <volume>
         13
        </volume>
        <issue>
         11
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1246
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="pmid">
         16885402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chacko
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Morsch
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disaster Medicine: Public Health Preparedness for Natural Disasters
        </article-title>
        <source>
         FP Essent
        </source>
        <volume>
         487
        </volume>
        <year>
         2019
        </year>
        <fpage>
         17
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         31799816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schlosser
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Creedon
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Michelson
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Michelson
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lessons From the 2013 Boston Marathon: Incorporating Residents Into Institutional Emergency Plans
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         139
        </volume>
        <issue>
         6
        </issue>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niska
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Burt
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bioterrorism and mass casualty preparedness in hospitals: United States, 2003
        </article-title>
        <source>
         Adv Data
        </source>
        <issue>
         364
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         14
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Bush
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lynch
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A national survey of terrorism preparedness training among pediatric, family practice, and emergency medicine programs
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         118
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e620
        </fpage>
        <lpage>
         626
        </lpage>
        <pub-id pub-id-type="pmid">
         16950954
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           White
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Katz
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Luce
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Who should receive life support during a public health emergency? Using ethical principles to improve allocation decisions
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         150
        </volume>
        <issue>
         2
        </issue>
        <year>
         2009
        </year>
        <fpage>
         132
        </fpage>
        <lpage>
         138
        </lpage>
        <pub-id pub-id-type="pmid">
         19153413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <mixed-citation id="sref17" publication-type="other">
        Monella LM. Coronavirus: Italy doctors 'forced to prioritise ICU care for patients with best chance of survival'. euronews. 2020.
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www.euronews.com/2020/03/12/coronavirus-italy-doctors-forced-to-prioritise-icu-care-for-patients-with-best-chance-of-s">
         https://www.euronews.com/2020/03/12/coronavirus-italy-doctors-forced-to-prioritise-icu-care-for-patients-with-best-chance-of-s
        </ext-link>
        . Published March 13,2020.
       </mixed-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hollander
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Carr
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virtually Perfect? Telemedicine for Covid-19
        </article-title>
        <source>
         The New England journal of medicine
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <mixed-citation id="sref19" publication-type="other">
        Nittari G, Khuman R, Baldoni S, et al. Telemedicine Practice: Review of the Current Ethical and Legal Challenges. Telemed J E Health. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           North
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Varkey
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bartel
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can an office practice telephonic response meet the needs of a pandemic?
        </article-title>
        <source>
         Telemed J E Health
        </source>
        <volume>
         16
        </volume>
        <issue>
         10
        </issue>
        <year>
         2010
        </year>
        <fpage>
         1012
        </fpage>
        <lpage>
         1016
        </lpage>
        <pub-id pub-id-type="pmid">
         21058892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <mixed-citation id="sref21" publication-type="other">
        COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures [press release]. March 17,2020 2020.
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="editorial" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       AIDS Behav
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       AIDS Behav
      </journal-id>
      <journal-title-group>
       <journal-title>
        AIDS and Behavior
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1090-7165
      </issn>
      <issn pub-type="epub">
       1573-3254
      </issn>
      <publisher>
       <publisher-name>
        Springer US
       </publisher-name>
       <publisher-loc>
        New York
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7114952
      </article-id>
      <article-id pub-id-type="publisher-id">
       2837
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s10461-020-02837-x
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Notes from the Field
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Achieve Research Continuity During Social Distancing by Rapidly Implementing Individual and Group Videoconferencing with Participants: Key Considerations, Best Practices, and Protocols
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Marhefka
         </surname>
         <given-names>
          Stephanie
         </given-names>
        </name>
        <address>
         <email>
          smarkhefk@usf.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lockhart
         </surname>
         <given-names>
          Elizabeth
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Turner
         </surname>
         <given-names>
          DeAnne
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.170693.a
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2353 285X
         </institution-id>
         <institution>
          College of Public Health,
         </institution>
         <institution>
          University of South Florida,
         </institution>
        </institution-wrap>
        13201 Bruce B. Downs Blvd., MDC 56, Tampa, FL 33612 USA
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.47100.32
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419368710
         </institution-id>
         <institution>
          Center for Interdisciplinary Research on AIDS,
         </institution>
         <institution>
          Yale University School of Public Health,
         </institution>
        </institution-wrap>
        New Haven, CT USA
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        2
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <fpage>
       1
      </fpage>
      <lpage>
       7
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Science+Business Media, LLC, part of Springer Nature 2020
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        The novel coronavirus has upended many traditional research procedures as universities and other research entities have closed to activate social distancing. Some social and behavioral research activities (e.g. data analysis, manuscript preparation) can be continued from other environments with appropriate security protocols in place. For studies involving in-person interactions, continuity may be more difficult. Phone-based interactions provide a low-tech solution that may suffice in some cases. Yet, videoconferencing platforms can nearly replicate in-person interactions, activating both auditory and visual senses and potentially resulting in more substantial engagement. Staff can meet with participants individually or in groups, each seeing and hearing one another in real time. This paper provides guidance for researchers transitioning in-person assessments and interventions to a synchronous videoconferencing platform. Best practices, key considerations, examples from the field, and sample protocols are presented to ease transition for ongoing studies and maximize the potential of videoconferencing—and social distancing.
       </p>
       <sec>
        <title>
         Electronic supplementary material
        </title>
        <p>
         The online version of this article (10.1007/s10461-020-02837-x) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Social distancing
       </kwd>
       <kwd>
        Videoconferencing
       </kwd>
       <kwd>
        Intervention research
       </kwd>
       <kwd>
        ehealth
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p id="Par2">
      Currently, much of the world is practicing social distancing to mitigate the risk of the novel coronavirus spreading beyond our healthcare capacity [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. While not as concerning as the lives that have been and will be lost due to this pandemic, social and behavioral HIV researchers are facing a situation that could stall or hinder data collection and intervention delivery. The health impacts of COVID-19 on participants and staff will likely affect many projects, but mhealth research projects will likely be less disrupted, as their platforms and interactions are largely impervious to social distancing measures. Ongoing research projects that have relied on in-person contact may be in jeopardy as people self-isolate, and as in-person data collection has been banned or discouraged by some institutions. This is problematic for achieving research objectives—especially considering the pandemic and related social distancing practices may continue for months. Stopping studies or data collection may also have unexpected negative impacts on participants. Participants living with and those at-risk for HIV who are currently enrolled in research may rely, in part, on remuneration from research participation to help with costs of food and housing. Additionally, the social connections participants experience from taking part in research may be especially valuable to their mental health—particularly during this pandemic, which is anxiety-inducing and isolating.
     </p>
     <p id="Par3">
      Videoconferencing offers a valuable solution in this critical time. Over the past 11 years, our team has been studying videoconferencing as a means of delivering interventions to people living with HIV (PLWH) [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      –
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. During that time, we have adapted programs to the videoconferencing platform and engaged in one-on-one as well as group-based videoconferencing interactions for research [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. We have obtained promising findings regarding the feasibility, acceptability and potential efficacy of videoconferencing-adapted versions of the group-based Healthy Relationships intervention and a tobacco cessation program—both specific to PLWH [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. We have also engaged in focus groups and individual assessments over videoconferencing, resulting in quantitative and qualitative data to understand experiences and nuances [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. Moreover, our work has helped us to understand access to internet and devices needed for videoconferencing (i.e., “smart-phones,” tablets, desktops or laptop computers) and potential willingness to engage in videoconferencing individually and in groups [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. These experiences provide the basis for this manuscript, which reports on processes and considerations for rapidly implementing videoconferencing to connect with participants for data collection, as well as for individual and group-based interventions. While spurred by the need for project continuity during this public health crisis, this article may also be beneficial for researchers who are planning to commence a study employing videoconferencing in the future.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methodological Considerations
     </title>
     <sec id="Sec34">
      <title>
       How can Videoconferencing Best Fit your Project?
      </title>
      <p id="Par4">
       Research teams should assess the potential fit between videoconferencing, their project goals, participants, and staff.
      </p>
      <sec id="Sec4">
       <title>
        For Which Projects will Videoconferencing Work?
       </title>
       <p id="Par5">
        <italic>
         For non-intervention studies
        </italic>
        that rely on self-report paper or computer-based questionnaires that participants read and complete independently, videoconferencing may be unnecessary; online survey platforms should meet the needs of such studies. However, if the protocol involves staff reading aloud to participants and recording the selected responses, or if an open-ended interview is involved, videoconferencing could be a great option. Screen sharing options enable participants to read along, which may speed the process. The ability to view participants’ faces and body language could help the staff when a participant is silent due to confusion, contemplation, or distraction. Additionally, the ability of participants to see the staff member may increase engagement and attention.
       </p>
       <p id="Par6">
        <italic>
         For individual or group-based intervention studies,
        </italic>
        videoconferencing serves to mimic the face-to-face interactions in many ways [
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
        ]. Participants can see and hear one another in real time, which may help with group cohesion. For interventions specific to living with HIV—or even those which involve discussing sexual risk behaviors with persons not living with HIV, seeing other’s reactions to personal stories and revelations can make it much easier to share. When we initially adapted Healthy Relationships for videoconferencing, prior Healthy Relationships participants said they would miss “the hugs” [
        <xref ref-type="bibr" rid="CR5">
         5
        </xref>
        ]. Yet, in our work we found participants developed ways to successfully demonstrate their affection for group members, including putting their hands into a heart shape to communicate warmth. Additionally, the videoconferencing setting typically allows for screen sharing, which means content can be shared with participants in real time. We have implemented a virtual whiteboard [
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
        ] simply by opening a document and typing key points during individual or group interaction. While individual or group-based interventions could be delivered via phone if not in person, the visual connection provides interpersonal and educational advantages.
       </p>
      </sec>
      <sec id="Sec67">
       <title>
        For Which Participants will Videoconferencing Work?
       </title>
       <p id="Par7">
        If you are considering incorporating videoconferencing, it will be important to acknowledge that—as with many strategies—this will not work for everyone. Although “smart phones” are common, in a recent study [
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
        ] we found that 30.3% of a large sample of PLWH in Florida reported that they did not have access to a phone with internet [
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
        ]. 13.6% did not have internet at home via any device [
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
        ]. In qualitative interviews, some PLWH reported sharing phones with friends or roommates, which could pose challenges. Others reported having limited data plans that might preclude videoconferencing. Most (94%) of those who had the required technology were willing to engage in videoconferencing related to HIV, but not everyone was willing [
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
        ]. If you decide to use videoconferencing, to reduce inequities and maximize the reach of your work, consider alternative ways to engage those who cannot or will not use this medium [
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
        ]. Flexibility is advised.
       </p>
      </sec>
      <sec id="Sec45">
       <title>
        Which Staff are a Good Fit for Videoconferencing Engagement?
       </title>
       <p id="Par8">
        Not every staff member will be the best fit for videoconferencing assessments or intervention delivery. Some people may be uncomfortable managing the technology or seeing their face on the screen. When we were adapting Healthy Relationships for videoconferencing [
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
        ], we had a community advisory board member, who had extensively facilitated Healthy Relationships in-person, facilitate a mock session over videoconferencing. Despite being a comfortable, professional, and engaging facilitator at his community organization, he froze in front of the videoconferencing camera. We recommend having facilitators and staff practice videoconferencing engagement before graduating them to videoconferencing sessions with participants; those who are uncomfortable with videoconferencing may need to be shifted to other tasks.
       </p>
      </sec>
      <sec id="Sec46">
       <title>
        Where can Participants and Staff be When they Engage in Video-Calls?
       </title>
       <p id="Par9">
        Many people have the capability of joining videoconferencing from nearly anywhere [
        <xref ref-type="bibr" rid="CR10">
         10
        </xref>
        ], but the need for privacy and confidentiality means clear protocols for research participation are critical. Individual video-calls may necessitate fewer requirements than group video-calls. For individual engagement with staff, we recommend participants attend while in a “private space” without distractions (people, pets, etc.) and sit in a room in which they can speak freely about HIV or other topics. If the space is noisy, we suggest they use headphones or ear buds. For our video-group interactions, we have always required a “private space”, but have learned concrete rules are necessary (See Supplemental File 1). In our work, when we saw another person walking in the background of one participant’s screen during a video-group session, we learned that it was important to define “private space.” Having other people in the background means persons not part of the group could see and hear other group members [
        <xref ref-type="bibr" rid="CR6">
         6
        </xref>
        ], constituting privacy breeches that diminish trust in the process and the research team. If participants believe their privacy is being compromised, they may leave the group or not actively participate. We now require participants to join from a locked room in which they are the only person. Staff should also engage from private spaces with headphones or earbuds. If others must be in the room (i.e., you have an observer with the facilitator) the person should be introduced to the participant(s). See further text and Tables
        <xref ref-type="table" rid="Tab1">
         1
        </xref>
        ,
        <xref ref-type="table" rid="Tab2">
         2
        </xref>
        ,
        <xref ref-type="table" rid="Tab3">
         3
        </xref>
        and Supplemental Files 1 and 3–5 for best practices, guidelines, and protocols for maintaining privacy in the video-group setting.
        <table-wrap id="Tab1">
         <label>
          Table 1
         </label>
         <caption>
          <p>
           Key considerations for choosing a platform
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <tbody>
           <tr>
            <td align="left" rowspan="2">
             Accessible
            </td>
            <td align="left">
             What devices (e.g., phone, tablet, computer) and operating systems support the platform (or do not)?
            </td>
           </tr>
           <tr>
            <td align="left">
             How much bandwidth is required to run the platform?
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="3">
             User friendly
            </td>
            <td align="left">
             Is it easy for participants to join? Can participants access the platform without downloading a program?
            </td>
           </tr>
           <tr>
            <td align="left">
             Can participants access the platform free of charge?
            </td>
           </tr>
           <tr>
            <td align="left">
             What types of technical support are available (e.g., written support, chats, “how-to” video(s)?
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="2">
             <p>
              Available
             </p>
             <p>
              Features
             </p>
            </td>
            <td align="left">
             <p>
              What features are needed to conduct your research?
             </p>
             <p>
              Does the platform have: chat functions, polling, extra rooms, facilitator/host controls, recording, screen/document sharing, range of viewing options (how do those differ based on viewing device), muting options?
             </p>
            </td>
           </tr>
           <tr>
            <td align="left">
             What are the limits to the number of simultaneous participants or co-occurring video sessions?
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="2">
             Cost
            </td>
            <td align="left">
             Does your institution have licenses for a viable videoconferencing platform that would work for your project at no additional cost?
            </td>
           </tr>
           <tr>
            <td align="left">
             What charges can you expect per platform? Do any features require additional fees?
            </td>
           </tr>
           <tr>
            <td align="left" rowspan="4">
             Appropriate Security
            </td>
            <td align="left">
             Is end-to-end encryption available? Is there an associated fee?
            </td>
           </tr>
           <tr>
            <td align="left">
             What methods can the host use to ensure
             <italic>
              only
             </italic>
             participants have access to the session (e.g., meeting passwords, ability to limit who enters the session or preventing additional participants from entering)?
            </td>
           </tr>
           <tr>
            <td align="left">
             What protections are available to prevent participants from recording the meeting or using screen capture?
            </td>
           </tr>
           <tr>
            <td align="left">
             If needed, are HIPAA-compliant settings available? Is an additional fee or agreement required?
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
        <table-wrap id="Tab2">
         <label>
          Table 2
         </label>
         <caption>
          <p>
           Rationale for selected features of videoconferencing platforms
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <tbody>
           <tr>
            <td align="left">
             Bandwidth Required
            </td>
            <td align="left">
             <p>
              • Can impact a participant’s ability to view videos or participate in real time discussion
             </p>
             <p>
              – Important consideration if participants have low internet speed or shared internet
             </p>
            </td>
           </tr>
           <tr>
            <td align="left">
             User accounts
            </td>
            <td align="left">
             <p>
              • May act as an extra security measure depending on the participants/study
             </p>
             <p>
              • For participants, remembering usernames and passwords can pose an extra, possibly unnecessary, layer of difficulty
             </p>
             <p>
              • Using a URL (delivered via email) to directly access meetings has been vital for people of all technology abilities to participate in our research
             </p>
            </td>
           </tr>
           <tr>
            <td align="left">
             Screen sharing
            </td>
            <td align="left">
             <p>
              • May be important if the research requires participants to see and interact with different materials
             </p>
             <p>
              • Researchers may need to screen share with participants if their intervention typically refers to slides, handouts, videos, and/or pictures
             </p>
            </td>
           </tr>
           <tr>
            <td align="left">
             Host controls
            </td>
            <td align="left">
             <p>
              • Can limit/grant access and override participant controls (most useful for managing participation in group-based (vs. one-on-one) videoconferencing)
             </p>
             <p>
              – May enable facilitators/staff to mute participants whose background noise interferes with group sessions
             </p>
             <p>
              – May allow facilitators/staff to remove permissions for participants to privately chat with each other, which help maintain focus
             </p>
            </td>
           </tr>
           <tr>
            <td align="left">
             Session recording
            </td>
            <td align="left">
             <p>
              • Used to assess fidelity of the intervention session curricula
             </p>
             <p>
              • Removes need for real-time intervention observers for supervision and fidelity assessment
             </p>
             <p>
              • Caution: storing this recording may increase privacy risks
             </p>
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
        <table-wrap id="Tab3">
         <label>
          Table 3
         </label>
         <caption>
          <p>
           Facilitator/staff best practices
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <tbody>
           <tr>
            <td align="left">
             1. Environment
            </td>
            <td align="left">
             <p>
              • In general, follow the same privacy rules/guidelines as participants
             </p>
             <p>
              • Privacy is critical—regardless of whether at work or elsewhere
             </p>
             <p>
              • Be alone in a room with a locked door
             </p>
             <p>
              • Do not join from public spaces
             </p>
             <p>
              • Use only password-protected internet connections
             </p>
             <p>
              • If another person must be present for training or quality assurance purposes, introduce that person to participant(s) at call onset and explain why they are present
             </p>
             <p>
              • Remove any private, controversial, or other information from the wall behind you (it could be visible on the screen) to limit distracting and/or offending participants
             </p>
             <p>
              • If there are others in the space outside of your door, consider putting a sign on the door or talking with them to request a quiet environment
             </p>
            </td>
           </tr>
           <tr>
            <td align="left">
             2. Professionalism
            </td>
            <td align="left">
             • Maintain a professional appearance; wear professional attire
            </td>
           </tr>
           <tr>
            <td align="left">
             3. Managing challenges
            </td>
            <td align="left">
             <p>
              • Be prepared for challenges that may arise
             </p>
             <p>
              – Have technical support manuals or guides on hand. Even if staff are comfortable with the software, participants may encounter challenges with their devices or with using the platform
             </p>
             <p>
              – Especially for group calls, have a staff member on call to enable the facilitator to continue while a participant is receiving technical assistance
             </p>
             <p>
              – Have a contingency plan. What will happen if the connection is unsuccessful for one or more participants? Will you allow some or all join via phone instead?
             </p>
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
      </sec>
      <sec id="Sec8">
       <title>
        How can my Team Implement Videoconferencing?
       </title>
       <p id="Par10">
        Here, we have some suggestions about how to proceed once you decide videoconferencing is the best solution for your project.
       </p>
       <sec id="Sec48">
        <title>
         Ensure Technical Capacity
        </title>
        <p id="Par11">
         Depending on the platform, your staff and participants will likely have the option of participating from a variety of devices. You will need to ensure an adequate internet connection (
         <italic>
          may vary based on platform
         </italic>
         ) and devices with working cameras, and microphones (internal or external to the device). As noted, headphones and earbuds should be secured to maximize privacy—your staff may already have their own.
        </p>
       </sec>
       <sec id="Sec49">
        <title>
         Choose a Platform
        </title>
        <p id="Par12">
         When transitioning to a videoconferencing software, it is important to assess fit between the platform and the project needs (Table
         <xref ref-type="table" rid="Tab1">
          1
         </xref>
         ). Choose a platform that is user friendly and accessible by both research staff and participants. If participants do not find the platform easy to use, participation may decline. Depending on the nature of the study, required interactions between research staff and participants, and required interactions between participants in group-based interventions, the features needed to successfully transition an in-person study to videoconferencing may vary. Although not comprehensive, Table
         <xref ref-type="table" rid="Tab2">
          2
         </xref>
         . delineates reasons to carefully consider which features are available in the platform you select.
        </p>
        <p id="Par13">
         The security of the videoconferencing platform, especially when working with PWLH, may be the most important feature to consider. Steps being taken to ensure security should be clearly communicated with participants in simple language (See Supplemental File 2). Check with your institution about whether additional security assurances may be needed (e.g., HIPAA compliance, written agreements). The availability of these measures differs by platform and may require additional levels of administrative approval.
        </p>
        <p id="Par14">
         Our team has experience using a variety of videoconferencing platforms for research and non-research purposes and have settled on Zoom®, for its accessibility across devices and operating systems, ease of use for participants with no or limited videoconferencing experience, performance in low-bandwidth situations, screen-sharing features, host controls, and security settings. Our participants report satisfaction with the platform and even those with no prior videoconferencing experience have been able to use Zoom with ease [
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
         ]. As the videoconferencing market has experienced substantial growth in recent years, many alternatives are available and may be conducive to research, depending on characteristics of the population under study. Each team should identify the best fit for their project(s).
        </p>
       </sec>
       <sec id="Sec56">
        <title>
         Confirm Granting Agency Approval and Institutional Compliance
        </title>
        <p id="Par15">
         Before transitioning to videoconferencing, check with funders and institutional review boards. In this unprecedented time of social distancing, we expect support for using alternative approaches to achieve research continuity, but assure that approvals are in place before you pivot. Emailing a program/project officer may be sufficient for receiving funder approvals. Determine if rapid review by the institutional review board (IRB) is possible. Information about platform security and other videoconferencing-specific measures to promote participant privacy (See Table
         <xref ref-type="table" rid="Tab3">
          3
         </xref>
         and Supplemental File 1) should be communicated to IRBs and included in the research consent process. Note that for future studies it may be useful to include contingency plans with initial IRB submissions for in-person studies to allow for transitioning to videoconferencing or other online options if the need arises.
        </p>
       </sec>
       <sec id="Sec35">
        <title>
         Develop Protocols for Videoconferencing Implementation
        </title>
        <p id="Par16">
         Once an appropriate and user-friendly platform is identified, engaging with participants via that platform should be relatively straightforward. Having protocols in place will simplify the process and help reduce unexpected challenges.
        </p>
        <p id="Par17">
         Protocols for
         <italic>
          Facilitators and staff
         </italic>
         should include standards for promoting privacy and confidentiality, professionalism, and responses to challenges. For considerations, see Table
         <xref ref-type="table" rid="Tab3">
          3
         </xref>
         . For a sample protocol you can adapt for your project, see Supplemental File 3.
        </p>
        <p id="Par18">
         Protocols for
         <italic>
          Participants
         </italic>
         may include instructions for setting up the videoconferencing platform and, depending on platform, downloading software before first use. We have found when participants test out the platform individually in advance of any formal sessions, it alleviates participant anxiety and reduces complications during formal sessions. See Supplemental File 4. for a sample videoconferencing testing protocol.
        </p>
        <p id="Par19">
         Whether conducting individual or group-based video-sessions, ground rules are helpful in promoting appropriate interactions. Ground rules can foster focused participation, comfort, and group cohesion; they can also help to avert uncomfortable situations (Supplemental Files 1 &amp; 5).
        </p>
       </sec>
       <sec id="Sec57">
        <title>
         Revise Study Materials and Procedures for the Video-Call Environment
        </title>
        <p id="Par20">
         Depending on the purpose for using videoconferencing in research, it may be helpful to revise study materials. If your team is planning to use videoconferencing to complete a structured or semi-structured interview that had formally been conducted in person, revisions may be limited to introducing participants to the videoconferencing environment and ensuring participation from a space in which their privacy is unlikely to be compromised. However, if you were previously conducting in-person group sessions and now plan to deliver them over video-groups, some processes may need to be changed.
        </p>
        <p id="Par21">
         When we adapted the Healthy Relationships program for video group delivery [
         <xref ref-type="bibr" rid="CR8">
          8
         </xref>
         ], it required changing the way certain components were delivered while still maintaining the core elements. For example, Healthy Relationships in-person involves some “fish bowl” activities, in which two participants sit in the center of a circle and role play conversations related to HIV status disclosure and sexual risk reduction. We were able to maintain the activity but the implementation was altered. While video-group participants cannot sit around a room together, they can see and hear one another in real time. In this study, we took advantage of the way our platform always showed the person who was speaking in a large box on the screen, and that the person who was speaking never saw their own face in that large box (instead, they saw the last person who spoke before themselves). Facilitators asked the person who would respond to the main speaker (we’ll call her Diana) to say one word to cue the large box and asked the main speaker (let’s call him Robert) to then begin the role play. This enabled Diana to see Robert’s face in the large box during the dialogue, while Robert saw Diana’s face at that same time (the others saw the person currently speaking in the large box). In doing this, Robert could feel more like he was speaking directly with Diana, while, Diana would feel as if she was speaking directly with Robert.
        </p>
        <p id="Par22">
         Participant materials were distributed differently in our Healthy Relationships adaptation vs. in-person groups. Upon consent to do so, staff mailed or emailed handouts to participants and showed handouts via screen share as appropriate during the sessions. In a tobacco cessation program for PLWH, handouts were mailed and/or emailed depending on the participant’s preference. Researchers working with PLWH should assess the feasibility of distributing handouts via mail or email, which could compromise privacy if the handouts reveal participants’ HIV status—especially for participants residing with, or sharing email addresses with, people unaware the participant is living with HIV.
        </p>
        <p id="Par23">
         Biological specimen collection is a challenge for research with only online interactions. Creative solutions were needed when we began a pilot study of a video-group tobacco cessation intervention for PLWH and required biochemical verification of tobacco abstinence. To address this, we developed a strategy to send oral swab tests for cotinine (measuring presence of nicotine) to participants and then guide them through the process during individual video-calls [
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
         ]. The video component enabled our team to ensure proper swab technique, ensure the swab reflected the participant’s nicotine levels (vs. those of their dog or roommate), and help the participant prepare the packet for the express shipping service. This strategy could be adopted for analyses involving other specimens. For example, a video-call could be used to support participants in collecting dried blood spots for analysis [
         <xref ref-type="bibr" rid="CR11">
          11
         </xref>
         ,
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ].
        </p>
       </sec>
       <sec id="Sec14">
        <title>
         Create Meaningful Interactions
        </title>
        <p id="Par24">
         It is possible to create meaningful interactions when hosting meetings or sessions via videoconferencing. Existing guidance for videoconferencing etiquette [
         <xref ref-type="bibr" rid="CR13">
          13
         </xref>
         ,
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ] can be applied in both individual and group-based interventions. A simple suggestion for staff/facilitators is to maintain eye contact with the camera. Although a small action, this effort can contribute to meaningful connections with research participants. In our work, participants have noted the connection they felt with staff and fellow participants. Relatedly, across intervention groups and studies, participants have developed hand gestures to express compassion. In a study of video-groups among women living with HIV, women made a fist with one hand, then held that wrist with their opposite hand and raised their arms just over their heads to indicate a hug. Similarly, to show support in a video-group tobacco cessation study, participants made the shape of a heart with their hands to show support. Despite not interacting with their peers in-person, participants developed strong social support and cohesion (e.g., “
         <italic>
          That was what really brought us back, is, you know, the, the friendships that we have built here in, in talking to each other. And, and you actually, like, look forward to, like, oh, you know, I can’t wait till the next session…
         </italic>
         “—participant of a tobacco cessation program for people living with HIV).
        </p>
       </sec>
       <sec id="Sec15">
        <title>
         Help Participants Prepare for the Video-Call Experience
        </title>
        <p id="Par25">
         Data from one of our recent studies suggests many PLWH may not have engaged in videoconferencing previously [
         <xref ref-type="bibr" rid="CR9">
          9
         </xref>
         ]. In our projects, lack of prior experience has not been problematic when participants were provided with instructions and assistance from our team [
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
         ]. For teams new to using videoconferencing for research, it may be helpful to provide participants and staff video tutorials like this one provided by Zoom before the first video-call with a participant [
         <xref ref-type="bibr" rid="CR15">
          15
         </xref>
         ]. Other platforms have video tutorials available, as well [
         <xref ref-type="bibr" rid="CR16">
          16
         </xref>
         ,
         <xref ref-type="bibr" rid="CR17">
          17
         </xref>
         ]. Alternatively, you may wish to create your own.
        </p>
        <p id="Par26">
         Our team assesses a person’s ability to join a videoconference as part of eligibility screening. We start with a phone call, and guide participants through the connection process, ultimately stopping the phone conversation and finishing the interaction on the videoconference. On the occasion that a potential participant has trouble connecting, we do our best to help them problem-solve. Persons who are unable to make the connection are disqualified. However, as noted above, teams transitioning to videoconferencing due to social distancing practices may instead allow such participants to participate via other technologies. For video-groups, based on feedback received in early focus groups [
         <xref ref-type="bibr" rid="CR5">
          5
         </xref>
         ], we would caution against allowing some participants to join via audio only while other participants in the same session are showing their video. As noted, those showing their live video feed may feel especially vulnerable and unwilling to speak frankly if they cannot see some group members’ live feed. Instead, participants unable to join a videoconference may be given the option of an individual encounter via phone or joining a group that involves phone/audio interactions exclusively.
        </p>
       </sec>
       <sec id="Sec16">
        <title>
         Consider Pandemic-Specific Needs, as Appropriate
        </title>
        <p id="Par27">
         During this pandemic, research staff should be cognizant of the many stressors participants may be facing. Like much of the world, it is likely that at least some research participants will become ill with COVID-19. Teams should be familiar with local guidance for seeking medical attention for possible COVID-19 to inform participants if needed. Although the primary role of the research team is not to provide pandemic-specific social support, teams should have lists of local referral sources, as appropriate, to assist them in connecting participants with basic needs (e.g., food, housing) as well as other supportive services (e.g., mental health).
        </p>
       </sec>
      </sec>
     </sec>
    </sec>
    <sec id="Sec17">
     <title>
      Summary
     </title>
     <p id="Par28">
      During times of social distancing and beyond, researchers conducting social-behavioral studies may want to transition their research to videoconferencing, which many participants and staff can join from their own homes. Consideration will need to be given to what projects are most appropriate and feasible to be transitioned to videoconferencing, which is the best fit for their study, how to prepare participants and staff, how to ensure support from institutions and funders, and how to create meaningful interactions. If done thoughtfully, the transition to videoconferencing can help ensure the continuity of research and provide a way for participants to benefit from potentially meaningful social interaction during a time of isolation.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Electronic supplementary material
     </title>
     <sec id="Sec18">
      <p>
       Below is the link to the electronic supplementary material.
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="10461_2020_2837_MOESM1_ESM.docx">
         <caption>
          <p>
           Supplementary file1 (DOCX 13 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM2">
        <media xlink:href="10461_2020_2837_MOESM2_ESM.docx">
         <caption>
          <p>
           Supplementary file2 (DOCX 13 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM3">
        <media xlink:href="10461_2020_2837_MOESM3_ESM.docx">
         <caption>
          <p>
           Supplementary file3 (DOCX 15 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM4">
        <media xlink:href="10461_2020_2837_MOESM4_ESM.docx">
         <caption>
          <p>
           Supplementary file4 (DOCX 13 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM5">
        <media xlink:href="10461_2020_2837_MOESM5_ESM.docx">
         <caption>
          <p>
           Supplementary file5 (DOCX 13 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher's Note
        </bold>
       </p>
       <p>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
     </fn-group>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak
        </article-title>
        <source>
         J Travel Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Lockhart
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advantages and disadvantages for receiving Internet-based HIV/AIDS interventions at home or at community-based organizations
        </article-title>
        <source>
         AIDS Care
        </source>
        <year>
         2015
        </year>
        <volume>
         27
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1304
        </fpage>
        <lpage>
         1308
        </lpage>
        <pub-id pub-id-type="pmid">
         26357907
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lockhart
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding women's willingness to use ehealth for HIV-related services: a novel application of the technology readiness and acceptance model to highly stigmatized medical condition
        </article-title>
        <source>
         Telemed J E Health.
        </source>
        <year>
         2019
        </year>
        <volume>
         25
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         511
        </fpage>
        <lpage>
         518
        </lpage>
        <pub-id pub-id-type="pmid">
         30074862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Buhi
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Baldwin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lynn
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effectiveness of healthy relationships video-group—a videoconferencing group intervention for women living with HIV: preliminary findings from a randomized controlled trial
        </article-title>
        <source>
         Telemed J E Health
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         128
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="pmid">
         24237482
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Fuhrmann
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Gilliam
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Baldwin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interest in, concerns about, and preferences for potential video-group delivery of an effective behavioral intervention among women living with HIV
        </article-title>
        <source>
         AIDS Behav
        </source>
        <year>
         2012
        </year>
        <volume>
         16
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1961
        </fpage>
        <lpage>
         1969
        </lpage>
        <pub-id pub-id-type="pmid">
         21947780
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lockhart
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Rivara
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Shuter
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Meeting our patients “where they are”: video-group smoking cessation for people living with HIV
        </article-title>
        <source>
         J Assoc Nurses AIDS Care
        </source>
        <year>
         2018
        </year>
        <volume>
         29
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         338
        </fpage>
        <lpage>
         344
        </lpage>
        <pub-id pub-id-type="pmid">
         29033093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lockhart
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Willingness of MSM living with HIV to take part in video-groups: application of the technology readiness and acceptance model
        </article-title>
        <source>
         AIDS Behav
        </source>
        <year>
         2019
        </year>
        <volume>
         23
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         3165
        </fpage>
        <lpage>
         3174
        </lpage>
        <pub-id pub-id-type="pmid">
         31123856
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Iziduh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fuhrmann
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Glueckauf
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Lynn
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Internet-based video-group delivery of healthy relationships—A “prevention with positives” intervention: report on a single group pilot test among women living with HIV
        </article-title>
        <source>
         AIDS Care
        </source>
        <year>
         2013
        </year>
        <volume>
         25
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         904
        </fpage>
        <lpage>
         909
        </lpage>
        <pub-id pub-id-type="pmid">
         23713756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marhefka
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Lockhart
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Social determinants of potential eHealth engagement among people living with HIV receiving ryan white case management: health equity implications from project TECH
        </article-title>
        <source>
         AIDS Behav
        </source>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        Ryan CL. Computer and internet use in the United States: 2016. US Department of Commerce, Economics and Statistics Administration, US, 2018 Contract No.: Report Number ACS 39.
       </mixed-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hirshfield
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Teran
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Downing
          </surname>
          <given-names>
           MJ
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Chiasson
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Tieu
          </surname>
          <given-names>
           H-V
          </given-names>
         </name>
         <name>
          <surname>
           Dize
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Quantification of HIV-1 RNA among men who have sex with men using an at-home self-collected dried blood spot specimen: feasibility study
        </article-title>
        <source>
         JMIR Public Health Surveill
        </source>
        <year>
         2018
        </year>
        <volume>
         4
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         e10847
        </fpage>
        <pub-id pub-id-type="pmid">
         30389648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ngo-Giang-Huong
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Khamduang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Leurent
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Nantasen
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Leechanachai
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Early HIV-1 diagnosis using in-house real time PCR amplification on dried blood spots for infants in remote and resource limited settings
        </article-title>
        <source>
         J Acquir Immune Defic Syndr
        </source>
        <year>
         2008
        </year>
        <volume>
         49
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         465
        </fpage>
        <pub-id pub-id-type="pmid">
         18989220
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="other">
        Inc. ZVC. Video Communications Best Practice Guide 2020.
        <ext-link ext-link-type="uri" xlink:href="https://blog.zoom.us/wordpress/2018/07/03/video-communications-best-practice-guide/">
         https://blog.zoom.us/wordpress/2018/07/03/video-communications-best-practice-guide/
        </ext-link>
        . Accessed 16 March 2020.
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Northwestern University. Videoconferencing Tips for Success 2016.
        <ext-link ext-link-type="uri" xlink:href="https://www.it.northwestern.edu/videoconferencing/tips.html">
         https://www.it.northwestern.edu/videoconferencing/tips.html
        </ext-link>
        . Accessed 16 March 2020
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="other">
        Zoom Video Communications Inc. Zoom Video Tutorials 2019.
        <ext-link ext-link-type="uri" xlink:href="https://support.zoom.us/hc/en-us/articles/206618765-Zoom-Video-Tutorials">
         https://support.zoom.us/hc/en-us/articles/206618765-Zoom-Video-Tutorials
        </ext-link>
        . Accessed 15 March 2020
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        Microsoft. Getting started 2020.
        <ext-link ext-link-type="uri" xlink:href="https://support.skype.com/en/skype/all/start/">
         https://support.skype.com/en/skype/all/start/
        </ext-link>
        . Accessed 16 March 2020
       </mixed-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="other">
        LogMeIn Inc. GoToMeeting Quick Guide for Attendees 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.gotomeeting.com/meeting/resources/gotomeeting-quick-and-helpful-guide-for-attendees">
         https://www.gotomeeting.com/meeting/resources/gotomeeting-quick-and-helpful-guide-for-attendees
        </ext-link>
        . Accessed 16 March 2020
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Thorac Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J Thorac Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JTD
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Thoracic Disease
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2072-1439
      </issn>
      <issn pub-type="epub">
       2077-6624
      </issn>
      <publisher>
       <publisher-name>
        Pioneer Bioscience Publishing Company
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       23977429
      </article-id>
      <article-id pub-id-type="pmc">
       3747523
      </article-id>
      <article-id pub-id-type="publisher-id">
       jtd-05-S2-S103
      </article-id>
      <article-id pub-id-type="doi">
       10.3978/j.issn.2072-1439.2013.06.02
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Keynote Lecture
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        From SARS coronavirus to novel animal and human coronaviruses
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          To
         </surname>
         <given-names>
          Kelvin K. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hung
         </surname>
         <given-names>
          Ivan F. N.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper F. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        State Key Laboratory of Emerging Infectious Diseases, the University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Corresponding to: Kwok-Yung Yuen. Carol Yu Centre for Infection, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, China. Email:
        <email xlink:href="kyyuen@hkucc.hku.hk">
         kyyuen@hkucc.hku.hk
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
       <month>
        8
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
       <month>
        8
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <volume>
       5
      </volume>
      <issue>
       Suppl 2
      </issue>
      <fpage>
       S103
      </fpage>
      <lpage>
       S108
      </lpage>
      <history>
       <date date-type="received">
        <day>
         15
        </day>
        <month>
         5
        </month>
        <year>
         2013
        </year>
       </date>
       <date date-type="accepted">
        <day>
         04
        </day>
        <month>
         6
        </month>
        <year>
         2013
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        2013 Pioneer Bioscience Publishing Company. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2013
       </copyright-year>
       <copyright-holder>
        Pioneer Bioscience Publishing Company.
       </copyright-holder>
      </permissions>
      <abstract>
       <p>
        In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) caused one of the most devastating epidemics known to the developed world. There were two important lessons from this epidemic. Firstly, coronaviruses, in addition to influenza viruses, can cause severe and rapidly spreading human infections. Secondly, bats can serve as the origin and natural animal reservoir of deadly human viruses. Since then, researchers around the world, especially those in Asia where SARS-CoV was first identified, have turned their focus to find novel coronaviruses infecting humans, bats, and other animals. Two human coronaviruses, HCoV-HKU1 and HCoV-NL63, were identified shortly after the SARS-CoV epidemic as common causes of human respiratory tract infections. In 2012, a novel human coronavirus, now called Middle East respiratory syndrome coronavirus (MERS-CoV), has emerged in the Middle East to cause fatal human infections in three continents. MERS-CoV human infection is similar to SARS-CoV in having a high fatality rate and the ability to spread from person to person which resulted in secondary cases among close contacts including healthcare workers without travel history to the Middle East. Both viruses also have close relationships with bat coronaviruses. New cases of MERS-CoV infection in humans continue to occur with the origins of the virus still unknown in many cases. A multifaceted approach is necessary to control this evolving MERS-CoV outbreak. Source identification requires detailed epidemiological studies of the infected patients and enhanced surveillance of MERS-CoV or similar coronaviruses in humans and animals. Early diagnosis of infected patients and appropriate infection control measures will limit the spread in hospitals, while social distancing strategies may be necessary to control the outbreak in communities if it remained uncontrolled as in the SARS epidemic.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        KEY WORDS
       </title>
       <kwd>
        Severe acute respiratory syndrome coronavirus (SARS-CoV)
       </kwd>
       <kwd>
        novel coronaviruses
       </kwd>
       <kwd>
        Middle East respiratory syndrome coronavirus (MERS-CoV)
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
   </article>
   <article article-type="letter" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Asian J Psychiatr
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Asian J Psychiatr
      </journal-id>
      <journal-title-group>
       <journal-title>
        Asian Journal of Psychiatry
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1876-2018
      </issn>
      <issn pub-type="epub">
       1876-2026
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7161472
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1876-2018(20)30180-5
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ajp.2020.102069
      </article-id>
      <article-id pub-id-type="publisher-id">
       102069
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Mental Health and Psychosocial Aspects of Coronavirus Outbreak in Pakistan: Psychological Intervention for Public Mental Health Crisis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="aut0005">
        <name>
         <surname>
          Mukhtar
         </surname>
         <given-names>
          Ms. Sonia
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       University of Management and Technology, Lahore, Pakistan
      </aff>
      <pub-date pub-type="pmc-release">
       <day>
        16
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        16
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       102069
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         31
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0005">
       <title>
        Highlights
       </title>
       <p>
        <list id="lis0005" list-type="simple">
         <list-item id="lsti0005">
          <label>
           •
          </label>
          <p id="par0005">
           Through this correspondence, I aim to highlight the eminent need of psychological crisis intervention in the wake of ongoing novel coronavirus outbreak that took place in China and has transmitted throughout the world.
          </p>
         </list-item>
         <list-item id="lsti0010">
          <label>
           •
          </label>
          <p id="par0010">
           The planned initiative could prevent any further progression of secondary crisis of compromised mental health of those suffered from coronavirus, and those in self-isolation, social-distancing and quarantined.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwd0005">
       <title>
        Keywords
       </title>
       <kwd>
        Mental health
       </kwd>
       <kwd>
        Psychosocial Aspects
       </kwd>
       <kwd>
        Coronavirus Outbreak
       </kwd>
       <kwd>
        Pakistan
       </kwd>
       <kwd>
        Psychological Crisis Intervention
       </kwd>
       <kwd>
        Public Mental Health Crisis
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="m0005">
       Sonia Mukhtar, MS (Counseling Psychology), certified in Integrative Counseling and Narrative Therapy, published books’ author, is a former-visiting faculty and Alumnus at University of Management and Technology, Lahore, Pakistan. She is an independent researcher and private practitioner counselling psychologist at Lahore, Pakistan.
      </p>
     </notes>
    </front>
    <p id="par0015">
     With the advent of Coronavirus (COVID-19) – an unchartered territory – in Pakistan on February 26, 2020, state is on high alert and has reinforced partial lockdown. There are over 697,244 confirmed cases with more than 33,257 deaths worldwide and in Pakistan coronavirus tally has risen to 1,625 as of 31
     <sup>
      st
     </sup>
     of March, 2020. The worst hit countries (China, United States, Italy, Spain, Iran, France, United Kingdom, and Germany) are intensifying their efforts to manage the pandemic through collective public health intervention measures. Although WHO has labeled the outbreak the pandemic and Europe the epicenter of coronavirus, Pakistan – a relatively less effected poverty-ridden third-world country viewed coronavirus as the least of their problems, perhaps both by the state and the public (
     <xref ref-type="bibr" rid="bib0025">
      Shams, 2020
     </xref>
     ). Absence of complete ban of congregational prayers in mosques fearing a backlash from the religious groups, and reluctance of complete lockdown and curfew fearing the state of emergency, could not avert the crisis of coronavirus in Pakistan (
     <xref ref-type="bibr" rid="bib0025">
      Shams, 2020
     </xref>
     ).
    </p>
    <p id="par0020">
     During the outbreak of pandemic COVID-19, psychological crisis intervention for affected, suspected, susceptible, and at-risk patients, care-givers, families, staff, and the general public, is urgently needed for timely prevention of inestimable hazards from secondary mental health crisis. The premise of psychological crisis intervention is to control the side- and after-effects on psychosocial aspects of an infectious disease and attempt to minimize psychological impact with timely assessment and management of prevention and control (
     <xref ref-type="bibr" rid="bib0020">
      Kang et al, 2020
     </xref>
     ). The two- O’s prolonged approach (onsite and online) is necessary to implement psychological crisis intervention. The present suggestions are presented as a temporary emergency proposition in an exceptional circumstance such as the widespread pandemic outbreak of COVID-19.
    </p>
    <p id="par0025">
     Experts have advised people to stay in self-isolation and quarantined but the necessary restrictions would have short and potentially long term detrimental impact on mental health. Pakistan being a collectivistic culture highly dependent on socialization (social support and social connectedness) has been critical towards self-isolation, social-distancing and quarantine and are reluctantly dealing with emotional, psychological, behavioral and social impacts of this crisis’ uncertainty and unpredictability. The psychological impact of quarantine includes post-traumatic stress disorder, confusion and frustration (Brooks, et al, 2020). This study highlighted the importance of proper guideline of the coronavirus, information and provision of resources during quarantined for better well-being. In that scenario, reframing the situation as an opportunity to improve the mental health, mindfulness and personal growth through personal activities could become a resilient and protective factor against the psychological impact of coronavirus. Anxiety usually stemmed from the perception of uncontrollable events, thus focusing on the controlled actions (change what you can) such as improving hygiene, healthy diet, exercising, sleeping, introspection, meditation, practicing minimalism, painting, composing, movement dancing, learning instruments, acquiring languages, knitting, gardening, cooking, reading books, listening songs, watching movies/serials, playing games and journaling the personal observation and experience during the period of coronavirus – any factor that could offer resilient and protective strategies to cope with stress, anxiety, and panic should be practiced (
     <xref ref-type="bibr" rid="bib0030">
      Wood and Runger, 2020
     </xref>
     ). While government and health departments manage physical pandemic, experts (mental health practitioners, counselling psychologists, psychotherapists) could manage mental health well-being and psychological factors of the varied risks, resilience and recovery predictors. Mental health practitioners could offer online and onsite support through counselling, psychotherapy and direct them to reputable sources of information to avoid misinfodemics.
    </p>
    <p id="par0030">
     Pakistan must issue guidelines for emergency psychological crisis intervention for public health emergencies affected by coronavirus. Psychiatric and psychological institutions should operate platforms to strengthen mental health initiatives and provide psychological guidance to quarantined patients, families, self-isolated people, health-care workers of medical and social-service personnel in hospitals, laboratories, field, and in quarantine (
     <xref ref-type="bibr" rid="bib0010">
      Banerjee, 2020
     </xref>
     ). Psychological crisis intervention, during and after the outbreak period, must focus on the practical implementation of intervention. The challenge which psychological crisis intervention is encountering includes the establishment of psychological intervention teams during lockdown and personal health risks (
     <xref ref-type="bibr" rid="bib0040">
      Zandifar and Badrfam, 2020
     </xref>
     ). Moreover, after the assessment of mental health states of individuals affected by coronavirus would remain confounded in the physical health department, and even after the remission of the pandemic, patients cannot be immediately transferred from hospital to counselling psychological intervention departments. During the vulnerability and frailty of the individual’s conditions prior- during- and after- the COVID-19, professionally experienced and standardized well-trained mental health practitioners, counseling psychologists, practicing psychotherapists, psychiatrists, and psychiatrist nurses who are familiar with the complicated case structures and work procedure is a basic tenet in dealing with emotional distress and public mental health emergencies caused by the pandemics, while inexperienced psychology degree holders, untrained fresh graduates, non-practicing psychology teachers at academic institutes, certification/diploma holders or any other undue personnel – until trained – who are not always familiarized with the psychological crisis might have adverse effects in the current pandemic situation which eventually would reduce the effectiveness of the entire intervention program (
     <xref ref-type="bibr" rid="bib0005">
      Bai et al, 2004
     </xref>
     ).This condition could become worsen because of the officially un-established accreditation, registration and licensure requirements for counselling psychologists, psychotherapists, counselors and mental health practitioners (
     <xref ref-type="bibr" rid="bib0035">
      Yao et al, 2020
     </xref>
     ). This situation can be resolved through strengthening personnel training, and optimizing institutional and management policies. Psychological crisis intervention would be implemented and adapted on a) quarantined patients with confirmed/suspected infection, b) self-isolated individuals susceptible to mental health concerns, c) medical and related personnel directly in-contact with patients, d) family caretakers of the patients, e) reluctant groups like older people, children, and pregnant women, and f) general public. Psychological crisis intervention should be based on the comprehensive assessment of risk factors for a standardized psychological/mental health management. Such major pandemic outbreak would have negative effects on physical and psychological health of individuals and society (
     <xref ref-type="bibr" rid="bib0010">
      Banerjee, 2020
     </xref>
     ;
     <xref ref-type="bibr" rid="bib0015">
      Brooks et al, 2020
     </xref>
     ;
     <xref ref-type="bibr" rid="bib0020">
      Kang et al, 2020
     </xref>
     ), for instance, psychological issues, mental distress, grief and bereavement, deliberate or unintentional harm to family, loss/separation from family, self-injury, shame, guilt, helplessness, posttraumatic stress symptoms, addiction or substance use, medical mistrust and inclination towards conspiracies, panic attacks, stress, anxiety, depression, loneliness, suicidal ideation, mood problems, sleep problems, worry, denial, boredom, ambivalence, uncertainty, frustration, anger, fear, stigmatization, marginalization, xenophobia, mass hysteria, socio-economic status, and other mental health concerns would require pre-established coalition to mobilize resources for effective intervention, management and preventive measures for affected individuals. Psychiatrists and practicing psychologists could offer a balanced perspective to improve the knowledge, attitude and Misinfodemics: a) educate people about the common psychological reactions, measures and responses, b) encourage healthy activities during self-isolation, c) optimize available health-care, d) and empower health-care and volunteer personnel.
    </p>
    <p id="par0035">
     First, psychological intervention technical support team established by health authorities at regional and national levels should deliver psychological intervention, and mental health support. Second, accurate coordination and regular communication about the COVID-19 should be provided by health authority and psychosocial response teams to eliminate sense of uncertainty. Third, ensure sound mental health through psychological counselling using government sanctioned hotline teams. Fourth, patients with diagnosed coronavirus and health care professionals should receive screening and counseling by professional mental health practitioners. However, in low and middle income countries like Pakistan which has low rate of mental health service utilization and barely active online mental health services and inaccessibility of digital technology and health service for individuals with low socioeconomic status could be a risk factor in online mental health service which should be considered (
     <xref ref-type="bibr" rid="bib0035">
      Yao et al, 2020
     </xref>
     ). This paper marks the need of establishment of guidelines for psychological crisis intervention effective immediately in Pakistan.
    </p>
    <sec id="sec0005">
     <title>
      Contributor’s Statement
     </title>
     <p id="par0040">
      Sonia Mukhtar drafted and conceptualized the manuscript.
     </p>
    </sec>
    <sec id="sec0010" sec-type="COI-statement">
     <title>
      Declaration of interests
     </title>
     <p id="par0045">
      I declare no competing interests.
     </p>
    </sec>
    <sec id="sec0015">
     <title>
      Funding
     </title>
     <p id="par0050">
      No funding sources.
     </p>
    </sec>
    <sec id="sec0020">
     <title>
      Ethical approval
     </title>
     <p id="par0055">
      Not required.
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C.-C
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chue
          </surname>
          <given-names>
           C.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survey of stress reactions among health care workers involved with the SARS outbreak
        </article-title>
        <source>
         Psychiatr Serv
        </source>
        <volume>
         55
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1055
        </fpage>
        <lpage>
         1057
        </lpage>
        <pub-id pub-id-type="pmid">
         15345768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Banerjee
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The COVID-19 outbreak: Crucial role the psychiatrists can play
        </article-title>
        <source>
         Asian J. Psychiatr
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         102014
        </object-id>
        <pub-id pub-id-type="doi">
         10.1016/j.ajp.2020.102014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Woodland
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wessely
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Gideon
          </surname>
          <given-names>
           JR.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The psychological impact of quarantine and how to reduce it: rapid review of the evidence
        </article-title>
        <source>
         The Lancet.
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         10227
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus
        </article-title>
        <source>
         Lancet Psychiatry
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2215-0366(20)30047-X
        </pub-id>
        <comment>
         published online Feb 5
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <element-citation id="sbref0025" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shams
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus: Is Pakistan taking COVID-19 too lightly
        </article-title>
        <ext-link ext-link-type="uri" id="intr0005" xlink:href="https://www.dw.com/en/coronavirus-is-pakistan-taking-covid-19-too-lightly/a-52824403">
         https://www.dw.com/en/coronavirus-is-pakistan-taking-covid-19-too-lightly/a-52824403
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         (accessed March 24, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Runger
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychology of habit
        </article-title>
        <source>
         Annu
        </source>
        <volume>
         67
        </volume>
        <year>
         2016
        </year>
        <fpage>
         289
        </fpage>
        <lpage>
         314
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.-F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rethinking online mental health services in China during the COVID-19 epidemic
        </article-title>
        <source>
         Asian J. Psychiatr
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         102015
        </object-id>
        <pub-id pub-id-type="doi">
         10.1016/j.ajp.2020.102015
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zandifar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Badrfam
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Iranian mental health during the COVID-19 epidemic
        </article-title>
        <source>
         Asian J. Psychiatr
        </source>
        <volume>
         51
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         101990
        </object-id>
        <pub-id pub-id-type="doi">
         10.1016/j.ajp.2020.101990
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0005">
      <title>
       Acknowledgments
      </title>
      <p>
       A special thanks to
       <funding-source id="gs0005">
        Sakina Mukhtar who provided daily news regarding the COVID-19
       </funding-source>
       . A meritorious tribute to all the front-line health-care workers in the face of the coronavirus.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Am Soc Cytopathol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J Am Soc Cytopathol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of the American Society of Cytopathology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2213-2945
      </issn>
      <issn pub-type="epub">
       2213-2945
      </issn>
      <publisher>
       <publisher-name>
        American Society of Cytopathology. Published by Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32284276
      </article-id>
      <article-id pub-id-type="pmc">
       7104051
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2213-2945(20)30045-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jasc.2020.03.001
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The COVID-19 pandemic: implications for the cytology laboratory
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Pambuccian
         </surname>
         <given-names>
          Stefan E.
         </given-names>
        </name>
        <degrees>
         MD, MIAC
        </degrees>
        <email>
         spambuccian@lumc.edu
        </email>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author: Stefan E. Pambuccian, MD, MIAC; Department of Pathology and Laboratory Medicine, Loyola University Chicago Stritch School of Medicine, Loyola University Medical Center, 2160 S 1st Avenue, Maywood, IL 60153; Tel.: (708) 327 2295x2618; Fax: (708) 327 620.
        <email>
         spambuccian@lumc.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <history>
       <date date-type="received">
        <day>
         23
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         23
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        American Society of Cytopathology
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The coronavirus disease 2019 (COVID-19) is a pandemic caused by the SARS-CoV-2 virus. The infection has predominantly respiratory transmission and is transmitted through large droplets or aerosols, and less commonly by contact with infected surfaces or fomites. The alarming spread of the infection and the severe clinical disease that it may cause have led to the widespread institution of social distancing measures. Because of repeated exposure to potentially infectious patients and specimens, health care and laboratory personnel are particularly susceptible to contract COVID-19. This review paper provides an assessment of the current state of knowledge about the disease and its pathology, and the potential presence of the virus in cytology specimens. It also discusses the measures that cytology laboratories can take to function during the pandemic, and minimize the risk to their personnel, trainees, and pathologists. In addition, it explores potential means to continue to educate trainees during the COVID-19 pandemic.
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        Cytology
       </kwd>
       <kwd>
        Pathology education
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p id="p0010">
     At the time of the writing of this review, the COVID-19 pandemic, caused by a novel coronavirus, has already affected over 1,350,000 people in 209 countries and territories, and killed almost 75,000 people worldwide. The number of cases reported worldwide and in the United States increase daily at an alarming rate, in part as a consequence of more widespread testing. As the fears of a global coronavirus COVID-19 pandemic, a disease caused by the SARS-CoV-2 virus, continue to grow, the cytology laboratory must also brace itself to continue to offer the best service to patients, while protecting its technicians, technologists, trainees, and pathologists.
    </p>
    <p id="p0015">
     Recently, a series of public health measures have been taken to reduce the spread of the disease. These “social distancing” measures vary somewhat by state and city but are generally wide-ranging. They include cancelling sports, music, cultural and even political events; the closing of gyms, schools, and colleges; recommendations to work from home, to avoid discretionary travel, and to avoid eating or drinking in bars, restaurants, and food courts; and avoid social gatherings in groups of more than 10 people. This situation is not unprecedented, although the 100-year-old precedent is mostly forgotten. During the 1918-19 H1N1 “Spanish” influenza pandemic, which infected one fifth to one third of the world population, and during which 50 million people died worldwide,
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     <sup>
      ,
     </sup>
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     including an estimated 675,000 Americans, the United States has adopted a range of nonpharmaceutical (public health) interventions. These measures, which were similar to those currently adopted, included closure of schools and churches, banning of mass gatherings, mandated mask wearing, case isolation, and disinfection/hygiene measures.
     <xref ref-type="bibr" rid="bib3">
      <sup>
       3
      </sup>
     </xref>
     These measures were not implemented at the same time or for the same duration in different cities, however, nor were they uniformly followed. A recent analysis concluded that in some cities (San Francisco, St Louis, Milwaukee, and Kansas City) where the measures were implemented early, these measures reduced transmission rates by up to 30% to 50%.
     <xref ref-type="bibr" rid="bib3">
      <sup>
       3
      </sup>
     </xref>
     Cities that implemented such measures earlier had greater delays in reaching peak mortality, and had lower peak mortality rates and lower total mortality.
     <xref ref-type="bibr" rid="bib4">
      <sup>
       4
      </sup>
     </xref>
     The duration that these “social distancing” measures were kept in place correlated with a reduced total mortality burden.
     <xref ref-type="bibr" rid="bib4">
      <sup>
       4
      </sup>
     </xref>
     Although we still have no known effective therapy or vaccine prevention for this coronavirus, and the world is a quite different place than it was 100 years ago, the efficacy of the measures instituted during the 1918-19 pandemic gives us hope that the current measures will also limit the impact of the COVID-19 pandemic.
    </p>
    <p id="p0020">
     Because it is caused by a novel virus, the current pandemic has created plenty of anxiety, much of it due to the understandable fear of the unknown. We do not know how long this pandemic will last, and what its toll on communities will be in terms of fatalities, or in psychological, physical, and economic well-being. Mathematical models using available data predict widely different outcomes, but worst-case scenarios, which have to be taken into account, predict the potential for millions of infected patients with an unacceptably high number of fatalities. The problem with such modeling is not only that different models make different projections, but that the basic assumptions about the virus, based on which these models were developed, are far from certain. This is especially true for the 2 most basic values that predict the spread and impact of a virus: its basic reproductive number (R
     <sub>
      0
     </sub>
     ) and its case fatality rate (CFR). The R
     <sub>
      0
     </sub>
     is the number of secondary cases that 1 case would produce in a susceptible community. The value of R
     <sub>
      0
     </sub>
     usually decreases during an outbreak of infection, as the susceptible population decreases, and measures to prevent the transmission are established. R
     <sub>
      0
     </sub>
     values over 1 indicate a propensity for the infection to spread, while R
     <sub>
      0
     </sub>
     lower than 1 indicate that the infection is likely to die out. The other important number is the CFR, which is calculated by dividing the number of deaths caused by the disease by the number of patients affected with that disease. For COVID-19, this number also varies greatly and is impacted by under-testing, the under-reporting of mild and asymptomatic cases, and the focus on more severe cases. This may be, at least in part, the reason why the CFR is much higher in studies from the Wuhan province in China, where it was 2.3%, than in studies from elsewhere in China that show a CFR around 1%.
     <xref ref-type="bibr" rid="bib5">
      <sup>
       5
      </sup>
     </xref>
     The case fatality rate is usually quoted to be around 2% and is similar in China,
     <xref ref-type="bibr" rid="bib6">
      <sup>
       6
      </sup>
     </xref>
     Iran,
     <xref ref-type="bibr" rid="bib7">
      <sup>
       7
      </sup>
     </xref>
     and Italy.
     <xref ref-type="bibr" rid="bib8">
      <sup>
       8
      </sup>
     </xref>
     It varies between 0.25% and 3%, however, and lower estimates may be closer to the true value.
     <xref ref-type="bibr" rid="bib9">
      <sup>
       9
      </sup>
     </xref>
     <sup>
      ,
     </sup>
     <xref ref-type="bibr" rid="bib10">
      <sup>
       10
      </sup>
     </xref>
     The estimated infection fatality risk—that is, the risk of death among all infected individuals (including those with no apparent disease)—is 0.3% to 0.6%, which is comparable to the Asian influenza pandemic of 1957-1958.
     <xref ref-type="bibr" rid="bib11">
      <sup>
       11
      </sup>
     </xref>
     However, other influenza pandemics had very different mortality rates and ranged from 0.001% to 0.007% for the 2009 H1N1 influenza to estimates ranging from 0.5% to 3%
     <xref ref-type="bibr" rid="bib12">
      <sup>
       12
      </sup>
     </xref>
     <sup>
      ,
     </sup>
     <xref ref-type="bibr" rid="bib13">
      <sup>
       13
      </sup>
     </xref>
     for the 1918 influenza pandemic. The high mortality rate of the 1918 influenza pandemic was related only in part to the pathogenicity of the virus itself, and the cytokine storm that it produced. Important contributors were the context in which the 1918 pandemic occurred, at the end of World War I, with overcrowded barracks, poverty, poor nutrition, poor hygiene, household/community-level crowding, lack of preparation of the population and decision-makers due to cognitive inertia,
     <xref ref-type="bibr" rid="bib14">
      <sup>
       14
      </sup>
     </xref>
     and poor medical and insufficient nursing care.
    </p>
    <p id="p0025">
     The case fatality rate also depends on the affected population, and is higher in hospitalized patients (4.3%),
     <xref ref-type="bibr" rid="bib15">
      <sup>
       15
      </sup>
     </xref>
     in male patients (4.5% compared with 1.3% in female patients), in older patients (5.3% in patients aged ≥60 years compared with 1.4% in those aged &lt;60 years), and in patients with cardiovascular, diabetic, and chronic respiratory comorbidities.
     <xref ref-type="bibr" rid="bib16">
      <sup>
       16
      </sup>
     </xref>
     Given the fact that it appears that both the generally accepted R
     <sub>
      0
     </sub>
     and the CFR are most likely overestimated, the impact of the pandemic may be severe, but will not attain the levels predicted in worst-case scenarios.
    </p>
    <p id="p0030">
     At this time, we still have many unanswered questions about this virus. For some of these questions we may not have answers based on hard data for months to come, maybe until the epidemic is over and an analysis of the worldwide data can be performed. Nonetheless, even before we have all the answers, we should neither panic, nor treat it too lightly. We have to “keep calm and carry on” and continue to function as a cytology laboratory dedicated to provide the best service to our patients in this health care emergency, but at the same time maximize the safety of health care workers and prevent unnecessary risks, which could help the dissemination of the virus.
    </p>
    <sec id="sec1">
     <title>
      Comparison of COVID with other coronavirus outbreaks
     </title>
     <p id="p0035">
      Notwithstanding our imperfect understanding of the SARS-CoV-2 infection, we can summarize what we know from the current COVID-19 outbreak in China and the lessons from other outbreaks of severe respiratory diseases caused by coronaviruses. These include the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV). SARS-CoV, SARS-CoV-2, and MERS-CoV, are all members of betacoronavirus genus. SARS-CoV has about 80% sequence homology with SARS-CoV-2, whereas MERS-CoV has only about 50% sequence homology with SARS-CoV-2. These differences, as well as differences in the source of infection and cellular receptors for coronavirus, make the SARS outbreak a source of more relevant information to the COVID-19 pandemic than the MERS outbreaks. The other human coronaviruses, including the 2 alphacoronaviruses (HCoV-229E and HCoV-NL63) and 2 other betacoronaviruses (HCoV-OC43 and HKU1) do not appear related to COVID-19, as these viruses continually circulate worldwide causing mild respiratory infections (“common cold”) in adults and children.
     </p>
     <p id="p0040">
      Coronaviridae got their name from the club-shaped protein spikes on their surface, which give the appearance of a crown or “corona” in the 2-dimensional image of transmission electron microscopy. They are rather large (120 nm), enveloped positive-sense single-stranded RNA viruses. Their specific tissue tropism, infectivity, and species range are conferred by the spike protein, which interacts with a specific cell receptor. In the case of SARS-CoV and SARS-CoV-2, the receptor for the virus is the angiotensin-converting enzyme 2 (ACE2) receptor on ciliated bronchial epithelial cells, whereas for MERS-CoV, the receptor is DPP4/CD26 on nonciliated respiratory epithelial cells.
     </p>
     <p id="p0045">
      The fact that the receptor for SARS-CoV and SARS-CoV-2 is ACE2, a protein with a wide species distribution, may explain the observed cross-species transmission,
      <xref ref-type="bibr" rid="bib17">
       <sup>
        17
       </sup>
      </xref>
      as both SARS-CoV and SARS-CoV-2 viruses appear to have originated from animals. They derive most likely from bats, the mammals with the highest diversity of coronaviruses. The transmission may have resulted through the intermediary of civets, the pangolin, or other animals. This is supported by the fact that SARS-CoV-2 has a remarkable 96% genetic homology to a bat coronavirus,
      <xref ref-type="bibr" rid="bib18">
       <sup>
        18
       </sup>
      </xref>
      and a 99% sequence homology with a coronavirus from the pangolin species.
      <xref ref-type="bibr" rid="bib6">
       <sup>
        6
       </sup>
      </xref>
      MERS-CoV probably also originated from bats,
      <xref ref-type="bibr" rid="bib17">
       <sup>
        17
       </sup>
      </xref>
      but the intermediate hosts are dromedary camels. Camel to human transmission of MERS-CoV may occur through contact with camels, unpasteurized camel milk, and medicinal use of camel urine,
      <xref ref-type="bibr" rid="bib19">
       <sup>
        19
       </sup>
      </xref>
      but human to human transmission of the virus also occurs and has been documented in health care workers.
      <xref ref-type="bibr" rid="bib20">
       <sup>
        20
       </sup>
      </xref>
      MERS has a much higher case fatality rate (about 35% for the 2500 patients with clinical infections
      <xref ref-type="bibr" rid="bib21">
       <sup>
        21
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib22">
       <sup>
        22
       </sup>
      </xref>
      ). All 3 diseases (SARS, MERS, and COVID-19) have similar, but not identical, clinical manifestations, spanning the entire range from mild flu-like symptoms to severe pneumonia and acute respiratory distress syndrome. COVID-19 presents more frequently with lower respiratory system symptoms, including chest tightness, dry cough, and dyspnea, and less commonly with gastrointestinal symptoms, like nausea, vomiting, and diarrhea.
     </p>
     <p id="p0050">
      Although statistics usually include only patients who were tested for the disease because they were symptomatic and presented to their physician or health care facility, the infection is most likely much more prevalent, if one considers asymptomatic or subclinical infections. A recent study showed that 0.2% of healthy adult blood donors in Saudi Arabia have specific antibodies against MERS-CoV, suggesting the existence of a large number of asymptomatic or mild infections, which may act as an unrecognized source of infection.
      <xref ref-type="bibr" rid="bib22">
       <sup>
        22
       </sup>
      </xref>
      Similar high numbers of asymptomatic or minimally symptomatic infections have probably occurred during the SARS epidemic. Although the exact incidence of such asymptomatic infection remains unknown, a meta-analysis of SARS data showed overall seroprevalence rates of 0.1% for the general population and 0.23% for health care workers.
      <xref ref-type="bibr" rid="bib23">
       <sup>
        23
       </sup>
      </xref>
      It is therefore very likely that, when the dust has settled and serologic testing of populations exposed to SARS-CoV-2 is performed, we will realize than asymptomatic or subclinical cases of COVID-19 are much more common than clinical cases and may have played an important role in the spread of the disease.
     </p>
     <p id="p0055">
      SARS was a new human disease that first occurred in Southern China in the November 2002 and has apparently disappeared since 2003, but not before it had spread to 29 countries affecting 8098 people and resulting in 774 fatalities. Compared with SARS, COVID-19 appears to be much more widespread but less deadly. The CFR of SARS was much higher than that of COVID-19, about 10% compared with 2.3% for COVID-19.
      <xref ref-type="bibr" rid="bib16">
       <sup>
        16
       </sup>
      </xref>
      The overall transmissibility of SARS was relatively low, with a R
      <sub>
       0
      </sub>
      of around 3 (ie, 1 case would produce 3 secondary cases of disease in a susceptible community). This number was in large part determined by the much higher transmissibility in the hospital setting (R
      <sub>
       0
      </sub>
      = 4), however. In the community setting, R0 of SARS was much lower, and may have even been less than 1, after the initiation of transmission control measures.
      <xref ref-type="bibr" rid="bib24">
       <sup>
        24
       </sup>
      </xref>
     </p>
     <p id="p0060">
      The most common form of spread of the SARS-CoV-2 causing COVID-19 has been from human to human transmission in settings that frequently involve close and prolonged (15 minutes or more) interaction between infected and uninfected people, facilitating large droplet and contact transmission. After exposure to an infected individual, or less likely to a contaminated surface or fomite, the mean incubation period of COVID-19 is about 5 days, but can be much longer, up to 24 days. Nonetheless, 95% of patients who develop clinical disease do so within 12.5 days. The initial presentation is with fever (90%-96% of cases
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      ) and mild to severe respiratory symptoms including cough in 70%, dyspnea in 45%, and muscle soreness or fatigue in 40%.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Ten percent of patients or fewer have sore throat, headaches, or diarrhea.
      <xref ref-type="bibr" rid="bib25">
       <sup>
        25
       </sup>
      </xref>
      Imaging findings are usually those of pneumonia, with bilateral pulmonary infiltrates in 97% of cases
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Compared with other pneumonias, COVID-19 pneumonia is more likely to have a peripheral distribution, ground-glass or fine reticular opacities, and is less likely to have a central involvement, pleural effusion, or lymphadenopathy.
      <xref ref-type="bibr" rid="bib26">
       <sup>
        26
       </sup>
      </xref>
      Laboratory findings are nonspecific but usually include leukocytosis with lymphopenia, mildly increased liver enzymes, muscle enzymes, myoglobin, and lactate dehydrogenase and increase in acute phase reactants. Increased procalcitonin, severe lymphopenia, and elevated D-dimers were features that correlated with more severe disease. In severe cases, the disease may progress to respiratory, circulatory, and renal failure, and ultimately death due to multiorgan failure.
     </p>
     <p id="p0065">
      A meta-analysis of 50,466 hospitalized patients showed that 18% had severe disease and 15% developed acute respiratory distress syndrome.
      <xref ref-type="bibr" rid="bib15">
       <sup>
        15
       </sup>
      </xref>
      Among the cases reported to the World Health Organization (WHO), 3% were critical, 15% severe, and 82% were mild.
      <xref ref-type="bibr" rid="bib27">
       <sup>
        27
       </sup>
      </xref>
      This distribution of cases shows that COVID-19 is on average less severe than SARS, in which the majority of patients had moderate to severe disease, and 20% to 30% required intensive care including mechanical ventilation. In the COVID-19 outbreak in China, the duration of viral shedding ranged from 8 to 37 days. Survivors had a median duration of viral shedding of 20 days, but viral shedding continued until death in fatal cases.
      <xref ref-type="bibr" rid="bib28">
       <sup>
        28
       </sup>
      </xref>
     </p>
     <p id="p0070">
      Due to the respiratory tissue and cell tropism seen in early infection, the virus can be isolated from saliva, nasopharynx, and lower respiratory tract specimens. In advanced or severe cases, viral RNA can be found in the plasma of 15% of patients and may be found in feces, raising the possibility of fecal transmission. Because the receptor for SARS-CoV-2, ACE2, is also expressed on cardiac myocytes and vascular endothelial cells, the virus could, at least theoretically, directly involve the heart and vascular endothelium. This would explain the fulminant myocarditis that some patients develop clinically,
      <xref ref-type="bibr" rid="bib29">
       <sup>
        29
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib30">
       <sup>
        30
       </sup>
      </xref>
      or show myocardial interstitial mononuclear inflammatory infiltrates. To date, however, no studies have been performed on cardiac tissue to determine the presence of the virus. Involvement of endothelial cells may be implicated in the pathogenesis of the severe complications of the disease, including diffuse alveolar damage and disseminated intravascular coagulation.
     </p>
     <p id="p0075">
      Based on the limited evidence available to date, the pathology of COVID-19 is similar to that of SARS and MERS,
      <xref ref-type="bibr" rid="bib31">
       <sup>
        31
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib32">
       <sup>
        32
       </sup>
      </xref>
      which, in severe or fatal forms, show lung injury in varying stages of exudation and organization.
      <xref ref-type="bibr" rid="bib32">
       <sup>
        32
       </sup>
      </xref>
      These include acute fibrinous and organizing pneumonia, and diffuse alveolar damage, characterized by hyaline membrane formation, interstitial lymphocytic infiltrates, and desquamation of pneumocytes. In lung tissue, in situ hybridization and/or immunohistochemical stains demonstrated the presence of the virus in the cytoplasm of epithelial cells of the trachea (over 50% of ciliated cells), bronchi, and bronchioles, and in pneumocytes, both intact and degenerated, desquamated or forming syncytial giant cells.
      <xref ref-type="bibr" rid="bib33">
       <sup>
        33
       </sup>
      </xref>
      They were also present in the lymphocytes located in the septal infiltrates and within blood vessels. The SARS virus could also be demonstrated in circulating lymphocytes and less frequently in monocytes. At autopsy, the virus was also found in the epithelial cells of the intestinal mucosa and distal renal tubules, and the neurons of the brain.
      <xref ref-type="bibr" rid="bib33">
       <sup>
        33
       </sup>
      </xref>
     </p>
     <p id="p0080">
      Superimposed infections with bacterial (
      <italic>
       Pseudomonas aeruginosa, Staphylococcus aureus
      </italic>
      ), fungal (
      <italic>
       Aspergillus
      </italic>
      and
      <italic>
       Mucor
      </italic>
      species) and viral (cytomegalovirus) pathogens can occur as complications of severe lung disease.
      <xref ref-type="bibr" rid="bib32">
       <sup>
        32
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib34">
       <sup>
        34
       </sup>
      </xref>
      In some of these cases, especially those with associated bronchopneumonia, intra-alveolar neutrophils may predominate. Lymphoid organs may show lymphoid depletion and the liver may show microvesicular steatosis, while the gastrointestinal tract and kidneys show no specific pathologic changes.
      <xref ref-type="bibr" rid="bib35">
       <sup>
        35
       </sup>
      </xref>
     </p>
     <p id="p0085">
      The few reports documenting the findings of COVID-19 show that the pathology is dominated by pulmonary findings, including pulmonary edema and prominent proteinaceous exudates, vascular congestion, and intra-alveolar fibrinoid material and various degrees of organization (fibroblastic plugs) corresponding to acute pulmonary injury patterns. In addition, there may be reactive type II pneumocyte hyperplasia, and atypical enlarged pneumocytes with large nuclei, amphophilic granular cytoplasm, but no definite intranuclear or cytoplasmic viral inclusions were identified.
      <xref ref-type="bibr" rid="bib36">
       <sup>
        36
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib37">
       <sup>
        37
       </sup>
      </xref>
      The inflammatory infiltrate is predominantly lymphocytic without significant neutrophil participation.
      <xref ref-type="bibr" rid="bib38">
       <sup>
        38
       </sup>
      </xref>
      Immunohistochemistry for the Rp3 NP protein of SARS–CoV-2 showed staining of alveolar epithelial cells, including the damaged, desquamated cells present within alveolar spaces,
      <xref ref-type="bibr" rid="bib39">
       <sup>
        39
       </sup>
      </xref>
      but viral protein expression was only minimal in endothelial cells. This finding is similar to that seen in MERS, where immunohistochemistry with 4 antibodies against MERS-CoV showed the presence of the virus scattered in cytokeratin-staining pneumocytes and syncytial cells, but not in CD68-positive macrophages.
      <xref ref-type="bibr" rid="bib40">
       <sup>
        40
       </sup>
      </xref>
     </p>
    </sec>
    <sec id="sec2">
     <title>
      SARS-CoV-2 and the cytology laboratory
     </title>
     <p id="p0090">
      Our response to the COVID-19 pandemic can be regarded at the society level, hospital level, laboratory level, and the individual level. At the society level, local, state, and federal governments have instituted travel bans, and either governments or various organizations have introduced restrictions or cancelled larger gatherings, including sports events and cultural events (music, theater, cinema), and even political rallies. These measures are meant mostly as a mitigation strategy, to limit transmission, and to prevent the fast spread of the virus and “level the infection curve” to prevent overwhelming of the health care system.
     </p>
     <p id="p0095">
      At the level of hospitals and other health care institutions, decisions are made to prioritize the essential health care work and reduce elective outpatient visits and inpatient admissions for elective interventions or operations. These measures are meant both to decrease the risk of infection to patients with routine annual and preventive health visits and elective procedures, and to increase the available capacity of the hospitals in case of a large surge of infections.
      <xref ref-type="bibr" rid="bib41">
       <sup>
        41
       </sup>
      </xref>
     </p>
     <p id="p0100">
      The abovementioned hospital measures to limit activities that can be safely postponed will undoubtedly affect the cytology laboratory, which will receive fewer specimens. This gives the cytology laboratory an opportunity to re-evaluate their staffing needs and perhaps change the workflow. Measures may include working in shifts, and staggered meal breaks, to avoid contact between people, and having only the strictly necessary personnel in the laboratory. A paper from Singapore advises that laboratory personnel should record their temperature twice a day, to allow early identification of COVID-19, but in the current US context it is uncertain if this measure, and especially the ensuing measures, including viral testing, isolation, and quarantine measures, are feasible and practical. Clearly, any person having respiratory symptoms that could be caused by COVID-19 should not come to work and should instead consult their physician or health care professional. Emergency plans and contingency plans should be made for the possibility that a large proportion of the laboratory personnel has either fallen ill or is under quarantine. Communicating any changes or delays in service to the clinical service providers and departments is particularly important, to avoid overwhelming the laboratory with inquiries about test results.
     </p>
     <p id="p0105">
      The role of the cytology laboratory in a patient with known COVID-19 is limited. In analogy to the role of the cytology laboratory in SARS, it is mainly to rule out superimposed pulmonary infections in sputum and other respiratory specimens. The cytologic features seen in sputa are nonspecific and reflect the underlying acute pulmonary injury pattern. They consist of the presence of increased number of macrophages, forming loose macrophage aggregates. The macrophages may also show cytoplasmic changes, including the presence of foamy cytoplasm or larger cytoplasmic vacuoles or nuclear changes, including multinucleation and ground glass appearance of nuclei.
      <xref ref-type="bibr" rid="bib42">
       <sup>
        42
       </sup>
      </xref>
      Because bronchoalveolar lavage (BAL) fluid is sometimes obtained for viral identification
      <xref ref-type="bibr" rid="bib43">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      and is occasionally positive when nasopharyngeal and oropharyngeal swab samples are negative,
      <xref ref-type="bibr" rid="bib46">
       <sup>
        46
       </sup>
      </xref>
      an aliquot may also be sent to the cytology laboratory. However, the cytologic findings of BAL samples of patients with COVID-19 are not yet reported. In patients with MERS, cytological examination of BAL fluid reportedly showed high numbers of neutrophils and macrophages.
      <xref ref-type="bibr" rid="bib47">
       <sup>
        47
       </sup>
      </xref>
      Based on the histopathology of SARS, MERS, and COVID-19, BAL specimens may also show squamous metaplasia, and features of repair, together with the presence multinucleated cells and highly atypical alveolar type 2 pneumocytes showing cellular and nuclear enlargement, prominent nucleolim and chromatin clearing.
      <xref ref-type="bibr" rid="bib34">
       <sup>
        34
       </sup>
      </xref>
      These cytomorphologic features may represent a potential diagnostic pitfall.
     </p>
    </sec>
    <sec id="sec3">
     <title>
      Laboratory measures
     </title>
     <p id="p0110">
      Given the extraordinary fast spread of the disease and the pace of change in the information about it and guidelines on how to deal with various aspects of fighting it, one can only give general suggestions for the cytology laboratory's response (see
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). The recommendations are similar to those given for general and histopathology laboratories,
      <xref ref-type="bibr" rid="bib48">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="bib49">
       49
      </xref>
      ,
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      but also include the situations in which cytology laboratory personnel is involved either in the care of patients potentially infected with SARS-CoV-2 during FNA procedures or rapid-onsite evaluation of aspiration or core biopsies or in the preparation of fresh specimens from such patients.
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Laboratory measures.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td>
           <list id="ulist0010" list-type="simple">
            <list-item id="u0010">
             <label>
              •
             </label>
             <p id="p0175">
              Review your procedures and reduce or eliminate steps that could result in aerosol formation or creation of droplets.
             </p>
            </list-item>
            <list-item id="u0015">
             <label>
              •
             </label>
             <p id="p0180">
              Review the indications for rapid onside evaluations (ROSE), and reassess their need after discussions with the provides requesting these services, to eliminate unnecessary exposure.
             </p>
            </list-item>
            <list-item id="u0020">
             <label>
              •
             </label>
             <p id="p0185">
              Establish a chain of command, emergency plan, and contingency plan.
             </p>
            </list-item>
            <list-item id="u0025">
             <label>
              •
             </label>
             <p id="p0190">
              Reassess the situation weekly or biweekly and make any changes necessary.
             </p>
            </list-item>
            <list-item id="u0030">
             <label>
              •
             </label>
             <p id="p0195">
              Implement measures to reduce crowding: review staffing and realign staffing needs with the workload; consider working in shifts to reduce overlap.
             </p>
            </list-item>
            <list-item id="u0035">
             <label>
              •
             </label>
             <p id="p0200">
              Follow CDC/WHO guidelines for routine specimen processing in accordance to biosafety level 2 guidelines.
             </p>
            </list-item>
            <list-item id="u0040">
             <label>
              •
             </label>
             <p id="p0205">
              Process all specimens that have steps that could result in aerosols or droplets (including making smears, staining them and air-drying or heat fixing them), in a class II biosafety cabinet (BSC).
             </p>
            </list-item>
            <list-item id="u0045">
             <label>
              •
             </label>
             <p id="p0210">
              Follow any additional or updated CDC guidelines.
             </p>
            </list-item>
            <list-item id="u0050">
             <label>
              •
             </label>
             <p id="p0215">
              Keep informed about the latest developments regarding the COVID-19 pandemic and inform the staff about any new scientific knowledge; dispel misconceptions.
             </p>
            </list-item>
            <list-item id="u0055">
             <label>
              •
             </label>
             <p id="p0220">
              Keep informed about the newest hospital policies and procedures and inform the staff of any changes.
             </p>
            </list-item>
            <list-item id="u0060">
             <label>
              •
             </label>
             <p id="p0225">
              Keep open communication channels with colleagues and staff and provide a virtual community through daily “fireside chats”, including people working from home.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Don'ts
           <list id="ulist0015" list-type="simple">
            <list-item id="u0065">
             <label>
              •
             </label>
             <p id="p0230">
              Don't cause unnecessary concerns or panic, but be frank about the risks.
             </p>
            </list-item>
            <list-item id="u0070">
             <label>
              •
             </label>
             <p id="p0235">
              Don't disseminate or endorse rumors or information not coming from a reputable source (CDC, FDA, WHO, peer-reviewed publication).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="p0115">
      Although the situation is fluid and guidelines can change, making it imperative to keep up to date with high quality information and guidance from Web sites like
      <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://www.coronavirus.gov">
       https://www.coronavirus.gov
      </ext-link>
      or
      <ext-link ext-link-type="uri" id="intref0015" xlink:href="https://www.nih.gov/coronavirus">
       https://www.nih.gov/coronavirus
      </ext-link>
      , as the pandemic unfolds, I believe that some general principles can be applied.
      <list id="olist0010" list-type="simple">
       <list-item id="o0010">
        <label>
         1.
        </label>
        <p id="p0120">
         Use universal precautions. Although it is important to know which cytology specimens can contain viable and therefore transmissible virus, it is important to emphasize the use of universal standard precautions when dealing with any cytology specimen. From the experience with SARS we can extrapolate that SARS-CoV-2 can be present in fecal and urine samples, in addition to peripheral blood and respiratory samples. SARS-CoV-2 may be present in samples in patients without known COVID-19, in undiagnosed patients, in pre-symptomatic patients, in patients with asymptomatic or minimally symptomatic infections, and in convalescent patients, who may still be shedding the virus. From the available data it is very likely that many, if not most, infections occur through contact with individuals who either don't have the disease or were not diagnosed with COVID-19. In addition, as with most specimens, the clinical diagnosis may not be indicated in the requisition. For all these reasons, all fresh specimens should be considered potentially infectious.
        </p>
       </list-item>
       <list-item id="o0015">
        <label>
         2.
        </label>
        <p id="p0125">
         Special precautions should be taken in handling specimens for which the preparation involves steps that can lead to aerosol formation. All technical procedures should be performed in a way that minimizes the generation of aerosols and droplets. Preparatory steps that may generate aerosols or droplets include expelling aspirates from the needle or syringe; smearing the aspirated material; and potentially, air-drying or heat drying the smears, in which pathologists, trainees, or cytotechnologists may be involved during rapid on site evaluation (ROSE). Air-drying or heat drying of smears is best performed under Class II Biosafety Cabinets (BSC).
         <xref ref-type="bibr" rid="bib51">
          <sup>
           51
          </sup>
         </xref>
         Agitating the smears by hand or using hand-held fans to speed up the drying of smears should be avoided. ROSE is an important measure to ensure the adequacy of specimens. However, during an epidemic of a virus with respiratory-transmission, like SARS-CoV-2, clinical judgement should be used to determine whether ROSE is absolutely necessary for the success of the biopsy procedure.
        </p>
       </list-item>
      </list>
     </p>
     <p id="p0130">
      If ROSE is performed, it should be performed with appropriate personal protective equipment (PPE) including gloves, laboratory coat/gown, and goggles or face shields for eye protection and respiratory protection using a properly fit-tested filter respirator (N-95 or higher level) or a powered air-purifying respirator. The anticipated shortage of facemasks and filter respirators
      <xref ref-type="bibr" rid="bib52">
       <sup>
        52
       </sup>
      </xref>
      makes a very selective use of this procedure important, as it is vital that we reserve this equipment for essential patient encounters and procedures. For similar reasons, it may be safer to suspend the activity of a pathologist-run fine-needle aspiration (FNA) clinic for the duration of the pandemic, and consider performing FNAs only on a case-by-case basis, weighing the risks and benefits of the procedure for each patient.
     </p>
     <p id="p0135">
      Cytopreparatory steps performed by technicians that can lead to aerosol/droplet formation include opening of containers and removing tube caps, blending, vigorous shaking or mixing, vortexing, pipetting, aliquoting, diluting, or centrifugation of fluids and discarding the supernatant. All these cytopreparatory steps should be performed in class II BSC, providing protection for the user, the sample, and the environment. The use of PPE, including gloves, gown, and face shield, are also recommended for these procedures. Splash shields and sealed centrifuge rotors or sample cups are recommended for centrifugation; rotors and cups should be loaded and unloaded in a BSC.
      <xref ref-type="bibr" rid="bib51">
       <sup>
        51
       </sup>
      </xref>
      <list id="olist0015" list-type="simple">
       <list-item id="o0020">
        <label>
         3.
        </label>
        <p id="p0140">
         The virus is inactivated by formalin and gamma irradiation. Therefore, according to the Centers of Disease Control and Prevention (CDC) guidelines,
         <xref ref-type="bibr" rid="bib51">
          <sup>
           51
          </sup>
         </xref>
         cytology laboratory activities, such as the pathologic examination and processing of formalin-fixed or otherwise inactivated tissues (cell block preparations), and the routine staining and microscopic analysis of fixed smears are assigned biosafety level 2. This is the typical biosafety level of all pathology laboratories and is assigned when working with agents associated with human diseases that pose a moderate health hazard or when working with any human-derived sample, including blood, body fluids, or tissue, in which the presence of an infectious agent is unknown. Most cytology specimens are fixed in either formalin or alcohol solutions with over 70% alcohol, which are considered effective to destroy this virus. It is not known whether fixatives using much weaker alcohol solutions, such as PreservCyt and CytoLyt (Hologic, Inc, Marlborough, MA) and SurePath (BD, Franklin Lakes, NJ) are adequately inactivating the virus. Therefore additional precautions, like the use of gloves, may be indicated while handling and interpreting cytologic preparations processed with these fixatives. Some pathologists may prefer using gloves for all their slides, since glass slides are touched by multiple hands until they reach the pathologist's desk, and cannot be easily decontaminated. Although dipping the slides in 95% alcohol (or similar) for a couple of minutes would inactivate the virus, it would also erase the marks (“dots”) on the slides. Other surface disinfectants, especially ones with short contact times, as mentioned later in this paper, can be tried to determine the practicality of their use on cytology slides.
        </p>
       </list-item>
       <list-item id="o0025">
        <label>
         4.
        </label>
        <p id="p0145">
         General safe laboratory practices, especially procedures that are basic to good microbiological practices and procedures, should be followed as recommended by the WHO
         <xref ref-type="bibr" rid="bib53">
          <sup>
           53
          </sup>
         </xref>
         and the CDC.
         <xref ref-type="bibr" rid="bib51">
          <sup>
           51
          </sup>
         </xref>
         <sup>
          ,
         </sup>
         <xref ref-type="bibr" rid="bib54">
          <sup>
           54
          </sup>
         </xref>
         This includes training all personnel in the use of the protective equipment, limiting access to the laboratory, frequent handwashing, and wearing PPE. Handwashing should be performed thoroughly with soap and water for at least 20 seconds. Alternatively, an alcohol-based hand sanitizer containing at least 62% alcohol can be used, if soap and water are not available. The use of PPE includes wearing gloves for all procedures, wearing a buttoned lab coat or gown, eye protection and, when needed, wearing a mask. Touching mucosal membranes of the eyes, nose, and mouth should be avoided. In addition, because the virus can remain viable on surfaces (especially plastic and stainless steel surfaces) for up to 72 hours,
         <xref ref-type="bibr" rid="bib55">
          <sup>
           55
          </sup>
         </xref>
         it is recommended to decontaminate all work surfaces multiple times per day, using Environmental Protection Agency–approved disinfectant solutions, wipes, towelettes, or sprays. In addition to benches, this includes decontamination of computer keyboards, phones, and frequently touched areas of microscopes. The chemical substances involved include, among others, ethanol (minimum concentration of 62%-71%), 0.5% hydrogen peroxide, quaternary ammonium, sodium hypochlorite (0.1%), and a variety of acid solutions in various concentrations. These substances should be used with the manufacturer-recommended disinfection directions and preparations for human coronavirus and the recommended contact time (ie, the time the surface remains wet) which may range from 30 seconds to 10 minutes.
         <xref ref-type="bibr" rid="bib56">
          <sup>
           56
          </sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="sec4">
     <title>
      Educational measures in academic institutions
     </title>
     <p id="p0150">
      Academic institutions should temporarily suspend, limit, or move online activities involving over 10 people, such as lectures, Grand Rounds presentations, journal clubs, and so forth (see
      <xref ref-type="table" rid="tbl2">
       Table 2
      </xref>
      ). Residents and fellows can be taught by using online lectures and unknown sessions using digitized slides and by facilitating and encouraging self-directed learning. Sign-out with trainees could be performed on a digital platform such as Zoom (Zoom Video Communications, Inc, San Jose, CA), although it might significantly slow the sign-out. Finally, if allowed by existing rules and regulations, after prior validation, pathologists can sign out a portion of cases on virtual slides (whole slide images) in institutions equipped with US Food and Drug Administration–approved high capacity whole slide scanners. Trainees could also be incorporated into the workflow to preview the whole slide images. It is obvious that most if not all of us have little experience with online teaching and the use of videoconferencing technologies for teaching pathology. Therefore, during these unprecedented times, we have to constantly seek to improve the delivery of online training by keeping in touch with colleagues using similar technologies and adopting or adapting the strategies that work best. Seeking feedback from trainees is essential, not only to assess the impact of the online teaching, but also to get advice on the use of technologies that the trainees may be more familiar with.
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Educational measures: dos and don'ts for teaching/training residents and fellows.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td>
           Do
           <list id="ulist0020" list-type="simple">
            <list-item id="u0075">
             <label>
              •
             </label>
             <p id="p0240">
              Cancel educational session involving over 10 people, such as lectures, Grand Rounds presentations, journal clubs, etc.
             </p>
            </list-item>
            <list-item id="u0080">
             <label>
              •
             </label>
             <p id="p0245">
              Limit face to face activities such as lectures or sign-out session in a multiheaded microscope.
             </p>
            </list-item>
            <list-item id="u0085">
             <label>
              •
             </label>
             <p id="p0250">
              Consider moving to sequential viewing of slides rather than “double-head” scoping or review.
             </p>
            </list-item>
            <list-item id="u0090">
             <label>
              •
             </label>
             <p id="p0255">
              Move online learning such as using online lectures and unknown sessions using digitized slides.
             </p>
            </list-item>
            <list-item id="u0095">
             <label>
              •
             </label>
             <p id="p0260">
              Make sure that trainees have access to the technologies used, even from home.
             </p>
            </list-item>
            <list-item id="u0100">
             <label>
              •
             </label>
             <p id="p0265">
              Encourage and facilitate self-directed learning.
             </p>
            </list-item>
            <list-item id="u0105">
             <label>
              •
             </label>
             <p id="p0270">
              Identify “teachable moments” in your daily work and share them with the trainees.
             </p>
            </list-item>
            <list-item id="u0110">
             <label>
              •
             </label>
             <p id="p0275">
              Give brief “teaching points” summaries for more unusual or difficult cases.
             </p>
            </list-item>
            <list-item id="u0115">
             <label>
              •
             </label>
             <p id="p0280">
              Give mini-assignments; consider giving mini-quizzes.
             </p>
            </list-item>
            <list-item id="u0120">
             <label>
              •
             </label>
             <p id="p0285">
              Consider setting up discussion groups (“fireside chats”) to maintain a sense of community.
             </p>
            </list-item>
            <list-item id="u0125">
             <label>
              •
             </label>
             <p id="p0290">
              Encourage questions and be accessible to provide answers.
             </p>
            </list-item>
            <list-item id="u0130">
             <label>
              •
             </label>
             <p id="p0295">
              Give regular and meaningful feedback; be as specific as possible.
             </p>
            </list-item>
            <list-item id="u0135">
             <label>
              •
             </label>
             <p id="p0300">
              Ask for informal feedback and try to make any changes suggested.
             </p>
            </list-item>
            <list-item id="u0140">
             <label>
              •
             </label>
             <p id="p0305">
              Use the best tools or platforms available for online teaching, reevaluating them frequently.
             </p>
            </list-item>
            <list-item id="u0145">
             <label>
              •
             </label>
             <p id="p0310">
              Keep up with developments in online teaching and adopt best practices for distance learning.
             </p>
            </list-item>
            <list-item id="u0150">
             <label>
              •
             </label>
             <p id="p0315">
              Keep in touch with your colleagues and adopt the techniques that work.
             </p>
            </list-item>
            <list-item id="u0155">
             <label>
              •
             </label>
             <p id="p0320">
              Consider providing an online “office hour”, and to be available to answer trainees questions during this time.
             </p>
            </list-item>
            <list-item id="u0160">
             <label>
              •
             </label>
             <p id="p0325">
              Check on the mental and physical well-being of your trainees.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Don't
           <list id="ulist0025" list-type="simple">
            <list-item id="u0165">
             <label>
              •
             </label>
             <p id="p0330">
              Don't abandon teaching during this undetermined period of time.
             </p>
            </list-item>
            <list-item id="u0170">
             <label>
              •
             </label>
             <p id="p0335">
              Don't forget about trainees working from home.
             </p>
            </list-item>
            <list-item id="u0175">
             <label>
              •
             </label>
             <p id="p0340">
              Don't use any protected patient information during teaching unless using an institution-approved VPN or a HIPAA compliant platform.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="sec5">
     <title>
      Communication
     </title>
     <p id="p0155">
      It is important to address the fact that this epidemic will unavoidably generate stress, fear, and anxiety among all laboratory personnel, trainees and pathologists.
      <xref ref-type="bibr" rid="bib57">
       <sup>
        57
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib58">
       <sup>
        58
       </sup>
      </xref>
      Psychologic stress may be experienced differently by different people, and may be modulated by personal factors like age, sex, health status, baseline anxiety level, and risk perception. More severe psychologic distress may be followed by increased levels of posttraumatic stress symptomatology.
      <xref ref-type="bibr" rid="bib59">
       <sup>
        59
       </sup>
      </xref>
      Psychological distress may be related to increased work load due to coworker absenteeism; lack of socialization with friends and colleagues; lack of recreational activities due to the closure of gyms, restaurants, movie theaters, and other recreational avenues; and increased family stress and parenting issues due to children being at home as a result of school closings. It may also relate to having a friend or family member affected by the disease. All health care workers may also feel anxious and stressed because of the fear of contracting the disease, fear of transmitting the disease to family members, or financial fears related to the changes implemented during this period. During this period, laboratory directors and other pathologists should be prepared to provide up-to-date information regarding the most recent developments in our knowledge about the disease and candid information regarding all aspects of the personnel's job. Although such information may also be available from a variety of sources, including the CDC and the health care center's Web site, in order to alleviate the fear and anxiety, it is important to have clear channels of communication, transmit the information in person, and respond to any questions that may arise. Providing emotional support and an opportunity to discuss any personal and family concerns is crucial during these times. It is very important to communicate effectively the risk to laboratory personnel and trainees, without overly reassuring them, and acknowledging that much is unknown about this infection. It is equally important to communicate any changes in policy or schedule as soon as possible.
      <xref ref-type="bibr" rid="bib60">
       <sup>
        60
       </sup>
      </xref>
      If physical meetings are not possible because of the social distancing measures implemented, Web-based conferences using a variety of platforms can be used. This can include SMS text messages, e-mails, using both institutional and personal e-mail, if needed, small group discussions, and Web sites, in addition to online discussion through apps such as Skype or Microsoft Teams (Microsoft Redmond, WA), FaceTime (Apple Inc, Cupertino, CA), GoToMeeting (LogMeIn, Inc, Boston, MA), Zoom (Zoom Video Communications, Inc), Webex (Cisco Webex, Milpitas, CA), and so on.
     </p>
     <p id="p0160">
      It is crucial to ensure efficient and redundant channels of communication, including lower-tech solutions to ensure the access of health care workers with all levels of technological skills and savviness. Remember that it may be difficult to access to the organization's intranet and e-mail from home, and access to high-speed Internet may be an issue, too. When using any of these means of communication that are not secure or HIPAA compliant, use the same basic principles governing the use of social media
      <xref ref-type="bibr" rid="bib61">
       <sup>
        61
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib62">
       <sup>
        62
       </sup>
      </xref>
      , ie, do not use any specific patient information or data about the number or severity of patients treated at the health care center.
     </p>
     <p id="p0165">
      Finally, in addition to these measures meant to prevent infection in the workplace, all pathologists, trainees, cytotechnologists and laboratory personnel should also apply commonsense measures to prevent getting infected outside the laboratory environment. This may include, in addition to personal hygiene measures (handwashing, avoiding touching eyes, nose and mouth), “social distancing”, avoiding close contact with other people, and, if possible, avoiding public transportation, and avoiding crowds and gatherings of over 10 people, avoiding contact with people who might be sick (ie, people having fever and respiratory symptoms).
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           N.P.
          </given-names>
         </name>
         <name>
          <surname>
           Mueller
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic
        </article-title>
        <source>
         Bull Hist Med
        </source>
        <volume>
         76
        </volume>
        <year>
         2002
        </year>
        <fpage>
         105
        </fpage>
        <lpage>
         115
        </lpage>
        <pub-id pub-id-type="pmid">
         11875246
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taubenberger
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Morens
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         1918 Influenza: the mother of all pandemics
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         15
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         16494711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bootsma
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of public health measures on the 1918 influenza pandemic in U.S. cities
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         104
        </volume>
        <year>
         2007
        </year>
        <fpage>
         7588
        </fpage>
        <lpage>
         7593
        </lpage>
        <pub-id pub-id-type="pmid">
         17416677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Markel
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lipman
          </surname>
          <given-names>
           H.B.
          </given-names>
         </name>
         <name>
          <surname>
           Navarro
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         298
        </volume>
        <year>
         2007
        </year>
        <fpage>
         644
        </fpage>
        <lpage>
         654
        </lpage>
        <pub-id pub-id-type="pmid">
         17684187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mizumoto
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating risk for death from 2019 novel coronavirus disease, China, January-February 2020
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China
        </article-title>
        <source>
         J Autoimmun
        </source>
        <year>
         2020
        </year>
        <fpage>
         102434
        </fpage>
        <pub-id pub-id-type="pmid">
         32143990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Team C-NIRS
         </collab>
        </person-group>
        <article-title>
         COVID-19, Australia: epidemiology report 6 (reporting week ending 19:00 AEDT 7 March 2020)
        </article-title>
        <source>
         Commun Dis Intell (2018)
        </source>
        <volume>
         44
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Porcheddu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Serra
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kelvin
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kelvin
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Rubino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China
        </article-title>
        <source>
         J Infect Dev Ctries
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         32146445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kvalsvig
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Battegay
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuehl
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Tschudin-Sutter
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hirsch
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Widmer
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
         <name>
          <surname>
           Neher
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         2019-novel coronavirus (2019-nCoV): estimating the case fatality rate—a word of caution
        </article-title>
        <source>
         Swiss Med Wkly
        </source>
        <volume>
         150
        </volume>
        <year>
         2020
        </year>
        <fpage>
         w20203
        </fpage>
        <pub-id pub-id-type="pmid">
         32031234
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The rate of underascertainment of novel coronavirus (2019-ncov) infection: estimation using Japanese passengers data on evacuation flights
        </article-title>
        <source>
         J Clin Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taubenberger
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Morens
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The 1918 influenza pandemic and its legacy
        </article-title>
        <source>
         Cold Spring Harb Perspect Med
        </source>
        <year>
         2019
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bradley
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Bryan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella
        </article-title>
        <source>
         Semin Diagn Pathol
        </source>
        <volume>
         36
        </volume>
        <year>
         2019
        </year>
        <fpage>
         152
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="pmid">
         31054790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dicke
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Waiting for the flu: cognitive inertia and the Spanish influenza pandemic of 1918-19
        </article-title>
        <source>
         J Hist Med Allied Sci
        </source>
        <volume>
         70
        </volume>
        <year>
         2015
        </year>
        <fpage>
         195
        </fpage>
        <lpage>
         217
        </lpage>
        <pub-id pub-id-type="pmid">
         24957069
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Qie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Xi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 50 466 hospitalized patients with 2019-nCoV infection
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prompetchara
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Ketloy
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Palaga
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic
        </article-title>
        <source>
         Asian Pac J Allergy Immunol
        </source>
        <volume>
         38
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         32105090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         270
        </fpage>
        <lpage>
         273
        </lpage>
        <pub-id pub-id-type="pmid">
         32015507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sayed
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Malek
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Abushahba
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroprevalence of Middle East respiratory syndrome corona virus in dromedaries and their traders in upper Egypt
        </article-title>
        <source>
         J Infect Dev Ctries
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         191
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         32146454
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         369
        </volume>
        <year>
         2013
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abbad
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Anga
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         24
        </volume>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Degnah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Amri
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011-2016
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        <volume>
         134
        </volume>
        <year>
         2006
        </year>
        <fpage>
         211
        </fpage>
        <lpage>
         221
        </lpage>
        <pub-id pub-id-type="pmid">
         16490123
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Why SARS will not return: a polemic
        </article-title>
        <source>
         CMAJ
        </source>
        <volume>
         170
        </volume>
        <year>
         2004
        </year>
        <fpage>
         68
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         14707224
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Cardona-Ospina
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez-Ocampo
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         101623
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           H.X.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <fpage>
         200823
        </fpage>
        <pub-id pub-id-type="pmid">
         32155105
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vetter
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19: a puzzle with many missing pieces
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         368
        </volume>
        <year>
         2020
        </year>
        <fpage>
         m627
        </fpage>
        <pub-id pub-id-type="pmid">
         32075791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1054
        </fpage>
        <lpage>
         1062
        </lpage>
        <pub-id pub-id-type="pmid">
         32171076
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruan
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 and the cardiovascular system
        </article-title>
        <source>
         Nat Rev Cardiol
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alsaad
          </surname>
          <given-names>
           K.O.
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al Balwi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study
        </article-title>
        <source>
         Histopathology
        </source>
        <volume>
         72
        </volume>
        <year>
         2018
        </year>
        <fpage>
         516
        </fpage>
        <lpage>
         524
        </lpage>
        <pub-id pub-id-type="pmid">
         28858401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chamberlain
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Asa
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Butany
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pulmonary pathology of severe acute respiratory syndrome in Toronto
        </article-title>
        <source>
         Mod Pathol
        </source>
        <volume>
         18
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="pmid">
         15272286
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple organ infection and the pathogenesis of SARS
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         202
        </volume>
        <year>
         2005
        </year>
        <fpage>
         415
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="pmid">
         16043521
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Franks
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore
        </article-title>
        <source>
         Hum Pathol
        </source>
        <volume>
         34
        </volume>
        <year>
         2003
        </year>
        <fpage>
         743
        </fpage>
        <lpage>
         748
        </lpage>
        <pub-id pub-id-type="pmid">
         14506633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsiao
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           M.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chien
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinicopathology of severe acute respiratory syndrome: an autopsy case report
        </article-title>
        <source>
         J Formos Med Assoc
        </source>
        <volume>
         103
        </volume>
        <year>
         2004
        </year>
        <fpage>
         787
        </fpage>
        <lpage>
         792
        </lpage>
        <pub-id pub-id-type="pmid">
         15490031
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathological findings of COVID-19 associated with acute respiratory distress syndrome
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <volume>
         8
        </volume>
        <year>
         2020
        </year>
        <fpage>
         420
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="pmid">
         32085846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Z.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [A pathological report of three COVID-19 cases by minimally invasive autopsies]
        </article-title>
        <source>
         Zhonghua Bing Li Xue Za Zhi
        </source>
        <volume>
         49
        </volume>
        <year>
         2020
        </year>
        <fpage>
         E009
        </fpage>
        <pub-id pub-id-type="pmid">
         32172546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer
        </article-title>
        <source>
         J Thorac Oncol
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Keating
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014
        </article-title>
        <source>
         Am J Pathol
        </source>
        <volume>
         186
        </volume>
        <year>
         2016
        </year>
        <fpage>
         652
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Interim guidance for healthcare facilities: preparing for community transmission of COVID-19 in the United States
        </article-title>
        <comment>
         Available at:
        </comment>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/guidance-hcf.html">
         https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/guidance-hcf.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sputum cytology of patients with severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         J Clin Pathol
        </source>
        <volume>
         57
        </volume>
        <year>
         2004
        </year>
        <fpage>
         256
        </fpage>
        <lpage>
         259
        </lpage>
        <pub-id pub-id-type="pmid">
         14990595
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ojcius
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China
        </article-title>
        <source>
         Microbes Infect
        </source>
        <volume>
         22
        </volume>
        <year>
         2020
        </year>
        <fpage>
         74
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         32017984
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Irwin
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emergence of SARS-like coronavirus poses new challenge in China
        </article-title>
        <source>
         J Infect
        </source>
        <volume>
         80
        </volume>
        <year>
         2020
        </year>
        <fpage>
         350
        </fpage>
        <lpage>
         371
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Broberg
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Winichakoon
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chaiwarith
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Liwsrisakun
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Negative nasopharyngeal and oropharyngeal swab does not rule out COVID-19
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         209
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1331
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwen
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Stiles
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Pentella
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety considerations in the laboratory testing of specimens suspected or known to contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Am J Clin Pathol
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Henwood
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus disinfection in histopathology
        </article-title>
        <source>
         J Histotechnol
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Saw
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore
        </article-title>
        <source>
         J Clin Pathol
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sref51" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Laboratory biosafety guidelines for handling and processing specimens associated with SARS-CoV
        </article-title>
        <comment>
         Available at:
        </comment>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.cdc.gov/sars/guidance/f-lab/app5.html">
         https://www.cdc.gov/sars/guidance/f-lab/app5.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sref52" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Coronavirus disease 2019 (COVID-19). Facemasks
        </article-title>
        <comment>
         Available at:
        </comment>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sref53" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV). Interim guidance
        </article-title>
        <comment>
         Available at:
        </comment>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.who.int/docs/default-source/coronaviruse/laboratory-biosafety-novel-coronavirus-version-1-1.pdf?sfvrsn=912a9847_2">
         https://www.who.int/docs/default-source/coronaviruse/laboratory-biosafety-novel-coronavirus-version-1-1.pdf?sfvrsn=912a9847_2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sref54" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          U.S. Department of Health and Human Services
         </collab>
        </person-group>
        <article-title>
         Biosafety in microbiological and biomedical laboratories. 5th ed.
        </article-title>
        <comment>
         HHS Publication No. (CDC) 21-1112. Available at:
        </comment>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF">
         https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sref56" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          United States Environmental Protection Agency
         </collab>
        </person-group>
        <article-title>
         List N: Disinfectants for use against SARS-CoV-2
        </article-title>
        <comment>
         Available at:
        </comment>
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2">
         https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sref57" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alsubaie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hani Temsah
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Eyadhy
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus epidemic impact on healthcare workers' risk perceptions, work and personal lives
        </article-title>
        <source>
         J Infect Dev Ctries
        </source>
        <volume>
         13
        </volume>
        <year>
         2019
        </year>
        <fpage>
         920
        </fpage>
        <lpage>
         926
        </lpage>
        <pub-id pub-id-type="pmid">
         32084023
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bukhari
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Temsah
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Aleyadhy
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak perceptions of risk and stress evaluation in nurses
        </article-title>
        <source>
         J Infect Dev Ctries
        </source>
        <volume>
         10
        </volume>
        <year>
         2016
        </year>
        <fpage>
         845
        </fpage>
        <lpage>
         850
        </lpage>
        <pub-id pub-id-type="pmid">
         27580330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Styra
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Hawryluck
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kasapinovic
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fones
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gold
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact on health care workers employed in high-risk areas during the Toronto SARS outbreak
        </article-title>
        <source>
         J Psychosom Res
        </source>
        <volume>
         64
        </volume>
        <year>
         2008
        </year>
        <fpage>
         177
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="pmid">
         18222131
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rambaldini
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rath
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of severe acute respiratory syndrome on medical house staff: a qualitative study
        </article-title>
        <source>
         J Gen Intern Med
        </source>
        <volume>
         20
        </volume>
        <year>
         2005
        </year>
        <fpage>
         381
        </fpage>
        <lpage>
         385
        </lpage>
        <pub-id pub-id-type="pmid">
         15963157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sref61" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crane
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gardner
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology image-sharing on social media: recommendations for protecting privacy while motivating education
        </article-title>
        <source>
         AMA J Ethics
        </source>
        <volume>
         18
        </volume>
        <year>
         2016
        </year>
        <fpage>
         817
        </fpage>
        <lpage>
         825
        </lpage>
        <pub-id pub-id-type="pmid">
         27550566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sref62" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gardner
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Keep calm and tweet on: legal and ethical considerations for pathologists using social media
        </article-title>
        <source>
         Arch Pathol Lab Med
        </source>
        <volume>
         143
        </volume>
        <year>
         2019
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         30132683
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0010">
      <title>
       Acknowledgments
      </title>
      <p>
       The author would like to thank Güliz A. Barkan, MD, and Eva M. Wojcik, MD (Loyola University Medical Center), and J. Carlos Manivel, MD (Minneapolis VA Health Care System), for their helpful advice, insightful comments. and suggestions.
      </p>
     </ack>
     <fn-group>
      <fn id="d32e633">
       <p id="ntpara0010">
        This work was performed without specific funding. The author has no financial interest in any of the companies mentioned in the paper.
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="editorial" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Can J Anaesth
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Can J Anaesth
      </journal-id>
      <journal-title-group>
       <journal-title>
        Canadian Journal of Anaesthesia
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0832-610X
      </issn>
      <issn pub-type="epub">
       1496-8975
      </issn>
      <publisher>
       <publisher-name>
        Springer International Publishing
       </publisher-name>
       <publisher-loc>
        Cham
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7155950
      </article-id>
      <article-id pub-id-type="publisher-id">
       1651
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s12630-020-01651-2
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Editorials
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Social distancing: implications for the operating room in the face of COVID-19
       </article-title>
       <trans-title-group>
        <trans-title xml:lang="fr">
         Implications de la distanciation sociale en salle d’opération face à la COVID-19
        </trans-title>
       </trans-title-group>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Prin
         </surname>
         <given-names>
          Meghan
         </given-names>
        </name>
        <degrees>
         MD, MS
        </degrees>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0003-2028-4664
        </contrib-id>
        <name>
         <surname>
          Bartels
         </surname>
         <given-names>
          Karsten
         </given-names>
        </name>
        <degrees>
         MD, PhD
        </degrees>
        <address>
         <email>
          karsten.bartels@ucdenver.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.430503.1
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 0703 675X
         </institution-id>
         <institution>
          Department of Anesthesiology,
         </institution>
         <institution>
          University of Colorado, School of Medicine,
         </institution>
        </institution-wrap>
        Aurora, CO USA
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.430503.1
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 0703 675X
         </institution-id>
         <institution>
          Department of Surgery,
         </institution>
         <institution>
          University of Colorado, School of Medicine,
         </institution>
        </institution-wrap>
        University of Colorado Anschutz Medical Campus, 12401 E. 17th Ave., Leprino Office Building, 7th Floor, MS B-113, Aurora, CO 80045 USA
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        14
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <fpage>
       1
      </fpage>
      <lpage>
       9
      </lpage>
      <history>
       <date date-type="received">
        <day>
         21
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         26
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         26
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © Canadian Anesthesiologists' Society 2020
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <funding-group>
       <award-group>
        <funding-source>
         <institution-wrap>
          <institution-id institution-id-type="FundRef">
           http://dx.doi.org/10.13039/100000026
          </institution-id>
          <institution>
           National Institute on Drug Abuse
          </institution>
         </institution-wrap>
        </funding-source>
        <award-id>
         K23DA040923
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Bartels
          </surname>
          <given-names>
           Karsten
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
    <p id="Par1">
     The novel coronavirus (SARS-CoV-2) causing the disease COVID-19 originated in Wuhan, China and has been declared a pandemic by the World Health Organization.
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     As of 25 March 2020, a total of 454,398 patients have been infected worldwide and 20,550 patients have died of the disease.
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     The rapid global expansion of COVID-19 is due in part to its biology—i.e., the absence of immunity in the population, its attack rate, its ability to survive on surfaces and in droplets, and its incubation period, which allows for a high prevalence of subclinical yet contagious cases. Nevertheless, the pattern, speed, and duration of this pandemic also reflects the weaknesses in our global healthcare systems’ infrastructure. A profound weakness unveiled by this pandemic is the vulnerability of front-line clinical healthcare providers. The Chinese National Health Commission acknowledged in February 2020 that at least 3.8% of the total infections in mainland China occurred in medical workers.
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     This proportion is likely to rise as the epidemiology of the COVID-19 pandemic is studied further, particularly as healthcare worker infections are common during outbreaks. Healthcare-related spread of similar diseases has previously been reported. For example, among 2,223 laboratory-confirmed cases of Middle East Respiratory Syndrome coronavirus, 19% were among healthcare workers.
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     In the 2003 Severe Acute Respiratory Syndrome (SARS) outbreak in Toronto, 44% of infections were among healthcare workers.
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     Studies of 22 outbreaks of Ebola virus and Marburg virus show healthcare worker infection rates ranging from 2-100% of Ebola cases and 5-50% of Marburg virus cases.
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
    </p>
    <p id="Par2">
     Infected clinicians represent a “triple threat” to the slowing of the present COVID-19 pandemic—i.e., they become patients within an already overwhelmed healthcare system; they reduce the number of available healthcare providers; and they serve as vectors in their own homes and communities. Safeguarding front-line healthcare workers is imperative to pandemic control.
    </p>
    <p id="Par3">
     The COVID-19 pandemic has spawned a growing literature on the protection of healthcare workers. Nevertheless, most of that literature focuses on describing the appropriate personal protective equipment and how to address its shortage during this crisis. In this article, we aim to add to the discussion of occupational safety with a focus on how anesthesiologists and other operating room (OR) personnel can apply social-distancing practices at work to reduce the risk of COVID-19 transmission.
    </p>
    <sec id="Sec1">
     <title>
      What is social distancing?
     </title>
     <p id="Par4">
      Social distancing is deliberately increasing the physical space between people to avoid spreading illness. During an epidemic or pandemic, social distancing should be employed among the general population.
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      Social distancing can also be practiced within contained environments (e.g., homes, offices) and shared spaces (e.g., cafeterias, public transit) as well as natural spaces (e.g., parks); however, it can be culturally and socially challenging to enforce. Edicts to close non-essential businesses and cancel community events are employed by various levels of governments in an attempt to implement, or indirectly enforce, social distancing. Social distancing is distinct from self- or group-quarantine, which refers to restricting the movement of asymptomatic people who have been exposed to the disease (e.g., staying at home or some other designated location, having no visitors). It is also distinct from isolation, which refers to keeping people with known infections away from susceptible people.
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </p>
     <p id="Par5">
      Social distancing within the hospital is an important part of safeguarding healthcare workers. During the 2009 influenza A (H1N1) pandemic, social distancing in the workplace contributed to a 23% median decline in the cumulative influenza attack rate.
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      The most recent Canadian Public Health Agency and United States Department of Labor Occupational Safety and Health Administration recommendations for social distancing to reduce COVID-19 transmission is a distance of about two metres between people in workplaces and communities.
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      This means no handshakes at work (and no hugs at home).
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      While simple in theory, this is difficult in practice. In the OR, where anesthesiologists, surgeons, and nurses are accustomed to working together closely, it is especially challenging. We must discuss new frameworks for working within this pandemic and build reinforcements for this behaviour to shift the
      <italic>
       Overton Window
      </italic>
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      of implementation.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Communication in the OR
     </title>
     <p id="Par6">
      How we communicate with one another in the OR is an integral part of patient care, safety, and perioperative culture. This OR communication has been studied qualitatively and quantitatively and was shown to improve overall team function.
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      –
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      Optimizing OR communication is especially complex as these teams often change, not only from day to day but also from case to case, thus limiting their adaptive capacity. The literature indicates that several factors are integral to success, including: 1) shared knowledge and understanding, 2) shared goals, and 3) mutual respect.
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
     </p>
     <p id="Par7">
      How can we achieve these goals alongside the need for social distancing? Some advocate to increase the adaptive capacity of OR teams by making them as consistent as possible. For example, team members that perform the same activities together every day will know one another, and this decreases the likelihood of miscommunication.
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      During a pandemic, however, this is simply not realistic, particularly as team members will change secondary to infection, exposure, and burnout. Limiting speaking, and even the volume of our voices (which is associated with droplet and aerosol generation)
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      in the OR could be important. Limiting the proximity of staff to one another is also important, so that any droplets or aerosols generated by speaking are less likely to move between people. And yet messages must be clear and precise. We frame this issue through four different types of communication identified in OR team dynamics. Proactive, intuitive communication is described first, as an ideal team management strategy during an emergency pandemic response. We then describe three other communication styles observed in OR teams, and why they must be limited during a crisis.
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
     </p>
     <p id="Par8">
      <italic>
       Proactive, intuitive communication
      </italic>
      is characterized by broad, shared goals and mutual respect. This includes starting the surgical procedure in a timely manner, completing all necessary checklist items, and supporting the functions of other team members. This communication is not necessarily always verbal—e.g., a scrub technologist who prepares surgical trays according to the surgeons’ preferences, or a circulating nurse who begins to check blood products with the anesthesiologist without being asked. This type of communication generally requires team member experience and has often been used by teams working in especially complex procedures or environments. For this reason, it may be most useful in the midst of a pandemic. Notably, this type of communication can be created or reinforced through preoperative preparation. Examples include a shared text message thread reviewing the surgery start time and team member names, or even anticipated surgical challenges; or, a positive hand gesture to confirm the correct completion of a task. These can contribute to team management success without increasing infection risk.
     </p>
     <p id="Par9">
      <italic>
       Silent communication
      </italic>
      has also been observed in OR teams that work together extensively, often on routine procedures. Members know each other so well that words are often minimized to focus on tasks. While these teams may have great adaptive capacity and they minimize speaking, silent communication is not an ideal strategy in the midst of a pandemic—i.e., OR teams are more likely to comprise different team members and shared assumptions may be incorrect. Teams that utilize silent communication have also been observed to skip over details such as a surgical checklist; while this may not meaningfully affect outcomes during routine procedures, in the midst of an emergency this may adversely affect team function.
     </p>
     <p id="Par10">
      <italic>
       Ambiguous communication
      </italic>
      has been observed in teams for whom individual functional goals outweigh shared goals—e.g., if a surgeon is unavailable and delays a procedure, or if team members disagree about the most efficient way to prepare for surgery. Sarcasm and irony are often observed in these types of teams, which may reflect a stress response.
     </p>
     <p id="Par11">
      <italic>
       Dynamic and contradictory communication
      </italic>
      is also a style that has been observed in OR teams that perform both routine and complex surgery. This style includes respectful, collaborative communication, but also finger-pointing and rude communication. While this style may work well during routine surgeries for some teams that know each other, it can also detract from team function. It may especially detract from team function during a crisis in which team members do not necessarily know each other very well. These last three types of communication clearly exist during routine OR conduct, but they must be suppressed during a pandemic response, particularly as team members start to experience both personal and job-related stress and anxiety.
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Reinforcing new behavioural expectations
     </title>
     <p id="Par12">
      Perioperative care teams worldwide have established new protocols in the face of the COVID-19 pandemic. For example, the Joint Task Force of the Chinese Society for Anesthesiology (CSA) and the Chinese Association of Anesthesiologists recommends: 1) the use of dedicated, clustered COVID-19 ORs with negative pressure systems, 2) dedicated anesthesia machines for these rooms, and 3) allowing only the minimum number of staff required for direct patient care.
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      The CSA also recommends proceeding directly to modified rapid sequence induction and intubation for suspected COVID-19 patients in respiratory distress, rather than risk exposing healthcare workers to the aerosol formation associated with bag-mask ventilation.
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      In Singapore, specific work spaces near the ORs were designated for the donning and doffing of personal protective equipment and numbered posters were hung to guide staff through the steps. Routine pre- and postoperative patient assessments were suspended or replaced with phone conferences to limit both person-to-person contact and hospital traffic.
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
     </p>
     <p id="Par13">
      The response to the COVID-19 pandemic requires not only building a new OR work culture but also implementing and sustaining it.
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      To attain this, we must build the necessary reinforcements. For example, repeated OR door-opening has been associated with surgical site infections and environmental contamination.
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      –
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      It obviously must be limited during a pandemic response for the safety of both patients and healthcare workers. This is even more important during the COVID-19 pandemic response, as the SARS-CoV-2 virus may be transmitted via aerosols and maintenance of appropriate laminar air-flow in ORs is imperative. Successful interventions that have reduced OR door-opening and overall traffic provide a reference for changing OR work culture. In a Canadian study,
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      key changes that led to decreased OR door-opening included phone communication rather than in-person communication, signs on doors that remind staff to limit traffic, signs on doors requiring staff to log why they are entering or leaving a room, cessation of all traffic through the OR during key surgical periods, and the use of templates or wall-hangings to guide shared tasks. In Singapore, amidst the COVID-19 outbreak, all OR doors except for the scrub room were locked.
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
     </p>
     <p id="Par14">
      In the past decade, the idea that workplace “champions” are integral to changing team behaviour has also proliferated. Studies have consistently found that champions are important positive influences on implementation effectiveness.
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      As our nationwide healthcare systems prepare for and experience surges in COVID-19 cases, it is reasonable to try several overlapping strategies. We encourage OR managers to use champions to reinforce the elements of staff behaviour most crucial to safeguarding our healthcare workers.
     </p>
     <p id="Par15">
      Implementing social distancing in the OR environment will be a challenging but necessary part of the response to slow the COVID-19 pandemic. Furthermore, OR personnel must also be vigilant to extend these practices to the workplace environments adjacent to the OR such as sub-sterile cores, hallways, break rooms, and hospital cafeterias. These areas are often designed to accommodate a relatively large number of people compared with the OR, and we are not necessarily trained or accustomed to extending safety precautions to these areas. We recommend extending the same strategies as discussed above for these areas. This includes posting reminder signs on break room doors and in sub-sterile cores, prohibiting all non-OR personnel from OR hallways, and allowing OR staff to use alternative spaces (e.g., lecture rooms) as break areas to spread out and maintain social distancing. In the authors’ academic hospital setting, large tables in the OR break room were replaced with several small tables so that staff were forced to sit apart from one another. Signs were posted in the locker rooms to encourage social distancing of 2 m between people. All departmental meetings were shifted to video-conferencing applications rather than in-person.
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      Breaks
     </title>
     <p id="Par16">
      As reviewed above, it is recommended to limit potential exposure in the OR to infectious sources such as SARS-CoV-2 to only the minimum number of healthcare workers. This means excusing commercial representatives, students, redundant staff members, and minimizing socialization in the OR. Nevertheless, it should not mean eliminating breaks for anesthesia providers, even though this may require the use of an “extra” person. Rest breaks are an important part of safety culture in many high intensity work settings (from pilots
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      to truck drivers,
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      because they improve attention and vigilance. Staff should continue to work collaboratively to facilitate breaks for anesthesia providers in the OR, especially those involved in prolonged surgical procedures.
     </p>
    </sec>
    <sec id="Sec5" sec-type="conclusion">
     <title>
      Conclusions
     </title>
     <p id="Par17">
      Protecting healthcare workers is not only about keeping them healthy so that they can remain in the workforce, particularly during this pandemic. It is also about preventing them from becoming disease vectors in the community. Hospitals worldwide have employed different strategies to mitigate this risk.
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      As such, it is not only important to consider the physical OR environments and personal protective equipment use in this crisis, but also the communication strategies and healthcare-specific social distancing perspectives. All of these contribute to maximizing provider safety. Anesthesiology is a field regarded for its vigilance to patient safety. It is now the time to refocus that vigilance to protect anesthesia providers themselves, and in doing so, prevent the consequences to pandemic control of the “triple threat” of anesthesia provider infection.
     </p>
     <p id="Par18">
      Le nouveau coronavirus (SARS-CoV-2), qui provoque la maladie COVID-19, a comme point d’origine Wuhan, en Chine, et a été déclaré pandémie par l’Organisation mondiale de la Santé.
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      En date du 25 mars 2020, 454 398 patients ont été infectés dans le monde; 20 550 en sont décédés.
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      La propagation rapide de la COVID-19 dans le monde est en partie due à sa biologie – en d’autres termes, à l’absence d’immunité au sein de la population, à son taux d’attaque, à sa capacité à survivre sur les surfaces et dans les gouttelettes, ainsi qu’à sa période d’incubation, qui donne lieu à une forte prévalence de cas sous-cliniques mais déjà contagieux. Toutefois la propagation, la rapidité et la durée de cette pandémie révèlent également des failles présentes dans l’infrastructure de nos systèmes de santé mondiaux. Une faiblesse flagrante que cette pandémie dévoile est la vulnérabilité du personnel de soins de santé cliniques de première ligne. La Commission nationale de santé chinoise a reconnu, en février 2020, qu’au moins 3,8 % des infections totales en Chine continentale touchaient les travailleurs de la santé.
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      Cette proportion va probablement augmenter au fur et à mesure qu’on étudie davantage l’épidémiologie de la pandémie de COVID-19, surtout parce que les infections des travailleurs de la santé sont fréquentes pendant les épidémies. La propagation liée aux soins de santé de maladies semblables a déjà été rapportée par le passé. Par exemple, parmi 2223 cas confirmés par laboratoire de coronavirus du syndrome respiratoire du Moyen-Orient (MERS), 19 % touchaient des travailleurs de la santé.
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      Lors de l’épidémie de syndrome respiratoire aigu sévère (SRAS) à Toronto en 2003, 44 % des infections ont affecté des travailleurs de la santé.
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      Des études portant sur 22 épidémies du virus Ebola et du virus Marburg montrent des taux d’infection des travailleurs de la santé allant de 2-100 % des cas d’Ebola et de 5-50 % des cas de virus de Marburg.
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
     </p>
     <p id="Par19">
      Les cliniciens infectés représentent une triple menace au ralentissement de la pandémie actuelle de COVID-19 : ils deviennent des patients dans un système de santé déjà submergé, réduisent le nombre de professionnels de la santé disponibles, et servent de vecteurs dans leurs propres foyers et communautés. C’est pourquoi la protection des travailleurs de la santé de première ligne est essentielle au contrôle de la pandémie.
     </p>
     <p id="Par20">
      La pandémie de COVID-19 a donné naissance à une littérature croissante sur la protection des travailleurs de la santé. La majorité de cette littérature se concentre toutefois sur la description des équipements de protection individuelle adaptés et sur la manière de gérer leur pénurie pendant cette crise. Dans cet article, nous aimerions étoffer la discussion sur la sécurité au travail en mettant l’accent sur les façons dont les anesthésiologistes et les autres personnes travaillant en salle d’opération (SOP) peuvent mettre en œuvre les pratiques de distanciation sociale au travail afin de réduire le risque de transmission de la COVID-19.
     </p>
    </sec>
    <sec id="Sec6">
     <title>
      En quoi consiste la distanciation sociale?
     </title>
     <p id="Par21">
      La distanciation sociale est l’augmentation délibérée de la distance physique entre des individus afin d’éviter la transmission de maladies. Pendant une épidémie ou une pandémie, la distanciation sociale devrait être employée au sein de l’ensemble de la population.
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      La distanciation sociale peut également être pratiquée dans des environnements confinés (à la maison, au bureau), des espaces partagés (cafétérias, transports en commun) ainsi que dans les espaces extérieurs (parcs); il peut toutefois être difficile de faire respecter la distanciation sociale, tant d’un point de vue culturel que social. Dans une tentative de mettre en œuvre la distanciation sociale ou de l’imposer de façon indirecte, divers niveaux de gouvernement promulguent des décrets exigeant la cessation des activités commerciales non essentielles et l’annulation des événements sociaux. La distanciation sociale se distingue de la quarantaine, individuelle ou en groupe, qui fait référence à la restriction de mouvement de personnes asymptomatiques qui ont été exposées à la maladie (par ex., l’exigence de rester à la maison ou dans tout autre lieu désigné, de ne pas avoir de visites). Elle se distingue également de l’isolation, qui fait référence au fait de maintenir les personnes ayant des infections connues à l’écart des personnes à risque.
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </p>
     <p id="Par22">
      Au sein d’un milieu hospitalier, la distanciation sociale constitue une part importante de la protection des travailleurs de la santé. Pendant la pandémie d’influenza A (H1N1) de 2009, la distanciation sociale pratiquée au travail a contribué à un déclin médian de 23 % dans le taux d’attaque cumulatif de l’influenza.
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      Les recommandations les plus récentes de l’Agence de la santé publique du Canada et de l’Administration de la sécurité et de la santé au travail du Ministère du travail américain préconisent une distance d’environ deux mètres pour la distanciation sociale entre les individus sur le lieu de travail et dans les collectivités afin de réduire la transmission de la COVID-19.
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      En d’autres termes : pas de poignées de main au travail (et pas de câlin à la maison).
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      Bien que cela paraisse simple en théorie, c’est plus difficile en pratique. En SOP, un espace où anesthésiologistes, chirurgiens et personnel infirmier ont l’habitude de travailler à proximité l’un de l’autre, cette recommandation est particulièrement difficile à appliquer. Nous devons discuter de nouveaux cadres de travail dans le contexte de cette pandémie et renforcer ces nouveaux comportements afin de modifier la
      <italic>
       Fenêtre d’Overton
      </italic>
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      de sa mise en œuvre.
     </p>
    </sec>
    <sec id="Sec7">
     <title>
      La communication en SOP
     </title>
     <p id="Par23">
      La façon dont nous communiquons en SOP fait partie intégrante des soins au patient, de la sécurité et de la culture périopératoire. Cette communication en SOP a été étudiée d’un point de vue qualitatif et quantitatif et il a été démontré qu’elle améliorait le fonctionnement global de l’équipe.
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      –
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      L’optimisation de la communication en SOP est particulièrement complexe étant donné que les équipes changent souvent, non seulement d’un jour à l’autre mais également d’un cas au suivant, ce qui limite leur capacité d’adaptation. La littérature indique que de nombreux facteurs sont partie intégrante du succès de cette communication, notamment : 1) des connaissances et une compréhension partagées; 2) des objectifs partagés; et 3) un respect mutuel.
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
     </p>
     <p id="Par24">
      Comment pouvons-nous atteindre ces objectifs tout en respectant la nécessité de pratiquer la distanciation sociale? Certains préconisent d’augmenter la capacité d’adaptation des équipes de SOP en les rendant les plus constantes possibles. Par exemple, les membres d’une équipe qui réalisent les mêmes activités ensemble tous les jours se connaissent bien, ce qui réduit par conséquent la probabilité de mauvaise communication.
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      Toutefois, pendant une pandémie, ceci n’est tout simplement pas réaliste, particulièrement parce que les membres d’une équipe changeront en fonction de leur infection, de leur exposition, et de leur épuisement professionnel. En revanche, le fait de limiter nos communications, voire le volume de nos voix (lequel est associé à la génération de gouttelettes et d’aérosols)
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      en SOP pourrait être important. Il est également important de limiter la proximité des membres du personnel entre eux; ainsi, toutes les gouttelettes ou aérosols générés en parlant ont moins de chances de passer d’un individu à l’autre. Les messages doivent néanmoins demeurer clairs et précis. Nous traiterons de cette question par le biais de quatre différents types de communication identifiés dans les dynamiques d’équipe en SOP. La communication proactive et intuitive sera décrite en premier, en tant que stratégie de gestion d’équipe idéale pendant la réaction d’urgence à une pandémie. Nous décrirons ensuite trois autres styles de communication observés dans les équipes de SOP, et expliquerons pourquoi ces styles devraient être limités en période de crise.
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
     </p>
     <p id="Par25">
      La
      <italic>
       communication proactive et intuitive
      </italic>
      se caractérise par des objectifs globaux et partagés et par le respect mutuel. Cela comprend le début de l’intervention chirurgicale à l’heure, la complétion de tous les éléments nécessaires énumérés sur des listes de contrôle, et le soutien aux rôles des autres membres de l’équipe. Cette communication n’est pas toujours verbale – citons l’exemple d’un technologue en stérilisation qui prépare les plateaux chirurgicaux selon les préférences des chirurgiens, ou d’un infirmier en service externe qui commence à vérifier les produits sanguins avec l’anesthésiologiste sans qu’on le lui demande. Ce type de communication requiert en général l’expérience des membres de l’équipe et est fréquemment utilisé par les équipes travaillant dans des interventions ou des environnements complexes. C’est pourquoi ce type de communication pourrait être le plus utile dans le contexte d’une pandémie. Fait notable, ces échanges peuvent être créés ou renforcés grâce à une bonne préparation préopératoire. Par exemple, on peut imaginer un fil de message texto partagé passant en revue l’heure de début de la chirurgie et les noms des membres de l’équipe, ou même les difficultés chirurgicales anticipées; ou un geste positif afin de confirmer la complétion adéquate d’une tâche. De tels échanges peuvent contribuer à la réussite de la gestion d’équipe et ce, sans augmenter le risque d’infection.
     </p>
     <p id="Par26">
      On observe également une
      <italic>
       communication silencieuse
      </italic>
      dans les équipes de SOP qui travaillent beaucoup ensemble, souvent dans le cadre d’interventions de routine. Les membres se connaissent tellement bien que les mots sont souvent minimisés pour se concentrer sur les tâches. Alors que ces équipes pourraient posséder une très grande capacité d’adaptation et minimisent les échanges verbaux, la communication silencieuse ne constitue pas une stratégie idéale lors d’une pandémie – c’est-à-dire, dans un contexte où les équipes de SOP compteront probablement davantage de membres d’équipe différents et donc, les présomptions partagées pourraient s’avérer erronées. On a également observé que les équipes qui utilisaient la communication silencieuse omettaient certains détails, tels qu’une liste de contrôle chirurgicale; alors que cela pourrait ne pas avoir d’impact significatif sur les devenirs lors d’interventions de routine, lors d’une urgence, cela pourrait avoir un impact négatif sur le fonctionnement d’une équipe.
     </p>
     <p id="Par27">
      On observe une
      <italic>
       communication ambiguë
      </italic>
      au sein des équipes dans lesquelles les objectifs fonctionnels individuels l’emportent sur les objectifs partagés – par exemple, si un chirurgien n’est pas disponible et retarde l’intervention, ou si les membres de l’équipe ne s’entendent pas quant à la façon la plus efficace de préparer la chirurgie. Le sarcasme et l’ironie font souvent partie intégrante de la communication dans ce type d’équipes, ce qui pourrait être le reflet d’une réponse de stress.
     </p>
     <p id="Par28">
      <italic>
       La communication dynamique et contradictoire
      </italic>
      constitue un autre style observé dans les équipes de SOP qui réalisent tant des chirurgies de routine que des chirurgies complexes. Ce style comprend une communication respectueuse et collaborative, mais également la désignation de coupables et une communication vulgaire. Bien que ce style de communication puisse bien fonctionner pendant les chirurgies de routine dans certaines équipes qui se connaissent bien, il peut également nuire au bon fonctionnement de l’équipe. Ce style pourrait être particulièrement nuisible au bon fonctionnement de l’équipe pendant une crise au cours de laquelle les membres d’une équipe ne se connaissent pas très bien. Ces trois derniers types de communication existent clairement pendant le fonctionnement normal en SOP, mais ils doivent être éliminés pendant la réponse à une pandémie, particulièrement lorsque les membres de l’équipe commencent à ressentir du stress et de l’anxiété aux niveaux personnel et professionnel.
     </p>
    </sec>
    <sec id="Sec8">
     <title>
      Renforcer les nouvelles attentes comportementales
     </title>
     <p id="Par29">
      Partout dans le monde, les équipes de soins périopératoires ont établi de nouveaux protocoles pour faire face à la pandémie de la COVID-19. Par exemple, le Groupe de travail mixte de la Société chinoise d’anesthésiologie (
      <italic>
       Joint Task Force of the Chinese Society for Anesthesiology
      </italic>
      (CSA)) et l’Association chinoise des anesthésiologistes (
      <italic>
       Chinese Association of Anesthesiologists
      </italic>
      ) recommandent : 1) l’utilisation de SOP dédiées et regroupées pour la COVID-19 munies de système de pression négative; 2) des machines anesthésiques dédiées pour ces salles; et 3) ne permettre que le personnel minimum requis pour les soins directs au patient.
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      La CSA recommande également de procéder directement à une induction en séquence rapide modifiée avec intubation chez les patients suspectés de COVID-19 en détresse respiratoire, plutôt que de risquer d’exposer les travailleurs de la santé à la formation d’aérosols associés à la ventilation au masque.
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      À Singapour, des espaces de travail spécifiques proches des SOP ont été désignés pour le revêtement et le retrait de l’équipement de protection individuelle et des affiches numérotées ont été apposées afin de guider le personnel à travers ces étapes. Les évaluations pré- et postopératoires de routine des patients ont été suspendues ou remplacées par des téléconférences afin de limiter les contacts interpersonnels et la circulation au sein des hôpitaux.
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
     </p>
     <p id="Par30">
      En réponse à la pandémie de la COVID-19, nous avons besoin non seulement de l’élaboration d’une nouvelle culture de travail en SOP, mais également de sa mise en œuvre et de sa continuation.
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      Pour ce faire, nous devons bâtir les renforcements nécessaires. Par exemple, l’ouverture répétée des portes de SOP a été associée à des infections du site chirurgical et à la contamination environnementale.
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      –
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      Il faut évidemment limiter l’ouverture des portes pendant une réponse à une pandémie, pour la sécurité tant des patients que des travailleurs de la santé. Ces mesures sont encore plus importantes pendant notre réponse à la pandémie de COVID-19, étant donné que le virus du SARS-CoV-2 peut se transmettre par aérosols et que le maintien du flux d’air liminaire approprié dans les SOP est essentiel. Les interventions réussies pour réduire l’ouverture des portes de SOP et la circulation globale fournissent un cadre pour modifier la culture de travail en SOP. Dans une étude canadienne,
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      les changements clés ayant mené à une réduction de l’ouverture des portes de la SOP comprenaient la communication par téléphone plutôt qu’en personne, des affiches sur les portes pour rappeler au personnel de limiter la circulation, des affiches sur les portes exigeant que les personnes entrant ou quittant la salle inscrivent leurs raisons pour ce faire, l’interruption de toute circulation dans la SOP pendant les périodes chirurgicales clés, et l’utilisation de modèles ou d’affiches pour guider les tâches partagées. À Singapour, au cours de l’éclosion de COVID-19, toutes les portes de SOP, à l’exception de celles de la salle de brossage, étaient verrouillées.
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
     </p>
     <p id="Par31">
      Au cours de la dernière décennie, l’idée que des « champions » du lieu de travail soient essentiels pour modifier les comportements d’équipe s’est également propagée. Les études ont à maintes reprises démontré que de tels champions constituent d’importantes influences positives sur l’efficacité de mise en œuvre.
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      Alors que les systèmes de santé de notre pays se préparent et affrontent une hausse rapide des cas de COVID-19, il est tout à fait raisonnable de tenter plusieurs stratégies qui se recoupent. Nous encourageons les gestionnaires de SOP à recourir à des champions pour renforcer les éléments comportementaux les plus cruciaux pour protéger nos travailleurs de la santé.
     </p>
     <p id="Par32">
      La mise en œuvre de la distanciation sociale dans un environnement de SOP sera une étape difficile mais nécessaire de notre réponse pour ralentir la pandémie de COVID-19. En outre, le personnel de SOP doit également être vigilant et étendre ces pratiques aux zones de travail adjacentes à la SOP telles que les salles de niveau stérile moins élevé, les corridors, les salles de repos et les cafétérias des hôpitaux. Ces espaces sont souvent conçus de manière à accommoder un nombre relativement élevé de personnes par rapport à une SOP, et nous ne sommes pas nécessairement formés ou habitués à appliquer des précautions de sécurité à ces espaces. Nous recommandons d’étendre les mêmes stratégies que discutées ci-dessus à ces espaces. Cela comprend l’affichage d’aide-mémoires sur les portes des salles de repos et des environnements non stériles, l’interdiction de circulation de tout personnel non impliqué en SOP dans les corridors menant aux SOP, et l’autorisation, pour le personnel de SOP, d’utiliser d’autres espaces (par exemple les salles de conférence) comme salles de repos afin de maintenir une distanciation sociale adaptée. Dans l’hôpital universitaire des auteurs, les grandes tables de la salle de repos des SOP ont été remplacées par plusieurs petites tables afin de forcer les membres du personnel à se tenir éloignés les uns des autres. Des affiches ont été apposées dans les vestiaires afin d’encourager une distanciation sociale de 2 mètres entre les individus. Toutes les réunions de département ont désormais lieu via des applications de vidéoconférence plutôt qu’en personne.
     </p>
    </sec>
    <sec id="Sec9">
     <title>
      Pauses
     </title>
     <p id="Par33">
      Comme nous l’avons mentionné ci-dessus, il est recommandé de limiter l’exposition potentielle en SOP à des sources infectieuses telles que le SARS-CoV-2 au nombre minimal de travailleurs de la santé seulement. Il convient donc d’éliminer les représentants commerciaux, étudiants et membres du personnel redondants, et de minimiser la socialisation en SOP. Cela ne veut cependant pas dire qu’il faille éliminer les pauses pour le personnel d’anesthésie, même si cela veut dire qu’il faut faire appel à une personne supplémentaire. Les pauses sont une partie importante de la culture de sécurité de nombreuses professions d’intensité de travail élevée (des pilotes
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      aux chauffeurs de poids lourds
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      parce qu’elles améliorent l’attention et la vigilance. Le personnel devrait continuer de travailler en collaboration afin de faciliter les pauses du personnel d’anesthésie en SOP, et particulièrement du personnel participant à des interventions chirurgicales prolongées.
     </p>
    </sec>
    <sec id="Sec10" sec-type="conclusion">
     <title>
      Conclusion
     </title>
     <p id="Par34">
      La protection des travailleurs de la santé ne se limite pas à les garder en santé afin qu’ils demeurent au travail, particulièrement pendant cette pandémie. Leur protection a également pour but de les empêcher de devenir à leur tour des vecteurs de la maladie dans la communauté. Les hôpitaux du monde entier ont eu recours à différentes stratégies pour mitiger ce risque.
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      En tant que tel, il est non seulement important de penser aux environnements physiques de SOP et à l’utilisation d’équipements de protection individuelle pendant cette crise, mais également aux stratégies de communication et aux perspectives de distanciation sociale spécifiques aux soins de santé. Tous ces facteurs contribuent à maximiser la sécurité des travailleurs de la santé. L’anesthésiologie est un domaine connu pour sa vigilance en matière de sécurité des patients. Aujourd’hui, le moment est venu d’appliquer notre vigilance au personnel d’anesthésie afin de le protéger et, par le fait même, de prévenir les conséquences sur le contrôle de la pandémie de la « triple menace » que constitue l’infection de ces professionnels.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher's Note
        </bold>
       </p>
       <p>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
     </fn-group>
     <ack>
      <sec id="FPar1">
       <title>
        Conflicts of interest
       </title>
       <p id="Par35">
        None.
       </p>
      </sec>
      <sec id="FPar2">
       <title>
        Funding statement
       </title>
       <p id="Par36">
        The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of any funding agencies.
       </p>
      </sec>
      <sec id="FPar3">
       <title>
        Editorial responsibility
       </title>
       <p id="Par37">
        This submission was handled by Dr. Hilary P. Grocott, Editor-in-Chief,
        <italic>
         Canadian Journal of Anesthesia.
        </italic>
       </p>
      </sec>
      <sec id="FPar4">
       <title>
        Conflit d’intérêt
       </title>
       <p id="Par38">
        Aucun.
       </p>
      </sec>
      <sec id="FPar5">
       <title>
        Déclaration de financement
       </title>
       <p id="Par39">
        Le contenu de cet article reflète exclusivement l’opinion des auteurs et ne représente pas nécessairement le point de vue officiel d’un organisme de financement.
       </p>
      </sec>
      <sec id="FPar6">
       <title>
        Responsabilit‚ ‚ditoriale
       </title>
       <p id="Par40">
        Cet article a été traité par Dr Hilary P. Grocott, rédacteur en chef,
        <italic>
         Journal canadien d’anesthésie
        </italic>
        .
       </p>
      </sec>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahase
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1136/bmj.m1036
        </pub-id>
        <pub-id pub-id-type="pmid">
         32273285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU).
        </italic>
        Coronavirus COVID-19 Global Cases. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">
         https://coronavirus.jhu.edu/map.html
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Ma J, Pinghui Z
        </italic>
        . Chinese medical staff paying ‘too high a price’ in battle to curb coronavirus South China Morning Post. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://www.scmp.com/news/china/society/article/3050748/chinese-medical-staff-paying-too-high-price-battle-curb">
         https://www.scmp.com/news/china/society/article/3050748/chinese-medical-staff-paying-too-high-price-battle-curb
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elkholy
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Elhakim
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV infection among healthcare workers and risk factors for death: retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <year>
         2020
        </year>
        <volume>
         13
        </volume>
        <fpage>
         418
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jiph.2019.04.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         31056437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name>
          <surname>
           Simor
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS in healthcare facilities, Toronto and Taiwan
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         777
        </fpage>
        <lpage>
         781
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1005.030791
        </pub-id>
        <pub-id pub-id-type="pmid">
         15200808
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Selvaraj
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Harrell
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ivanov
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Allegranzi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection rates and risk factors for infection among health workers during Ebola and Marburg Virus outbreaks: a systematic review
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         218
        </volume>
        <issue>
         Suppl 5
        </issue>
        <fpage>
         S679
        </fpage>
        <lpage>
         S689
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiy435
        </pub-id>
        <pub-id pub-id-type="pmid">
         30202878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zviedrite
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Uzicanin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2018
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         518
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12889-018-5446-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         29669545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <collab>
          National Institutes of Health
         </collab>
        </person-group>
        <source>
         Ethical and Legal Considerations in Mitigating Pandemic Disease: Workshop Summary
        </source>
        <year>
         2007
        </year>
        <publisher-loc>
         Washington (DC)
        </publisher-loc>
        <publisher-name>
         The National Academies Press
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         U.S. Department of Labor Occupational Safety and Health Administration.
        </italic>
        Guidance on Preparing Workplaces for COVID-19. OSHA 3990-03 2020. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.osha.gov/Publications/OSHA3990.pdf">
         www.osha.gov/Publications/OSHA3990.pdf
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Government of Canada.
        </italic>
        Coronavirus disease (COVID-19): Prevention and risks Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html">
         https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Mackinac Center for Public Policy.
        </italic>
        The Overton Window, 2019. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://www.mackinac.org/OvertonWindow">
         https://www.mackinac.org/OvertonWindow
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McNeer
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Bennett
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Horn
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Dudaryk
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors affecting acoustics and speech intelligibility in the operating room: size matters
        </article-title>
        <source>
         Anesth Analg
        </source>
        <year>
         2017
        </year>
        <volume>
         124
        </volume>
        <fpage>
         1978
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="doi">
         10.1213/ANE.0000000000002118
        </pub-id>
        <pub-id pub-id-type="pmid">
         28525511
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russ
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Rout
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sevdalis
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Moorthy
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Darzi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Do safety checklists improve teamwork and communication in the operating room?
        </article-title>
        <source>
         A systematic review. Ann Surgery
        </source>
        <year>
         2013
        </year>
        <volume>
         258
        </volume>
        <fpage>
         856
        </fpage>
        <lpage>
         871
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buljac-Samardzic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Doekhie
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         <name>
          <surname>
           van Wijngaarden
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interventions to improve team effectiveness within health care: a systematic review of the past decade
        </article-title>
        <source>
         Human Res Health
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1186/s12960-019-0411-3
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Singer
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Molina
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Relationship between operating room teamwork, contextual factors, and safety checklist performance
        </article-title>
        <source>
         J Am Coll Surg
        </source>
        <year>
         2016
        </year>
        <volume>
         223
        </volume>
        <issue>
         568–80
        </issue>
        <fpage>
         e2
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Gittell JH
        </italic>
        . Relational Coordination: Guidelines for Theory, Measurement and Analysis. Heller School, Brandeis University, USA: Relational coordination research collaborative. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/profile/Carmen_De_Pablos-Heredero/publication/269772701_Relational_coordination_and_healthcare_management_in_lung_cancer/links/55f87ec708aec948c47f41a3.pdf">
         https://www.researchgate.net/profile/Carmen_De_Pablos-Heredero/publication/269772701_Relational_coordination_and_healthcare_management_in_lung_cancer/links/55f87ec708aec948c47f41a3.pdf
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Torring
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Gittell
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Laursen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Sorensen
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Communication and relationship dynamics in surgical teams in the operating room: an ethnographic study
        </article-title>
        <source>
         BMC Health Serv Res
        </source>
        <year>
         2019
        </year>
        <pub-id pub-id-type="doi">
         10.1186/s12913-019-4362-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         31358000
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Centers for Disease Control and Prevention.
        </italic>
        Transmission-Based Precautions. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.html">
         https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.html
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Asadi S, Wexler AS, Cappa CD, Barreda S, Bouvier NM, Ristenpart WD.
        </italic>
        Aerosol emission and superemission during human speech increase with voice loudness. Sci Rep 2019; DOI: 10.1038/s41598-019-38808-z.
       </mixed-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Chen X, Liu Y, Gong Y, et al.
        </italic>
        Perioperative management of patients infected with the novel coronavirus: recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. Anesthesiology 2020; DOI: 10.1097/aln.0000000000003301.
       </mixed-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           MZ
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           YG
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Expert recommendations for tracheal intubation in critically ill patients with noval coronavirus disease 2019
        </article-title>
        <source>
         Chin Med Sci J
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.24920/003724
        </pub-id>
        <pub-id pub-id-type="pmid">
         32102726
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Goh
          </surname>
          <given-names>
           QY
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore
        </article-title>
        <source>
         Can J Anesth
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1007/s12630-020-01620-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         32212103
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okuyama
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wagner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bijnen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Speaking up for patient safety by hospital-based health care professionals: a literature review
        </article-title>
        <source>
         BMC Health Serv Res
        </source>
        <year>
         2014
        </year>
        <pub-id pub-id-type="doi">
         10.1186/1472-6963-14-61
        </pub-id>
        <pub-id pub-id-type="pmid">
         24507747
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mears
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Blanding
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Belkoff
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Door opening affects operating room pressure during joint arthroplasty
        </article-title>
        <source>
         Orthopedics
        </source>
        <year>
         2015
        </year>
        <volume>
         38
        </volume>
        <fpage>
         e991
        </fpage>
        <lpage>
         e994
        </lpage>
        <pub-id pub-id-type="doi">
         10.3928/01477447-20151020-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         26558679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Birnbach
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Rosen
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <name>
          <surname>
           Fitzpatrick
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Carling
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Munoz-Price
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
        </person-group>
        <article-title>
         The use of a novel technology to study dynamics of pathogen transmission in the operating room
        </article-title>
        <source>
         Anesth Analg
        </source>
        <year>
         2015
        </year>
        <volume>
         120
        </volume>
        <fpage>
         844
        </fpage>
        <lpage>
         847
        </lpage>
        <pub-id pub-id-type="doi">
         10.1213/ANE.0000000000000226
        </pub-id>
        <pub-id pub-id-type="pmid">
         24810261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perez
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Holloway
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ehrenfeld
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Door openings in the operating room are associated with increased environmental contamination
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2018
        </year>
        <volume>
         46
        </volume>
        <fpage>
         954
        </fpage>
        <lpage>
         956
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2018.03.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         29735254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Camus S, Forbes J, Kite A, et al.
        </italic>
        Minimizing operating room traffic may improve patient safety by lowering rates of surgical site infection. Abstract session presentation at the 2016 American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) Conference. July 18, 2016 as reported in ACS (American College of Surgeons). ACS Press Release July 18, 2016. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.facs.org/media/press-releases/2016/nsqip-ssi-071816">
         www.facs.org/media/press-releases/2016/nsqip-ssi-071816
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miech
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Rattray
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name>
          <surname>
           Flanagan
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Damschroder
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Schmid
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Damush
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inside help: an integrative review of champions in healthcare-related implementation
        </article-title>
        <source>
         SAGE Open Med
        </source>
        <year>
         2018
        </year>
        <pub-id pub-id-type="doi">
         10.1177/2050312118773261
        </pub-id>
        <pub-id pub-id-type="pmid">
         30083320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaslona
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           O’Keeffe
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Signal
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Gander
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Shared responsibility for managing fatigue: hearing the pilots
        </article-title>
        <source>
         PloS One
        </source>
        <year>
         2018
        </year>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0195530
        </pub-id>
        <pub-id pub-id-type="pmid">
         29782533
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modeling the safety impacts of driving hours and rest breaks on truck drivers considering time-dependent covariates
        </article-title>
        <source>
         J Saf Res
        </source>
        <year>
         2014
        </year>
        <volume>
         51
        </volume>
        <fpage>
         57
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jsr.2014.09.006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="other">
        <italic>
         Gawande A.
        </italic>
        Keeping the Coronavirus from Infecting Health-Care Workers. What Singapore’s and Hong Kong’s success is teaching us about the pandemic. The New Yorker March 21, 2020. Available from URL:
        <ext-link ext-link-type="uri" xlink:href="https://www.newyorker.com/news/news-desk/keeping-the-coronavirus-from-infecting-health-care-workers">
         https://www.newyorker.com/news/news-desk/keeping-the-coronavirus-from-infecting-health-care-workers
        </ext-link>
        (accessed March 2020).
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       BMJ Open
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       BMJ Open
      </journal-id>
      <journal-id journal-id-type="hwp">
       bmjopen
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       bmjopen
      </journal-id>
      <journal-title-group>
       <journal-title>
        BMJ Open
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2044-6055
      </issn>
      <publisher>
       <publisher-name>
        BMJ Publishing Group
       </publisher-name>
       <publisher-loc>
        BMA House, Tavistock Square, London, WC1H 9JR
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       23535701
      </article-id>
      <article-id pub-id-type="pmc">
       3612822
      </article-id>
      <article-id pub-id-type="publisher-id">
       bmjopen-2012-002518
      </article-id>
      <article-id pub-id-type="doi">
       10.1136/bmjopen-2012-002518
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Infectious Diseases
        </subject>
        <subj-group>
         <subject>
          Research
         </subject>
        </subj-group>
       </subj-group>
       <subj-group subj-group-type="hwp-journal-coll">
        <subject>
         1506
        </subject>
        <subject>
         1706
        </subject>
        <subject>
         1692
        </subject>
        <subject>
         1699
        </subject>
        <subject>
         1706
        </subject>
        <subject>
         1724
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Pandemic influenza in Papua New Guinea: a modelling study comparison with pandemic spread in a developed country
       </article-title>
       <alt-title alt-title-type="short">
        Modelling pandemic influenza in Papua New Guinea
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Milne
         </surname>
         <given-names>
          George J
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Baskaran
         </surname>
         <given-names>
          Pravin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Halder
         </surname>
         <given-names>
          Nilimesh
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Karl
         </surname>
         <given-names>
          Stephan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kelso
         </surname>
         <given-names>
          Joel
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <aff>
       <institution>
        School of Computer Science and Software Engineering, University of Western Australia
       </institution>
       ,
       <addr-line>
        Perth, Western Australia
       </addr-line>
       ,
       <country>
        Australia
       </country>
      </aff>
      <author-notes>
       <corresp>
        <label>
         Correspondence to
        </label>
        Professor George J Milne;
        <email>
         milne@csse.uwa.edu.au
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2013
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <volume>
       3
      </volume>
      <issue>
       3
      </issue>
      <elocation-id>
       e002518
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         12
        </month>
        <year>
         2012
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         27
        </day>
        <month>
         2
        </month>
        <year>
         2013
        </year>
       </date>
       <date date-type="accepted">
        <day>
         4
        </day>
        <month>
         3
        </month>
        <year>
         2013
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
       </copyright-statement>
       <copyright-year>
        2013
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         this is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see:
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/">
          http://creativecommons.org/licenses/by-nc/2.0/
         </ext-link>
         and
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/legalcode">
          http://creativecommons.org/licenses/by-nc/2.0/legalcode
         </ext-link>
         .
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="bmjopen-2012-002518.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2012-002518.draft_revisions.pdf" xlink:type="simple">
      </self-uri>
      <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2012-002518.reviewer_comments.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <sec>
        <title>
         Objectives
        </title>
        <p>
         The possible occurrence of a highly pathogenic influenza strain is of concern to health authorities worldwide. It is known that during past influenza pandemics developing countries have experienced considerably higher death rates compared with developed countries. Furthermore, many developing countries lack appropriate pandemic preparedness plans. Mathematical modelling studies to guide the development of such plans are largely focused on predicting pandemic influenza spread in developed nations. However, intervention strategies shown by modelling studies to be highly effective for developed countries give limited guidance as to the impact which an influenza pandemic may have on low-income countries given different demographics and resource constraints. To address this, an individual-based model of a Papua New Guinean (PNG) community was created and used to simulate the spread of a novel influenza strain. The results were compared with those obtained from a comparable Australian model.
        </p>
       </sec>
       <sec>
        <title>
         Design
        </title>
        <p>
         A modelling study.
        </p>
       </sec>
       <sec>
        <title>
         Setting
        </title>
        <p>
         The towns of Madang in PNG (population ∼35 000) and Albany (population ∼30 000) in Australia.
        </p>
       </sec>
       <sec>
        <title>
         Outcome measures
        </title>
        <p>
         Daily and cumulative illness attack rates in both models following introduction of a novel influenza strain into a naive population, for an unmitigated scenario and two social distancing intervention scenarios.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         The unmitigated scenario indicated an approximately 50% higher attack rate in PNG compared with the Australian model. The two social distancing-based interventions strategies were 60–70% less effective in a PNG setting compared with an Australian setting.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p>
         This study provides further evidence that an influenza pandemic occurring in a low-income country such as PNG may have a greater impact than one occurring in a developed country, and that PNG-feasible interventions may be substantially less effective. The larger average household size in PNG, the larger proportion of the population under 18 and greater community-wide contact all contribute to this feature.
        </p>
       </sec>
      </abstract>
      <kwd-group>
       <kwd>
        Epidemiology
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <boxed-text position="float">
     <caption>
      <title>
       Article summary
      </title>
     </caption>
     <sec>
      <title>
       Article focus
      </title>
      <list list-type="bullet">
       <list-item>
        <p>
         This modelling study investigated the impact of an influenza pandemic on a community in Papua New Guinea (PNG) and compared it with that in a similar-sized community in Australia.
        </p>
       </list-item>
       <list-item>
        <p>
         The effectiveness of social distancing interventions was determined using the PNG model and contrasted with the Australian model.
        </p>
       </list-item>
      </list>
     </sec>
     <sec>
      <title>
       Key messages
      </title>
      <list list-type="bullet">
       <list-item>
        <p>
         A moderately transmissible pandemic occurring in PNG may be expected to result in a larger illness attack rate compared with that in a developed country setting.
        </p>
       </list-item>
       <list-item>
        <p>
         Feasible social distancing intervention strategies may be significantly less effective in PNG compared with the Australian setting.
        </p>
       </list-item>
       <list-item>
        <p>
         Compared with Australia, the larger household sizes contribute both to the larger attack rates in PNG and to the lower effectiveness of the interventions.
        </p>
       </list-item>
       <list-item>
        <p>
         The larger proportion of children in PNG and the fact that 50% do not attend school lessen the effectiveness of school closure interventions.
        </p>
       </list-item>
      </list>
     </sec>
     <sec>
      <title>
       Strength and limitations of this study
      </title>
      <list list-type="bullet">
       <list-item>
        <p>
         The findings are a first step in understanding how an influenza pandemic will impact on a low-income country.
        </p>
       </list-item>
       <list-item>
        <p>
         As with all modelling studies obtaining high-quality field data with which to ‘populate’ models is crucial and accessing such data in countries such as PNG is a challenge.
        </p>
       </list-item>
       <list-item>
        <p>
         These results and those from future research will permit better pandemic planning and allow intervention strategies to be tailored to the specific demographics and resource constraints found in developing countries.
        </p>
       </list-item>
      </list>
     </sec>
    </boxed-text>
    <sec id="s1">
     <title>
      Introduction
     </title>
     <p>
      Novel influenza virus strains have resulted in pandemics costing millions of lives
      <xref ref-type="bibr" rid="R1">
       1
      </xref>
      and the possible occurrence of a highly pathogenic virus strain is of concern to health authorities worldwide.
     </p>
     <p>
      It has been shown under laboratory conditions that the highly pathogenic H5N1 avian influenza strain may reassort or mutate to become readily transmissible between humans.
      <xref ref-type="bibr" rid="R2">
       2
      </xref>
      In response to the threat of influenza pandemics, most countries have developed pandemic preparedness plans.
      <xref ref-type="bibr" rid="R3 R4 R5 R6 R7 R8">
       3–8
      </xref>
      However, the level of completeness of these plans with regard to WHO guidelines
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
      varies dramatically between developed high-income countries and developing low-income countries.
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
     </p>
     <p>
      Low-income countries suffer the highest rates of morbidity and mortality from influenza pandemics. Data from the 1918/1919 pandemic suggest much higher death rates in India compared with Europe and the USA. While in northern Europe and the USA death rates were consistently below 1%, over 4.3% average mortality was reported from India, with some Indian provinces exceeding death rates of 7%.
      <xref ref-type="bibr" rid="R10">
       10
      </xref>
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      Even in the mild H1N1 pandemic of 2009, 59% of the estimated 284 500 deaths occurred in Africa and South-East Asia.
      <xref ref-type="bibr" rid="R2">
       2
      </xref>
      These differences are most likely due to the significant association of influenza mortality with comorbidities usually absent in the developed countries (such as chronic malnutrition, malaria, tuberculosis, pneumonia and HIV).
      <xref ref-type="bibr" rid="R12">
       12
      </xref>
      Furthermore it has been shown that the increased death rate due to an influenza pandemic is strongly associated with per capita income.
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      It is apparent that the burden of the next pandemic will also be focused overwhelmingly on the developing world, a point made by the WHO and others.
      <xref ref-type="bibr" rid="R5">
       5
      </xref>
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      <xref ref-type="bibr" rid="R13 R14 R15">
       13–15
      </xref>
     </p>
     <p>
      A substantial number of pandemic influenza models have been constructed in the past decade. A key goal of this effort is to determine the effectiveness of interventions, in terms of their ability to reduce infection and consequential death rates. Although it has been recognised that the major burden of mortality from influenza pandemics is suffered by low-income countries,
      <xref ref-type="bibr" rid="R5">
       5
      </xref>
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      <xref ref-type="bibr" rid="R16">
       16
      </xref>
      the primary focus of the vast majority of these models is on examining intervention effectiveness in developed (eg, the USA and European countries
      <xref ref-type="bibr" rid="R17 R18 R19 R20">
       17–20
      </xref>
      ) and middle-income countries (eg, Thailand
      <xref ref-type="bibr" rid="R21">
       21
      </xref>
      <xref ref-type="bibr" rid="R22">
       22
      </xref>
      ). Given the markedly different demographic and community structure, as well as resource and infrastructural constraints in comparison with developed countries, these models have limited capability to predict the impact of an influenza pandemic on low-income countries.
      <xref ref-type="bibr" rid="R23">
       23
      </xref>
      In addition, many low-income countries are located in tropical or subtropical regions where the timing and impact of influenza epidemics are more poorly understood than in temperate regions, where they are known to have a well-defined winter season.
      <xref ref-type="bibr" rid="R15">
       15
      </xref>
     </p>
     <p>
      To address this ‘modelling gap’ an individual-based disease transmission model of pandemic influenza has been developed for Papua New Guinea (PNG), based on the methods used previously to develop a pandemic influenza model of Albany, Western Australia.
      <xref ref-type="bibr" rid="R20">
       20
      </xref>
      <xref ref-type="bibr" rid="R24">
       24
      </xref>
      <xref ref-type="bibr" rid="R25">
       25
      </xref>
      The chosen location of Madang, a town of approximately 35 000 on the northern coast of the island of New Guinea has, along with all of PNG, different demographics and individual-to-individual contact patterns compared with those in developed countries. PNG has an annual per capita income of about US$2500—and is thus at a similar level of development as many African nations.
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
     </p>
     <p>
      The model was used to describe the spread of a novel influenza strain after introduction into the community. The resulting illness attack rate was determined together with data indicating where person-to-person transmission occurred. An unmitigated outbreak and two outbreaks with PNG-feasible intervention strategies activated were simulated and the results compared with those obtained using the Albany, Australia model.
     </p>
    </sec>
    <sec id="s2" sec-type="methods">
     <title>
      Methods
     </title>
     <p>
      Census and country-wide data from the PNG National Statistics Office
      <xref ref-type="bibr" rid="R27">
       27
      </xref>
      together with data collected in a field survey in Madang were used to construct the Madang model. Following the methodology used to construct the Albany model, each household is explicitly represented, with occupants in one of seven age categories. Schools, workplace and other mixing hubs were also explicitly represented. Individuals were allocated to these mixing hubs according to their age category, so connecting households and hubs as shown in
      <xref ref-type="fig" rid="BMJOPEN2012002518F1">
       figure 1
      </xref>
      . Using virus intrinsic transmission characteristics calibrated with the Australian model, simulations were performed using the Madang model. These simulations captured the day-to-day susceptible, exposed, infectious and recovered/immune infection profile of the population following introduction of a novel strain of influenza into the modelled community, assuming no existing immunity.
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
     </p>
     <fig id="BMJOPEN2012002518F1" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Schematic diagram of the Madang model.
       </p>
      </caption>
      <graphic xlink:href="bmjopen2012002518f01">
      </graphic>
     </fig>
     <sec id="s2a">
      <title>
       Madang demographics
      </title>
      <p>
       Madang model development used the most recent census data from 2001, other PNG government data and additional data collected in our field survey.
       <xref ref-type="bibr" rid="R29">
        29
       </xref>
       Census data provided the location groups of approximately 50 adjacent households, known as the census unit (CU). The specific demographics of each household in Madang in terms of number of individuals, their ages and occupation of adults was also provided by the census and each individual is uniquely identified in the model.
      </p>
      <p>
       From July to September 2011 we also conducted a survey in Madang to obtain data on the number of people working in smaller workplaces, school class sizes, market sizes and the number of people attending the major tertiary education centres in Madang (Divine Word University (DWU), Madang Teachers College, Madang Technical College and Madang Maritime College). We asked the headmasters of schools and colleges, the human resource department at DWU and business owners of small-to-medium scale businesses about the respective numbers and, if no records existed relied on their estimates. We also obtained estimates on the size of informal settlements within the town boundaries from the Madang provincial government. The data obtained in the survey are presented in online supplementary table A1.
      </p>
      <p>
       These data allowed for the construction of an explicit contact network linking households, schools, workplaces and other meeting places by allocating individuals to workplaces and schools, as with the Albany model.
       <xref ref-type="bibr" rid="R10">
        10
       </xref>
      </p>
     </sec>
     <sec id="s2b">
      <title>
       Contact network
      </title>
      <p>
       The model captures explicit person-to-person contact with the contact network describing population mobility occurring between households, schools, workplaces and the wider community as shown in
       <xref ref-type="fig" rid="BMJOPEN2012002518F1">
        figure 1
       </xref>
       . The virus spreads through the community due to this mobility, as transmission occurs between individuals when they are co-located, possibly following a move from one location to another.
      </p>
      <p>
       The number of contacts made by each individual each day in school, work and community settings were adjusted to reproduce the proportion of cases occurring in different settings as reported by empirical studies, specifically 40% of infections occurred in households, 30% in schools and workplaces and 30% in the wider community.
       <xref ref-type="bibr" rid="R30 R31 R32">
        30–32
       </xref>
       Contacts within schools and workplaces occurred in fixed-size mixing groups of maximum size 10. Within mixing groups contact was assumed to be homogeneous. Community contacts occurred between randomly selected individuals, weighted towards pairs of individuals located in neighbouring households.
      </p>
      <p>
       Each household contains uniquely identified individuals. Children and adults are assigned by an allocation algorithm to school classes and workplaces according to age based on class sizes and employee numbers obtained in the field survey. The field survey described above revealed that 50% of school-age children do not attend school, and this percentage is thought to be similar to most urban areas in PNG, with still lower rates in rural areas. Of those children not attending school 50% are allocated to neighbourhood hubs, as described below. In addition to contact occurring in households and mixing hubs, community contact is introduced to capture mixing which occurs out with these locales and in the wider community. The community contact occurs at a fixed rate, similarly to the Albany model.
      </p>
     </sec>
     <sec id="s2c">
      <title>
       Madang-specific contact locations
      </title>
      <p>
       Census data provided the occupation/activity of individuals, namely ‘wage-job’, ‘garden’, ‘business’ and ‘unemployed’. This was used to locate individuals denoted as wage-job with known workplaces. The numbers in this census category exceeded those found in the survey of major workplaces and knowledge of Madang suggested the creation of small, local workplaces to locate these additional adults and those in the business category. Adults with gardening as their occupation work in family-owned gardens, subsistence farming and generating produce for sale. For each household containing a garden worker, a garden workplace was created whose members matched those of the household.
      </p>
      <p>
       Three significant populations in Madang were not counted in the 2001 census, namely, those in settlements (unofficial housing areas also found in other parts of the developing world), those in the University and Chinese workers at a mine/processing site on the edge of the town. The field survey provided numbers resident in each of these locations: the two settlement areas in Madang with ∼750 inhabitants each; ∼3000 students and staff living in hostels at the DWU (a further ∼280 live in households in town and appeared in the census) and ∼650 overseas workers accommodated in hostels at the mine/processing site.
      </p>
      <p>
       To model the settlements new households were created and individuals allocated to mixing hubs to match overall Madang demographics. The populations at the University and the mine-site had virtual households created to replicate friendship groups of average size 7, and these locations were also designated as the workplace for these individuals. Contact between the wider Madang population and those at the University involved household and neighbourhood contacts for local students and staff living in town while resident staff and students were restricted to community contact. Contact between the mine-site and the town was also restricted to community contact.
      </p>
      <p>
       Census data classified a significant proportion (16.2%) of adults as unemployed and not attending a designated workplace.
       <xref ref-type="bibr" rid="R27">
        27
       </xref>
       Knowledge gathered from the field survey in Madang indicated that these adults do have daytime contact with others outwith the home, such as working or visiting the two informal markets. To address this feature an additional daytime contact location (neighbourhood hubs) was introduced, with unemployed adults in each CU allocated to neighbourhood hubs of 10 individuals. In addition, these hubs also have 25% of all local school age pupils allocated to them, accounting for half of the 50% of school age children which do not attend school.
      </p>
      <p>
       The introduction of neighbourhood hubs, which do not exist in the Albany model, give a model which the field survey and local knowledge indicate is representative of the contact patterns found in urban PNG. A Madang model which omits neighbourhood hubs, called Madang-nnh (no neighbourhood hubs), is also used in the simulation experiments and the resulting attack rates are presented in
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       . This allows influenza spread dynamics within the three models to be compared and indicates the sensitivity of the Madang model to the presence of the neighbourhood hubs.
      </p>
      <table-wrap id="BMJOPEN2012002518TB1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Simulation outcomes of
         <italic>
          no intervention
         </italic>
         ,
         <italic>
          school closure
         </italic>
         and
         <italic>
          rigorous social distancing
         </italic>
         (
         <italic>
          School Closure+WR+CCR
         </italic>
         ) scenarios
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
         <col align="left" span="1"/>
        </colgroup>
        <thead valign="bottom">
         <tr>
          <th colspan="1" rowspan="1">
          </th>
          <th align="left" colspan="1" rowspan="1">
           Albany model
          </th>
          <th align="left" colspan="1" rowspan="1">
           Madang model
          </th>
          <th align="left" colspan="1" rowspan="1">
           Madang-nnh model
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="4" rowspan="1">
           <italic>
            No intervention
           </italic>
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           R
           <sub>
            0
           </sub>
          </td>
          <td colspan="1" rowspan="1">
           1.5
          </td>
          <td colspan="1" rowspan="1">
           1.88
          </td>
          <td colspan="1" rowspan="1">
           1.74
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (1.47 to 1.54)
          </td>
          <td colspan="1" rowspan="1">
           (1.84 to 1.93)
          </td>
          <td colspan="1" rowspan="1">
           (1.70 to 1.79)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Illness attack rate
          </td>
          <td colspan="1" rowspan="1">
           31.7%
          </td>
          <td colspan="1" rowspan="1">
           46.6%
          </td>
          <td colspan="1" rowspan="1">
           40.8%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (31.3 to 32.0)
          </td>
          <td colspan="1" rowspan="1">
           (46.4 to 46.7)
          </td>
          <td colspan="1" rowspan="1">
           (40.6 to 41.0)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Illness locations
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Households
          </td>
          <td colspan="1" rowspan="1">
           37.8%
          </td>
          <td colspan="1" rowspan="1">
           48.7%
          </td>
          <td colspan="1" rowspan="1">
           51.8%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (37.5 to 38.0)
          </td>
          <td colspan="1" rowspan="1">
           (48.6 to 48.9)
          </td>
          <td colspan="1" rowspan="1">
           (51.6 to 52.0)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Hubs
          </td>
          <td colspan="1" rowspan="1">
           32.5%
          </td>
          <td colspan="1" rowspan="1">
           30.5%
          </td>
          <td colspan="1" rowspan="1">
           25%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (32.3 to 32.7)
          </td>
          <td colspan="1" rowspan="1">
           (30.3 to 30.6)
          </td>
          <td colspan="1" rowspan="1">
           (24.8 to 25.1)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Community
          </td>
          <td colspan="1" rowspan="1">
           27.9%
          </td>
          <td colspan="1" rowspan="1">
           20.1%
          </td>
          <td colspan="1" rowspan="1">
           22.2%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (27.7 to 28.1)
          </td>
          <td colspan="1" rowspan="1">
           (19.9 to 20.1)
          </td>
          <td colspan="1" rowspan="1">
           (22.1 to 22.3)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Imported
          </td>
          <td colspan="1" rowspan="1">
           1.8%
          </td>
          <td colspan="1" rowspan="1">
           0.7%
          </td>
          <td colspan="1" rowspan="1">
           1%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (1.7 to 1.8)
          </td>
          <td colspan="1" rowspan="1">
           (0.72 to 0.76)
          </td>
          <td colspan="1" rowspan="1">
           (0.96 to 1.01)
          </td>
         </tr>
         <tr>
          <td colspan="4" rowspan="1">
           <italic>
            Intervention: school closure
           </italic>
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Illness attack rate
          </td>
          <td colspan="1" rowspan="1">
           16.3%
          </td>
          <td colspan="1" rowspan="1">
           42.2%
          </td>
          <td colspan="1" rowspan="1">
           35.4%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (15.9 to 16.7)
          </td>
          <td colspan="1" rowspan="1">
           (42.0 to 42.4)
          </td>
          <td colspan="1" rowspan="1">
           (35.2 to 35.7)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Illness locations
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Households
          </td>
          <td colspan="1" rowspan="1">
           42.8%
          </td>
          <td colspan="1" rowspan="1">
           53.2%
          </td>
          <td colspan="1" rowspan="1">
           56.4%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (42.2 to 43.4)
          </td>
          <td colspan="1" rowspan="1">
           (53.0 to 53.4)
          </td>
          <td colspan="1" rowspan="1">
           (56.2 to 56.6)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Hubs
          </td>
          <td colspan="1" rowspan="1">
           20.9%
          </td>
          <td colspan="1" rowspan="1">
           24.9%
          </td>
          <td colspan="1" rowspan="1">
           19%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (20.5 to 21.3)
          </td>
          <td colspan="1" rowspan="1">
           (24.8 to 25.0)
          </td>
          <td colspan="1" rowspan="1">
           (18.9 to 19.2)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Community
          </td>
          <td colspan="1" rowspan="1">
           31.8%
          </td>
          <td colspan="1" rowspan="1">
           21%
          </td>
          <td colspan="1" rowspan="1">
           23.3%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (31.3 to 32.3)
          </td>
          <td colspan="1" rowspan="1">
           (20.8–21.0)
          </td>
          <td colspan="1" rowspan="1">
           (23.2 to 23.5)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Imported
          </td>
          <td colspan="1" rowspan="1">
           4.5%
          </td>
          <td colspan="1" rowspan="1">
           0.9%
          </td>
          <td colspan="1" rowspan="1">
           1.3%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (4.4 to 4.6)
          </td>
          <td colspan="1" rowspan="1">
           (0.92 to 0.96)
          </td>
          <td colspan="1" rowspan="1">
           (1.26 to 1.32)
          </td>
         </tr>
         <tr>
          <td colspan="4" rowspan="1">
           <italic>
            Intervention: school closure+WR+CCR
           </italic>
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Illness attack rate
          </td>
          <td colspan="1" rowspan="1">
           5.4%
          </td>
          <td colspan="1" rowspan="1">
           17.4%
          </td>
          <td colspan="1" rowspan="1">
           12.5%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (5.2 to 5.7)
          </td>
          <td colspan="1" rowspan="1">
           (17.1 to 17.7)
          </td>
          <td colspan="1" rowspan="1">
           (12.3 to 12.7)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Illness locations
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Households
          </td>
          <td colspan="1" rowspan="1">
           42.1%
          </td>
          <td colspan="1" rowspan="1">
           67.9%
          </td>
          <td colspan="1" rowspan="1">
           67.9%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (40.8 to 43)
          </td>
          <td colspan="1" rowspan="1">
           (67.3 to 68.5)
          </td>
          <td colspan="1" rowspan="1">
           (67.0 to 68.5)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Hubs
          </td>
          <td colspan="1" rowspan="1">
           27.4%
          </td>
          <td colspan="1" rowspan="1">
           13.2%
          </td>
          <td colspan="1" rowspan="1">
           10.7%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (25.8 to 28.8)
          </td>
          <td colspan="1" rowspan="1">
           (13.0 to 13.4)
          </td>
          <td colspan="1" rowspan="1">
           (10.4 to 10.9)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Community
          </td>
          <td colspan="1" rowspan="1">
           15.1%
          </td>
          <td colspan="1" rowspan="1">
           15.2%
          </td>
          <td colspan="1" rowspan="1">
           16%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (14.6 to 15.5)
          </td>
          <td colspan="1" rowspan="1">
           (15.0 to 15.4)
          </td>
          <td colspan="1" rowspan="1">
           (15.8 to 16.2)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Imported
          </td>
          <td colspan="1" rowspan="1">
           15.4%
          </td>
          <td colspan="1" rowspan="1">
           3.7%
          </td>
          <td colspan="1" rowspan="1">
           5.4%
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
          </td>
          <td colspan="1" rowspan="1">
           (15.1 to 15.7)
          </td>
          <td colspan="1" rowspan="1">
           (3.6 to 3.8)
          </td>
          <td colspan="1" rowspan="1">
           (5.3 to 5.5)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Mean simulation outcomes of no intervention, school closure and rigorous social distancing presented as percentages and their corresponding 95% CI (presented in parentheses, shaded rows). WR, workforce reduction and CCR, community contact reduction; Hubs represent schools, workplaces and neighbourhoods together; Community represents general community;  Imported represents seeded cases.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       The number of individuals in each of the daytime locations for the Albany, Madang and Madang-nnh models are presented in online
       <ext-link ext-link-type="uri" xlink:href="http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002518/-/DC1">
        supplementary table
       </ext-link>
       A1. Additional information on the data used to construct the Madang model is given in.
       <xref ref-type="bibr" rid="R33">
        33
       </xref>
      </p>
     </sec>
     <sec id="s2d">
      <title>
       Influenza transmission
      </title>
      <p>
       Each individual has their influenza infection history modelled using an SEIR approach and are in one of four infection states, namely susceptible, exposed, infectious or recovered and thus immune.
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
       The passage of infection in each individual reflects the known time-changing infectiousness profile (ie, virus shedding
       <xref ref-type="bibr" rid="R34">
        34
       </xref>
       ) of influenza at two discrete points-of-time every 24 h, during a day-time and a night-time period.
      </p>
      <p>
       Disease transmission is realised using a probabilistic transmission function, implemented by the simulation algorithm. Together with mobility data, the transmission function captures disease spread throughout the modelled community and may be adjusted to reflect pandemics with various transmission characteristics, corresponding to the basic reproduction number R
       <sub>
        0
       </sub>
       of a particular influenza strain, as discussed further in.
       <xref ref-type="bibr" rid="R20">
        20
       </xref>
       <xref ref-type="bibr" rid="R24">
        24
       </xref>
       <xref ref-type="bibr" rid="R25">
        25
       </xref>
      </p>
      <p>
       It is assumed that infection transmission may occur when an infectious and a susceptible individual come into contact, in a stochastic fashion. Once infected, an individual progresses through a series of infectious states according to a fixed timeline, taking them from susceptible, to exposed state, to infectious and then to an immune, recovered state.
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
      </p>
      <p>
       The probability that an infectious individual infects a susceptible was calculated using the following function.
       <disp-formula>
        <inline-graphic xlink:href="bmjopen2012002518ueq1.jpg">
        </inline-graphic>
       </disp-formula>
      </p>
      <p>
       The factors which determine probability of transmission from an infectious individual (I
       <sub>
        i
       </sub>
       ) to a susceptible individual (I
       <sub>
        s
       </sub>
       ) are the basic virus transmissibility (β
       <sub>
        v
       </sub>
       ), the age-based susceptibility of I
       <sub>
        s
       </sub>
       the current level of infectiousness of I
       <sub>
        i
       </sub>
       , and, if the contact between I
       <sub>
        i
       </sub>
       and I
       <sub>
        s
       </sub>
       occurs in a household, the household size Household(I
       <sub>
        i
       </sub>
       , I
       <sub>
        s
       </sub>
       ). Details of the household size factor are given below; further details of the influenza transmission model can be found in ref.
       <xref ref-type="bibr" rid="R35">
        35
       </xref>
       .
      </p>
      <p>
       To achieve simulations for a particular basic reproduction number R
       <sub>
        0
       </sub>
       , β
       <sub>
        v
       </sub>
       was adjusted; details of the procedure for estimating β
       <sub>
        v
       </sub>
       and R
       <sub>
        0
       </sub>
       are given in ref.
       <xref ref-type="bibr" rid="R20">
        20
       </xref>
       . A pandemic with a basic reproduction number of 1.5 is used in this study, and corresponds to some estimations of the 2009 H1N1 pandemic
       <xref ref-type="bibr" rid="R36 R37 R38 R39">
        36–39
       </xref>
       and the 1957 and 1968 pandemics.
       <xref ref-type="bibr" rid="R40">
        40
       </xref>
       <xref ref-type="bibr" rid="R41">
        41
       </xref>
       Since it is virus intrinsic, we assumed that β
       <sub>
        v
       </sub>
       was similar in Madang and thus calculated R
       <sub>
        0
       </sub>
       in the Madang and Madang-nnh models using the β
       <sub>
        v
       </sub>
       corresponding to an R
       <sub>
        0
       </sub>
       of 1.5 in the Albany model. Details of parameter settings used in each model are given in online
       <ext-link ext-link-type="uri" xlink:href="http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002518/-/DC1">
        supplementary table
       </ext-link>
       A2.
      </p>
     </sec>
     <sec id="s2e">
      <title>
       Simulation
      </title>
      <p>
       A simulation algorithm, realised in the C++ programming language, manipulates the underlying demographic model and captures both population mobility and the time-changing infectivity profile of each individual. Each individual has their infectivity status denoted by one of the four (S, E, I, R) states at any time point during the duration of the simulated period. The simulation algorithm captures the state of the whole population twice per day, a daytime point-in-time snapshot and an evening snapshot, with individuals (possibly) moving locations between successive day or night periods, such as household to school or workplace for the day phase, returning home for the night period. Individuals come into contact with other individuals on a one-to-one basis in each location, with possible influenza transmission then occurring.
      </p>
      <p>
       Individuals in each household and contact hub make contacts within a close-contact mixing group, taken to be the entire household or a subset of larger hubs, and also make additional non hub-based random community contacts. The individual-to-individual transmission probability in larger households was moderated by household size using data from a study by Cauchemez
       <italic>
        et al
       </italic>
       <xref ref-type="bibr" rid="R42">
        42
       </xref>
       The reduction of the probability of within-household transmission with household size is also shown in online
       <ext-link ext-link-type="uri" xlink:href="http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002518/-/DC1">
        supplementary figure A1
       </ext-link>
       . This reflects the assumed reduction in pairwise contact in households with greater than three members and is significant in the Madang context, where the average household size is 6.32 compared with 2.54 in Albany.
      </p>
      <p>
       Using the contact, mobility and transmission features described above, stochastic simulations of influenza spread in Madang were conducted. All simulations were repeated 40 times with random numbers controlling the outcome of stochastic events (the locality of seeded infected individuals and the probability of transmission) and the results were averaged. Analysis of this simulation model has shown that the 40-run mean attack rate is highly unlikely (95% CI) to differ by more than 1.2% from the mean attack rate of a much larger set of experiment repeats.
       <xref ref-type="bibr" rid="R20">
        20
       </xref>
       Where 95% CIs are reported in the results, these were calculated from the mean and SD of 40 randomly seeded simulation runs, using the normal approximation method.
      </p>
      <p>
       One new infection per day was introduced into the population during the whole period of the simulations, and randomly allocated to a household.
      </p>
      <p>
       This seeding assumption of one case per day was chosen to reliably begin a local epidemic in every stochastic simulation. For the transmission characteristics described above, analysis shows that seeding at this rate for 7 days results in a sustained epidemic in &gt;97% of the simulation runs and 100% with 2 weeks of seeding, with higher percentages for the higher transmissibility scenarios. Seeding at this rate is continued throughout the simulation to capture the case where an epidemic may be initially suppressed by a rigorous intervention strategy, but may subsequently break out if intervention measures are relaxed.
      </p>
      <p>
       After the beginning of a sustained local epidemic, any subsequent variation in the amount of seeding has very little effect on the progress of the local epidemic, as the number of imported cases is much smaller than those generated by the local epidemic. Preliminary analyses using the present model have shown that even if the seeding rate is increased to five infections per day, after 7 days the number of infections generated from the self-sustained local epidemic is twice the number of imported infections, and by 14 days local infections outnumber imported infections by a factor of 8.
      </p>
      <p>
       The simulation period was divided into 12 h day/night periods and during each period a nominal location for each individual was determined. This took into consideration the cycle type (day/night, weekday/weekend), infection state of each individual and whether child supervision was needed to look after a child at home. Individuals occupying the same location during the same time period were assumed to come into potential infective contact. Details of the simulation procedure are presented in ref.
       <xref ref-type="bibr" rid="R20">
        20
       </xref>
       .
      </p>
     </sec>
     <sec id="s2f">
      <title>
       Interventions
      </title>
      <p>
       The effectiveness of social distancing interventions, such as school or workplace closure, may be quantified by comparing the passage of the influenza virus in the community with and without interventions activated, and presented as the reduction in the daily and cumulative illness attack rates. Pharmaceutical-based interventions were not considered as antiviral agents may only be available in limited quantities in a PNG setting, while a vaccination campaign would face significant delay, supply and delivery constraints. Two intervention strategies considered feasible in a PNG setting were examined. These were: school closure involving all schools, with home isolation of all affected children; and a more rigorous strategy involving school closure coupled with 50% reductions in community-wide contact, workplace participation and contact in neighbourhood hubs.
      </p>
      <p>
       Both Madang models, (with and without neighbourhood hubs), were used to compare a pandemic in PNG with one occurring in Albany, Australia. Simulations were conducted involving: no interventions; only school closure applied; and rigorous social distancing, for each of the three models.
      </p>
     </sec>
    </sec>
    <sec id="s3" sec-type="results">
     <title>
      Results
     </title>
     <sec id="s3a">
      <title>
       Synopsis
      </title>
      <p>
       General comparative trends are presented in
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       , were the Albany and Madang models are compared. For a pandemic in a developed country setting having a basic reproduction number R
       <sub>
        0
       </sub>
       of 1.5 and an illness attack rate of 31.7%, the same pandemic characteristics applied in a PNG setting with no interventions activated resulted in higher rates of influenza transmission, with an attack rate of 46.6% and reproduction number R
       <sub>
        0
       </sub>
       =1.88 (
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       ). Comparing the attack rates when interventions were activated, both intervention strategies (solely school closure and rigorous social distancing) were much less effective in the PNG setting compared with the Australian one. The mitigated illness attack rates in the PNG model were approximately three times higher than those in the Australian model with the interventions being 60–70% less effective.
       <xref ref-type="table" rid="BMJOPEN2012002518TB2">
        Table 2
       </xref>
       indicates where transmission that resulted in illness occurred, showing a significantly higher number and proportion of transmissions occurring in households, as opposed to other contact/transmission locations, in the Madang compared with the Australian model (
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       ). The average household size in the PNG model is 2.5 times larger than that in Albany and this had a significant impact on the overall infection rate, making it noticeably higher in the PNG model.
      </p>
      <table-wrap id="BMJOPEN2012002518TB2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Number of symptomatic influenza cases at different locations
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <colgroup span="1">
         <col align="left" span="1"/>
         <col align="char" char="(" span="1"/>
         <col align="char" char="(" span="1"/>
         <col align="char" char="(" span="1"/>
        </colgroup>
        <thead valign="bottom">
         <tr>
          <th align="left" colspan="1" rowspan="1">
           Locations
          </th>
          <th align="left" colspan="1" rowspan="1">
           Albany model
          </th>
          <th align="left" colspan="1" rowspan="1">
           Madang model
          </th>
          <th align="left" colspan="1" rowspan="1">
           Madang-nnh model
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="4" rowspan="1">
           <italic>
            No intervention
           </italic>
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Households
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            3511
           </italic>
           (3487 to 3536)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            8028
           </italic>
           (8004 to 8053)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            7476
           </italic>
           (7442 to 7498)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Child care
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            88
           </italic>
           (84 to 91)
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Neighbourhood
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            1258
           </italic>
           (1249 to 1267)
          </td>
          <td colspan="1" rowspan="1">
           to
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Child education
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            1269
           </italic>
           (1256 to 1285)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            990
           </italic>
           (980 to 1001)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            950
           </italic>
           (939 to 962)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Adult education
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            157
           </italic>
           (152 to 161)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            270
           </italic>
           (261 to 280)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            253
           </italic>
           (244 to 262)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Work place
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            1508
           </italic>
           (1494 to 1521)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2495
           </italic>
           (2481 to 2510)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2395
           </italic>
           (2380 to 2410)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Community
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2594
           </italic>
           (2572 to 2616)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            3300
           </italic>
           (3281 to 3317)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            3199
           </italic>
           (3182 to 3216)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Imported
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            167
           </italic>
           (162 to 169)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            122
           </italic>
           (119 to 125)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            144
           </italic>
           (139 to 148)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Total
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            9294
           </italic>
           (9199 to 9390)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            16463
           </italic>
           (16407 to 16521)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            14417
           </italic>
           (14350 to 14486)
          </td>
         </tr>
         <tr>
          <td colspan="4" rowspan="1">
           <italic>
            Intervention: school closure
           </italic>
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Households
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2048
           </italic>
           (2019 to 2075)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            7939
           </italic>
           (7914 to 7964)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            7070
           </italic>
           (7042 to 7098)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Child care
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            3
           </italic>
           (2 to 4)
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Neighbourhood
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            1172
           </italic>
           (1162 to 1181)
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Child education
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            38
           </italic>
           (35 to 43)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            13
           </italic>
           (11 to 15)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            15
           </italic>
           (14 to 18)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Adult education
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            80
           </italic>
           (76 to 84)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            196
           </italic>
           (190 to 202)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            182
           </italic>
           (176 to 189)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Work place
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            879
           </italic>
           (861 to 897)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2334
           </italic>
           (2318 to 2349)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2186
           </italic>
           (2169 to 2202)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Community
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            1522
           </italic>
           (1500 to 1545)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            3121
           </italic>
           (3105 to 3141)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2923
           </italic>
           (2906 to 2941)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Imported
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            215
           </italic>
           (211 to 219)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            141
           </italic>
           (137 to 143)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            162
           </italic>
           (158 to 165)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Total
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            4785
           </italic>
           (4672 to 4899)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            14916
           </italic>
           (14856 to 14987)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            12538
           </italic>
           (12456 to 12613)
          </td>
         </tr>
         <tr>
          <td colspan="4" rowspan="1">
           <italic>
            Intervention: school closure+WR+CCR
           </italic>
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Households
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            672
           </italic>
           (654 to 689)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            4181
           </italic>
           (4143 to 4218)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            2992
           </italic>
           (2960 to 3026)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Child care
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            19
           </italic>
           (15 to 22)
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Neighbourhood
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            213
           </italic>
           (209 to 218)
          </td>
          <td colspan="1" rowspan="1">
           –
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Child education
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            272
           </italic>
           (249 to 295)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            17
           </italic>
           (15 to 20)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            18
           </italic>
           (16 to 21)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Adult education
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            29
           </italic>
           (26 to 31)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            116
           </italic>
           (110 to 121)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            97
           </italic>
           (91 to 101)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Work place
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            117
           </italic>
           (112 to 124)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            468
           </italic>
           (458 to 478)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            355
           </italic>
           (348 to 364)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Community
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            242
           </italic>
           (234 to 248)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            935
           </italic>
           (925 to 948)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            707
           </italic>
           (696 to 717)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Imported
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            246
           </italic>
           (242 to 252)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            228
           </italic>
           (224 to 233)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            237
           </italic>
           (233 to 243)
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           Total
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            1597
           </italic>
           (1524 to 1679)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            6158
           </italic>
           (6065 to 6254)
          </td>
          <td colspan="1" rowspan="1">
           <italic>
            4406
           </italic>
           (4334 to 4506)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Mean number (italic face) of symptomatic influenza cases and their corresponding 95% CI (in parentheses) at different locations for no intervention, school closure and rigorous social distancing presented. WR, workforce reduction and CCR, community contact reduction.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       We also conducted experiments with the Madang-nnh model, where neighbourhood contact hubs were omitted, to contrast the transmission characteristics with and without these contact hubs. The results of these simulation experiments are included in
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        tables 1
       </xref>
       and
       <xref ref-type="table" rid="BMJOPEN2012002518TB2">
        2
       </xref>
       . It should be noted that the Madang model with neighbourhood hubs included is believed to be more representative of population mixing characteristics in PNG, following local knowledge. Neighbourhood hubs were introduced to reflect the known mixing patterns occurring with adults not working in designated workplaces, such as those found in the regular contact which may occur among individuals in marketplaces. The addition of such contact hubs increased individual-to-individual contacts and hence infection transmission opportunities (see
       <xref ref-type="table" rid="BMJOPEN2012002518TB2">
        table 2
       </xref>
       ) with approximately 2000 additional symptomatic infections resulting, for all three (mitigated and non-mitigated) scenarios. In terms of cumulative illness attack rate, the Madang model gave a basic reproduction number R
       <sub>
        0
       </sub>
       of 1.88 and an illness attack rate of 46.6%, compared with that of the Madang-nnh (no neighbourhood hub) model with R
       <sub>
        0
       </sub>
       =1.74 and an illness attack rate of 40.8%. The daily case incidence resulting from simulating the Albany, Madang and Madang-nnh models is presented in
       <xref ref-type="fig" rid="BMJOPEN2012002518F2">
        figure 2
       </xref>
       for the three scenarios.
      </p>
      <fig id="BMJOPEN2012002518F2" position="float">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Daily case incidence for different intervention scenarios. Daily case incidence for the no intervention, school closure and rigorous social distancing (school closure and workplace and community contact reductions) scenarios is shown. The blue, red and green curves represent the Albany, Madang and Madang-nnh models, respectively.
        </p>
       </caption>
       <graphic xlink:href="bmjopen2012002518f02">
       </graphic>
      </fig>
     </sec>
     <sec id="s3b">
      <title>
       No intervention scenario
      </title>
      <p>
       The results given in
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       show that there is an approximately 47% increase in the illness attack rate in the Madang setting compared with that resulting from the Albany model; from 31.7% to 46.6%. If no neighbourhood hub contact occurs, as with the Madang-nnh model, there is still an increase in illness attack rate compared with that resulting from the Albany model, with an approximately 29% increase in the attack rate; from 31.7% to 40.8%.
      </p>
      <p>
       It is apparent from the results presented in
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       that there is a greater proportion of influenza cases occurring within households in both Madang models compared with that of the Albany model. This arises from the average Madang household size being larger than that in Albany. The number of cases occurring in Madang due to household transmission is ∼8000 compared with ∼3500 in Albany; note that Madang has a total population of ∼35 000 compared with ∼30 000 in Albany.
      </p>
     </sec>
     <sec id="s3c">
      <title>
       School closure scenario
      </title>
      <p>
       The school closure intervention in the Madang model is found to be approximately five times less effective compared with that of the Albany model. Simulation results suggest a 9.4% reduction (46.6% to 42.2%) in the illness attack rate can be achieved in Madang due to school closure whereas a 48.6% reduction (31.7–16.3%) can be achieved in Albany (see
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       ). For the Madang-nnh (no neighbourhood hub) model, school closure is approximately 3.5 times less effective compared with the Albany model.
      </p>
      <p>
       <xref ref-type="table" rid="BMJOPEN2012002518TB2">
        Table 2
       </xref>
       (middle panel) indicates an illness attack rate of ∼15 000 in Madang compared with ∼4800 in Albany. Much higher case numbers occur in households, workplaces and the wider community (including neighbourhood hubs) than in Albany, highlighting the poorer efficacy of this intervention strategy in a PNG setting. The Madang-nnh model also results in higher household and workplace transmission than the Albany model. Note that while there is a significantly higher proportion of under 17-year-old children in Madang (40%) compared with Albany (28%), our field survey indicates that 50% of school age children in Madang do not attend school, hence school closure is less effective in disrupting the transmission chain (ie, household 1-to-school-to-household 2) compared with Australia. This feature is also present in the rigorous social distancing intervention.
      </p>
     </sec>
     <sec id="s3d">
      <title>
       Rigorous social distancing scenario
      </title>
      <p>
       Previous simulation studies
       <xref ref-type="bibr" rid="R20">
        20
       </xref>
       <xref ref-type="bibr" rid="R43">
        43
       </xref>
       <xref ref-type="bibr" rid="R44">
        44
       </xref>
       show that rigorous social distancing interventions involving school closure coupled to contact reductions in other locations may be highly effective in reducing the attack rate within a developed country setting. Comparing the effectiveness of rigorous social distancing between the Albany and Madang models, an ∼83% reduction (from 31.7% to 5.4%) reduction may be achieved in Albany whereas a smaller ∼62.7% reduction (from 46.6% to 17.4%), is achieved in the Madang model; see
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        table 1
       </xref>
       . In the Madang-nnh model a ∼69.4% reduction in the attack rate (40.8–12.5%) can be achieved by this rigorous social distancing intervention.
      </p>
      <p>
       <xref ref-type="table" rid="BMJOPEN2012002518TB2">
        Table 2
       </xref>
       (bottom panel) indicates an illness attack rate of ∼6000 in Madang (and ∼4400 for Madang-nnh) compared with ∼1600 for the Albany model. Much higher case numbers occur due to household transmission, ∼4200 in Madang versus ∼670 in Albany (and ∼3000 in Madang-nnh). Workplace and community-wide transmission are also higher in the two Madang models compared with Albany.
      </p>
      <p>
       These results suggest that both social distancing strategies are much less effective in a PNG setting compared with what might be achieved in a developed country.
       <xref ref-type="fig" rid="BMJOPEN2012002518F2">
        Figure 2
       </xref>
       also reveals this clear trend, with peak case incidence and the area under the curves (the attack rate) being higher in both Madang models compared with the Albany model.
      </p>
     </sec>
     <sec id="s3e">
      <title>
       Sensitivity analysis
      </title>
      <p>
       The sensitivity of key model parameters, such as school contact group size, illness withdrawal rates and intervention duration have been extensively examined for the Albany model.
       <xref ref-type="bibr" rid="R44">
        44
       </xref>
       <xref ref-type="bibr" rid="R45">
        45
       </xref>
       These indicate that while the model is sensitive to some parameter settings, the relative effectiveness of social distancing interventions remains unchanged, a feature also shared by the Madang models.
      </p>
      <p>
       The major difference between the Albany and Madang models is the presence of neighbourhood hubs. We have included a Madang model which has no neighbourhood hubs (Madang-nnh) and present comparative results for all three models in
       <xref ref-type="table" rid="BMJOPEN2012002518TB1">
        tables 1
       </xref>
       and
       <xref ref-type="table" rid="BMJOPEN2012002518TB2">
        2
       </xref>
       ,
       <xref ref-type="fig" rid="BMJOPEN2012002518F2">
        figure 2
       </xref>
       and online supplementary tables A3–A6. Simulations comparing neighbourhood mixing group sizes 10 (baseline), 20 and 30 indicate that for hubs of size 20 and 30, the increased transmission results in higher attack rates, as expected (see online supplementary table A3).
      </p>
      <p>
       The effect of varying compliance with home isolation of school children following school closure on attack rate was examined. Compliance was reduced from 100% to 50%. Reduced compliance increased the attack rate in Albany as those children affected made additional daytime contacts with other children. In Madang, the reduction in compliance had only minimal effect since approximately 50% of school age children do not attend school and continue to make daytime contacts in neighbourhood hubs (see online supplementary table A4).
      </p>
      <p>
       The effect of using different probabilities of voluntary withdrawal to the home of symptomatic adults and children is presented in online supplementary table A5. Lower rates of voluntary withdrawal lead to higher attack rates in all three models. Voluntary withdrawal from work or school has a more pronounced effect in the Albany model, as a significant proportion of children in Madang still transmit through daytime contacts in neighbourhood hubs.
      </p>
      <p>
       The effects of variation of the timing of intervention initiation are presented in online supplementary table A6. In the school closure scenario, delayed response had the most severe impact on the attack rates in Albany, whereas for the Madang models the changes in attack rate were marginal. This is again due to a large fraction of children not attending school and the existence of neighbourhood hubs. Similarly, in the rigorous contact reduction scenario the effect of delayed response on attack rate was more pronounced in the Albany model, due to lower effectiveness of interventions in a PNG setting.
      </p>
     </sec>
    </sec>
    <sec id="s4" sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      Introduction of a pandemic influenza strain with identical transmissibility characteristics results in a significantly higher infection and illness rate in a PNG setting when compared with that of a developed country. Social distancing intervention strategies suitable for a developing country may be significantly less effective in reducing the attack rate when compared with the outcomes expected in an Australian setting. Substantially more infections occurred in PNG households compared with that of the Australian model. The significantly larger size of households, a feature shared by many developing countries, together with higher community-wide contact in PNG, contributed to the higher infection rates. Interventions are less effective in a PNG setting since they are not targeted at household transmission, and given the larger household sizes, are applicable to a smaller proportion of transmissions compared with the Australian scenario. In addition, as only half the school-age children in Madang attend school, the two school closure based interventions impact fewer individuals.
     </p>
     <p>
      While care was taken to obtain detailed data used to populate the Madang and Albany models, government data was found to be more limited in PNG. While a field survey was conducted in Madang to fill in missing data and make the models as directly comparable as possible, there is still scope for conducting further data collection. As with all modelling studies, the accuracy of results is limited by the quality of data used to construct the model. In the case of influenza epidemic modelling, outcomes are dependent on assumptions about the number, duration and physical closeness of contacts between people and how these attributes of contact affect transmission probability. These data are very difficult to estimate, with the best data source available being.
      <xref ref-type="bibr" rid="R46">
       46
      </xref>
      In the absence of high-quality reliable data, we have made plausible assumptions regarding interpersonal contact, and, in the Albany case, these are reflective of the data in.
      <xref ref-type="bibr" rid="R46">
       46
      </xref>
     </p>
     <p>
      The lack of similar low-income modelling studies prevents comparison with related studies, and suggests that this is an area requiring further attention. Research studies expanding on that reported here suggest themselves: the construction and use of a number of additional PNG models capturing different population structures, such as rural villages and island communities; and the determination of health outcomes following a moderately severe influenza pandemic, taking into account comorbidities with extant diseases such as malaria and tuberculosis, diseases common to many low-income countries.
     </p>
     <p>
      The interventions used in the present study are based on social distancing. Surveys have shown that a higher proportion of low-income countries have social distancing interventions planned in the case of a pandemic, compared with high-income European countries due to their feasibility and cost-effectiveness.
      <xref ref-type="bibr" rid="R3">
       3
      </xref>
      <xref ref-type="bibr" rid="R4">
       4
      </xref>
      <xref ref-type="bibr" rid="R6">
       6
      </xref>
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      <xref ref-type="bibr" rid="R47">
       47
      </xref>
      <xref ref-type="bibr" rid="R48">
       48
      </xref>
      Pharmaceutical-based interventions were not considered in this study due to cost and delivery issues found with low-income countries.
      <xref ref-type="bibr" rid="R4">
       4
      </xref>
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
     </p>
     <p>
      Consideration may need to be given to some form of antiviral agent use, possibly for case treatment, given the poor performance of purely social distancing interventions in developing countries as suggested by this study. The advantage of antiviral use is that it may be targeted at reducing within-household transmission, a location of transmission otherwise not impacted by social distancing interventions. The present study shows that larger numbers of transmissions occur within households due to the larger household sizes in countries such as PNG. Furthermore, low-income countries generally have population health profiles not seen in developed countries, including the prevalence of diseases such as malaria, tuberculosis and HIV.
      <xref ref-type="bibr" rid="R49">
       49
      </xref>
      Antiviral treatment of influenza cases coinfected with such diseases may be an appropriate intervention strategy given the poorer health outcomes which comorbidity may impose.
      <xref ref-type="bibr" rid="R12">
       12
      </xref>
      The provision and use of antiviral agents will have challenges not faced by industrialised countries, due to the cost of providing an antiviral stockpile and subsequent distribution of antivirals in countries which have health systems already stretched to capacity.
      <xref ref-type="bibr" rid="R15">
       15
      </xref>
     </p>
     <p>
      The importance of suitable pandemic influenza preparedness plans for low-income countries is recognised by the WHO.
      <xref ref-type="bibr" rid="R50">
       50
      </xref>
      <xref ref-type="bibr" rid="R51">
       51
      </xref>
      Disease transmission models will play a role in guiding policy makers in determining the effectiveness of possible pandemic countermeasures. History tells us that low-income countries are likely to be more affected, yet almost all models deal with mitigation strategies for developed nations with good health infrastructure and low prevalence of endemic diseases. These countries have poorer access to antiviral drug and vaccine-based interventions and higher extant disease burdens, compared with developed countries. For the reasons, development of appropriate intervention strategies focused on countries such as PNG needs to occur.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supplementary Material
     </title>
     <supplementary-material content-type="local-data" id="d35e152">
      <caption>
       <title>
        Author's manuscript
       </title>
      </caption>
      <media mime-subtype="pdf" mimetype="application" xlink:href="bmjopen-2012-002518.draft_revisions.pdf">
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="d35e153">
      <caption>
       <title>
        Reviewer comments
       </title>
      </caption>
      <media mime-subtype="pdf" mimetype="application" xlink:href="bmjopen-2012-002518.reviewer_comments.pdf">
      </media>
     </supplementary-material>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Contributions:
        </bold>
        GJM conceived the study. GJM, PB, SK and JK designed the model. PB and NH conducted the experiments. SK supervised data collection. All authors analysed the results and contributed to drafts of the manuscript.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Funding:
        </bold>
        Australian National Health and Medical Research Council (grant number 1004415).
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Competing interests:
        </bold>
        None.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Provenance and peer review:
        </bold>
        Not commissioned; externally peer reviewed.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Data sharing statement:
        </bold>
        Demographic dataset available to researchers from the corresponding author at milne@csse.uwa.edu.au.
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tumpey
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Basler
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name>
          <surname>
           Aguilar
          </surname>
          <given-names>
           PV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization of the reconstructed 1918 Spanish influenza pandemic virus
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         310
        </volume>
        :
        <fpage>
         77
        </fpage>
        –
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         16210530
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herfst
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Schrauwen
          </surname>
          <given-names>
           EJA
          </given-names>
         </name>
         <name>
          <surname>
           Linster
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Airborne transmission of influenza A/H5N1 virus between ferrets
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         336
        </volume>
        :
        <fpage>
         1534
        </fpage>
        –
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         22723413
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         UK preparedness for pandemic influenza
        </article-title>
        .
        <source>
         BMJ
        </source>
        <year>
         2007
        </year>
        ;
        <volume>
         334
        </volume>
        :
        <fpage>
         965
        </fpage>
        –
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         17493986
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Mounier-Jack
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic influenza preparedness in the Asia-Pacific region
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         368
        </volume>
        :
        <fpage>
         886
        </fpage>
        –
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         16950366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drake
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Chalabi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cost-effectiveness analysis of pandemic influenza preparedness: what's missing?
        </article-title>
        <source>
         Bull World Health Organ
        </source>
        <volume>
         90
        </volume>
        :
        <fpage>
         940
        </fpage>
        –
        <lpage>
         1
        </lpage>
        <pub-id pub-id-type="pmid">
         23284200
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mensua
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mounier-Jack
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic influenza preparedness in Latin America: analysis of national strategic plans
        </article-title>
        .
        <source>
         Health Policy Plann
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         253
        </fpage>
        –
        <lpage>
         60
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mounier-Jack
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         How prepared is Europe for pandemic influenza? Analysis of national plans
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         367
        </volume>
        :
        <fpage>
         1405
        </fpage>
        –
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         16650650
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ortu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Mounier-Jack
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic influenza preparedness in Africa is a profound challenge for an already distressed region: analysis of national preparedness plans
        </article-title>
        .
        <source>
         Health Policy Plann
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         161
        </fpage>
        –
        <lpage>
         9
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9
       </label>
       <mixed-citation publication-type="book">
        <collab>
         WHO
        </collab>
        <source>
         Pandemic influenza preparedness and response
        </source>
        .
        <publisher-loc>
         Geneva, Switzerland
        </publisher-loc>
        :
        <publisher-name>
         WHO press
        </publisher-name>
        ,
        <year>
         2009
        </year>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mathews
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Chesson
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           McCaw
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Understanding influenza transmission, immunity and pandemic threats
        </article-title>
        .
        <source>
         Influenza Other Respi Viruses
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         143
        </fpage>
        –
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         19627371
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Chin
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         368
        </volume>
        :
        <fpage>
         2211
        </fpage>
        –1
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         17189032
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Archer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Naidoo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <comment>
         pii=19369
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fedson
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Meeting the challenge of influenza pandemic preparedness in developing countries
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         365
        </fpage>
        –
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         19239746
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ortiz
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Lafond
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pandemic influenza in Africa, lessons learned from 1968: a systematic review of the literature
        </article-title>
        .
        <source>
         Influenza Other Respi Viruses
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         11
        </fpage>
        –
        <lpage>
         24
        </lpage>
        <pub-id pub-id-type="pmid">
         21668669
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oshitani
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kamigaki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Major issues and challenges of influenza pandemic preparedness in developing countries
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         875
        </fpage>
        –
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         18507896
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dawood
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Iuliano
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         687
        </fpage>
        –
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         22738893
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Germann
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <name>
          <surname>
           Kadau
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Longini
          </surname>
          <given-names>
           IM
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mitigation strategies for pandemic influenza in the United States
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         103
        </volume>
        :
        <fpage>
         5935
        </fpage>
        –
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         16585506
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glass
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Glass
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Beyeler
          </surname>
          <given-names>
           WE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeted social distancing design for pandemic influenza
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         1671
        </fpage>
        –
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         17283616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davey
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Glass
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Min
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e2606
        </fpage>
        <pub-id pub-id-type="pmid">
         18596963
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A small community model for the transmission of infectious diseases: comparison of school closure as an intervention in individual-based models of an influenza pandemic
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e4005
        </fpage>
        <pub-id pub-id-type="pmid">
         19104659
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Longini
          </surname>
          <given-names>
           IM
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Nizam
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Containing pandemic influenza at the source
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         309
        </volume>
        :
        <fpage>
         1083
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         16079251
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           DAT
          </given-names>
         </name>
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Strategies for containing an emerging influenza pandemic in Southeast Asia
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         437
        </volume>
        :
        <fpage>
         209
        </fpage>
        –
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         16079797
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Debellut
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Gessner
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Improving influenza surveillance in sub-Saharan Africa
        </article-title>
        .
        <source>
         B World Health Organ
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         301
        </fpage>
        –
        <lpage>
         5
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines
        </article-title>
        .
        <source>
         J R Soc Interface
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         573
        </fpage>
        –
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="pmid">
         19755499
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halder
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of the effectiveness of interventions used during the 2009 H1N1 influenza pandemic
        </article-title>
        .
        <source>
         BMC Public Health
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         168
        </fpage>
        <pub-id pub-id-type="pmid">
         20346187
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26
       </label>
       <mixed-citation publication-type="other">
        <collab>
         The World Fact Book
        </collab>
        ,
        <comment>
         Central Intelligence Agency
        </comment>
        ,
        <year>
         2011
        </year>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27
       </label>
       <mixed-citation publication-type="other">
        <comment>
         National Statistics Office of Papua New Guinea
        </comment>
        <year>
         2012
        </year>
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           May
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <source>
         Infectious diseases of humans: dynamics and control
        </source>
        .
        <publisher-loc>
         Oxford
        </publisher-loc>
        :
        <publisher-name>
         Oxford University Press
        </publisher-name>
        ,
        <year>
         1991
        </year>
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Rambaut
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral evolution and the emergence of SARS coronavirus
        </article-title>
        .
        <source>
         Philos T Roy Soc B
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         359
        </volume>
        :
        <fpage>
         1059
        </fpage>
        –
        <lpage>
         65
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Carrat
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Viboud
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data
        </article-title>
        .
        <source>
         Stat Med
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         3469
        </fpage>
        –
        <lpage>
         87
        </lpage>
        <pub-id pub-id-type="pmid">
         15505892
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Valleron
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Boelle
          </surname>
          <given-names>
           PY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Estimating the impact of school closure on influenza transmission from Sentinel data
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         452
        </volume>
        :
        <fpage>
         750
        </fpage>
        –
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         18401408
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Strategies for mitigating an influenza pandemic
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         442
        </volume>
        :
        <fpage>
         448
        </fpage>
        –
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         16642006
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baskaran
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         A demographic model of a community in Papua New Guinea to be used for simulating disease spread dynamics
        </article-title>
        <comment>
         [masters thesis]. School of Computer Science and Software Engineering
        </comment>
        <publisher-loc>
         Crawley, Western Australia
        </publisher-loc>
        :
        <publisher-name>
         University of Western Australia
        </publisher-name>
        ,
        <year>
         2011
        </year>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carrat
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Vergu
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Time lines of infection and disease in human influenza: a review of volunteer challenge studies
        </article-title>
        .
        <source>
         Am J Epidemiol
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         167
        </volume>
        :
        <fpage>
         775
        </fpage>
        –
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         18230677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halder
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Developing guidelines for school closure interventions to be used during a future influenza pandemic
        </article-title>
        .
        <source>
         BMC Infect Dis
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         221
        </fpage>
        <pub-id pub-id-type="pmid">
         20659348
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Christl
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pandemic potential of a strain of influenza A (H1N1): early findings
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         324
        </volume>
        :
        <fpage>
         1557
        </fpage>
        –
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         19433588
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Mercer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pandemic (H1N1) 2009 influenza community transmission was established in one Australian state when the virus was first identified in North America
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e11341
        </fpage>
        <pub-id pub-id-type="pmid">
         20596536
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R38">
       <label>
        38
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimating the reproduction number of the novel influenza A virus (H1N1) in a Southern Hemisphere setting: preliminary estimate in New Zealand
        </article-title>
        .
        <source>
         N Z Med Assoc
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         122
        </volume>
        :
        <fpage>
         73
        </fpage>
        –
        <lpage>
         7
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R39">
       <label>
        39
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munayco
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gomez
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Laguna-Torres
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and transmissibility analysis of influenza A (H1N1) v in a southern hemisphere setting: Peru
        </article-title>
        .
        <source>
         Euro Surveill
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <comment>
         pii=19299
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R40">
       <label>
        40
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vynnycky
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analyses of the 1957 (Asian) influenza pandemic in the United Kingdom and the impact of school closures
        </article-title>
        .
        <source>
         Epidemiol Infect
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         136
        </volume>
        :
        <fpage>
         166
        </fpage>
        –
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         17445311
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R41">
       <label>
        41
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Viboud
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic
        </article-title>
        .
        <source>
         Vaccine
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         6701
        </fpage>
        –
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         16806596
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R42">
       <label>
        42
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States
        </article-title>
        .
        <source>
         NEJM
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         2619
        </fpage>
        –
        <lpage>
         27
        </lpage>
        <pub-id pub-id-type="pmid">
         20042753
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R43">
       <label>
        43
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Simulation suggests that rapid activation of social distancing can arrest epidemic development due to a novel strain of influenza
        </article-title>
        .
        <source>
         BMC Public Health
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         117
        </fpage>
        <pub-id pub-id-type="pmid">
         19400970
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R44">
       <label>
        44
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halder
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cost-effective strategies for mitigating a future influenza pandemic with H1N1 2009 characteristics
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         e22087
        </fpage>
        <pub-id pub-id-type="pmid">
         21760957
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R45">
       <label>
        45
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milne
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Kelso
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quantifying the effect of vaccination and non-pharmaceutical interventions during an influenza pandemic via a simulation model
        </article-title>
        .
        <publisher-name>
         Report to the World Health Organization
        </publisher-name>
        ,
        <publisher-loc>
         Geneva, Switzerland
        </publisher-loc>
        ,
        <year>
         2008
        </year>
       </mixed-citation>
      </ref>
      <ref id="R46">
       <label>
        46
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mossong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hens
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jit
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Social contacts and mixing patterns relevant to the spread of infectious diseases
        </article-title>
        .
        <source>
         PLoS Med
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e74
        </fpage>
        <pub-id pub-id-type="pmid">
         18366252
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R47">
       <label>
        47
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drake
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Chalabi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Coker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cost-effectiveness analysis of pandemic influenza preparedness: what's missing
        </article-title>
        ?
        <source>
         B World Heath Organ
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         940
        </fpage>
        –
        <lpage>
         1
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R48">
       <label>
        48
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hanvoravongchai
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Adisasmito
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chau
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pandemic influenza preparedness and health systems challenges in Asia: results from rapid analyses in 6 Asian countries
        </article-title>
        .
        <source>
         BMC Public Health
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         322
        </fpage>
        <pub-id pub-id-type="pmid">
         20529345
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R49">
       <label>
        49
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Dwyer-Lindgren
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lofgren
          </surname>
          <given-names>
           KT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         380
        </volume>
        :
        <fpage>
         2071
        </fpage>
        –
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         23245603
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R50">
       <label>
        50
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perdue
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         The WHO research agenda for influenza: two years later
        </article-title>
        .
        <source>
         B World Heath Organ
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         246
        </fpage>
        –
        <lpage>
         56
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="R51">
       <label>
        51
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shindo
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Briand
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza at the beginning of the 21st century
        </article-title>
        .
        <source>
         B World Heath Organ
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         247
        </fpage>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="editorial" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cell Stress
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cell Stress
      </journal-id>
      <journal-id journal-id-type="pmc">
       Cell Stress
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       Cell Stress
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cell Stress
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2523-0204
      </issn>
      <publisher>
       <publisher-name>
        Shared Science Publishers OG
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32292881
      </article-id>
      <article-id pub-id-type="pmc">
       7146059
      </article-id>
      <article-id pub-id-type="doi">
       10.15698/cst2020.04.216
      </article-id>
      <article-id pub-id-type="publisher-id">
       CST0270E115
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Editorial
        </subject>
       </subj-group>
       <subj-group>
        <subject>
         Coronavirus
        </subject>
        <subject>
         MERS-CoV
        </subject>
        <subject>
         SARS-CoV
        </subject>
        <subject>
         sARS-CoV-2
        </subject>
        <subject>
         COVID-19
        </subject>
        <subject>
         epidemiology
        </subject>
        <subject>
         immunology
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses
       </article-title>
       <alt-title alt-title-type="running-head">
        COVID-19 - Analyses and hypotheses
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raoult
         </surname>
         <given-names>
          Didier
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zumla
         </surname>
         <given-names>
          Alimuddin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Locatelli
         </surname>
         <given-names>
          Franco
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ippolito
         </surname>
         <given-names>
          Giuseppe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kroemer
         </surname>
         <given-names>
          Guido
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         6
        </xref>
        <xref ref-type="aff" rid="aff7">
         7
        </xref>
        <xref ref-type="aff" rid="aff8">
         8
        </xref>
        <xref ref-type="aff" rid="aff9">
         9
        </xref>
        <xref ref-type="aff" rid="aff10">
         10
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, Marseille, France.
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK.
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        The National Institute of Health Research Biomedical Research Centre at UCL Hospitals, London, UK.
       </aff>
       <aff id="aff4">
        <label>
         4
        </label>
        Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
       </aff>
       <aff id="aff5">
        <label>
         5
        </label>
        National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
       </aff>
       <aff id="aff6">
        <label>
         6
        </label>
        Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
       </aff>
       <aff id="aff7">
        <label>
         7
        </label>
        Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
       </aff>
       <aff id="aff8">
        <label>
         8
        </label>
        Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
       </aff>
       <aff id="aff9">
        <label>
         9
        </label>
        Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
       </aff>
       <aff id="aff10">
        <label>
         10
        </label>
        Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        * Corresponding Author:
        <underline>
         Guido Kroemer
        </underline>
        , E-mail:
        <email>
         Kroemer@orange.fr
        </email>
       </corresp>
       <fn fn-type="COI-statement">
        <p>
         Conflict of interest: The authors declare that they have no relevant conflict of interest.
        </p>
       </fn>
       <fn>
        <p>
         Please cite this article as: Didier Raoult, Alimuddin Zumla, Franco Locatelli, Giuseppe Ippolito and Guido Kroemer
         <bold>
          (2020)
         </bold>
         . Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.
         <bold>
          Cell Stress
         </bold>
         4(4): 66-75. doi: 10.15698/cst2020.04.216
        </p>
       </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
       <day>
        02
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       4
      </volume>
      <issue>
       4
      </issue>
      <fpage>
       66
      </fpage>
      <lpage>
       75
      </lpage>
      <history>
       <date date-type="received">
        <day>
         01
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         02
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright: © 2020 Raoult et al.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Coronaviruses (CoVs) are a large family of enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1), are globally endemic and account for a substantial fraction of upper respiratory tract infections. Non-SARS-like CoV can occasionally produce severe diseases in frail subjects but do not cause any major (fatal) epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The current epidemic caused by the highly contagious SARS-CoV-2 and its rapid spread globally is of major concern. There is scanty knowledge on the actual pandemic potential of this new SARS-like virus. It might be speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the infection is silently spreading across the globe with two consequences: (i) clusters of severe infections among frail subjects could haphazardly occur linked to unrecognized index cases; (ii) the current epidemic could naturally fall into a low-level endemic phase when a significant number of subjects will have developed immunity. Understanding the role of paucisymptomatic subjects and stratifying patients according to the risk of developing severe clinical presentations is pivotal for implementing reasonable measures to contain the infection and to reduce its mortality. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The emergence of yet another global epidemic underscores the permanent challenges that infectious diseases pose and underscores the need for global cooperation and preparedness, even during inter-epidemic periods.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        sARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        epidemiology
       </kwd>
       <kwd>
        immunology
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec sec-type="introduction">
     <title>
      INTRODUCTION
     </title>
     <p>
      Infections have been limiting quality of life and longevity throughout human history. Endemic infections have been associated to a significant number of avoidable deaths and a significant increase of morbidity all around the word. In addition, human-to-human transmission of newly emergent pathogens with pandemic potential regularly produce panic, with a negative impact on the economy and general welfare of large human communities.
     </p>
     <p>
      The advent of public hygiene, vaccine and antibiotics has greatly reduced the probability to succumb to infectious disease and has improved the confidence of the public in the capacity of mitigating the possible consequences of infectious outbreaks. Nevertheless, also in recent times, several events produce significant concern in the general population. Panic spread as the consequence of overwhelming information on a series of potential epidemics rather than due to the actual diseases. These were the cases of Zika virus (a mild disease without any mortality excess whose impact is significant for vertical transmission only (increased rate of birth defect), [
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      ] variant Creutzfeldt–Jakob disease (“mad cow disease”) [
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      ] and avian influenza [
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ]. The latter two diseases are both zoonotic infections without any pandemic potential due to the lack of efficient inter-human transmission. Moreover, the global community has successfully dealt with more scaring emerging agents. For example, the 2014-2015 Ebola hemorrhagic fever outbreak was successfully contained, and specific experience accrued during the West Africa epidemic, permitting to implement new vaccination strategies and therapeutic interventions Ebola outbreak (2014-2016) [
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ].
     </p>
     <p>
      The study of respiratory viral infections has recently changed due to the standardized use of molecular biology in diagnostic tests. Therefore, molecular techniques today are not substantially influenced by the level of knowledge of those who practice them. Commercially available tests allow for the simultaneous detection of 20 common viral and bacterial pathogens within one hour, but tests leading to the identification of ever larger panels of infectious agents are under development [
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ].
     </p>
    </sec>
    <sec>
     <title>
      PATHOGENIC HUMAN CORONAVIRUSES
     </title>
     <p>
      Among the causative agents of human respiratory tract infections are coronaviruses (CoVs) which are enveloped, single positive-strand RNA viruses belonging to the large subfamily Coronavirinae which infect birds and mammals. The viral RNA is the largest genome known and it is between 26 to 32 kilobases in length. There are seven CoVs known to cause human disease, which are divided into low pathogenic and highly pathogenic CoVs [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      ]. Four coronaviruses (HCoVs, namely HCoV 229E, NL63, OC43, and HKU1), are known as non- severe acute respiratory syndrome (SARS)-like CoVs. They cause mild diseases and are globally endemic. Over the past two decades three highly pathogenic, novel zoonotic CoVs have emerged, which cause lethal human disease, and have thus generated much media hype and public concern: the SARS coronavirus (SARS-CoV now named SARS-CoV-1) discovered in November, 2002 [
      <xref ref-type="bibr" rid="B9">
       9
      </xref>
      ], the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) in June, 2012 [
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ]; and SARS-CoV-2, initially named 2019-nCoV when it was identified in December 2019 after sequencing of clinical samples from a cluster of patients with pneumonia in Wuhan, China [
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      ]. The disease caused by SARS-CoV-2 is named Coronavirus Diseases-2019 (COVID-19)
     </p>
     <p>
      All three CoVs are listed in the WHO Blueprint list for priority pathogens for research because of their epidemic potential and lack of effective treatments. SARS-CoV was first identified in humans in Guangdong, China, in November, 2002 and subsequently spread rapidly worldwide to 29 countries, resulting in 8098 human SARS cases with 774 deaths (9.6% mortality) [
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      ]. The SARS epidemic ended abruptly in July, 2003, and no human cases of SARS have been detected since 2004. MERS-CoV was first isolated from a lung sample of an adult patient who died of pneumonia at the Al-Fakieh hospital in Jeddah, Saudi Arabia. MERS-CoV. A retrospective study then linked MERS-CoV to a hospital outbreak in April, 2012, in Jordan [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ]. Dromedaries and camels are implicated as the zoonotic source of infection [
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ]. MERS-CoV continues to circulate and cause human disease with intermittent community clusters, and nosocomial outbreaks in the Middle East. MERS-CoV continues to cause human disease and as of Feb 29, 2020, there have been 2494 laboratory-confirmed human cases of MERS-CoV infection, with 858 deaths (34·0% mortality) reported from 27 countries in all continents, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths) [
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ].
     </p>
    </sec>
    <sec>
     <title>
      CLINICAL CHARACTERISTICS OF HUMAN CORONAVIRUS INFECTIONS
     </title>
     <p>
      The clinical features of low pathogenic non-SARS CoV infections are undistinguishable from those found in patients with influenza virus (up to 61,000 lethal infections per year only in the US according to the Centers for Disease Control and Prevention, [
      <xref ref-type="bibr" rid="B16">
       16
      </xref>
      ]). As with influenza and respiratory syncytial virus (RSV) infections, the majority of CoV infections usually lead to an asymptomatic or mild flu-like syndrome. Hence, without molecular diagnosis, these viral respiratory diseases, which all follow a seasonal pattern with a higher incidence in winter, are classed together as “flu”, irrespective of their exact infectious etiology. Non-SARS like CoV account for up to 20% of upper respiratory tract infections in adults [
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      ]
      <bold>
       (
       <xref ref-type="table" rid="Tab1">
        Table 1
       </xref>
       )
      </bold>
      . However, non-SARS-like CoVs can be occasionally associated with severe acute respiratory illness (SARI) in the elderly, diabetics, and those with immunosuppression from any cause, although they have never been associated with major epidemics regionally or globally. In contrast, the highly pathogenic SARS-CoV and MERS-CoV have spurred locally intense short-lived fatal community and nosocomial outbreaks [
      <xref ref-type="bibr" rid="B18">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ]. SARS-like viruses are poorly adapted to the human host and unlike non-SARS-CoV viruses, they are generally associated with more severe clinical presentations.
     </p>
     <table-wrap id="Tab1" orientation="portrait" position="float">
      <label>
       TABLE 1.
      </label>
      <caption>
       <p>
        Respiratory tract infections with non-SARS coronaviruses.
       </p>
      </caption>
      <table frame="box" rules="groups">
       <thead>
        <tr>
         <th colspan="1" rowspan="1" style="text-align:center">
          Country
         </th>
         <th colspan="1" rowspan="1" style="text-align:center">
          Number of cases investigated
         </th>
         <th colspan="1" rowspan="1" style="text-align:center">
          Percentage positive
         </th>
         <th colspan="1" rowspan="1" style="text-align:center">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Brazil
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          775
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          7.6%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B65">
           65
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Brazil (slums)
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          282
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          21.2%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B66">
           66
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Hong Kong, China
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          4181
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          2.1%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B67">
           67
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Ghana
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          593
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          13.7%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B68">
           68
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Guangzou, China
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          13,048
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          2.3%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B69">
           69
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Guangzou, China
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          11,399
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          4.3%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B70">
           70
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Kenya
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          417
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          8.4%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B71">
           71
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          Kenya
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          5,573
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          10.1%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B72">
           72
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          South Africa
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          620 without TB
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          10.5%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B73">
           73
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          214 with TB
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          8%
         </td>
         <td colspan="1" rowspan="1">
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          South Africa
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          860
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          4.8%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B74">
           74
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          South Africa
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          1,026
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          15%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B75">
           75
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:left">
          USA
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          854,575
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          4,6%
         </td>
         <td colspan="1" rowspan="1" style="text-align:left">
          [
          <xref ref-type="bibr" rid="B76">
           76
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn fn-type="abbr">
        <p>
         TB: tuberculosis.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      The novel SARS coronavirus-2 (SARS-CoV-2) appears highly transmissible from human to human pathogen which causes a wide spectrum of clinical manifestations in patients with COVID-19 [
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ]. COVID-19 undoubtedly has attracted more attention by the mass news and social media than any other disease [
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ]. The rapid spread and ensuing public health control measures have led to unprecedented isolation and quarantine of large populations, international travel restrictions and economic paralysis of Wuhan, the entire Hubei province, vast areas of China followed by entire regions in South Korea and Northern Italy during January/February 2020. In these few weeks, there have been several scientific publications related to the epidemiology, clinical features, immunology and virological characteristics and a comparison of these could yield new insights into the pathogenesis of COVID-19.
     </p>
    </sec>
    <sec>
     <title>
      EPIDEMIOLOGY: RAPID SPREAD AND THE ROLE OF SYMPTOMATIC CASES
     </title>
     <p>
      Despite seven years since first discovery, MERS-CoV transmission dynamics remain largely undefined and the roles of transmission, direct or indirect contact, airborne, droplet, or ingestion, have yet to be defined. MERS-CoV does not easily transmit from person to person unless contact with a MERS-CoV-infected subject is close. Several reports from Saudi Arabia describe transmission of silent or subclinical secondary infections after exposure to patients with MERS-CoV infections, some being apparently healthy individuals who were household contacts carrying MERS-CoV in their upper respiratory tract at low levels low amounts indicating that MERS-CoV can be transmitted from asymptomatic household or hospital contacts [
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      –
      <xref ref-type="bibr" rid="B23">
       23
      </xref>
      ].
     </p>
     <p>
      The ongoing SARS-CoV-2 outbreak has rapidly evolved and spread globally. As of Feb 29, 2020, there have been 83,652 laboratory confirmed cases of COVID-19, with 2791 deaths (3.4% mortality). Outside China, there have been 4691 cases reported from 51 countries with 67 deaths [
      <xref ref-type="bibr" rid="B24">
       24
      </xref>
      ]. Whilst there have been several epidemiological links to bats, and other animals have been proposed, the source of primary SARS-CoV-2 transmission to humans remains unknown. The main clinical features of COVID-19 disease appear similar to other CoVs infections of humans. SARS-CoV-2 is generally associated with upper respiratory tract and high viral loads in upper respiratory tract secretions. This may evolve and progress towards SARI and in some cases to acute respiratory distress syndrome (ARDS), in the elderly, patients with comorbidities and immunosuppression [
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ]. Similar to other CoVs, it is now evident that health care services play an important role in the amplification of SARS-CoV-2 local epidemics. Asymptomatic carriage of SARS-CoV-2 has been described [
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ] and the role of asymptomatic SARS-CoV-2 infected individuals in disseminating the infection (and sometimes to act as so-called ‘superspreaders') remains to be defined.
     </p>
    </sec>
    <sec>
     <title>
      LEARNING FROM THE SARS AND MERS OUTBREAKS
     </title>
     <p>
      The propensity of SARS-CoV and MERS-CoV to generate large hospital outbreaks has been well established [
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      ]. The SARS epidemic in 2002-2003 emphasized that correct management of symptomatic cases within and outside hospital was crucial for containing the epidemic. In fact, the correct management of several imported cases of SARS into Vancouver (British Columbia, Canada), resulted in stopping secondary transmissions within the city. In contrast, inadequate application of infection control measures in Toronto (Ontario, Canada) and Taipei (Taiwan) led to significant hospital clusters and further spread [
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      ]. The case of MERS is even more emblematic and enigmatic. MERS has no natural epidemic potential in the community and the transmission rate R0 in humans remains significantly below 1. Nevertheless, its potential to cause large and fatal hospital outbreaks is well established [
      <xref ref-type="bibr" rid="B29">
       29
      </xref>
      ].
     </p>
    </sec>
    <sec>
     <title>
      COVID-19 OUTBREAKS IN ITALY AND SOUTH KOREA
     </title>
     <p>
      An unexpected rise in the numbers of COVID-19 cases in northern Italy and South Korea in the third week of February 2020, indicated the global spread of the epidemic [
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      ]. As of 25 February, 2020, 219 people have tested positive SARS-CoV-2 and towns in north of Italy were quarantined [
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      ].
     </p>
     <p>
      Preliminary information from Italy suggests that a large proportion of the primary clusters reported form Lombardy were actually linked to an emergency department where a symptomatic case was received on February 16
      <sup>
       th
      </sup>
      (currently the whole hospital building is on quarantine). Similarly, the current COVID-19 spreading in South Korea has been largely fostered by several hospital outbreaks, the most recent of which occurred in a hospital in Cheongdo county, where COVID spread within the psychiatric unit [
      <xref ref-type="bibr" rid="B31">
       31
      </xref>
      ]. In Lombardy, Veneto, Piedmont, Trentino-Alto Adige, and Friuli Venezia Giulia schools and public places like museums, monuments, libraries and tourist sites, were closed and public sporting events and other mass gatherings were banned. Patient zero for the Italian outbreak was sought after and spread by asymptomatic individuals considered.
     </p>
    </sec>
    <sec>
     <title>
      HOSPITAL OUTBREAKS OF NON-SARS-LIKE CoVs
     </title>
     <p>
      The increased risk of spread of CoVs within healthcare services and of causing severe disease in susceptible individuals is not only restricted to SARS-CoV-1, MERS-CoV and SARS-CoV-2. Epidemiological analysis of the endemic non-SARS-like CoVs reveals a similar pattern. Severe infections with CoV-229E have been described in association with an outbreak in a neonatal intensive care unit (University Hospital, Brest, France) [
      <xref ref-type="bibr" rid="B32">
       32
      </xref>
      ]. CoV-NL63 has recently been described to cause a fatal outbreak of SARI in a long-term care facility with a 27.7% infection rate and 1.5% lethality in Baton Rouge, Louisiana, USA [
      <xref ref-type="bibr" rid="B33">
       33
      </xref>
      ]. Reports on hospital outbreaks of CoV-OC43 and CoV-HKU1 are scanty, and infections by these CoVs resulting in SARI are typically seen in frail subjects [
      <xref ref-type="bibr" rid="B34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="B35">
       35
      </xref>
      ]. The propensity for nosocomial spreading and the dominant role played by symptomatic patients in the spreading of the infection are supported by basic virology. CoVs, such as CoV-NL63, SARS-CoV-1 and SARS-CoV-2, use a specific receptor, angiotensin converting enzyme 2 (ACE2), a type I transmembrane metallocarboxypeptidase with homology to ACE, which is expressed in human airway epithelial cells, lung parenchyma, heart, lung, kidney and intestinal tract [
      <xref ref-type="bibr" rid="B36">
       36
      </xref>
      ,
      <xref ref-type="bibr" rid="B37">
       37
      </xref>
      ]. Since ACE2 is primarily expressed in the lower respiratory tract, meaning that subjects exposed to index cases producing virus-containing aerosol (e.g. intubated patients or patients with high viral load and severe cough) are the most likely to develop primary (severe) pulmonary infection [
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="B38">
       38
      </xref>
      –
      <xref ref-type="bibr" rid="B40">
       40
      </xref>
      ].
     </p>
    </sec>
    <sec>
     <title>
      PATHOGENESIS, DISEASE SEVERITY AND EPIDEMIC SPREAD
     </title>
     <p>
      Epidemiological studies suggest that SARS-CoV-2 has an intrinsic capacity to cause epidemic spread [
      <xref ref-type="bibr" rid="B41">
       41
      </xref>
      ]. The current fatality rate for COVID-19 cases is about 3.4%, significantly less than SARS and MERS but potentially higher than those reported for endemic human non-SARS CoV infections [
      <xref ref-type="bibr" rid="B42">
       42
      </xref>
      ]. During the first two months of the current outbreak, COVID-19 has spread rapidly throughout China and caused varying degrees of illness [
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ].
     </p>
     <p>
      Several studies suggest that antibodies against non-SARS-CoVs are highly prevalent in the general population including in children, suggesting that most individuals have been infected by CoVs and have potentially developed a certain degree of (protective) immune response [
      <xref ref-type="bibr" rid="B43">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="B44">
       44
      </xref>
      ]. There is no clear evidence on whether and how prior exposure to a strain of CoV can produce permanent immunity against the strain species or even cross-immunity for other CoV species [
      <xref ref-type="bibr" rid="B43">
       43
      </xref>
      ]. Unlike other respiratory diseases that have a quadratic ("U"-shaped) lethality curve (killing infants and elderly, but sparing adults, presumably because adults have a higher chance to be immune against the infection), SARS-CoV-2 has a lethality that continuously rises with age (sparing children but mostly killing elderly). The severity and the clinical picture could be even related to the activation of exaggerated immune mechanism, causing uncontrolled inflammation as this has been suspected for SARS and MERS [
      <xref ref-type="bibr" rid="B45">
       45
      </xref>
      ]. Hence, there is uncertainty on the impact of individual immune responses on the severity of SARS-like CoV infections.
     </p>
     <p>
      The discrepancy between the severity of cases observed in China and those outside China could be a result of prior exposure community circulation of non-SARS-CoVs and their antigenic epitopes, leading to antibody-dependent enhancement (ADE) of SARS-CoV-2. ADE can elicit sustained inflammation, lymphopenia, and/or cytokine storm, which have been observed in severe cases and those who die. This might explain observed the geographic discrepancies of severe cases and lower mortality than SARS of MERS [
      <xref ref-type="bibr" rid="B46">
       46
      </xref>
      ].
     </p>
     <p>
      SARS-CoV-1 caused an important outbreak in 2002-2003, but it is currently though to be extinct [
      <xref ref-type="bibr" rid="B32">
       32
      </xref>
      ]. This eradication of SARS-CoV-1 has been attributed to successful contention by public action, consisting in quarantining potentially affected persons and isolating affected areas. However, other factors might have played a role in the fall of the SARS epidemic leading to the eventual extinction of the virus. In particular, it is possibility that only a minority of the population was actually susceptible to develop severe illness (some HLA haplotypes reportedly conferred resistance to SARS-CoV-1, but these studies have not been confirmed or even disproven) [
      <xref ref-type="bibr" rid="B44">
       44
      </xref>
      ,
      <xref ref-type="bibr" rid="B47">
       47
      </xref>
      –
      <xref ref-type="bibr" rid="B50">
       50
      </xref>
      ]. The hypothesis that SARS-CoV-1 (or other, antigenically similar CoV-1) have silently infected a significant proportion of the local population, inducing herd immunity needs to be confirmed. Indeed, immunity against the infection, or also patterns of semi-immunity (capacity of the immune system to avoid severe infection) may be due to cellular rather than humoral immune responses. Animal models suggest that the efficiency of T lymphocyte-mediated immune responses is pivotal for controlling MERS-CoV and SARS-CoV infections [
      <xref ref-type="bibr" rid="B51">
       51
      </xref>
      ,
      <xref ref-type="bibr" rid="B52">
       52
      </xref>
      ]. Evidence in animals are confirmed by observational studies in humans suggesting that MERS-CoV-specific T-cell responses is a strong predictor of the clinical outcome in patients [
      <xref ref-type="bibr" rid="B53">
       53
      </xref>
      ]. Of note, antibodies against MERS-CoV have been detected in a significant fraction of persons exposed to camels and dromedaries without any clinical evidence of prior MERS [
      <xref ref-type="bibr" rid="B54">
       54
      </xref>
      –
      <xref ref-type="bibr" rid="B56">
       56
      </xref>
      ], suggesting that MERS-CoV can infect individuals in an asymptomatic fashion, yet induce signs of a (protective?) immune response.
     </p>
    </sec>
    <sec>
     <title>
      ROLES OF HUMORAL AND CELLULAR IMMUNE RESPONSES
     </title>
     <p>
      There are currently no data on the specific role of either humoral or cellular immunity or innate immunity in patients recovering from COVID-19. Only highly specialized laboratories are able to conduct experiments to investigate immune responses against HLA class-I and class-II-restricted viral epitopes mediated by CD8+ and CD4+ T lymphocytes, respectively, to confirm the conjecture of a cellular (rather than humoral) immunity against SARS-CoV-2. Moreover, the T lymphocytes responsible for clinically relevant antiviral immune responses have high chances to be locally present in, or close to, respiratory epithelia but have comparatively low chances to be detectable in peripheral blood [
      <xref ref-type="bibr" rid="B57">
       57
      </xref>
      –
      <xref ref-type="bibr" rid="B59">
       59
      </xref>
      ]. It is well possible that the exclusive detection of humoral immunity (antibodies against SARS-CoV-2) leads to an underestimation of the anti-SARS-CoV-2 immune responses. Thus, it is possible that the actual incidence of infections with SARS-CoV-2 is much higher than the observed number of clinically and serologically evident cases of COVID-19. In fact, a larger epidemic might be smoldering. This silent epidemic, made of mild and paucisymptomatic (usually flu-like) infections, could parallel the evident COVID-19 outbreaks that are detected when patients develop radiological or functional signs of pneumonitis and they are tested for SARS-CoV-2. This scenario may have two consequences. First, over the forthcoming months, symptomatic cases could haphazardly occur either as (apparently) sporadic cases or as epidemic clusters among frail subjects (e.g. as nosocomial outbreaks), driven by unrecognized occasional spreaders. Second, these occasional spreaders might accelerate the induction of immunity at the population level.
     </p>
     <p>
      By analogy to other CoVs, SARS-CoV-2 might induce a T-lymphocyte-mediated protective immune response. However, patients infected by SARS-CoV-2 that are hospitalized frequently manifest a lymphopenia, suggesting that cellular immune responses may be suppressed [
      <xref ref-type="bibr" rid="B60">
       60
      </xref>
      ,
      <xref ref-type="bibr" rid="B61">
       61
      </xref>
      ]. In this context, it becomes plausible that, after infection by SARS-CoV-2, a sort of race decides the course of the events. Either a cellular immune response rapidly clears SARS-CoV-2 – in the best-case-scenario without any (or mild) clinical signs of infection – or the virus causes a state of immunosuppression that debilitates and sometimes overwhelms the host's defense
      <bold>
       (
       <xref ref-type="fig" rid="fig1">
        Fig. 1A
       </xref>
       )
      </bold>
      . In this context, the initial dose of the viral inoculum leading to infection may have a decisive impact on all subsequent events
      <bold>
       (
       <xref ref-type="fig" rid="fig1">
        Fig. 1B
       </xref>
       )
      </bold>
      . A small burden of SARS-CoV-2 should have a higher chance to stimulate a protective immune response than a high one, although additional factors like the fitness of the individual's immune system and prior exposure to other in part cross-reactive CoVs might influence the outcome of the race between viral replication and T-lymphocyte responses as well. Hence, it is possible, but remains to be demonstrated, that SARS-CoV-2 transmission from indolent or mildly symptomatic persons to naive individuals generally occurs at a relatively low viral load (lower than if the infection stems from severely affected patients), which then might have higher probabilities to induce immunity instead of severe and sometimes lethal infection
      <bold>
       (
       <xref ref-type="fig" rid="fig1">
        Fig. 1C
       </xref>
       )
      </bold>
      . That said, current evidence suggests that the most solid predictors of disease severity after infection with SARS-COV-2 are the patient's age and the concurrence of specific co-morbidities. In contrast, there is no proof (yet) that infection by a pauci-symptomatic person would result in a milder clinical course of immunocompetent neo-infected person.
     </p>
     <fig id="fig1" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <title>
        FIGURE 1: Proposed relationships between COVID-19 and anti-SARS-CoV-2 immune responses.
       </title>
       <p>
        <bold>
         (A)
        </bold>
        The precarious equilibrium between SARS-CoV-2 and the immune system. While the virus elicits an immune response leading to elimination of infected cells (and hence clearance of the infection), it tends to suppress the immune response. Therefore, the outcome of infection is determined by the kinetics of the immune response leading to viral elimination versus viral replication leading to immunosuppression.
        <bold>
         (B)
        </bold>
        Hypothetical effect of the initial contagion on the course of the infection caused by SARS-CoV-2. A low-level contagion would favor an efficient immune response and indolent infection, leading to immunity of the infected person. Transmission of a large number of viral particles would tend to cause multifocal respiratory infection leading to immunosuppression and severe illness and possibly death.
        <bold>
         (C)
        </bold>
        Possible modes of transmission of SARS-CoV-2. Indolent carriers would tend to transmit a low viral load to their contacts, leading to indolent disease and antiviral immune responses in immunocompetent individuals. This mode of transmission might be considered as desirable because it leads to population immunity if it attains a large fraction of the population. In contrast, symptomatic carriers might transmit larger amounts of viral particles with a higher probability of leading to severe disease.
       </p>
      </caption>
      <graphic xlink:href="ces-04-066-g001">
      </graphic>
     </fig>
    </sec>
    <sec>
     <title>
      CHALLENGES FOR CONTROL OF THE EPIDEMIC
     </title>
     <p>
      COVID-19 outbreak poses significant challenges for curtailing global spread and maintaining global health security. Implementation of collective infection control measures (e.g. social isolation, distancing or quarantine of entire communities) may be useful. Nonetheless, these measures should be implemented in a prudent fashion while considering their cost efficiency (e.g. for controlling small clusters of sporadic transmission). There is a real need to avoid an unmanageable epidemic wave that would saturate the capacity of health services. It is important to note that collective infection control measures can actually reduce the frequency of infection, though at the price of a prolongation of the epidemic period. Thus, in the absence of an effective vaccine and effective antiviral drugs, all infection control measures should be properly undertaken with the aim of modulating the trajectory of the epidemic so that the impact on global health is minimized and each epidemic wave does not exceed the healthcare system capabilities.
     </p>
    </sec>
    <sec>
     <title>
      TAKING FORWARD INTERVENTIONS TO CONTROL THE EPIDEMIC
     </title>
     <p>
      The first pillar for interventions is to preserve the healthcare system. The implementation of infection control measures within hospitals is crucial to protect healthcare workers, maintain adequate work force levels and to prevent hospital outbreaks that eventually foster larger community epidemics.
     </p>
     <p>
      Second, there is a growing need for providing advice on proper management of COVID-19 patients so that each individual can receive the most appropriate treatment. Currently, most of the SARS-CoV-2 infections need no therapy, and overtreatment of patients without current or future medical needs should be avoided.
     </p>
     <p>
      Third, trust between people and institutions (at the local, national and international levels) must be maintained or reestablished so that local communities and individual subjects adhere to medical advice, for instance by respecting temporary individual restrictive measure (i.e. fiduciary isolation at home for mild-symptomatic cases of COVID-19).
     </p>
     <p>
      Fourth, any antagonism between countries and their governments must be carefully avoided. The scientific community is global, by definition and for necessity. There is no individual solution for a globally spreading infection. Antagonism and lack of trust between countries will affect scientific collaboration and will retard or even jeopardize the control of SARS-CoV-2.
     </p>
     <p>
      Fifth, research on effective prevention or treatment of COVID-19 must be accelerated. Yet unconfirmed reports indicated that inhibitors of SARS-CoV-2 replication including chloroquine are clinical efficient against declared SARS-CoV-2 infection [
      <xref ref-type="bibr" rid="B62">
       62
      </xref>
      –
      <xref ref-type="bibr" rid="B64">
       64
      </xref>
      ]. If these findings are confirmed, chloroquine might be used to prophylactically treat vulnerable individuals (in particular the elderly and patients with existing medical problems) that have a high risk of viral exposure. Chloroquine has been used for decades for the prevention and treatment of malaria with minimal side effects and at a low cost, suggesting the practicability of such a measure.
     </p>
     <p>
      Sixth, it is essential to control panic and to minimize the potential for social disruption that is typical of any global epidemic event. Again, exaggerated infection control measures may be pernicious as they increase frustration among the population, undermine the economy, and evoke a false feeling of safety.
     </p>
     <p>
      Despite the fact that SARS-CoV-2 appears much less virulent than SARS-CoV-1 and MERS-CoV, it is associated with significant mortality among susceptible individuals with comorbidities. Moreover, the hype and scaremongering going viral on mass news and social media, predicting the dawn of a new fatal pandemic, are spurring global hysteria. Thus, the current COVID-19 epidemic is resulting in a social rather than a viral catastrophe. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The development of the response cannot be standardized as ‘one size fits all' but should be tailored based on the local evolution of the epidemic and the socio-economic settings involved. Indeed, the emergence of yet another global epidemic unveils the permanent challenge that infectious diseases represent for humankind and underscores the need for global cooperation and preparedness, even during inter-epidemic periods.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       Didier Roult is supported by the French Government under the « Investissements d'avenir » (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03).
      </p>
      <p>
       Alimuddin Zumla and Giuseppe Ippolito are co-principal investigators of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET), funded by the European &amp; Developing Countries Clinical Trials Partnership, supported under Horizon 2020. Sir Zumla is in receipt of a National Institutes of Health Research senior investigator award. Giuseppe Ippolito is supported by the Italian Ministry of Health (Ricerca Corrente Linea 1.
      </p>
      <p>
       GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Le Cancer du Sein, Parlons-en!”; Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).
      </p>
     </ack>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="B1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macciocchi
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lanini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vairo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Figueiredo
          </surname>
          <given-names>
           LT
          </given-names>
         </name>
         <name>
          <surname>
           Lauria
          </surname>
          <given-names>
           FN
          </given-names>
         </name>
         <name>
          <surname>
           Strada
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Puro
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Krishna
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kremsner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Scognamiglio
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kohler
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Short-term economic impact of the Zika virus outbreak.
        </article-title>
        <source>
         New Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         39
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         287
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="pmid">
         28004846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liuzzi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Puro
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Lanini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vairo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Nicastri
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Capobianchi
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Piacentini
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zumla A and Ippolito
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zika virus and microcephaly: is the correlation causal or coincidental?
        </article-title>
        <source>
         New Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         39
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         83
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         27196544
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         vCJD remains an enigma as UK deaths fall to zero for 2012.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         914
        </fpage>
        <lpage>
         915
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(12)70304-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         23316491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sutton
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses.
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2018
        </year>
        <volume>
         10
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         461
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/v10090461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5">
       <label>
        5
       </label>
       <element-citation publication-type="web">
        <collab>
         WHO.
        </collab>
        <article-title>
         Ebola 2014-2016.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/ebola/en/">
          https://www.who.int/csr/disease/ebola/en/
         </ext-link>
         . [Accessed: 29.02.2020]
        </comment>
       </element-citation>
      </ref>
      <ref id="B6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Le-Viet
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           VN
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           QD
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           TV
          </given-names>
         </name>
         <name>
          <surname>
           Abat
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Raoult D and Parola
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective case-control analysis of the aetiologies of acute undifferentiated fever in Vietnam.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <year>
         2019
        </year>
        <volume>
         8
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         339
        </fpage>
        <lpage>
         352
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/22221751.2019.1580539
        </pub-id>
        <pub-id pub-id-type="pmid">
         30866787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Chan JF and Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS coronavirus to novel animal and human coronaviruses.
        </article-title>
        <source>
         J Thorac Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         5
        </volume>
        <issue>
         Suppl 2
        </issue>
        <fpage>
         S103
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="doi">
         10.3978/j.issn.2072-1439.2013.06.02
        </pub-id>
        <pub-id pub-id-type="pmid">
         23977429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Abdalla
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wang Y and Guo
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS–CoV-2 and SARS-CoV.
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2020
        </year>
        <volume>
         12
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         E244
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/v12020244
        </pub-id>
        <pub-id pub-id-type="pmid">
         32098422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9">
       <label>
        9
       </label>
       <element-citation publication-type="web">
        <collab>
         WHO.
        </collab>
        <article-title>
         SARS (severe acute respiratory syndrome).
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/ith/diseases/sars/en/">
          https://www.who.int/ith/diseases/sars/en/
         </ext-link>
         [Accessed: 29.02.2020]
        </comment>
       </element-citation>
      </ref>
      <ref id="B10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus AD and Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11">
       <label>
        11
       </label>
       <element-citation publication-type="web">
        <collab>
         WHO.
        </collab>
        <article-title>
         Coronavirus disease (COVID-19) outbreak.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019
         </ext-link>
         [Accessed: 29.02.2020]
        </comment>
       </element-citation>
      </ref>
      <ref id="B12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus AD and Stohr
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         349
        </volume>
        <issue>
         25
        </issue>
        <fpage>
         2431
        </fpage>
        <lpage>
         2441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMra032498
        </pub-id>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Abdallat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sayaydeh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jaarour
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Alsheikh S and Alsanouri
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation.
        </article-title>
        <source>
         East Mediterr Health J
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <issue>
         Suppl 1
        </issue>
        <fpage>
         S12
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="doi">
         10.26719/2013.19.supp1.s12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Saeed
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Hashem AM and Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <issue>
         26
        </issue>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmc1409847
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15">
       <label>
        15
       </label>
       <element-citation publication-type="web">
        <collab>
         WHO.
        </collab>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV).
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
          https://www.who.int/emergencies/mers-cov/en/
         </ext-link>
         [Accessed: 29.02.2020]
        </comment>
       </element-citation>
      </ref>
      <ref id="B16">
       <label>
        16
       </label>
       <element-citation publication-type="web">
        <collab>
         CDC.
        </collab>
        <article-title>
         Coronavirus Disease 2019.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov">
          https://www.cdc.gov
         </ext-link>
         <underline>
          [Accessed: 29.02.2020]
         </underline>
        </comment>
       </element-citation>
      </ref>
      <ref id="B17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paules
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Marston HD and Fauci
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus Infections-More Than Just the Common Cold.
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <volume>
         323
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         707
        </fpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.0757
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Memish ZA and Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
        </article-title>
        <source>
         Curr Opin Pulm Med
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         233
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/mcp.0000000000000046
        </pub-id>
        <pub-id pub-id-type="pmid">
         24626235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19">
       <label>
        19
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           CQ
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           JX
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Shan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DSC
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical Characteristics of Coronavirus Disease 2019 in China.
        </article-title>
        <source>
         N Engl J Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2002032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20">
       <label>
        20
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ippolito
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Ntoumi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Maeurer M and Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toning down the 2019-nCoV media hype—and restoring hope.
        </article-title>
        <source>
         Lancet Respir Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/s2213-2600(20)30070-9
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Aloraini
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           KZ
          </given-names>
         </name>
         <name>
          <surname>
           Almohammadi
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Swerdlow
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Watson JT and Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah–a link to health care facilities.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2015
        </year>
        <volume>
         372
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hossain
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Hajomar
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        <volume>
         371
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         828
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman S and Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spread of MERS to South Korea and China.
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2015
        </year>
        <volume>
         3
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         509
        </fpage>
        <lpage>
         510
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s2213-2600(15)00238-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         26050550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24">
       <label>
        24
       </label>
       <element-citation publication-type="web">
        <collab>
         WHO.
        </collab>
        <article-title>
         Coronavirus disease (COVID-19) outbreak.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019
         </ext-link>
         [Accessed: 29.02.2020)]
        </comment>
       </element-citation>
      </ref>
      <ref id="B25">
       <label>
        25
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           DY
          </given-names>
         </name>
         <name>
          <surname>
           Chen L and Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presumed Asymptomatic Carrier Transmission of COVID-19.
        </article-title>
        <source>
         JAMA.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.2565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <collab>
         Novel Coronavirus Pneumonia Emergency Response Epidemiology Team
        </collab>
        <article-title>
         The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.
        </article-title>
        <source>
         Zhonghua Liu Xing Bing Xue Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         41
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         145
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="doi">
         10.3760/cma.j.issn.0254-6450.2020.02.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         32064853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Oh MD and Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         18
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         e217
        </fpage>
        <lpage>
         e227
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(18)30127-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         29680581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DSC
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features.
        </article-title>
        <source>
         Infect Dis Clin North Am
        </source>
        <year>
         2019
        </year>
        <volume>
         33
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         869
        </fpage>
        <lpage>
         889
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.idc.2019.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         31668196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui DS and Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <issue>
         9997
        </issue>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely.
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2020
        </year>
        <volume>
         368
        </volume>
        <fpage>
         m751
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.m751
        </pub-id>
        <pub-id pub-id-type="pmid">
         32098875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31">
       <label>
        31
       </label>
       <element-citation publication-type="web">
        <collab>
         Reuters
        </collab>
        <article-title>
         South Korea reports doubling of coronavirus patients to 433, with over 1,000 at new outbreak site feeling ill.
        </article-title>
        <source>
         The Japan Times.
        </source>
        <year>
         2020
        </year>
        <comment>
         Available at
         <ext-link ext-link-type="uri" xlink:href="https://www.japantimes.co.jp/news/2020/02/22/asia-pacific/covid-19-south-korea/#.XlbglGhKg_E">
          https://www.japantimes.co.jp/news/2020/02/22/asia-pacific/covid-19-south-korea/#.XlbglGhKg_E
         </ext-link>
         [Accessed: 29.02.2020]
        </comment>
       </element-citation>
      </ref>
      <ref id="B32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Vallet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Legrand-Quillien
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Picard
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Payan C and Sizun
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreaks of human coronavirus in a pediatric and neonatal intensive care unit.
        </article-title>
        <source>
         Eur J Pediatr
        </source>
        <year>
         2008
        </year>
        <volume>
         167
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1427
        </fpage>
        <lpage>
         1434
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00431-008-0687-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         18335238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hand
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
         <name>
          <surname>
           Salinas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Sakthivel
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Schneider E and Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Respiratory Illness Outbreak Associated with Human Coronavirus NL63 in a Long-Term Care Facility.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         24
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1964
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2410.180862
        </pub-id>
        <pub-id pub-id-type="pmid">
         30226169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vandroux
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Allou
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jabot
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li Pat Yuen
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Brottet
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Roquebert B and Martinet
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intensive care admission for Coronavirus OC43 respiratory tract infections.
        </article-title>
        <source>
         Med Mal Infect
        </source>
        <year>
         2018
        </year>
        <volume>
         48
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         141
        </fpage>
        <lpage>
         144
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.medmal.2018.01.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         29402475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kanwar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Selvaraju S and Esper
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human Coronavirus-HKU1 Infection Among Adults in Cleveland, Ohio.
        </article-title>
        <source>
         Open Forum Infect Dis
        </source>
        <year>
         2017
        </year>
        <volume>
         4
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         ofx052
        </fpage>
        <pub-id pub-id-type="doi">
         10.1093/ofid/ofx052
        </pub-id>
        <pub-id pub-id-type="pmid">
         28616442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <name>
          <surname>
           Choe H and Farzan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <issue>
         6965
        </issue>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           IC
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Radoshitzky
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Choe H and Farzan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         367
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         367
        </fpage>
        <lpage>
         374
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.035
        </pub-id>
        <pub-id pub-id-type="pmid">
         17631932
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ning G and Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.
        </article-title>
        <source>
         Cell Discov
        </source>
        <year>
         2020
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <pub-id pub-id-type="doi">
         10.1038/s41421-020-0147-1
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano D and Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and MERS: recent insights into emerging coronaviruses.
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         523
        </fpage>
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro.2016.81
        </pub-id>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41">
       <label>
        41
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rocklov
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sjodin H and Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures.
        </article-title>
        <source>
         J Travel Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1093/jtm/taaa030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42">
       <label>
        42
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention.
        </article-title>
        <source>
         JAMA.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.2648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Severance
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
         <name>
          <surname>
           Bossis
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Dickerson
          </surname>
          <given-names>
           FB
          </given-names>
         </name>
         <name>
          <surname>
           Stallings
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Origoni
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Sullens
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Yolken RH and Viscidi
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population.
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        <year>
         2008
        </year>
        <volume>
         15
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1805
        </fpage>
        <lpage>
         1810
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/cvi.00124-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         18945884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Tsao
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Yen
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <name>
          <surname>
           Huang JC and Chen
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection.
        </article-title>
        <source>
         Viral Immunol
        </source>
        <year>
         2011
        </year>
        <volume>
         24
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         421
        </fpage>
        <lpage>
         426
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/vim.2011.0024
        </pub-id>
        <pub-id pub-id-type="pmid">
         21958371
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newton
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Cardani A and Braciale
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The host immune response in respiratory virus infection: balancing virus clearance and immunopathology.
        </article-title>
        <source>
         Semin Immunopathol
        </source>
        <year>
         2016
        </year>
        <volume>
         38
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         471
        </fpage>
        <lpage>
         482
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00281-016-0558-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         26965109
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46">
       <label>
        46
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tetro
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is COVID-19 Receiving ADE From Other Coronaviruses?
        </article-title>
        <source>
         Microbes Infect.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2020.02.006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           XW
          </given-names>
         </name>
         <name>
          <surname>
           Gong FL and Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lack of association between HLA-A, -B and -DRB1 alleles and the development of SARS: a cohort of 95 SARS-recovered individuals in a population of Guangdong, southern China.
        </article-title>
        <source>
         Int J Immunogenet
        </source>
        <year>
         2008
        </year>
        <volume>
         35
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         69
        </fpage>
        <lpage>
         74
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1744-313x.2007.00741.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         18186801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Khoo
          </surname>
          <given-names>
           US
          </given-names>
         </name>
         <name>
          <surname>
           Zee BC and Sung
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenetics in SARS: a case-control study.
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <issue>
         5 Suppl 4
        </issue>
        <fpage>
         29
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         20864745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           OW
          </given-names>
         </name>
         <name>
          <surname>
           Chia
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Jadi
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Leong
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Bertoletti A and Tan
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2016
        </year>
        <volume>
         34
        </volume>
        <issue>
         17
        </issue>
        <fpage>
         2008
        </fpage>
        <lpage>
         2014
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.02.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         26954467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           FF
          </given-names>
         </name>
         <name>
          <surname>
           Velickovic
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ashton
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyer
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Geczy
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name>
          <surname>
           Dunckley
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lynch GW and Sullivan
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus.
        </article-title>
        <source>
         Virol Sin
        </source>
        <year>
         2014
        </year>
        <volume>
         29
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         128
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12250-014-3398-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         24643938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Mangalam
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           David CS and Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.
        </article-title>
        <source>
         Immunity
        </source>
        <year>
         2016
        </year>
        <volume>
         44
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         1379
        </fpage>
        <lpage>
         1391
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.immuni.2016.05.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27287409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Sisk
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Halasz
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Venkataraman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Rajagopalan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kyratsous CA and Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <issue>
         1
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/jvi.01825-16
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Bokhari
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Nehdi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Layqah
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Al Gethamy
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Dada
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Boujelal
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Al Johani
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses.
        </article-title>
        <source>
         Sci Immunol
        </source>
        <year>
         2017
        </year>
        <volume>
         2
        </volume>
        <issue>
         14
        </issue>
        <fpage>
         eaan5393
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/sciimmunol.aan5393
        </pub-id>
        <pub-id pub-id-type="pmid">
         28778905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Turkestani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Aldabbagh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         559
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(15)70090-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         495
        </fpage>
        <lpage>
         497
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(15)70128-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Kahlout
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Nasrallah
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           El Zowalaty
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Al Thani AA and Yassine
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.
        </article-title>
        <source>
         J Immunol Res
        </source>
        <year>
         2019
        </year>
        <volume>
         2019
        </volume>
        <fpage>
         1386740
        </fpage>
        <pub-id pub-id-type="doi">
         10.1155/2019/1386740
        </pub-id>
        <pub-id pub-id-type="pmid">
         30906787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kroemer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cuende E and Martinez
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compartmentalization of the peripheral immune system.
        </article-title>
        <source>
         Adv Immunol
        </source>
        <year>
         1993
        </year>
        <volume>
         53
        </volume>
        <fpage>
         157
        </fpage>
        <lpage>
         216
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s0065-2776(08)60500-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         8512035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woodward Davis
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Roozen
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Dufort
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           DeBerg
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Delaney
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Mair
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Slichter
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Berkson
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Klock
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Mack
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lwo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The human tissue-resident CCR5(+) T cell compartment maintains protective and functional properties during inflammation.
        </article-title>
        <source>
         Sci Transl Med
        </source>
        <year>
         2019
        </year>
        <volume>
         11
        </volume>
        <issue>
         521
        </issue>
        <pub-id pub-id-type="doi">
         10.1126/scitranslmed.aaw8718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haddadi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vaseghi-Shanjani
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Afkhami
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           D'Agostino
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Zganiacz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jeyanathan M and Xing
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mucosal-Pull Induction of Lung-Resident Memory CD8 T Cells in Parenteral TB Vaccine-Primed Hosts Requires Cognate Antigens and CD4 T Cells.
        </article-title>
        <source>
         Front Immunol
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         2075
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fimmu.2019.02075
        </pub-id>
        <pub-id pub-id-type="pmid">
         31552032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60">
       <label>
        60
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
        </article-title>
        <source>
         JAMA.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.1585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B61">
       <label>
        61
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           YY
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           YD
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           YB
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           YQ
          </given-names>
         </name>
         <name>
          <surname>
           Akdis CA and Gao
          </surname>
          <given-names>
           YD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
        </article-title>
        <source>
         Allergy.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1111/all.14238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B62">
       <label>
        62
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhong W and Xiao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1038/s41422-020-0282-0
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rolain JM and Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         2020
        </volume>
        <fpage>
         105923
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijantimicag.2020.105923
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64">
       <label>
        64
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tian Z and Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
        </article-title>
        <source>
         Biosci Trends.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.5582/bst.2020.01047
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trombetta
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Faggion
          </surname>
          <given-names>
           HZ
          </given-names>
         </name>
         <name>
          <surname>
           Leotte
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Nogueira
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Vidal LR and Raboni
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus and severe acute respiratory infection in Southern Brazil.
        </article-title>
        <source>
         Pathog Glob Health
        </source>
        <year>
         2016
        </year>
        <volume>
         110
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         113
        </fpage>
        <lpage>
         118
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/20477724.2016.1181294
        </pub-id>
        <pub-id pub-id-type="pmid">
         27195607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66">
       <label>
        66
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goes
          </surname>
          <given-names>
           LGB
          </given-names>
         </name>
         <name>
          <surname>
           Zerbinati
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Tateno
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name>
          <surname>
           de Souza
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <name>
          <surname>
           Ebach
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Moreira-Filho
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Durigon
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           da Silva Filho
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Typical epidemiology of respiratory virus infections in a Brazilian slum.
        </article-title>
        <source>
         J Med Virol.
        </source>
        <year>
         2019
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus HKU1 and other coronavirus infections in Hong Kong.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2006
        </year>
        <volume>
         44
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         2063
        </fpage>
        <lpage>
         2071
        </lpage>
        <pub-id pub-id-type="doi">
         10.5353/th_b4501060
        </pub-id>
        <pub-id pub-id-type="pmid">
         16757599
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Owusu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Larbi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Anti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Agbenyega
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Adu-Sarkodie Y and Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana.
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         e99782
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0099782
        </pub-id>
        <pub-id pub-id-type="pmid">
         25080241
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Tuo
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           XB
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Cao KY and Xu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou.
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2018
        </year>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         e0191789
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0191789
        </pub-id>
        <pub-id pub-id-type="pmid">
         29377913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           ZQ
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           WP
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           HX
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           MX
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           ZS
          </given-names>
         </name>
         <name>
          <surname>
           Liu WK and Zhou
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China.
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         37
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         363
        </fpage>
        <lpage>
         369
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10096-017-3144-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         29214503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sipulwa
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Ongus
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Coldren RL and Bulimo
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular characterization of human coronaviruses and their circulation dynamics in Kenya, 2009-2012.
        </article-title>
        <source>
         Virol J
        </source>
        <year>
         2016
        </year>
        <volume>
         13
        </volume>
        <fpage>
         18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12985-016-0474-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         26833249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kiyuka
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Agoti
          </surname>
          <given-names>
           CN
          </given-names>
         </name>
         <name>
          <surname>
           Munywoki
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Njeru
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bett
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Otieno
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Otieno
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <name>
          <surname>
           Kamau
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Nokes DJ and Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya.
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         217
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1728
        </fpage>
        <lpage>
         1739
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiy098
        </pub-id>
        <pub-id pub-id-type="pmid">
         29741740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dube
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Kaba
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Robberts
          </surname>
          <given-names>
           FJ
          </given-names>
         </name>
         <name>
          <surname>
           Ah Tow
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lubbe
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zar HJ and Nicol
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory microbes present in the nasopharynx of children hospitalised with suspected pulmonary tuberculosis in Cape Town, South Africa.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         597
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1934-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         27776489
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subramoney
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hellferscee
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Pretorius
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tempia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           McMorrow
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           von Gottberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wolter
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Variava
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Dawood
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kahn
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Walaza
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Madhi
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human bocavirus, coronavirus, and polyomavirus detected among patients hospitalised with severe acute respiratory illness in South Africa, 2012 to 2013.
        </article-title>
        <source>
         Health Sci Rep
        </source>
        <year>
         2018
        </year>
        <volume>
         1
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         e59
        </fpage>
        <pub-id pub-id-type="doi">
         10.1002/hsr2.59
        </pub-id>
        <pub-id pub-id-type="pmid">
         30623094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nunes
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Kuschner
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Rabede
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Madimabe
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Van Niekerk
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Moloi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kuwanda
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Rossen
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Klugman
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Adrian PV and Madhi
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children.
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         e86448
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0086448
        </pub-id>
        <pub-id pub-id-type="pmid">
         24498274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Killerby
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Biggs
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dahl
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Mustaquim
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gerber SI and Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus circulation in the United States 2014-2017.
        </article-title>
        <source>
         J Clin Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         101
        </volume>
        <fpage>
         52
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2018.01.019
        </pub-id>
        <pub-id pub-id-type="pmid">
         29427907
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <glossary>
      <title>
       Abbreviations:
      </title>
      <def-list>
       <def-item>
        <term>
         ACE
        </term>
        <def>
         <p>
          – angiotensin converting enzyme;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ADE
        </term>
        <def>
         <p>
          – antibody-dependent enhancement;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ARDS
        </term>
        <def>
         <p>
          – acute respiratory distress syndrome;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CoV
        </term>
        <def>
         <p>
          – coronavirus;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         COVID-19
        </term>
        <def>
         <p>
          – coronavirus disease 2019;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         HCoV
        </term>
        <def>
         <p>
          – human coronavirus;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MERS
        </term>
        <def>
         <p>
          – Middle-East respiratory syndrome;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SARI
        </term>
        <def>
         <p>
          – severe acute respiratory illness;
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SARS
        </term>
        <def>
         <p>
          – severe acute respiratory syndrome.
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Travel Med Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Travel Med Infect Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        Travel Medicine and Infectious Disease
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1477-8939
      </issn>
      <issn pub-type="epub">
       1873-0442
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32247926
      </article-id>
      <article-id pub-id-type="pmc">
       7129170
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1477-8939(20)30121-6
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.tmaid.2020.101653
      </article-id>
      <article-id pub-id-type="publisher-id">
       101653
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Escalera-Antezana
         </surname>
         <given-names>
          Juan Pablo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Lizon-Ferrufino
         </surname>
         <given-names>
          Nicolas Freddy
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Maldonado-Alanoca
         </surname>
         <given-names>
          Americo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Alarcón-De-la-Vega
         </surname>
         <given-names>
          Gricel
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Alvarado-Arnez
         </surname>
         <given-names>
          Lucia Elena
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Balderrama-Saavedra
         </surname>
         <given-names>
          María Alejandra
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Bonilla-Aldana
         </surname>
         <given-names>
          D. Katterine
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Rodríguez-Morales
         </surname>
         <given-names>
          Alfonso J.
         </given-names>
        </name>
        <email>
         arodriguezm@utp.edu.co
        </email>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
        <xref ref-type="aff" rid="aff8">
         h
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
       <on-behalf-of>
        on behalf of
       </on-behalf-of>
       <contrib contrib-type="author">
        <collab>
         LANCOVID
         <xref ref-type="aff" rid="aff9">
          i
         </xref>
        </collab>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       National Responsible for Telehealth Program, Ministry of Health, La Paz, Bolivia
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Universidad Privada Franz Tamayo/UNIFRANZ, Cochabamba, Bolivia
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Interim Direction Epidemiology Unit, Ministry of Health, La Paz, Bolivia
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       National Coordination of Laboratories, Ministry of Health, La Paz, Bolivia
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       Rodent-Borne Diseases Program, Epidemiology Unit, Ministry of Health, La Paz, Bolivia
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Incubator in Zoonosis (SIZOO), Biodiversity and Ecosystem Conservation Research Group (BIOECOS), Fundación Universitaria Autónoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       Public Health and infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia
      </aff>
      <aff id="aff8">
       <label>
        h
       </label>
       Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia
      </aff>
      <aff id="aff9">
       <label>
        i
       </label>
       Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19)
       <xref ref-type="fn" rid="fn1">
        1
       </xref>
       , Colombia
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia.
        <email>
         arodriguezm@utp.edu.co
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p id="ntpara0010">
         <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://www.lancovid.org">
          www.lancovid.org
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        2
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        2
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       101653
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         22
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         26
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         27
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <sec>
        <title>
         Introduction
        </title>
        <p>
         In March 2020, Coronavirus Disease 2019 (COVID-19) arrived in Bolivia. Here, we report the main clinical findings, and epidemiological features of the first series of cases, and a cluster, confirmed in Bolivia.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         For this observational, retrospective and cross-sectional study, information was obtained from the Hospitals and the Ministry of Health for the cases that were laboratory-diagnosed and related, during March 2020. rRT-PCR was used for the detection of the RNA of SARS-CoV-2 following the protocol Charité, Berlin, Germany, from nasopharyngeal swabs.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         Among 152 suspected cases investigated, 12 (7.9%) were confirmed with SARS-CoV-2 infected by rRT-PCR. The median age was 39 years (IQR 25–43), six of them male. Two cases proceed from Italy and three from Spain. Nine patients presented fever, and cough, five sore throat, and myalgia, among other symptoms. Only a 60 y-old woman with hypertension was hospitalized. None of the patients required ICU nor fatalities occurred in this group.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p>
         This is the first report of surveillance of COVID-19 in Bolivia, with patients managed mainly with home isolation. Preparedness for a significant epidemic, as is going on in other countries, and the deployment of response plans for it, in the country is now taking place to mitigate the impact of the COVID-19 pandemic in the population.
        </p>
       </sec>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus disease 2019 (COVID-19)
       </kwd>
       <kwd>
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Bolivia
       </kwd>
       <kwd>
        Latin America
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0010">
      After its zoonotic emergence in China, during November–December 2019 [
      <xref ref-type="bibr" rid="bib1">
       [1]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib4">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      ], the Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ], spread significantly into other countries in Asia [
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       [12]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      ]. Then, to other continents such as the Pacific region [
      <xref ref-type="bibr" rid="bib15">
       15
      </xref>
      ], North America [
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      ], Europe [
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       [19]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib20">
       [20]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib21">
       [21]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      ], and even Africa [
      <xref ref-type="bibr" rid="bib23">
       [23]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       [24]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      ].
     </p>
     <p id="p0015">
      On February 25, 2020, a Brazilian traveller returned home from Lombardy, northern Italy, to São Paulo, Brazil, presenting fever, dry cough, sore throat, and coryza, being tested by the real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), and with a positive result, becoming the first confirmed case in Latin America [
      <xref ref-type="bibr" rid="bib27">
       [27]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       [28]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib29">
       [29]
      </xref>
      ]. After it, other countries in Latin America, such as Mexico [
      <xref ref-type="bibr" rid="bib30">
       30
      </xref>
      ], Costa Rica, Honduras [
      <xref ref-type="bibr" rid="bib31">
       31
      </xref>
      ], Panama, in Central America, as well as Argentina, Chile, Colombia, among others in South America, including also on March 2, 2020, Bolivia, have received travellers, and diagnosed imported cases of COVID-19 in their territories.
     </p>
     <p id="p0020">
      In most of the countries of Latin America, confirmed cases have been specially imported from Italy but also from Spain. Although this scenario, no case reports or series from South America are yet available in scientific journals.
     </p>
     <p id="p0025">
      During March 2–15, 2020, the first 12 cases of SARS-CoV-2-laboratory confirmed, arrived and were diagnosed in different areas of Bolivia. Herein, we report the main clinical findings and epidemiological features of them.
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Methods
     </title>
     <p id="p0030">
      Bolivia is a South American country constituted by nine departments (main administrative level), 112 provinces (second administrative level) and 337 municipalities (third administrative level) (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ). The territory presents climatic, geographic, social, and epidemiological conditions suitable for the transmission of many infectious diseases (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ). Before SARS-CoV-2 arrival, Influenza and RSV, among other respiratory viruses, represent significant causes of hospitalization in different cities of the country, especially among children under one year of age [
      <xref ref-type="bibr" rid="bib32">
       [32]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       [33]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib34">
       [34]
      </xref>
      ].
      <fig id="fig1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Relationship and contacts between the cases of SARS-CoV-2 infection/COVID-19 in Bolivia, March 2–15, 2020.
        </p>
       </caption>
       <alt-text id="alttext0010">
        Fig. 1
       </alt-text>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0035">
      For this observational, retrospective and cross-sectional study, the epidemiological data records were collected from the Hospitals and the Ministry of Health of Bolivia, obtaining the clinical and epidemiological data of the COVID-19 cases that were laboratory-diagnosed during March 2–15, 2020. Samples were tested by rRT-PCR to SARS-CoV-2 at the Laboratory of the National Center of Tropical Diseases (CENETROP), 2020, following the protocol Charité, Berlin, Germany [
      <xref ref-type="bibr" rid="bib35">
       35
      </xref>
      ].
     </p>
     <p id="p0040">
      Given the small number of cases, the summary of continuous variables considered the median and interquartile ranges (IQR). All analyses were performed with the statistical software Stata®14IC, licensed for Universidad Tecnológica de Pereira.
     </p>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <p id="p0045">
      During March 2–15, 2020, 152 suspected cases were investigated in Bolivia, especially from international travellers, most from China, Italy and Spain. Although active enhanced surveillance for respiratory tract infection begun in January 2020, considering the international warning for the 2019 novel Coronavirus, later designated as COVID-19. The first suspected cases were investigated between February 2, and March 1, 2020, including ten travellers, all negative by rRT-PCR in that period.
     </p>
     <p id="p0050">
      A total of 12 cases (7.9%) were diagnosed with COVID-19 at different departments of Bolivia (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ). The median age of patients was 39.0 y-old (IQR 25.3–43.4); six of them were male. On March 2th, 2020, a 64-year-old woman (Case 1), a Bolivian from Oruro, visiting Lombardy, Italy, during the last 14 days, with no previous history of comorbidities, returned to Bolivia, arriving at Santa Cruz, then travelling to La Paz, Cochabamba, and finally to her home in Oruro. She presented at the outpatient department of the General Hospital of Oruro, on March 3rd, 2020, complaining with fever, cough, vomiting, malaise and abdominal pain, but with no other significant signs or symptoms. Nasopharyngeal swabs obtained, and she isolated at home. Her samples tested positive for SARS-CoV-2 on rRT-PCR assays at the Laboratory of the National Center of Tropical Diseases (CENETROP) on March 10th, 2020. She was in contact with seven relatives, six in Oruro (Cases 3–7 and 10) and one in Cochabamba (Case 8), all investigated and tested positive (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ) (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). Although negative, cases have been investigated in the rest of the departments of Bolivia (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ), including initial phone call -telemedicine- for over 15,000 individuals in the first month.
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Clinical and epidemiological characteristics of cases of SARS-CoV-2 infection/COVID-19 in Bolivia, March 2–15, 2020.
        </p>
       </caption>
       <alt-text id="alttext0015">
        Table 1
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th rowspan="2">
           <break>
           </break>
           Case
          </th>
          <th rowspan="2">
           Date of March 2020
          </th>
          <th rowspan="2">
           Department
          </th>
          <th rowspan="2">
           Age
          </th>
          <th rowspan="2">
           Sex
          </th>
          <th rowspan="2">
           Date Symptoms Initiated, 2020
          </th>
          <th rowspan="2">
           Date Consultation (month/day)
          </th>
          <th rowspan="2">
           Days
          </th>
          <th rowspan="2">
           Hospitalization
          </th>
          <th colspan="11">
           Clinical manifestations
           <hr/>
          </th>
          <th rowspan="2">
           Comorbidities or history
          </th>
          <th rowspan="2">
           Traveller from
          </th>
          <th rowspan="2">
           Started day
          </th>
          <th rowspan="2">
           Returning day
          </th>
          <th rowspan="2">
           Long of travel
          </th>
          <th rowspan="2">
           Link to cases
          </th>
          <th rowspan="2">
           Sampling place
          </th>
         </tr>
         <tr>
          <th>
           Fever
          </th>
          <th>
           Cough
          </th>
          <th>
           Malaise
          </th>
          <th>
           Vomiting
          </th>
          <th>
           Abdominal Pain
          </th>
          <th>
           Tachypnea
          </th>
          <th>
           Myalgia
          </th>
          <th>
           Sore throat
          </th>
          <th>
           Diarrhoea
          </th>
          <th>
           Cephalea
          </th>
          <th>
           Conjunctival injection
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           1
          </td>
          <td align="left">
           8th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           64
          </td>
          <td align="left">
           F
          </td>
          <td align="left">
           3/2
          </td>
          <td align="left">
           3/3
          </td>
          <td align="left">
           1
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Italia
          </td>
          <td align="left">
           3/1
          </td>
          <td align="left">
           3/2
          </td>
          <td align="left">
           3.01 years
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Hospital
          </td>
         </tr>
         <tr>
          <td align="left">
           2
          </td>
          <td align="left">
           9th
          </td>
          <td align="left">
           Santa Cruz
          </td>
          <td align="left">
           60
          </td>
          <td align="left">
           F
          </td>
          <td align="left">
           2/29
          </td>
          <td align="left">
           3/8
          </td>
          <td align="left">
           8
          </td>
          <td align="left">
           Hosp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           HTA
          </td>
          <td align="left">
           Italia
          </td>
          <td align="left">
           2/7
          </td>
          <td align="left">
           3/8
          </td>
          <td align="left">
           30 days
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Hospital
          </td>
         </tr>
         <tr>
          <td align="left">
           3
          </td>
          <td align="left">
           10th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           41
          </td>
          <td align="left">
           F
          </td>
          <td align="left">
           3/9
          </td>
          <td align="left">
           3/9
          </td>
          <td align="left">
           0
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           4
          </td>
          <td align="left">
           10th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           13
          </td>
          <td align="left">
           M
          </td>
          <td align="left">
           Unknown
          </td>
          <td align="left">
           3/8
          </td>
          <td align="left">
           Unknown
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           5
          </td>
          <td align="left">
           10th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           44
          </td>
          <td align="left">
           M
          </td>
          <td align="left">
           3/10
          </td>
          <td align="left">
           3/10
          </td>
          <td align="left">
           0
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           6
          </td>
          <td align="left">
           10th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           39
          </td>
          <td align="left">
           M
          </td>
          <td align="left">
           3/2
          </td>
          <td align="left">
           3/11
          </td>
          <td align="left">
           9
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           7
          </td>
          <td align="left">
           10th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           39
          </td>
          <td align="left">
           F
          </td>
          <td align="left">
           Unknown
          </td>
          <td align="left">
           3/10
          </td>
          <td align="left">
           Unknown
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           8
          </td>
          <td align="left">
           11th
          </td>
          <td align="left">
           Cochabamba
          </td>
          <td align="left">
           43
          </td>
          <td align="left">
           M
          </td>
          <td align="left">
           3/6
          </td>
          <td align="left">
           3/9
          </td>
          <td align="left">
           3
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Previous CAP
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           9
          </td>
          <td align="left">
           11th
          </td>
          <td align="left">
           Santa Cruz
          </td>
          <td align="left">
           27
          </td>
          <td align="left">
           M
          </td>
          <td align="left">
           3/9
          </td>
          <td align="left">
           3/11
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Spain
          </td>
          <td align="left">
           2/23
          </td>
          <td align="left">
           3/8
          </td>
          <td align="left">
           14 days
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Hospital
          </td>
         </tr>
         <tr>
          <td align="left">
           10
          </td>
          <td align="left">
           11th
          </td>
          <td align="left">
           Oruro
          </td>
          <td align="left">
           18
          </td>
          <td align="left">
           M
          </td>
          <td align="left">
           3/8
          </td>
          <td align="left">
           3/11
          </td>
          <td align="left">
           3
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           –
          </td>
          <td align="left">
           C1
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           11
          </td>
          <td align="left">
           13th
          </td>
          <td align="left">
           Santa Cruz
          </td>
          <td align="left">
           20
          </td>
          <td align="left">
           F
          </td>
          <td align="left">
           3/9
          </td>
          <td align="left">
           3/10
          </td>
          <td align="left">
           1
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Spain
          </td>
          <td align="left">
           2/5
          </td>
          <td align="left">
           3/11
          </td>
          <td align="left">
           35 days
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Home
          </td>
         </tr>
         <tr>
          <td align="left">
           12
          </td>
          <td align="left">
           15th
          </td>
          <td align="left">
           Santa Cruz
          </td>
          <td align="left">
           30
          </td>
          <td align="left">
           F
          </td>
          <td align="left">
           3/13
          </td>
          <td align="left">
           3/15
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           Outp
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Y
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Spain
          </td>
          <td align="left">
           3/9
          </td>
          <td align="left">
           3/11
          </td>
          <td align="left">
           2 days
          </td>
          <td align="left">
           N
          </td>
          <td align="left">
           Hospital
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          F, Female; M, Male; Outp, Outpatient; Hosp, Hospitalization; Y, Yes; N, No; HTA, hypertension; CAP, Community-acquired pneumonia; C1, Case 1.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="p0055">
      In Santa Cruz de la Sierra, four cases were confirmed, three of them travellers from Italy and one from Spain (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ) (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). None of these was initially detected by border officials, as suspected, but in hospitals. The median time between the initial symptoms and consultation was two days (IQR 0.25–3.00 days). From the total, only one patient was hospitalized, and the rest were isolated at home initially per 14 days. The hospitalized patient was a 60 y-old woman with hypertension, then as presenting more two risk factors, decided for close clinical observation.
     </p>
     <p id="p0060">
      Nine patients presented fever, and cough, five sore throat, and myalgia, among other symptoms (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). Only two patients reported previous comorbidities, hypertension and community-acquired pneumonia (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). None of the patients was previously immunized against Influenza.
     </p>
     <p id="p0065">
      Chest radiographs obtained for the patient showed no abnormalities. Real-time RT-PCR and ELISA assays for influenza A and B viruses, NS1 antigen rapid tests for dengue viruses, chikungunya, and Zika, were negative in all cases.
     </p>
     <p id="p0070">
      Patients did not receive antiviral anti-SARS-CoV-2 treatment, especially, as most of them were managed at home, symptomatically, and without further need of specialized medical care.
     </p>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p id="p0075">
      Emerging infectious diseases, such as is the case of COVID-19 are currently prone for the risk of epidemics, or even, as has been this case, to became a Public Health Emergency of International Concern (PHEIC), and later a pandemic, as declared by the World Health Organization (WHO) [
      <xref ref-type="bibr" rid="bib36">
       [36]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib37">
       [37]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       [38]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       [39]
      </xref>
      ].
     </p>
     <p id="p0080">
      In this context, Latin America was the last significant region where COVID-19 arrived [
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bib40">
       40
      </xref>
      ]. In this case, coming mainly from two European countries, Italy and Spain [
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       [19]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib20">
       [20]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib21">
       [21]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      ]. In Bolivia, the first two cases came from Italy. Especially in the north of that country, significant epidemics are going on. For the moment of the arrival of the first Bolivian COVID-19 case, there were 7,375 cases in Italy, with 366 deaths. The ninth, eleventh, and twelfth cases came from Spain. For the moment of the arrival of these cases, the last on March 15, 2020, there were 7,988 cases in Spain. That issue has been a common trend in Latin America now, imported cases from Italy and Spain [
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bib41">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="bib42">
       42
      </xref>
      ]. This highlights the relevance of the spread of the COVID-19 due to population movements that has affected Bolivia, but also countries in South America, and most in the Latin American and the Caribbean region.
     </p>
     <p id="p0085">
      As has occurred in other affected countries elsewhere, there is a risk of local clusters of transmission from imported cases [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib43">
       [43]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       [44]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       [45]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       [46]
      </xref>
      ]. Precisely, the first case in Bolivia, originated the transmission to other seven cases in two different departments of the country, as the patient travelled to Santa Cruz, Cochabamba, La Paz and Oruro (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ). Close contact with active cases of COVID-19 represents a significant risk for SARS-CoV-2 transmission, even during the asymptomatic or presymptomatic stage, especially for relatives or friends [
      <xref ref-type="bibr" rid="bib19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       [46]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       [47]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib48">
       [48]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib49">
       [49]
      </xref>
      ].
     </p>
     <p id="p0090">
      None of the cases in this study required intensive care unit (ICU). The hospitalized case evolved good and was only hospitalized due to risk factors (age and hypertension) [
      <xref ref-type="bibr" rid="bib1">
       [1]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib4">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ].
     </p>
     <p id="p0095">
      The clinical manifestations of these patients were according to the expected as reported in the literature [
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ], presenting mainly fever, and cough, among other symptoms. Ten of the twelve cases were younger than 60 y-old, and with no risk factors, except in two cases with hypertension and a history of community-acquired pneumonia. Then, the clinical evolution was favorable with no complications and no deaths among these patients. Early healthcare with appropriate training of healthcare works would be critical to keeping mostly this in a similar trend for future cases in the country that is now taken severe actions, such as home isolation and quarantine [
      <xref ref-type="bibr" rid="bib51">
       [51]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib52">
       [52]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib53">
       [53]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      ], primarily to protect those with risk factors. According to the National Institute of Statistics of Bolivia, for 2019, there were 11,513,101 inhabitants. From them, 10.19% corresponded to people older than 60 years-old [
      <xref ref-type="bibr" rid="bib55">
       55
      </xref>
      ]. For some risk factors, such as diabetes mellitus, Bolivia is amongst the country with the lowest prevalence, around 6.6% in 2016 [
      <xref ref-type="bibr" rid="bib56">
       56
      </xref>
      ]. However, is estimated that a third of the Bolivian population presents high blood pressure [
      <xref ref-type="bibr" rid="bib57">
       57
      </xref>
      ], which is considered among the most prevalent risk factors in patients with COVID-19, for worse clinical progression [
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ], then the case 2 in Santa Cruz, was hospitalized for close monitoring while having age and hypertension as risk factors.
     </p>
     <p id="p0100">
      Bolivia is a developing country with limited resources. In this scenario, the previous overlapping health events, such as dengue [
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ], chikungunya, Zika, hantavirus and even hemorrhagic fevers caused by arenaviruses [
      <xref ref-type="bibr" rid="bib58">
       [58]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib59">
       [59]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib60">
       [60]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib61">
       [61]
      </xref>
      ], as well as regular viral respiratory infections [
      <xref ref-type="bibr" rid="bib32">
       [32]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       [33]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib34">
       [34]
      </xref>
      ], may pose a challenge for diagnosis, and the healthcare together the ongoing COVID-19 outbreak.
     </p>
     <p id="p0105">
      There has been a rapid surge in research in response to the outbreak of COVID-19 [
      <xref ref-type="bibr" rid="bib62">
       62
      </xref>
      ]. During this early period, published research primarily explored the epidemiology [
      <xref ref-type="bibr" rid="bib63">
       63
      </xref>
      ], causes, clinical manifestation and diagnosis [
      <xref ref-type="bibr" rid="bib64">
       64
      </xref>
      ], as well as prevention and control of the novel coronavirus. Although these studies are relevant to control the current public emergency, more high-quality research is needed to provide valid and reliable ways to manage this kind of public health emergency in both the short- and long-term, including therapeutic options [
      <xref ref-type="bibr" rid="bib65">
       [65]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib66">
       [66]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib67">
       [67]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib68">
       [68]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib69">
       [69]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib70">
       [70]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib71">
       [71]
      </xref>
      ].
     </p>
     <p id="p0110">
      During the current phase of COVID-19 outbreak in Bolivia, only of imported cases, all of them are being tested by rRT-PCR. However, the question is if the spread occurs rapidly in the country, with community-transmission as is now observed in other countries in the continent [
      <xref ref-type="bibr" rid="bib72">
       [72]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib73">
       [73]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib74">
       [74]
      </xref>
      ], Bolivia, as well as other low- and middle-income countries in the region, e.g. Haiti, Venezuela [
      <xref ref-type="bibr" rid="bib75">
       75
      </xref>
      ], Nicaragua, among others, will not be able to afford large-scale diagnostics [
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ]. Therefore, in the absence of testing, triage based on clinical case definition or presumptive diagnosis should be prioritized. A proposal for surveillance at that point, if diagnostics are limited, is to develop a definition of a clinical confirmed case. As occurred with chikungunya, and Zika, in most countries in Latin America, this would be “a patient with fever, cough and other respiratory symptoms, not explained by other etiological agents or causes, that is diagnosed in a municipality where at least a laboratory-confirmed case was identified” [
      <xref ref-type="bibr" rid="bib76">
       [76]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib77">
       [77]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       [78]
      </xref>
      ].
     </p>
     <p id="p0115">
      The number of patients that may require ventilatory support and attention at an intensive care unit (ICU) may collapse the health system of larger countries. In the case of Bolivia, there are only 35 ICU beds. Then, as expected, the health authorities are working on the general beds that can be rapidly converted to ICU beds and some general hospitals to be converted into critical care hospitals. Additional physicians and nurses are now widely trained in critical care medicine and specifically on COVID-19 in order to answer the epidemic. A national telehealth program is running for multiple purposes, including training on COVID-19. Albeit that, it is debatable whether countries such as Bolivia can fund the additional cost of critical care units from our limited health budgets [
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ], that need to attend not only the epidemic of COVID-19 but also other non-communicable diseases as well as communicable diseases, such as dengue, diarrhoea, malaria, HIV, tuberculosis, among many other diseases [
      <xref ref-type="bibr" rid="bib27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bib75">
       75
      </xref>
      ].
     </p>
     <p id="p0120">
      Finally, in the absence of vaccines and specific treatments available and approved for COVID-19, the only available public health tools to control person-to-person transmittable diseases are isolation and quarantine, social distancing, and community containment measures, and this is now in place in Bolivia, as well as in most countries of Latin America [
      <xref ref-type="bibr" rid="bib54">
       54
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       79
      </xref>
      ]. There is an urgent need to train most of the healthcare workforce on biosecurity, isolation, and quarantine, in order to be massively applied in the country. If these measures are implemented soon, more possibilities to control spreading will have the countries, which is even critical in countries, such as Bolivia, with limited resources.
     </p>
     <p id="p0125">
      In conclusion, while the global awareness and response to the COVID-19 pandemic are well known, each country faces its considerations and scenarios to face the epidemic in their territories. In the case of Bolivia, the less developed nation of South America, national and international cooperation, advise and support, lead to enhance surveillance and early case detection of COVID-19, scaling up the training activities at the healthcare sector and the community for proper education as well as quarantine. In this report, the first 12 confirmed cases were analyzed, showing that most of the evolve positively with no severe disease nor fatalities. Nevertheless, preparedness for a significant epidemic, as is going on in other countries, and the deployment of response plans for it, in the country is now taking place to mitigate the impact of the COVID-19 pandemic in the population.
     </p>
     <p id="p0130">
      Preparedness in South America should include the increase in the diagnostic capacity for rapid testing for the virus, including not only imported but also secondary and tertiary cases. It is important to avoid the delay from identification of suspected cases to their confirmation and isolation, in order to affect the possible disease transmission [
      <xref ref-type="bibr" rid="bib25">
       25
      </xref>
      ]. Also, there is a need for improvement of the volume of personnel trained to run such tests, and to warrant an adequate stock of materials needed to do them. Health authorities should train, equip, and strengthen the diagnostic capacities of hospital laboratories close to infectious disease and emergency departments to reduce the time to deliver results, manage confirmed cases and contacts more rapidly, and preserve strict infection control measures [
      <xref ref-type="bibr" rid="bib25">
       25
      </xref>
      ]. Finally, in the differential diagnosis with other febrile conditions, especially in Latin America, also coinfections with dengue [
      <xref ref-type="bibr" rid="bib75">
       75
      </xref>
      ] and with respiratory viruses, such as Influenza and Metapneumovirus [
      <xref ref-type="bibr" rid="bib80">
       [80]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib81">
       [81]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib82">
       [82]
      </xref>
      ], among others, already reported together with SARS-CoV-2, should be considered.
     </p>
    </sec>
    <sec id="sec5">
     <label>
      5
     </label>
     <title>
      Limitations
     </title>
     <p id="p0135">
      The main limitation of our study is the lack of long follow up of the patients, but this analysis is a rapid preliminary study for the outbreak assessment in Bolivia, focused on epidemiological and clinical aspects. Secondly, still, there are no available serological tests to assess the antibody response. Third, due to constraining in the use of the rRT-PCR, only initial testing was provided, although after ceased of symptoms, for the case hospitalized, it will be repeated to assess if became negative. More comprehensive contact tracing for these cases should be performed to assess the possibility of community transmission. Finally, soon, Bolivia will also need to have sequencing and phylogenetic studies that would be useful as this may diverge from other SARS-CoV-2 isolates or strain, that even, would be related to clinical evolution and outcomes.
     </p>
    </sec>
    <sec id="sec6">
     <title>
      Funding source
     </title>
     <p id="p0140">
      Universidad Franz Tamayo, Cochabamba, Bolivia. Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Study sponsors had no role in the study design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.
     </p>
    </sec>
    <sec id="sec7">
     <title>
      Ethical approval
     </title>
     <p id="p0145">
      Approval was not required.
     </p>
    </sec>
    <sec id="sec8">
     <title>
      CRediT authorship contribution statement
     </title>
     <p id="p0150">
      <bold>
       Juan Pablo Escalera-Antezana:
      </bold>
      Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing - review &amp; editing.
      <bold>
       Nicolas Freddy Lizon-Ferrufino:
      </bold>
      Data curation, Formal analysis, Writing - review &amp; editing.
      <bold>
       Americo Maldonado-Alanoca:
      </bold>
      Data curation, Formal analysis, Writing - review &amp; editing.
      <bold>
       Gricel Alarcón-De-la-Vega:
      </bold>
      Data curation, Formal analysis, Writing - review &amp; editing.
      <bold>
       Lucia Elena Alvarado-Arnez:
      </bold>
      Data curation, Formal analysis, Writing - review &amp; editing.
      <bold>
       María Alejandra Balderrama-Saavedra:
      </bold>
      Data curation, Formal analysis, Writing - review &amp; editing.
      <bold>
       D. Katterine Bonilla-Aldana:
      </bold>
      Data curation, Formal analysis, Writing - review &amp; editing.
      <bold>
       Alfonso J. Rodríguez-Morales:
      </bold>
      Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing - original draft, Writing - review &amp; editing.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0155">
      All authors report no potential conflicts.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K.-H.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020; 382(13):1199-1207
        </year>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus emerging in China - key questions for impact assessment
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         692
        </fpage>
        <lpage>
         694
        </lpage>
        <pub-id pub-id-type="pmid">
         31978293
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China
        </article-title>
        <comment>
         2019
        </comment>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Dhama
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Revisiting the one health approach in the context of COVID-19: a look into the ecology of this emerging disease
        </article-title>
        <source>
         Adv Anim Vet Sci
        </source>
        <volume>
         8
        </volume>
        <year>
         2020
        </year>
        <fpage>
         234
        </fpage>
        <lpage>
         237
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Balbin-Ramon
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Paniz-Mondolfi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sah
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         History is repeating itself, a probable zoonotic spillover as a cause of an epidemic: the case of 2019 novel Coronavirus
        </article-title>
        <source>
         Inf Med
        </source>
        <volume>
         28
        </volume>
        <year>
         2020
        </year>
        <fpage>
         3
        </fpage>
        <lpage>
         5
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Foley
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1002/jmv.25731
        </comment>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bastola
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sah
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lal
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
         <name>
          <surname>
           Jha
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ojha
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The first 2019 novel coronavirus case in Nepal
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         20
        </volume>
        <year>
         2020
        </year>
        <fpage>
         279
        </fpage>
        <lpage>
         280
        </lpage>
        <pub-id pub-id-type="pmid">
         32057299
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           L.T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           A.Y.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covert COVID-19 and false-positive dengue serology in Singapore
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Shu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Ja
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1016/S2213-2600(20)30079-5
        </comment>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           T.V.
          </given-names>
         </name>
         <name>
          <surname>
           Luong
          </surname>
          <given-names>
           Q.C.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           T.V.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Importation and human-to-human transmission of a novel coronavirus in vietnam
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yee
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1977
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           COVID-19 National Incident Room Surveillance Team
          </surname>
         </name>
        </person-group>
        <chapter-title>
         COVID-19, Australia: epidemiology report 2
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First case of 2019 novel coronavirus in the United States
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020; 382(10):929-936
        </year>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Silverstein
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Stroud
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cleghorn
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Leis
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10225
        </issue>
        <year>
         2020
        </year>
        <fpage>
         734
        </fpage>
        <pub-id pub-id-type="pmid">
         32061312
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           ECDC
          </surname>
         </name>
        </person-group>
        <chapter-title>
         ECDC statement following reported confirmed case of 2019-nCoV in Germany
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="https://www.ecdc.europa.eu/en/news-events/ecdc-statement-following-reported-confirmed-case-2019-ncov-germany">
         https://www.ecdc.europa.eu/en/news-events/ecdc-statement-following-reported-confirmed-case-2019-ncov-germany
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schunk
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sothmann
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bretzel
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Froeschl
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wallrauch
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         368
        </volume>
        <year>
         2020
        </year>
        <fpage>
         m751
        </fpage>
        <pub-id pub-id-type="pmid">
         32098875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Porcheddu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Serra
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kelvin
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kelvin
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Rubino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China
        </article-title>
        <source>
         J Infect Dev Ctries
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         32146445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giovanetti
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Benvenuto
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Angeletti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ciccozzi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The first two cases of 2019-nCoV in Italy: where they come from?
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020; 92(5):518-521
        </year>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kapata
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ihekweazu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ntoumi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Raji
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chanda-Kapata
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mwaba
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         93
        </volume>
        <year>
         2020
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="pmid">
         32119980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hopman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Allegranzi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Mehtar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Managing COVID-19 in low- and middle-income countries
        </article-title>
        <source>
         J Am Med Assoc
        </source>
        <year>
         2020 doi: 10.1001/jama.2020.4169
        </year>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pullano
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pinotti
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Valdano
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Poletto
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Boelle
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         871
        </fpage>
        <lpage>
         877
        </lpage>
        <pub-id pub-id-type="pmid">
         32087820
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adepoju
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nigeria responds to COVID-19; first case detected in sub-Saharan Africa
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1038/d41591-020-00004-2
        </comment>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gallego
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Escalera-Antezana
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Mendez
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zambrano
          </surname>
          <given-names>
           L.I.
          </given-names>
         </name>
         <name>
          <surname>
           Franco-Paredes
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 in Latin America: the implications of the first confirmed case in Brazil
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         101613
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           da Cunha
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cimerman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Weissmann
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chebabo
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bellei
          </surname>
          <given-names>
           N.C.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Informativo da Sociedade Brasileira de Infectologia: primeiro caso confirmado de doença pelo novo Coronavírus (COVID-19) no Brasil – 26/02/2020
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Sociedade Brasileira de Infectologia
        </publisher-name>
        <publisher-loc>
         Sao Paulo, Brasil
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sao Paulo State Health Secretary
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Plan of response of the sao Paulo state for the human infection due to novel coronavirus - 2019nCoV
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gardner
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An interactive web-based dashboard to track COVID-19 in real time
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1016/S1473-3099(20)30120-1
        </comment>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zambrano
          </surname>
          <given-names>
           L.I.
          </given-names>
         </name>
         <name>
          <surname>
           Fuentes-Barahona
          </surname>
          <given-names>
           I.C.
          </given-names>
         </name>
         <name>
          <surname>
           Bejarano-Torres
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bustillo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Vallecillo-Chinchilla
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pregnant woman with COVID-19 in Central America
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         101639
        </comment>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chavez
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales-Armayo
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Mendoza
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Palekar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Rivera
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of influenza and respiratory syncytial virus hospitalizations using sentinel surveillance data-La Paz, Bolivia
        </article-title>
        <comment>
         2012-2017
        </comment>
        <source>
         Influenza Other Respir Viruses
        </source>
        <volume>
         13
        </volume>
        <year>
         2019
        </year>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         31206257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delangue
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Roca Sanchez
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Piorkowski
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Bessaud
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baronti
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Thirion-Perrier
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral aetiology influenza like illnesses in Santa Cruz, Bolivia (2010-2012)
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         11
        </volume>
        <year>
         2014
        </year>
        <fpage>
         35
        </fpage>
        <pub-id pub-id-type="pmid">
         24564892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mamani
          </surname>
          <given-names>
           O.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Salazar
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <x>
          …
         </x>
        </person-group>
        <chapter-title>
         Perfil epidemiológico de la Influenza Humana A H1N1 en Cochabamba, Bolivia, gestiones 2009 a 2014: scielo.org.bo
        </chapter-title>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Molenkamp
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Meijer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
        </article-title>
        <source>
         Euro Surveill
        </source>
        <year>
         2020
        </year>
        <fpage>
         25
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Novel coronavirus (2019-nCoV) - situation report - 4 - 24 january 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200124-sitrep-4-2019-ncov.pdf?sfvrsn=9272d086_2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200124-sitrep-4-2019-ncov.pdf?sfvrsn=9272d086_2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Statement on the meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV)
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov">
         https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Novel coronavirus (2019-nCoV) - situation report - 7 - 27 january 2020
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200127-sitrep-7-2019--ncov.pdf?sfvrsn=98ef79f5_2020">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200127-sitrep-7-2019--ncov.pdf?sfvrsn=98ef79f5_2020
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
        </chapter-title>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov">
         https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           MacGregor
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kanagarajah
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Schlagenhauf
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Going global - travel and the 2019 novel coronavirus
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <volume>
         33
        </volume>
        <year>
         2020
        </year>
        <fpage>
         101578
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millan-Oñate
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rodríguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Camacho-Moreno
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Mendoza-Ramírez
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Rodríguez-Sabogal
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <name>
          <surname>
           Álvarez-Moreno
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19)
        </article-title>
        <source>
         Infectio
        </source>
        <year>
         2020
        </year>
        <fpage>
         24
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sánchez-Duque
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hernández-Botero
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pérez-Díaz
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Villamil-Gómez
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Méndez
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preparación y control de la enfermedad por coronavirus 2019 (COVID-19) en América Latina
        </article-title>
        <source>
         Acta Méd Peru
        </source>
        <volume>
         37
        </volume>
        <year>
         2020
        </year>
        <fpage>
         3
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gamber
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Indirect virus transmission in cluster of COVID-19 cases, wenzhou, China, 2020
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         26
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           X.D.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of pediatric patients with COVID-19: a report of two family cluster cases
        </article-title>
        <source>
         World J Pediatr
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1007/s12519-020-00356-2
        </comment>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of COVID-19 in the terminal stage of incubation period: a familial cluster
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <year>
         2020 doi: 10.1016/j.ijid.2020.03.027
        </year>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1002/jmv.25776
        </comment>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Hammadi
          </surname>
          <given-names>
           Z.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Al Mulla
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tarnini
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates
        </article-title>
        <comment>
         May 2015
        </comment>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2197
        </fpage>
        <lpage>
         2200
        </lpage>
        <pub-id pub-id-type="pmid">
         26584223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: extent and implications for infection control: a systematic review
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <volume>
         27
        </volume>
        <year>
         2019
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         32
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China
        </article-title>
        <source>
         Sci China Life Sci
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1007/s11427-020-1661-4
        </comment>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Cardona-Ospina
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutiérrez-Ocampo
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Villamizar-Peña
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Holguin-Rivera
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Escalera-Antezana
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         101623
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cetron
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Landwirth
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public health and ethical considerations in planning for quarantine
        </article-title>
        <source>
         Yale J Biol Med
        </source>
        <volume>
         78
        </volume>
        <year>
         2005
        </year>
        <fpage>
         329
        </fpage>
        <lpage>
         334
        </lpage>
        <pub-id pub-id-type="pmid">
         17132339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Siddique
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nabi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus, poor quarantine, and the risk of pandemic
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2020 doi: 10.1016/j.jhin.2020.02.002
        </year>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lombardi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bozzi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Mangioni
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Muscatello
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peri
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Taramasso
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2020 doi: 10.1016/j.jhin.2020.03.003
        </year>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sref54" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           D.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak
        </article-title>
        <source>
         J Trav Med
        </source>
        <volume>
         27
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sref55" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           INstituto Nacional de Estadística
          </surname>
         </name>
        </person-group>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.ine.gob.bo/">
         https://www.ine.gob.bo/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sref56" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           OPS Bolivia
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Bolivia está entre los países con menor prevalencia de diabetes de las Américas
        </chapter-title>
        <year>
         2016
        </year>
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.paho.org/bol/index.php?option=com_content&amp;view=article&amp;id=1853:dms20162&amp;Itemid=481">
         https://www.paho.org/bol/index.php?option=com_content&amp;view=article&amp;id=1853:dms20162&amp;Itemid=481
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sref57" publication-type="book">
        <source>
         Naciones unidas Bolivia
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="http://www.nu.org.bo/noticias/uno-de-cada-tres-adultos-en-bolivia-tiene-hipertension/">
         http://www.nu.org.bo/noticias/uno-de-cada-tres-adultos-en-bolivia-tiene-hipertension/
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Escalera-Antezana
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Murillo-Garcia
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Gomez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Unzueta-Quiroga
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chikungunya in Bolivia: domestic imported case series in Cochabamba
        </article-title>
        <source>
         J Formos Med Assoc
        </source>
        <volume>
         117
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1133
        </fpage>
        <lpage>
         1134
        </lpage>
        <pub-id pub-id-type="pmid">
         30389275
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Escalera-Antezana
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Murillo-Garcia
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chikungunya in Bolivia: still a neglected disease?
        </article-title>
        <source>
         Arch Med Res
        </source>
        <volume>
         49
        </volume>
        <year>
         2018
        </year>
        <fpage>
         288
        </fpage>
        <pub-id pub-id-type="pmid">
         30269966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Escalera-Antezana
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez-Villena
          </surname>
          <given-names>
           O.J.
          </given-names>
         </name>
         <name>
          <surname>
           Arancibia-Alba
          </surname>
          <given-names>
           A.W.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarado-Arnez
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of fatal cases of Chapare virus hemorrhagic fever originating from rural La Paz, Bolivia, 2019: a cluster analysis
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         101589
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sref61" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Escalera-Antezana
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Torrez-Fernandez
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Montalvan-Plata
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Montenegro-Narvaez
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Aviles-Sarmiento
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarado-Arnez
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Orthohantavirus pulmonary syndrome in Santa Cruz and tarija, Bolivia, 2018
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         90
        </volume>
        <year>
         2020
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="pmid">
         31672659
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sref62" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adhikari
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           Y.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           R.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review
        </article-title>
        <source>
         Infect Dis Poverty
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         29
        </fpage>
        <pub-id pub-id-type="pmid">
         32183901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Holguin-Rivera
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cortes-Bonilla
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Cardona-Trujillo
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           García-Barco
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bedoya-Arias
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections reported by ProMED, february 2000–january 2020
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         101575
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sref64" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Quintero-Rada
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Montoya-Posada
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ramirez
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Paniz-Mondolfi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV, MERS-CoV and now the 2019-novel CoV: have we investigated enough about coronaviruses? - a bibliometric analysis
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         101566
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2020; 30(3):269-271
        </year>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <fpage>
         105932
        </fpage>
        <pub-id pub-id-type="pmid">
         32145363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cortegiani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ingoglia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ippolito
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Giarratano
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Einav
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
        </article-title>
        <source>
         J Crit Care
        </source>
        <year>
         2020 doi: 10.1016/j.jcrc.2020.03.005
        </year>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sref68" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Devaux
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <fpage>
         105938
        </fpage>
        <pub-id pub-id-type="pmid">
         32171740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sref69" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Breakthrough
          </surname>
          <given-names>
           Yang X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="pmid">
         32074550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sahraei
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shabani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shokouhi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Saffaei
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <fpage>
         105945
        </fpage>
        <pub-id pub-id-type="pmid">
         32194152
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sref71" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Touret
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Of chloroquine and COVID-19
        </article-title>
        <source>
         Antivir Res
        </source>
        <volume>
         177
        </volume>
        <year>
         2020
        </year>
        <fpage>
         104762
        </fpage>
        <pub-id pub-id-type="pmid">
         32147496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sref72" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Aiello
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public health measures to slow community spread of COVID-19
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2020 doi: 10.1093/infdis/jiaa123
        </year>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sref73" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwon
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak
        </article-title>
        <source>
         J Kor Med Sci
        </source>
        <volume>
         35
        </volume>
        <year>
         2020
        </year>
        <fpage>
         e123
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sref74" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Community transmission of severe acute respiratory syndrome coronavirus 2, shenzhen, China, 2020
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2020
        </year>
        <fpage>
         26
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sref75" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Suarez
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Risquez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Delgado-Noguera
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Paniz-Mondolfi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The current syndemic in Venezuela: measles, malaria and more co-infections coupled with a breakdown of social and healthcare infrastructure. Quo vadis?
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <volume>
         27
        </volume>
        <year>
         2019
        </year>
        <fpage>
         5
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sref76" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Bonilla-Aldana
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mondragon-Cardona
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chikungunya and Zika in huila: mapping their incidence in a neglected area of Colombia
        </article-title>
        <source>
         Arch Med Res
        </source>
        <volume>
         49
        </volume>
        <year>
         2018
        </year>
        <fpage>
         512
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         30799053
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sref77" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Galindo-Marquez
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Loaiza
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sabogal-Roman
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marin-Loaiza
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ayala
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mapping Zika virus disease incidence in Valle del Cauca
        </article-title>
        <source>
         Infection
        </source>
        <volume>
         45
        </volume>
        <year>
         2017
        </year>
        <fpage>
         93
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="pmid">
         27743307
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <element-citation id="sref78" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez-Morales
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ruiz
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tabares
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ossa
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Yepes-Echeverry
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ramirez-Jaramillo
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mapping the ecoepidemiology of Zika virus infection in urban and rural areas of Pereira, Risaralda, Colombia, 2015-2016: implications for public health and travel medicine
        </article-title>
        <source>
         Trav Med Infect Dis
        </source>
        <volume>
         18
        </volume>
        <year>
         2017
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         66
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sref79" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chiew
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can we contain the COVID-19 outbreak with the same measures as for SARS?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1016/S1473-3099(20)30129-8
        </comment>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <comment>
         10.1002/jmv.25781
        </comment>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sref81" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Touzard-Romo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Tape
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lonks
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-infection with SARS-CoV-2 and human Metapneumovirus
        </article-title>
        <source>
         R I Med J
        </source>
        <volume>
         103
        </volume>
        <year>
         2013
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         76
        </lpage>
        <comment>
         2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sref82" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0010">
      <title>
       Acknowledgements
      </title>
      <p>
       To the Epidemiology Department of the Ministry of Health of Bolivia for providing additional data of the patients. To CENETROP for rRT-PCR results.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Law Psychiatry
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int J Law Psychiatry
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Law and Psychiatry
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0160-2527
      </issn>
      <issn pub-type="epub">
       1873-6386
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7151525
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0160-2527(20)30019-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijlp.2020.101560
      </article-id>
      <article-id pub-id-type="publisher-id">
       101560
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Capacity in the time of Coronavirus
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Barrister
         </surname>
         <given-names>
          Alex Ruck Keene
         </given-names>
        </name>
        <email>
         alex.ruckkeene@39essex.com
        </email>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       King's College London, Institute of Psychiatry, Psychology &amp; Neuroscience, Essex Autonomy Project, Dickson Poon School of Law, University of Essex, 39 Essex Chambers, London
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author.
        <email>
         alex.ruckkeene@39essex.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        11
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       101560
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         6
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         8
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         8
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <p>
        In the course of a few short weeks, many of the established legal frameworks relating to decision-making in England &amp; Wales in respect of those with impaired decision-making capacity have been ripped up, or apparently rendered all but unusable. Although the Mental Capacity Act 2005 itself was not amended, the impact of other legislation (especially the Coronavirus Act 2020) means that duties towards those with impaired decision-making capacity have been radically changed. This article reflects the experience of a practising barrister in England &amp; Wales grappling with the impact of COVID-19 upon the Mental Capacity Act 2005 across a range of fields in the weeks after the world appeared to change in mid-March 2020.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0005">
      This paper is avowedly a report from the front line, rather than an abstract academic disquisition. It is, further, at best, a first draft of history. It reflects the experience of a practising barrister in England &amp; Wales grappling with the impact of COVID-19 upon the Mental Capacity Act 2005 (‘MCA 2005’) across a range of fields in the weeks after the world appeared to change in mid-March 2020.
      <xref ref-type="fn" rid="fn0005">
       1
      </xref>
      In the course of a few short weeks, many of the established legal frameworks relating to decision-making in England &amp; Wales in respect of those with impaired decision-making capacity were ripped up, or apparently rendered all but unusable. Although the MCA 2005 itself was not amended, the impact of other legislation (especially the Coronavirus Act 2020) meant that duties towards those with impaired decision-making capacity were radically changed. Questions of isolation and social distancing raised stark questions about protection – and the ends of protection – with particular difficulties in the context of those who could not understand what they were being asked or required to do. The intense pressure upon hospitals, and, in particular intensive care units, meant that best interests decision-making as the choice between available options suddenly took on a new and very stark character, and advance care planning started – in some cases – to appear to be a threat rather than an opportunity. And the Court of Protection itself, the statutory court charged with oversight of the MCA 2005, had in a matter of weeks to transform itself into a virtual court, raising deep questions about the functions of justice and participation.
     </p>
     <p id="p0010">
      This article surveys each of these areas and provides some initial reflections – and predictions – in relation to them.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Section 1: Context
     </title>
     <p id="p0015">
      For those not familiar with the law of England and Wales, a brief overview may be of assistance.
     </p>
     <p id="p0020">
      This article discusses both England and Wales. Devolution means that there are similarities and differences between the two.
      <xref ref-type="fn" rid="fn0010">
       2
      </xref>
      The MCA 2005 applies in England &amp; Wales as the framework through which decisions are made (most often informally) about capacity and best interests, on the basis of a functional model of mental capacity. The MCA 2005 also provides an administrative route for deprivation of liberty for purposes of enabling care and treatment of adults in hospitals and care homes, the so-called Deprivation of Liberty Safeguards (‘DoLS’). Outside hospitals/care homes, or in relation to those aged under 18, court authorisation will be required. Separately, and long-predating the MCA 2005 the Mental Health Act 1983 (‘MHA 1983’), which applies in both England &amp; Wales, provides for the assessment and treatment of mental disorder, by compulsion if required. Challenges to authorisations under DoLS are to the Court of Protection, a statutory court established to oversee the MCA 2005;
      <xref ref-type="fn" rid="fn0015">
       3
      </xref>
      challenges to detention under the MHA 1983 are to the Mental Health Tribunal/Mental Health Review Tribunal for Wales.
     </p>
     <p id="p0025">
      The MCA 2005 does not provide any mechanism to compel the delivery of health or social care to an individual. The Court of Protection has a duty to act in the best interests of the person before it, as do others (outside the court room arena) making best interests decision on their behalf. But the Court of Protection:
      <disp-quote>
       <p>
        <italic>
         35.
        </italic>
        […]
        <italic>
         only has power to take a decision that P himself could have taken? It has no greater power to oblige others to do what is best than P would have himself. This must mean that, just like P, the court can only choose between the ‘available options.’
        </italic>
       </p>
       <p>
        […]
       </p>
       <p>
        <italic>
         37. Other service-providing powers and duties
        </italic>
        [outlined immediately below]
        <italic>
         also have their own principles and criteria, which do not depend upon what is best for the service user, although that will no doubt be a relevant consideration. Decisions can, of course, be challenged on the usual judicial review principles. Decisions on health or social care services may also engage the right to respect for private (or family) life under article 8 of the European Convention on Human Rights, but decisions about the allocation of limited resources may well be justified as necessary in the interests of the economic wellbeing of the country (see McDonald v United Kingdom [2015] 60 EHRR 1). Here again, therefore, the legal considerations, both for the public authority and for the court, are different from those under the 2005 Act.
        </italic>
        <xref ref-type="fn" rid="fn0020">
         4
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0030">
      Challenges by way of judicial review are to a different court, the Administrative Court, for which it is more difficult (as a generalisation) to get public funding to pay for legal assistance,
      <xref ref-type="fn" rid="fn0025">
       5
      </xref>
      and are more limited in scope, focusing on the
      <bold>
       process
      </bold>
      of decision-making much more than the
      <bold>
       outcome
      </bold>
      of the decision.
     </p>
     <p id="p0035">
      The National Health Service Act 2006 sets out the powers and duties of the National Health Service to provide healthcare; the Care Act 2014 (in England) and the Social Services and Well-Being (Wales) Act 2014 sets out the powers and duties of local authorities to provide social care to individuals.
      <xref ref-type="fn" rid="fn0030">
       6
      </xref>
      If an individual's needs are such as to amount to a ‘continuing healthcare’ need, then it is the responsibility of the NHS to meet them, and to do so for free. Social care is means-tested, such that a charge can be made for the provision of such care by local authorities. In very broad terms, in relation to both healthcare (outside hospital) and social care, the relevant public body is under a duty to assess the needs of the person, determine whether they are eligible needs, and then meet them.
     </p>
     <p id="p0040">
      Finally, the Public Health (Control of Diseases) Act 1984 contains an extensive range of powers (in Part 2A) in relation to public health protection, including, most materially, the power to the Secretary of State (in England) and the Welsh Ministers (in Wales) to make ‘health protection regulations’ “for the purpose of preventing, protecting against, controlling or providing a public health response to the incidence or spread of infection or contamination in England and Wales (whether from risks originating there or elsewhere).”
      <xref ref-type="fn" rid="fn0035">
       7
      </xref>
     </p>
    </sec>
    <sec id="s0015">
     <label>
      3
     </label>
     <title>
      Section 2: Health and social care outside hospital
     </title>
     <p id="p0045">
      If decisions are made under the MCA 2005 between the options that are actually available to the person, then changes made in relation to the powers and duties upon the state to secure the needs of individuals with impaired decision-making capacity will have a dramatic – knock-on – effect upon the scope of those options. This is precisely what the Coronavirus Act 2020 (‘CA 2020’) has done, and I go into the changes it has introduced in some detail for two reasons:
      <list id="l0005" list-type="simple">
       <list-item id="li0005">
        <label>
         (1)
        </label>
        <p id="p0050">
         for the benefit of those within England &amp; Wales who are grappling with (for whatever reasons) the new landscape;
        </p>
       </list-item>
       <list-item id="li0010">
        <label>
         (2)
        </label>
        <p id="p0055">
         as a case study for those concerned more broadly with the UN Convention on the Rights of Persons with Disabilities (‘CRPD’), to make the point that examining whether persons with disabilities are able to ‘enjoy legal capacity on an equal basis with others in all aspects of life’
         <xref ref-type="fn" rid="fn0040">
          8
         </xref>
         in any jurisdiction requires examination not just of the laws that on their face govern legal capacity, but also the wider framework within which those laws are placed.
        </p>
       </list-item>
      </list>
     </p>
     <p id="p0060">
      The CA 2020 was introduced into Parliament on 19 March 2020, and received Royal Assent under a week later, on 26 March 2020. Its long title “An Act to make provision in connection with coronavirus; and for connected purposes” does not adequately convey its scope. Reflecting the impact of COVID-19 across all aspects of society, the Act includes provisions ranging from emergency registration of health professionals, to the power to require information relating to food supply, to powers relating to the temporary closure of educational institutions and childcare premises, to postponement of elections to the General Synod of the Church of England. For present purposes, I focus upon the duties upon public bodies to assess and meet the continuing healthcare and social care needs of individuals, the latter because of their profound, indirect, impact upon decision-making in relation to those within the scope of the MCA 2005.
     </p>
     <p id="p0065">
      Even prior to the introduction of the Coronavirus Bill, it had become clear that local authorities would become hugely stretched. On the day that the Bill was introduced into Parliament, the Government published on 19 March 2020 an unprecedented document,
      <italic>
       Responding to COVID-19: Ethical Framework for Adult Social Care
      </italic>
      .
      <xref ref-type="fn" rid="fn0045">
       9
      </xref>
      This document, in essence, transposed principles that had been developed in relation to triage for inpatient medical treatment in the context of pandemic flu
      <xref ref-type="fn" rid="fn0050">
       10
      </xref>
      to the social care setting:
     </p>
     <p id="p0070">
      <disp-quote>
       <p>
        <italic>
         Recognising increasing pressures and expected demand, it might become necessary to make challenging decisions on how to redirect resources where they are most needed and to prioritise individual care needs. This framework intends to serve as a guide for these types of decisions and reinforce that consideration of any potential harm that might be suffered, and the needs of all individuals, are always central to decision-making.
        </italic>
       </p>
      </disp-quote>
     </p>
     <p id="p0075">
      It was not just local authorities, but also the NHS, which would be stretched. I deal at section 6 below with decision-making in hospital. Here, I focus on the position outside hospital where, as noted above, the NHS (through – in England – Clinical Commissioning Groups) has both powers and duties to meet continuing healthcare needs.
      <xref ref-type="fn" rid="fn0055">
       11
      </xref>
      The CA 2020, with immediate effect, suspended
      <xref ref-type="fn" rid="fn0060">
       12
      </xref>
      the duty on the NHS in England to carry out assessments of whether a person is in need of continuing healthcare. Crucially, such continuing healthcare needs are free to access, unlike social care provision for which charges can be made. The Explanatory Notes to the Act rather coyly suggested this section “changes the procedure for discharge from an acute hospital setting for those with a social care need […] It allows NHS providers to delay undertaking the NHS Continuing Healthcare (NHS CHC) Assessment and pending that assessment, the patient will continue to receive NHS care.”
      <xref ref-type="fn" rid="fn0065">
       13
      </xref>
      The provisions of the CA 2020 in this respect were not, in fact, so limited. Although s.14 CA 2020 does not
      <bold>
       stop
      </bold>
      Clinical Commissioning Groups carrying out such assessments, the (temporary) repeal of the duty mean that, overnight, individuals with profound healthcare needs lose any entitlement to assessment of those needs as a precursor to the potential for those needs to be met, for free. Those of such individuals with impaired decision-making capacity therefore lose – in many cases – the potential for options to be made available for them in terms of their residence and care arrangements.
     </p>
     <p id="p0080">
      Further, given the abolition of the duty to assess, recourse to judicial review to challenge a failure to carry out an assessment becomes a nigh-on impossible task (and the Court of Protection can offer no assistance
      <xref ref-type="fn" rid="fn0070">
       14
      </xref>
      ). Given that there is a considerable overlap between individuals with impaired decision-making capacity and those with continuing healthcare needs, their options have been immediately and dramatically narrowed by this legislative change.
     </p>
     <p id="p0085">
      The CA 2020 also introduced what the Government (but not the Act) described as ‘easements’
      <xref ref-type="fn" rid="fn0075">
       15
      </xref>
      to the governing legislation relating to social care provision in England (the Care Act 2014) and Wales (the Social Services and Well-Being (Wales) Act 2014).
      <xref ref-type="fn" rid="fn0080">
       16
      </xref>
      Both came into force shortly after the CA 2020 was passed.
      <xref ref-type="fn" rid="fn0085">
       17
      </xref>
      For present purposes, I focus upon the English position.
     </p>
     <p id="p0090">
      Statutory guidance published
      <xref ref-type="fn" rid="fn0090">
       18
      </xref>
      on 31 March 2020 makes clear that there was a process through which local authorities have to go before they can take advantage of the ‘easements’ provided by the Act, and, in particular, that:
     </p>
     <p id="p0095">
      <disp-quote>
       <p>
        <italic>
         A Local Authority should only take a decision to begin exercising the Care Act easements when the workforce is significantly depleted, or demand on social care increased, to an extent that it is no longer reasonably practicable for it to comply with its Care Act duties (as they stand prior to amendment by the Coronavirus Act) and where to continue to try to do so is likely to result in urgent or acute needs not being met, potentially risking life. Any change resulting from such a decision should be proportionate to the circumstances in a particular Local Authority.
        </italic>
       </p>
      </disp-quote>
     </p>
     <p id="p0100">
      At the time of writing, no local authority has yet gone through this procedure, but such is only a matter of time. At that point, any local authority would not have to comply with the following duties in terms of assessment: (1) the duty to assess needs under s.9;
      <xref ref-type="fn" rid="fn0095">
       19
      </xref>
      (2) the duty to assess the needs of a carer under s.10;
      <xref ref-type="fn" rid="fn0100">
       20
      </xref>
      (3) the duty to give written records of an assessment under s.12 (3) and (4);
      <xref ref-type="fn" rid="fn0105">
       21
      </xref>
      (4) the duty to determine whether needs meet the eligibility criteria under s.13 (or regulations made under s.13);
      <xref ref-type="fn" rid="fn0110">
       22
      </xref>
      (5) the duty to assess financial resources consequent upon a determination that needs meet the eligibility criteria under s.17 if it is intending to charge for the provision of services.
      <xref ref-type="fn" rid="fn0115">
       23
      </xref>
      Further, the local authority's duty and powers to meet needs under ss.18 and 19 of the Care Act 2014 were essentially re-written. Section 18 was rewritten
      <xref ref-type="fn" rid="fn0120">
       24
      </xref>
      so as to impose a duty upon a local authority to meet an adult's needs for care and support if (and only if): (1) the adult was ordinarily resident in the authority's area or was present in its area but of no settled residence; (2) the authority considered that it was necessary to meet those needs for the purpose of avoiding a breach of the adult's rights under the European Convention on Human Rights and; (3) there was no charge (under s.14) for meeting those needs or, in so far as there was, condition 1, 2 or 3 was met.
      <xref ref-type="fn" rid="fn0125">
       25
      </xref>
      The power under s.19 to meet an adult's needs for care and support was expanded, so as to take effect without any prior requirement for a needs, eligibility and/or financial assessment, s.19(1) for instance being re-written to read “[a]
      <italic>
       local authority may meet an adult's needs for care and support if (a) the adult is ordinarily resident in the authority's area or is present in the area but of no settled residence; and (2) the authority is satisfied it is not required to meet the adult's needs under section 18
      </italic>
      .” The statutory guidance did not explain when and how such power was to be used. Section 20 of the Care Act 2014 is also (when ‘eased’) watered down
      <xref ref-type="fn" rid="fn0130">
       26
      </xref>
      so that that the duty to meet a carer's need for support is to be tied to the necessity to avoid a breach of the carer's rights under the ECHR.
     </p>
     <p id="p0105">
      The CA 2020 does not suspend
      <bold>
       every
      </bold>
      duty upon local authority where an ‘easement’ was in force: as the statutory guidance
      <xref ref-type="fn" rid="fn0135">
       27
      </xref>
      noted.
     </p>
     <p id="p0110">
      <disp-quote>
       <p>
        <italic>
         Duties in the Care Act to promote wellbeing and duties relating to safeguarding adults at risk remain in place.
        </italic>
        […]
       </p>
      </disp-quote>
     </p>
     <p id="p0115">
      <disp-quote>
       <p>
        <italic>
         Duties in the Mental Capacity Act 2005 relating to Deprivation of Liberty Safeguards (DoLS) remain in place.
        </italic>
        […]
       </p>
      </disp-quote>
     </p>
     <p id="p0120">
      <disp-quote>
       <p>
        <italic>
         Duties imposed under the Equality Act 2010 also remain, including duties to make reasonable adjustments, the Public Sector Equality Duty and duties towards people with protected characteristics. These should underpin any decisions made with regard to the care and support someone receives during this period.
        </italic>
        […]
       </p>
      </disp-quote>
     </p>
     <p id="p0125">
      I return to Deprivation of Liberty Safeguards at section 4 below.
     </p>
     <p id="p0130">
      <italic>
       The ECHR to the rescue?
      </italic>
     </p>
     <p id="p0135">
      It will be clear that the watering down of duties under the Care Act 2014 to a ‘bare bones’ approach, so as to avoid a breach of the ECHR,
      <xref ref-type="fn" rid="fn0140">
       28
      </xref>
      means that in many cases the options available for individuals with impaired decision-making capacity are dramatically reduced.
     </p>
     <p id="p0140">
      That having been said, and as a possible – and very tentative – silver lining to the cloud, the sudden and very immediate focus upon the ECHR may mean a renewed focus by the English courts upon the
      <bold>
       positive
      </bold>
      aspects of rights under the ECHR, and what those aspects mean in the context of those who cannot make their own choices.
     </p>
     <p id="p0145">
      The statutory guidance, itself, identifies as of importance the right to life under Article 2 of the ECHR, the right to freedom from inhuman and degrading treatment under Article 3 and the right to private and family life under Article 8.
      <xref ref-type="fn" rid="fn0145">
       29
      </xref>
      In order for these rights to be effective, the courts have over time identified that they contain not just injunctions upon the state
      <bold>
       not
      </bold>
      to things, but also to take positive steps to ensure that the right is enjoyed.
      <xref ref-type="fn" rid="fn0150">
       30
      </xref>
     </p>
     <p id="p0150">
      The ECHR has been ‘domesticated’ through the Human Rights Act 1998, such that individuals can rely upon the rights it contains before the courts, and public bodies are required to comply with it in the discharge of their functions, so, on one view, the changes introduced by the CA 2020 do nothing other than repeat a commitment which already exists. However, traditionally, ECHR rights have played only a relatively limited part in consideration of Care Act 2014 duties and powers. A useful summary can be found in the judgment of Michael Fordham QC in
      <italic>
       R (Aburas v London Borough of Southwark).
      </italic>
      <xref ref-type="fn" rid="fn0155">
       31
      </xref>
      Ordinarily, as that judgment makes clear, “
      <italic>
       Convention rights which relate to ‘looked-after needs’, if not met through the
      </italic>
      <ext-link ext-link-type="uri" id="ir0030" xlink:href="http://uk.westlaw.com/Document/I6C57E820E61C11E3A350A156035B4697/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
       <italic>
        section 18
       </italic>
      </ext-link>
      <italic>
       duty and”eligible needs”, must be secured through the exercise of the
      </italic>
      <ext-link ext-link-type="uri" id="ir0035" xlink:href="http://uk.westlaw.com/Document/I6A335A70E61C11E3A350A156035B4697/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
       <italic>
        section 19
       </italic>
      </ext-link>
      <italic>
       power
      </italic>
      .”
      <xref ref-type="fn" rid="fn0160">
       32
      </xref>
      In other words, recourse will only rarely be required to the ECHR as opposed to the terms of s.18 Care Act 2014 itself. Further, only very limited recourse would be had to the ECHR in order to leverage the provision of social care to a person. Such could explain the majority decision of the Supreme Court
      <italic>
       in R (McDonald) v Royal Borough of Kensington and Chelsea
      </italic>
      ,
      <xref ref-type="fn" rid="fn0165">
       33
      </xref>
      in which it was found that the decision of a local authority to meet the claimant's needs in relation to incontinence by way of incontinence pads rather than overnight support did not even engage her rights under Article 8(1).
      <xref ref-type="fn" rid="fn0170">
       34
      </xref>
     </p>
     <p id="p0155">
      Indeed, to date, almost the only situation in which recourse had routinely had been to the ECHR to ground a
      <bold>
       duty
      </bold>
      to support
      <xref ref-type="fn" rid="fn0175">
       35
      </xref>
      was in the immigration context, in which s.54 and Paragraph 1 of Schedule 3 to the Nationality, Immigration and Asylum Act 2002 (‘NIAA 2002’) prevents local authorities from providing support under the provisions listed in the Schedule (including, now, the provision of care and support under the Care Act 2014) to those subject to immigration control. Paragraph 3 of Schedule 3 to the NIAA 2002 provides that this exclusion:
     </p>
     <p id="p0160">
      <disp-quote>
       <p>
        “
        <italic>
         does not prevent the exercise of a power or the performance of a duty if, and to the extent that, its exercise or performance is necessary for the purpose of avoiding a breach of—
        </italic>
       </p>
       <p>
        <italic>
         (a) a person's Convention rights, or
        </italic>
       </p>
       <p>
        <italic>
         (b) a person's rights under the Community Treaties
        </italic>
        .”
       </p>
      </disp-quote>
     </p>
     <p id="p0165">
      The case-law decided in relation to this paragraph sets the bar high, for instance. It was usefully summarised by Deputy High Court Judge Peter Marquand in
      <italic>
       R (GS) v Camden London Borough Council
      </italic>
      ,
      <xref ref-type="fn" rid="fn0180">
       36
      </xref>
      the key passages being as follows:
     </p>
     <p id="p0170">
      <disp-quote>
       <p>
        <italic>
         … In
        </italic>
        <ext-link ext-link-type="uri" id="ir0040" xlink:href="http://uk.westlaw.com/Document/I7A2300B0E42811DA8FC2A0F0355337E9/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
         <italic>
          Limbuela's case [2006] 1 AC 396
         </italic>
        </ext-link>
        <italic>
         , paras 7–8, Lord Bingham of Cornhill reviewed the principles of article 3 … “Treatment is inhuman or degrading if, to a seriously detrimental extent, it denies the most basic needs of any human being. As in all article 3 cases, the treatment, to be proscribed, must achieve a minimum standard of severity, and … in a context such as this, not involving the deliberate infliction of pain or suffering, the threshold is a high one.
        </italic>
        [….]
        <italic>
         When does the … duty … arise? The answer must in my opinion be: when it appears on a fair and objective assessment of all relevant facts and circumstances that an individual applicant faces an imminent prospect of serious suffering caused or materially aggravated by denial of shelter, food or the most basic necessities of life.
        </italic>
       </p>
      </disp-quote>
     </p>
     <p id="p0175">
      And this passage, in which the judge made clear that Article 8 is, to date, rarely seen as adding anything to Article 3:
     </p>
     <p id="p0180">
      <disp-quote>
       <p>
        <italic>
         In
        </italic>
        <ext-link ext-link-type="uri" id="ir0045" xlink:href="http://uk.westlaw.com/Document/I5E9EE4E0E42711DA8FC2A0F0355337E9/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
         <italic>
          Anufrijeva's case [2004] QB 1124
         </italic>
        </ext-link>
        <italic>
         , para 43, which concerned allegations that there was a failure to take positive action to avoid breaches of article 8 rights by denying benefits to the claimants, the Court of Appeal (Lord Woolf CJ, Lord Phillips of Worth Matravers MR and Auld LJ) stated: “We find it hard to conceive, however, of a situation in which the predicament of an individual will be such that article 8 requires him to be provided with welfare support, where his predicament is not sufficiently severe to engage article 3. Article 8 may more readily be engaged where a family unit is involved. Where the welfare of children is at stake, article 8 may require the provision of welfare support in a manner which enables family life to continue
        </italic>
        .
        <xref ref-type="fn" rid="fn0185">
         37
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0185">
      In the context of immigration control, the fiction (and it is frequently a fiction) is that the individual concerned could always return to the country from where they came from, so it is not surprising that the courts have interpreted the ECHR as providing a minimalist safety net designed to ensure that the UK does not breach its obligations to those individuals under the Convention. No such fiction could now operate across the piece. It seems to me, therefore, that (as perhaps presciently
      <italic>
       Aburas
      </italic>
      might be said to recognise
      <xref ref-type="fn" rid="fn0190">
       38
      </xref>
      ), the context is very different because, in effect, the ECHR is being required to do the heavy-lifting across the piece.
     </p>
     <p id="p0190">
      Long experience before the courts means that I do not underestimate the difficulty in persuading either a local authority or – in due course – a court that it should not follow the very high bar set by the cases discussed above, which include jurisprudence up to and including the Supreme Court.
     </p>
     <p id="p0195">
      That having been said, it seems to me that there are good arguments that courts should be more willing to place weight upon Article 8 ECHR alone as opposed to the general position that (absent where a family is involved
      <xref ref-type="fn" rid="fn0195">
       39
      </xref>
      ) Article 8 does not add to Article 3 ECHR. Article 8 is a qualified right – i.e. interference with it can be justified under the circumstances provided for under Article 8(2)
      <xref ref-type="fn" rid="fn0200">
       40
      </xref>
      – so that it does not have the same leverage as the absolute right under Article 3 ECHR. However, if the Government has (by the Coronavirus Act 2020, amplified by the guidance) squarely invited public bodies, and in due course, the courts to proceed by reference to Article 8 ECHR, then there is undoubtedly an argument that it should be asked to do more work to address the middle ground where the person's circumstances are not so dire as to cross the very high threshold of Article 3 ECHR, but positive steps are nonetheless required so as to secure their physical health
      <xref ref-type="fn" rid="fn0205">
       41
      </xref>
      or, importantly, “psychological integrity.”
      <xref ref-type="fn" rid="fn0210">
       42
      </xref>
     </p>
     <p id="p0200">
      I would also suggest the courts should be willing to have regard to the recent jurisprudence from Strasbourg relating to Article 5 which – oddly – does not seem to have been considered domestically before the courts in England.
      <xref ref-type="fn" rid="fn0215">
       43
      </xref>
      I note, in particular, the decision of the Grand Chamber of the European Court of Human Rights in
      <italic>
       Rooman v Belgium
      </italic>
      , in which it held, after a review of its case-law relating to Article 5 ECHR that:
     </p>
     <p id="p0205">
      <disp-quote>
       <p>
        <italic>
         the current case-law clearly indicates that the administration of suitable therapy has become a requirement in the context of the wider concept of the “lawfulness” of the deprivation of liberty. Any detention of mentally ill persons must have a therapeutic purpose, aimed specifically, and in so far as possible, at curing or alleviating their mental-health
        </italic>
        condition
        <italic>
         , including, where appropriate, bringing about a reduction in or control over their dangerousness. The Court has stressed that, irrespective of the facility in which those persons are placed, they are entitled to be provided with a suitable medical environment accompanied by real therapeutic measures, with a view to preparing them for their eventual release
        </italic>
        .
        <xref ref-type="fn" rid="fn0220">
         44
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0210">
      and also the decision in
      <italic>
       Hiller v Austria
      </italic>
      <xref ref-type="fn" rid="fn0225">
       45
      </xref>
      in which the court held that:
     </p>
     <p id="p0215">
      <disp-quote>
       <p>
        <italic>
         today's paradigm in mental health care is to give persons with mental disabilities the greatest possible personal freedom in order to facilitate their re-integration into society. The Court considers that from a Convention point of view, it is not only permissible to grant hospitalised persons the maximum freedom of movement but also desirable in order to preserve as much as possible their dignity and their right to self-determination.
         <bold>
          It also follows from the case-law on Article 5 of the Convention that a deprivation of liberty must be lifted immediately if the circumstances necessitating it cease to exist or change
         </bold>
        </italic>
        […]
        <bold>
         <italic>
          or must be scaled down to the extent which is absolutely necessary under the given circumstances
         </italic>
        </bold>
        […]
        <xref ref-type="fn" rid="fn0230">
         46
        </xref>
        (emphasis added).
       </p>
      </disp-quote>
     </p>
     <p id="p0220">
      Transposed to the social context, these cases could be used to found arguments that the environment in a particular care home (or another placement) is so unsuitable that to continue to require the person to live there (by exercising their functions under s.18 Care Act 2014) would be to either give rise to or perpetuate a breach of their Article 5 rights. It would, in other words, be an argument that the local authority was exercising its (revised) powers under s.18 Care Act 2014 incompatibly with the ECHR, and hence unlawfully for purposes of s.6 Human Rights Act 1998.
     </p>
     <p id="p0225">
      Finally, and given what became rapidly and tragically clear was the very real risk to life posed by COVID-19
      <bold>
       within
      </bold>
      care homes,
      <xref ref-type="fn" rid="fn0235">
       47
      </xref>
      it could also be argued that, within the specific context of COVID-19, there would be cases in which the state's positive duty to secure life under Article 2 would mandate moving an individual from a care home into a place where they could benefit from better protection.
     </p>
     <p id="p0230">
      In these arguments, the CRPD can no doubt be deployed,
      <xref ref-type="fn" rid="fn0240">
       48
      </xref>
      and this may be a circumstance in which the English courts' reluctance to engage substantively with the CRPD – as an unincorporated international treaty – may be amenable to challenge. To date, the approach of the courts to the CRPD in the context of the Care Act 2014 can be seen in the decision of the Court of Appeal in
      <italic>
       R (Davey) v Oxfordshire County Council &amp; Ors
      </italic>
      ,
      <xref ref-type="fn" rid="fn0245">
       49
      </xref>
      where Bean LJ noted (and endorsed) the fact that:
     </p>
     <p id="p0235">
      <disp-quote>
       <p>
        <italic>
         the UNCRPD could be resorted to as a construction of a particular provision of the 2014 Act in case of ambiguity or uncertainty. However, great care must be taken in deploying provisions of a convention or treaty which set out broad and basic principles as determinative tools for the interpretation of a concrete measure such as a particular provision of a UK statute.
         <bold>
          Provisions which are aspirational cannot qualify the clear language of primary legislation
         </bold>
         .
        </italic>
        (emphasis added)
        <xref ref-type="fn" rid="fn0250">
         50
        </xref>
        .
       </p>
      </disp-quote>
     </p>
     <p id="p0240">
      In other contexts, the courts have been willing to accept that the CRPD can be of assistance in interpreting the application of the ECHR.
      <xref ref-type="fn" rid="fn0255">
       51
      </xref>
      If the statute
      <bold>
       itself
      </bold>
      now directs the courts to consider the provisions of the ECHR (and, by extension, the CRPD), then the approach in
      <italic>
       Davey
      </italic>
      may no longer seem quite so tenable. Put another way, if the statute itself asks the ECHR to do more work as the safety net for those with disabilities, it is legitimate to ask those applying the statute to look to the CRPD to assist in ensuring that safety net has as few holes in as possible.
     </p>
     <p id="p0245">
      Whether advocates and – in due course – the courts will be willing to run with arguments such as those set out above is, at the time of writing, an open question. But if they do, they may, ironically, have further blurred the distinction between the civil and political rights traditionally seen as the core of the ECHR and socio-economic rights (i.e. rights which actually require states to spend money). They would, therefore, have potentially served as a Trojan Horse for making enforceable, at an individual level, the rights to independent living and to health enshrined in the CRPD.
      <xref ref-type="fn" rid="fn0260">
       52
      </xref>
      Such would be of inestimable benefit to those with impaired decision-making capacity.
     </p>
    </sec>
    <sec id="s0020">
     <label>
      4
     </label>
     <title>
      Section 3: Public Health Restrictions
     </title>
     <p id="p0250">
      The lives of those with impaired decision-making capacity have also directly, and, as will be seen, disproportionately, been affected by the public health measures taken to respond to the COVID-19 crisis.
     </p>
     <p id="p0255">
      In the same week as the CA 2020 came into force, regulations made under the Public Health (Control of Disease) Act 1984 radically changed the legal landscape in England &amp; Wales, effectively placing the population under severe restrictions (which the Daily Mail might even characterise as house arrest) for their good, and the good of society.
     </p>
     <sec id="s0025">
      <label>
       4.1
      </label>
      <title>
       Health Protection (Coronavirus, Restrictions) (England) Regulations 2020
      </title>
      <p id="p0260">
       The Health Protection (Coronavirus, Restrictions) (England) Regulations 2020
       <xref ref-type="fn" rid="fn0265">
        53
       </xref>
       are set to expire in 6 months' from the date of their coming into force on 26 March 2020,
       <xref ref-type="fn" rid="fn0270">
        54
       </xref>
       although with reviews by the Secretary of State every 21 days.
       <xref ref-type="fn" rid="fn0275">
        55
       </xref>
       Whilst the regulations are in force however, there are statutory restrictions on every person in England from leaving the place where they are living “without reasonable excuse.”
       <xref ref-type="fn" rid="fn0280">
        56
       </xref>
       The regulations provided for statutory steps which could be taken to enforce this, including the power for a relevant person
       <xref ref-type="fn" rid="fn0285">
        57
       </xref>
       to direct the person to return the place to where they were living or remove them to the place where they are living (including by the use of reasonable force). The person would also be also committing a criminal offence (which can be discharged by way of the issue of a fixed penalty notice).
       <xref ref-type="fn" rid="fn0290">
        58
       </xref>
       What constituted a “reasonable excuse” for these purposes is set out in Regulation 6(2). This included taking exercise, as well as ‘to avoid illness or injury or to escape a risk of harm.’
       <xref ref-type="fn" rid="fn0295">
        59
       </xref>
      </p>
      <p id="p0265">
       There are some very interesting questions that arose as to whether the Regulations were ultra vires the Act under which they were made (the Public Health (Control of Disease) Act 1984). I do not address them here, but David Anderson QC wrote a stimulating blogpost on the question.
       <xref ref-type="fn" rid="fn0300">
        60
       </xref>
       Interesting questions also arise as to whether they gave rise to the deprivation of liberty of the entire population of England &amp; Wales for purposes of Article 5(1) ECHR (and, if so, whether it is justified under Article 5(1)(e) for purposes of the “prevention of the spreading of infectious diseases”). These are both interesting questions, my tentative thoughts being, respectively (1) probably not;
       <xref ref-type="fn" rid="fn0305">
        61
       </xref>
       but (2) if they do, it would be challenging to justify the position by reference to Article 5(1)(e), at least without further clear evidence that this was both necessary and proportionate.
       <xref ref-type="fn" rid="fn0310">
        62
       </xref>
      </p>
      <p id="p0270">
       <italic>
        For present purposes, I focus on the fact
       </italic>
       the Regulations did not make any provision in relation to those with impaired decision-making capacity. The question arises, therefore, as to how they should be applied to someone who lacks the capacity (applying the MCA 2005, or any common law test that might be said to apply) to understand: (1) that they are required not to leave the place where they are living without a (statutory) reasonable excuse); or (2) the consequences of so doing without such a reasonable excuse? And should they be subject to criminal sanction if they do so?
      </p>
      <p id="p0275">
       One would like to think that it would be very unlikely that any prosecution would be brought against a person who did not – because they could not – understand what it is that they should or should not have been doing. The guidance issued by the Crown Prosecution Service
       <xref ref-type="fn" rid="fn0315">
        63
       </xref>
       in relation to prosecution of offences under the Regulations provided that:
      </p>
      <p id="p0280">
       <disp-quote>
        <p>
         <italic>
          Given that the offences in the Regulations are related to measures imposed to prevent the spread of infection throughout the UK, and potentially high incidences of serious illness and death, they should be considered serious. A prosecution will therefore likely be required in the public interest in the majority of cases.
         </italic>
        </p>
       </disp-quote>
      </p>
      <p id="p0285">
       The guidance made no reference to the presence of impaired decision-making capacity as a factor. It is also, equally, troubling that it would even be possible for a criminal prosecution to be in contemplation in such circumstances.
      </p>
      <p id="p0290">
       It may, perhaps, be that the answer is to be found in the wording of Regulation 6(2), which is not
       <bold>
        exclusive
       </bold>
       in terms of reasonable excuses. Rather, it provides that “a reasonable excuse
       <bold>
        includes
       </bold>
       .” That a person lacks the capacity to understand what it is that the new regime requires would appear, on its face, to be a reasonable excuse. Whether any of the near constant stream of guidance coming out (but not, so far, relating to the MCA specifically) will address this issue is not known, but I would hope it would.
      </p>
      <p id="p0295">
       I should note that, under Regulation 8(4), it would undoubtedly be possible for a person to be returned to the place where they are living by the use of reasonable force whether or not they had the capacity to agree to the steps being taken. Interestingly, and undoubtedly by a side-wind, this suddenly given a previously missing power
       <xref ref-type="fn" rid="fn0320">
        64
       </xref>
       to police offices, and other authorised people to return individuals subject to DoLS authorisations in care homes
       <xref ref-type="fn" rid="fn0325">
        65
       </xref>
       where they have ‘wandered’ (a term I put in parenthesis because in many cases, it is very far from purposeless wandering on the part of a person with dementia). But this was undoubtedly not the purpose for which Regulation 8(4) was enacted. It would also leave anyone who does take steps to return an individual to somewhere
       <bold>
        other
       </bold>
       than a care home in a difficult position. The Regulations did not provide the power for the person returning the person to where they live to prevent them from leaving their home; any such power would have to (legally) be found in another source, and (practically) be exercised by someone. And what if the person lived in their own home, and did not appear to have anyone there to ‘receive’ them?
      </p>
      <p id="p0300">
       Finally, I note that those caring (formally or informally) for those with impaired decision-making capacity are left in a very invidious position. Should they be seeking to prevent the individual from leaving home so as not to breach the Regulations, or should they let them do so in the hopes that the individual does not then encounter an unsympathetic relevant individual. It is very likely that many carers will feel (rightly or wrongly) that they have to take steps to stop the person leaving. In many cases, this is likely then to mean that the individual then meets the ‘acid test’ of not being free to leave the place they live and also being subject to continuous supervision and control.
       <xref ref-type="fn" rid="fn0330">
        66
       </xref>
       If they cannot consent to that confinement, then it is very likely that they are then to be seen as deprived of their liberty for purposes of Article 5 ECHR.
       <xref ref-type="fn" rid="fn0335">
        67
       </xref>
       I return to this issue below having looked at the further powers that the CA 2020 introduced in the public health sphere.
      </p>
     </sec>
     <sec id="s0030">
      <label>
       4.2
      </label>
      <title>
       CA 2020
      </title>
      <p id="p0305">
       Section 51 and Schedule 21 CA 2020 contain powers relating to potentially infectious persons. Part 1 relates to England; Part 2 to Scotland and Part 3 to Wales. They are materially identical, and for present purposes I will only give references to the paragraph numbers in Part 1 (for England).
      </p>
      <p id="p0310">
       Schedule 21 provides public health officers, constables and (in some circumstances) immigration officers with the means to enforce public health restrictions, including returning people to places that they have been required to stay. Where necessary and proportionate, constables and immigration officers are able to direct individuals to attend, remove them to, or keep them at suitable locations for screening and assessment. Where a person has been screened and assessed and either tested positive, or the screening is inconclusive, paragraph 14 of Schedule 21 enables a public health officer to impose requirements including to remain at a specified place (which may be a place suitable for screening and assessment) for a specified period; and/or to remain at a specified place in isolation from others for a specified period. (‘a requirement to remain’). The public health officer has when imposing a requirement or restriction to inform the person of the reason for doing so, and that it was an offence to fail to comply with the requirement or restriction. A person can only be required to remain at a place for a maximum of 28 days,
       <xref ref-type="fn" rid="fn0340">
        68
       </xref>
       , although can be required to remain in isolation indefinitely (although with a review every 24 h after 28 days). A failure to comply with the requirement to remain at a place or in isolation is a criminal offence.
       <xref ref-type="fn" rid="fn0345">
        69
       </xref>
       A public health officer, constable or immigration officer can give reasonable instructions to a person in connection with removing someone to or keeping the person at a place under the powers identified here;
       <xref ref-type="fn" rid="fn0350">
        70
       </xref>
       failure to comply with a reasonable instruction is a criminal offence.
       <xref ref-type="fn" rid="fn0355">
        71
       </xref>
       A constable or immigration officer (but not a public health officer) can use reasonable force, if necessary, in the exercise of the powers outlined here.
       <xref ref-type="fn" rid="fn0360">
        72
       </xref>
       The recourse against the exercise of the draconian (if justified) imposition of a requirement to remain is by way of appeal to the magistrates' court.
       <xref ref-type="fn" rid="fn0365">
        73
       </xref>
      </p>
      <p id="p0315">
       None of the provisions outlined above make any reference to the position of persons with impaired decision-making capacity. The closest that they come are in paragraph 14, where a public health officer is required in deciding whether to impose a requirement to remain “must have regard to a person's wellbeing and personal circumstances.” “Personal circumstances” here could – and arguably should – include whether they have capacity to understand what it is that they are being required to do, and the consequences if they do not.
      </p>
      <p id="p0320">
       In the event that a requirement to remain was imposed, it was not obvious from the face of the CA 2020 how it is that a person with impaired decision-making capacity is to make any appeal to the magistrates' court. So as to comply with the provisions of Articles 6 and 8 ECHR (read alone or in conjunction with Article 14 ECHR), it is clear
       <xref ref-type="fn" rid="fn0370">
        74
       </xref>
       that the appeal provisions in paragraph 17 will have to be interpreted (1) as placing the threshold for bringing an application extremely low (as per the approach before the Mental Health Tribunal or the Court of Protection
       <xref ref-type="fn" rid="fn0375">
        75
       </xref>
       ); and (2) where the person does not meet that threshold, enabling another person to act on their behalf to bring the application.
      </p>
     </sec>
     <sec id="s0035">
      <label>
       4.3
      </label>
      <title>
       Deprivation of liberty
      </title>
      <p id="p0325">
       It was entirely possible that there are those who
       <bold>
        do
       </bold>
       have impaired decision-making capacity and pose a public health risk because they are either potentially or actually infectious with COVID-19. Precisely what legal powers could be exercised to require them to remain either in a place or (within that place, within isolation) is a question that has exercised many commentators.
       <xref ref-type="fn" rid="fn0380">
        76
       </xref>
       Four key issues are:
       <list id="l0010" list-type="simple">
        <list-item id="li0015">
         <label>
          1.
         </label>
         <p id="p0330">
          Whether a person already subject to a DoLS authorisation at a particular care home or hospital (or, indeed, a patient detained in hospital under the MHA 1983) was then subject to sufficient additional restrictions in consequence of being kept in isolation within that facility so as to give rise to an
          <bold>
           additional
          </bold>
          deprivation of their liberty (requiring additional authorisation);
          <xref ref-type="fn" rid="fn0385">
           77
          </xref>
         </p>
        </list-item>
        <list-item id="li0020">
         <label>
          2.
         </label>
         <p id="p0335">
          Whether it was legitimate to use DoLS to authorise deprivation of liberty for purposes of preventing the spread of infection from the person given the statutory requirement that a DoLS authorisation is only lawful where deprivation of liberty was not only in the best interests of the person, but also necessary and proportionate to the likelihood and seriousness of the harm that they would suffer otherwise.
          <xref ref-type="fn" rid="fn0390">
           78
          </xref>
         </p>
        </list-item>
        <list-item id="li0025">
         <label>
          3.
         </label>
         <p id="p0340">
          The interaction between DoLS/the MHA 1983 and the powers granted under Schedule 21 to the CA 2020 to public health officers to require individuals to remain in isolation – did they extend to directing isolation
          <bold>
           within
          </bold>
          a facility?
         </p>
        </list-item>
        <list-item id="li0030">
         <label>
          4.
         </label>
         <p id="p0345">
          The practicality of obtaining judicial authorisation where no administrative route could be used –for instance in the person's own home – especially given the pressures under which the courts were under (see further section 5 below). In this, it was also of relevance that, whilst s.4B MCA provides authority to deprive a person of their liberty upon the
          <bold>
           making
          </bold>
          of an application to court and pending its determination, it is only authority where the actions are being taken in the context of either providing life-sustaining treatment or preventing a serious deterioration in the person's condition. It is not obvious that preventing transmission of illness to
          <bold>
           others
          </bold>
          could fall within this.
         </p>
        </list-item>
       </list>
      </p>
      <p id="p0350">
       The Department of Health and Social Care is expected to produce guidance upon the MCA and DoLS (see further section 4). However, it is likely that, even with such guidance, practitioners and professionals remain in considerable doubt as to how to proceed and with a distinct unease as to the operation of pragmatism.
      </p>
     </sec>
    </sec>
    <sec id="s0040">
     <label>
      5
     </label>
     <title>
      Section 4: The MCA under strain
     </title>
     <p id="p0355">
      So far, I have primarily examined the context within which decisions under the MCA 2005 are now being made, as opposed to the MCA 2005. I now turn to look at the MCA 2005 itself. Attempts were made to introduce amendments to address the near impossibility of complying with the requirements of DoLS in the context of COVID-19,
      <xref ref-type="fn" rid="fn0395">
       79
      </xref>
      but without avail.
      <xref ref-type="fn" rid="fn0400">
       80
      </xref>
      At Second Reading of the Coronavirus Bill in the House of Lords on 24 March 2020, Lord Bethell on behalf of the Government:
     </p>
     <p id="p0360">
      <disp-quote>
       <p>
        <italic>
         recognise
        </italic>
        [d]
        <italic>
         that we have to strike a careful balance between the need to protect some of the most vulnerable in our society with preventing the spread of the virus. Therefore, we have decided not to alter deprivation of liberty safeguards in primary legislation. However, we think that we can achieve significant improvement to the process through emergency guidance. That will include making clearer when a deprivation of liberty safeguards authorisation is necessary, and the basis on which an assessment can be made, including, for example, phone or video calling for assessment. We are especially grateful to the noble Baroness, Lady Finlay, and other experts, who have worked with us on this.
        </italic>
        <xref ref-type="fn" rid="fn0405">
         81
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0365">
      Although that emergency guidance had yet to be published at the time of writing, it is clear that it will essentially rip up much of the DoLS Code of Practice in terms of the approach to be adopted,
      <xref ref-type="fn" rid="fn0410">
       82
      </xref>
      but significant doubts remain as to the thickness of legal ice upon which professionals are standing. Had the Mental Capacity (Amendment) Act 2019 been in force, professionals would have had the ability to rely upon a revised version of s.4B MCA 2005 making clear the basis upon which they were able to deprive an individual in need of care and treatment in an emergency, and then pending completion of the relevant statutory processes.
      <xref ref-type="fn" rid="fn0415">
       83
      </xref>
      However, the likelihood of implementation of that Act, requiring a substantial amount of work on the part of local authorities and NHS bodies, which was already looking unlikely for 1 October 2020, receded rapidly into the distance.
     </p>
     <p id="p0370">
      Very shortly after ‘lockdown’ started, the Court of Protection had cause to consider how DoLS was working in the context of a care home which – as with many others – had barred visitors. In
      <italic>
       BP v Surrey County Council &amp; Anor
      </italic>
      <xref ref-type="fn" rid="fn0420">
       84
      </xref>
      the Vice-President of the Court of Protection, Hayden J, was already considering an application under s.21A MCA 2005, by which a man, known as BP, was seeking to challenge the deprivation of liberty to which he was subject. On 20 March 2020, however, the care home decided to suspend all visits from any family members to BP and indeed to the others living in the home. The restriction also extended to any other visitors. As Hayden J noted,
     </p>
     <p id="p0375">
      <disp-quote>
       <p>
        <italic>
         9.
        </italic>
        […]
        <italic>
         there can be no doubt that the change to BP's quality of life from 5 o'clock on Friday 20th March 2020 was seismic. Additionally, the restriction extended to the Mental Capacity Assessor visiting.
        </italic>
        [
        <xref ref-type="fn" rid="fn0425">
         85
        </xref>
        ]
        <italic>
         Thus, there is need for heightened vigilance to ensure that BP's fundamental rights are not eclipsed by the exigencies of the Coronavirus pandemic. Fundamental to my consideration of the issues presented by this case is Article 11 UN Convention of the Rights of Persons with Disabilities (‘CRPD’) which provides:
        </italic>
       </p>
       <p>
        <italic>
         “Article 11 – Situations of risk and humanitarian emergencies.
        </italic>
       </p>
       <p>
        <italic>
         States Parties shall take, in accordance with their obligations under international law, including international humanitarian law and international human rights law, all necessary measures to ensure the protection and safety of persons with disabilities in situations of risk, including situations of armed conflict, humanitarian emergencies and the occurrence of natural disasters.”
        </italic>
       </p>
       <p>
        <italic>
         10. The COVID-19 pandemic plainly falls within the circumstances contemplated by Article 11 and signals the obligation on the Courts, in particular, and society more generally to hold fast to maintaining a human rights based approach to people with disabilities when seeking to regulate the impact of this unprecedented public health emergency.
        </italic>
       </p>
      </disp-quote>
     </p>
     <p id="p0380">
      By his litigation friend, his daughter FP, BP brought an emergency application for a:
      <disp-quote>
       <p>
        <italic>
         a) A declaration that if, within 72
        </italic>
        <italic>
         h of SH Care Home being served with a copy of the relevant order it has failed to take steps to facilitate the attendance of Dr Babalola and to reinstate daily family visits to BP, then it is not in BP's best interests to reside in the interim at SH Care Home;
        </italic>
       </p>
       <p>
        <italic>
         b) An order that if the above has not been complied with by SH Care Home, the order dated 6 March 2020 extending the standard authorisation be revoked and the standard authorisation shall terminate at the expiry of that 72-h period;
        </italic>
       </p>
       <p>
        <italic>
         c) A declaration that the total ban on visits is a disproportionate interference with BP's rights under Articles 5 and 8 (read with Article 14) of the European Convention on Human Rights;
        </italic>
       </p>
       <p>
        <italic>
         d) An interim declaration that whilst the restrictions on visits remain in place it is in BP's best interests to return home with a package of care.
        </italic>
        <xref ref-type="fn" rid="fn0430">
         86
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0385">
      BP, who was diagnosed with Alzheimer's disease in December 2018, was deaf, but able to communicate through a “communication board.” Hayden J considered that:
      <disp-quote>
       <p>
        <italic>
         his age and with his underlying health problems BP is vulnerable to the most serious impact of the Coronavirus. In my view, it is necessary to state the risk BP faces, were he to contract the virus, in uncompromising terms: there would be a very real risk to his life. Manifestly, there are powerful and competing rights and interests engaged when considering this application.
        </italic>
        <xref ref-type="fn" rid="fn0435">
         87
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0390">
      Having considered decisions of the European Court of Human Rights, the statement of principle of the European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment relating to the treatment of individuals deprived of their liberty in consequence of the COVID-19 pandemic,
      <xref ref-type="fn" rid="fn0440">
       88
      </xref>
      and Article 25 of the CRPD (the right to health), Hayden J rejected the application brought on FP's behalf, noting that:
      <disp-quote>
       <p>
        <italic>
         The case is, in any event, listed for further directions on 3rd June 2020. Accordingly, the interim declarations relating to BP's lack of capacity to conduct these proceedings and to make decisions concerning his residence and care remain valid. The focus of the arguments is therefore on whether it remains in BP's best interest to stay in the care home. It is in this context that I must consider the relevant rights and freedoms that all agree are engaged.
        </italic>
        <xref ref-type="fn" rid="fn0445">
         89
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0395">
      Although the judgment does not expressly provide this, it is clear that the consequence was that the application was dismissed, although with clear judicial approval of the plan drawn up to seek to maintain as much contact as possible between BP and his family. However, Hayden J outlined the plans that were being developed – under his encouragement – to seek to secure continuing contact, including:
      <disp-quote>
       <p>
        <italic>
         for BP's education in to the world of Skype with creative use of a communication board and the exploration of concurrent instant messaging. Additionally, the family can, by arrangement, go to BP's bedroom window which is on the ground floor and wave to him and use the communication board. All this will require time, effort and some creativity. I am clear that there is mutual resolve by all concerned..
        </italic>
        <xref ref-type="fn" rid="fn0450">
         90
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0400">
      Importantly, Hayden J also held that:
      <disp-quote>
       <p>
        <italic>
         Accordingly, though I recognise the challenges, I consider that the outstanding assessment [of mental capacity] by Dr Babalola can be undertaken
        </italic>
        via
        <italic>
         Skype or facetime with BP being properly prepared and supported by staff and, to the extent that it is possible, by his family too.
        </italic>
        <xref ref-type="fn" rid="fn0455">
         91
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0405">
      The outcome of the application was, not, perhaps entirely surprising, although reflective of the changes that had been wrought by COVID-19 – only a few weeks prior, a care home that sought to impose such draconian restrictions would have been the subject of fierce criticism by a court. The judgment does have its oddities, including that Hayden J sought
      <xref ref-type="fn" rid="fn0460">
       92
      </xref>
      himself to derogate from the ECHR under Article 15,
      <xref ref-type="fn" rid="fn0465">
       93
      </xref>
      when such is not a course open to a judge as opposed to the relevant authorities of the Member State.
     </p>
     <p id="p0410">
      It is also striking (but perhaps reflective of the haste with which the application was brought on and considered) that Hayden J did not address the fact that the DoLS regime does not, itself, provide authority to restrict contact,
      <xref ref-type="fn" rid="fn0470">
       94
      </xref>
      so it is not immediately obvious upon what legal basis contact could be restricted
      <bold>
       except
      </bold>
      by going to court.
     </p>
     <p id="p0415">
      Finally, it is also, perhaps, striking that no arguments were addressed to Hayden J (or raised by Hayden J of his own motion) as to the risk posed to individuals
      <bold>
       within
      </bold>
      the care home by COVID-19. On one view it could have been argued (see further section 2) above that BP's Article 2 rights in fact pointed not to the cessation of contact between him and his family, but for his rapid move to his daughter's house, and the provision of such support to her there as required to ensure he could be kept safe there.
     </p>
    </sec>
    <sec id="s0045">
     <label>
      6
     </label>
     <title>
      Section 5: The Court of Protection
     </title>
     <p id="p0420">
      A word about the Court of Protection.
      <xref ref-type="fn" rid="fn0475">
       95
      </xref>
      In the space of little more than a week, it became clear that it could not be business as usual for the court (as with all the other courts in England &amp; Wales), and a rapid transition had to begin into, in essence, a virtual court, sitting remotely and proceeding either by video or audio. The pace of the transition can be seen in the number of guidance documents that the Vice-President had to issue, culminating in (the first iteration of) a document published on 31 March 2020 entitled
      <italic>
       Remote Access to the Court of Protection Guidance
      </italic>
      ,
      <xref ref-type="fn" rid="fn0480">
       96
      </xref>
      in which he noted that.
      <disp-quote>
       <p>
        <italic>
         The present viral pandemic presents real and obvious challenges to the effective and fair operation of the Court of Protection. Remote access to the Court has become a necessity and it is the responsibility of all involved to ensure that such hearings continue to provide proper access to justice. These arrangements are driven by the inevitable restrictions on freedom of movement that have been put in place to protect public health. Remote hearings,
        </italic>
        i.e.
        <italic>
         by Skype or alternative versions of video link, will sometimes fall short of providing the opportunities that are available in a live hearing in a court room. Recognising this, it is important to keep in focus that the procedure should seek to ensure that those who lack capacity do not become more disadvantaged than their capacitous counterparts. It remains the obligation of all involved and at all stages of the hearing, to continue to evaluate whether fairness to all the parties is being achieved. Fairness cannot be sacrificed to convenience.
        </italic>
       </p>
      </disp-quote>
     </p>
     <p id="p0425">
      Prior to this guidance, an all Skype hearing (over 3 days) had been conducted remotely to determine whether life-sustaining treatment should be continued for a man named AF.
      <xref ref-type="fn" rid="fn0485">
       97
      </xref>
      Counsel involved in the case and the judge himself were very positive;
      <xref ref-type="fn" rid="fn0490">
       98
      </xref>
      the man's daughter had a very different perspective, stating that it.
      <disp-quote>
       <p>
        <italic>
         It felt like a second-best option. It didn't feel professional. It didn't feel like justice. It felt like a stop gap to ensure a box was ticked – rather than a serious and engaged attempt to make decisions about my Dad.
        </italic>
        <xref ref-type="fn" rid="fn0495">
         99
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0430">
      Not only would the Court of Protection have to find ways in which to ensure that family members and/or informal carers did not feel excluded by the arrangements, the court would have to find ways in which to ensure that sometimes painful progress towards the greater participation of the subject of proceedings – ‘P' – was not lost.
      <xref ref-type="fn" rid="fn0500">
       100
      </xref>
      The guidance noted above from Hayden J actively solicited “[i]
      <italic>
       maginative ideas
      </italic>
      […]
      <italic>
       to ensure that P participates in their proceedings where they are able to so do safely and proportionately
      </italic>
      .”
      <xref ref-type="fn" rid="fn0505">
       101
      </xref>
      But given that “[w]
      <italic>
       here judicial meetings with P are
       <bold>
        necessary
       </bold>
       for a determination of the issues then remote conferencing technology to facilitate that meeting is the only likely mechanism
      </italic>
      ,”
      <xref ref-type="fn" rid="fn0510">
       102
      </xref>
      immediate hurdles towards an important way in which such participation could take place were clear. The energy and commitment of those concerned with the court to ensure that it could continue both to offer a service, and to serve P was clear, but the task at the time of writing appeared formidable.
     </p>
    </sec>
    <sec id="s0050">
     <label>
      7
     </label>
     <title>
      Section 6: Medical decision-making, the MCA and scarce resource
     </title>
     <p id="p0435">
      Space precludes a detailed consideration of the issues that arise in the context of the effect of COVID-19 upon the scarce critical care resource within England &amp; Wales, and also the scarce resource of ventilation.
      <xref ref-type="fn" rid="fn0515">
       103
      </xref>
      However, they do need to be touched on briefly as radically changing the framework for medical decision-making. In a series of cases starting in 2013,
      <xref ref-type="fn" rid="fn0520">
       104
      </xref>
      the Court of Protection had developed an increasingly sophisticated notion of best interests in this context in which even interventions with a very small chance of success could be said to be in the best interests of the patient if it was clear that this is what they wanted.
      <xref ref-type="fn" rid="fn0525">
       105
      </xref>
      This did not – quite – cross the line into holding that approaching matters through the prism of best interests could require that clinicians provide treatment that they did not consider clinically appropriate,
      <xref ref-type="fn" rid="fn0530">
       106
      </xref>
      but on occasion came very close.
      <xref ref-type="fn" rid="fn0535">
       107
      </xref>
     </p>
     <p id="p0440">
      The impact of COVID-19, however, means that it appears clear that decision-making in the case of those with impaired decision-making (and whether or not they have COVID-19) might have to be undertaken on the basis not of what was in their best interests, but on a utilitarian basis in order to save the maximum number of lives. What had been a perennial question for ethicists and the subject of planning that had never had to be moved into anything close to an operational phrase
      <xref ref-type="fn" rid="fn0540">
       108
      </xref>
      has become an ever more pressing issue.
     </p>
     <p id="p0445">
      However, national bodies (in particular national NHS bodies) have been notably slow to produce guidance addressing the issues, perhaps because of political (including health service political) concerns as to the public reactions that would be engendered by the recognition of the reality of the position. They are also perhaps aware of how guidance produced under speed in countries that had been affected ahead of England (most notably that produced by in the Italian context by SIAARTI, which suggested that there might need to be a simple age cut-off for admission to ICU
      <xref ref-type="fn" rid="fn0545">
       109
      </xref>
      ) would look if transposed directly into the English context.
     </p>
     <p id="p0450">
      Further, an early – and very high-level – attempt to provide guidance (the NICE ‘rapid response’ guideline NG159
      <xref ref-type="fn" rid="fn0550">
       110
      </xref>
      ) was the subject of threatened judicial review proceeding within hours because of the perception that its reliance upon a tool known as the Critical Frailty Score would discriminate against individuals with learning disability or other ‘stable’ cognitive impairments.
      <xref ref-type="fn" rid="fn0555">
       111
      </xref>
      It was perhaps not a coincidence that it took another 10 days before any other body (this time the British Medical Association) put its head above the parapet,
      <xref ref-type="fn" rid="fn0560">
       112
      </xref>
      that time to press coverage including the headline “Virus patients more likely to die may have ventilators taken away”).
      <xref ref-type="fn" rid="fn0565">
       113
      </xref>
      Guidance from the Chief Medical Officers (who appeared frequently in the 17:00 press conferences that became such a feature of the crisis) was still not forthcoming at the time of writing.
     </p>
     <p id="p0455">
      Whilst there was limited ‘off-the-shelf’ material that could be drawn upon, much of that material did not, in fact, provide the sort of detailed operational detail as to either procedures or criteria that was really required. This meant, therefore, that clinicians have bene left at a vital period in the run up to the peak essentially trying to make it up as they went along, frequently seeking to do so whilst juggling heavy, and increasing, clinical loads at the same time. They have also been left unclear – and in many cases in real moral distress in consequence – as to the point at which they were supposed to stop applying ordinary principles of medical decision-making and instead to start operating in a world governed by some form of utilitarianism. A further consequence of the slowness of national bodies to give direction was that NHS Trusts have not been not given either the ‘push’ or the tools to start creating the governance structures which would be crucial to ensure that triage decisions take place within structures that could provide both oversight of the process and support to clinicians operating within it.
     </p>
     <p id="p0460">
      This has had one particularly pernicious consequence in the case of those with disabilities, including those with impaired decision-making capacity. Whether out of a misplaced excess of zeal in attempting to undertake advance care planning, a misunderstanding of the law,
      <xref ref-type="fn" rid="fn0570">
       114
      </xref>
      or otherwise, it appeared that significant numbers of individuals were having decisions made as to resuscitation without any form of consultation; in other cases, it appeared that individuals were being pressured into signing their own DNACPR notices.
      <xref ref-type="fn" rid="fn0575">
       115
      </xref>
      Many such individuals were elderly, but did not have specific disabilities. In other cases, it appeared that judgments were being made that (e.g) CPR should not be attempted because they had, for instance, a learning disability. This prompted an urgent letter from the National Director for Mental Health, NHS England and NHS Improvement, the National Clinical Director - Learning Disability and Autism NHS England and NHS Improvement and the Medical Director for Primary Care, NHS England and NHS Improvement to remind Trusts and GPs that:
      <disp-quote>
       <p>
        <italic>
         The health of some people who have a learning disability and/or a diagnosis of autism may be at risk from the presence of co-existing physical conditions and also from inequities in access to and delivery of appropriate and timely assessment and treatment for physical health conditions.
        </italic>
       </p>
      </disp-quote>
      <disp-quote>
       <p>
        <italic>
         It is imperative that decisions regarding appropriateness of admission to hospital and for assessment and treatment for people with learning disabilities and/or autism are made on an individual basis and in consultation with their family and/or paid carers, taking into account the person's usual physical health, the severity of any co-existing conditions and their frailty at the time of examination. Treatment decisions should not be made on the basis of the presence of learning disability and/or autism alone.
        </italic>
        <xref ref-type="fn" rid="fn0580">
         116
        </xref>
       </p>
      </disp-quote>
     </p>
     <p id="p0465">
      At the time of writing, it remained unclear whether this letter would produce a material effect.
     </p>
    </sec>
    <sec id="s0055">
     <label>
      8
     </label>
     <title>
      Section 7: Mental health law
     </title>
     <p id="p0470">
      The focus of this article has been upon mental capacity, rather than mental health law. However, for completeness, and because of the overlap between individuals with impaired decision-making capacity and those falling within the scope of the MHA 1983, it is important to note that here, too, the landscape has been changed. This is not just because of the complexities of addressing public health concerns within psychiatric hospitals, which bring with them similar issues to those discussed above in relation to DoLS, but also because of changes to primary legislation.
     </p>
     <p id="p0475">
      The CA 2020 includes (in s.10 and Schedule 8) the power to make temporary changes to mental health and mental capacity legislation across the United Kingdom. Those powers include the ability drastically to strip back the procedural safeguards around admission and treatment under the Mental Health Act 1983;
      <xref ref-type="fn" rid="fn0585">
       117
      </xref>
      it is perhaps odd, given how much more relevant the MCA 2005 is to the response to the pandemic, that the CA 2020 only addressed the MHA 1983 in primary legislation.
      <xref ref-type="fn" rid="fn0590">
       118
      </xref>
     </p>
     <p id="p0480">
      At the time of time of writing, those powers have not been brought into force. However, the power under the Act
      <xref ref-type="fn" rid="fn0595">
       119
      </xref>
      to enable changes to the composition of the Mental Health Review Tribunal for Wales was brought into force on enactment, mirrored by a Pilot Practice Direction
      <xref ref-type="fn" rid="fn0600">
       120
      </xref>
      in England. At a stroke, tribunals were reduced to single judges (as opposed to a judge sitting with a medical member and a specialist lay member) sitting remotely, with hearings taking place largely by telephone. I do not dwell further upon these changes, except to say that the reader can easily imagine the practical impact upon all concerned, above all the patients.
      <xref ref-type="fn" rid="fn0605">
       121
      </xref>
     </p>
    </sec>
    <sec id="s0060">
     <label>
      9
     </label>
     <title>
      Conclusion
     </title>
     <p id="p0485">
      As noted at the outset, this tour d'horizon of the state of mental capacity law in England &amp; Wales only a short time into the COVID-19 pandemic presents a challenging picture. Across the board, options are being removed, and constraints necessary for utilitarian goals being imposed with inadvertent, and often disproportionate consequences. But there are glimmers of hope – for instance in the potential for the ECHR to be a very much more powerful tool than it has been to date in terms of securing service provision.
      <xref ref-type="fn" rid="fn0610">
       122
      </xref>
     </p>
     <p id="p0490">
      And in a world where nothing appears certain, and everyone, irrespective of disability, is seeking answers, it is arguably easier than it was ever before for supported decision-making to appear something of universal relevance. Whether and how the second draft of history to be written after the end of the pandemic makes a more or less cheering read than it does at present will depend, in very significant part, upon the actions taken by those who care about capacity law over the coming months, when it will be tested as never before.
     </p>
    </sec>
    <back>
     <ack id="ac0005">
      <title>
       Acknowledgements
      </title>
      <p>
       The author thanks Mary Donnelly for her very rapid assistance with editing, and the two reviewers for their incisive, constructive, and exceptionally speedy responses. Any errors remaining are the responsibility of the author.
      </p>
     </ack>
     <fn-group>
      <fn id="fn0005">
       <label>
        1
       </label>
       <p id="np0005">
        The world had, of course, changed some time ago in other countries, from China in late 2019.
       </p>
      </fn>
      <fn id="fn0010">
       <label>
        2
       </label>
       <p id="np0010">
        I do not address these in detail, but keen observers will no doubt wish to keep an eye upon whether and how devolution means that the paths taken in the two differ.
       </p>
      </fn>
      <fn id="fn0015">
       <label>
        3
       </label>
       <p id="np0015">
        For more detail, see Ruck Keene, A. R., Kane, N. B., Kim, S. Y., &amp; Owen, G. S. (2019). Taking capacity seriously? Ten years of mental capacity disputes before England's Court of Protection.
        <italic>
         International journal of law and psychiatry
        </italic>
        ,
        <italic>
         62
        </italic>
        , 56–76.
       </p>
      </fn>
      <fn id="fn0020">
       <label>
        4
       </label>
       <p id="np0020">
        See
        <italic>
         MN v ACCG
        </italic>
        [2017] UKSC 22, per Lady Hale. See also
        <italic>
         PW v Chelsea And Westminster Hospital NHS Foundation Trust &amp; Ors
        </italic>
        [2018] EWCA Civ 1067, in the context of medical treatment.
       </p>
      </fn>
      <fn id="fn0025">
       <label>
        5
       </label>
       <p id="np0025">
        Where, importantly, it is more difficutl
       </p>
      </fn>
      <fn id="fn0030">
       <label>
        6
       </label>
       <p id="np0030">
        Separate regimes exist in relation to children, which are not discussed in this article.
       </p>
      </fn>
      <fn id="fn0035">
       <label>
        7
       </label>
       <p id="np0035">
        PH(CD) A 1984, s.45C.
       </p>
      </fn>
      <fn id="fn0045">
       <label>
        9
       </label>
       <p id="np0045">
        Department of Health and Social Care, 19 March 2020:
        <ext-link ext-link-type="uri" id="ir0005" xlink:href="https://www.gov.uk/government/publications/covid-19-ethical-framework-for-adult-social-care/responding-to-covid-19-the-ethical-framework-for-adult-social-care">
         https://www.gov.uk/government/publications/covid-19-ethical-framework-for-adult-social-care/responding-to-covid-19-the-ethical-framework-for-adult-social-care
        </ext-link>
        (accessed 4 April 2020).
       </p>
      </fn>
      <fn id="fn0050">
       <label>
        10
       </label>
       <p id="np0050">
        By the Committee on Ethical Aspects of Pandemic Influenza in 2007: see Department of Health ‘Responding to pandemic influenza—the ethical framework for policy and planning (London: Department of Health, 2007).
       </p>
      </fn>
      <fn id="fn0055">
       <label>
        11
       </label>
       <p id="np0055">
        Under, in particular, the National Health Service Act 2006.
       </p>
      </fn>
      <fn id="fn0060">
       <label>
        12
       </label>
       <p id="np0060">
        CA 2020s.14.
       </p>
      </fn>
      <fn id="fn0065">
       <label>
        13
       </label>
       <p id="np0065">
        Coronavirus Act 2020 Explanatory Notes,
        <ext-link ext-link-type="uri" id="ir0010" xlink:href="http://www.legislation.gov.uk/ukpga/2020/7/contents/enacted">
         http://www.legislation.gov.uk/ukpga/2020/7/contents/enacted
        </ext-link>
        (accessed 4 April 2020), paragraphs 229–230.
       </p>
      </fn>
      <fn id="fn0070">
       <label>
        14
       </label>
       <p id="np0070">
        <italic>
         MN v ACCG
        </italic>
        [2017] UKSC 22 at paragraph 35, per Lady Hale.
       </p>
      </fn>
      <fn id="fn0075">
       <label>
        15
       </label>
       <p id="np0075">
        See (for England), Department of Health and Social Care ‘Care Act easements: guidance for local authorities’ (31 March 2020), available at
        <ext-link ext-link-type="uri" id="ir0015" xlink:href="https://www.gov.uk/government/publications/coronavirus-covid-19-changes-to-the-care-act-2014/care-act-easements-guidance-for-local-authorities">
         https://www.gov.uk/government/publications/coronavirus-covid-19-changes-to-the-care-act-2014/care-act-easements-guidance-for-local-authorities
        </ext-link>
        (accessed 4 April 2020).
       </p>
      </fn>
      <fn id="fn0080">
       <label>
        16
       </label>
       <p id="np0080">
        CA 2020 s. 15 and Parts 1 and 2 respectively of Sch. 12 to the CA 2020.
       </p>
      </fn>
      <fn id="fn0085">
       <label>
        17
       </label>
       <p id="np0085">
        By Coronavirus Act 2020 (Commencement No. 2) Regulations 2020 (SI 2020/388) and The Coronavirus Act 2020 (Commencement No. 1) (Wales) Regulations 2020 (SI 2020 No. 366 (W. 81)).
       </p>
      </fn>
      <fn id="fn0090">
       <label>
        18
       </label>
       <p id="np0090">
        CA 2020 Sch. 12 para 18.
       </p>
      </fn>
      <fn id="fn0095">
       <label>
        19
       </label>
       <p id="np0095">
        CA 2020 Sch. 12 para. 2(1)(1). This also means that there is no duty to comply with regulations made relating to such assessments under s.11 CA 2014 Sch. 12 para. 2(1).
       </p>
      </fn>
      <fn id="fn0100">
       <label>
        20
       </label>
       <p id="np0100">
        CA 2020 Sch. 12, para. 2(1)(b). This also means that there is no duty to comply with regulations made relating to such assessments under s.11 CA 2014 (Sch. 12 para 2(1).
       </p>
      </fn>
      <fn id="fn0105">
       <label>
        21
       </label>
       <p id="np0105">
        CA 2020 Sch 12, para 2(1)(c).
       </p>
      </fn>
      <fn id="fn0110">
       <label>
        22
       </label>
       <p id="np0110">
        CA 2020 Sch. 12, para. 2(2).
       </p>
      </fn>
      <fn id="fn0115">
       <label>
        23
       </label>
       <p id="np0115">
        CA 2020 Sch. 12, para. 3(1) of Schedule 12. However, a local authority could not charge for services unless such an assessment had been carried out:CA 2020 Sch. 12.,para. 3(2).
       </p>
      </fn>
      <fn id="fn0120">
       <label>
        24
       </label>
       <p id="np0120">
        CA 2020 Sch. 12, para. 4.
       </p>
      </fn>
      <fn id="fn0125">
       <label>
        25
       </label>
       <p id="np0125">
        These are, respectively, (1) the local authority is satisfied on the basis of the financial assessment it carried out that the adult's financial resources are at or below the financial limit; (2) the local authority is satisfied on the basis of the financial assessment it carried out that the adult's financial resources are above the financial limit, but the adult nonetheless asks the authority to meet the adult's needs; and (3) the adult lacks capacity to arrange for the provision of care and support, but there is no person authorised to do so under the Mental Capacity Act 2005 or otherwise in a position to do so on the adult's behalf.
       </p>
      </fn>
      <fn id="fn0130">
       <label>
        26
       </label>
       <p id="np0130">
        CA 2020 Sch. 12, para. 6.
       </p>
      </fn>
      <fn id="fn0135">
       <label>
        27
       </label>
       <p id="np0135">
        Department of Health and Social Care ‘Care Act easements: guidance for local authorities’ (31 March 2020), available at
        <ext-link ext-link-type="uri" id="ir0020" xlink:href="https://www.gov.uk/government/publications/coronavirus-covid-19-changes-to-the-care-act-2014/care-act-easements-guidance-for-local-authorities">
         https://www.gov.uk/government/publications/coronavirus-covid-19-changes-to-the-care-act-2014/care-act-easements-guidance-for-local-authorities
        </ext-link>
        (accessed 4 April 2020).
       </p>
      </fn>
      <fn id="fn0140">
       <label>
        28
       </label>
       <p id="np0140">
        In Wales, the position was arguably even starker: local authorities were only under duties to meet needs under the Social Services and Well-Being (Wales) Act 2014 where “the local authority considers it necessary to meet the needs in order to protect the adult from abuse or neglect or a risk of abuse or neglect” (CA 2020 Sch. 12, para. 27, amending s.35 Social Services and Well-Being (Wales) Act 2014.
       </p>
      </fn>
      <fn id="fn0145">
       <label>
        29
       </label>
       <p id="np0145">
        Department of Health and Social Care ‘Care Act easements: guidance for local authorities’ (31 March 2020), available at
        <ext-link ext-link-type="uri" id="ir0025" xlink:href="https://www.gov.uk/government/publications/coronavirus-covid-19-changes-to-the-care-act-2014/care-act-easements-guidance-for-local-authorities">
         https://www.gov.uk/government/publications/coronavirus-covid-19-changes-to-the-care-act-2014/care-act-easements-guidance-for-local-authorities
        </ext-link>
       </p>
      </fn>
      <fn id="fn0150">
       <label>
        30
       </label>
       <p id="np0150">
        For an overview, see Jean-François Akandji-Kombe, ‘Positive obligations under the European Convention on Human Rights,’ A guide to the implementation of the European Convention on Human Rights (Council of Europe, Human Rights Handbook No.7, 2007).
       </p>
      </fn>
      <fn id="fn0155">
       <label>
        31
       </label>
       <p id="np0155">
        [2019] EWHC 2754 (Admin).
       </p>
      </fn>
      <fn id="fn0160">
       <label>
        32
       </label>
       <p id="np0160">
        [2019] EWHC 2754 (Admin),para. 10.
       </p>
      </fn>
      <fn id="fn0165">
       <label>
        33
       </label>
       <p id="np0165">
        [2011] UKSC 33
       </p>
      </fn>
      <fn id="fn0170">
       <label>
        34
       </label>
       <p id="np0170">
        See [2011] UKSC 33 paras. 15–19 in the judgment of Lord Brown, with whom the other members of the majority agreed (they also agreed with his conclusion that even if her rights were engaged, any interference with them would have been justified by reference to Article 8(2) “
        <italic>
         on the grounds that it is necessary for the economic well-being of the respondents and the interests of their other service-users and is a proportionate response to the appellant's needs because it affords her the maximum protection from injury, greater privacy and independence, and results in a substantial costs saving
        </italic>
        ” (para. 19)).
       </p>
      </fn>
      <fn id="fn0175">
       <label>
        35
       </label>
       <p id="np0175">
        As opposed to framing the exercise of a power, as per
        <italic>
         R(Aburas v London Borough of Southwark)
        </italic>
        [2019] EWHC 2754 (Admin)..
       </p>
      </fn>
      <fn id="fn0180">
       <label>
        36
       </label>
       <p id="np0180">
        [2016] EWHC 1762 (Admin)
       </p>
      </fn>
      <fn id="fn0185">
       <label>
        37
       </label>
       <p id="np0185">
        [2016] EWHC 1762 (Admin) at paragraphs 64–70
       </p>
      </fn>
      <fn id="fn0190">
       <label>
        38
       </label>
       <p id="np0190">
        Note this passage: “
        <italic>
         authoritative guidance as to the relevant level of severity of the implications for the individual [in order to engage Article 3 ECHR, and hence require the s.19 power to be exercised under the Care Act 2014] can be discerned from the passages citing
        </italic>
        <ext-link ext-link-type="uri" id="ir0050" xlink:href="http://uk.westlaw.com/Document/I7A2300B0E42811DA8FC2A0F0355337E9/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
         <italic>
          Limbuela
         </italic>
        </ext-link>
        <italic>
         and
        </italic>
        <ext-link ext-link-type="uri" id="ir0055" xlink:href="http://uk.westlaw.com/Document/I5E9EE4E0E42711DA8FC2A0F0355337E9/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
         Anufrijeva
        </ext-link>
        <italic>
         . No alternative line of authority was cited to me and no alternative formulation of relevant standards was contended for. The observations in
        </italic>
        <ext-link ext-link-type="uri" id="ir0060" xlink:href="http://uk.westlaw.com/Document/I7A2300B0E42811DA8FC2A0F0355337E9/View/FullText.html?originationContext=document&amp;transitionType=DocumentItem&amp;vr=3.0&amp;rs=PLUK1.0&amp;contextData=(sc.DocLink)">
         <italic>
          Limbuela
         </italic>
        </ext-link>
        <italic>
         can, in my judgment, aptly inform the ‘looked-after needs’ context,
         <bold>
          if that context is borne in mind
         </bold>
        </italic>
        .” (emphasis added).
       </p>
      </fn>
      <fn id="fn0195">
       <label>
        39
       </label>
       <p id="np0195">
        This is how subsequent decisions have distinguished
        <italic>
         R (Bernard) v Enfield London Borough Council
        </italic>
        [2002] EWHC 2282 (Admin), in which the situation was found to have breached Article 8 ECHR even though it did not breach Article 3 ECHR, because the entire family were in such dire straits as a result of the local authority's actions.
       </p>
      </fn>
      <fn id="fn0200">
       <label>
        40
       </label>
       <p id="np0200">
        Art. 8(2) applies. Where the interference is in accordance with the law and is necessary in a democratic society in the interests of national security, public safety or the economic well-being of the country, for the prevention of disorder or crime, for the protection of health or morals, or for the protection of the rights and freedoms of others.
       </p>
      </fn>
      <fn id="fn0205">
       <label>
        41
       </label>
       <p id="np0205">
        <italic>
         Botta v Italy
        </italic>
        (1998) 26 EHRR 241.
       </p>
      </fn>
      <fn id="fn0210">
       <label>
        42
       </label>
       <p id="np0210">
        On the scope of this concept, see, for instance,
        <italic>
         Dordevic v Croatia
        </italic>
        [2012] ECHR 1650: “
        <italic>
         152. The Court has previously held, in various contexts, that the concept of private life includes a person's psychological integrity. Under Article 8, States have in some circumstances a duty to protect the moral integrity of an individual from acts of other persons. The Court has also held that States have a positive obligation to ensure respect for human dignity and the quality of life in certain respects (see
        </italic>
        L.
        <italic>
         v. Lithuania, no. 27527/03, § 56, ECHR 2007-IV, and,
        </italic>
        mutatis mutandis
        <italic>
         , Pretty, cited above, § 65)
        </italic>
        .”
       </p>
      </fn>
      <fn id="fn0215">
       <label>
        43
       </label>
       <p id="np0215">
        The Court of Protection, in particular, having understood Article 5(1)(e) in principle not to relate to the suitability of the conditions under which the person is deprived of their liberty. See
        <italic>
         North Yorkshire County Council &amp; Anor v MAG &amp; Anor
        </italic>
        [2016] EWCOP 5, in particular the discussion of the jurisprudence relating to Article 5(1)(e) at paragraph 26, which predates both this decision and the decision in
        <italic>
         Rooman
        </italic>
        .
       </p>
      </fn>
      <fn id="fn0220">
       <label>
        44
       </label>
       <p id="np0220">
        [2019] ECHR 109 at para.286.
       </p>
      </fn>
      <fn id="fn0225">
       <label>
        45
       </label>
       <p id="np0225">
        [2016] ECHR 1028.
       </p>
      </fn>
      <fn id="fn0230">
       <label>
        46
       </label>
       <p id="np0230">
        <italic>
         Hiller v Austria
        </italic>
        [2016] ECHR 1028 at paragraph 54.
       </p>
      </fn>
      <fn id="fn0235">
       <label>
        47
       </label>
       <p id="np0235">
        As powerfully identified by the statement of the Council of Europe's Commissioner for Human Rights of 2 April 2020, ‘Persons with disabilities must not be left behind in the response to the COVID-19 pandemic’ (
        <ext-link ext-link-type="uri" id="ir0065" xlink:href="https://www.coe.int/en/web/commissioner/-/persons-with-disabilities-must-not-be-left-behind-in-the-response-to-the-covid-19-pandemic">
         https://www.coe.int/en/web/commissioner/-/persons-with-disabilities-must-not-be-left-behind-in-the-response-to-the-covid-19-pandemic
        </ext-link>
        ).
       </p>
      </fn>
      <fn id="fn0240">
       <label>
        48
       </label>
       <p id="np0240">
        A helpful summary of the extensive range of pronouncements from international human rights bodies in relation to the application of the CRPD and other instruments in the context of COVID-19 can be found in Oliver Lewis, Disability, coronavirus and international human rights,
        <ext-link ext-link-type="uri" id="ir0070" xlink:href="https://insights.doughtystreet.co.uk/post/102g27s/disability-coronavirus-and-international-human-rights">
         https://insights.doughtystreet.co.uk/post/102g27s/disability-coronavirus-and-international-human-rights
        </ext-link>
        (accessed 4 April 2020).
       </p>
      </fn>
      <fn id="fn0245">
       <label>
        49
       </label>
       <p id="np0245">
        <italic>
         R (Davey) v Oxfordshire County Council &amp; Ors
        </italic>
        [2017] EWCA Civ 1308.
       </p>
      </fn>
      <fn id="fn0250">
       <label>
        50
       </label>
       <p id="np0250">
        [2017] EWCA Civ 1308 at para. 62.
       </p>
      </fn>
      <fn id="fn0255">
       <label>
        51
       </label>
       <p id="np0255">
        See, in particular,
        <italic>
         Burnip v Birmingham City Council
        </italic>
        [2012] EWCA Civ 629 (obiter, in the context of interpretation of Article 14 ECHR). See also Lawson, A. and Series, L. ‘United Kingdom’ in Waddington, L., &amp; Lawson, A. (Eds.). (2018).
        <italic>
         The UN Convention on the Rights of Persons with Disabilities in Practice: A Comparative Analysis of the Role of Courts
        </italic>
        . Oxford University Press.
       </p>
      </fn>
      <fn id="fn0260">
       <label>
        52
       </label>
       <p id="np0260">
        As recognised under CRPD Articles 19 and 25 respectively.
       </p>
      </fn>
      <fn id="fn0265">
       <label>
        53
       </label>
       <p id="np0265">
        SI 2020/350. The counterpart in Wales (which were nearly, but not quite, identical – limiting by statute the reasonable excuse relating to exercise to once a day) were the Health Protection (Coronavirus, Restrictions) (Wales) Regulations 2020 (SI 2020/308 (W.68).
       </p>
      </fn>
      <fn id="fn0270">
       <label>
        54
       </label>
       <p id="np0270">
        Regulation 12.
       </p>
      </fn>
      <fn id="fn0275">
       <label>
        55
       </label>
       <p id="np0275">
        Regulation 3(2).
       </p>
      </fn>
      <fn id="fn0280">
       <label>
        56
       </label>
       <p id="np0280">
        Regulation 6(1).
       </p>
      </fn>
      <fn id="fn0285">
       <label>
        57
       </label>
       <p id="np0285">
        Defined in regulation 8(12) as including police officers, police community support officers, and other people to be designated (either by a local authority, for specific purposes, or the Secretary of State).
       </p>
      </fn>
      <fn id="fn0290">
       <label>
        58
       </label>
       <p id="np0290">
        Regulations 9 and 10.
       </p>
      </fn>
      <fn id="fn0295">
       <label>
        59
       </label>
       <p id="np0295">
        Regulation 6(2)(m).
       </p>
      </fn>
      <fn id="fn0300">
       <label>
        60
       </label>
       <p id="np0300">
        David Anderson QC, ‘Can we be forced to stay at home?’ (26 March 2020)
        <ext-link ext-link-type="uri" id="ir0075" xlink:href="https://www.daqc.co.uk/2020/03/26/can-we-be-forced-to-stay-at-home/">
         https://www.daqc.co.uk/2020/03/26/can-we-be-forced-to-stay-at-home/
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0305">
       <label>
        61
       </label>
       <p id="np0305">
        Because the Supreme Court has held that, for purposes of the law in England &amp; Wales, deprivation of liberty requires not only that a person not be free to leave, but also that they are under continuous supervision and control: see, in the context of deprivation of liberty on the basis of ‘unsoundness of mind,’
        <italic>
         Surrey County Council v P, Cheshire West and Chester Council v P
        </italic>
        [2014] UKSC 19 at paragraph 49. See also, earlier, and in the context of ‘control orders’ relating to terrorism,
        <italic>
         Secretary of State for the Home Department v JJ &amp; Ors
        </italic>
        [2007] UKHL 45 at paragraph 57, per Lady Hale.
       </p>
      </fn>
      <fn id="fn0310">
       <label>
        62
       </label>
       <p id="np0310">
        On these points, see also Tom Hickman QC, Emma Dixon and Rachel Jones, ‘Coronavirus and Civil Liberties in the UK’ (6 April 2020),
        <ext-link ext-link-type="uri" id="ir0080" xlink:href="https://coronavirus.blackstonechambers.com/coronavirus-and-civil-liberties-uk/">
         https://coronavirus.blackstonechambers.com/coronavirus-and-civil-liberties-uk/
        </ext-link>
        (Accessed 8 April 2020).
       </p>
      </fn>
      <fn id="fn0315">
       <label>
        63
       </label>
       <p id="np0315">
        Crown Prosecution Service, Coronavirus: Health Protection (Coronavirus, Restrictions) (England) Regulations 2020 (26 March 2020),
        <ext-link ext-link-type="uri" id="ir0085" xlink:href="https://www.cps.gov.uk/legal-guidance/coronavirus-health-protection-coronavirus-restrictions-england-regulations-2020">
         https://www.cps.gov.uk/legal-guidance/coronavirus-health-protection-coronavirus-restrictions-england-regulations-2020
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0320">
       <label>
        64
       </label>
       <p id="np0320">
        See for a discussion of this, Law Commission (2017),
        <italic>
         Mental Capacity and Deprivation of Liberty
        </italic>
        (Law Com 372), at 7.10 and 7.13.
       </p>
      </fn>
      <fn id="fn0325">
       <label>
        65
       </label>
       <p id="np0325">
        I am excluding hospitals here, the other place where a person can be subject to a DoLS authorisation, but a hospital would falls within this power if (on the facts of the case) the person could be said to ‘be a place where they are living.’).
       </p>
      </fn>
      <fn id="fn0330">
       <label>
        66
       </label>
       <p id="np0330">
        The ‘acid test’ being the phrase used by Lady Hale to capture the objective element of deprivation of liberty – confinement – in
        <italic>
         Surrey County Council v P, Cheshire West and Chester Council v P
        </italic>
        [2014] UKSC 19 at paragraph 47.
       </p>
      </fn>
      <fn id="fn0335">
       <label>
        67
       </label>
       <p id="np0335">
        Deprivation of liberty requiring (1) confinement; (2) a lack of valid consent; and (3) state imputability. The last limb will be satisfied wherever the state knows or ought to know of the confinement:
        <italic>
         D (A Child)
        </italic>
        [2019] UKSC 42 at paragraph 43.
       </p>
      </fn>
      <fn id="fn0340">
       <label>
        68
       </label>
       <p id="np0340">
        CA 2020 Sch. 21, para. 15.
       </p>
      </fn>
      <fn id="fn0345">
       <label>
        69
       </label>
       <p id="np0345">
        CA 2020 Sch. 21, para. 23.
       </p>
      </fn>
      <fn id="fn0350">
       <label>
        70
       </label>
       <p id="np0350">
        CA 2020 Sch. 21, para. 20(1).
       </p>
      </fn>
      <fn id="fn0355">
       <label>
        71
       </label>
       <p id="np0355">
        CA 2020 Sch. 21, para. 20(1), 20 (2) and 23.
       </p>
      </fn>
      <fn id="fn0360">
       <label>
        72
       </label>
       <p id="np0360">
        CA 2020 Sch. 21, para. (4)
       </p>
      </fn>
      <fn id="fn0365">
       <label>
        73
       </label>
       <p id="np0365">
        CA 2020 Sch. 21, para. 17.
       </p>
      </fn>
      <fn id="fn0370">
       <label>
        74
       </label>
       <p id="np0370">
        And it was anticipated at the time of writing that statutory guidance would confirm this position.
       </p>
      </fn>
      <fn id="fn0375">
       <label>
        75
       </label>
       <p id="np0375">
        See
        <italic>
         RD &amp; Ors (Duties and Powers of Relevant Person's Representatives and Section 39D IMCAS)
        </italic>
        [2016] EWCOP 49at paragraph 86(a), where Baker J held that the capacity to ask to issue proceedings “simply requires P to understand that the court has the power to decide that he/she should not be subject to his/her current care arrangements. It is a lower threshold than the capacity to conduct proceedings.”
       </p>
      </fn>
      <fn id="fn0380">
       <label>
        76
       </label>
       <p id="np0380">
        For an early discussion, see 39 Essex Chambers, ‘Rapid Response Guidance Note: COVID-19, Social Distancing and Mental Capacity’ (31 March 2020),
        <ext-link ext-link-type="uri" id="ir0090" xlink:href="https://www.39essex.com/rapid-response-guidance-note-covid-19-social-distancing-and-mental-capacity/">
         https://www.39essex.com/rapid-response-guidance-note-covid-19-social-distancing-and-mental-capacity/
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0395">
       <label>
        79
       </label>
       <p id="np0395">
        Personal knowledge of the author.
       </p>
      </fn>
      <fn id="fn0400">
       <label>
        80
       </label>
       <p id="np0400">
        Changes were, however, made to the provisions of the Mental Capacity Act (Northern Ireland) 2016 relating to deprivation of liberty which had recently been brought into force: s.10 and Schedule 11 to the CA 2020. These came into force on 2 April 2020: The Coronavirus Act 2020 (Commencement No.1) Order (Northern Ireland) 2020 (Northern Ireland Statutory Rules 2020 No. 58)
       </p>
      </fn>
      <fn id="fn0405">
       <label>
        81
       </label>
       <p id="np0405">
        Hansard, HL, 24 March 2020, Vol 802, col. 1734 (the author being one).
       </p>
      </fn>
      <fn id="fn0410">
       <label>
        82
       </label>
       <p id="np0410">
        And, in the process, ironically laying bare the fact that the primary legislation does not, itself, require such things as face-to-face assessment of capacity.
       </p>
      </fn>
      <fn id="fn0415">
       <label>
        83
       </label>
       <p id="np0415">
        For an overview of this Act, see Alex Ruck Keene, ‘LPS – where are we, and where are we going?’ (March 2020, updated February 2020),
        <ext-link ext-link-type="uri" id="ir0095" xlink:href="https://www.mentalcapacitylawandpolicy.org.uk/lps-where-are-we-and-where-are-we-going/">
         https://www.mentalcapacitylawandpolicy.org.uk/lps-where-are-we-and-where-are-we-going/
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0420">
       <label>
        84
       </label>
       <p id="np0420">
        [2020] EWCOP 17, heard on 25 March 2020.
       </p>
      </fn>
      <fn id="fn0425">
       <label>
        85
       </label>
       <p id="np0425">
        For purposes of assessing and reporting to the court as to BP's capacity to decide upon his residence and care arrangements.
       </p>
      </fn>
      <fn id="fn0430">
       <label>
        86
       </label>
       <p id="np0430">
        [2020] EWCOP 17 at para.11.
       </p>
      </fn>
      <fn id="fn0435">
       <label>
        87
       </label>
       <p id="np0435">
        [2020] EWCOP 17 at para. 12.
       </p>
      </fn>
      <fn id="fn0440">
       <label>
        88
       </label>
       <p id="np0440">
        European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment, ‘Statement of principles relating to the treatment of persons deprived of their liberty in the context of the coronavirus disease (COVID-19) pandemic,’ CPT/Inf(2020)13 (20 March 2020),
        <ext-link ext-link-type="uri" id="ir0100" xlink:href="https://rm.coe.int/16809cfa4b">
         https://rm.coe.int/16809cfa4b
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0445">
       <label>
        89
       </label>
       <p id="np0445">
        [2020] EWCOP 17 at para. 26.
       </p>
      </fn>
      <fn id="fn0450">
       <label>
        90
       </label>
       <p id="np0450">
        [2020] EWCOP 17 at para. 36.
       </p>
      </fn>
      <fn id="fn0455">
       <label>
        91
       </label>
       <p id="np0455">
        [2020] EWCOP 17 at para. 38.
       </p>
      </fn>
      <fn id="fn0460">
       <label>
        92
       </label>
       <p id="np0460">
        [2020] EWCOP 17 at para. 27.
       </p>
      </fn>
      <fn id="fn0465">
       <label>
        93
       </label>
       <p id="np0465">
        He did this by sending notice of his judgment to the Council of Europe.
       </p>
      </fn>
      <fn id="fn0470">
       <label>
        94
       </label>
       <p id="np0470">
        See, inter alia,
        <italic>
         SR v A Local Authority &amp; Anor
        </italic>
        [2018] EWCOP 36.
       </p>
      </fn>
      <fn id="fn0475">
       <label>
        95
       </label>
       <p id="np0475">
        For an overview of the Court of Protection and its work, see Ruck Keene, A. R., Kane, N. B., Kim, S. Y., &amp; Owen, G. S. (2019). Taking capacity seriously? Ten years of mental capacity disputes before England's Court of Protection.
        <italic>
         International journal of law and psychiatry
        </italic>
        ,
        <italic>
         62
        </italic>
        , 56–76.
       </p>
      </fn>
      <fn id="fn0480">
       <label>
        96
       </label>
       <p id="np0480">
        Most easily accessible at time of writing at
        <ext-link ext-link-type="uri" id="ir0105" xlink:href="https://www.mentalcapacitylawandpolicy.org.uk/wp-content/uploads/2020/03/Remote-Hearings-COP-31-March-2020.pdf">
         https://www.mentalcapacitylawandpolicy.org.uk/wp-content/uploads/2020/03/Remote-Hearings-COP-31-March-2020.pdf
        </ext-link>
        (accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0485">
       <label>
        97
       </label>
       <p id="np0485">
        <italic>
         A Clinical Commissioning Group v AF &amp; Ors
        </italic>
        [2020] EWCOP 16
       </p>
      </fn>
      <fn id="fn0490">
       <label>
        98
       </label>
       <p id="np0490">
        See Nageena Khalique QC &amp; Sophia Roper, ‘Skype in the Court of Protection’ (23 March 2020):
        <ext-link ext-link-type="uri" id="ir0110" xlink:href="http://ukmedicaldecisionlawblog.co.uk/rss-feed/115-skype-in-the-court-of-protection-the-courts-in-the-time-of-coronavirus">
         http://ukmedicaldecisionlawblog.co.uk/rss-feed/115-skype-in-the-court-of-protection-the-courts-in-the-time-of-coronavirus
        </ext-link>
        (Accessed 5 April 2020). Note, as the blog itself makes clear, it was revised subsequently to reflect the views of the man's daughter. As to the judge's perspective, see Catherine Baksi, “Pioneering Skype trial ‘went without a hitch’, says judge,” The Law Society Gazette, 31 March 2020 (
        <ext-link ext-link-type="uri" id="ir0115" xlink:href="https://www.lawgazette.co.uk/practice/pioneering-skype-trial-went-without-a-hitch-says-judge/5103698.article">
         https://www.lawgazette.co.uk/practice/pioneering-skype-trial-went-without-a-hitch-says-judge/5103698.article
        </ext-link>
        ) (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0495">
       <label>
        99
       </label>
       <p id="np0495">
        See Celia Kitzinger, ‘Remote justice: a family perspective’ (29 March 2020),
        <ext-link ext-link-type="uri" id="ir0120" xlink:href="http://www.transparencyproject.org.uk/remote-justice-a-family-perspective/">
         http://www.transparencyproject.org.uk/remote-justice-a-family-perspective/
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0500">
       <label>
        100
       </label>
       <p id="np0500">
        For an overview of how the court had been seeking to improve participation, see Mr. Justice Charles, ‘Facilitating participation of ‘P' and vulnerable persons in Court of Protection proceedings,’ (3 November 2016),
        <ext-link ext-link-type="uri" id="ir0125" xlink:href="https://www.familylaw.co.uk/docs/pdf-files/Practice_Guidance_Vulnerable_Persons.pdf">
         https://www.familylaw.co.uk/docs/pdf-files/Practice_Guidance_Vulnerable_Persons.pdf
        </ext-link>
        (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0505">
       <label>
        101
       </label>
       <p id="np0505">
        <italic>
         A Clinical Commissioning Group v AF &amp; Ors
        </italic>
        [2020] EWCOP 16 at para. 73.
       </p>
      </fn>
      <fn id="fn0510">
       <label>
        102
       </label>
       <p id="np0510">
        <italic>
         A Clinical Commissioning Group v AF &amp; Ors
        </italic>
        [2020] EWCOP 16 at para. 74.
       </p>
      </fn>
      <fn id="fn0515">
       <label>
        103
       </label>
       <p id="np0515">
        For a discussion of the issues more widely as they stood at the start of April 2020, see Dominic Wilkinson, ‘ICU triage in an impending crisis: uncertainty, pre- emption and preparation,’ (1 April 2020),
        <italic>
         Journal of Medical Ethics
        </italic>
        online first, http://dx.doi.org/10.1136/medethics-2020-106226 (Accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0520">
       <label>
        104
       </label>
       <p id="np0520">
        With
        <italic>
         Aintree v James
        </italic>
        [2013] UKSC 67.
       </p>
      </fn>
      <fn id="fn0525">
       <label>
        105
       </label>
       <p id="np0525">
        For an overview, see Ruck Keene, A &amp; Lee, A. (2019). Withdrawing life-sustaining treatment: a stock-take of the legal and ethical position.
        <italic>
         Journal of medical ethics
        </italic>
        ,
        <italic>
         45
        </italic>
        (12), 794–799.
       </p>
      </fn>
      <fn id="fn0530">
       <label>
        106
       </label>
       <p id="np0530">
        Which
        <italic>
         Aintree
        </italic>
        reinforced could not happen: see paragraph 18.
       </p>
      </fn>
      <fn id="fn0535">
       <label>
        107
       </label>
       <p id="np0535">
        For a good example, see
        <italic>
         University Hospitals Birmingham NHS Foundation Trust v HB
        </italic>
        [2018] EWCOP 39, I which Keehan J, considering the submission that CPR would not be in the best interests of the person, noted that “key to the decision must be the wishes and feelings of HB and it is plain that administering CPR in the event of a further collapse and giving her, albeit a very, very small chance of life, is what she would wish. In my judgment, at the moment, it remains in her best interests for that treatment to be provided to her” (paragraph 36).
       </p>
      </fn>
      <fn id="fn0540">
       <label>
        108
       </label>
       <p id="np0540">
        The closest previous shave had been during the 2009 swine flu outbreak. For an overview of the legal and ethical issues that arose in that context (together with the framework within planning had started), see Alex Ruck Keene, ‘The Legal and Ethical Principles of Rationing Critical Clinical Services - Particularly in Relation to Swine Flu’ (2009) (
        <ext-link ext-link-type="uri" id="ir0130" xlink:href="https://www.mentalcapacitylawandpolicy.org.uk/wp-content/uploads/2020/03/Pandemic-Rationing-Talk-August-2009-Final.pdf">
         https://www.mentalcapacitylawandpolicy.org.uk/wp-content/uploads/2020/03/Pandemic-Rationing-Talk-August-2009-Final.pdf
        </ext-link>
        ) (Accessed 5 April 2020)
       </p>
      </fn>
      <fn id="fn0545">
       <label>
        109
       </label>
       <p id="np0545">
        SIAARTI (Italian Society of Anaesthesia, Analgesia, Resuscitation and Intensive Care): Clinical Ethics Recommendations for the Allocation of Intensive Care Treatments in exceptional, resource-limited circumstances - Version n. 1 (March, 16th 2020). The age cut-off was proposed in paragraph 3.
       </p>
      </fn>
      <fn id="fn0550">
       <label>
        110
       </label>
       <p id="np0550">
        <italic>
         COVID-19 rapid guideline: critical care in adults NICE guideline
        </italic>
        (20 March 2020)
        <ext-link ext-link-type="uri" id="ir0135" xlink:href="http://www.nice.org.uk/guidance/ng159">
         www.nice.org.uk/guidance/ng159
        </ext-link>
        (Accessed 5 April 2020)
       </p>
      </fn>
      <fn id="fn0555">
       <label>
        111
       </label>
       <p id="np0555">
        <ext-link ext-link-type="uri" id="ir0140" xlink:href="https://www.independent.co.uk/news/health/coronavirus-nhs-treatment-disabled-autism-nice-covid-19-a9423441.html?fbclid=IwAR0T_53QtZG8axyfRs78tUYGfaT3seLd2FJf9PhSeoWTg64A_0XdkdkoEq8">
         https://www.independent.co.uk/news/health/coronavirus-nhs-treatment-disabled-autism-nice-covid-19-a9423441.html?fbclid=IwAR0T_53QtZG8axyfRs78tUYGfaT3seLd2FJf9PhSeoWTg64A_0XdkdkoEq8
        </ext-link>
        (Accessed 5 April 2020)
       </p>
      </fn>
      <fn id="fn0560">
       <label>
        112
       </label>
       <p id="np0560">
        <ext-link ext-link-type="uri" id="ir0145" xlink:href="https://beta.bma.org.uk/advice-and-support/covid-19/ethics/covid-19-ethical-issues">
         https://beta.bma.org.uk/advice-and-support/covid-19/ethics/covid-19-ethical-issues
        </ext-link>
        (1 April 2020) (Accessed 5 April 2020)
       </p>
      </fn>
      <fn id="fn0565">
       <label>
        113
       </label>
       <p id="np0565">
        The Guardian, ‘Virus patients more likely to die may have ventilators taken away’ (1 April 2020,
        <ext-link ext-link-type="uri" id="ir0150" xlink:href="https://www.theguardian.com/society/2020/apr/01/ventilators-may-be-taken-from-stable-coronavirus-patients-for-healthier-ones-bma-says">
         https://www.theguardian.com/society/2020/apr/01/ventilators-may-be-taken-from-stable-coronavirus-patients-for-healthier-ones-bma-says
        </ext-link>
        (Accessed 5 April 2020)
       </p>
      </fn>
      <fn id="fn0570">
       <label>
        114
       </label>
       <p id="np0570">
        Which was absolutely clear as to the requirement to involve the patient or (where they lacked capacity) those appropriately concerned with their welfare: see
        <italic>
         R (Tracey) v Cambridge University Hospitals NHS Foundation Trust &amp; Anor
        </italic>
        [2014] EWCA Civ 33 and
        <italic>
         Winspear v City Hospitals Sunderland NHS Foundation Trust
        </italic>
        [2015] EWHC 3250 (QB).
       </p>
      </fn>
      <fn id="fn0575">
       <label>
        115
       </label>
       <p id="np0575">
        See e.g. BBC News, “Coronavirus: GP surgery apology over ‘do not resuscitate’ form” (1 April 2020),
        <ext-link ext-link-type="uri" id="ir0155" xlink:href="https://www.bbc.co.uk/news/uk-wales-52117814">
         https://www.bbc.co.uk/news/uk-wales-52117814
        </ext-link>
        (Accessed 5 April 2020). Requiring someone to complete their own DNACPR was, in fact, legally impossible unless they were being asked to make advance decisions to refuse CPR, which would then require compliance with the statutory provisions of the MCA (including that they be witnessed): see s.25 MCA 2005.
       </p>
      </fn>
      <fn id="fn0580">
       <label>
        116
       </label>
       <p id="np0580">
        ‘Dear Colleagues’ letter dated 3 April 2020,
        <ext-link ext-link-type="uri" id="ir0160" xlink:href="https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0166-Letter-DNACPR.pdf">
         https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0166-Letter-DNACPR.pdf
        </ext-link>
        (accessed 5 April 2020).
       </p>
      </fn>
      <fn id="fn0585">
       <label>
        117
       </label>
       <p id="np0585">
        For an overview, see the 39 Essex Chambers Rapid Response Guidance Note: COVID-19 and the Mental Health Act 1983, available at
        <ext-link ext-link-type="uri" id="ir0165" xlink:href="https://www.39essex.com/tag/mental-capacity-guidance-notes/">
         https://www.39essex.com/tag/mental-capacity-guidance-notes/
        </ext-link>
        (accessed 4 April 2020).
       </p>
      </fn>
      <fn id="fn0590">
       <label>
        118
       </label>
       <p id="np0590">
        It is quite possible that this was down to the fact that changes had had to be contemplated in relation to the MHA 1983 in 2009 in the context of swine flu, so, to some extent, there were legislative amendments which could be taken off the shelf.
       </p>
      </fn>
      <fn id="fn0595">
       <label>
        119
       </label>
       <p id="np0595">
        Section 10 of and Part 1 of and paragraphs 11, 12 and 13 of Schedule 8, by virtue of The Coronavirus Act 2020 (Commencement No. 1) (Wales) Regulations 2020 (SI 2020 No. 366 (W. 81))
       </p>
      </fn>
      <fn id="fn0600">
       <label>
        120
       </label>
       <p id="np0600">
        Pilot Practice Direction: Health, Education and Social Care Chamber of the First-Tier Tribunal (Mental Health), 19 March 2020.
       </p>
      </fn>
      <fn id="fn0605">
       <label>
        121
       </label>
       <p id="np0605">
        Linked also to this were the very substantial difficulties caused by the practicalities of complying with a legal aid system dependent upon a set of procedures that were not easily adaptable for remote working.
       </p>
      </fn>
      <fn id="fn0610">
       <label>
        122
       </label>
       <p id="np0610">
        There of course, a considerable irony to this given that the Conservative Government has repeatedly expressed hostility to the ECHR, and a desire to revisit how human rights are protected in the United Kingdom, including through a British Bill of Rights.
       </p>
      </fn>
     </fn-group>
     <fn-group>
      <fn id="fn0040">
       <label>
        8
       </label>
       <p id="np0040">
        UNCRPD, Article 12.
       </p>
      </fn>
      <fn id="fn0385">
       <label>
        77
       </label>
       <p id="np0385">
        See, by analogy,
        <italic>
         Munjaz v United Kingdom
        </italic>
        [2012] ECHR 1704
       </p>
      </fn>
      <fn id="fn0390">
       <label>
        78
       </label>
       <p id="np0390">
        Paragraph 14 of Schedule A1 to the MCA 2005.
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Surg
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int J Surg
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Surgery (London, England)
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1743-9191
      </issn>
      <issn pub-type="epub">
       1743-9159
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7162753
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1743-9191(20)30316-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijsu.2020.04.018
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Nicola
         </surname>
         <given-names>
          Maria
         </given-names>
        </name>
        <email>
         maria_n02@hotmail.com
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Alsafi
         </surname>
         <given-names>
          Zaid
         </given-names>
        </name>
        <email>
         zchazal@ucl.ac.uk
        </email>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Sohrabi
         </surname>
         <given-names>
          Catrin
         </given-names>
        </name>
        <email>
         ha17021@qmul.ac.uk
        </email>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Kerwan
         </surname>
         <given-names>
          Ahmed
         </given-names>
        </name>
        <email>
         ahmedkerwan@live.co.uk
        </email>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Al-Jabir
         </surname>
         <given-names>
          Ahmed
         </given-names>
        </name>
        <email>
         ahmed@aljabir.co.uk
        </email>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Iosifidis
         </surname>
         <given-names>
          Christos
         </given-names>
        </name>
        <email>
         Iosifidischristos1@gmail.com
        </email>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Agha
         </surname>
         <given-names>
          Maliha
         </given-names>
        </name>
        <email>
         maliha@ijspg.com
        </email>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Agha
         </surname>
         <given-names>
          Riaz
         </given-names>
        </name>
        <email>
         mail@riazagha.com
        </email>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Imperial College Healthcare NHS Trust, London, United Kingdom
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       UCL Medical School, University College London, United Kingdom
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       GKT School of Medical Education, King’s College London
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       IJS Publishing Group
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Barts Health NHS Trust, London, United Kingdom
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author.
        <email>
         maria_n02@hotmail.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        17
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <history>
       <date date-type="received">
        <day>
         24
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         9
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         12
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The COVID-19 pandemic has resulted in over 1.4 million confirmed cases and over 83,000 deaths globally. It has also sparked fears of an impending economic crisis and recession. Social distancing, self-isolation and travel restrictions forced a decrease in the workforce across all economic sectors and caused many jobs to be lost. Schools have closed down, and the need of commodities and manufactured products has decreased. In contrast, the need for medical supplies has significantly increased. The food sector has also seen a great demand due to panic-buying and stockpiling of food products. In response to this global outbreak, we summarise the socio-economic effects of COVID-19 on individual aspects of the world economy.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           Central banks globally commit to a ‘Whatever it takes’ approach in an attempt to save the global economy.
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           Europe pledges a €1.7tn rescue package.
          </p>
         </list-item>
         <list-item id="u0020">
          <label>
           •
          </label>
          <p id="p0020">
           The road to economic recovery is predicted to be a long one, with a period of economic inactivity for years to come.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Economy
       </kwd>
       <kwd>
        economic impact
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        Coronavirus
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0025">
      Labelled as a black swan event (
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ) and likened to the economic scene of World War Two (
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ), the outbreak of COVID-19 (the disease caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-COV-2)) has had a detrimental effect on global healthcare systems with a ripple effect on every aspect of human life as we know it. Sohrabi et al. highlighted the extent of the outbreak with the World Health Organization (WHO) declaring the COVID-19 outbreak as a global emergency on 30th January 2020. (
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ) In a response to ‘flatten the curve’ (
      <xref ref-type="bibr" rid="bib4">
       4
      </xref>
      ), governments have enforced border shutdowns, travel restrictions and quarantine (
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ) in countries which constitute the world’s largest economies, sparking fears of an impending economic crisis and recession. (
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ) In an attempt to understand the turmoil effect on the economy, we summarize the effect of COVID-19 on individual aspects of the world economy, focusing on
      <bold>
       primary sectors
      </bold>
      which include industries involved in the extraction of raw materials,
      <bold>
       secondary
      </bold>
      sectors involved in the production of finished products and
      <bold>
       tertiary sectors
      </bold>
      to include all service provision industries. (see
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      )
      <fig id="fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Global impact of COVID-19 on school closures. Figure produced by UNESCO. (
         <xref ref-type="bibr" rid="bib21">
          21
         </xref>
         )
        </p>
       </caption>
       <alt-text id="alttext0010">
        Figure 1
       </alt-text>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Primary Sectors
     </title>
     <sec id="sec2.1">
      <label>
       2.1
      </label>
      <title>
       Agriculture
      </title>
      <p id="p0030">
       The resilience of the agricultural sector has been tested by the COVID-19 outbreak. A global crash in demand from hotels and restaurants has seen prices of agricultural commodities drop by 20%. (
       <xref ref-type="bibr" rid="bib8">
        8
       </xref>
       ) Countries around the world have imposed a number of protective measures to contain the exponentially increasing spread. This includes social distancing, avoiding unnecessary travel, and a ban on congregations. Advice on self-isolation upon contact with suspected carriers of the virus is likely to impact the number of available inspectors and delivery staff critical to ensuring verification and transportation of products. This will have pronounced implications for perishable goods such as meat and vegetables. Furthermore, markets have gone a step further by shutting down floor trading which has impacted the ability of commodity exchange. The Chicago Mercantile Exchange is a recent example. (
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ) ‘Panic buying’ is further complicating shortages beyond supermarket shelves. The American Veterinary Medical Association (AVMA) have expressed concern over low levels of animal pharmaceuticals for several large drug suppliers. (
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       )
      </p>
     </sec>
     <sec id="sec2.2">
      <label>
       2.2
      </label>
      <title>
       Petroleum &amp; Oil
      </title>
      <p id="p0035">
       During a meeting at the Organisation of the Petroleum Exporting Countries (OPEC) in Vienna on March 6th, a refusal by Russia to slash oil production triggered Saudi Arabia to retaliate with extraordinary discounts to buyers and a threat to pump more crude. (
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ) Saudi, regarded as the de facto leader of OPEC, heightened its provision of oil by a quarter more than February – taking production volume to an unprecedented level. This caused the steepest one-day price crash seen in nearly 30 years – On March 23rd, Brent Crude dropped by 24% to $34/barrel (
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ) to stand at $25.70. (
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ) Although a slowdown in the number of COVID-related deaths has caused some stabilisation of oil prices, there is still much uncertainty.
      </p>
      <p id="p0040">
       On the background of a viral outbreak already dampening the demand for oil, this oil-price war is predicted to have grave implications for the global economy. In more ordinary times, cheap oil may have functioned as an advantage for economies. However, savings on petrol are unlikely to be redirected into more spending as populations are instructed to practise social distancing and the working class are uncertain about job security. Furthermore, any increase to consumer activity is likely to be outweighed by damage caused to populations reliant on revenue from other forms of energy such as Shale gas. (
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ) Economic modelling from Imperial College’s Centre for Climate Finance and Investment has suggested ‘Carbon Dividends’. A £50/tonne of CO2 tax could be channeled into UK households in order to stimulate consumer spending whilst keeping oil prices at the same level as February 2020. (
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ) However, this relies on turbulence between Saudi Arabia and Russia thus should not be considered sustainable for the long-term.
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      Secondary Sectors
     </title>
     <sec id="sec3.1">
      <label>
       3.1
      </label>
      <title>
       Manufacturing Industry
      </title>
      <p id="p0045">
       A survey conducted by the British Plastics Federation (BPF) explored how COVID-19 is impacting manufacturing businesses in the United Kingdom (UK). Over 80% of respondents anticipated a decline in turnover over the next 2 quarters, with 98% admitting concern about the negative impact of the pandemic on business operations. (
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ) Importation issues and staffing deficiencies stood out as the key concerns for businesses due to disruption to supply chains and self-isolation policies. Indeed, for many roles within a manufacturing company, ‘working from home’ is not a viable option. As the UK is adopting similar protective measures to the rest of the world, and due to the global overlap of supply chains, we can expect these anxieties to transcend borders. The Chemical Industry is predicted to reduce its global production by 1.2% -- the worst growth for the sector since the 2008 financial crash. (
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       ) Major chemical manufacturing companies such as BASF who were in the process of upscaling production in China have had to delay their activities, contributing to a slowdown in predicted growth. (
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        18
       </xref>
       )
      </p>
     </sec>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Tertiary Sectors
     </title>
     <sec id="sec4.1">
      <label>
       4.1
      </label>
      <title>
       Education
      </title>
      <p id="p0050">
       COVID-19 has also affected all levels of the education system from pre-school to tertiary education. Different countries have had different policies ranging from complete closure in Germany and Italy (
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ) to targeted closure in the United Kingdom for all but workers in key industries (
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ) with over 100 countries imposing nationwide closures of education facilities. UNESCO estimates that close to 900 million learners have been affected by the closure of educational institutions (
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ).
      </p>
      <p id="p0055">
       Whilst the intention of these closures is on a public health basis to prevent both spread of the virus within institutions as well as to prevent carriage to other vulnerable individuals, these closures have had a widespread socioeconomic impact.
      </p>
      <p id="p0060">
       Some of these impacts include on nutrition due to the lack of free school meals provided in many countries to children from low-income families, social isolation, dropout rates with students less likely to return once closures are ended, and an impact on childcare costs for families with younger children. Additionally, there exists a wide disparity amongst populations with higher-income families able to access technology that can ensure education continues digitally as of social isolation. In Dubai, 13,900 people have backed a petition to decrease private school fees by 30% as parents struggle to source these funds amidst recent pay cuts reaching as high as 50%, and high costs of living. Furthermore, parents are being asked to provide schools with confidential information such as bank statements and profit and loss company statements. (
       <xref ref-type="bibr" rid="bib112">
        112
       </xref>
       )
      </p>
      <p id="p0065">
       The impact of long-term school closure is yet to be seen however a study by Chen et al (
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ) of a one week closure of schools in Taiwan during the 2009 H1N1 outbreak found that 27% of families could not go to work as a direct result, 18% lost income with $6433 of wages lost in a sample size of one single school in addition to a significant impact on school staff. A study by the Brookings Institution (
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       ) modelling closures in major US cities and nationwide suggest that there would be a median cost of $142 per student per week. This then leads to an estimate that a four-week closure of New York City would lead to an economic impact of $1.1 billion and that a nationwide closure for 12 weeks would cost 1% of GDP. Furthermore, this study looks at the direct impact of closures on the children of healthcare workers with an estimated 6-19% of healthcare workforce hours lost. An estimate in the UK suggested that protracted closures could cost 3% of UK GDP (
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ). However, Wren-Lewis (
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ) posits a view that this impact will be short-lived as its cause is known and defined and therefore will have a clear endpoint, unlike a normal economic recession.
      </p>
      <p id="p0070">
       Furthermore, the impact continues into the tertiary sector. As well as the impact on undergraduate education, the most significant impact is on the postgraduate research community with research into many non-COVID related topics paused or suspended. In the United Kingdom, the national funding body for health research has paused all non-COVID research in order to allow clinically trained staff who are normally on academic secondments to return to the frontline. (
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ) In the United States, similar action has been taken by the National Institute for Health to shut down all non-critical research in order to free up staff and resources for ‘mission-critical’ research. (
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       ) Outside of the healthcare research setting, many humanities, social science and other research has stopped completely with Harvard University closing all laboratories in the Faculty of Arts and Sciences. (
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       )
      </p>
      <p id="p0075">
       Additionally, concern has been raised about the number of scientific conferences that have been cancelled or postponed. (
       <xref ref-type="bibr" rid="bib29">
        29
       </xref>
       ) These conferences are the key to scientific research in many disciplines, allowing dissemination of research as well as providing networking opportunities for collaboration and job-seeking. Many conferences have moved online, however these ‘virtual conferences’ are often not as amenable to networking and a more informal means of scientific communication.
      </p>
     </sec>
     <sec id="sec4.2">
      <label>
       4.2
      </label>
      <title>
       Finance Industry
      </title>
      <p id="p0080">
       COVID-19 has impacted communities, businesses and organisations globally, inadvertently affecting the financial markets and the global economy. Uncoordinated governmental responses and lockdowns have led to a disruption in the supply and demand chain. Initially, in China, lockdown restrictions meant a grave decrease in product supply by Chinese factories, while quarantine and self-isolation policies decreased consumption, demand and utilisation of products and services. (
       <xref ref-type="bibr" rid="bib30">
        30
       </xref>
       ) As COVID-19 has progressed to affect the rest of the world, China will begin to recover faster than the rest of the countries, strengthening its trade negotiating power against the US. In fact, chinese companies will be in the advantageous position to acquire their western counterparts, which are greatly dependent and will be inevitably affected by the stock market. (
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       )
      </p>
      <p id="p0085">
       In addition to the disruption in the supply chain, the capital market sector has also been affected. In the US, the S&amp;P 500, a stock market index that measures the stock performance of 500 large companies on the US stock exchange, the Dow Jones Industrial Average and the Nasdaq fell dramatically until the US government secured the Coronavirus Aid, Relief, and Economic Security (CARES) Act, with the indexes raising by 7.3% (
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ), 7.73% (
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       ) and 7.33% (
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ) respectively. (
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ) Furthermore,10-year US Treasury bond yields have dropped to 0.67%.(
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ) (
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       ) In the Asian markets, the same pattern followed with China’s Shanghai Composite, Hong Kong’s Hang Seng and South Korea’s KOSPI initially dropping and followed by a rise in stocks after governmental support. Japan’s Nikkei was up 2.01%. (
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ) Europe’s bond yields mostly declined, reaching market stress hit levels faced in the eurozone crisis of 2011-2012. (
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ) Germany’s DAX, the UK’s FTSE 100 and the Euro Stoxx 50 were all down on March 23rd, but rose significantly after the EU’s rescue package was agreed. Gold dropped against the dollar by 0.65%. (
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       )
      </p>
      <p id="p0090">
       The decline in global stock markets has festered a volatile environment with critical liquidity levels. (
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ) To combat these effects, Central banks globally have intervened to ensure liquidity is maintained and mitigate the economic shock, with several leaders embarking on a ‘Whatever it takes’ approach. (
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        41
       </xref>
       ) Professor of Financial Economics, David Miles, from Imperial College London has likened such government spending to the post-Napoleonic, first and second world war eras where public sector liabilities rose greatly. He further explains that bond markets could have difficulties in coping with large scale government bond issuance and that central banks may have to intervene by purchasing these bonds on an unprecedented scale. (
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       )
      </p>
      <sec id="sec4.2.1">
       <title>
        European Response
       </title>
       <p id="p0095">
        Europe has pledged a €1.7tn rescue package in an attempt to dampen the economic effects of COVID-19 on the eurozone with contributions from all member states, the UK, as well as countries in the area which do not for part of the European Union (eg. Switzerland). (
        <xref ref-type="bibr" rid="bib42">
         42
        </xref>
        )
       </p>
       <p id="p0100">
        The European Central Bank (ECB) has announced a €750bn asset-purchase programme in hope of stabilising and strengthening the Euro through the pandemic. Moreover, the European Commision has collated a €25bn investment fund for the cause and has agreed to a more relaxed policy on budget rules to encourage public spending and the support of affected businesses by their corresponding government. (
        <xref ref-type="bibr" rid="bib7">
         7
        </xref>
        )
       </p>
       <p id="p0105">
        In Germany, the state development bank (KfW) is to provide €500bn in loans to aid companies affected by the pandemic, dubbed the ‘biggest post-war aid package’. (
        <xref ref-type="bibr" rid="bib43">
         43
        </xref>
        ) The Kurzarbeitergeld, a subsidised scheme by the German Federal parliament (the Bundenstag), will look to compensate employees who fall ill or are unable to work due to the virus. (
        <xref ref-type="bibr" rid="bib44">
         44
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ) France, Spain and Italy have promised €345bn, €200bn and €25bn respectively, to help support businesses. (
        <xref ref-type="bibr" rid="bib42">
         42
        </xref>
        )
       </p>
      </sec>
      <sec id="sec4.2.2">
       <title>
        UK Response
       </title>
       <p id="p0110">
        In the UK, Chancellor Rishi Sumak announced a £330bn package of emergency loan guarantees to help those in financial difficulty. (
        <xref ref-type="bibr" rid="bib46">
         46
        </xref>
        ,
        <xref ref-type="bibr" rid="bib47">
         47
        </xref>
        ) A further £20bn of fiscal support on top of the £7bn financial support package already issued in the preceding weeks in attempts to save UK businesses. The package of measures includes:
        <list id="ulist0015" list-type="simple">
         <list-item id="u0025">
          <label>
           •
          </label>
          <p id="p0115">
           a Coronavirus Job Retention Scheme
          </p>
         </list-item>
         <list-item id="u0030">
          <label>
           •
          </label>
          <p id="p0120">
           deferring VAT and Income Tax payments
          </p>
         </list-item>
         <list-item id="u0035">
          <label>
           •
          </label>
          <p id="p0125">
           a Statutory Sick Pay relief package for SMEs (Small and Medium sized Enterprises)
          </p>
         </list-item>
         <list-item id="u0040">
          <label>
           •
          </label>
          <p id="p0130">
           a 12-month business rates holiday for all retail, hospitality, leisure and nursery businesses in England
          </p>
         </list-item>
         <list-item id="u0045">
          <label>
           •
          </label>
          <p id="p0135">
           small business grant funding of £10,000 for all business in receipt of small business rate relief or rural rate relief
          </p>
         </list-item>
         <list-item id="u0050">
          <label>
           •
          </label>
          <p id="p0140">
           grant funding of £25,000 for retail, hospitality and leisure businesses with property with a rateable value between £15,000 and £51,000
          </p>
         </list-item>
         <list-item id="u0055">
          <label>
           •
          </label>
          <p id="p0145">
           the Coronavirus Business Interruption Loan Scheme offering loans of up to £5 million for SMEs through the British Business Bank
          </p>
         </list-item>
         <list-item id="u0060">
          <label>
           •
          </label>
          <p id="p0150">
           a new lending facility from the Bank of England to help support liquidity among larger firms, helping them bridge coronavirus disruption to their cash flows through loans
          </p>
         </list-item>
         <list-item id="u0065">
          <label>
           •
          </label>
          <p id="p0155">
           the HMRC Time To Pay Scheme
          </p>
         </list-item>
        </list>
       </p>
       <p id="p0160">
        The Bank of England has cut interest rates to 0.1 pc, an unprecedented response, in an attempt to dampen the effects of COVID-19 (
        <xref ref-type="bibr" rid="bib48">
         48
        </xref>
        ) as well as an attempt to maintain the confidence of unnerved investors. (
        <xref ref-type="bibr" rid="bib15">
         15
        </xref>
        )
       </p>
       <p id="p0165">
        On the 20th March 2020, The Chancellor announced that the government will pay up to 80% of the salary of staff (up to £2,500 per month) who are kept on by their employer. (
        <xref ref-type="bibr" rid="bib49">
         49
        </xref>
        ) There are no calls to deal with those who are self-employed and wouldn’t be covered by this policy with no statutory sick pay available to them. (
        <xref ref-type="bibr" rid="bib50">
         50
        </xref>
        ) (
        <xref ref-type="bibr" rid="bib51">
         51
        </xref>
        )
       </p>
      </sec>
      <sec id="sec4.2.3">
       <title>
        US Response
       </title>
       <p id="p0170">
        The US Federal Reserve (the Fed) has recently decreased interest rates by 0.5% in an attempt to soften the blow of the deadly virus on the US Economy. (
        <xref ref-type="bibr" rid="bib52">
         52
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        ) On March 23rd, the Fed also announced that it would further aid the market by purchasing $125 billion in bonds. It will also offer a $300 billion lending programme for Main Street businesses as well as ensure that Asset Backed Loan facility which was used in 2008-2009 would be restarted. (
        <xref ref-type="bibr" rid="bib34">
         34
        </xref>
        ) The Trump administration has managed to secure on the 27th March (
        <xref ref-type="bibr" rid="bib54">
         54
        </xref>
        ) a $2 trillion ‘virus-aid package’- the CARES Act (
        <xref ref-type="bibr" rid="bib55">
         55
        </xref>
        ), to support the economy through these times. (
        <xref ref-type="bibr" rid="bib56">
         56
        </xref>
        ) This bill is to cover:
        <list id="ulist0020" list-type="simple">
         <list-item id="u0070">
          <label>
           •
          </label>
          <p id="p0175">
           $1,200 to be given to every adult American with an income less than $75,000 or couples less than $150,000.
          </p>
         </list-item>
         <list-item id="u0075">
          <label>
           •
          </label>
          <p id="p0180">
           $500 for every child under the age of 17
          </p>
         </list-item>
         <list-item id="u0080">
          <label>
           •
          </label>
          <p id="p0185">
           Increase unemployment compensation by $600 per week, increase unemployment benefit support by 13 months and extend eligibility to the self-employed and independent contractors
          </p>
         </list-item>
         <list-item id="u0085">
          <label>
           •
          </label>
          <p id="p0190">
           $500bn in loans and loan guarantees to be issued by the US Treasury Department to small and large businesses. Businesses who receive such aid are obligated to keep 90% of their employees until September 30, must pay their loans back within five years and are prohibited to issue dividends for up to a year after the full amount of their loan is repaid.
          </p>
         </list-item>
         <list-item id="u0090">
          <label>
           •
          </label>
          <p id="p0195">
           $377bn to provide small businesses with loans and grants, $10bn for emergency grants and $17bn will also be made available to enable deferral of existing payments.
          </p>
         </list-item>
         <list-item id="u0095">
          <label>
           •
          </label>
          <p id="p0200">
           Student loan payments to be deferred until 30th September without penalty charges
          </p>
         </list-item>
         <list-item id="u0100">
          <label>
           •
          </label>
          <p id="p0205">
           Ban on foreclosures of federally backed mortgages until mid-May
          </p>
         </list-item>
         <list-item id="u0105">
          <label>
           •
          </label>
          <p id="p0210">
           Ban on evictions of tenants in federal housing programmes for four months
          </p>
         </list-item>
         <list-item id="u0110">
          <label>
           •
          </label>
          <p id="p0215">
           $25bn in food assistance
          </p>
         </list-item>
         <list-item id="u0115">
          <label>
           •
          </label>
          <p id="p0220">
           $100bn for healthcare
          </p>
         </list-item>
         <list-item id="u0120">
          <label>
           •
          </label>
          <p id="p0225">
           $45bn to be directed to the Disaster Relief Fund (which includes the supply of protective equipment)
          </p>
         </list-item>
         <list-item id="u0125">
          <label>
           •
          </label>
          <p id="p0230">
           $29bn in grants and $29bn in loans, loan guarantees, excise and fuel tax relief
          </p>
         </list-item>
         <list-item id="u0130">
          <label>
           •
          </label>
          <p id="p0235">
           $17bn towards national security
          </p>
         </list-item>
         <list-item id="u0135">
          <label>
           •
          </label>
          <p id="p0240">
           $14bn to farmers
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="sec4.2.4">
       <title>
        China and Japan Response
       </title>
       <p id="p0245">
        China and Japan took similar action with the People’s Bank of China (PBoC) and the Bank of Japan (BoJ) providing the equivalent of $240bn and $43bn to maintain bank liquidity, respectively. (
        <xref ref-type="bibr" rid="bib52">
         52
        </xref>
        ,
        <xref ref-type="bibr" rid="bib57">
         57
        </xref>
        )
       </p>
       <p id="p0250">
        Leaders from the G20 (Group of 20) richest nations expect recovery from the economic crisis to take the form of a ‘V’ shaped curve, with a sharp and short-lived dip, followed by a rapid recovery and economic growth. Mr Angel Gurría, secretary general of the Organisation for Economic Co-operation and Development (OECD), disagrees with these claims, stating that the road to economic recovery is more likely to resemble a ‘U’ shaped curve, with a prolonged period of economic inactivity for years to come. (
        <xref ref-type="bibr" rid="bib58">
         58
        </xref>
        )
       </p>
      </sec>
     </sec>
     <sec id="sec4.3">
      <label>
       4.3
      </label>
      <title>
       Healthcare and the pharmaceutical industry
      </title>
      <sec id="sec4.3.1">
       <title>
        Healthcare
       </title>
       <p id="p0255">
        The COVID-19 pandemic has caused an unprecedented challenge for healthcare systems worldwide. In particular, the risk to healthcare workers is one of the greatest vulnerabilities of healthcare systems worldwide. Considering most healthcare workers are unable to work remotely, strategies including the early deployment of viral testing for asymptomatic and/or frontline healthcare staff is imperative. (
        <xref ref-type="bibr" rid="bib59">
         59
        </xref>
        ) High healthcare costs, shortages of protective equipment including N95 face masks, and low medical capacity, ICU beds and ventilators have ultimately exposed weaknesses in the delivery of patient care. In the US, there is concern regarding uninsured individuals, who may work in jobs predisposed to an increased risk of viral infection which may lead to significant financial consequences in the event of illness. (
        <xref ref-type="bibr" rid="bib60">
         60
        </xref>
        )
       </p>
      </sec>
      <sec id="sec4.3.2">
       <title>
        Pharmaceutical industry
       </title>
       <p id="p0260">
        Profound changes to the dynamics of healthcare are likely to ensue, leading to massive investment into disease prevention infrastructure, and the accelerated digital transformation of healthcare delivery. In the US, active pharmaceutical ingredients are imported largely from India (18%) and the EU (26%), while China accounts for 13%. China is also the biggest exporter of medical devices to the US, accounting for 39.3%. Production slow-downs and limitations in supply would inadvertently lead to revenue loss. (
        <xref ref-type="bibr" rid="bib61">
         61
        </xref>
        ) In the UK, AstraZeneca have indicated that COVID-19 is likely to affect its 2020 revenue growth.
       </p>
       <p id="p0265">
        Conversely, opportunities for companies engaged in vaccine and drug development have simultaneously emerged, with US-based companies including Johnson &amp; Johnson, Vir Biotechnology, Novavax and NanoViricides having announced collaborative plans to develop a viral vaccine. A Phase 1 clinical trial evaluating an investigational COVID-19 vaccine is currently underway, and will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. (
        <xref ref-type="bibr" rid="bib62">
         62
        </xref>
        )
       </p>
      </sec>
     </sec>
     <sec id="sec4.4">
      <label>
       4.4
      </label>
      <title>
       Hospitality, tourism and aviation
      </title>
      <sec id="sec4.4.1">
       <title>
        Hospitality
       </title>
       <p id="p0270">
        The hospitality and travel industry have perhaps been most hard-hit, with hourly workers facing potential devastating hardships. Marriott International with approximately 174,000 employees is poised to place tens of thousands of workers on furlough. (
        <xref ref-type="bibr" rid="bib63">
         63
        </xref>
        ) Hilton Worldwide has also notified lenders on 5th March 2020 borrowing a precautionary $1.75 billion under a revolving loan to preserve money and to maintain flexibility “in light of uncertainty in the global markets”. (
        <xref ref-type="bibr" rid="bib64">
         64
        </xref>
        )
       </p>
       <p id="p0275">
        Hotel industry revenue per available room in the United States fell 11.6% for the week ending 7th March 2020, whilst in China occupancy rates fell 89% by the end of January 2020. Other United States hotel companies are seeking approximately $150 billion in direct aid for employees due to an unprecedented fall in demand, along with an estimated $1.5 billion loss since mid-February. (
        <xref ref-type="bibr" rid="bib65">
         65
        </xref>
        ) MGM Resorts International have also announced a temporary suspension in operation at its Las Vegas properties, with casino operations closing on 16th March, followed by hotel operations. (
        <xref ref-type="bibr" rid="bib66">
         66
        </xref>
        ) Since 1st March 2020, hotel occupancy in Germany decreased by over 36%. (
        <xref ref-type="bibr" rid="bib67">
         67
        </xref>
        ) Italian cities including Rome have been inadvertently affected with a current occupancy rate of 6%, whilst London remains the most stable with an occupancy rate of approximately 47%. (
        <xref ref-type="bibr" rid="bib67">
         67
        </xref>
        ) Overall, the COVID-19 crises has led to international distortions for the hospitality industry, and significant slumps for the European hotel market.
       </p>
      </sec>
      <sec id="sec4.4.2">
       <title>
        Tourism
       </title>
       <p id="p0280">
        The tourism sector is currently one of the hardest-hit by the outbreak of COVID-19, with impacts on both travel supply and demand. As a direct consequence of COVID-19, The World Travel and Tourism Council has warned that 50 million jobs in the global travel and tourism sector may be at risk. (
        <xref ref-type="bibr" rid="bib68">
         68
        </xref>
        ) In Europe, the European Tourism Manifesto alliance, encompassing over 50 European public and private organisations from the travel and tourism sector, have highlighted the need to implement urgent measures. These include temporary state aid for the tourism and travel sector from national governments, fast and easy access to short- and medium-term loans to overcome liquidity shortages, including funds made available by the EU through the Corona Response Investment Initiative, and fiscal relief. (
        <xref ref-type="bibr" rid="bib69">
         69
        </xref>
        ) The alliance has also called for the launch of the European Unemployment Reinsurance Scheme. (
        <xref ref-type="bibr" rid="bib70">
         70
        </xref>
        )
       </p>
       <p id="p0285">
        Internationally, Vietnam received approximately 1.45 million Chinese visitors in the first quarter of 2019, dropping by 644,000 in January of 2020. It is estimated that Vietnam’s tourist sector will suffer a $5 billion loss should the COVID-19 pandemic extend into the second quarter of 2020.(
        <xref ref-type="bibr" rid="bib71">
         71
        </xref>
        ) Moreover, the Philippines is projecting a 0.3-0.7% slowdown in the country’s full year GDP. (
        <xref ref-type="bibr" rid="bib72">
         72
        </xref>
        ) In the United States, restriction of all non-essential travel, US-Canada border closure, (
        <xref ref-type="bibr" rid="bib73">
         73
        </xref>
        ) and the suspension of visa services (
        <xref ref-type="bibr" rid="bib74">
         74
        </xref>
        ) may accelerate disruption of the American economy. In the UK, many parks are now closing to further enforce social distancing as they have in Italy. (
        <xref ref-type="bibr" rid="bib75">
         75
        </xref>
        )
       </p>
      </sec>
      <sec id="sec4.4.3">
       <title>
        Aviation
       </title>
       <p id="p0290">
        The travel industry is grappling with an unprecedented wave of cancellations and a significant drop in demand amid strict governmental instructions to implement social distancing and the restriction of unnecessary travel. Globally, border closures are on the rise. In the US, all foreign nationals from China, Iran, certain EU countries are barred from entering. (
        <xref ref-type="bibr" rid="bib76">
         76
        </xref>
        ) This ban includes anyone who visited these countries within the 14 days prior to their US trip. The UK Foreign Office has also advised UK nationals against all but essential international travel. (
        <xref ref-type="bibr" rid="bib77">
         77
        </xref>
        ) In Europe, the president of the EU commission has proposed all non-essential travel from outside the EU be suspended for 30 days. Travel suspensions have similarly been implemented across Asia and Africa. (
        <xref ref-type="bibr" rid="bib78">
         78
        </xref>
        )
       </p>
       <p id="p0295">
        In light of these events, Malaysia Airport reported a 30% decline in international passenger traffic for February. (
        <xref ref-type="bibr" rid="bib79">
         79
        </xref>
        ) More recently, Airlines for America sought a government bailout encompassing $25 billion in grants, $25 billion in loans, and significant tax relief to ensure survival. (
        <xref ref-type="bibr" rid="bib80">
         80
        </xref>
        ) UK airlines have also called for an immediate £7.5 billion emergency bailout to prevent a widespread shutdown. (
        <xref ref-type="bibr" rid="bib81">
         81
        </xref>
        ) Ministers in the Netherlands have also reported implementing strategies to ensure the continued operation of Air France-KLM and Amsterdam’s Schiphol airport, whilst the Italian Government have been said to be close to taking full control of ailing airline Alitalia.
       </p>
      </sec>
     </sec>
     <sec id="sec4.5">
      <label>
       4.5
      </label>
      <title>
       Real estate and housing sector
      </title>
      <p id="p0300">
       The real estate industry is facing great uncertainty due to COVID-19. At an individual level social distancing precautions have reduced house views, a key part of the selling process, and both buyers and sellers are having to reconsider their plans. Increasingly, sellers are looking for reassurance regarding the health of potential buyers coming to view properties. (
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ) Some brokers are offering house tours via Skype and FaceTime to minimise the risk of infection propagation. Brokers around the United States are also asking potential buyers to preregister for viewings in order to gauge their level of interest and likelihood of purchase. (
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       )
      </p>
      <p id="p0305">
       Additionally, thousands of workers around the world have been made redundant or have been placed on temporary, unpaid leave of absence. Inevitably this will have a significant impact on individuals’ abilities to pay rent, mortgages and various household expenditures. To tackle this, part of the £350bn lifeline the United Kingdom (UK) government has released will be used to allow mortgage lenders to offer a three-month mortgage holiday to those in financial difficulty. (
       <xref ref-type="bibr" rid="bib47">
        47
       </xref>
       ) The government has also recommended that buyers and lenders delay negotiations during the lockdown, bringing transactions to a halt. (
       <xref ref-type="bibr" rid="bib84">
        84
       </xref>
       ) Many are worried that we will face another financial crisis, similar to that of 2008 that will impact confidence in real estate. Banks within the UK have begun to take precautions; high street lenders require up to 40% deposits or equity for a new mortgage to be approved. It is however too early to speculate on the impact of COVID-19; as of yet, the infection has not had a significant impact on the housing market. (
       <xref ref-type="bibr" rid="bib86">
        86
       </xref>
       )
      </p>
     </sec>
     <sec id="sec4.6">
      <label>
       4.6
      </label>
      <title>
       Sports industry
      </title>
      <p id="p0310">
       COVID-19 is having a significant impact on sporting schedules as some of the world’s largest sporting events come to view in 2020. Football’s much anticipated Euro 2020 tournament has been postponed for 12 months while play-offs have been postponed till June 2020 at the earliest. (
       <xref ref-type="bibr" rid="bib87">
        87
       </xref>
       ) The international Olympic committee was committed to staging the Tokyo 2020 Olympics this summer without delay. However, they have now made the decision to postpone the games to 2021, a decision that is supported by athletes ans their respective nations. (
       <xref ref-type="bibr" rid="bib87">
        87
       </xref>
       ,
       <xref ref-type="bibr" rid="bib88">
        88
       </xref>
       ,
       <xref ref-type="bibr" rid="bib89">
        89
       </xref>
       ) In a similar vein, the Australian Formula one Grand Prix has been postponed with Bahrain and Vietnam opting to cancel their fixture until further notice. (
       <xref ref-type="bibr" rid="bib87">
        87
       </xref>
       ) These are but a few examples; golf, tennis, athletics, basketball, rugby, cycling, boxing, snooker and ice-skating fixtures have all faced cancellations and delays in an attempt to curb the spread of disease. Inevitably this will have a significant financial burden, the gravity of which has yet to come to light. (
       <xref ref-type="bibr" rid="bib87">
        87
       </xref>
       )
      </p>
     </sec>
     <sec id="sec4.7">
      <label>
       4.7
      </label>
      <title>
       Information Technology, Media, Research &amp; Development
      </title>
      <p id="p0315">
       With the WHO raising COVD-19’s status to a pandemic, 35 companies and academic institutions are racing to develop an effective vaccine. Four potential vaccines are currently being tested on animals with the biotech firm Moderna preparing to enter human trials imminently. (
       <xref ref-type="bibr" rid="bib90">
        90
       </xref>
       ) The Coalition for Epidemic Preparedness Innovations (CEPI), is leading various efforts to finance and coordinate Covid-19 vaccine development. (
       <xref ref-type="bibr" rid="bib90">
        90
       </xref>
       ) They have announced a $4.4m partnership funding with Novavax and University of Oxford to develop a viable solution. (
       <xref ref-type="bibr" rid="bib90">
        90
       </xref>
       ) The Gates Foundation, Wellcome and Mastercard have also committed $125 million to find new treatments for COVID-19. (
       <xref ref-type="bibr" rid="bib91">
        91
       </xref>
       )
      </p>
      <p id="p0320">
       Social distancing precautions are paramount to the containment effort. Additionally, COVID-19 has left several hospitals in turmoil, having reached maximal capacity. As a result, various countries are turning towards technological solutions, to care for patients and at the same time, minimise the risk of person to person transmission. In various cities across China, tele-response bots powered by fifth-generation wireless networks are being utilised that allow health care staff to communicate with patients, monitor their health and deliver medical supplies. (
       <xref ref-type="bibr" rid="bib92">
        92
       </xref>
       ) Drones that deliver medication and work-from-home apps are also being adopted. Automation of services has been a major goal for China. COVID-19 has helped to accelerate uptake and has taken them one step closer to this goal. (
       <xref ref-type="bibr" rid="bib92">
        92
       </xref>
       )
      </p>
      <p id="p0325">
       The demand for respiratory ventilators has skyrocketed due to the outbreak of COVID-19. However, it is clear that the current supply across the United States and Europe does not meet demand. It is estimated that the USA has 160,000 ventilators. (
       <xref ref-type="bibr" rid="bib93">
        93
       </xref>
       ) This is 580,000 short of what would be required in a severe pandemic to a study conducted by the Centre for Health Security at Johns Hopkins. (
       <xref ref-type="bibr" rid="bib93">
        93
       </xref>
       ) Governments around the world are attempting to buy ventilators. In the United Kingdom, the prime minister has asked companies such as Rolls Royce and Dyson to divert their manufacturing power to medical supplies. (
       <xref ref-type="bibr" rid="bib93">
        93
       </xref>
       ) However, industry leaders have stated that this is easier said than done as many of these companies do not produce medical equipment such as ventilators. In addition to this, production of ventilators requires strict regulation and testing to ensure their safety which can be a lengthy process. (
       <xref ref-type="bibr" rid="bib93">
        93
       </xref>
       )
      </p>
     </sec>
     <sec id="sec4.8">
      <label>
       4.8
      </label>
      <title>
       Food Sector
      </title>
      <p id="p0330">
       The food sector, including food distribution and retailing, has been put under strain as a result of people panic-buying and stockpiling on food. (
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ) This has led to increased concerns about shortages of food products such as long-life milk, pasta, rice and tinned vegetables. Panic-buying has resulted in an increase of £1bn worth of food in the UK homes over the last week. (
       <xref ref-type="bibr" rid="bib95">
        95
       </xref>
       ) This high demand on food products has also affected online food delivery. Companies are struggling with excessive bookings, while deliveries arrive late or not at all. (
       <xref ref-type="bibr" rid="bib96">
        96
       </xref>
       ) Moreover, food banks have also been affected by panic-buying and food stockpiling as donations have reduced. Concerns about food running out mean that vulnerable populations who can’t afford to stockpile, will be unable to find food. The result of which is newer restrictions being made to provide food only to those in greatest need. (
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="bib98">
        98
       </xref>
       )
      </p>
      <p id="p0335">
       In response to these concerns, the UK government has made efforts to provide certain populations with food parcels and free meals to collect and take home. These populations include high-risk vulnerable individuals such as the elderly who have no support network, and school children of low-income families. (
       <xref ref-type="bibr" rid="bib99">
        99
       </xref>
       ,
       <xref ref-type="bibr" rid="bib100">
        100
       </xref>
       ,
       <xref ref-type="bibr" rid="bib101">
        101
       </xref>
       )
      </p>
      <p id="p0340">
       The UK government has also reduced restrictions on delivery hours for retailers in order to allow stores to restock with basic food products. Furthermore, the British Retail Consortium (BRC) has reassured the public that despite low inventory of certain food products in local stores, there are no such shortages of food. Similar statements have been made by the US Food and Drug Administration (FDA). (
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="bib103">
        103
       </xref>
       )
      </p>
      <p id="p0345">
       In addition to, and despite reassurance by the government, stores have nonetheless made drastic changes by restricting the amount of each product that people can buy, providing more than 30,000 new jobs to meet the high pressure of restocking shelves, and setting special shopping hours for the elderly, vulnerable populations and NHS stuff. A further change being implemented includes a decrease in the range of products being made by manufacturers, with the aim of focusing on products that are in greater need. (
       <xref ref-type="bibr" rid="bib104">
        104
       </xref>
       )
      </p>
      <p id="p0350">
       Independent supermarkets have also been affected by the high demand on food products. Measures implemented by these local stores include free delivery of food products to customers to avoid panic-buying, putting restrictions on the number of customers allowed in at any given time to avoid overcrowding, and expanding on the number of suppliers whom they buy their products from to avoid food shortage. (
       <xref ref-type="bibr" rid="bib105">
        105
       </xref>
       )
      </p>
      <p id="p0355">
       Although supermarkets have seen a huge demand on food products, other stores such as restaurants and cafes have been forced to close. As a result, many of these food stores have been put at risk of permanent closure and many of their employees have lost their jobs. This impact of COVID-19 on the food industry has forced Leon, a UK fast-food chain, to change its business model. 65 of its restaurants were said to turn into shops that sell refrigerated ready meal-type plastic pouches. (
       <xref ref-type="bibr" rid="bib106">
        106
       </xref>
       )
      </p>
     </sec>
    </sec>
    <sec id="sec5">
     <label>
      5
     </label>
     <title>
      Social Impact
     </title>
     <sec id="sec5.1">
      <label>
       5.1
      </label>
      <title>
       Family dynamics: Domestic violence &amp; Home Video-gaming
      </title>
      <p id="p0360">
       Lockdown and social distancing measures to prevent spread of the Coronavirus have heightened fears of increasing domestic violence, which includes physical, emotional and sexual abuse. (
       <xref ref-type="bibr" rid="bib107">
        107
       </xref>
       )
      </p>
      <p id="p0365">
       Refuge, one of the UK’s domestic abuse charities, has made reports of a 25% increase in calls made to its helpline since lockdown measures were announced. (
       <xref ref-type="bibr" rid="bib108">
        108
       </xref>
       )
      </p>
      <p id="p0370">
       The concentrated time spent in lockdown means that vulnerable people are more exposed to abuse and it is more difficult for them to seek help. In response to the increasing concerns, the UK government has published guidelines on how to recognise domestic abuse, how to report and where with a list of all the services available. (
       <xref ref-type="bibr" rid="bib109">
        109
       </xref>
       )
      </p>
      <p id="p0375">
       In addition, a significant impact of the coronavirus pandemic has been seen within the video-gaming industry. With many individuals self-isolating and/or remaining home under strict governmental regulations, online gaming has seen the emergence of record numbers of players, which has facilitated a boost in revenue for many companies. (
       <xref ref-type="bibr" rid="bib110">
        110
       </xref>
       ) Conversely, negative impacts include cancellation of the annual and major trade event E3 2020, alongside the rescheduling and/or cancellation of popular esport leagues. (
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       )
      </p>
     </sec>
    </sec>
    <sec id="sec6">
     <label>
      6
     </label>
     <title>
      Conclusion
     </title>
     <p id="p0380">
      With fears of a new recession and financial collapse, times like these call for resilient and strong leadership in healthcare, business, government and wider society. Immediate relief measures need to be implemented and adjusted for those that may fall through the cracks. Medium and longer term planning is needed for how the economy is rebalanced and re-energised following this crisis. A broad socioeconomic development plan including sector by sector plans and an ecosystem that encourages entrepreneurship so that those with robust and sustainable business models can be allowed to flourish. It is prudent that governments and financial institutions constantly re-assess and re-evaluate the state of play and ensure that the ‘
      <italic>
       whatever it takes’
      </italic>
      promise is truly delivered.
     </p>
    </sec>
    <sec id="sec7">
     <title>
      Ethical Approval
     </title>
     <p id="p0385">
      No ethical approval required.
     </p>
    </sec>
    <sec id="sec8">
     <title>
      Sources of funding
     </title>
     <p id="p0390">
      No funding received.
     </p>
    </sec>
    <sec id="sec9">
     <title>
      Author contribution
     </title>
     <p id="p0395">
      Maria Nicola, Catrin Sohrabi, Ahmed Kerwan, Riaz Agha: Conceptualization, Data curation, Resources, Writing original draft, Editing drafts, Approval of final article. Zaid Alsafi, Ahmed Al-Jabir, Christos Iosifidis, Maliha Agha: Conceptualization, Data curation, Resources, Writing original draft, Approval of final article.
     </p>
    </sec>
    <sec id="sec10">
     <title>
      Unique Identifying Number (UIN)
     </title>
     <p id="p0400">
      <list id="olist0010" list-type="simple">
       <list-item id="o0010">
        <label>
         1.
        </label>
        <p id="p0405">
         Name of the registry: Not Relevant
        </p>
       </list-item>
       <list-item id="o0015">
        <label>
         2.
        </label>
        <p id="p0410">
         Unique Identifying number or registration ID: Not Relevant
        </p>
       </list-item>
       <list-item id="o0020">
        <label>
         3.
        </label>
        <p id="p0415">
         Hyperlink to your specific registration (must be publicly accessible and will be checked):
        </p>
       </list-item>
      </list>
     </p>
     <p id="p0420">
      Not Relevant.
     </p>
    </sec>
    <sec id="sec11">
     <title>
      Guarantor
     </title>
     <p id="p0425">
      Maria Nicola – Corresponding Author:
      <ext-link ext-link-type="uri" id="intref0010" xlink:href="mailto:maria_n02@hotmail.com">
       maria_n02@hotmail.com
      </ext-link>
      .
     </p>
     <p id="p0430">
      Riaz Agha – Senior Author
      <ext-link ext-link-type="uri" id="intref0015" xlink:href="mailto:mail@riazagha.com">
       mail@riazagha.com
      </ext-link>
      .
     </p>
    </sec>
    <sec id="sec12">
     <title>
      Provenance and peer review
     </title>
     <p id="p0435">
      Not commissioned, externally peer-reviewed.
     </p>
    </sec>
    <sec id="sec13">
     <title>
      Data statement
     </title>
     <p id="p0440">
      The data in this review is not sensitive in nature and is accessible in the public domain. The data is therefore available and not of a confidential nature.
     </p>
    </sec>
    <sec id="sec14">
     <title>
      Uncited References
     </title>
     <p id="p0445">
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      .
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of Competing Interest
     </title>
     <p id="p0450">
      No conflicts of interest.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <mixed-citation id="sref1" publication-type="other">
        Resilient leadership responding to COVID-19 | Deloitte Insights [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www2.deloitte.com/global/en/insights/economy/covid-19/heart-of-resilient-leadership-responding-to-covid-19.html">
         https://www2.deloitte.com/global/en/insights/economy/covid-19/heart-of-resilient-leadership-responding-to-covid-19.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <mixed-citation id="sref2" publication-type="other">
        Reuters. ECB asset purchase programme boosts Euro. The Guardian [Internet]. 2020 Mar 19 [cited 2020 Mar 20]; Available from:
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.theguardian.com/world/2020/mar/19/ecb-asset-purchase-programme-boosts-euro">
         https://www.theguardian.com/world/2020/mar/19/ecb-asset-purchase-programme-boosts-euro
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohrabi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alsafi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           O’Neill
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kerwan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Jabir
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)
        </article-title>
        <source>
         Int J Surg
        </source>
        <volume>
         76
        </volume>
        <year>
         2020 Apr
        </year>
        <fpage>
         71
        </fpage>
        <lpage>
         76
        </lpage>
        <pub-id pub-id-type="pmid">
         32112977
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <mixed-citation id="sref4" publication-type="other">
        Loeb AB Avi. Flattening the COVID-19 Curves [Internet]. Scientific American Blog Network. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="https://blogs.scientificamerican.com/observations/flattening-the-covid-19-curves/">
         https://blogs.scientificamerican.com/observations/flattening-the-covid-19-curves/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <mixed-citation id="sref5" publication-type="other">
        Coronavirus: Travel restrictions, border shutdowns by country | Coronavirus pandemic News | Al Jazeera [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.aljazeera.com/news/2020/03/coronavirus-travel-restrictions-border-shutdowns-country-200318091505922.html">
         https://www.aljazeera.com/news/2020/03/coronavirus-travel-restrictions-border-shutdowns-country-200318091505922.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <mixed-citation id="sref6" publication-type="other">
        Guidance on social distancing for everyone in the UK [Internet]. GOV.UK. [cited 2020 Mar 22]. Available from:
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults">
         https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <mixed-citation id="sref7" publication-type="other">
        Buck T, Arnold M, Chazan G, Cookson C. Coronavirus declared a pandemic as fears of economic crisis mount [Internet]. 2020 [cited 2020 Mar 19]. Available from:
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.ft.com/content/d72f1e54-6396-11ea-b3f3-fe4680ea68b5">
         https://www.ft.com/content/d72f1e54-6396-11ea-b3f3-fe4680ea68b5
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <mixed-citation id="sref8" publication-type="other">
        Prices of agricultural commodities drop 20% post COVID-19 outbreak - Rediff Realtime News [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://realtime.rediff.com/news/india/Prices-of-agricultural-commodities-drop-20-post-COVID19-outbreak/955078599584b749?src=interim_alsoreadimage">
         https://realtime.rediff.com/news/india/Prices-of-agricultural-commodities-drop-20-post-COVID19-outbreak/955078599584b749?src=interim_alsoreadimage
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <mixed-citation id="sref9" publication-type="other">
        CME closing trading floors indefinitely amid coronavirus concerns [Internet]. Crain’s Chicago Business. 2020 [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0055" xlink:href="https://www.chicagobusiness.com/finance-banking/cme-closing-trading-floors-indefinitely-amid-coronavirus-concerns">
         https://www.chicagobusiness.com/finance-banking/cme-closing-trading-floors-indefinitely-amid-coronavirus-concerns
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <mixed-citation id="sref10" publication-type="other">
        COVID-19 [Internet]. American Veterinary Medical Association. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="https://www.avma.org/resources-tools/animal-health-and-welfare/covid-19">
         https://www.avma.org/resources-tools/animal-health-and-welfare/covid-19
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <mixed-citation id="sref11" publication-type="other">
        OPEC’s pact with Russia falls apart, sending oil into tailspin. Reuters [Internet]. 2020 Mar 6 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://www.reuters.com/article/us-opec-meeting-idUSKBN20T0Y2">
         https://www.reuters.com/article/us-opec-meeting-idUSKBN20T0Y2
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <mixed-citation id="sref12" publication-type="other">
        Oil Prices, Stocks Plunge After Saudi Arabia Stuns World With Massive Discounts [Internet]. NPR.org. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="https://www.npr.org/2020/03/08/813439501/saudi-arabia-stuns-world-with-massive-discount-in-oil-sold-to-asia-europe-and-u-">
         https://www.npr.org/2020/03/08/813439501/saudi-arabia-stuns-world-with-massive-discount-in-oil-sold-to-asia-europe-and-u-
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <mixed-citation id="sref13" publication-type="other">
        GmbH finanzen net. ‘There is no escape’: Stocks, oil, and bitcoin plunge as US lawmakers fight over coronavirus rescue package | Markets Insider [Internet]. markets.businessinsider.com. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0075" xlink:href="https://markets.businessinsider.com/news/stocks/no-escape-stocks-oil-bitcoin-plunge-senate-argues-coronavirus-bill-2020-3-1029021850">
         https://markets.businessinsider.com/news/stocks/no-escape-stocks-oil-bitcoin-plunge-senate-argues-coronavirus-bill-2020-3-1029021850
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <mixed-citation id="sref14" publication-type="other">
        Breakeven Oil Prices Underscore Shale’s Impact on the Market [Internet]. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0080" xlink:href="https://www.dallasfed.org:443/research/economics/2019/0521">
         https://www.dallasfed.org:443/research/economics/2019/0521
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <mixed-citation id="sref15" publication-type="other">
        The economic impact of coronavirus: analysis from Imperial experts | Imperial News | Imperial College London [Internet]. Imperial News. [cited 2020 Apr 6]. Available from:
        <ext-link ext-link-type="uri" id="intref0085" xlink:href="https://www.imperial.ac.uk/news/196514/the-economic-impact-coronavirus-analysis-from/">
         https://www.imperial.ac.uk/news/196514/the-economic-impact-coronavirus-analysis-from/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <mixed-citation id="sref16" publication-type="other">
        Plastics Trade Body Publishes First Study of Coronavirus Impact on UK Manufacturing [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0090" xlink:href="https://www.bpf.co.uk/article/plastics-trade-body-publishes-first-study-of-coronavirus-impact-1602.aspx">
         https://www.bpf.co.uk/article/plastics-trade-body-publishes-first-study-of-coronavirus-impact-1602.aspx
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <mixed-citation id="sref17" publication-type="other">
        COVID-19 is Coming for the Chemical Industry in 2020, BASF Frets | IndustryWeek [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0095" xlink:href="https://www.industryweek.com/supply-chain/planning-forecasting/article/21125045/covid19-is-coming-for-the-chemical-industry-in-2020-basf-frets">
         https://www.industryweek.com/supply-chain/planning-forecasting/article/21125045/covid19-is-coming-for-the-chemical-industry-in-2020-basf-frets
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <mixed-citation id="sref18" publication-type="other">
        Knieps S. Will COVID-19 turn Germany’s export-oriented economy into a weakness? [Internet].
        <ext-link ext-link-type="uri" id="intref0100" xlink:href="http://www.euractiv.com">
         www.euractiv.com
        </ext-link>
        . 2020 [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0105" xlink:href="https://www.euractiv.com/section/economy-jobs/news/will-covid-19-turn-germanys-export-oriented-economy-into-a-weakness/">
         https://www.euractiv.com/section/economy-jobs/news/will-covid-19-turn-germanys-export-oriented-economy-into-a-weakness/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <mixed-citation id="sref19" publication-type="other">
        Unterricht an bayerischen Schulen wird eingestellt [Internet]. Bayerisches Staatsministerium für Unterricht und Kultus. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0110" xlink:href="https://www.km.bayern.de/allgemein/meldung/6901/unterricht-an-bayerischen-schulen-wird-eingestellt.html">
         https://www.km.bayern.de/allgemein/meldung/6901/unterricht-an-bayerischen-schulen-wird-eingestellt.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <mixed-citation id="sref20" publication-type="other">
        Guidance for schools, childcare providers, colleges and local authorities in England on maintaining educational provision [Internet]. GOV.UK. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0115" xlink:href="https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision">
         https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <mixed-citation id="sref21" publication-type="other">
        <ext-link ext-link-type="uri" id="intref0120" xlink:href="https://plus.google.com/+UNESCO.%20COVID-19">
         https://plus.google.com/+UNESCO. COVID-19
        </ext-link>
        Educational Disruption and Response [Internet]. UNESCO. 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0125" xlink:href="https://en.unesco.org/themes/education-emergencies/coronavirus-school-closures">
         https://en.unesco.org/themes/education-emergencies/coronavirus-school-closures
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <mixed-citation id="sref22" publication-type="other">
        Social and economic impact of school closure resulting from pandemic influenza A/H1N1 - Journal of Infection [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0130" xlink:href="https://www.journalofinfection.com/article/S0163-4453(11)00008-9/fulltext">
         https://www.journalofinfection.com/article/S0163-4453(11)00008-9/fulltext
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <mixed-citation id="sref23" publication-type="other">
        0930_school_closure_presentation.pdf [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0135" xlink:href="https://www.brookings.edu/wp-content/uploads/2016/06/0930_school_closure_presentation.pdf">
         https://www.brookings.edu/wp-content/uploads/2016/06/0930_school_closure_presentation.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keogh‐Brown
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Wren‐Lewis
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Beutels
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The possible macroeconomic impact on the UK of an influenza pandemic
        </article-title>
        <source>
         Health Econ
        </source>
        <volume>
         19
        </volume>
        <issue>
         11
        </issue>
        <year>
         2010
        </year>
        <fpage>
         1345
        </fpage>
        <lpage>
         1360
        </lpage>
        <pub-id pub-id-type="pmid">
         19816886
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <mixed-citation id="sref25" publication-type="other">
        Economics in the Time of COVID-19 | VOX, CEPR Policy Portal [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0140" xlink:href="https://voxeu.org/content/economics-time-covid-19">
         https://voxeu.org/content/economics-time-covid-19
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <mixed-citation id="sref26" publication-type="other">
        DHSC issues guidance on the impact of COVID-19 on research funded or supported by NIHR [Internet]. [cited 2020 Mar 21]. Available from:
        <ext-link ext-link-type="uri" id="intref0145" xlink:href="https://www.nihr.ac.uk/news/dhsc-issues-guidance-on-the-impact-on-covid-19-on-research-funded-or-supported-by-nihr/24469">
         https://www.nihr.ac.uk/news/dhsc-issues-guidance-on-the-impact-on-covid-19-on-research-funded-or-supported-by-nihr/24469
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <mixed-citation id="sref27" publication-type="other">
        NIH shifts non-mission-critical laboratory operations to minimal maintenance phase [Internet]. National Institutes of Health (NIH). 2020 [cited 2020 Mar 21]. Available from:
        <ext-link ext-link-type="uri" id="intref0150" xlink:href="https://www.nih.gov/news-events/news-releases/nih-shifts-non-mission-critical-laboratory-operations-minimal-maintenance-phase">
         https://www.nih.gov/news-events/news-releases/nih-shifts-non-mission-critical-laboratory-operations-minimal-maintenance-phase
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <mixed-citation id="sref28" publication-type="other">
        Coronavirus (COVID-19) [Internet]. Harvard University. [cited 2020 Mar 21]. Available from:
        <ext-link ext-link-type="uri" id="intref0155" xlink:href="https://www.harvard.edu/coronavirus">
         https://www.harvard.edu/coronavirus
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <mixed-citation id="sref29" publication-type="other">
        Impey C. Coronavirus: Social distancing is delaying vital scientific research [Internet]. The Conversation. [cited 2020 Mar 21]. Available from:
        <ext-link ext-link-type="uri" id="intref0160" xlink:href="http://theconversation.com/coronavirus-social-distancing-is-delaying-vital-scientific-research-133689">
         http://theconversation.com/coronavirus-social-distancing-is-delaying-vital-scientific-research-133689
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yap
          </surname>
          <given-names>
           C.-W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         China’s Factories Struggle to Resume Operations After Virus Shutdown
        </article-title>
        <comment>
         [Internet]
        </comment>
        <source>
         Wall Street Journal
        </source>
        <year>
         2020 Feb 8
        </year>
        <comment>
         [cited 2020 Mar 20]; Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0165" xlink:href="https://www.wsj.com/articles/chinas-factories-struggle-to-resume-operations-after-virus-shutdown-11581157800">
         https://www.wsj.com/articles/chinas-factories-struggle-to-resume-operations-after-virus-shutdown-11581157800
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <mixed-citation id="sref31" publication-type="other">
        SPX | S&amp;P 500 Index | MarketWatch [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0170" xlink:href="https://www.marketwatch.com/investing/index/spx">
         https://www.marketwatch.com/investing/index/spx
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <mixed-citation id="sref32" publication-type="other">
        DJIA | Dow Jones Industrial Average | MarketWatch [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0175" xlink:href="https://www.marketwatch.com/investing/index/djia">
         https://www.marketwatch.com/investing/index/djia
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <mixed-citation id="sref33" publication-type="other">
        COMP | NASDAQ Composite Index | MarketWatch [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0180" xlink:href="https://www.marketwatch.com/investing/index/comp">
         https://www.marketwatch.com/investing/index/comp
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <mixed-citation id="sref34" publication-type="other">
        Daily IB. Dow Jones Today, Stocks Drop: Fed Stimulus; New York, California Lockdown; NYSE Floor Closes [Internet]. Investor’s Business Daily. 2020 [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0185" xlink:href="https://www.investors.com/market-trend/stock-market-today/dow-jones-today-futures-slide-fed-stimulus-impasse-new-york-california-lockdown-nyse-floor-closes/">
         https://www.investors.com/market-trend/stock-market-today/dow-jones-today-futures-slide-fed-stimulus-impasse-new-york-california-lockdown-nyse-floor-closes/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <mixed-citation id="sref35" publication-type="other">
        10 Year Treasury Rate [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0190" xlink:href="https://ycharts.com/indicators/10_year_treasury_rate">
         https://ycharts.com/indicators/10_year_treasury_rate
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <mixed-citation id="sref36" publication-type="other">
        Smith YL Elliot. 10-year yield dives below 0.7% after Fed announces unlimited asset purchases [Internet]. CNBC. 2020 [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0195" xlink:href="https://www.cnbc.com/2020/03/23/treasury-yields-fall-as-coronavirus-cases-rise-relief-bill-stalls.html">
         https://www.cnbc.com/2020/03/23/treasury-yields-fall-as-coronavirus-cases-rise-relief-bill-stalls.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <mixed-citation id="sref37" publication-type="other">
        ˆN225 18,950.18 373.88 2.01% : Nikkei 225 - Yahoo Finance [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0200" xlink:href="https://finance.yahoo.com/quote/%5EN225/?guccounter=1">
         https://finance.yahoo.com/quote/%5EN225/?guccounter=1
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <mixed-citation id="sref38" publication-type="other">
        Stocks Sink 12% Amid COVID-19 Pandemic | Time [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0205" xlink:href="https://time.com/5803847/coronavirus-stocks-fall/">
         https://time.com/5803847/coronavirus-stocks-fall/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <mixed-citation id="sref39" publication-type="other">
        XAU/USD (Gold/USD Dollar) [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0210" xlink:href="https://www.fxstreet.com/rates-charts/xauusd">
         https://www.fxstreet.com/rates-charts/xauusd
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <mixed-citation id="sref40" publication-type="other">
        The economic impact of COVID-19 | Deloitte Insights [Internet]. [cited 2020 Mar 19]. Available from:
        <ext-link ext-link-type="uri" id="intref0215" xlink:href="https://www2.deloitte.com/global/en/insights/economy/covid-19/economic-impact-covid-19.html">
         https://www2.deloitte.com/global/en/insights/economy/covid-19/economic-impact-covid-19.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <mixed-citation id="sref41" publication-type="other">
        Mitigating the COVID Economic Crisis: Act Fast and Do Whatever It Takes | VOX, CEPR Policy Portal [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0220" xlink:href="https://voxeu.org/content/mitigating-covid-economic-crisis-act-fast-and-do-whatever-it-takes">
         https://voxeu.org/content/mitigating-covid-economic-crisis-act-fast-and-do-whatever-it-takes
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <mixed-citation id="sref42" publication-type="other">
        Europe’s economic rescue packages worth combined €1.7tn | World news | The Guardian [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0225" xlink:href="https://www.theguardian.com/world/2020/mar/19/europes-economic-rescue-packages-worth-combined-17tn">
         https://www.theguardian.com/world/2020/mar/19/europes-economic-rescue-packages-worth-combined-17tn
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <mixed-citation id="sref43" publication-type="other">
        Germany unleashes biggest post-war aid package against virus [Internet]. CNA. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0230" xlink:href="https://www.channelnewsasia.com/news/business/germany-unleashes-biggest-post-war-aid-package-coronavirus-12536540">
         https://www.channelnewsasia.com/news/business/germany-unleashes-biggest-post-war-aid-package-coronavirus-12536540
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <mixed-citation id="sref44" publication-type="other">
        COVID-19 Update: Germany to Give Easier Access to State-Funded Short-Time Working Allowance | Orrick - Global Employment Law Group - JDSupra [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0235" xlink:href="https://www.jdsupra.com/legalnews/covid-19-update-germany-to-give-easier-36702/">
         https://www.jdsupra.com/legalnews/covid-19-update-germany-to-give-easier-36702/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <mixed-citation id="sref45" publication-type="other">
        Kurzarbeitergeld: Übersicht - Bundesagentur für Arbeit [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0240" xlink:href="https://www.arbeitsagentur.de/unternehmen/finanziell/kurzarbeitergeld-uebersicht-kurzarbeitergeldformen">
         https://www.arbeitsagentur.de/unternehmen/finanziell/kurzarbeitergeld-uebersicht-kurzarbeitergeldformen
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <mixed-citation id="sref46" publication-type="other">
        Support for those affected by COVID-19 [Internet]. GOV.UK. [cited 2020 Mar 19]. Available from:
        <ext-link ext-link-type="uri" id="intref0245" xlink:href="https://www.gov.uk/government/publications/support-for-those-affected-by-covid-19/support-for-those-affected-by-covid-19">
         https://www.gov.uk/government/publications/support-for-those-affected-by-covid-19/support-for-those-affected-by-covid-19
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <mixed-citation id="sref47" publication-type="other">
        Chancellor unveils £350bn lifeline for economy. BBC News [Internet]. 2020 Mar 17 [cited 2020 Mar 20]; Available from:
        <ext-link ext-link-type="uri" id="intref0250" xlink:href="https://www.bbc.com/news/business-51935467">
         https://www.bbc.com/news/business-51935467
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <mixed-citation id="sref48" publication-type="other">
        Harding L, Ashworth L. Markets climb higher after Bank of England goes ‘all in’ with further interest rate cut – live updates. The Telegraph [Internet]. 2020 Mar 19 [cited 2020 Mar 19]; Available from:
        <ext-link ext-link-type="uri" id="intref0255" xlink:href="https://www.telegraph.co.uk/business/2020/03/19/markets-live-latest-news-pound-euro-ftse-100/">
         https://www.telegraph.co.uk/business/2020/03/19/markets-live-latest-news-pound-euro-ftse-100/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <mixed-citation id="sref49" publication-type="other">
        UK to pay wages for workers facing job losses. BBC News [Internet]. 2020 Mar 20 [cited 2020 Mar 22]; Available from:
        <ext-link ext-link-type="uri" id="intref0260" xlink:href="https://www.bbc.com/news/business-51982005">
         https://www.bbc.com/news/business-51982005
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <mixed-citation id="sref50" publication-type="other">
        COVID-19: support for businesses [Internet]. GOV.UK. [cited 2020 Mar 22]. Available from:
        <ext-link ext-link-type="uri" id="intref0265" xlink:href="https://www.gov.uk/government/publications/guidance-to-employers-and-businesses-about-covid-19/covid-19-support-for-businesses">
         https://www.gov.uk/government/publications/guidance-to-employers-and-businesses-about-covid-19/covid-19-support-for-businesses
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <mixed-citation id="sref51" publication-type="other">
        Coronavirus: Ministers urged to assist ‘forgotten’ self-employed [Internet]. Sky News. [cited 2020 Mar 22]. Available from:
        <ext-link ext-link-type="uri" id="intref0270" xlink:href="https://news.sky.com/story/coronavirus-ministers-urged-to-assist-forgotten-self-employed-11961485">
         https://news.sky.com/story/coronavirus-ministers-urged-to-assist-forgotten-self-employed-11961485
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <mixed-citation id="sref52" publication-type="other">
        Banking and capital markets: Implications of COVID-19 | Deloitte Insights [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0275" xlink:href="https://www2.deloitte.com/global/en/insights/economy/covid-19/banking-and-capital-markets-impact-covid-19.html">
         https://www2.deloitte.com/global/en/insights/economy/covid-19/banking-and-capital-markets-impact-covid-19.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <mixed-citation id="sref53" publication-type="other">
        Smialek J. Fed Official Says Central Bankers Are Aligned in Coronavirus Response. The New York Times [Internet]. 2020 Mar 5 [cited 2020 Mar 20]; Available from:
        <ext-link ext-link-type="uri" id="intref0280" xlink:href="https://www.nytimes.com/2020/03/05/business/economy/fed-rate-cut-coronavirus.html">
         https://www.nytimes.com/2020/03/05/business/economy/fed-rate-cut-coronavirus.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <mixed-citation id="sref54" publication-type="other">
        Related Bills - S.3548 - 354116th Congress (2019-2020): CARES Act | Congress.gov | Library of Congress [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0285" xlink:href="https://www.congress.gov/bill/116th-congress/senate-bill/3548/related-bills">
         https://www.congress.gov/bill/116th-congress/senate-bill/3548/related-bills
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <mixed-citation id="sref55" publication-type="other">
        The Anatomy of the $2 Trillion COVID-19 Stimulus Bill - Visual Capitalist [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0290" xlink:href="https://www.visualcapitalist.com/the-anatomy-of-the-2-trillion-covid-19-stimulus-bill/">
         https://www.visualcapitalist.com/the-anatomy-of-the-2-trillion-covid-19-stimulus-bill/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <mixed-citation id="sref56" publication-type="other">
        Who gets what from the $2 trillion US virus aid package | USA News | Al Jazeera [Internet]. [cited 2020 Apr 6]. Available from:
        <ext-link ext-link-type="uri" id="intref0295" xlink:href="https://www.aljazeera.com/ajimpact/2-trillion-virus-aid-package-200325144213604.html">
         https://www.aljazeera.com/ajimpact/2-trillion-virus-aid-package-200325144213604.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <mixed-citation id="sref57" publication-type="other">
        Bank of Japan pumps $43b in liquidity, largest amount since 2008, Economy News &amp; Top Stories - The Straits Times [Internet]. [cited 2020 Apr 6]. Available from:
        <ext-link ext-link-type="uri" id="intref0300" xlink:href="https://www.straitstimes.com/business/economy/bank-of-japan-pumps-43b-in-liquidity-largest-amount-since-2008">
         https://www.straitstimes.com/business/economy/bank-of-japan-pumps-43b-in-liquidity-largest-amount-since-2008
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <mixed-citation id="sref58" publication-type="other">
        Jack SPC Simon. Global economy will suffer for ‘years to come’. BBC News [Internet]. 2020 Mar 23 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0305" xlink:href="https://www.bbc.com/news/business-52000219">
         https://www.bbc.com/news/business-52000219
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <mixed-citation id="sref59" publication-type="other">
        Tanne JH, Hayasaki E, Zastrow M, Pulla P, Smith P, Rada AG. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide. BMJ [Internet]. 2020 Mar 18 [cited 2020 Mar 20];368. Available from:
        <ext-link ext-link-type="uri" id="intref0310" xlink:href="https://www.bmj.com/content/368/bmj.m1090">
         https://www.bmj.com/content/368/bmj.m1090
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <mixed-citation id="sref60" publication-type="other">
        Mar 16 JTP, 2020. What Issues Will Uninsured People Face with Testing and Treatment for COVID-19? [Internet]. The Henry J. Kaiser Family Foundation. 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0315" xlink:href="https://www.kff.org/uninsured/fact-sheet/what-issues-will-uninsured-people-face-with-testing-and-treatment-for-covid-19/">
         https://www.kff.org/uninsured/fact-sheet/what-issues-will-uninsured-people-face-with-testing-and-treatment-for-covid-19/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <mixed-citation id="sref61" publication-type="other">
        COVID-19 USA: Coronavirus outbreak measures and effect on the US [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0320" xlink:href="https://www.pharmaceutical-technology.com/features/coronavirus-affected-countries-usa-covid-19-measures-impact-pharma-hotel-tourism-medical/">
         https://www.pharmaceutical-technology.com/features/coronavirus-affected-countries-usa-covid-19-measures-impact-pharma-hotel-tourism-medical/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <mixed-citation id="sref62" publication-type="other">
        NIH clinical trial of investigational vaccine for COVID-19 begins [Internet]. National Institutes of Health (NIH). 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0325" xlink:href="https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins">
         https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <mixed-citation id="sref63" publication-type="other">
        Marriott furloughs tens of thousands of employees due to coronavirus [Internet]. usatoday. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0330" xlink:href="https://www.usatoday.com/story/money/2020/03/17/marriott-furloughs-layoffs-coronavirus-covid-19/5068070002/">
         https://www.usatoday.com/story/money/2020/03/17/marriott-furloughs-layoffs-coronavirus-covid-19/5068070002/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <mixed-citation id="sref64" publication-type="other">
        Hotels Chains Maneuver to Deal With Coronavirus Gut Punch [Internet]. Skift. 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0335" xlink:href="https://skift.com/2020/03/18/hotels-chains-maneuver-to-deal-with-coronavirus-gut-punch/">
         https://skift.com/2020/03/18/hotels-chains-maneuver-to-deal-with-coronavirus-gut-punch/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <mixed-citation id="sref65" publication-type="other">
        Airbnb, hotels seek US government aid as demand flattens [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0340" xlink:href="https://uk.news.yahoo.com/airbnb-hotels-seek-us-government-172429553.html?guccounter=1&amp;guce_referrer=aHR0cHM6Ly9jb25zZW50LnlhaG9vLmNvbS8&amp;guce_referrer_sig=AQAAACZRvUSdil8yqD6uLCzjwgPt_7XCCtMra5nOk6lAtxj4SWgWhXMr4rizq7LTkeApX3xbRoQwNY4T2U7cs1rdUK1DjYjwHYPJ6E_CCo_YKLtTjg1vGBUIESTjyJ6wGm_w5FxnqL3vXYkw3ORZQ-ckANg0QEuBYUhWsnfIiKlUQfBa">
         https://uk.news.yahoo.com/airbnb-hotels-seek-us-government-172429553.html?guccounter=1&amp;guce_referrer=aHR0cHM6Ly9jb25zZW50LnlhaG9vLmNvbS8&amp;guce_referrer_sig=AQAAACZRvUSdil8yqD6uLCzjwgPt_7XCCtMra5nOk6lAtxj4SWgWhXMr4rizq7LTkeApX3xbRoQwNY4T2U7cs1rdUK1DjYjwHYPJ6E_CCo_YKLtTjg1vGBUIESTjyJ6wGm_w5FxnqL3vXYkw3ORZQ-ckANg0QEuBYUhWsnfIiKlUQfBa
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <mixed-citation id="sref66" publication-type="other">
        Net H. MGM Resorts International Statement On Temporary Closure Of Las Vegas Properties [Internet]. Hospitality Net. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0345" xlink:href="https://www.hospitalitynet.org/news/4097568.html">
         https://www.hospitalitynet.org/news/4097568.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <mixed-citation id="sref67" publication-type="other">
        Net H. Coronavirus Hits German Hotel Industry Hard: More Than Every-3-Guests Stay Away [Internet]. Hospitality Net. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0350" xlink:href="https://www.hospitalitynet.org/performance/4097569.html">
         https://www.hospitalitynet.org/performance/4097569.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <mixed-citation id="sref68" publication-type="other">
        This is how coronavirus could affect the travel and tourism industry [Internet]. World Economic Forum. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0355" xlink:href="https://www.weforum.org/agenda/2020/03/world-travel-coronavirus-covid19-jobs-pandemic-tourism-aviation/">
         https://www.weforum.org/agenda/2020/03/world-travel-coronavirus-covid19-jobs-pandemic-tourism-aviation/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <mixed-citation id="sref69" publication-type="other">
        Amy. European Tourism Sector Demands Urgent Supportive Measures to Reduce Devastating Impact of COVID-19 [Internet]. Hotel-Online. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0360" xlink:href="https://www.hotel-online.com/press_releases/release/european-tourism-sector-demands-urgent-supportive-measures-to-reduce-devastating-impact-of-covid-19/">
         https://www.hotel-online.com/press_releases/release/european-tourism-sector-demands-urgent-supportive-measures-to-reduce-devastating-impact-of-covid-19/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <mixed-citation id="sref70" publication-type="other">
        Tourism alliance demands measures to reduce COVID-19 impact | The Budapest Business Journal on the web | bbj.hu [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0365" xlink:href="https://bbj.hu/coronavirus/tourism-alliance-demands-measures-to-reduce-covid-19-impact_179888">
         https://bbj.hu/coronavirus/tourism-alliance-demands-measures-to-reduce-covid-19-impact_179888
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <mixed-citation id="sref71" publication-type="other">
        Times V. Vietnam’s tourism sector could lose US$ 5bln due to COVID 19 [Internet]. Vietnam Times. 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0370" xlink:href="https://vietnamtimes.org.vn/vietnams-tourism-sector-could-lose-us-5bln-due-to-covid-19-17829.html">
         https://vietnamtimes.org.vn/vietnams-tourism-sector-could-lose-us-5bln-due-to-covid-19-17829.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <mixed-citation id="sref72" publication-type="other">
        COVID-19 Outbreak Expected To Impact On The Local Economy; DOH Bracing For Local Transmission | OneNews.PH [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0375" xlink:href="https://onenews.ph/covid-19-outbreak-expected-to-impact-on-the-local-economy-doh-bracing-for-local-transmission">
         https://onenews.ph/covid-19-outbreak-expected-to-impact-on-the-local-economy-doh-bracing-for-local-transmission
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <mixed-citation id="sref73" publication-type="other">
        US-Canada border to close amid virus crisis. BBC News [Internet]. 2020 Mar 18 [cited 2020 Mar 20]; Available from:
        <ext-link ext-link-type="uri" id="intref0380" xlink:href="https://www.bbc.com/news/world-us-canada-51949243">
         https://www.bbc.com/news/world-us-canada-51949243
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <mixed-citation id="sref74" publication-type="other">
        Status of U.S. Consular Operations in Mexico in Light of COVID-19 [Internet]. U.S. Embassy &amp; Consulates in Mexico. 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0385" xlink:href="https://mx.usembassy.gov/status-of-u-s-consular-operations-in-mexico-in-light-of-covid-19/">
         https://mx.usembassy.gov/status-of-u-s-consular-operations-in-mexico-in-light-of-covid-19/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <mixed-citation id="sref75" publication-type="other">
        Parks closing as areas urge tourists to stay away. BBC News [Internet]. 2020 Mar 22 [cited 2020 Mar 22]; Available from:
        <ext-link ext-link-type="uri" id="intref0390" xlink:href="https://www.bbc.com/news/uk-england-51995092">
         https://www.bbc.com/news/uk-england-51995092
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <mixed-citation id="sref76" publication-type="other">
        Coronavirus travel bans: Countries impose travel restrictions [Internet]. usatoday. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0395" xlink:href="https://www.usatoday.com/story/travel/news/2020/03/17/coronavirus-travel-bans-countries-impose-travel-restrictions/5058513002/">
         https://www.usatoday.com/story/travel/news/2020/03/17/coronavirus-travel-bans-countries-impose-travel-restrictions/5058513002/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <mixed-citation id="sref77" publication-type="other">
        Britons urged to avoid non-essential travel abroad. BBC News [Internet]. 2020 Mar 17 [cited 2020 Mar 20]; Available from:
        <ext-link ext-link-type="uri" id="intref0400" xlink:href="https://www.bbc.com/news/uk-51924405">
         https://www.bbc.com/news/uk-51924405
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <mixed-citation id="sref78" publication-type="other">
        Coronavirus travel updates: which countries have restrictions and FCO warnings in place? | Travel | The Guardian [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0405" xlink:href="https://www.theguardian.com/travel/2020/mar/19/coronavirus-travel-updates-which-countries-have-restrictions-and-fco-warnings-in-place">
         https://www.theguardian.com/travel/2020/mar/19/coronavirus-travel-updates-which-countries-have-restrictions-and-fco-warnings-in-place
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <mixed-citation id="sref79" publication-type="other">
        Commentary: COVID-19, the biggest crisis ever for Singapore’s aviation industry and Singapore Airlines - CNA [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0410" xlink:href="https://www.channelnewsasia.com/news/commentary/covid-19-coronavirus-airline-sia-flight-air-travel-industry-cut-12542996">
         https://www.channelnewsasia.com/news/commentary/covid-19-coronavirus-airline-sia-flight-air-travel-industry-cut-12542996
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <mixed-citation id="sref80" publication-type="other">
        U.S. airlines seek $50 billion coronavirus bailout to avoid collapse. Reuters [Internet]. 2020 Mar 16 [cited 2020 Mar 20]; Available from:
        <ext-link ext-link-type="uri" id="intref0415" xlink:href="https://in.reuters.com/article/uk-health-coronavirus-usa-aviation-idINKBN21337Q">
         https://in.reuters.com/article/uk-health-coronavirus-usa-aviation-idINKBN21337Q
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <mixed-citation id="sref81" publication-type="other">
        UK airlines call for multibillion bailout to survive Covid-19 crisis | World news | The Guardian [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0420" xlink:href="https://www.theguardian.com/world/2020/mar/15/uk-airlines-call-for-multibillion-bailout-to-survive-covid-19-crisis">
         https://www.theguardian.com/world/2020/mar/15/uk-airlines-call-for-multibillion-bailout-to-survive-covid-19-crisis
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <mixed-citation id="sref82" publication-type="other">
        Pickford J. Coronavirus fears hit UK property market as viewings dry up [Internet]. 2020 [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0425" xlink:href="https://www.ft.com/content/e30ccb84-6799-11ea-800d-da70cff6e4d3">
         https://www.ft.com/content/e30ccb84-6799-11ea-800d-da70cff6e4d3
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <mixed-citation id="sref83" publication-type="other">
        How Coronavirus Has Affected Real Estate - The New York Times [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0430" xlink:href="https://www.nytimes.com/2020/03/17/realestate/how-coronavirus-has-affected-real-estate.html">
         https://www.nytimes.com/2020/03/17/realestate/how-coronavirus-has-affected-real-estate.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <mixed-citation id="sref84" publication-type="other">
        What should I do if I am selling a house during the coronavirus outbreak? The latest property advice [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0435" xlink:href="https://www.telegraph.co.uk/property/uk/should-do-selling-house-coronavirus-outbreak-latest-property/">
         https://www.telegraph.co.uk/property/uk/should-do-selling-house-coronavirus-outbreak-latest-property/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <mixed-citation id="sref85" publication-type="other">
        Coronavirus: UK mortgage market goes into partial lockdown - BBC News [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0440" xlink:href="https://www.bbc.co.uk/news/business-52106119#">
         https://www.bbc.co.uk/news/business-52106119#
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <mixed-citation id="sref86" publication-type="other">
        House prices: Could house prices crash over coronavirus? | Express.co.uk [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0445" xlink:href="https://www.express.co.uk/life-style/property/1254712/house-prices-crash-coronavirus-could-house-prices-go-down-fall">
         https://www.express.co.uk/life-style/property/1254712/house-prices-crash-coronavirus-could-house-prices-go-down-fall
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <mixed-citation id="sref87" publication-type="other">
        Coronavirus: Sport-by-sport look at the global impact of COVID-19 | The Independent [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0450" xlink:href="https://www.independent.co.uk/sport/sport-football-basketball-rugby-olympics-cancelled-coronavirus-impact-around-the-world-a9398186.html">
         https://www.independent.co.uk/sport/sport-football-basketball-rugby-olympics-cancelled-coronavirus-impact-around-the-world-a9398186.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <mixed-citation id="sref88" publication-type="other">
        UEFA.com. UEFA EURO 2020 [Internet]. UEFA.com. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0455" xlink:href="https://www.uefa.com/uefaeuro-2020/">
         https://www.uefa.com/uefaeuro-2020/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <mixed-citation id="sref89" publication-type="other">
        Tokyo Olympics postponed to 2021 due to coronavirus pandemic | Sport | The Guardian [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0460" xlink:href="https://www.theguardian.com/sport/2020/mar/24/tokyo-olympics-to-be-postponed-to-2021-due-to-coronavirus-pandemic">
         https://www.theguardian.com/sport/2020/mar/24/tokyo-olympics-to-be-postponed-to-2021-due-to-coronavirus-pandemic
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <mixed-citation id="sref90" publication-type="other">
        When will a coronavirus vaccine be ready? | World news | The Guardian [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0465" xlink:href="https://www.theguardian.com/world/2020/mar/18/when-will-a-coronavirus-vaccine-be-ready">
         https://www.theguardian.com/world/2020/mar/18/when-will-a-coronavirus-vaccine-be-ready
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <mixed-citation id="sref91" publication-type="other">
        Gates Foundation, Wellcome, Mastercard commit $125 million to COVID-19 drugs - Business Insider [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0470" xlink:href="https://www.businessinsider.com/gates-foundation-wellcome-mastercard-commit-125-million-to-covid-19-drugs-2020-3?r=US&amp;IR=T">
         https://www.businessinsider.com/gates-foundation-wellcome-mastercard-commit-125-million-to-covid-19-drugs-2020-3?r=US&amp;IR=T
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <mixed-citation id="sref92" publication-type="other">
        Coronavirus pushes robots to front lines of China’s hospitals | The Japan Times [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0475" xlink:href="https://www.japantimes.co.jp/news/2020/02/07/business/tech/coronavirus-robots-china-hospitals/#.XnRD-ZP7RmB">
         https://www.japantimes.co.jp/news/2020/02/07/business/tech/coronavirus-robots-china-hospitals/#.XnRD-ZP7RmB
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <mixed-citation id="sref93" publication-type="other">
        Coronavirus: Ventilator rush faces regulatory and logistical obstacles [Internet]. [cited 2020 Mar 20]. Available from:
        <ext-link ext-link-type="uri" id="intref0480" xlink:href="https://www.nbcnews.com/news/world/coronavirus-ventilator-rush-faces-regulatory-logistical-obstacles-n1161651">
         https://www.nbcnews.com/news/world/coronavirus-ventilator-rush-faces-regulatory-logistical-obstacles-n1161651
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <mixed-citation id="sref94" publication-type="other">
        MPs in plea to government over UK’s Covid-19 stockpiling | World news | The Guardian [Internet]. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0485" xlink:href="https://www.theguardian.com/world/2020/mar/21/mps-plea-government-uk-covid-19-stockpiling-coronavirus">
         https://www.theguardian.com/world/2020/mar/21/mps-plea-government-uk-covid-19-stockpiling-coronavirus
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <mixed-citation id="sref95" publication-type="other">
        Jack S. What are shops doing about stockpiling? BBC News [Internet]. 2020 Mar 22 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0490" xlink:href="https://www.bbc.com/news/business-51737030">
         https://www.bbc.com/news/business-51737030
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <mixed-citation id="sref96" publication-type="other">
        Jack S. Online shopping website Ocado suspends service. BBC News [Internet]. 2020 Mar 18 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0495" xlink:href="https://www.bbc.com/news/business-51941987">
         https://www.bbc.com/news/business-51941987
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <mixed-citation id="sref97" publication-type="other">
        Stockpiling ‘will hit vulnerable’, food bank warns. BBC News [Internet]. 2020 Mar 13 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0500" xlink:href="https://www.bbc.com/news/uk-england-beds-bucks-herts-51856592">
         https://www.bbc.com/news/uk-england-beds-bucks-herts-51856592
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <mixed-citation id="sref98" publication-type="other">
        Food bank shortage blamed on coronavirus panic. BBC News [Internet]. 2020 Mar 13 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0505" xlink:href="https://www.bbc.com/news/uk-england-london-51837892">
         https://www.bbc.com/news/uk-england-london-51837892
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <mixed-citation id="sref99" publication-type="other">
        Food parcels coming for vulnerable individuals [Internet]. BBC News. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0510" xlink:href="https://www.bbc.com/news/av/uk-politics-51995298/coronavirus-minister-urges-food-shoppers-to-be-considerate">
         https://www.bbc.com/news/av/uk-politics-51995298/coronavirus-minister-urges-food-shoppers-to-be-considerate
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <mixed-citation id="sref100" publication-type="other">
        First food parcels delivered to clinically vulnerable people - GOV.UK [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0515" xlink:href="https://www.gov.uk/government/news/first-food-parcels-delivered-to-clinically-vulnerable-people">
         https://www.gov.uk/government/news/first-food-parcels-delivered-to-clinically-vulnerable-people
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <mixed-citation id="sref101" publication-type="other">
        Coronavirus (COVID-19): free school meals guidance for schools [Internet]. GOV.UK. [cited 2020 Apr 6]. Available from:
        <ext-link ext-link-type="uri" id="intref0520" xlink:href="https://www.gov.uk/government/publications/covid-19-free-school-meals-guidance/covid-19-free-school-meals-guidance-for-schools">
         https://www.gov.uk/government/publications/covid-19-free-school-meals-guidance/covid-19-free-school-meals-guidance-for-schools
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <mixed-citation id="sref102" publication-type="other">
        Commissioner O of the. Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions. FDA [Internet]. 2020 Mar 22 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0525" xlink:href="http://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19-frequently-asked-questions">
         http://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19-frequently-asked-questions
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <mixed-citation id="sref103" publication-type="other">
        Jack S. Supermarkets urge shoppers to stop stockpiling. BBC News [Internet]. 2020 Mar 15 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0530" xlink:href="https://www.bbc.com/news/business-51883440">
         https://www.bbc.com/news/business-51883440
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <mixed-citation id="sref104" publication-type="other">
        5 things supermarkets want you to know during the COVID-19 pandemic | World Economic Forum [Internet]. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0535" xlink:href="https://www.weforum.org/agenda/2020/03/supermarkets-grocery-coronavirus-covid19-supply/">
         https://www.weforum.org/agenda/2020/03/supermarkets-grocery-coronavirus-covid19-supply/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <mixed-citation id="sref105" publication-type="other">
        Coronavirus: What are independent supermarkets doing to help? - BBC News [Internet]. [cited 2020 Mar 23]. Available from:
        <ext-link ext-link-type="uri" id="intref0540" xlink:href="https://www.bbc.co.uk/news/uk-england-51947391">
         https://www.bbc.co.uk/news/uk-england-51947391
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <mixed-citation id="sref106" publication-type="other">
        Jack SJ Simon. Fast food chain turns its restaurants into shops. BBC News [Internet]. 2020 Mar 22 [cited 2020 Mar 23]; Available from:
        <ext-link ext-link-type="uri" id="intref0545" xlink:href="https://www.bbc.com/news/business-51996773">
         https://www.bbc.com/news/business-51996773
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <mixed-citation id="sref107" publication-type="other">
        Coronavirus: Domestic abuse calls up 25% since lockdown, charity says - BBC News [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0550" xlink:href="https://www.bbc.co.uk/news/uk-52157620">
         https://www.bbc.co.uk/news/uk-52157620
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <mixed-citation id="sref108" publication-type="other">
        25% increase in calls to National Domestic Abuse Helpline since lockdown measures began - Refuge Charity - Domestic Violence Help [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0555" xlink:href="https://www.refuge.org.uk/25-increase-in-calls-to-national-domestic-abuse-helpline-since-lockdown-measures-began/">
         https://www.refuge.org.uk/25-increase-in-calls-to-national-domestic-abuse-helpline-since-lockdown-measures-began/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <mixed-citation id="sref109" publication-type="other">
        Domestic abuse: how to get help - GOV.UK [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0560" xlink:href="https://www.gov.uk/guidance/domestic-abuse-how-to-get-help">
         https://www.gov.uk/guidance/domestic-abuse-how-to-get-help
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <mixed-citation id="sref110" publication-type="other">
        The world is turning to video games amid coronavirus outbreak [Internet]. [cited 2020 Apr 7]. Available from:
        <ext-link ext-link-type="uri" id="intref0565" xlink:href="https://finance.yahoo.com/news/coronavirus-world-turning-to-video-games-150704969.html?guccounter=1&amp;guce_referrer=aHR0cHM6Ly9lbi5tLndpa2lwZWRpYS5vcmcv&amp;guce_referrer_sig=AQAAAKXHUfQ3HFeK9PeV4LcIWWvEeAu0CkT9qygqOvb0SSBl1wvamT3OWV3_4SxvDucVgsomxVEDfPFPfSzPUTN4pruawSnzGE4YXW8NpkEHpxnJgXnmV2uoXsUxK2K2BAlSd9qw7_2jCW82mOrdTq5edbC7NxhD-uPPdaAmm4ahcWbb">
         https://finance.yahoo.com/news/coronavirus-world-turning-to-video-games-150704969.html?guccounter=1&amp;guce_referrer=aHR0cHM6Ly9lbi5tLndpa2lwZWRpYS5vcmcv&amp;guce_referrer_sig=AQAAAKXHUfQ3HFeK9PeV4LcIWWvEeAu0CkT9qygqOvb0SSBl1wvamT3OWV3_4SxvDucVgsomxVEDfPFPfSzPUTN4pruawSnzGE4YXW8NpkEHpxnJgXnmV2uoXsUxK2K2BAlSd9qw7_2jCW82mOrdTq5edbC7NxhD-uPPdaAmm4ahcWbb
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <mixed-citation id="sref111" publication-type="other">
        Kent E. Coronavirus outbreak forces cancellation of multiple esports events [Internet]. Eurogamer. 2020 [cited 2020 Apr 8]. Available from:
        <ext-link ext-link-type="uri" id="intref0570" xlink:href="https://www.eurogamer.net/articles/2020-01-30-coronavirus-outbreak-forces-cancellation-of-multiple-esports-events">
         https://www.eurogamer.net/articles/2020-01-30-coronavirus-outbreak-forces-cancellation-of-multiple-esports-events
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <mixed-citation id="sref112" publication-type="other">
        Expats in Dubai call for cut in their children’s school fees [Internet]. Ft.com. 2020 [cited 8 April 2020]. Available from:
        <ext-link ext-link-type="uri" id="intref0575" xlink:href="https://www.ft.com/content/c9f83ca9-9107-436f-864b-da1b7e28f56f">
         https://www.ft.com/content/c9f83ca9-9107-436f-864b-da1b7e28f56f
        </ext-link>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       BMC Public Health
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       BMC Public Health
      </journal-id>
      <journal-title-group>
       <journal-title>
        BMC Public Health
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1471-2458
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24920395
      </article-id>
      <article-id pub-id-type="pmc">
       4063987
      </article-id>
      <article-id pub-id-type="publisher-id">
       6689
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/1471-2458-14-589
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Public perceptions of non-pharmaceutical interventions for reducing transmission of respiratory infection: systematic review and synthesis of qualitative studies
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Teasdale
         </surname>
         <given-names>
          Emma
         </given-names>
        </name>
        <address>
         <email>
          e.j.teasdale@soton.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Santer
         </surname>
         <given-names>
          Miriam
         </given-names>
        </name>
        <address>
         <email>
          M.Santer@soton.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Geraghty
         </surname>
         <given-names>
          Adam W A
         </given-names>
        </name>
        <address>
         <email>
          a.w.geraghty@soton.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Little
         </surname>
         <given-names>
          Paul
         </given-names>
        </name>
        <address>
         <email>
          P.Little@soton.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yardley
         </surname>
         <given-names>
          Lucy
         </given-names>
        </name>
        <address>
         <email>
          L.Yardley@soton.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.5491.9
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419369297
         </institution-id>
         <institution>
          Primary Care and Population Sciences, Faculty of Medicine,
         </institution>
         <institution>
          University of Southampton,
         </institution>
        </institution-wrap>
        Southampton, UK
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.5491.9
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419369297
         </institution-id>
         <institution>
          Academic Unit of Psychology, Faculty of Social and Human Sciences,
         </institution>
         <institution>
          University of Southampton,
         </institution>
        </institution-wrap>
        Southampton, UK
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        6
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        11
       </day>
       <month>
        6
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <elocation-id>
       589
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         2
        </day>
        <month>
         4
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="accepted">
        <day>
         2
        </day>
        <month>
         6
        </month>
        <year>
         2014
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © Teasdale et al.; licensee BioMed Central Ltd. 2014
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">
          http://creativecommons.org/licenses/by/4.0
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         ) applies to the data made available in this article, unless otherwise stated.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p>
         Non-pharmaceutical public health interventions may provide simple, low-cost, effective ways of minimising the transmission and impact of acute respiratory infections in pandemic and non-pandemic contexts. Understanding what influences the uptake of non-pharmaceutical interventions such as hand and respiratory hygiene, mask wearing and social distancing could help to inform the development of effective public health advice messages. The aim of this synthesis was to explore public perceptions of non-pharmaceutical interventions that aim to reduce the transmission of acute respiratory infections.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         Five online databases (MEDLINE, PsycINFO, CINAHL, EMBASE and Web of Science) were systematically searched. Reference lists of articles were also examined. We selected papers that used a qualitative research design to explore perceptions and beliefs about non-pharmaceutical interventions to reduce transmission of acute respiratory infections. We excluded papers that only explored how health professionals or children viewed non-pharmaceutical respiratory infection control. Three authors performed data extraction and assessment of study quality. Thematic analysis and components of meta-ethnography were adopted to synthesise findings.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         Seventeen articles from 16 studies in 9 countries were identified and reviewed. Seven key themes were identified: perceived benefits of non-pharmaceutical interventions, perceived disadvantages of non-pharmaceutical interventions, personal and cultural beliefs about infection transmission, diagnostic uncertainty in emerging respiratory infections, perceived vulnerability to infection, anxiety about emerging respiratory infections and communications about emerging respiratory infections. The synthesis showed that some aspects of non-pharmaceutical respiratory infection control (particularly hand and respiratory hygiene) were viewed as familiar and socially responsible actions to take. There was ambivalence about adopting isolation and personal distancing behaviours in some contexts due to their perceived adverse impact and potential to attract social stigma. Common perceived barriers included beliefs about infection transmission, personal vulnerability to respiratory infection and concerns about self-diagnosis in emerging respiratory infections.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p>
         People actively evaluate non-pharmaceutical interventions in terms of their perceived necessity, efficacy, acceptability, and feasibility. To enhance uptake, it will be necessary to address key barriers, such as beliefs about infection transmission, rejection of personal risk of infection and concern about the potential costs and stigma associated with some interventions.
        </p>
       </sec>
       <sec>
        <title>
         Electronic supplementary material
        </title>
        <p>
         The online version of this article (doi:10.1186/1471-2458-14-589) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Qualitative
       </kwd>
       <kwd>
        Thematic synthesis
       </kwd>
       <kwd>
        Systematic review
       </kwd>
       <kwd>
        Respiratory infection
       </kwd>
       <kwd>
        Non-pharmaceutical intervention
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2014
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p>
      Acute respiratory infections represent a significant public health issue. They place a continual and considerable burden on public health (serious illness, reduced quality of life), overstretched healthcare services, and on public prosperity (increased absenteeism and reduced workforce productivity) [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      –
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. Reducing the transmission of acute respiratory infections could therefore be extremely valuable to the general public, healthcare services and society as a whole.
     </p>
     <p>
      Respiratory infection control comprises pharmaceutical (e.g. vaccination) and non-pharmaceutical public health interventions. Research suggests that non-pharmaceutical respiratory infection control may provide simple, low-cost, effective ways of reducing the transmission and minimising impact of acute respiratory infections in pandemic and non-pandemic contexts [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      –
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. In the early stages of an emerging respiratory infection outbreak or pandemic, it is unlikely that there will be immediate and sufficient availability of a vaccine on a global scale due to the novelty of the virus [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. Non-pharmaceutical interventions may be particularly important in the early phase of influenza pandemics, in which slowing the spread of infection could help to reduce the number of people who become infected whilst a vaccine is developed [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      –
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. Minimising the spread of infection would enable the continued functioning of vital public services and lessen the socioeconomic impact of a pandemic [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ].
     </p>
     <p>
      Non-pharmaceutical respiratory infection control comprises public health interventions that communities and individuals can adopt both when well (to reduce exposure to the virus and avoid becoming infected) and when infected (to avoid affecting others and to recover from illness). Non-pharmaceutical interventions involve behaviours such as isolation e.g. staying home if feeling ill, personal protective measures e.g. covering coughs and sneezes and washing hands often with soap or hand gel, social distancing e.g. postponing or cancelling large public gatherings and using remote healthcare services (Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      ). Effective management of acute respiratory infections could involve isolation and treatment where appropriate, and advising the general public on both the pharmaceutical and non-pharmaceutical protective actions that they can take to help control the spread of infection in both pandemic and non-pandemic contexts [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ].
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         <bold>
          Non-pharmaceutical interventions for respiratory infection control
         </bold>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Behaviour
          </th>
          <th>
           Definition
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           <bold>
            Isolation
           </bold>
          </td>
          <td>
           Staying home if symptomatic for at least 7 days (minimising contact with other household members) to reduce peak incidence of respiratory infection.
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            Personal Protective Measures (PPM)
           </bold>
          </td>
          <td>
           Hygiene and distancing behaviours to reduce an individual’s chance of catching and passing on respiratory infections
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            <italic>
             -Respiratory hygiene
            </italic>
           </bold>
          </td>
          <td>
           Covering/catching coughs and sneezes using disposable tissues
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            <italic>
             -Hand hygiene
            </italic>
           </bold>
          </td>
          <td>
           Washing hands regularly and thoroughly with soap and water or hand gel
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            <italic>
             -Mask wearing
            </italic>
           </bold>
          </td>
          <td>
           Wearing a surgical face mask
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            <italic>
             -Personal distancing
            </italic>
           </bold>
          </td>
          <td>
           Keeping a distance of about 1 metre (3 feet) from people who appear symptomatic
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            Social Distancing
           </bold>
          </td>
          <td>
           Actions taken by communities to reduce social contact and to literally increase the space between people
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            <italic>
             -in children
            </italic>
           </bold>
          </td>
          <td>
           Temporarily closing schools and childcare facilities
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            <italic>
             -in adults
            </italic>
           </bold>
          </td>
          <td>
           Postponing or cancelling large public gatherings, altering workplace environments, e.g. offering telework or remote-meeting options.
          </td>
         </tr>
         <tr>
          <td>
           <bold>
            Remote healthcare
           </bold>
          </td>
          <td>
           Accessing website or phone line advice and support, and setting up ’Flu friends’ (if ill) rather than going to local healthcare facilities to reduce spread of respiratory infection and avoid overstretching healthcare services.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p>
      Theoretical models such as Theory of Planned Behaviour [
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ] and Protection Motivation Theory [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ] emphasise the importance of perceptions and beliefs in predicting protective behaviour. Previous research has shown that how people respond to the threat of a new respiratory infection can be positively influenced by briefly addressing their beliefs about the efficacy and perceived costs of protective behaviours [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. Improving our understanding of perceptions, beliefs and other factors likely to motivate people to adopt non-pharmaceutical interventions in both pandemic and non-pandemic contexts would facilitate the development of public health advice messages that effectively promote non-pharmaceutical respiratory infection control.
     </p>
     <p>
      Factors that influence the adoption of non-pharmaceutical respiratory infection control include perception of risk, anxiety and efficacy beliefs (i.e. beliefs about one's ability to successfully adopt behaviours and the effectiveness of adopting behaviours in eliminating the health threat). This has been demonstrated in both anticipated and actual respiratory infection outbreaks e.g. SARS coronavirus outbreak and H1N1 2009 pandemic [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      –
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. Much of the existing research on non-pharmaceutical interventions has adopted a quantitative design, which provides important information about the frequency of people's views and the potential determinants of behaviour but does not enable us to understand more about why those views are held.
     </p>
     <p>
      Qualitative research enables an in-depth exploration of people’s beliefs and perceptions in varying contexts, and consideration of other (non-cognitive) determinants such as emotional and sociocultural factors. For example, qualitative research on how the public make sense of emerging infectious diseases suggests that, rather than rationally assessing the likelihood and severity of infection, people interpret its potential impact by drawing on similar past events to make the unfamiliar seem more familiar and by transforming abstract concepts into concrete symbols. One such mechanism is to blame ‘the other’ or other groups of people and to underestimate the risks faced by ‘the self’ [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      –
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. Synthesising qualitative research aims to identify and draw together the findings of individual qualitative studies in order to generate new insights and to further interpret and understand the findings of the pool of research [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]. The process of synthesising qualitative research can provide valuable insights into the needs, preferences and experiences of the public regarding healthcare advice or interventions and as such has a significant role to play in informing the development of effective healthcare [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. Greater understanding of how people in different circumstances make sense of public health advice on non-pharmaceutical interventions may allow us to examine where current public health communication efforts could be undermined.
     </p>
     <p>
      To our knowledge, there has been no previous attempt to synthesise qualitative studies on non-pharmaceutical respiratory infection control. Our aim was to synthesis the qualitative literature on public perceptions of non-pharmaceutical public health interventions that aim to reduce the transmission of acute respiratory infections.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Search strategy and inclusion criteria
      </title>
      <p>
       We sought papers whose primary focus was public perceptions (general public or patient groups) of non-pharmaceutical measures to reduce transmission of acute respiratory infections and/or interventions that aimed to promote non-pharmaceutical respiratory infection control. To be eligible for the review, studies had to use qualitative methods of data collection and data analysis. Studies that used a mixed methodology were included if they comprised a substantive qualitative component (i.e. the depth and breadth of the qualitative data was sufficient to form a stand-alone qualitative paper). Studies whose primary focus was the views of healthcare professionals, views of children or views about respiratory infections with no data on reduction of transmission were excluded (Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ).
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          <bold>
           Inclusion and exclusion criteria
          </bold>
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
           </th>
           <th>
            Inclusion criteria
           </th>
           <th>
            Exclusion criteria
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            <bold>
             Population of interest
            </bold>
           </td>
           <td>
            Adults ≥17years old
           </td>
           <td>
            Health professionals, Children
           </td>
          </tr>
          <tr>
           <td rowspan="8">
            <bold>
             Exposure of interest
            </bold>
           </td>
           <td>
            Non-pharmaceutical respiratory infection control:
           </td>
           <td>
            Pharmaceutical respiratory infection control:
           </td>
          </tr>
          <tr>
           <td>
            ●Hand hygiene
           </td>
           <td>
            ●Vaccination
           </td>
          </tr>
          <tr>
           <td>
            ●Respiratory hygiene
           </td>
           <td rowspan="6">
            ●Antivirals
           </td>
          </tr>
          <tr>
           <td>
            ●Mask wearing
           </td>
          </tr>
          <tr>
           <td>
            ●Isolation
           </td>
          </tr>
          <tr>
           <td>
            ●Social distancing
           </td>
          </tr>
          <tr>
           <td>
            ●Remote health care
           </td>
          </tr>
          <tr>
           <td>
            ●Precautionary avoidance
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Outcome of interest
            </bold>
           </td>
           <td>
            Public perspectives of respiratory infection control (including beliefs, views, concerns, understandings and emotional and sociocultural factors)
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Study design
            </bold>
           </td>
           <td>
            Qualitative
            <italic>
             (ethnography, grounded theory, phenomenology, focus groups, Interviews and participant observation)
            </italic>
            and mixed methods
           </td>
           <td>
            Quantitative
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <p>
       Five electronic databases were searched: Medline (1946 to January Week 3 2013), PsycINFO (1887 to February week 1 2013), Embase (1980 to 2013 Week 05) CINAHL (1982 to February week 3 2013), and Web of Science (1981 to February week 4 2013). The last search was conducted on 26th February 2013. We conducted scoping exercises to develop comprehensive search strategies for each database (Additional file
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       ). We adopted a pre-planned, comprehensive search strategy, rather than using iterative theoretical sampling seeking conceptual saturation, to enhance the transparency and reproducibility of the review [
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ]. As many electronic databases do not yet have gold standard indexing of qualitative research our search terms for qualitative research were adopted from lists of qualitative search terms from key literature [
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ]. No language restrictions or year limits were applied to the searches. Potentially relevant studies not published in English were translated by a native speaker. Although the focus of this review was non-pharmaceutical respiratory infection control, the search term ‘vaccination’ was initially included to allow for papers that included both pharmaceutical and non-pharmaceutical measures to be identified. Studies whose primary focus was vaccination alone were then excluded.
      </p>
      <p>
       One author (ET) screened titles and abstracts of all identified papers against the inclusion criteria. Those that did not meet the inclusion criteria or were duplicates were excluded. A second author (MS) screened 10% of the title and abstracts to check that potentially relevant studies had not been missed. Full papers for the remaining identified records were retrieved and assessed for eligibility. Multiple papers from a single study were included if each paper presented unique data. Reference lists of all potentially relevant papers were reviewed and corresponding authors of included papers contacted to allow additional relevant studies to be identified.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Quality appraisal and data extraction
      </title>
      <p>
       Prior to synthesis, 3 authors (ET, MS &amp; AG) extracted data and appraised the quality of included papers. Details about study design, participants (number and characteristics), type of non-pharmaceutical intervention and study context (timing, location, type of respiratory infection) were extracted into a Microsoft Word template. Papers were appraised using the Critical Appraisal Skills Programme (CASP) quality assessment tool for qualitative studies [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ]. This tool enabled independent critical review of the quality of our identified studies. We employed this tool in order to systematically examine and document the strengths and weaknesses of the studies but not necessarily to exclude them. We acknowledge the potential risk that valuable new insights, grounded in data, might be missed when studies are excluded from a synthesis due to methodological flaws or lack of reporting. However, through discussion and consensus, one paper was excluded following appraisal as it reported no details about data collection, management and analysis. As such we could not be confident that this paper met our inclusion criteria of using qualitative methods of data collection and data analysis.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Synthesis
      </title>
      <p>
       We used thematic synthesis [
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
       ] and meta-ethnographic [
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ] methods to synthesise findings. Meta-ethnography uses the notion of first, second and third order constructs to synthesise qualitative papers, where first order constructs reflect data on participant views, second-order constructs are the original researchers’ interpretations of themes arising from data, and third-order constructs are the new, common themes or interpretations derived by the synthesis of second-order constructs from multiple papers. Many of the papers included in this synthesis were applied studies that offered more descriptive analyses rather than conceptually rich analyses so a meta-ethnography was not possible and thematic synthesis was employed to identify and organise the synthesis data into themes. Components were adopted from meta-ethnography (reciprocal translational analysis and refutational synthesis) in order to facilitate synthesis across heterogeneous circumstances (different respiratory infections, different non-pharmaceutical interventions and groups with very different demographic, sociocultural and illness-related characteristics). Each paper was read repeatedly to become familiar with the data. The findings from each paper (participants’ views and author interpretation of findings) were then extracted verbatim and imported into Nvivo version 9.2. Data for each paper were coded line by line by ET according to meaning and content. Coding was inductive in nature (i.e. codes were grounded in the data, reflecting the language present in original studies). The list of codes generated for each paper was then systematically compared and developed as subsequent papers were coded (i.e. codes translated into one another or new codes added to the list). A coding manual was produced by ET to ensure transparent coding of the data. Initial themes and sub-themes were developed and refined through discussion with MS, AG and LY. ET then carried out consistency checks on the text coded to each theme and sub theme and organised themes into grids and tables to be compared and juxtaposed to examine variability between studies and by infection context, populations and intervention type. ET, MS, AG and LY then reviewed and discussed the evolving coding manual further and more abstract themes were developed based on the authors’ inferences and interpretation of the data. Diagramming was then employed to explore links and illustrate the key themes within the data.
      </p>
     </sec>
    </sec>
    <sec id="Sec6">
     <title>
      Results
     </title>
     <p>
      The database searches yielded 966 records in total. After screening for duplicates and eligibility, 17 papers (from 16 studies) satisfied the selection criteria and were included in the synthesis (Figure
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ).
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         <bold>
          Flowchart of systematic search.
         </bold>
        </p>
       </caption>
       <graphic id="d29e654" xlink:href="12889_2014_Article_6689_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <sec id="Sec7">
      <title>
       Study characteristics
      </title>
      <p>
       The characteristics of the 16 included studies are shown in Table
       <xref ref-type="table" rid="Tab3">
        3
       </xref>
       . Studies were published between 2005 and 2012 and represented the views of 1,022 participants from 9 different countries. The majority of studies (n = 12) recruited members of the general public with varying demographics and in different contexts. Two studies focused on specific ethnic groups and two on people with a chronic illness. In terms of infection context, 10 studies focused on an actual respiratory infection outbreak/pandemic, namely SARS and the H1N1 2009 pandemic. Typically, the included studies explored multiple non-pharmaceutical interventions or combined mitigation strategies involving pharmaceutical and non-pharmaceutical interventions. Personal protective measures were most commonly studied (n = 10).
       <table-wrap id="Tab3">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          <bold>
           Characteristics of included studies
          </bold>
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Study (country)
           </th>
           <th align="center">
            Infection context (timing)
           </th>
           <th align="center">
            Participants (sampling)
           </th>
           <th align="center">
            Data collection and analysis
           </th>
           <th align="center">
            Behaviour type
           </th>
           <th align="center">
            Aims
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            <bold>
             Cava et al. (2005)
            </bold>
            [
            <xref ref-type="bibr" rid="CR36">
             36
            </xref>
            ,
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ] Canada
           </td>
           <td align="center">
            <bold>
             SARS
            </bold>
            (During SARS, 2003-2004)
           </td>
           <td align="center">
            21 adults quarantined during SARS outbreak in Toronto. (Stratified random)
           </td>
           <td align="center">
            Semi-structured interviews (21) Not stated (Miles &amp; Huberman 1994)
            <sup>
             †
            </sup>
           </td>
           <td align="center">
            <bold>
             ISOLATION
            </bold>
            (Quarantine)
           </td>
           <td>
            <italic>
             To explore the experience of being on quarantine for severe acute respiratory syndrome (SARS) with a focus on the relationship between perceived risk of contracting SARS and reported compliance with the quarantine order and protocols.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Janssen et al. (2006)
            </bold>
            [
            <xref ref-type="bibr" rid="CR38">
             38
            </xref>
            ]USA
           </td>
           <td align="center">
            <bold>
             Avian Flu
            </bold>
            (Non-pandemic, 2005)
           </td>
           <td align="center">
            136 members of the general public. (Purposive)
           </td>
           <td align="center">
            Focus groups Not stated
           </td>
           <td align="center">
            <bold>
             PPM*
            </bold>
            (hygiene &amp; vaccination)
           </td>
           <td>
            <italic>
             To test pandemic influenza messages with the public for understandability, believability/credibility, level of interest in the subject, perceived importance of the information, likelihood of action after being exposed to the information, and unanticipated consequences of the information.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Elledge et al. (2008)
            </bold>
            [
            <xref ref-type="bibr" rid="CR39">
             39
            </xref>
            ] USA
           </td>
           <td align="center">
            <bold>
             Avian Flu
            </bold>
            (Non-pandemic, 2006)
           </td>
           <td align="center">
            60 members of the general public.(Not stated)
           </td>
           <td align="center">
            Focus groups (12) Not stated
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (hygiene)
           </td>
           <td>
            <italic>
             To determine the level of awareness of avian and pandemic flu for the county health department to develop effective communication messages
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Jiang et al. (2009)
            </bold>
            [
            <xref ref-type="bibr" rid="CR40">
             40
            </xref>
            ]UK &amp; Netherlands
           </td>
           <td align="center">
            <bold>
             SARS
            </bold>
            (Post SARS, 2005-2006)
           </td>
           <td align="center">
            164 European Chinese adults living in the UK &amp; Netherlands. (Purposive)
           </td>
           <td align="center">
            Focus groups (23) Framework analysis (Ritchie J, Lewis J 2003)
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Mask wearing and personal distancing)
           </td>
           <td>
            <italic>
             To examine SARS-related risk perceptions and their impacts on precautionary actions and adverse consequences from the perspective of vulnerable communities living in unaffected regions.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Morrison &amp; Yardley (2009)
            </bold>
            [
            <xref ref-type="bibr" rid="CR41">
             41
            </xref>
            ]UK
           </td>
           <td align="center">
            <bold>
             Pandemic Flu
            </bold>
            (Non-pandemic, 2008)
           </td>
           <td align="center">
            31 members of the general public. (Purposive)
           </td>
           <td align="center">
            Focus groups (8) &amp; semi structured interview (1) Thematic analysis (Joffe H, Yardley L, 2004)
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Hygiene &amp; personal distancing)
           </td>
           <td>
            <italic>
             To examine perceptions of infection control measures in the context of pandemic influenza.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Baum et al. (2009)
            </bold>
            [
            <xref ref-type="bibr" rid="CR42">
             42
            </xref>
            ]USA
           </td>
           <td align="center">
            <bold>
             Pandemic Flu
            </bold>
            (Non-pandemic, 2008)
           </td>
           <td align="center">
            37 members of the general public. (Purposive)
           </td>
           <td align="center">
            Focus groups (4) Thematic analysis (Creswell 2006; Krueger 1998; Weber 1990).
           </td>
           <td align="center">
            <bold>
             DISTANCING
            </bold>
            (closure of schools, workplaces, public gatherings and quarantine)
           </td>
           <td>
            <italic>
             To characterize public perceptions about social distancing measures likely to be implemented during a pandemic.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Caress et al. (2010)
            </bold>
            [
            <xref ref-type="bibr" rid="CR43">
             43
            </xref>
            ]UK
           </td>
           <td align="center">
            <bold>
             H1N1 2009
            </bold>
            (Pandemic, 2009-2010)
           </td>
           <td align="center">
            50 adults with a clinician-diagnosed chest problem &amp; their family members(Purposive)
           </td>
           <td align="center">
            One to one interviews (20) &amp; focus groups (3) Framework analysis (Ritchie &amp; Spencer, 1994)
           </td>
           <td align="center">
            <bold>
             ISOLATION &amp; REMOTE CARE
            </bold>
            (Social isolation, help seeking and vaccination)
           </td>
           <td>
            <italic>
             To explore and compare information needs, worries and concerns, and health-related behaviours regarding swine flu in people with respiratory conditions and their family members.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Yardley et al. (2010)
            </bold>
            [
            <xref ref-type="bibr" rid="CR44">
             44
            </xref>
            ]UK
           </td>
           <td align="center">
            <bold>
             Seasonal Flu and H1N1 2009
            </bold>
            (Pandemic, 2009)
           </td>
           <td align="center">
            28 members of the general public.(Purposive)
           </td>
           <td align="center">
            Semi structured -think aloud interviews Thematic analysis (Braun &amp; Clarke, 2006; Joffe &amp; Yardley, 2004)
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Hand washing)
           </td>
           <td>
            <italic>
             To explore attitudes towards preventive behaviours to reduce the risk of transmission of seasonal and pandemic flu in the UK in order to inform development of an intervention.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Sui (2010)
            </bold>
            [
            <xref ref-type="bibr" rid="CR45">
             45
            </xref>
            ] Hong Kong
           </td>
           <td align="center">
            <bold>
             H1N1 2009
            </bold>
            (Pandemic, 2009)
           </td>
           <td align="center">
            30 chronic renal disease patients (Purposive)
           </td>
           <td align="center">
            Participant observation, semi-structured interviewsThematic content analysis (Liamputtong &amp; Ezzy, 2005)
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Mask wearing and personal distancing)
           </td>
           <td>
            <italic>
             To demonstrate the knowledge perceptions of and the preventive health behaviours toward the influenza A H1N1 pandemic among the chronic renal disease patients in Hong Kong.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Hilton &amp; Smith (2010)
            </bold>
            [
            <xref ref-type="bibr" rid="CR46">
             46
            </xref>
            ] UK
           </td>
           <td align="center">
            <bold>
             H1N1 2009
            </bold>
            (Pandemic, 2009-2010)
           </td>
           <td align="center">
            73 members of the general public. (Purposive)
           </td>
           <td align="center">
            Focus groups (14) Not stated (Pope &amp; Mays 2000)
            <sup>
             †
            </sup>
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Hygiene &amp; vaccination)
           </td>
           <td>
            <italic>
             To examine public understandings of the swine flu pandemic, exploring how people deciphered the threat and perceived they could control the risks.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Ferng et al. (2011)
            </bold>
            [
            <xref ref-type="bibr" rid="CR47">
             47
            </xref>
            ] USA
           </td>
           <td align="center">
            <bold>
             Influenza-like illness
            </bold>
            (Non-pandemic, 2008)
           </td>
           <td align="center">
            15 Hispanic females living in USA (Purposive)
           </td>
           <td align="center">
            Participant observation and one focus group Not stated
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Mask wearing)
           </td>
           <td>
            <italic>
             To identify barriers to mask wearing for influenza-like illness and to examine the factors associated with the willingness to wear masks among households.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Nizame et al. (2011)
            </bold>
            [
            <xref ref-type="bibr" rid="CR48">
             48
            </xref>
            ] Bangladesh
           </td>
           <td align="center">
            <bold>
             Respiratory infections
            </bold>
            (Non-pandemic, 2008-2009)
           </td>
           <td align="center">
            178 members of the general public. (Purposive)
           </td>
           <td align="center">
            Interviews (34) &amp; Focus Groups (16) Thematic content analysis
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Hand and respiratory hygiene
           </td>
           <td>
            <italic>
             To explore community perceptions on respiratory infections, why they occur, how they are spread, and the preventive measures that people take to protect themselves and their families.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Teasdale &amp; Yardley (2011)
            </bold>
            [
            <xref ref-type="bibr" rid="CR49">
             49
            </xref>
            ] UK
           </td>
           <td align="center">
            <bold>
             H1N1 2009
            </bold>
            (Pandemic, 2009)
           </td>
           <td align="center">
            48 members of the general public. sive)
           </td>
           <td align="center">
            Focus groups (11) Thematic analysis (Braun &amp; Clarke, 2006; Joffe &amp; Yardley, 2004)
           </td>
           <td align="center">
            <bold>
             ISOLATION &amp; REMOTE CARE
            </bold>
            (Social isolation, remote health care &amp; vaccination)
           </td>
           <td>
            <italic>
             To explore people’s beliefs, perceptions, reasoning, and emotional and contextual factors that may influence responses to government recommendations for managing flu pandemics.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Gray et al. (2012)
            </bold>
            [
            <xref ref-type="bibr" rid="CR50">
             50
            </xref>
            ] New Zealand
           </td>
           <td align="center">
            <bold>
             H1N1 2009
            </bold>
            (Pandemic, 2010)
           </td>
           <td align="center">
            80 members of the general public. (Purposive)
           </td>
           <td align="center">
            Focus groups (8) Thematic analysis (Braun and Clarke, 2006)
           </td>
           <td align="center">
            <bold>
             PPM &amp; DISTANCING
            </bold>
            (social isolation, social distancing &amp; vaccination)
           </td>
           <td>
            <italic>
             To provide qualitative data about community responses to key health messages in the 2009 and 2010 H1N1 campaigns, the impact of messages on behavioural change and the differential impact on vulnerable groups in New Zealand.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Rodriguez (2012)
            </bold>
            [
            <xref ref-type="bibr" rid="CR51">
             51
            </xref>
            ] Spain
           </td>
           <td align="center">
            <bold>
             H1N1 2009
            </bold>
            (Pandemic, 2010)
           </td>
           <td align="center">
            51 members of the general public.(Purposive)
           </td>
           <td align="center">
            Focus groups (10) Not stated
           </td>
           <td align="center">
            <bold>
             PPM
            </bold>
            (Hygiene &amp; vaccination)
           </td>
           <td>
            <italic>
             To explore the views of the general population, the risk groups and medical personnel on the H1N1 influenza epidemic of winter 2009-2010.
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Seale et al. (2012)
            </bold>
            [
            <xref ref-type="bibr" rid="CR52">
             52
            </xref>
            ] Australia
           </td>
           <td align="center">
            <bold>
             Seasonal Flu and H1N1 2009
            </bold>
            (Pandemic, 2010)
           </td>
           <td align="center">
            20 university students in New South Wales. (Convenience)
           </td>
           <td align="center">
            Semi-structured interviews Not stated
           </td>
           <td align="center">
            <bold>
             PPM &amp; DISTANCING
            </bold>
            (Hygiene, social distancing and isolation)
           </td>
           <td>
            <italic>
             To examine the knowledge, attitudes, risk perceptions, practices and barriers towards influenza and infection control strategies.
            </italic>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          *PPM – Personal Protective Measures † Analytical method was not explicitly stated, however relevant reference was provided.
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Key themes
      </title>
      <p>
       The synthesis findings comprised three parts: 1) the ways in which the public evaluate non-pharmaceutical interventions, 2) public beliefs about respiratory infections and emerging outbreaks, 3) presentation of advice on adopting non-pharmaceutical respiratory infection control i.e. public preferences for how and by whom non-pharmaceutical respiratory infection control advice is presented. This paper focuses on the first two parts as they were relevant to the original aim of the review of understanding public perceptions of non-pharmaceutical interventions rather than views about how advice about adopting these behaviours is presented. Seven key themes were identified:
       <italic>
        perceived benefits of non-pharmaceutical interventions, perceived disadvantages of non-pharmaceutical interventions, personal and cultural beliefs about infection transmission, diagnostic uncertainty in emerging respiratory infections, perceived vulnerability to respiratory infection, anxiety about emerging respiratory infections and communications about emerging respiratory infections
       </italic>
       (Figure
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       ). Table
       <xref ref-type="table" rid="Tab4">
        4
       </xref>
       presents the definitions of each theme and an index of which themes were present in each paper. The themes and corresponding quotes are described below. Quotes are labelled with study reference, population, infection context and location.
       <fig id="Fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          <bold>
           Themes and sub-themes of synthesis data.
          </bold>
         </p>
        </caption>
        <graphic id="d29e1285" xlink:href="12889_2014_Article_6689_Fig2_HTML">
        </graphic>
       </fig>
      </p>
      <table-wrap id="Tab4">
       <label>
        Table 4
       </label>
       <caption>
        <p>
         <bold>
          Contribution of key themes from each study
         </bold>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th>
           Theme Sub-theme
          </th>
          <th>
           Summary definition
          </th>
          <th colspan="7">
           Study reference by infection context and study population
          </th>
         </tr>
         <tr>
          <th colspan="3" rowspan="2">
          </th>
          <th colspan="2">
           SARS
          </th>
          <th colspan="2">
           Non-pandemic
          </th>
          <th colspan="3">
           H1N1 2009 pandemic
          </th>
         </tr>
         <tr>
          <th>
           S1
          </th>
          <th>
           S2
          </th>
          <th>
           N1
          </th>
          <th>
           N2
          </th>
          <th>
           P1
          </th>
          <th>
           P2
          </th>
          <th>
           P3
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           1
          </td>
          <td colspan="9">
           Perceived benefits of non-pharmaceutical interventions
          </td>
         </tr>
         <tr>
          <td>
           a
          </td>
          <td>
           Hand and respiratory hygiene is common sense/familiar
          </td>
          <td>
           Hygiene behaviours are seen as familiar and acceptable in varying contexts and populations
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR38">
            38
           </xref>
           ,
           <xref ref-type="bibr" rid="CR39">
            39
           </xref>
           ,
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ,
           <xref ref-type="bibr" rid="CR48">
            48
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR44">
            44
           </xref>
           ,
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           –
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           b
          </td>
          <td>
           Mask wearing demonstrates responsibility and reduces stigma
          </td>
          <td>
           Mask wearing is seen as a way of visibly demonstrating one’s desire to protect self and others from infection, which can in turn reduce social stigma experienced.
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR45">
            45
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           c
          </td>
          <td>
           Social isolation and distancing are socially responsible actions
          </td>
          <td>
           Isolation and distancing are believed to be socially responsible actions and seen as necessary for the protection of society as a whole
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR36">
            36
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ,
           <xref ref-type="bibr" rid="CR42">
            42
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           2
          </td>
          <td colspan="9">
           Perceived disadvantages of non-pharmaceutical interventions
          </td>
         </tr>
         <tr>
          <td>
           a
          </td>
          <td>
           Hand washing for respiratory infection control is irrelevant
          </td>
          <td>
           Additional hand washing behaviours are seen as irrelevant by those who class themselves as regular hand washers
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR44">
            44
           </xref>
           ,
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           b
          </td>
          <td>
           Hand washing and mask wearing can attract social stigma
          </td>
          <td>
           Hand washing and mask wearing are perceived as socially unacceptable due to the potential to attract discrimination and embarrassment
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR40">
            40
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR47">
            47
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR44">
            44
           </xref>
           ,
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           c
          </td>
          <td>
           Non-pharmaceutical behaviours have negative personal and socioeconomic impacts
          </td>
          <td>
           Perceived physical, practical, emotional and socioeconomic costs of isolation social distancing, mask wearing and hygiene behaviours
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR36">
            36
           </xref>
           ,
           <xref ref-type="bibr" rid="CR37">
            37
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ,
           <xref ref-type="bibr" rid="CR42">
            42
           </xref>
           ,
           <xref ref-type="bibr" rid="CR48">
            48
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR47">
            47
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR44">
            44
           </xref>
           ,
           <xref ref-type="bibr" rid="CR49">
            49
           </xref>
           –
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           ]
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           3
          </td>
          <td colspan="9">
           Personal/cultural beliefs about infection transmission
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
           Common beliefs about respiratory infections are caught and spread e.g. via air, from symptomatic others and in cold temperatures
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR36">
            36
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR40">
            40
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ,
           <xref ref-type="bibr" rid="CR48">
            48
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR44">
            44
           </xref>
           ,
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR49">
            49
           </xref>
           ,
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           4
          </td>
          <td colspan="9">
           Diagnostic uncertainty in emerging respiratory infections
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
           Identifying symptoms of and having to diagnose infection in an emerging respiratory infection is seen as confusing and concerning and can lead to uncertainty about when to adopt infection control
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR36">
            36
           </xref>
           ,
           <xref ref-type="bibr" rid="CR37">
            37
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR49">
            49
           </xref>
           –
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           5
          </td>
          <td colspan="9">
           Perceived vulnerability to respiratory infections
          </td>
         </tr>
         <tr>
          <td>
           a
          </td>
          <td>
           Perceived health status
          </td>
          <td>
           Evaluating one’s vulnerability to respiratory infection in terms of own perceived health status and the health of others
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR44">
            44
           </xref>
           ,
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           –
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ,
           <xref ref-type="bibr" rid="CR45">
            45
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           b
          </td>
          <td>
           Proximity to the origin of outbreak
          </td>
          <td>
           Evaluating susceptibility to a new respiratory infection in terms of geographical proximity to the origin of the outbreak and type of living environment
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR40">
            40
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR38">
            38
           </xref>
           ,
           <xref ref-type="bibr" rid="CR39">
            39
           </xref>
           ,
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ,
           <xref ref-type="bibr" rid="CR42">
            42
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           ,
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           6
          </td>
          <td>
           Anxiety about emerging respiratory infections
          </td>
          <td colspan="8">
          </td>
         </tr>
         <tr>
          <td>
           a
          </td>
          <td>
           Decreasing anxiety over the course of an outbreak
          </td>
          <td>
           Initial anxiety in an outbreak decreases over the course of the outbreak as public reassess the risk/impact of a new respiratory infection according to personal experience vs. information presented in the media
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR40">
            40
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR49">
            49
           </xref>
           ,
           <xref ref-type="bibr" rid="CR51">
            51
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           b
          </td>
          <td>
           High anxiety if perceived to be more vulnerable
          </td>
          <td>
           Greater anxiety experienced during H1N1 by those who perceived themselves to be more vulnerable to infection.
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR51">
            51
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           c
          </td>
          <td>
           Low anxiety
          </td>
          <td>
           Low levels of worry experienced during an emerging respiratory infection outbreak
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR49">
            49
           </xref>
           ,
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           7
          </td>
          <td colspan="9">
           Communications about emerging respiratory infections
          </td>
         </tr>
         <tr>
          <td>
           a
          </td>
          <td>
           Media reporting of information on new respiratory infection outbreaks is seen overhyped
          </td>
          <td>
           People appraise the credibility of information/communications about a new respiratory outbreak in terms of consistency of information and perceived exaggeration compared to actual/previous experience
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR36">
            36
           </xref>
           ,
           <xref ref-type="bibr" rid="CR37">
            37
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR40">
            40
           </xref>
           ]
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR39">
            39
           </xref>
           ,
           <xref ref-type="bibr" rid="CR41">
            41
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR46">
            46
           </xref>
           ,
           <xref ref-type="bibr" rid="CR49">
            49
           </xref>
           –
           <xref ref-type="bibr" rid="CR52">
            52
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           b
          </td>
          <td>
           Official communication about new respiratory infection outbreaks is not reliable (threat is downplayed)
          </td>
          <td>
           Some people’s evaluation of information influenced by scepticism about level of detail presented (i.e. not being given all the facts)
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR39">
            39
           </xref>
           ,
           <xref ref-type="bibr" rid="CR42">
            42
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR50">
            50
           </xref>
           ]
          </td>
          <td>
          </td>
          <td>
           [
           <xref ref-type="bibr" rid="CR43">
            43
           </xref>
           ]
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         S1: SARS general public, S2: SARS ethnic groups; N1: Non-pandemic general public, N2: Non-pandemic ethnic groups; P1: H1N1 general public, P2: H1N1 ethnic groups, P3: H1N1 patient groups.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec id="Sec9">
      <title>
       Perceived benefits of non-pharmaceutical interventions
      </title>
      <p>
       Some personal protective measures, such as hand-washing and respiratory hygiene, appeared to be widely acceptable methods for preventing respiratory infection transmission across several studies. Studies conducted prior to and during the H1N1 2009 pandemic indicated that people were generally very familiar with hand and respiratory hygiene behaviours (e.g. hand washing, cough/sneeze etiquette) and viewed them as usual, acceptable, common-sense actions to reduce infection transmission.
      </p>
      <p>
       <italic>
        “Mainly they tell you to wash your hands....Cover your mouth when you cough.......And don’t share hankies, they say, yeah.” (Pacific Peoples, H1N1 2009, New Zealand)
       </italic>
       [
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ]
      </p>
      <p>
       <italic>
        “I already do the necessary, like washing my hands after the loo, which is, well, common practice and basic hygiene and being aware of it” (General public, non-pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ]
      </p>
      <p>
       For people who perceive themselves to be at high risk of catching and spreading respiratory infections, mask wearing was seen not only as an effective but also as a visibly demonstrative method of respiratory infection control, which could reduce social stigma. Chronic kidney disease (CKD) patients in Hong Kong saw mask wearing as a useful way to demonstrate their desire to be socially responsible and protect themselves and others during H1N1 2009 pandemic. This was related to social stigma experienced by CKD patients in Hong Kong during SARS, where they were perceived publically as high risk ‘super spreaders’ of infection.
      </p>
      <p>
       <italic>
        “I wore facemasks all the time to tell others that I was responsible about my own and about others’ health. This strategy really worked as my friends and colleagues did not isolate me too much since then. I think I can use the same strategy in this swine flu to make others feel more comfortable with me, because I can show that even if I carry a lot of flu virus, I have already tried my best to protect their health by wearing facemasks.” (CKD patient, H1N1 2009, Hong Kong)
       </italic>
       [
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
       ]
      </p>
      <p>
       Similarly, isolation and social distancing behaviours were viewed as acceptable in some contexts as a way of being socially responsible (i.e. protecting wider society). For example, being isolated or quarantined during SARS was accepted as necessary in order to protect others from infection. Studies conducted in a non-pandemic context indicated that the general public viewed home isolation, closure of schools and public gathering places (e.g. religious centres), and travel restrictions during an emerging respiratory infection outbreak as important for the protection of society as a whole, and would adopt these behaviours in principle for the greater good.
      </p>
      <p>
       <italic>
        “We’re all trying to be good citizens. And we’re all trying to help, you know, other people by making sacrifices like being in quarantine.” (General public, SARS 2005, Canada)
       </italic>
       [
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ]
      </p>
      <p>
       <italic>
        “. . . you know, if you can’t go to church for one week because everyone’s sick, then you know, call everybody on the phone or something. Do something different for the good of everybody else; you may have to suffer a little bit here and there.” (General public, non-pandemic 2009, USA)
       </italic>
       [
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ]
       <italic>
        .
       </italic>
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Perceived disadvantages of non-pharmaceutical interventions
      </title>
      <p>
       Non-pharmaceutical respiratory infection control was seen as problematic for some in terms of its perceived irrelevance. In particular, studies conducted pre and during H1N1 2009 pandemic suggested that advice to carry out additional hand washing or to focus on hand washing solely or intentionally for respiratory infection control was not seen as necessary or relevant to members of the general public who perceived themselves to be ‘regular hand washers’ (i.e. already regularly wash their hands for basic hygiene). This highlights the habitual, ingrained nature of hand washing behaviour and the firmly established social norms around when is acceptable to wash hands (e.g. after going to the toilet), which are likely to influence the perceived acceptability of hygiene behaviours [
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ].
      </p>
      <p>
       <italic>
        “I don’t think that anybody washes their hands more than what they already do. You only wash your hands at normal intervals that I think you would normally, like if you're eating, after you've been to the toilet, etcetera.” (General public, non-pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ].
      </p>
      <p>
       <italic>
        “I can’t say I’ve changed anything cos I already do my hand washing, so others might benefit from this advice more really.” (General public, H1N1 2009 pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ].
      </p>
      <p>
       Potential to attract social stigma and cause embarrassment or discrimination was another perceived downside of adopting personal protective measures. Concerns about frequent hand-washing attracting social stigma (being perceived as overly fastidious or obsessive) or causing offence (insisting on hygienic behaviours in others) were evident in various infection contexts. Likewise, it appeared that mask wearing, although seen by some as an effective precaution, could generate concern about attracting discrimination. This was due to the presence of a mask being seen to explicitly indicate infection/illness in the wearer.
      </p>
      <p>
       <italic>
        ”If I’d said [when meeting friends for lunch] ah, before we touch any food we must all go and wash our hands, I’m not sure what everybody’s reaction would’ve been … I think people would’ve looked at me as if I’m slightly mad. ”(General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ].
      </p>
      <p>
       <italic>
        “Going out to the streets with a mask, people would stare at you as if you were contagious, but what they don’t know is that the mask is also protecting us from them” (Hispanic female, non-pandemic, USA)
       </italic>
       [
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
       ].
      </p>
      <p>
       <italic>
        “.. .is he ill or is he dangerous something like that?
       </italic>
      </p>
      <p>
       <italic>
        .. .like the old leprosy people in Europe.. .” (Domestic student, H1N1 2009, Australia)
       </italic>
       [
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ].
      </p>
      <p>
       Other perceived drawbacks revolved around the potential negative impact of adopting non-pharmaceutical respiratory infection control. Common perceived barriers to carrying out personal protective measures appeared to relate to personal impacts such as the perceived physical discomfort of mask wearing (e.g. difficulties breathing whilst wearing masks), and the perceived discomfort and impracticalities of hand and respiratory hygiene (e.g. dry, sore hands and noses from frequent hand washing and tissue use; not having tissues when you need them and inconvenience of frequent hand-washing).
      </p>
      <p>
       <italic>
        “It is hard to breathe with the mask. It is uncomfortable around chin area because I am sweating and the mask feels damp” (Hispanic female, non-pandemic, USA)
       </italic>
       [
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
       ].
      </p>
      <p>
       <italic>
        “People don’t wash their hands after sneezing and coughing. Is it possible to wash hands frequently? If you sneeze 100 times, will you wash your hands 100 times? But we should wash our hands before taking a meal.”(General public, non-pandemic, Bangladesh)
       </italic>
       [
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ].
      </p>
      <p>
       Common perceived barriers to social isolation and personal distancing from those who were symptomatic seemed to relate to perceived emotional costs. For example, people who were quarantined during SARS reported feeling segregated and stigmatised for being infected.
      </p>
      <p>
       <italic>
        “Well I didn’t know I was going to get into this, but I actually feel like crying just to think about it, because I’m sure you saw the movie Ben Hur. I thought of that movie all the time while I was in quarantine because I remember the part of him going and looking for his sister and his mother, where they had that . . . sickness, leprosy. And they could not be with the rest of the people. They were down in a valley where all these people were and that’s how I felt. I was separate from the world.” (General public, SARS 2005, Canada)
       </italic>
       [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ].
      </p>
      <p>
       Furthermore, personal distancing was viewed as unacceptable within households and some cultural groups as it may limit social interactions which were perceived as socially and culturally necessary. For Maori people in New Zealand during H1N1, concerns about being able to continue to observe specific cultural practices and greeting protocols seemed to outweigh the perceived need to adopt personal distancing behaviours. Similarly, studies conducted pre-H1N1 and during SARS, suggested that the perceived need or wish to care for sick (isolated) loved ones can override any concerns about self-protection and personal distancing.
      </p>
      <p>
       <italic>
        “My older sister said something about me having a really bad cold that weekend. And that’s only when I realized I could have got it. And I could have been very, very sick. I could have died. But it never, ever came to mind. We were so focused on her.” (General public, SARS 2005, Canada)
       </italic>
       [
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ].
      </p>
      <p>
       <italic>
        “But don't you have some kind of duty, or at least I think I do to look after that person.
       </italic>
      </p>
      <p>
       <italic>
        What if it’s a baby you've got to look after you can't do it can you?”
       </italic>
       <italic>
        (General public, non-pandemic 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ].
      </p>
      <p>
       People also seemed to consider the feasibility of distancing behaviours (social isolation and social distancing) in terms of the economic impact, both on a personal and societal level. Common perceived obstacles to staying home if sick and social distancing (such as school closures) during the H1N1 2009 pandemic were economic pressures to continue to work and concerns about familial and workplace commitments, and the wider adverse socioeconomic economic impact.
      </p>
      <p>
       <italic>
        “The girl downstairs who got swine flu, works in my office, came to work three times with swine flu because she was bored at home, felt that there were things that needed doing in the office, and felt guilty at being away for so long. She came in, not being able to find a manager, hang around for three hours and then got sent home again” (General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ].
      </p>
      <p>
       <italic>
        “. . if they keep your kids home from school so you can’t work, people are going to go, ’I can’t do that, you know, I have to go to work, I have to have somebody take care of my kids’ . . . some people might choose to keep their kids home from school if they had that luxury, but too many people now don’t.” (General public, non-pandemic, USA)
       </italic>
       [
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ].
      </p>
      <p>
       <italic>
        “If you shut down the schools though, you’ve basically shut down the economy because you’d have to have, then people would have to stay home so you’re affecting a lot more than people getting sick, you’ve just affected a huge financial working to the bulk of the country. That’s a big decision.” (General public, non-pandemic, USA)
       </italic>
       [
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ]
       <italic>
        .
       </italic>
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       Personal and cultural beliefs about infection transmission
      </title>
      <p>
       Common personal and cultural beliefs about how respiratory infections are caught and spread were evident across various infection contexts. Typically, respiratory viruses were seen as transmitted by air, caught via proximity to symptomatic others and more likely to be spread in cold ambient and water temperatures. Such beliefs are likely to influence the perceived efficacy of non-pharmaceutical interventions, particularly social isolation.
      </p>
      <p>
       <italic>
        “I’ve always thought that on an aeroplane, because they re-circulate the air, there’s a chance that viruses and things are perhaps recycled through the air or ventilation system.” (General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ]
      </p>
      <p>
       <italic>
        “Just because like you haven’t got any symptoms doesn’t mean you are not carrying the germ. You know, everyone thinks that umm you know if someone’s got a cold and you stand, don’t stand near me, but just by talking to them you’ve probably picked up the germ. So I don’t really see the point in staying at home if you’ve got the symptoms because the chances are everyone has already come into contact with it anyway” (General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ].
      </p>
      <p>
       <italic>
        “A person should not be in contact with cold water for a long time to avoid getting cold/cough.” (General public, non-pandemic, Bangladesh)
       </italic>
       [
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Diagnostic uncertainty in emerging respiratory infections
      </title>
      <p>
       People seemed to acknowledge that a degree of uncertainty is to be expected in an emerging respiratory infection such as SARS. However, during the H1N1 2009 pandemic, they expressed doubts about their ability to identify symptoms (e.g. distinguishing pandemic flu symptoms from seasonal flu symptoms) and concerns at having to self-diagnose or make their own judgement about the presence of infection. Such diagnostic uncertainty seemed to be exacerbated for people who had other health concerns. This suggests that people do not see it as their role to self-diagnose in an emerging respiratory infection outbreak, which could influence the likelihood of implementing non-pharmaceutical interventions such as social isolation and using remote healthcare when symptomatic.
      </p>
      <p>
       <italic>
        “I mean, the big thing is what are the symptoms, particularly what are the unique symptoms to whatever the pandemic is, that differentiates it from regular flu, or a cold? And how infectious is it, and what’s the mechanism of infection” (General public, H1N1 2009, New Zealand)
       </italic>
       [
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ].
      </p>
      <p>
       <italic>
        “I think the vagueness of the symptoms could be confused with perhaps ordinary flu or just your condition really. You know, if you’ve got COPD, then it’s not necessarily swine flu at all. And I don’t really know how you can say it’s swine flu without having any tests [others in group agreeing].” (Chest patient, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
       ].
      </p>
      <p>
       <italic>
        “I think probably the most difficult part is to decide whether you have swine flu or not. So lots of people will be confused, when they have symptoms, what should they do” (General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       Perceived vulnerability to respiratory infection
      </title>
      <p>
       In general the public appeared to accept the existence of risk to the community in an emerging respiratory infection outbreak. However, some may view themselves as less vulnerable or more capable than ‘others’ who they identify as high risk. During the H1N1 2009 pandemic the public seemed to evaluate their vulnerability to respiratory infection in terms of perceived health status and their proximity to the origin of outbreak (both in terms of geographical distance and perceived differences in living environments). A common belief expressed was that ‘others’ were at increased risk of infection, including people with chronic health problems, those in particular occupations (e.g. teachers), and those with impaired immune systems. This reflects a typical way of dealing with a health risk and its negative impact by “othering” i.e. blaming or differentiating the self from ‘the other’ or other groups of people and consequently denying personal risk [
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ]. This may result in people viewing non-pharmaceutical interventions to minimise the spread of infection in an emerging outbreak as more applicable to others than to themselves.
      </p>
      <p>
       <italic>
        P1: “I’m personally not worried. I think my immune system is working well and I’m not in the situation of having an illness. P2: Same. I know like thousands of people have got it, but…I don’t personally feel at risk.” (General public, H1N1 2009 pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ].
      </p>
      <p>
       Similarly, in non-pandemic contexts the public appeared to focus on their lack of geographical proximity to the perceived origins of an emerging respiratory infection outbreak. A common belief was that a novel respiratory virus was unlikely to originate in a ‘modern, developed country’ so they would have more time to prepare and cope better if and when it reached them. For some, the perceived lack of geographical proximity to the outbreak seemed to result in a perceived lack of immediacy of risk, which suggests that risk of infection would need to be locally imminent (evident) before advice messages would be considered and behaviours adopted.
      </p>
      <p>
       <italic>
        P2: “You've gotta think, I think we're a quite clean country compared to other places like I said it will be a less.
       </italic>
      </p>
      <p>
       <italic>
        P4: Developed P2: Developed country I think that develops it first P1: And that spreads it quicker P4: And that will educate us.
       </italic>
      </p>
      <p>
       <italic>
        P1: We can get a vaccine off of them, sounds nasty but it's true, it's how the world works” (General public, non-pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ].
      </p>
      <p>
       <italic>
        “. . . that right now it’s in some third world country and it may come here. I don’t think that’s going to be good enough. I think there’s going to have to be some indication that it is actually in your own community before you take steps as drastic as shutting down anything.” (General public, non-pandemic, USA)
       </italic>
       [
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ]
       <italic>
        .
       </italic>
      </p>
      <p>
       In a pandemic context, the concept of geographical proximity was challenged. Instead, it was recognised that respiratory viruses could spread worldwide quite rapidly and to more geographically remote locations due to air travel.
      </p>
      <p>
       <italic>
        “Well we think that we’re different because we’re far away. But actually, if you think of how people travelled here, it’s the biggest factor for it always, because everyone who comes here comes in an aeroplane, pretty much. And they come from everywhere.” (General public, H1N1 2009, New Zealand)
       </italic>
       [
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ].
      </p>
      <p>
       During the H1N1 2009 pandemic the public also appeared to evaluate their susceptibility to a new respiratory infection in terms of their own living environments compared to the living circumstances where they believed a novel respiratory infection was likely to emerge (e.g. low hygiene levels, high population density, poor border control and health systems).
      </p>
      <p>
       <italic>
        “It won’t be like ones in the past, years ago. There’s so much medical research been done. And things are cleaner, better housing, people are cleaner and the streets are cleaner so a pandemic wouldn’t be so bad now” (General public, H1N1 2009 pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ].
      </p>
      <p>
       <italic>
        “.. ..some cultures where they have let say more respect for traditional medicine than modern medicine.. .. …are also going to be a problem.. .that’s why lots of pandemic in say Asia and Africa, and not so much in Europe or America” (International postgraduate student, H1N1 2009, Australia)
       </italic>
       [
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ].
      </p>
      <p>
       This seems to reflect a belief that it ‘won’t happen to me, it happens to others, elsewhere’ and suggests that the public do not rationally evaluate their risk of infection but actively try to distance themselves from the threat by delineating themselves from others and other circumstances which are associated with risk of infection. This may lead to underestimating personal risk in an emerging respiratory infection outbreak and feeling that advice to adopt non-pharmaceutical interventions is not relevant.
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       Anxiety about emerging respiratory infections
      </title>
      <p>
       The novelty factor (shock of the new) appeared to affect public anxiety in the early stages of an emerging outbreak. During SARS and the H1N1 2009 pandemic public anxiety typically evolved over time from an initial state of anxiety gradually decreasing to the point of people making light of it as the public’s familiarity with the outbreak or respiratory infection increased through personal experience or knowing someone who had contracted it. This could be a further example of people distancing themselves from threat in order to cope with the novel health threat.
      </p>
      <p>
       <italic>
        “I think everyone has taken it a lot less seriously now than when it was first like, when it was first thing, then everyone was like ahhh, we have this swine flu and everybody is going to die but not now, it’s like if someone coughs, “ha swine flu!”, you know, no one cares now”
       </italic>
       <italic>
        (General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ].
      </p>
      <p>
       <italic>
        “There is so much joking about it, like I was on the train and this guy just coughed, and he was like, ’it’s ok, it’s not mutated, I don’t have swine flu’ and everyone just laughed. No, I don’t think people are worried about it” (General public, H1N1 2009 pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ].
      </p>
      <p>
       For some, particularly those who were regarded to be more vulnerable to infection (e.g. people with a chronic illness, pregnant women, mothers of young children), the novelty of the virus and in particular their perceived lack of protection from it seemed to contribute to their worry.
      </p>
      <p>
       <italic>
        “[with seasonal flu] we all feel quite safe because we’ve got a protection and we know ordinary seasonal flu can be serious. But we’ve got our jab and it’s protected us. And suddenly there’s a flu out there what there hasn’t been a jab for, and we can catch it as quick as anybody else. And nobody quite knows really what effect it’s going to have on us and I think this has been some of it, because right at this time we’re vulnerable, we’ve no protection given us. And we all feel as we need that protection to get through this … And I think that’s making us worry.” (Chest patient, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
       ].
      </p>
      <p>
       In contrast, some people with other health issues expressed less worry about becoming infected as they saw their current health issues as more pressing.
      </p>
      <p>
       <italic>
        “I can’t eat properly and while I’m eating I’m gasping for breath … so swine flu is the least of my worries, if you know my meaning … this [chest problem] is the priority. If I can get this right, if I can at least walk a little bit more than I can do now, I’d be happy.” (Chest patient, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec15">
      <title>
       Communications about emerging respiratory infections
      </title>
      <p>
       Diminishing anxiety over the course of an outbreak seemed to be influenced by people’s views about communications about an emerging respiratory infection outbreak. Whist some people felt that they were not given all the facts during the H1N1 2009 pandemic or that its severity was prematurely downplayed, generally the public were quite sceptical about the way information on the new respiratory infection was presented to them (especially by the media). Typically, communication efforts are seen as unreliable, premature, inconsistent, sensationalist and unduly alarmist.
      </p>
      <p>
       <italic>
        P1: they’ve [the media] set about and managed to get everyone, or the majority of people into quite a panic about the whole thing. P2: They do on purpose whip up panic and anxiety in people” (General public, H1N1 2009 pandemic, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ]
      </p>
      <p>
       <italic>
        “At the beginning sensationalism -a blast of information-, followed by information in small doses and poor, bad information” (Chronically ill patient, H1N1 2009, Spain)
       </italic>
       [
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
       ]
      </p>
      <p>
       <italic>
        “…the minister said one thing, someone else said another thing, Sarkozy said he was going to get everyone vaccinated, the German [leader] would say whatever, hence, we were getting so much contradictory information” (General public, H1N1 2009, Spain)
       </italic>
       [
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
       ]
      </p>
      <p>
       <italic>
        “I feel they’ve a lot of hype with a lot of things, not just the swine flu, and particularly the media, they like to blow things up, don’t they? They like to scare people really. On the other hand I suppose scaring people is only one way to get them to move.” (Chest patient, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
       ]
      </p>
      <p>
       A common belief was that media reporting in an emerging outbreak is over-hyped or can amplify the risks. It appeared that the public evaluated their personal risk by comparing personal experiences with the ‘official’ information they have been given. When this didn’t match up to actual experiences, the public doubted the credibility of the information being presented and further doubted the media as a reliable information source. This inconsistency may lead to public fatigue about respiratory infection communications and a blunting of advice messages on non-pharmaceutical interventions. Doubts about the perceived credibility and trustworthiness of information about a new respiratory infection outbreak are likely to influence public behavioural responses to an emerging respiratory infection outbreak and may also lead to people to disregard future advice.
      </p>
      <p>
       <italic>
        “It became reasonably clear reasonably quickly last time that hundreds and thousands and millions weren’t dying. Even when they kept on sort of saying things were happening, and then you saw the numbers, it just didn’t add up.” (General public, H1N1 2009, New Zealand)
       </italic>
       [
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ]
      </p>
      <p>
       <italic>
        “Before that we had avian flu, and before that SARS and they were all, this is the end of the world. Don’t travel, don’t eat chickens, watch out for the dead duck in the street. And yeah, it raises your expectations and then nothing happens, and then next time it comes along you are just more cynical” (General public, H1N1 2009, UK)
       </italic>
       [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ]
      </p>
     </sec>
    </sec>
    <sec id="Sec16">
     <title>
      Discussion
     </title>
     <sec id="Sec17">
      <title>
       Main findings
      </title>
      <p>
       Some aspects of non-pharmaceutical respiratory infection control were viewed favourably by participants in these studies due to their familiarity, potential to reduce social stigma and capacity to demonstrate social responsibility or community mindedness. Hand hygiene and respiratory hygiene, in particular, appeared to be well-established and accepted concepts in the minds of these participants. Doubts and concerns existed about the perceived relevance of non-pharmaceutical respiratory infection control, its potential to attract social stigma and its perceived adverse impact (physically, emotionally and socioeconomically). There were particular concerns about personal distancing and the wearing of masks in some contexts. The synthesis also suggested that the perceived necessity, efficacy and feasibility of adopting non-pharmaceutical respiratory infection control may be influenced by personal and cultural beliefs about respiratory infection transmission, perceptions and feelings about vulnerability to respiratory infections, and concerns around self-diagnosis of respiratory infections and the communication of reliable information about respiratory infections in emerging respiratory infection outbreaks.
      </p>
     </sec>
     <sec id="Sec18">
      <title>
       Interpretation of findings in relation to previously published work
      </title>
      <p>
       Synthesising the qualitative literature highlighted the ways in which the public evaluate the feasibility of non-pharmaceutical respiratory infection control. Instead of passively accepting non-pharmaceutical interventions that are recommended to reduce the transmission of respiratory infections, the public actively consider the perceived costs and benefits of adopting non-pharmaceutical interventions and reflect on their beliefs about and feelings towards respiratory infections and emerging outbreaks.
      </p>
      <p>
       Widespread public endorsement of non-pharmaceutical respiratory infection control was highlighted by the synthesis. However, such endorsement of non-pharmaceutical interventions, particularly hygiene, may not accurately and transparently reflect people’s beliefs about these behaviours. Agreeing with the socially desirable position of taking action to protect oneself and others from respiratory infection may instead reflect a more perfunctory or socio-linguistic function. Indeed, by demonstrating that you know and subscribe to what is accepted as ’common-sense’ correct behaviour could serve the purpose of affirming membership of a particular sociocultural group e.g. ‘good citizens’ [
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ]. Given the inconsistency between the socially desirable assertions about hygiene and social distancing behaviours and the numerous perceived barriers and costs of the behaviours that are subsequently raised, this seems quite probable.
      </p>
      <p>
       One reported barrier was diagnostic uncertainty in emerging respiratory infections. In particular, public concern seems to exist about identifying symptoms and making a judgement about the presence of a respiratory infection. The public do not see it as their role to self-diagnose and feel uncomfortable about taking on the perceived role of the doctor. This finding is consistent with previous research suggesting that members of the general public do not feel comfortable with making medical decisions [
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       –
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
       ]. In an emerging respiratory infection outbreak, promotion of self-diagnosis and accessing remote healthcare is vital to reduce spread of respiratory infection and avoid overstretching healthcare services. Further research is required to explore how public confidence in remote healthcare could be improved.
      </p>
      <p>
       Socio-economic barriers to adopting social distancing behaviours were also highlighted in the synthesis. This is consistent with previous research that has shown lack of access to child care and financial barriers with regards to social isolation exist, particularly for those on low incomes [
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       –
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       ]. Difficulties in following non-pharmaceutical interventions faced by those with fewer resources has the potential to exacerbate the socio-economic differences in the public health impact of a respiratory infection, particularly in an emerging outbreak [
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ].
      </p>
      <p>
       Another potential barrier to adopting non-pharmaceutical interventions appears to be the denial of personal risk. Although everyone is potentially at risk of respiratory infection, the public seem to deal with the threat of infection by attributing vulnerability to ‘other, less good’ groups of people. This process of ‘othering’ is consistent with previous qualitative research on how the public make sense of emerging infectious diseases [
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
       ,
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       ]. Such denial could be seen literally as public ignorance or erroneous evaluations of risk of infection. However, denial of personal risk also means asserting that one is not in the group of people who are vulnerable or in danger due to either their risky, unhygienic behaviour or being weak (e.g. due to illness or age) - so rather than a misunderstanding of risk this can reflect a means of coping with the threat of infection. This interpretation suggests an important role of emotional and sociocultural factors in shaping individual ways to perceive and react to respiratory infection risk, rather than assuming that people’s perceptions of respiratory infection risk are purely an individual, rational, cognitive process [
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec19">
      <title>
       Strengths and limitations of the synthesis
      </title>
      <p>
       Our systematic review and synthesis of qualitative studies on non-pharmaceutical respiratory infection control is novel. It provides helpful insight into the ways in which the general public process the risk of respiratory infection and evaluate the feasibility of non-pharmaceutical respiratory infection control. We used rigorous methods of systematic review and referred to the ENTREQ statement [
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       ] to facilitate clear reporting of our synthesis of qualitative research. Although we contacted all authors to obtain any further studies, we did not comprehensively search the grey literature, which may have excluded some relevant literature. The review is clearly limited to the perceptions of participants in the included primary studies, which were typically conducted in more developed countries and predominantly explored perceptions of personal protective measures. However, the synthesis did incorporate people’s perceptions of different non-pharmaceutical respiratory infection control behaviours in varying respiratory infection contexts and can offer a higher level of conceptual thinking about public responses to non-pharmaceutical respiratory infection control across different contexts. Nevertheless, it is acknowledged that the process of synthesising qualitative studies is inherently interpretive. Our synthesis is one possible interpretation of the data. It is entirely possible that another research team may generate another interpretation of this set of studies.
      </p>
     </sec>
     <sec id="Sec20">
      <title>
       Implications for future research, policy and practice
      </title>
      <p>
       Adoption of non-pharmaceutical public health measures is likely to be improved by addressing common public beliefs and concerns about the necessity, efficacy, acceptability and feasibility of non-pharmaceutical respiratory infection control. To maximise adoption of non-pharmaceutical interventions to reduce transmission of respiratory infections it may be necessary to find ways that allow people to associate non-pharmaceutical respiratory infection control with a positive identity rather than a negative or vulnerable identity, i.e. viewing non-pharmaceutical respiratory infection control as behaviours to be adopted by all, not just as actions for those perceived as more vulnerable to infection. For example, positive framing of advice messages around maintaining well-being rather than avoiding infection might improve the perceived relevance of non-pharmaceutical respiratory infection control to those who do not acknowledge that they could be at risk of infection. Further research is needed to clarify how best to reframe advice.
      </p>
     </sec>
    </sec>
    <sec id="Sec21">
     <title>
      Conclusions
     </title>
     <p>
      People engage in an active process of evaluating non-pharmaceutical public health measures to reduce the transmission of acute respiratory infections in terms of their feasibility, credibility and costs. Some aspects of non-pharmaceutical respiratory infection control are seen as familiar and socially responsible actions to take. However, some members of the public have doubts about the relevance of non-pharmaceutical respiratory infection control, its adverse impact and potential to attract social stigma. Potential barriers include beliefs, perceptions and feelings towards respiratory infections and concerns around self-diagnosis and communications in emerging respiratory infection outbreaks. Communication efforts may be improved by addressing such barriers and concerns.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Electronic supplementary material
     </title>
     <sec id="Sec22">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="12889_2014_6689_MOESM1_ESM.doc">
         <caption>
          <p>
           Additional file 1: Systematic review search history: examples from MEDLINE and CINAHL lowchart of systematic search.(DOC 19 KB)
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <app-group>
      <app id="App1">
       <sec id="Sec23">
        <title>
         Authors’ original submitted files for images
        </title>
        <p>
         Below are the links to the authors’ original submitted files for images.
         <media id="MOESM2" position="anchor" xlink:href="12889_2014_6689_MOESM2_ESM.pdf">
          <caption>
           <p>
            Authors’ original file for figure 1
           </p>
          </caption>
         </media>
         <media id="MOESM3" position="anchor" xlink:href="12889_2014_6689_MOESM3_ESM.pdf">
          <caption>
           <p>
            Authors’ original file for figure 2
           </p>
          </caption>
         </media>
        </p>
       </sec>
      </app>
     </app-group>
     <fn-group>
      <fn>
       <p>
        <bold>
         Competing interests
        </bold>
       </p>
       <p>
        The authors declare that they have no competing interests.
       </p>
      </fn>
      <fn>
       <p>
        <bold>
         Authors’ contributions
        </bold>
       </p>
       <p>
        ET helped develop and refine the protocol, carried out the systematic review, data extraction, quality assessment and data analysis, and drafted the manuscript. MS and AG helped develop and refine the protocol, carried out data extraction and quality assessment, provided support with data analysis and contributed to writing the manuscript. LY helped develop and refine the protocol, provided support with data analysis and contributed to writing the manuscript. PL contributed to gaining initial funding, helped develop and refine the protocol and contributed to writing the manuscript. All authors read and approved the final manuscript.
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       We are grateful to the authors who responded to our requests for further information about their research. This research was undertaken as part of doctoral research funded by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR).
      </p>
      <p>
       <bold>
        Disclaimer
       </bold>
      </p>
      <p>
       This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author (s) and not necessarily those of the NHS, the NIHR or the Department of Health.
      </p>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leaker
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sickness absence from work in the UK
        </article-title>
        <source>
         Econ Labour Mark Rev
        </source>
        <year>
         2008
        </year>
        <volume>
         2
        </volume>
        <fpage>
         18
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="doi">
         10.1057/elmr.2008.167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madjid
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Naghavi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Litovsky
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Casscells
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza and cardiovascular disease: A new opportunity for prevention and the need for further studies
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2003
        </year>
        <volume>
         108
        </volume>
        <fpage>
         2730
        </fpage>
        <lpage>
         2736
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.CIR.0000102380.47012.92
        </pub-id>
        <pub-id pub-id-type="pmid">
         14610013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pitman
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Melegaro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gelb
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessing the burden of influenza and other respiratory infections in England and Wales
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2007
        </year>
        <volume>
         54
        </volume>
        <fpage>
         530
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2006.09.017
        </pub-id>
        <pub-id pub-id-type="pmid">
         17097147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           CKY
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           ROP
          </given-names>
         </name>
         <name>
          <surname>
           Wai
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DWS
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           BCF
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           PWY
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <name>
          <surname>
           Uyeki
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Houck
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JSM
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Facemasks and Hand Hygiene to Prevent Influenza Transmission in HouseholdsA Cluster Randomized Trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         2009
        </year>
        <volume>
         151
        </volume>
        <fpage>
         437
        </fpage>
        <lpage>
         446
        </lpage>
        <pub-id pub-id-type="doi">
         10.7326/0003-4819-151-7-200910060-00142
        </pub-id>
        <pub-id pub-id-type="pmid">
         19652172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jefferson
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Foxlee
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Del Mar
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Dooley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ferroni
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Hewak
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Prabhala
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Nair
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Rivetti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review
        </article-title>
        <source>
         Br Med J
        </source>
        <year>
         2008
        </year>
        <volume>
         336
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.39393.510347.BE
        </pub-id>
        <pub-id pub-id-type="pmid">
         18042961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabie
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Curtis
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Handwashing and risk of respiratory infections: A quantitative systematic review
        </article-title>
        <source>
         Trop Med Int Health
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <fpage>
         258
        </fpage>
        <lpage>
         267
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-3156.2006.01568.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         16553905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <source>
         World Health Organisation. Pandemic influenza preparedness and response WHO guidance document
        </source>
        <year>
         2009
        </year>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Nicoll
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Fukuda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Horby
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Wylks
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sanders
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Van Tam
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonpharmaceutical interventions for pandemic influenza, national and community measures
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         88
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1208.060129
        </pub-id>
        <pub-id pub-id-type="pmid">
         16494723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bootsma
          </surname>
          <given-names>
           MCJ
          </given-names>
         </name>
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of public health measures on the 1918 influenza pandemic in U.S. cities
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2007
        </year>
        <volume>
         104
        </volume>
        <fpage>
         7588
        </fpage>
        <lpage>
         7593
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0611071104
        </pub-id>
        <pub-id pub-id-type="pmid">
         17416677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reducing the Impact of the Next Influenza Pandemic Using Household-Based Public Health Interventions
        </article-title>
        <source>
         PLoS Med
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <fpage>
         e361
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030361
        </pub-id>
        <pub-id pub-id-type="pmid">
         16881729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Keogh-Brown
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Barnett
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tait
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The economy-wide impact of pandemic influenza on the UK: A computable general equilibrium modelling experiment
        </article-title>
        <source>
         Br Med J
        </source>
        <year>
         2009
        </year>
        <volume>
         339
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Lye
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Combination strategies for pandemic influenza response - a systematic review of mathematical modelling studies
        </article-title>
        <source>
         BMC Med
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         76
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1741-7015-7-76
        </pub-id>
        <pub-id pub-id-type="pmid">
         20003249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ajzen
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         The theory of planned behavior
        </article-title>
        <source>
         Organ Behav Hum Decis Process
        </source>
        <year>
         1991
        </year>
        <volume>
         50
        </volume>
        <fpage>
         179
        </fpage>
        <lpage>
         211
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0749-5978(91)90020-T
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maddux
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protection motivation theory and self-efficacy: a revised theory of fear appeals and attitude change
        </article-title>
        <source>
         J Exp Soc Psychol
        </source>
        <year>
         1983
        </year>
        <volume>
         19
        </volume>
        <fpage>
         469
        </fpage>
        <lpage>
         479
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0022-1031(83)90023-9
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Cacioppo
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Petty
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cognitive and physiological processes in fear appeals and attitude change: a revised theory of protection motivation
        </article-title>
        <source>
         Social Psychophysiology
        </source>
        <year>
         1983
        </year>
        <publisher-loc>
         London
        </publisher-loc>
        <publisher-name>
         Guildford Press
        </publisher-name>
        <fpage>
         153
        </fpage>
        <lpage>
         176
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teasdale
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Yardley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Schlotz
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The importance of coping appraisal in behavioural responses to pandemic flu
        </article-title>
        <source>
         Br J Health Psychol
        </source>
        <year>
         2012
        </year>
        <volume>
         17
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.2044-8287.2011.02017.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         22233104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bish
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Demographic and attitudinal determinants of protective behaviours during a pandemic: a review
        </article-title>
        <source>
         Br J Health Psychol
        </source>
        <year>
         2010
        </year>
        <volume>
         15
        </volume>
        <fpage>
         797
        </fpage>
        <lpage>
         824
        </lpage>
        <pub-id pub-id-type="doi">
         10.1348/135910710X485826
        </pub-id>
        <pub-id pub-id-type="pmid">
         20109274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Ip
          </surname>
          <given-names>
           DKM
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Aiello
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Face masks to prevent transmission of influenza virus: a systematic review
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        <year>
         2010
        </year>
        <volume>
         138
        </volume>
        <fpage>
         449
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="doi">
         10.1017/S0950268809991658
        </pub-id>
        <pub-id pub-id-type="pmid">
         20092668
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goodwin
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Haque
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Neto
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initial psychological responses to Influenza A, H1N1 (“Swine flu”)
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2009
        </year>
        <volume>
         9
        </volume>
        <fpage>
         166
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2334-9-166
        </pub-id>
        <pub-id pub-id-type="pmid">
         19807908
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           JTF
          </given-names>
         </name>
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Au
          </surname>
          <given-names>
           DWH
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Changes in knowledge, perceptions, preventive behaviours and psychological responses in the pre-community outbreak phase of the H1N1 epidemic
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        <year>
         2011
        </year>
        <volume>
         139
        </volume>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="doi">
         10.1017/S0950268810001925
        </pub-id>
        <pub-id pub-id-type="pmid">
         20800008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           JTF
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anticipated and current preventive behaviors in response to an anticipated human-to-human H5N1 epidemic in the Hong Kong Chinese general population
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2007
        </year>
        <volume>
         7
        </volume>
        <fpage>
         18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2334-7-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         17359545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Situational awareness and health protective responses to pandemic influenza A (H1N1) in Hong Kong: A cross-sectional study
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2010
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e13350
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0013350
        </pub-id>
        <pub-id pub-id-type="pmid">
         20967280
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prati
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pietrantoni
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zani
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compliance with recommendations for pandemic influenza H1N1 2009: the role of trust and personal beliefs
        </article-title>
        <source>
         Health Educ Res
        </source>
        <year>
         2011
        </year>
        <volume>
         26
        </volume>
        <fpage>
         761
        </fpage>
        <lpage>
         769
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/her/cyr035
        </pub-id>
        <pub-id pub-id-type="pmid">
         21613380
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Potts
          </surname>
          <given-names>
           HWW
          </given-names>
         </name>
         <name>
          <surname>
           Michie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK
        </article-title>
        <source>
         Health Technol Assess
        </source>
        <year>
         2010
        </year>
        <volume>
         14
        </volume>
        <fpage>
         183
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="doi">
         10.3310/hta14340-03
        </pub-id>
        <pub-id pub-id-type="pmid">
         20630124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Amlot
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wessely
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public perceptions, anxiety, and behaviour change in relation to the swine flu outbreak: cross sectional telephone survey
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2009
        </year>
        <volume>
         339
        </volume>
        <fpage>
         b2651
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.b2651
        </pub-id>
        <pub-id pub-id-type="pmid">
         19574308
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Joffe
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk: from perception to social representation
        </article-title>
        <source>
         Br J Soc Psychol
        </source>
        <year>
         2003
        </year>
        <volume>
         42
        </volume>
        <fpage>
         55
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="doi">
         10.1348/014466603763276126
        </pub-id>
        <pub-id pub-id-type="pmid">
         12713756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Joffe
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           NYL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Social representation of a food risk: the Hong Kong avian bird flu epidemic
        </article-title>
        <source>
         J Health Psychol
        </source>
        <year>
         2004
        </year>
        <volume>
         9
        </volume>
        <fpage>
         517
        </fpage>
        <lpage>
         533
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1359105304044036
        </pub-id>
        <pub-id pub-id-type="pmid">
         15231054
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Joffe
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public apprehension of emerging infectious diseases: are changes afoot?
        </article-title>
        <source>
         Public Underst Sci
        </source>
        <year>
         2011
        </year>
        <volume>
         20
        </volume>
        <fpage>
         446
        </fpage>
        <lpage>
         460
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/0963662510391604
        </pub-id>
        <pub-id pub-id-type="pmid">
         21936260
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seers
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         What is a qualitative synthesis?
        </article-title>
        <source>
         Evidence Based Nursing
        </source>
        <year>
         2012
        </year>
        <volume>
         15
        </volume>
        <fpage>
         101
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/ebnurs-2012-100977
        </pub-id>
        <pub-id pub-id-type="pmid">
         23002176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        Ring N, Ritchie K, Mandava L, Jepson R: A guide to synthesising qualitative research for researchers undertaking health technology assessments and systematic reviews.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhshealthquality.org/nhsqis/8837.html">
         http://www.nhshealthquality.org/nhsqis/8837.html
        </ext-link>
        . 2010
       </mixed-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Hawaiian Medical Library
         </collab>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Petticrew
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hawaiian Medical Library evidence-based filters for CINAHL
        </article-title>
        <source>
         Systematic Reviews in the Social Sciences: a practical guide
        </source>
        <year>
         2009
        </year>
        <publisher-loc>
         Oxford
        </publisher-loc>
        <publisher-name>
         Blackwell Publishing
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pound
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Britten
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Morgan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yardley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Pope
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Daker-White
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Resisting medicines: a synthesis of qualitative studies of medicine taking
        </article-title>
        <source>
         Soc Sci Med
        </source>
        <year>
         2005
        </year>
        <volume>
         61
        </volume>
        <fpage>
         133
        </fpage>
        <lpage>
         155
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.socscimed.2004.11.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         15847968
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <collab>
          CASP
         </collab>
        </person-group>
        <source>
         Critical Appraisal Skills Programme: 10 questions to help you make sense of qualitative research
        </source>
        <year>
         2013
        </year>
        <publisher-loc>
         Oxford
        </publisher-loc>
        <publisher-name>
         Public Health Resource Unit
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Harden
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Methods for the thematic synthesis of qualitative research in systematic reviews
        </article-title>
        <source>
         BMC Med Res Methodol
        </source>
        <year>
         2008
        </year>
        <volume>
         8
        </volume>
        <fpage>
         45
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2288-8-45
        </pub-id>
        <pub-id pub-id-type="pmid">
         18616818
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Noblit
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Hare
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <source>
         Meta-ethnography: synthesizing qualitative studies
        </source>
        <year>
         1988
        </year>
        <publisher-loc>
         California
        </publisher-loc>
        <publisher-name>
         Sage: Newbury Park
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cava
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Fay
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Beanlands
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           McCay
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Wignall
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk Perception and Compliance With Quarantine During the SARS Outbreak
        </article-title>
        <source>
         J Nurs Scholarsh
        </source>
        <year>
         2005
        </year>
        <volume>
         37
        </volume>
        <fpage>
         343
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1547-5069.2005.00059.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         16396407
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cava
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Fay
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Beanlands
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           McCay
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Wignall
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Experience of Quarantine for Individuals Affected by SARS in Toronto
        </article-title>
        <source>
         Public Health Nurs
        </source>
        <year>
         2005
        </year>
        <volume>
         22
        </volume>
        <fpage>
         398
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.0737-1209.2005.220504.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         16229732
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Janssen
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Tardif
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Landry
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Warner
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        <article-title>
         ‘Why tell me now?’ the public and healthcare providers weigh in on pandemic influenza messages
        </article-title>
        <source>
         J Public J Health Manag Prac
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         388
        </fpage>
        <lpage>
         394
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00124784-200607000-00013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elledge
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Brand
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Regens
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Boatright
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Implications of public understanding of avian influenza for fostering effective risk communication
        </article-title>
        <source>
         Health Promot Pract
        </source>
        <year>
         2008
        </year>
        <volume>
         9
        </volume>
        <fpage>
         54 s
        </fpage>
        <lpage>
         59 s
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1524839908319089
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Elam
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Voeten
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           de Zwart
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Veldhuijzen
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Brug
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The perceived threat of SARS and its impact on precautionary actions and adverse consequences: a qualitative study among Chinese communities in the United Kingdom and the Netherlands
        </article-title>
        <source>
         Int J Behav Med
        </source>
        <year>
         2009
        </year>
        <volume>
         16
        </volume>
        <fpage>
         58
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12529-008-9005-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         19277874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         <name>
          <surname>
           Yardley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         What infection control measures will people carry out to reduce transmission of pandemic influenza?A focus group study
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2009
        </year>
        <volume>
         9
        </volume>
        <fpage>
         258
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2458-9-258
        </pub-id>
        <pub-id pub-id-type="pmid">
         19627568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baum
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name>
          <surname>
           Goold
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        <article-title>
         “Listen to the people”: public deliberation about social distancing measures in a pandemic
        </article-title>
        <source>
         Am J Bioeth
        </source>
        <year>
         2009
        </year>
        <volume>
         9
        </volume>
        <fpage>
         4
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/15265160903197531
        </pub-id>
        <pub-id pub-id-type="pmid">
         19882444
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Caress
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Duxbury
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Woodcock
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Luker
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Austin
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exploring the needs, concerns and behaviours of people with existing respiratory conditions in relation to the H1N1’swine influenza' pandemic: a multicentre survey and qualitative study
        </article-title>
        <source>
         Health Technol Assess
        </source>
        <year>
         2010
        </year>
        <volume>
         14
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="doi">
         10.3310/hta14340-01
        </pub-id>
        <pub-id pub-id-type="pmid">
         20630122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yardley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Teasdale
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Little
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <collab>
          Primit Team
         </collab>
        </person-group>
        <article-title>
         Using mixed methods to design a web-based behavioural intervention to reduce transmission of colds and flu
        </article-title>
        <source>
         J Health Psychol
        </source>
        <year>
         2011
        </year>
        <volume>
         16
        </volume>
        <fpage>
         353
        </fpage>
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1359105310377538
        </pub-id>
        <pub-id pub-id-type="pmid">
         20929941
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           JYM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Another Nightmare After SARS: Knowledge Perceptions of and Overcoming Strategies for H1N1 Influenza Among Chronic Renal Disease Patients in Hong Kong
        </article-title>
        <source>
         Qual Health Res
        </source>
        <year>
         2010
        </year>
        <volume>
         20
        </volume>
        <fpage>
         893
        </fpage>
        <lpage>
         904
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1049732310367501
        </pub-id>
        <pub-id pub-id-type="pmid">
         20363953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilton
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public views of the UK media and government reaction to the 2009 swine flu pandemic
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2010
        </year>
        <volume>
         10
        </volume>
        <fpage>
         697
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2458-10-697
        </pub-id>
        <pub-id pub-id-type="pmid">
         21078169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wong-McLoughlin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Barrett
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Currie
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Barriers to mask wearing for influenza-like illnesses among urban hispanic households
        </article-title>
        <source>
         Public Health Nurs
        </source>
        <year>
         2011
        </year>
        <volume>
         28
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1525-1446.2010.00918.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         21198810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nizame
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         <name>
          <surname>
           Nasreen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Unicomb
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Southern
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gurley
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Arman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kadir
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Azziz-Baumgartner
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Luby
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Winch
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding community perceptions, social norms and current practice related to respiratory infection in Bangladesh during 2009: a qualitative formative study
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2011
        </year>
        <volume>
         11
        </volume>
        <fpage>
         901
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2458-11-901
        </pub-id>
        <pub-id pub-id-type="pmid">
         22136080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teasdale
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Yardley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding responses to government health recommendations: Public perceptions of government advice for managing the H1N1 (swine flu) influenza pandemic
        </article-title>
        <source>
         Patient Educ Couns
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         413
        </fpage>
        <lpage>
         418
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.pec.2010.12.026
        </pub-id>
        <pub-id pub-id-type="pmid">
         21295434
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gray
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           MacDonald
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Mackie
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Community responses to communication campaigns for influenza A (H1N1): a focus group study
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <fpage>
         2012
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2458-12-205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodriguez Prieto
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Danet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           March
          </surname>
         </name>
         <name>
          <surname>
           Codina
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Nebot
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Public opinions about the 2009/2010 H1N1 pandemic influenza [Spanish]
        </article-title>
        <source>
         Index de Enfermeria
        </source>
        <year>
         2012
        </year>
        <volume>
         21
        </volume>
        <fpage>
         38
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="doi">
         10.4321/S1132-12962012000100009
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Mak
          </surname>
          <given-names>
           JPI
          </given-names>
         </name>
         <name>
          <surname>
           Razee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Examining the knowledge, attitudes and practices of domestic and international university students towards seasonal and pandemic influenza
        </article-title>
        <source>
         BMC Public Health
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <fpage>
         307
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2458-12-307
        </pub-id>
        <pub-id pub-id-type="pmid">
         22537252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Curtis
          </surname>
          <given-names>
           VA
          </given-names>
         </name>
         <name>
          <surname>
           Danquah
          </surname>
          <given-names>
           LO
          </given-names>
         </name>
         <name>
          <surname>
           Aunger
          </surname>
          <given-names>
           RV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Planned, motivated and habitual hygiene behaviour: an eleven country review
        </article-title>
        <source>
         Health Educ Res
        </source>
        <year>
         2009
        </year>
        <volume>
         24
        </volume>
        <fpage>
         655
        </fpage>
        <lpage>
         673
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/her/cyp002
        </pub-id>
        <pub-id pub-id-type="pmid">
         19286894
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backett
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name>
          <surname>
           Davison
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lifecourse and lifestyle: The social and cultural location of health behaviours
        </article-title>
        <source>
         Soc Sci Med
        </source>
        <year>
         1995
        </year>
        <volume>
         40
        </volume>
        <fpage>
         629
        </fpage>
        <lpage>
         638
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0277-9536(95)80007-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         7747198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilkinson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kitzinger
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thinking differently about thinking positive: a discursive approach to cancer patients talk
        </article-title>
        <source>
         Soc Sci Med
        </source>
        <year>
         2000
        </year>
        <volume>
         50
        </volume>
        <fpage>
         797
        </fpage>
        <lpage>
         811
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0277-9536(99)00337-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         10695978
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nijland
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           van Gemert-Pijnen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Boer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Steehouder
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Seydel
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of Internet-Based Technology for Supporting Self-Care: Problems Encountered by Patients and Caregivers When Using Self-Care Applications
        </article-title>
        <source>
         J Med Internet Res
        </source>
        <year>
         2008
        </year>
        <volume>
         10
        </volume>
        <fpage>
         e13
        </fpage>
        <pub-id pub-id-type="doi">
         10.2196/jmir.957
        </pub-id>
        <pub-id pub-id-type="pmid">
         18487137
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Cathain
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Goode
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Luff
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Strangleman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hanlon
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Greatbatch
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does NHS Direct empower patients?
        </article-title>
        <source>
         Soc Sci Med
        </source>
        <year>
         2005
        </year>
        <volume>
         61
        </volume>
        <fpage>
         1761
        </fpage>
        <lpage>
         1771
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.socscimed.2005.03.028
        </pub-id>
        <pub-id pub-id-type="pmid">
         15894416
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Say
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Murtagh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Thomson
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patients' preferences for involvement in medical decision making: a narrative review
        </article-title>
        <source>
         Patient Educ Couns
        </source>
        <year>
         2006
        </year>
        <volume>
         60
        </volume>
        <fpage>
         102
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.pec.2005.02.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         16442453
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Basurto-Davila
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Garza
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Meltzer
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
         <name>
          <surname>
           Carlino
          </surname>
          <given-names>
           OL
          </given-names>
         </name>
         <name>
          <surname>
           Albalak
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Orellano
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Uez
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Shay
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Santandrea
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           del Carmen Weis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Averhoff
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Widdowson
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Household economic impact and attitudes toward school closures in two cities in Argentina during the 2009 influenza A (H1N1) pandemic
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        <year>
         2013
        </year>
        <volume>
         7
        </volume>
        <fpage>
         1308
        </fpage>
        <lpage>
         1315
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/irv.12054
        </pub-id>
        <pub-id pub-id-type="pmid">
         23176127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blake
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         <name>
          <surname>
           Blendon
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Viswanath
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Employment and compliance with pandemic influenza mitigation recommendations
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <fpage>
         212
        </fpage>
        <lpage>
         218
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1602.090638
        </pub-id>
        <pub-id pub-id-type="pmid">
         20113549
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dalton
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Durrheim
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         <name>
          <surname>
           Conroy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Likely impact of school and childcare closures on public health workforce during an influenza pandemic: a survey
        </article-title>
        <source>
         Commun Dis Intell Q Rep
        </source>
        <year>
         2008
        </year>
        <volume>
         32
        </volume>
        <fpage>
         261
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="pmid">
         18767427
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garoon
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Duggan
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discourses of disease, discourses of disadvantage: a critical analysis of National Pandemic Influenza Preparedness Plans
        </article-title>
        <source>
         Soc Sci Med
        </source>
        <year>
         2008
        </year>
        <volume>
         67
        </volume>
        <fpage>
         1133
        </fpage>
        <lpage>
         1142
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.socscimed.2008.06.020
        </pub-id>
        <pub-id pub-id-type="pmid">
         18656294
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lupton
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk as moral danger: the social and political functions of risk discourse in public health
        </article-title>
        <source>
         Int J Health Serv
        </source>
        <year>
         1993
        </year>
        <volume>
         23
        </volume>
        <fpage>
         425
        </fpage>
        <lpage>
         435
        </lpage>
        <pub-id pub-id-type="doi">
         10.2190/16AY-E2GC-DFLD-51X2
        </pub-id>
        <pub-id pub-id-type="pmid">
         8375947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Flemming
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           McInnes
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Oliver
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Criag
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ
        </article-title>
        <source>
         BMC Med Res Methodol
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <fpage>
         181
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2288-12-181
        </pub-id>
        <pub-id pub-id-type="pmid">
         23185978
        </pub-id>
       </element-citation>
      </ref>
      <ref-list id="BSec1">
       <title>
        Pre-publication history
       </title>
       <ref id="CR65">
        <mixed-citation publication-type="other">
         The pre-publication history for this paper can be accessed here:
         <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2458/14/589/prepub">
          http://www.biomedcentral.com/1471-2458/14/589/prepub
         </ext-link>
        </mixed-citation>
       </ref>
      </ref-list>
     </ref-list>
    </back>
   </article>
   <article article-type="editorial" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cell Stress
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cell Stress
      </journal-id>
      <journal-id journal-id-type="pmc">
       Cell Stress
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       Cell Stress
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cell Stress
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2523-0204
      </issn>
      <publisher>
       <publisher-name>
        Shared Science Publishers OG
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7064018
      </article-id>
      <article-id pub-id-type="doi">
       10.15698/cst2020.04.216
      </article-id>
      <article-id pub-id-type="publisher-id">
       CST0270E115
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Editorial
        </subject>
       </subj-group>
       <subj-group>
        <subject>
         Coronavirus
        </subject>
        <subject>
         MERS-CoV
        </subject>
        <subject>
         SARS-CoV
        </subject>
        <subject>
         sARS-CoV-2
        </subject>
        <subject>
         COVID-19
        </subject>
        <subject>
         epidemiology
        </subject>
        <subject>
         immunology
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses
       </article-title>
       <alt-title alt-title-type="running-head">
        COVID-19 - Analyses and hypotheses
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raoult
         </surname>
         <given-names>
          Didier
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zumla
         </surname>
         <given-names>
          Alimuddin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Locatelli
         </surname>
         <given-names>
          Franco
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ippolito
         </surname>
         <given-names>
          Giuseppe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kroemer
         </surname>
         <given-names>
          Guido
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         6
        </xref>
        <xref ref-type="aff" rid="aff6">
         7
        </xref>
        <xref ref-type="aff" rid="aff6">
         8
        </xref>
        <xref ref-type="aff" rid="aff6">
         9
        </xref>
        <xref ref-type="aff" rid="aff1">
         10
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1
       </label>
       Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France; IHU Méditerranée Infection, Marseille, France.
      </aff>
      <aff id="aff2">
       <label>
        2
       </label>
       Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK.
      </aff>
      <aff id="aff3">
       <label>
        3
       </label>
       The National Institute of Health Research Biomedical Research Centre at UCL Hospitals, London, UK.
      </aff>
      <aff id="aff4">
       <label>
        4
       </label>
       Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
      </aff>
      <aff id="aff5">
       <label>
        5
       </label>
       National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
      </aff>
      <aff id="aff6">
       <label>
        6
       </label>
       Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
      </aff>
      <aff id="aff7">
       <label>
        7
       </label>
       Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
      </aff>
      <aff id="aff8">
       <label>
        8
       </label>
       Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
      </aff>
      <aff id="aff9">
       <label>
        9
       </label>
       Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
      </aff>
      <aff id="aff10">
       <label>
        10
       </label>
       Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
      </aff>
      <author-notes>
       <corresp id="cor1">
        * E-mail:
        <email>
         Kroemer@orange.fr
        </email>
       </corresp>
       <fn fn-type="COI-statement">
        <p>
         Conflict of interest: The authors declare that they have no relevant conflict of interest.
        </p>
       </fn>
       <fn>
        <p>
         Please cite this article as: Didier Raoult, Alimuddin Zumla, Franco Locatelli, Giuseppe Ippolito and Guido Kroemer (
         <bold>
          2020
         </bold>
         ). Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.
         <bold>
          Cell Stress
         </bold>
         :
         <italic>
          in press
         </italic>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        02
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <history>
       <date date-type="received" iso-8601-date="20000530">
        <day>
         01
        </day>
        <month>
         3
        </month>
        <year iso-8601-date="2000">
         2020
        </year>
       </date>
       <date date-type="accepted" iso-8601-date="20010627">
        <day>
         02
        </day>
        <month>
         3
        </month>
        <year iso-8601-date="2001">
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright: © 2020 Raoult et al.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Coronaviruses (CoVs) are a large family of enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1), are globally endemic and account for a substantial fraction of upper respiratory tract infections. Non-SARS-like CoV can occasionally produce severe diseases in frail subjects but do not cause any major (fatal) epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The current epidemic caused by the highly contagious SARS-CoV-2 and its rapid spread globally is of major concern. There is scanty knowledge on the actual pandemic potential of this new SARS-like virus. It might be speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the infection is silently spreading across the globe with two consequences: (i) clusters of severe infections among frail subjects could haphazardly occur linked to unrecognized index cases; (ii) the current epidemic could naturally fall into a low-level endemic phase when a significant number of subjects will have developed immunity. Understanding the role of paucisymptomatic subjects and stratifying patients according to the risk of developing severe clinical presentations is pivotal for implementing reasonable measures to contain the infection and to reduce its mortality. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The emergence of yet another global epidemic underscores the permanent challenges that infectious diseases pose and underscores the need for global cooperation and preparedness, even during inter-epidemic periods.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        sARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        epidemiology
       </kwd>
       <kwd>
        immunology
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec sec-type="introduction">
     <title>
      INTRODUCTION
     </title>
     <p>
      Infections have been limiting quality of life and longevity throughout human history. Endemic infections have been associated to a significant number of avoidable deaths and a significant increase of morbidity all around the word. In addition, human-to-human transmission of newly emergent pathogens with pandemic potential regularly produce panic, with a negative impact on the economy and general welfare of large human communities.
     </p>
     <p>
      The advent of public hygiene, vaccine and antibiotics has greatly reduced the probability to succumb to infectious disease and has improved the confidence of the public in the capacity of mitigating the possible consequences of infectious outbreaks. Nevertheless, also in recent times, several events produce significant concern in the general population. Panic spread as the consequence of overwhelming information on a series of potential epidemics rather than due to the actual diseases. These were the cases of Zika virus (a mild disease without any mortality excess whose impact is significant for vertical transmission only (increased rate of birth defect),
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      variant Creutzfeldt-Jakob disease ("mad cow disease")
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      and avian influenza
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      . The latter two diseases are both zoonotic infections without any pandemic potential due to the lack of efficient inter-human transmission. Moreover, the global community has successfully dealt with more scaring emerging agents. For example, the 2014-2015 Ebola hemorrhagic fever outbreak was successfully contained, and specific experience accrued during the West Africa epidemic, permitting to implement new vaccination strategies and therapeutic interventions Ebola outbreak (2014-2016)
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      .
     </p>
     <p>
      The study of respiratory viral infections has recently changed due to the standardized use of molecular biology in diagnostic tests. Therefore, molecular techniques today are not substantially influenced by the level of knowledge of those who practice them. Commercially available tests allow for the simultaneous detection of 20 common viral and bacterial pathogens within one hour, but tests leading to the identification of ever larger panels of infectious agents are under development
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      .
     </p>
    </sec>
    <sec>
     <title>
      PATHOGENIC HUMAN CORONAVIRUSES
     </title>
     <p>
      Among the causative agents of human respiratory tract infections are coronaviruses (CoVs) which are enveloped, single positive-strand RNA viruses belonging to the large subfamily Coronavirinae which infect birds and mammals. The viral RNA is the largest genome known and it is between 26 to 32 kilobases in length. There are seven CoVs known to cause human disease, which are divided into low pathogenic and highly pathogenic CoVs
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      . Four coronaviruses (HCoVs, namely HCoV 229E, NL63, OC43, and HKU1), are known as non- severe acute respiratory syndrome (SARS)-like CoVs. They cause mild diseases and are globally endemic. Over the past two decades three highly pathogenic, novel zoonotic CoVs have emerged, which cause lethal human disease, and have thus generated much media hype and public concern: the SARS coronavirus (SARS-CoV now named SARS-CoV-1) discovered in November, 2002
      <xref ref-type="bibr" rid="B9">
       9
      </xref>
      , the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) in June, 2012
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ; and SARS-CoV-2, initially named 2019-nCoV when it was identified in December 2019 after sequencing of clinical samples from a cluster of patients with pneumonia in Wuhan, China
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      . The disease caused by SARS-CoV-2 is named Coronavirus Diseases-2019 (COVID-19)
     </p>
     <p>
      All three CoVs are listed in the WHO Blueprint list for priority pathogens for research because of their epidemic potential and lack of effective treatments. SARS-CoV was first identified in humans in Guangdong, China, in November, 2002 and subsequently spread rapidly worldwide to 29 countries, resulting in 8098 human SARS cases with 774 deaths (9.6% mortality)
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      . The SARS epidemic ended abruptly in July, 2003, and no human cases of SARS have been detected since 2004. MERS-CoV was first isolated from a lung sample of an adult patient who died of pneumonia at the Al-Fakieh hospital in Jeddah, Saudi Arabia. MERS-CoV. A retrospective study then linked MERS-CoV to a hospital outbreak in April, 2012, in Jordan
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      . Dromedaries and camels are implicated as the zoonotic source of infection
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      . MERS-CoV continues to circulate and cause human disease with intermittent community clusters, and nosocomial outbreaks in the Middle East. MERS-CoV continues to cause human disease and as of Feb 29, 2020, there have been 2494 laboratory-confirmed human cases of MERS-CoV infection, with 858 deaths (34·0% mortality) reported from 27 countries in all continents, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths)
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      .
     </p>
    </sec>
    <sec>
     <title>
      CLINICAL CHARACTERISTICS OF HUMAN CORONAVIRUS INFECTIONS
     </title>
     <p>
      The clinical features of low pathogenic non-SARS CoV infections are undistinguishable from those found in patients with influenza virus (up to 61,000 lethal infections per year only in the US according to the Centers for Disease Control and Prevention,
      <xref ref-type="bibr" rid="B16">
       16
      </xref>
      ). As with influenza and respiratory syncytial virus (RSV) infections, the majority of CoV infections usually lead to an asymptomatic or mild flu-like syndrome. Hence, without molecular diagnosis, these viral respiratory diseases, which all follow a seasonal pattern with a higher incidence in winter, are classed together as "flu", irrespective of their exact infectious etiology. Non-SARS like CoV account for up to 20% of upper respiratory tract infections in adults
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      (
      <bold>
       Table 1
      </bold>
      ). However, non-SARS-like CoVs can be occasionally associated with severe acute respiratory illness (SARI) in the elderly, diabetics, and those with immunosuppression from any cause, although they have never been associated with major epidemics regionally or globally. In contrast, the highly pathogenic SARS-CoV and MERS-CoV have spurred locally intense short-lived fatal community and nosocomial outbreaks
      <xref ref-type="bibr" rid="B18">
       18
      </xref>
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      . SARS-like viruses are poorly adapted to the human host and unlike non-SARS-CoV viruses, they are generally associated with more severe clinical presentations.
     </p>
     <table-wrap id="Tab1" orientation="portrait" position="anchor">
      <label>
       TABLE 1.
      </label>
      <caption>
       <p>
        Respiratory tract infections with non-SARS coronaviruses.
       </p>
       <p>
        TB: tuberculosis
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th colspan="1" rowspan="1" style="text-align:center">
          <bold>
           Country
          </bold>
         </th>
         <th colspan="1" rowspan="1" style="text-align:center">
          <bold>
           Number of cases investigated
          </bold>
         </th>
         <th colspan="1" rowspan="1" style="text-align:center">
          <bold>
           Percentage positive
          </bold>
         </th>
         <th colspan="1" rowspan="1" style="text-align:center">
          <bold>
           Reference
          </bold>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Brazil
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          775
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          7.6%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B65">
           65
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Brazil (slums)
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          282
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          21.2%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B66">
           66
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Hong Kong, China
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          4181
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          2.1%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B67">
           67
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Ghana
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          593
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          13.7%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B68">
           68
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Guangzou, China
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          13,048
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          2.3%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B69">
           69
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Guangzou, China
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          11,399
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          4.3%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B70">
           70
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Kenya
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          417
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          8.4%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B71">
           71
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          Kenya
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          5,573
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          10.1%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B72">
           72
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          South Africa
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          620 without TB
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          18%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B73">
           73
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          214 with TB
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          South Africa
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          860
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          4.8%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B74">
           74
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          South Africa
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          1,026
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          15%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B75">
           75
          </xref>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1" style="text-align:center">
          USA
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          854,575
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          4,6%
         </td>
         <td colspan="1" rowspan="1" style="text-align:center">
          <xref ref-type="bibr" rid="B76">
           76
          </xref>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      The novel SARS coronavirus-2 (SARS-CoV-2) appears highly transmissible from human to human pathogen which causes a wide spectrum of clinical manifestations in patients with COVID-19
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      . COVID-19 undoubtedly has attracted more attention by the mass news and social media than any other disease
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      . The rapid spread and ensuing public health control measures have led to unprecedented isolation and quarantine of large populations, international travel restrictions and economic paralysis of Wuhan, the entire Hubei province, vast areas of China followed by entire regions in South Korea and Northern Italy during January/February 2020. In these few weeks, there have been several scientific publications related to the epidemiology, clinical features, immunology and virological characteristics and a comparison of these could yield new insights into the pathogenesis of COVID-19.
     </p>
    </sec>
    <sec>
     <title>
      EPIDEMIOLOGY: RAPID SPREAD AND THE ROLE OF SYMPTOMATIC CASES
     </title>
     <p>
      Despite seven years since first discovery, MERS-CoV transmission dynamics remain largely undefined and the roles of transmission, direct or indirect contact, airborne, droplet, or ingestion, have yet to be defined. MERS-CoV does not easily transmit from person to person unless contact with a MERS-CoV-infected subject is close. Several reports from Saudi Arabia describe transmission of silent or subclinical secondary infections after exposure to patients with MERS-CoV infections, some being apparently healthy individuals who were household contacts carrying MERS-CoV in their upper respiratory tract at low levels low amounts indicating that MERS-CoV can be transmitted from asymptomatic household or hospital contacts
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      <xref ref-type="bibr" rid="B22">
       22
      </xref>
      <xref ref-type="bibr" rid="B23">
       23
      </xref>
      .
     </p>
     <p>
      The ongoing SARS-CoV-2 outbreak has rapidly evolved and spread globally. As of Feb 29, 2020, there have been 83,652 laboratory confirmed cases of COVID-19, with 2791 deaths (3.4% mortality). Outside China, there have been 4691 cases reported from 51 countries with 67 deaths
      <xref ref-type="bibr" rid="B24">
       24
      </xref>
      . Whilst there have been several epidemiological links to bats, and other animals have been proposed, the source of primary SARS-CoV-2 transmission to humans remains unknown. The main clinical features of COVID-19 disease appear similar to other CoVs infections of humans. SARS-CoV-2 is generally associated with upper respiratory tract and high viral loads in upper respiratory tract secretions. This may evolve and progress towards SARI and in some cases to acute respiratory distress syndrome (ARDS), in the elderly, patients with comorbidities and immunosuppression
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      . Similar to other CoVs, it is now evident that health care services play an important role in the amplification of SARS-CoV-2 local epidemics. Asymptomatic carriage of SARS-CoV-2 has been described
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      and the role of asymptomatic SARS-CoV-2 infected individuals in disseminating the infection (and sometimes to act as so-called ‘superspreaders’) remains to be defined.
     </p>
    </sec>
    <sec>
     <title>
      LEARNING FROM THE SARS AND MERS OUTBREAKS
     </title>
     <p>
      The propensity of SARS-CoV and MERS-CoV to generate large hospital outbreaks has been well established
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      . The SARS epidemic in 2002-2003 emphasized that correct management of symptomatic cases within and outside hospital was crucial for containing the epidemic. In fact, the correct management of several imported cases of SARS into Vancouver (British Columbia, Canada), resulted in stopping secondary transmissions within the city. In contrast, inadequate application of infection control measures in Toronto (Ontario, Canada) and Taipei (Taiwan) led to significant hospital clusters and further spread
      <xref ref-type="bibr" rid="B28">
       28
      </xref>
      . The case of MERS is even more emblematic and enigmatic. MERS has no natural epidemic potential in the community and the transmission rate R0 in humans remains significantly below 1. Nevertheless, its potential to cause large and fatal hospital outbreaks is well established
      <xref ref-type="bibr" rid="B29">
       29
      </xref>
      .
     </p>
    </sec>
    <sec>
     <title>
      COVID-19 OUTBREAKS IN ITALY AND SOUTH KOREA
     </title>
     <p>
      An unexpected rise in the numbers of COVID-19 cases in northern Italy and South Korea in the third week of February 2020, indicated the global spread of the epidemic
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      . As of 25 February, 2020, 219 people have tested positive SARS-CoV-2 and towns in north of Italy were quarantined
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      .
     </p>
     <p>
      Preliminary information from Italy suggests that a large proportion of the primary clusters reported form Lombardy were actually linked to an emergency department where a symptomatic case was received on February 16
      <sup>
       th
      </sup>
      (currently the whole hospital building is on quarantine). Similarly, the current COVID-19 spreading in South Korea has been largely fostered by several hospital outbreaks, the most recent of which occurred in a hospital in Cheongdo county, where COVID spread within the psychiatric unit
      <xref ref-type="bibr" rid="B31">
       31
      </xref>
      . In Lombardy, Veneto, Piedmont, Trentino-Alto Adige, and Friuli Venezia Giulia schools and public places like museums, monuments, libraries and tourist sites, were closed and public sporting events and other mass gatherings were banned. Patient zero for the Italian outbreak was sought after and spread by asymptomatic individuals considered.
     </p>
    </sec>
    <sec>
     <title>
      HOSPITAL OUTBREAKS OF NON-SARS-LIKE CoVs
     </title>
     <p>
      The increased risk of spread of CoVs within healthcare services and of causing severe disease in susceptible individuals is not only restricted to SARS-CoV-1, MERS-CoV and SARS-CoV-2. Epidemiological analysis of the endemic non-SARS-like CoVs reveals a similar pattern. Severe infections with CoV-229E have been described in association with an outbreak in a neonatal intensive care unit (University Hospital, Brest, France)
      <xref ref-type="bibr" rid="B32">
       32
      </xref>
      . CoV-NL63 has recently been described to cause a fatal outbreak of SARI in a long-term care facility with a 27.7% infection rate and 1.5% lethality in Baton Rouge, Louisiana, USA
      <xref ref-type="bibr" rid="B33">
       33
      </xref>
      . Reports on hospital outbreaks of CoV-OC43 and CoV-HKU1 are scanty, and infections by these CoVs resulting in SARI are typically seen in frail subjects
      <xref ref-type="bibr" rid="B34">
       34
      </xref>
      <xref ref-type="bibr" rid="B35">
       35
      </xref>
      . The propensity for nosocomial spreading and the dominant role played by symptomatic patients in the spreading of the infection are supported by basic virology. CoVs, such as CoV-NL63, SARS-CoV-1 and SARS-CoV-2, use a specific receptor, angiotensin converting enzyme 2 (ACE2), a type I transmembrane metallocarboxypeptidase with homology to ACE, which is expressed in human airway epithelial cells, lung parenchyma, heart, lung, kidney and intestinal tract
      <xref ref-type="bibr" rid="B36">
       36
      </xref>
      <xref ref-type="bibr" rid="B37">
       37
      </xref>
      . Since ACE2 is primarily expressed in the lower respiratory tract, meaning that subjects exposed to index cases producing virus-containing aerosol (e.g. intubated patients or patients with high viral load and severe cough) are the most likely to develop primary (severe) pulmonary infection
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      <xref ref-type="bibr" rid="B38">
       38
      </xref>
      <xref ref-type="bibr" rid="B39">
       39
      </xref>
      <xref ref-type="bibr" rid="B40">
       40
      </xref>
      .
     </p>
    </sec>
    <sec>
     <title>
      PATHOGENESIS, DISEASE SEVERITY AND EPIDEMIC SPREAD
     </title>
     <p>
      Epidemiological studies suggest that SARS-CoV-2 has an intrinsic capacity to cause epidemic spread
      <xref ref-type="bibr" rid="B41">
       41
      </xref>
      . The current fatality rate for COVID-19 cases is about 3.4%, significantly less than SARS and MERS but potentially higher than those reported for endemic human non-SARS CoV infections
      <xref ref-type="bibr" rid="B42">
       42
      </xref>
      . During the first two months of the current outbreak, COVID-19 has spread rapidly throughout China and caused varying degrees of illness
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      .
     </p>
     <p>
      Several studies suggest that antibodies against non-SARS-CoVs are highly prevalent in the general population including in children, suggesting that most individuals have been infected by CoVs and have potentially developed a certain degree of (protective) immune response
      <xref ref-type="bibr" rid="B43">
       43
      </xref>
      <xref ref-type="bibr" rid="B44">
       44
      </xref>
      . There is no clear evidence on whether and how prior exposure to a strain of CoV can produce permanent immunity against the strain species or even cross-immunity for other CoV species
      <xref ref-type="bibr" rid="B43">
       43
      </xref>
      . Unlike other respiratory diseases that have a quadratic ("U"-shaped) lethality curve (killing infants and elderly, but sparing adults, presumably because adults have a higher chance to be immune against the infection), SARS-CoV-2 has a lethality that continuously rises with age (sparing children but mostly killing elderly). The severity and the clinical picture could be even related to the activation of exaggerated immune mechanism, causing uncontrolled inflammation as this has been suspected for SARS and MERS
      <xref ref-type="bibr" rid="B45">
       45
      </xref>
      . Hence, there is uncertainty on the impact of individual immune responses on the severity of SARS-like CoV infections.
     </p>
     <p>
      The discrepancy between the severity of cases observed in China and those outside China could be a result of prior exposure community circulation of non-SARS-CoVs and their antigenic epitopes, leading to antibody-dependent enhancement (ADE) of SARS-CoV-2. ADE can elicit sustained inflammation, lymphopenia, and/or cytokine storm, which have been observed in severe cases and those who die. This might explain observed the geographic discrepancies of severe cases and lower mortality than SARS of MERS
      <xref ref-type="bibr" rid="B46">
       46
      </xref>
      .
     </p>
     <p>
      SARS-CoV-1 caused an important outbreak in 2002-2003, but it is currently though to be extinct
      <xref ref-type="bibr" rid="B32">
       32
      </xref>
      . This eradication of SARS-CoV-1 has been attributed to successful contention by public action, consisting in quarantining potentially affected persons and isolating affected areas. However, other factors might have played a role in the fall of the SARS epidemic leading to the eventual extinction of the virus. In particular, it is possibility that only a minority of the population was actually susceptible to develop severe illness (some HLA haplotypes reportedly conferred resistance to SARS-CoV-1, but these studies have not been confirmed or even disproven)
      <xref ref-type="bibr" rid="B44">
       44
      </xref>
      <xref ref-type="bibr" rid="B47">
       47
      </xref>
      <xref ref-type="bibr" rid="B48">
       48
      </xref>
      <xref ref-type="bibr" rid="B49">
       49
      </xref>
      <xref ref-type="bibr" rid="B50">
       50
      </xref>
      . The hypothesis that SARS-CoV-1 (or other, antigenically similar CoV-1) have silently infected a significant proportion of the local population, inducing herd immunity needs to be confirmed. Indeed, immunity against the infection, or also patterns of semi-immunity (capacity of the immune system to avoid severe infection) may be due to cellular rather than humoral immune responses. Animal models suggest that the efficiency of T lymphocyte-mediated immune responses is pivotal for controlling MERS-CoV and SARS-CoV infections
      <xref ref-type="bibr" rid="B51">
       51
      </xref>
      <xref ref-type="bibr" rid="B52">
       52
      </xref>
      . Evidence in animals are confirmed by observational studies in humans suggesting that MERS-CoV-specific T-cell responses is a strong predictor of the clinical outcome in patients
      <xref ref-type="bibr" rid="B53">
       53
      </xref>
      . Of note, antibodies against MERS-CoV have been detected in a significant fraction of persons exposed to camels and dromedaries without any clinical evidence of prior MERS
      <xref ref-type="bibr" rid="B54">
       54
      </xref>
      <xref ref-type="bibr" rid="B55">
       55
      </xref>
      <xref ref-type="bibr" rid="B56">
       56
      </xref>
      , suggesting that MERS-CoV can infect individuals in an asymptomatic fashion, yet induce signs of a (protective?) immune response.
     </p>
    </sec>
    <sec>
     <title>
      ROLES OF HUMORAL AND CELLULAR IMMUNE RESPONSES
     </title>
     <p>
      There are currently no data on the specific role of either humoral or cellular immunity or innate immunity in patients recovering from COVID-19. Only highly specialized laboratories are able to conduct experiments to investigate immune responses against HLA class-I and class-II-restricted viral epitopes mediated by CD8+ and CD4+ T lymphocytes, respectively, to confirm the conjecture of a cellular (rather than humoral) immunity against SARS-CoV-2. Moreover, the T lymphocytes responsible for clinically relevant antiviral immune responses have high chances to be locally present in, or close to, respiratory epithelia but have comparatively low chances to be detectable in peripheral blood
      <xref ref-type="bibr" rid="B57">
       57
      </xref>
      <xref ref-type="bibr" rid="B58">
       58
      </xref>
      <xref ref-type="bibr" rid="B59">
       59
      </xref>
      . It is well possible that the exclusive detection of humoral immunity (antibodies against SARS-CoV-2) leads to an underestimation of the anti-SARS-CoV-2 immune responses. Thus, it is possible that the actual incidence of infections with SARS-CoV-2 is much higher than the observed number of clinically and serologically evident cases of COVID-19. In fact, a larger epidemic might be smoldering. This silent epidemic, made of mild and paucisymptomatic (usually flu-like) infections, could parallel the evident COVID-19 outbreaks that are detected when patients develop radiological or functional signs of pneumonitis and they are tested for SARS-CoV-2. This scenario may have two consequences. First, over the forthcoming months, symptomatic cases could haphazardly occur either as (apparently) sporadic cases or as epidemic clusters among frail subjects (e.g. as nosocomial outbreaks), driven by unrecognized occasional spreaders. Second, these occasional spreaders might accelerate the induction of immunity at the population level.
     </p>
     <p>
      By analogy to other CoVs, SARS-CoV-2 might induce a T-lymphocyte-mediated protective immune response. However, patients infected by SARS-CoV-2 that are hospitalized frequently manifest a lymphopenia, suggesting that cellular immune responses may be suppressed
      <xref ref-type="bibr" rid="B60">
       60
      </xref>
      <xref ref-type="bibr" rid="B61">
       61
      </xref>
      . In this context, it becomes plausible that, after infection by SARS-CoV-2, a sort of race decides the course of the events. Either a cellular immune response rapidly clears SARS-CoV-2 - in the best-case-scenario without any (or mild) clinical signs of infection - or the virus causes a state of immunosuppression that debilitates and sometimes overwhelms the host’s defense (
      <bold>
       Fig. 1A
      </bold>
      ). In this context, the initial dose of the viral inoculum leading to infection may have a decisive impact on all subsequent events (
      <bold>
       Fig. 1B
      </bold>
      ). A small burden of SARS-CoV-2 should have a higher chance to stimulate a protective immune response than a high one, although additional factors like the fitness of the individual’s immune system and prior exposure to other in part cross-reactive CoVs might influence the outcome of the race between viral replication and T-lymphocyte responses as well. Hence, it is possible, but remains to be demonstrated, that SARS-CoV-2 transmission from indolent or mildly symptomatic persons to naive individuals generally occurs at a relatively low viral load (lower than if the infection stems from severely affected patients), which then might have higher probabilities to induce immunity instead of severe and sometimes lethal infection (
      <bold>
       Fig. 1C
      </bold>
      ). That said, current evidence suggests that the most solid predictors of disease severity after infection with SARS-COV-2 are the patient’s age and the concurrence of specific co-morbidities. In contrast, there is no proof (yet) that infection by a pauci-symptomatic person would result in a milder clinical course of immunocompetent neo-infected person.
     </p>
     <fig id="fig1" orientation="portrait" position="anchor">
      <label>
       Figure 1
      </label>
      <caption>
       <title>
        FIGURE 1: Proposed relationships between COVID-19 and anti-SARS-CoV-2 immune responses.
       </title>
       <p>
        <bold>
         (A)
        </bold>
        The precarious equilibrium between SARS-CoV-2 and the immune system. While the virus elicits an immune response leading to elimination of infected cells (and hence clearance of the infection), it tends to suppress the immune response. Therefore, the outcome of infection is determined by the kinetics of the immune response leading to viral elimination versus viral replication leading to immunosuppression.
       </p>
       <p>
        <bold>
         (B)
        </bold>
        Hypothetical effect of the initial contagion on the course of the infection caused by SARS-CoV-2. A low-level contagion would favor an efficient immune response and indolent infection, leading to immunity of the infected person. Transmission of a large number of viral particles would tend to cause multifocal respiratory infection leading to immunosuppression and severe illness and possibly death.
       </p>
       <p>
        <bold>
         (C)
        </bold>
        Possible modes of transmission of SARS-CoV-2. Indolent carriers would tend to transmit a low viral load to their contacts, leading to indolent disease and antiviral immune responses in immunocompetent individuals. This mode of transmission might be considered as desirable because it leads to population immunity if it attains a large fraction of the population. In contrast, symptomatic carriers might transmit larger amounts of viral particles with a higher probability of leading to severe disease.
       </p>
      </caption>
      <graphic xlink:href="olf-ces-2020-cst2020.04.216-g001">
      </graphic>
     </fig>
    </sec>
    <sec>
     <title>
      CHALLENGES FOR CONTROL OF THE EPIDEMIC
     </title>
     <p>
      COVID-19 outbreak poses significant challenges for curtailing global spread and maintaining global health security. Implementation of collective infection control measures (e.g. social isolation, distancing or quarantine of entire communities) may be useful. Nonetheless, these measures should be implemented in a prudent fashion while considering their cost efficiency (e.g. for controlling small clusters of sporadic transmission). There is a real need to avoid an unmanageable epidemic wave that would saturate the capacity of health services. It is important to note that collective infection control measures can actually reduce the frequency of infection, though at the price of a prolongation of the epidemic period. Thus, in the absence of an effective vaccine and effective antiviral drugs, all infection control measures should be properly undertaken with the aim of modulating the trajectory of the epidemic so that the impact on global health is minimized and each epidemic wave does not exceed the healthcare system capabilities.
     </p>
    </sec>
    <sec>
     <title>
      TAKING FORWARD INTERVENTIONS TO CONTROL THE EPIDEMIC
     </title>
     <p>
      The first pillar for interventions is to preserve the healthcare system. The implementation of infection control measures within hospitals is crucial to protect healthcare workers, maintain adequate work force levels and to prevent hospital outbreaks that eventually foster larger community epidemics.
     </p>
     <p>
      Second, there is a growing need for providing advice on proper management of COVID-19 patients so that each individual can receive the most appropriate treatment. Currently, most of the SARS-CoV-2 infections need no therapy, and overtreatment of patients without current or future medical needs should be avoided.
     </p>
     <p>
      Third, trust between people and institutions (at the local, national and international levels) must be maintained or reestablished so that local communities and individual subjects adhere to medical advice, for instance by respecting temporary individual restrictive measure (i.e. fiduciary isolation at home for mild-symptomatic cases of COVID-19).
     </p>
     <p>
      Fourth, any antagonism between countries and their governments must be carefully avoided. The scientific community is global, by definition and for necessity. There is no individual solution for a globally spreading infection. Antagonism and lack of trust between countries will affect scientific collaboration and will retard or even jeopardize the control of SARS-CoV-2.
     </p>
     <p>
      Fifth, research on effective prevention or treatment of COVID-19 must be accelerated. Yet unconfirmed reports indicated that inhibitors of SARS-CoV-2 replication including chloroquine are clinical efficient against declared SARS-CoV-2 infection
      <xref ref-type="bibr" rid="B62">
       62
      </xref>
      <xref ref-type="bibr" rid="B63">
       63
      </xref>
      <xref ref-type="bibr" rid="B64">
       64
      </xref>
      . If these findings are confirmed, chloroquine might be used to prophylactically treat vulnerable individuals (in particular the elderly and patients with existing medical problems) that have a high risk of viral exposure. Chloroquine has been used for decades for the prevention and treatment of malaria with minimal side effects and at a low cost, suggesting the practicability of such a measure.
     </p>
     <p>
      Sixth, it is essential to control panic and to minimize the potential for social disruption that is typical of any global epidemic event. Again, exaggerated infection control measures may be pernicious as they increase frustration among the population, undermine the economy, and evoke a false feeling of safety.
     </p>
     <p>
      Despite the fact that SARS-CoV-2 appears much less virulent than SARS-CoV-1 and MERS-CoV, it is associated with significant mortality among susceptible individuals with comorbidities. Moreover, the hype and scaremongering going viral on mass news and social media, predicting the dawn of a new fatal pandemic, are spurring global hysteria. Thus, the current COVID-19 epidemic is resulting in a social rather than a viral catastrophe. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The development of the response cannot be standardized as ‘one size fits all’ but should be tailored based on the local evolution of the epidemic and the socio-economic settings involved. Indeed, the emergence of yet another global epidemic unveils the permanent challenge that infectious diseases represent for humankind and underscores the need for global cooperation and preparedness, even during inter-epidemic periods.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       Didier Roult is supported by the French Government under the "Investissements d’avenir" (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03).
      </p>
      <p>
       Alimuddin Zumla and Giuseppe Ippolito are co-principal investigators of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET), funded by the European &amp; Developing Countries Clinical Trials Partnership, supported under Horizon 2020. Sir Zumla is in receipt of a National Institutes of Health Research senior investigator award. Giuseppe Ippolito is supported by the Italian Ministry of Health (Ricerca Corrente Linea 1.
      </p>
      <p>
       GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association "Le Cancer du Sein, Parlons-en!"; Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a dona-tion by Elior; European Research Area Network on Car-diovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Pro-ject Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Univer-sitaire de France; LeDucq Foundation; the LabEx Immu-no-Oncology (ANR-18-IDEX-0001); the RHU Torino Lu-mière; the Seerave Foundation; the SIRIC Stratified On-cology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).
      </p>
     </ack>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="B1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macciocchi
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lanini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vairo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Figueiredo
          </surname>
          <given-names>
           LT
          </given-names>
         </name>
         <name>
          <surname>
           Lauria
          </surname>
          <given-names>
           FN
          </given-names>
         </name>
         <name>
          <surname>
           Strada
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Puro
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Krishna
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kremsner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Scognamiglio
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kohler
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Short-term economic impact of the Zika virus outbreak
        </article-title>
        <source>
         New Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         39
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         287
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="pmid">
         28004846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liuzzi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Puro
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Lanini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vairo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Nicastri
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Capobianchi
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Piacentini
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ippolito
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zika virus and microcephaly: is the correlation causal or coincidental?
        </article-title>
        <source>
         New Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         39
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         83
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         27196544
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         vCJD remains an enigma as UK deaths fall to zero for 2012.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         914
        </fpage>
        <lpage>
         915
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(12)70304-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         23316491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sutton
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses.
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2018
        </year>
        <volume>
         10
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         461
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/v10090461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <collab>
         WHO
        </collab>
        <article-title>
         Ebola 2014-2016.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/ebola/en/">
          https://www.who.int/csr/disease/ebola/en/
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Le-Viet
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           VN
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           QD
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           TV
          </given-names>
         </name>
         <name>
          <surname>
           Abat
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Parola
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective case-control analysis of the aetiologies of acute undifferentiated fever in Vietnam.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <year>
         2019
        </year>
        <volume>
         8
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         339
        </fpage>
        <lpage>
         352
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/22221751.2019.1580539
        </pub-id>
        <pub-id pub-id-type="pmid">
         30866787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS coronavirus to novel animal and human coronaviruses.
        </article-title>
        <source>
         J Thorac Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         5
        </volume>
        <issue>
         Suppl 2
        </issue>
        <fpage>
         S103
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="doi">
         10.3978/j.issn.2072-1439.2013.06.02
        </pub-id>
        <pub-id pub-id-type="pmid">
         23977429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Abdalla
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV.
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2020
        </year>
        <volume>
         12
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         E244
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/v12020244
        </pub-id>
        <pub-id pub-id-type="pmid">
         32098422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <collab>
         WHO
        </collab>
        <article-title>
         SARS (severe acute respiratory syndrome).
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/ith/diseases/sars/en/">
          https://www.who.int/ith/diseases/sars/en/
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <collab>
         WHO
        </collab>
        <article-title>
         Coronavirus disease (COVID-19) outbreak.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Stohr
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         349
        </volume>
        <issue>
         25
        </issue>
        <fpage>
         2431
        </fpage>
        <lpage>
         2441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMra032498
        </pub-id>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Abdallat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sayaydeh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jaarour
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Alsheikh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Alsanouri
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation.
        </article-title>
        <source>
         East Mediterr Health J
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <issue>
         Suppl 1
        </issue>
        <fpage>
         S12
        </fpage>
        <lpage>
         S18
        </lpage>
        <pub-id pub-id-type="doi">
         10.26719/2013.19.supp1.s12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Saeed
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <issue>
         26
        </issue>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmc1409847
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <collab>
         WHO
        </collab>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV).
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
          https://www.who.int/emergencies/mers-cov/en/
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <collab>
         CDC
        </collab>
        <article-title>
         Coronavirus Disease 2019.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov">
          https://www.cdc.gov
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paules
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Marston
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Fauci
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus Infections-More Than Just the Common Cold.
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <volume>
         323
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         707
        </fpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.0757
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
        </article-title>
        <source>
         Curr Opin Pulm Med
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         233
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/mcp.0000000000000046
        </pub-id>
        <pub-id pub-id-type="pmid">
         24626235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           CQ
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           JX
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Shan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DSC
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Clinical Characteristics of Coronavirus Disease 2019 in China.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2002032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ippolito
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Ntoumi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Maeurer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toning down the 2019-nCoV media hype—and restoring hope.
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/s2213-2600(20)30070-9
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Aloraini
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           KZ
          </given-names>
         </name>
         <name>
          <surname>
           Almohammadi
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Swerdlow
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah--a link to health care facilities.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2015
        </year>
        <volume>
         372
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hossain
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Hajomar
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts.
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
        <volume>
         371
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         828
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/nejmoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spread of MERS to South Korea and China.
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2015
        </year>
        <volume>
         3
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         509
        </fpage>
        <lpage>
         510
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s2213-2600(15)00238-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         26050550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <collab>
         WHO
        </collab>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV).
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
          https://www.who.int/emergencies/mers-cov/en/
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           DY
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presumed Asymptomatic Carrier Transmission of COVID-19.
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.2565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Novel Coronavirus Pneumonia Emergency Response Epidemiology Team
          </surname>
         </name>
        </person-group>
        <article-title>
         Novel Coronavirus Pneumonia Emergency Response Epidemiology Team
        </article-title>
        <source>
         Zhonghua Liu Xing Bing Xue Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         41
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         145
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="doi">
         10.3760/cma.j.issn.0254-6450.2020.02.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         32064853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         18
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         e217
        </fpage>
        <lpage>
         e227
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(18)30127-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         29680581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DSC
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features.
        </article-title>
        <source>
         Infect Dis Clin North Am
        </source>
        <year>
         2019
        </year>
        <volume>
         33
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         869
        </fpage>
        <lpage>
         889
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.idc.2019.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         31668196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <issue>
         9997
        </issue>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely.
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2020
        </year>
        <volume>
         368
        </volume>
        <fpage>
         m751
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.m751
        </pub-id>
        <pub-id pub-id-type="pmid">
         32098875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <collab>
         Reuters (2020). The Japan Times
        </collab>
        <article-title>
         South Korea reports doubling of coronavirus patients to 433, with over 1,000 at new outbreak site feeling ill.
        </article-title>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.japantimes.co.jp/news/2020/02/22/asia-pacific/covid-19-south-korea/#.XlbglGhKg_E">
          https://www.japantimes.co.jp/news/2020/02/22/asia-pacific/covid-19-south-korea/#.XlbglGhKg_E
         </ext-link>
         .[Accessed:
29.02.2020].
        </comment>
       </element-citation>
      </ref>
      <ref id="B32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Vallet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Legrand-Quillien
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Picard
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Payan
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreaks of human coronavirus in a pediatric and neonatal intensive care unit.
        </article-title>
        <source>
         Eur J Pediatr
        </source>
        <year>
         2008
        </year>
        <volume>
         167
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1427
        </fpage>
        <lpage>
         1434
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00431-008-0687-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         18335238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hand
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
         <name>
          <surname>
           Salinas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Sakthivel
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Respiratory Illness Outbreak Associated with Human Coronavirus NL63 in a Long-Term Care Facility.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         24
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1964
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2410.180862
        </pub-id>
        <pub-id pub-id-type="pmid">
         30226169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vandroux
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Allou
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jabot
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li Pat Yuen
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Brottet
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Roquebert
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Martinet
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intensive care admission for Coronavirus OC43 respiratory tract infections.
        </article-title>
        <source>
         Med Mal Infect
        </source>
        <year>
         2018
        </year>
        <volume>
         48
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         141
        </fpage>
        <lpage>
         144
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.medmal.2018.01.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         29402475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kanwar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Selvaraju
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Esper
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         uman Coronavirus-HKU1 Infection Among Adults in Cleveland, Ohio.
        </article-title>
        <source>
         Open Forum Infect Dis
        </source>
        <year>
         2017
        </year>
        <volume>
         4
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         ofx052
        </fpage>
        <pub-id pub-id-type="doi">
         10.1093/ofid/ofx052
        </pub-id>
        <pub-id pub-id-type="pmid">
         28616442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <issue>
         6965
        </issue>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           IC
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Radoshitzky
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         367
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         367
        </fpage>
        <lpage>
         374
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.035
        </pub-id>
        <pub-id pub-id-type="pmid">
         17631932
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ning
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.
        </article-title>
        <source>
         Cell Discov
        </source>
        <year>
         2020
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <pub-id pub-id-type="doi">
         10.1038/s41421-020-0147-1
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and MERS: recent insights into emerging coronaviruses.
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         523
        </fpage>
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro.2016.81
        </pub-id>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rocklov
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sjodin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures.
        </article-title>
        <source>
         J Travel Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1093/jtm/taaa030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention.
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.2648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Severance
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
         <name>
          <surname>
           Bossis
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Dickerson
          </surname>
          <given-names>
           FB
          </given-names>
         </name>
         <name>
          <surname>
           Stallings
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Origoni
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Sullens
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Yolken
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name>
          <surname>
           Viscidi
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population.
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        <year>
         2008
        </year>
        <volume>
         15
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1805
        </fpage>
        <lpage>
         1810
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/cvi.00124-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         18945884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Tsao
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Yen
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection.
        </article-title>
        <source>
         Viral Immunol
        </source>
        <year>
         2011
        </year>
        <volume>
         24
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         421
        </fpage>
        <lpage>
         426
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/vim.2011.0024
        </pub-id>
        <pub-id pub-id-type="pmid">
         21958371
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newton
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Cardani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Braciale
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The host immune response in respiratory virus infection: balancing virus clearance and immunopathology.
        </article-title>
        <source>
         Semin Immunopathol
        </source>
        <year>
         2016
        </year>
        <volume>
         38
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         471
        </fpage>
        <lpage>
         482
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00281-016-0558-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         26965109
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tetro
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is COVID-19 Receiving ADE From Other Coronaviruses?
        </article-title>
        <source>
         Microbes Infect
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2020.02.006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           XW
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lack of association between HLA-A, -B and -DRB1 alleles and the development of SARS: a cohort of 95 SARS-recovered individuals in a population of Guangdong, southern China.
        </article-title>
        <source>
         Int J Immunogenet
        </source>
        <year>
         2008
        </year>
        <volume>
         35
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         69
        </fpage>
        <lpage>
         74
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1744-313x.2007.00741.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         18186801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Khoo
          </surname>
          <given-names>
           US
          </given-names>
         </name>
         <name>
          <surname>
           Zee
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenetics in SARS: a case-control study.
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <issue>
         5 Suppl 4
        </issue>
        <fpage>
         29
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         20864745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           OW
          </given-names>
         </name>
         <name>
          <surname>
           Chia
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Jadi
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Leong
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Bertoletti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2016
        </year>
        <volume>
         34
        </volume>
        <fpage>
         2008
        </fpage>
        <lpage>
         2014
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.02.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         26954467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           FF
          </given-names>
         </name>
         <name>
          <surname>
           Velickovic
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ashton
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyer
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Geczy
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name>
          <surname>
           Dunckley
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lynch
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus.
        </article-title>
        <source>
         Virol Sin
        </source>
        <year>
         2014
        </year>
        <volume>
         29
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         128
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12250-014-3398-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         24643938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Mangalam
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           David
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.
        </article-title>
        <source>
         Immunity
        </source>
        <year>
         2016
        </year>
        <volume>
         44
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         1379
        </fpage>
        <lpage>
         1391
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.immuni.2016.05.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27287409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Sisk
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Halasz
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Venkataraman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Rajagopalan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kyratsous
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <issue>
         1
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/jvi.01825-16
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Bokhari
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Nehdi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Layqah
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Al Gethamy
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Dada
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Boujelal
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Al Johani
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses.
        </article-title>
        <source>
         Sci Immunol
        </source>
        <year>
         2017
        </year>
        <volume>
         2
        </volume>
        <issue>
         14
        </issue>
        <fpage>
         eaan5393
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/sciimmunol.aan5393
        </pub-id>
        <pub-id pub-id-type="pmid">
         28778905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Turkestani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Aldabbagh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         559
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(15)70090-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         495
        </fpage>
        <lpage>
         497
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s1473-3099(15)70128-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Kahlout
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Nasrallah
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           El Zowalaty
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Al Thani
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.
        </article-title>
        <source>
         J Immunol Res
        </source>
        <year>
         2019
        </year>
        <volume>
         2019
        </volume>
        <fpage>
         1386740
        </fpage>
        <pub-id pub-id-type="doi">
         10.1155/2019/1386740
        </pub-id>
        <pub-id pub-id-type="pmid">
         30906787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kroemer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cuende
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Martinez
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compartmentalization of the peripheral immune system.
        </article-title>
        <source>
         Adv Immunol
        </source>
        <year>
         1993
        </year>
        <volume>
         53
        </volume>
        <fpage>
         157
        </fpage>
        <lpage>
         216
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s0065-2776(08)60500-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         8512035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woodward Davis
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Roozen
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Dufort
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           DeBerg
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Delaney
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Mair
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Slichter
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Berkson
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Klock
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Mack
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lwo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         The human tissue-resident CCR5(+) T cell compartment maintains protective and functional properties during inflammation.
        </article-title>
        <source>
         Sci Transl Med
        </source>
        <year>
         2019
        </year>
        <volume>
         11
        </volume>
        <issue>
         521
        </issue>
        <pub-id pub-id-type="doi">
         10.1126/scitranslmed.aaw8718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haddadi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vaseghi-Shanjani
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Afkhami
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           D'Agostino
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Zganiacz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jeyanathan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mucosal-Pull Induction of Lung-Resident Memory CD8 T Cells in Parenteral TB Vaccine-Primed Hosts Requires Cognate Antigens and CD4 T Cells.
        </article-title>
        <source>
         Front Immunol
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         2075
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fimmu.2019.02075
        </pub-id>
        <pub-id pub-id-type="pmid">
         31552032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1001/jama.2020.1585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           YY
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           YD
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           YB
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           YQ
          </given-names>
         </name>
         <name>
          <surname>
           Akdis
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           YD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
        </article-title>
        <source>
         Allergy
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1111/all.14238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1038/s41422-020-0282-0
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         2020
        </volume>
        <fpage>
         105923
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijantimicag.2020.105923
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.5582/bst.2020.01047
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trombetta
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Faggion
          </surname>
          <given-names>
           HZ
          </given-names>
         </name>
         <name>
          <surname>
           Leotte
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Nogueira
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Vidal
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <name>
          <surname>
           Raboni
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus and severe acute respiratory infection in Southern Brazil.
        </article-title>
        <source>
         Pathog Glob Health
        </source>
        <year>
         2016
        </year>
        <volume>
         110
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         113
        </fpage>
        <lpage>
         118
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/20477724.2016.1181294
        </pub-id>
        <pub-id pub-id-type="pmid">
         27195607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goes
          </surname>
          <given-names>
           LGB
          </given-names>
         </name>
         <name>
          <surname>
           Zerbinati
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Tateno
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name>
          <surname>
           de Souza
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <name>
          <surname>
           Ebach
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Moreira-Filho
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Durigon
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           da Silva Filho
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Typical epidemiology of respiratory virus infections in a Brazilian slum.
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2019
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Coronavirus HKU1 and other coronavirus infections in Hong Kong.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2006
        </year>
        <volume>
         44
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         2063
        </fpage>
        <lpage>
         2071
        </lpage>
        <pub-id pub-id-type="doi">
         10.5353/th_b4501060
        </pub-id>
        <pub-id pub-id-type="pmid">
         16757599
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Owusu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Larbi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Anti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Agbenyega
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Agbenyega
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana.
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         e99782
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0099782
        </pub-id>
        <pub-id pub-id-type="pmid">
         25080241
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Tuo
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           XB
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou.
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2018
        </year>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         e0191789
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0191789
        </pub-id>
        <pub-id pub-id-type="pmid">
         29377913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           ZQ
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           WP
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           HX
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           MX
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           ZS
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China.
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         37
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         363
        </fpage>
        <lpage>
         369
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10096-017-3144-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         29214503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sipulwa
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Ongus
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Coldren
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Bulimo
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular characterization of human coronaviruses and their circulation dynamics in Kenya, 2009-2012.
        </article-title>
        <source>
         Virol J
        </source>
        <year>
         2016
        </year>
        <volume>
         13
        </volume>
        <fpage>
         18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12985-016-0474-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         26833249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kiyuka
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Agoti
          </surname>
          <given-names>
           CN
          </given-names>
         </name>
         <name>
          <surname>
           Munywoki
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Njeru
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bett
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Otieno
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Otieno
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <name>
          <surname>
           Kamau
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Nokes
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya.
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2018
        </year>
        <volume>
         217
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1728
        </fpage>
        <lpage>
         1739
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiy098
        </pub-id>
        <pub-id pub-id-type="pmid">
         29741740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dube
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Kaba
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Robberts
          </surname>
          <given-names>
           FJ
          </given-names>
         </name>
         <name>
          <surname>
           Ah Tow
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lubbe
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zar
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Nicol
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory microbes present in the nasopharynx of children hospitalised with suspected pulmonary tuberculosis in Cape Town, South Africa.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         597
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1934-z
        </pub-id>
        <pub-id pub-id-type="pmid">
         27776489
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subramoney
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hellferscee
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Pretorius
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tempia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           McMorrow
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           von Gottberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wolter
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Variava
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Dawood
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kahn
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Walaza
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Madhi
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           et al
          </surname>
         </name>
        </person-group>
        <article-title>
         Human bocavirus, coronavirus, and polyomavirus detected among patients hospitalised with severe acute respiratory illness in South Africa, 2012 to 2013.
        </article-title>
        <source>
         Health Sci Rep
        </source>
        <year>
         2018
        </year>
        <volume>
         1
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         e59
        </fpage>
        <pub-id pub-id-type="doi">
         10.1002/hsr2.59
        </pub-id>
        <pub-id pub-id-type="pmid">
         30623094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nunes
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Kuschner
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Rabede
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Madimabe
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Van Niekerk
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Moloi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kuwanda
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Rossen
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Klugman
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Adrian
          </surname>
          <given-names>
           PV
          </given-names>
         </name>
         <name>
          <surname>
           Madhi
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children.
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         e86448
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0086448
        </pub-id>
        <pub-id pub-id-type="pmid">
         24498274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Killerby
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Biggs
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dahl
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Mustaquim
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus circulation in the United States 2014-2017.
        </article-title>
        <source>
         J Clin Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         101
        </volume>
        <fpage>
         52
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2018.01.019
        </pub-id>
        <pub-id pub-id-type="pmid">
         29427907
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <glossary>
      <title>
       Abbreviations:
      </title>
      <def-list>
       <def-item>
        <term>
         ACE
        </term>
        <def>
         <p>
          – angiotensin converting enzyme,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ADE
        </term>
        <def>
         <p>
          – antibody-dependent enhancement,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ARDS
        </term>
        <def>
         <p>
          – acute respiratory distress syndrome,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CoV
        </term>
        <def>
         <p>
          – coronavirus,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         COVID-19
        </term>
        <def>
         <p>
          – coronavirus disease 2019,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         HCoV
        </term>
        <def>
         <p>
          – human coronavirus,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MERS
        </term>
        <def>
         <p>
          – Middle-East respiratory syndrome,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SARI
        </term>
        <def>
         <p>
          – severe acute respiratory illness,
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SARS
        </term>
        <def>
         <p>
          – severe acute respiratory syndrome,
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Am J Emerg Med
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Am J Emerg Med
      </journal-id>
      <journal-title-group>
       <journal-title>
        The American Journal of Emergency Medicine
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0735-6757
      </issn>
      <issn pub-type="epub">
       1532-8171
      </issn>
      <publisher>
       <publisher-name>
        W B Saunders
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32265065
      </article-id>
      <article-id pub-id-type="pmc">
       7102516
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0735-6757(20)30178-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ajem.2020.03.036
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus Disease (COVID-19): A primer for emergency physicians
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Chavez
         </surname>
         <given-names>
          Summer
         </given-names>
        </name>
        <degrees>
         DO, MPH
        </degrees>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Long
         </surname>
         <given-names>
          Brit
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <email>
         brit.long@yahoo.com
        </email>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Koyfman
         </surname>
         <given-names>
          Alex
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Liang
         </surname>
         <given-names>
          Stephen Y.
         </given-names>
        </name>
        <degrees>
         MD, MPHS
        </degrees>
        <email>
         syliang@wustl.edu
        </email>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       <label>
        a
       </label>
       Department of Emergency Medicine, MedStar Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, United States
      </aff>
      <aff id="af0010">
       <label>
        b
       </label>
       Brooke Army Medical Center, Department of Emergency Medicine, 3841 Roger Brooke Dr, Fort Sam Houston, TX 78234, United States
      </aff>
      <aff id="af0015">
       <label>
        c
       </label>
       The University of Texas Southwestern Medical Center, Department of Emergency Medicine, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States
      </aff>
      <aff id="af0020">
       <label>
        d
       </label>
       Divisions of Emergency Medicine and Infectious Diseases, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, United States
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author at: 3841 Roger Brooke Dr, Fort Sam Houston, TX 78234, United States.
        <email>
         brit.long@yahoo.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        24
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        24
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <history>
       <date date-type="received">
        <day>
         22
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         22
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <sec>
        <title>
         Introduction
        </title>
        <p>
         Rapid worldwide spread of Coronavirus Disease 2019 (COVID-19) has resulted in a global pandemic.
        </p>
       </sec>
       <sec>
        <title>
         Objective
        </title>
        <p>
         This review article provides emergency physicians with an overview of the most current understanding of COVID-19 and recommendations on the evaluation and management of patients with suspected COVID-19.
        </p>
       </sec>
       <sec>
        <title>
         Discussion
        </title>
        <p>
         Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19, is primarily transmitted from person-to-person through close contact (approximately 6 ft) by respiratory droplets. Symptoms of COVID-19 are similar to other viral upper respiratory illnesses. Three major trajectories include mild disease with upper respiratory symptoms, non-severe pneumonia, and severe pneumonia complicated by acute respiratory distress syndrome (ARDS). Emergency physicians should focus on identifying patients at risk, isolating suspected patients, and informing hospital infection prevention and public health authorities. Patients with suspected COVID-19 should be asked to wear a facemask. Respiratory etiquette, hand washing, and personal protective equipment are recommended for all healthcare personnel caring for suspected cases. Disposition depends on patient symptoms, hemodynamic status, and patient ability to self-quarantine.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         This narrative review provides clinicians with an updated approach to the evaluation and management of patients presenting to the emergency department with suspected COVID-19.
        </p>
       </sec>
      </abstract>
      <kwd-group id="ks0005">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus Disease
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Infectious disease
       </kwd>
       <kwd>
        Pulmonary
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0040">
      On January 30, 2020, the World Health Organization (WHO) designated an outbreak of a novel coronavirus not seen before in humans to be a “public health emergency of international concern” (PHEIC); this was followed by the declaration of a pandemic on March 11, 2020 [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0010">
       2
      </xref>
      ]. Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), previously referred to as 2019-nCoV, is the virus responsible for causing Coronavirus Disease 2019 (COVID-19) [
      <xref ref-type="bibr" rid="bb0015">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0020">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0025">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0030">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0035">
       [7]
      </xref>
      ]. The pandemic traces its early beginnings to the report of a cluster of 27 unexplained pneumonia cases in late December 2019 originating from a seafood and live animal market in Wuhan, Hubei Province, China [
      <xref ref-type="bibr" rid="bb0040">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0045">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0050">
       [10]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0055">
       [11]
      </xref>
      ]. From the outset, the causative agent was thought to be viral, with most patients reporting fever or dyspnea [
      <xref ref-type="bibr" rid="bb0045">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0055">
       11
      </xref>
      ]. With unprecedented numbers of individuals under travel restrictions or quarantine, worldwide spread, and no known cure or vaccine yet available, COVID-19 has proven a formidable adversary [
      <xref ref-type="bibr" rid="bb0060">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0065">
       [13]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0070">
       [14]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0075">
       [15]
      </xref>
      ].
     </p>
     <p id="p0045">
      The Ebola Virus Disease (EVD) outbreak of 2014 in West Africa provided valuable lessons with regards to emergency preparedness, personal protective equipment use, and triage processes and underscored the important role that emergency physicians play on the frontlines of emerging infectious diseases [
      <xref ref-type="bibr" rid="bb0080">
       [16]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0085">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0090">
       [18]
      </xref>
      ]. We describe the virology, epidemiology, clinical presentation, radiographic and laboratory findings, current testing protocols, and management of patients presenting with COVID-19 to the emergency department (ED). In this review article, we provide emergency physicians with best practices based on the rapidly evolving body of literature surrounding COVID-19.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Discussion
     </title>
     <sec id="s0015">
      <label>
       2.1
      </label>
      <title>
       Virology
      </title>
      <p id="p0050">
       SARS-CoV-2 is a member of the coronavirus family, named for the crown-like appearance of spikes on the virus surface [
       <xref ref-type="bibr" rid="bb0025">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0095">
        19
       </xref>
       ]. Other members of the coronavirus family include Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and SARS-CoV-1, as well as coronaviruses responsible for the common cold (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       ,
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ) [
       <xref ref-type="bibr" rid="bb0025">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0040">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0095">
        19
       </xref>
       ]. Like MERS-CoV and SARS-CoV-1, SARS-CoV-2 is a betacoronavirus and is likely associated with an animal reservoir (e.g., bats) [
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0040">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0070">
        14
       </xref>
       ]. While an exact animal source has not been confirmed for COVID-19, many of the early cases in China were linked to a live animal and seafood market [
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0070">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0100">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0105">
        21
       </xref>
       ].
       <fig id="f0005">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Transmission electronic microscope image of COVID-19 illustrating the characteristic crown-like spikes on the outer rim.
         </p>
        </caption>
        <alt-text id="al0005">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
        <attrib>
         Source: National Institute of Allergy and Infectious Diseases-Rocky Mountain Laboratories (NIAID-RML). Novel Coronavirus SARS-CoV-2.; 2020.
         <ext-link ext-link-type="uri" id="ir6005" xlink:href="https://www.flickr.com/photos/niaid/49534865371/">
          https://www.flickr.com/photos/niaid/49534865371/
         </ext-link>
         . Accessed February 18, 2020.
        </attrib>
       </fig>
       <fig id="f0010">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          This electron microscope image depicts the spikes on the outer surface of the COVID-19 in addition to several protein particles.
         </p>
        </caption>
        <alt-text id="al0010">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
        <attrib>
         Eckert A, Higgins D, Centers for Disease Control and Prevention. ID# 23313; 2020.
         <ext-link ext-link-type="uri" id="ir0010" xlink:href="https://phil.cdc.gov/Details.aspx?pid=23313">
          https://phil.cdc.gov/Details.aspx?pid=23313
         </ext-link>
         . Accessed February 18, 2020.
        </attrib>
       </fig>
      </p>
     </sec>
     <sec id="s0020">
      <label>
       2.2
      </label>
      <title>
       Epidemiology
      </title>
      <p id="p0055">
       The majority of initial COVID-19 cases were associated with travel to Hubei Province, China; however, a growing number of cases due to person-to-person transmission have been reported both in and outside of China (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ) [
       <xref ref-type="bibr" rid="bb0040">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0070">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0110">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0115">
        23
       </xref>
       ]. Up to 94% of COVID-19 cases were reported to originate from Hubei Province in December 2019; as of March 2020, the greatest number of new cases are now being reported in Italy, Spain, Germany, and the United States (U.S.) (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       ) [
       <xref ref-type="bibr" rid="bb0120">
        [24]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0125">
        [25]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0130">
        [26]
       </xref>
       ].
       <fig id="f0015">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Countries with at least 1 confirmed case of COVID-19 as of March 21, 2020.
         </p>
        </caption>
        <alt-text id="al0015">
         Fig. 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
        <attrib>
         Available from
         <ext-link ext-link-type="uri" id="ir0015" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/world-map.html">
          https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/world-map.html
         </ext-link>
         .
        </attrib>
       </fig>
       <fig id="f0020">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          United States cases as of March 21, 2020.
         </p>
        </caption>
        <alt-text id="al0020">
         Fig. 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
        <attrib>
         Available from
         <ext-link ext-link-type="uri" id="ir0020" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html">
          https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
         </ext-link>
         .
        </attrib>
       </fig>
      </p>
      <p id="p0060">
       Based on what is known about other coronaviruses, experts believe COVID-19 primarily spreads from person-to-person through close contact (approximately 6 ft) by respiratory droplets [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0040">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0070">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0115">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0135">
        27
       </xref>
       ]. Transmission of the virus through contaminated surfaces or fomites with subsequent contact with the eyes, nose, or mouth may also occur [
       <xref ref-type="bibr" rid="bb0070">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0115">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0135">
        27
       </xref>
       ]. Patients are felt to be at highest risk of spreading the illness when they are most symptomatic [
       <xref ref-type="bibr" rid="bb0115">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0135">
        27
       </xref>
       ]. Limited data support viral shedding in asymptomatic patients while increased levels of viral shedding may be more pronounced in those critically ill [
       <xref ref-type="bibr" rid="bb0140">
        [28]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0145">
        [29]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0150">
        [30]
       </xref>
       ]. Current epidemiologic patterns of COVID-19 in China indicate that it is highly contagious with sustained spread; the extent of person-to-person transmission within the U.S. was initially limited but has progressed now to community transmission in many parts of the country [
       <xref ref-type="bibr" rid="bb0115">
        23
       </xref>
       ]. The current R
       <sub>
        0
       </sub>
       or basic reproduction number is estimated to be &gt;2.2; for every case of COVID-19 identified in the population, &gt;2 additional cases are possible in the absence of adequate isolation. [
       <xref ref-type="bibr" rid="bb0100">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0155">
        [31]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0160">
        [32]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0165">
        [33]
       </xref>
       ]
      </p>
      <p id="p0065">
       In an early epidemiologic analysis of 425 COVID-19 cases in Wuhan, China, the median patient age was 59 years, and 56% were male [
       <xref ref-type="bibr" rid="bb0100">
        20
       </xref>
       ]. In the largest study to date of COVID-19, comprising over 72,000 patient records (up to February 11, 2020) from China, 86.6% of patients were 30–79 years of age [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ]. While 80.9% of these cases were reported to be mild, the overall case fatality rate was 2.3% [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ]. Few pediatric cases of COVID-19 have been reported, with patients aged 0–19 years representing just 2.1% of all cases [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0175">
        35
       </xref>
       ]. Approximately 3.8% of laboratory confirmed cases of COVID-19 occurred in healthcare personnel, and 14.6% of these cases were either severe or critical [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ]. To be classified as severe, the following characteristics were required: PaO2/FiO2 &lt; 300, oxygen saturation ≤ 93%, presence of &gt;50% lung infiltrates within 24–48 h, respirations ≥30 breaths/min, or dyspnea [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ]. Critical patients, defined as those with septic shock, multiple organ dysfunction/failure, and/or respiratory failure, accounted for approximately 5% of the study population with a case fatality rate of 49.0% [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0120">
        24
       </xref>
       ]. The highest case fatality rate was observed in those older than 80 years (14.8%) [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ]. Patients without comorbidities had a case fatality rate of just 0.9%, in contrast to those with comorbid conditions such as cardiovascular disease (10.5%) [
       <xref ref-type="bibr" rid="bb0170">
        34
       </xref>
       ].
      </p>
      <p id="p0070">
       Caution should be exercised in interpreting early findings, as underreporting and variable testing practices have been a concern with COVID-19 [
       <xref ref-type="bibr" rid="bb0180">
        36
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0185">
        37
       </xref>
       ]. Case fatality rates in Hubei Province have been reported to be 18% (95% confidence interval [CI] 11–18), while those outside mainland China range from 1.2–5.1% [
       <xref ref-type="bibr" rid="bb0190">
        38
       </xref>
       ]. Mortality rates have been calculated to be as high as 11–15% [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ]. When compared to other recent epidemics such as SARS (9.56) or EVD (39.53), the average case fatality rate (4.2%) for COVID-19 is much lower (
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       ) [
       <xref ref-type="bibr" rid="bb0205">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0210">
        42
       </xref>
       ]. In comparison, the 2009 H1N1 influenza pandemic and 2017 influenza season were responsible for approximately 220 times more cases [
       <xref ref-type="bibr" rid="bb0205">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0210">
        42
       </xref>
       ].
       <table-wrap id="t0005" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Comparison of epidemiological characteristics of recent global epidemics as of March 21, 2020 [
          <xref ref-type="bibr" rid="bb0205">
           41
          </xref>
          ,
          <xref ref-type="bibr" rid="bb0020">
           4
          </xref>
          ].
         </p>
        </caption>
        <alt-text id="al0030">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Disease
           </th>
           <th>
            Case fatality rate
           </th>
           <th>
            Deaths
           </th>
           <th>
            Cases
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            COVID-19 (2019)
           </td>
           <td>
            4.2
           </td>
           <td>
            11,299
           </td>
           <td>
            272,166
           </td>
          </tr>
          <tr>
           <td>
            Influenza (2017)
            <xref ref-type="table-fn" rid="tf0005">
             a
            </xref>
           </td>
           <td>
            N/A
           </td>
           <td>
            145,000
           </td>
           <td>
            54,481,000
           </td>
          </tr>
          <tr>
           <td>
            Ebola (2014)
           </td>
           <td>
            39.53
           </td>
           <td>
            11,323
           </td>
           <td>
            28,646
           </td>
          </tr>
          <tr>
           <td>
            H1N1 (2009)
           </td>
           <td>
            0.1
           </td>
           <td>
            18,449
           </td>
           <td>
            60,800,000
           </td>
          </tr>
          <tr>
           <td>
            SARS (2003)
           </td>
           <td>
            9.56
           </td>
           <td>
            774
           </td>
           <td>
            8096
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tf0005">
          <label>
           a
          </label>
          <p id="np0005">
           Estimated global burden of disease from influenza-related lower respiratory tract infections; excludes cases with alternative causes (i.e. cardiac).
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="p0075">
       Based on what is known about similar coronaviruses, the longest potential incubation period for COVID-19 is thought to be 14 days from initial exposure [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ]. The mean incubation period is 5.2 days (95% CI 4.1–7.0) but can range from 2 to 14 days [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0100">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0215">
        43
       </xref>
       ]. Co-infections occur in 22–33% of patients and may be higher in critical patients [
       <xref ref-type="bibr" rid="bb0220">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0225">
        45
       </xref>
       ].
      </p>
     </sec>
     <sec id="s0025">
      <label>
       2.3
      </label>
      <title>
       Special populations
      </title>
      <p id="p0080">
       Risk factors for severe COVID-19 disease include advanced age, chronic medical conditions, immunocompromise, and cancer [
       <xref ref-type="bibr" rid="bb0230">
        46
       </xref>
       ].
      </p>
      <p id="p0085">
       Data regarding pregnancy and COVID-19 are limited [
       <xref ref-type="bibr" rid="bb0235">
        47
       </xref>
       ]. Pregnant women and fetuses may be more vulnerable to COVID-19 infection compared to the general population [
       <xref ref-type="bibr" rid="bb0240">
        48
       </xref>
       ]. There are case reports of pregnant women diagnosed with COVID-19 complicated by adverse outcomes including preterm birth [
       <xref ref-type="bibr" rid="bb0235">
        47
       </xref>
       ]. Historically, infants born to mothers with other coronaviruses such as MERS-CoV or SARS-CoV-1 have been small for gestational age or preterm [
       <xref ref-type="bibr" rid="bb0235">
        47
       </xref>
       ]. Newborn infants are also an at-risk population [
       <xref ref-type="bibr" rid="bb0240">
        48
       </xref>
       ].
      </p>
      <p id="p0090">
       Occupational exposure to pathogens is an inherent risk of working in healthcare settings [
       <xref ref-type="bibr" rid="bb0245">
        49
       </xref>
       ]. During the 2003 SARS outbreak, 9% of healthcare professionals (HCPs) in Toronto, Canada participating in endotracheal intubation of infected patients became infected themselves [
       <xref ref-type="bibr" rid="bb0250">
        50
       </xref>
       ]. In another study, 77% of SARS patients in Toronto had ties to the hospital setting, and 51% of cases were HCPs [
       <xref ref-type="bibr" rid="bb0255">
        51
       </xref>
       ]. During the H1N1 influenza pandemic, HCPs were significantly more likely to develop infection (odds ratio [OR] 2.08, 95% CI 1.73–2.51) with a pooled prevalence of 6.3% [
       <xref ref-type="bibr" rid="bb0260">
        52
       </xref>
       ]. As COVID-19 has disproportionately affected HCPs, emergency physicians must be vigilant about potential exposure risks and adhere to appropriate infection prevention precautions [
       <xref ref-type="bibr" rid="bb0265">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0270">
        54
       </xref>
       ]. In Italy, anywhere from 8 to 30% of HCPs have been infected with SARS-CoV-2 [
       <xref ref-type="bibr" rid="bb0275">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0280">
        56
       </xref>
       ].
      </p>
     </sec>
     <sec id="s0030">
      <label>
       2.4
      </label>
      <title>
       Clinical presentation
      </title>
      <p id="p0095">
       The symptoms of COVID-19 are similar to other viral upper respiratory illnesses and include fever, cough, fatigue, and dyspnea [
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0040">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0215">
        43
       </xref>
       ]. The differential diagnosis for COVID-19 should be tailored to the patient and their presenting symptoms and comorbidities. Influenza, respiratory syncytial virus (RSV), other viral illnesses, and bacterial pneumonia should be considered, as well as other pulmonary diseases (ie, pulmonary embolism). Completing a thorough yet focused history and physical examination and obtaining collateral history from family members are vital. Aside from pulmonary symptoms, patients with COVID-19 may initially present with more vague complaints including diarrhea, lethargy, myalgias, and nausea [
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0285">
        57
       </xref>
       ]. Patients may also experience headache, confusion, vomiting, pleurisy, sore throat, sneezing, rhinorrhea, and nasal congestion [
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0290">
        58
       </xref>
       ]. A case series of 41 patients (median age 49.0 years) with COVID-19 from Wuhan, China found the most commonly reported symptoms were cough (76%), fever (98%), or dyspnea (55%) [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ]. In the same case series, patients also reported myalgias/fatigue (44%), productive cough (28%), headache (8%), hemoptysis (5%), and diarrhea (3%) [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ]. In a nationwide study of COVID-19 cases from across China, the most common presenting symptoms included cough (68%), fever (44%), fatigue (38%), sputum production (34%), and shortness of breath (19%) [
       <xref ref-type="bibr" rid="bb0295">
        59
       </xref>
       ]. Fever was not a predominant symptom at the time of initial presentation. In patients with more severe disease, dyspnea may be present in 37% of patients and progress to acute lung injury in 15% of patients [
       <xref ref-type="bibr" rid="bb0300">
        60
       </xref>
       ]. One study of 204 patients with confirmed COVID-19 suggests 48.5% of patients have gastrointestinal (GI) symptoms [
       <xref ref-type="bibr" rid="bb0305">
        61
       </xref>
       ]. These symptoms may include anorexia (83.8%), diarrhea (29.3%), vomiting (0.8%), and abdominal pain (0.4%). Seven of the 204 patients had only GI symptoms with no respiratory symptoms [
       <xref ref-type="bibr" rid="bb0305">
        61
       </xref>
       ].
      </p>
      <p id="p0100">
       Atypical presentations of infection in general may be more likely in the elderly and immunocompromised, who may not mount a febrile response [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0315">
        63
       </xref>
       ]. To increase sensitivity and identify potential COVID-19 patients sooner, the U.S. Centers for Disease Control and Prevention (CDC) recommends using a temperature cutoff of 100.0 F
       <sup>
        o
       </sup>
       [
       <xref ref-type="bibr" rid="bb0320">
        64
       </xref>
       ]. Patients older than 60 years of age and those with comorbidities may also present with more severe disease compared to other populations [
       <xref ref-type="bibr" rid="bb0290">
        58
       </xref>
       ].
      </p>
      <p id="p0105">
       Three major trajectories for COVID-19 have been described: mild disease with upper respiratory symptoms, non-severe pneumonia, and severe pneumonia complicated by acute respiratory distress syndrome (ARDS) necessitating aggressive resuscitative measures [
       <xref ref-type="bibr" rid="bb0325">
        65
       </xref>
       ]. Anywhere from 17 to 29% of patients may develop ARDS [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ]. Other complications of COVID-19 include secondary bacterial infection, acute kidney injury, septic shock, ventilator-associated pneumonia, and cardiac injury [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ].
      </p>
     </sec>
     <sec id="s0035">
      <label>
       2.5
      </label>
      <title>
       Initial approach to COVID-19 in the emergency department
      </title>
      <p id="p0110">
       An emergency medicine approach to COVID-19 should focus on identifying and isolating patients at risk for infection, informing hospital infection prevention and local public health authorities, and engaging infectious disease and other specialists early in care. The World Health Organization (WHO) has established case and contact definitions for COVID-19 to standardize global surveillance (
       <xref ref-type="table" rid="t0010">
        Table 2
       </xref>
       ). Most patients with confirmed COVID-19 have had a subjective or confirmed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing) [
       <xref ref-type="bibr" rid="bb0330">
        66
       </xref>
       ].
       <table-wrap id="t0010" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          World Health Organization (WHO) case and contact definitions for global surveillance of COVID-19.
         </p>
        </caption>
        <alt-text id="al0035">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td>
            Suspected case
            <break>
            </break>
            A. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset;
            <break>
            </break>
            <break>
            </break>
            OR
            <break>
            </break>
            <break>
            </break>
            B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset;
            <break>
            </break>
            <break>
            </break>
            OR
            <break>
            </break>
            <break>
            </break>
            C. A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.
           </td>
          </tr>
          <tr>
           <td>
            Probable case
            <break>
            </break>
            A. A suspect case for whom testing for the COVID-19 virus is inconclusive.
            <break>
            </break>
            <break>
            </break>
            OR
            <break>
            </break>
            <break>
            </break>
            B. A suspect case for whom testing could not be performed for any reason.
           </td>
          </tr>
          <tr>
           <td>
            Confirmed case
            <break>
            </break>
            A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
            <break>
            </break>
            <break>
            </break>
            See laboratory guidance for details:
            <ext-link ext-link-type="uri" id="ir0035" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/laboratory-guidance">
             https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/laboratory-guidance
            </ext-link>
           </td>
          </tr>
          <tr>
           <td>
            Contact
            <break>
            </break>
            A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case:
            <break>
            </break>
            <list id="l0005" list-type="simple">
             <list-item id="li0005">
              <label>
               •
              </label>
              <p id="p0005">
               Face-to-face contact with a probable or confirmed case within 1 m and for &gt;15 min;
              </p>
             </list-item>
             <list-item id="li0010">
              <label>
               •
              </label>
              <p id="p0010">
               Direct physical contact with a probable or confirmed case;
              </p>
             </list-item>
             <list-item id="li0015">
              <label>
               •
              </label>
              <p id="p0015">
               Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment; OR
              </p>
             </list-item>
             <list-item id="li0020">
              <label>
               •
              </label>
              <p id="p0020">
               Other situations as indicated by local risk assessments.
              </p>
             </list-item>
            </list>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           Note: For confirmed asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days after the
           <italic>
            date on which the sample was taken
           </italic>
           which led to confirmation.
          </p>
         </fn>
        </table-wrap-foot>
        <attrib>
         <ext-link ext-link-type="uri" id="ir0030" xlink:href="https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)">
          https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)
         </ext-link>
         .
        </attrib>
       </table-wrap>
      </p>
      <p id="p0115">
       In concert with clinician judgment regarding patient presentations compatible with COVID-19, CDC guidelines prioritize patients from defined populations for further evaluation and testing as persons under investigation (PUI) (
       <xref ref-type="table" rid="t0015">
        Table 3
       </xref>
       ). These criteria are not exhaustive, and patients with an unestablished etiology or equivocal history of exposure may be considered for further testing on an individual basis [
       <xref ref-type="bibr" rid="bb0335">
        67
       </xref>
       ]. Confirmed local COVID-19 cases in the setting of known community transmission should reduce the threshold for further COVID-19 evaluation in the ED. Collaboration with local and state public health departments is strongly recommended [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0335">
        67
       </xref>
       ]. A PUI should be asked to wear a facemask to reduce risk of transmission to others in the immediate vicinity.
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       details CDC recommendations for identifying and assessing suspected COVID-19.
       <table-wrap id="t0015" position="float">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Patient populations that should be prioritized for evaluation of COVID-19 in the setting of compatible signs and symptoms.
          <ext-link ext-link-type="uri" id="ir0005" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html">
           https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html
          </ext-link>
         </p>
        </caption>
        <alt-text id="al5005">
         Table 3
        </alt-text>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td>
            1. Hospitalized patients who have signs and symptoms compatible with COVID-19 in order to inform decisions related to infection control.
            <break>
            </break>
            2. Other symptomatic individuals such as, older adults and individuals with chronic medical conditions and/or an immunocompromised state that may put them at higher risk for poor outcomes (e.g., diabetes, heart disease, receiving immunosuppressive medications, chronic lung disease, chronic kidney disease).
            <break>
            </break>
            3. Any persons including healthcare personnel
            <sup>
             a
            </sup>
            , who within 14 days of symptom onset had close contact
            <sup>
             b
            </sup>
            with a suspect or laboratory-confirmed
            <sup>
             c
            </sup>
            COVID-19 patient, or who have a history of travel from affected geographic areas
            <sup>
             d
            </sup>
            within 14 days of their symptom onset.
           </td>
          </tr>
          <tr>
           <td colspan="1">
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            <underline>
             <bold>
              Notes:
             </bold>
            </underline>
            <break>
            </break>
            <sup>
             a
            </sup>
            For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19 without laboratory confirmation. Because of their often extensive and close contact with vulnerable patients in healthcare settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be evaluated among potentially exposed healthcare personnel. Additional information is available in CDC’s Interim U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with Coronavirus Disease 2019 (COVID-19).
            <break>
            </break>
            <sup>
             b
            </sup>
            Close contact is defined as—
            <break>
            </break>
            a) being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time; close contact can occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case
            <break>
            </break>
            – or –
            <break>
            </break>
            b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on)
            <break>
            </break>
            If such contact occurs while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection), criteria for PUI consideration are met.
            <break>
            </break>
            <sup>
             c
            </sup>
            Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for COVID-19 patients in other countries.
            <break>
            </break>
            <sup>
             d
            </sup>
            Affected areas are defined as geographic regions where sustained community transmission has been identified. For a list of relevant affected areas, see CDC’s Coronavirus Disease 2019 Information for Travel.
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
       <fig id="f0025">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Flowchart to Identify and Assess 2019 Novel Coronavirus from the CDC.
         </p>
        </caption>
        <alt-text id="al0025">
         Fig. 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
        <attrib>
         Available at
         <ext-link ext-link-type="uri" id="ir0025" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/2019-nCoV-identify-assess-flowchart-508.pdf">
          https://www.cdc.gov/coronavirus/2019-ncov/hcp/2019-nCoV-identify-assess-flowchart-508.pdf
         </ext-link>
         . Accessed February 26, 2020.
        </attrib>
       </fig>
      </p>
      <sec id="s0040">
       <label>
        2.5.1
       </label>
       <title>
        Pre-hospital setting
       </title>
       <p id="p0120">
        Emergency medical services (EMS) directors and public health authorities working in conjunction with the CDC will need to modify emergency preparedness strategies to address COVID-19 [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. Emergency medical dispatchers should consider whether callers describing risk factors and symptoms concerning for COVID-19 should be identified as a potential PUI [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. If so, EMS personnel arriving on-scene as well as HCPs at the receiving hospital should be notified immediately to ensure proper personal protective equipment (PPE) use and confirm that appropriate isolation facilities are available [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. Once contact is made with the patient, initial triage and assessment should be done at least 6 ft or 2 meters away and minimized until the PUI dons a facemask [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. In addition to limiting the number of EMS personnel in the patient compartment, those providing any direct patient care should follow standard, droplet (surgical mask), and contact precautions (gown and gloves) while wearing eye protection (face shield or goggles) [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. Airborne precautions (N95 respirator) should be employed if the patient is critically ill and/or if an aerosol-generating procedure is anticipated during transport. Ideally, transport vehicles with isolated compartments or high efficiency particulate air (HEPA) filtration should be used, and the patient should be transferred directly to a treatment room on arrival at the receiving healthcare facility [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. After the patient has been transported and EMS documentation is being completed, patient compartment doors should be left open to allow proper ventilation [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. When cleaning the vehicle, disposable gown, gloves, surgical mask, and face shield should be worn [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ]. Routine cleaning should be followed by application of a hospital-grade disinfectant, preferably one approved by the U.S. Environmental Protection Agency (EPA) for use against emerging viral pathogens including SARS-CoV-2 [
        <xref ref-type="bibr" rid="bb0340">
         68
        </xref>
        ].
       </p>
      </sec>
      <sec id="s0045">
       <label>
        2.5.2
       </label>
       <title>
        Emergency department setting
       </title>
       <p id="p0125">
        Patients presenting with symptoms concerning for COVID-19 to the ED should be separated from other patients by at least 6 ft or 2 m and asked to wear a facemask [
        <xref ref-type="bibr" rid="bb0310">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. Ideally, stable COVID-19 PUIs would be identified at time of check-in or triage and then placed in a private room with the door closed [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0320">
         64
        </xref>
        ]. Critically ill patients and those requiring aerosol-generating procedures should be placed in an airborne infection isolation room (AIIR), also known as a negative pressure isolation room, with HEPA filtration of the recirculated air [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. Once a PUI is identified, the appropriate health department or agency and institutional personnel should be notified in an expeditious manner [
        <xref ref-type="bibr" rid="bb0310">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0335">
         67
        </xref>
        ]. Movement into and out of the patient's treatment room should be limited to only essential HCPs involved in patient care [
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. While in the room, the PUI may remove their facemask [
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. However, it is reasonable to ask the patient to wear a facemask during interactions with HCPs (e.g., performing a physical examination) in the room as tolerated to contain respiratory droplets generated from coughing.
       </p>
       <p id="p0130">
        HCPs should either use alcohol-based hand sanitizer or wash their hands with soap and water before and after contact with a COVID-19 PUI [
        <xref ref-type="bibr" rid="bb0310">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. They should be trained in the appropriate use of PPE per hospital guidelines, including techniques to safely doff equipment protecting mucous membranes [
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. When caring for a stable PUI, HCPs should adhere to droplet (surgical mask), contact (gown and gloves), and standard precautions with the addition of eye protection (face shield or goggles) [
        <xref ref-type="bibr" rid="bb0040">
         8
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0285">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0310">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0320">
         64
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. If a PUI is critically ill or an aerosol-generating procedure (e.g., endotracheal intubation, suctioning of the airway, sputum induction) is necessary, HCPs should escalate to airborne precautions with the use of a fitted N95 respirator in place of a surgical mask [
        <xref ref-type="bibr" rid="bb0310">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0350">
         70
        </xref>
        ]. Reusable respirators such as powered air purifying respirators (PAPRs) may also be used, but should be disinfected and maintained appropriately [
        <xref ref-type="bibr" rid="bb0345">
         69
        </xref>
        ]. Patients with a history of COVID-19 exposure presenting with non-infectious symptoms may be evaluated and treated in adherence to standard precautions alone [
        <xref ref-type="bibr" rid="bb0320">
         64
        </xref>
        ].
       </p>
       <p id="p0135">
        If portable studies (e.g., plain radiography) cannot be completed within the patient's room or the patient requires transport elsewhere within the ED or hospital by wheelchair or stretcher, HCPs should don appropriate PPE [
        <xref ref-type="bibr" rid="bb0320">
         64
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0350">
         70
        </xref>
        ]. Healthcare professionals at the destination or receiving location should be made aware of the patient's arrival and likewise don appropriate PPE [
        <xref ref-type="bibr" rid="bb0320">
         64
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0355">
         71
        </xref>
        ]. Patients leaving their treatment room should wear a facemask, be dressed in a clean hospital gown (when possible), perform hand hygiene, and be educated in proper respiratory hygiene [
        <xref ref-type="bibr" rid="bb0355">
         71
        </xref>
        ].
       </p>
       <p id="p0140">
        Personnel cleaning empty PUI rooms should follow droplet, contact, and standard precautions with eye protection as infectious particles may be present [
        <xref ref-type="bibr" rid="bb0315">
         63
        </xref>
        ]. It is unclear how long SARS-CoV-2 remains in the air, but drawing parallels from other airborne disease such as tuberculosis can be helpful, particularly if an aerosol-generating procedure has been performed [
        <xref ref-type="bibr" rid="bb0315">
         63
        </xref>
        ]. Frequently used surfaces should be cleaned at least twice daily with implementation of standard institutional cleaning procedures [
        <xref ref-type="bibr" rid="bb0355">
         71
        </xref>
        ].
       </p>
      </sec>
      <sec id="s0050">
       <label>
        2.5.3
       </label>
       <title>
        Considerations for airway management
       </title>
       <p id="p0145">
        Intubation is a high-risk procedure due to the aerosolization of respiratory droplets [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. Rescue intubations should be avoided whenever possible as complete adherence to PPE may be inadequate in a time-sensitive critical scenario [
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. Society of Critical Care Medicine (SCCM) Surviving Sepsis COVID-19 guidelines recommend performing endotracheal intubation under airborne precautions, including use of a fitted N95 respirator and placement of the patient in an AIIR [
        <xref ref-type="bibr" rid="bb0350">
         70
        </xref>
        ]. Based on prior cases of HCPs infected with SARS-CoV-1 while using N95 respirators, some experts recommend using a PAPR [
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. The most experienced provider should intubate [
        <xref ref-type="bibr" rid="bb0350">
         70
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. To reduce inadvertent contamination by touching one's face or hair, a full face shield and head cover is recommended if a PAPR is not used [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. Wrist exposure can be minimized by using longer-sleeved gloves or vertically taping gloves to the gown [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ]. Applying tape circumferentially makes removing PPE more difficult and does not have added benefit [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ]. Shoe covers should be avoided, as they can lead to accidental self-contamination. Instead, impermeable shoes that can be appropriately decontaminated should be worn [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ]. If available, coveralls with or without a hood may be used, but processes and training in safe doffing should be established beforehand as HCPs may be less experienced in using these PPE ensembles [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ].
       </p>
       <p id="p0150">
        HCPs may consider double gloving and positioning waste and other transport receptacles close by to limit droplet and/or contact transmission when securing contaminated equipment for disposal or reprocessing [
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. Preoxygenation should be optimized with non-aerosol generating strategies including head of bed elevation, jaw thrust, and use of positive end expiratory pressure valves. Fiberoptic laryngoscopy should be avoided unless absolutely necessary as atomization of anesthetic will cause the virus to become aerosolized [
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. Preoxygenation for at least 5 min with 100% oxygen before performing rapid sequence intubation (RSI) may be used with nasal cannula, though this may increase the risk of contamination [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. To reduce this risk, a surgical mask can be placed on the patient over the device. Non-invasive positive pressure ventilation (NIPPV) may increase risk of aerosolization and is not recommended for preoxygenation [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. A high efficiency hydrophobic filter should be used between the facemask and the rest of the respiratory circuit [
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. Video laryngoscopy is preferred to direct laryngoscopy to increase distance between the intubator and the patient [
        <xref ref-type="bibr" rid="bb0150">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bb0350">
         70
        </xref>
        ]. A closed system should be utilized for suctioning. Once the intubation is complete, the emergency physician should immediately place the laryngoscope in their outer glove along with all other equipment used for intubation in a double zip-locked plastic bag [
        <xref ref-type="bibr" rid="bb0360">
         72
        </xref>
        ]. The presence of a high-efficiency particulate air (HEPA) filter should be verified in the expiratory limb of the mechanical ventilator prior to patient use.
       </p>
      </sec>
     </sec>
     <sec id="s0055">
      <label>
       2.6
      </label>
      <title>
       Laboratory and radiographic findings
      </title>
      <p id="p0155">
       The CDC has developed a real time reverse transcription polymerase chain reaction (RT-PCR) assay for detecting SARS-CoV-2 in upper and lower respiratory specimens obtained from COVID-19 PUIs [
       <xref ref-type="bibr" rid="bb0365">
        73
       </xref>
       ]. [
       <xref ref-type="bibr" rid="bb0370">
        74
       </xref>
       ] A nasopharyngeal swab specimen should be collected for testing [
       <xref ref-type="bibr" rid="bb0375">
        75
       </xref>
       ]. For lower respiratory tract specimens, sputum can be obtained from patients with productive cough, otherwise bronchoalveolar lavage or tracheal aspirate can be substituted [
       <xref ref-type="bibr" rid="bb0375">
        75
       </xref>
       ]. Serum samples are not necessary [
       <xref ref-type="bibr" rid="bb0375">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0380">
        76
       </xref>
       ].
      </p>
      <p id="p0160">
       There are few data available regarding sensitivity and specificity for the test, but false negatives may be seen in asymptomatic individuals or those early in the course of their disease who may not have high viral burden [
       <xref ref-type="bibr" rid="bb0135">
        27
       </xref>
       ]. Patients who test negative for COVID-19 using a sample taken while they were symptomatic likely do not have the disease [
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ]. However, the sensitivity of RT-PCR has been reported to range from 66% to 80% [
       <xref ref-type="bibr" rid="bb0385">
        77
       </xref>
       ]. A single negative RT-PCR should not be used to exclude the diagnosis, especially if the patient is in the early stages of the disease with no severe symptoms. A patient with negative RT-PCR with continued suspicion of COVID-19 should be isolated and rechecked several days later. Molecular testing (e.g., respiratory virus panel) for alternative diagnoses such as influenza should be considered for all PUIs [
       <xref ref-type="bibr" rid="bb0335">
        67
       </xref>
       ]. However, co-infection with other viruses may occur.
      </p>
      <p id="p0165">
       Anemia, lymphopenia, hypoxemia, abnormal kidney and liver function, elevated creatine kinase and D-dimer, thrombocytopenia, and increased lactate dehydrogenase can be present [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0290">
        58
       </xref>
       ]. Lymphocytopenia can occur in up to 80% of patients [
       <xref ref-type="bibr" rid="bb0300">
        60
       </xref>
       ]. Interestingly, one study found procalcitonin was elevated in just 6% of patients, while other inflammatory markers like serum ferritin and C-reactive protein were elevated [
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ]. Troponin and brain natriuretic peptide may be elevated in those with cardiac involvement and should be obtained in patients with suspected myocardial infarction or heart failure [
       <xref ref-type="bibr" rid="bb0390">
        78
       </xref>
       ].
      </p>
      <p id="p0170">
       Advanced imaging such as computed tomography (CT) is not required for diagnosis and may create additional infection prevention challenges in the ED. However, if obtained, CT may demonstrate several findings. Lung findings may be present on imaging before patients develop clinical manifestations. In a case series of patients from Wuhan, China admitted with COVID-19, 100% had chest CT findings consistent with pneumonia [
       <xref ref-type="bibr" rid="bb0195">
        39
       </xref>
       ]. Patients may also have radiographic ground-glass opacities [
       <xref ref-type="bibr" rid="bb0290">
        58
       </xref>
       ]. Another study of 99 COVID-19 patients found 75% of patients had bilateral pneumonia, 25% had unilateral pneumonia, and 14% had mottling and ground-glass opacities on chest X-ray and CT imaging [
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ].
      </p>
      <p id="p0175">
       Ultrasound can be utilized as well, as it is repeatable and reliable, has no radiation, and is inexpensive. Ultrasound findings depend on the stage and severity of the disease, and it cannot detect lesions deeper in the lung. Patients with COVID-19 typically demonstrate an irregular/thickened pleural line, scattered/confluent B lines, consolidations of various sizes, and both non-translobar and translobar consolidations on lung ultrasound [
       <xref ref-type="bibr" rid="bb0395">
        79
       </xref>
       ]. Pleural effusions are typically small and localized if they are present, and abnormalities are typically found in multiple lung zones.
      </p>
     </sec>
     <sec id="s0060">
      <label>
       2.7
      </label>
      <title>
       Treatment
      </title>
      <p id="p0180">
       Currently, no specific treatments exist nor are recommended for patients with COVID-19 [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0075">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. Several vaccines are under study, including DNA-based, vector-based, and protein based vaccines [
       <xref ref-type="bibr" rid="bb0400">
        80
       </xref>
       ]. Supportive care is the mainstay of treatment, preferably with acetaminophen [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0075">
        15
       </xref>
       ]. If pneumonia is present on imaging or the patient is critically ill, antibiotics are recommended. Patients presenting with respiratory insufficiency in the setting of potential COVID-19 infection should be given supplementary oxygen to maintain an oxygenation saturation ≥90% but no higher than 96% [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. Up to 76% of patients require oxygen therapy [
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ]. For those with acute hypoxemic respiratory failure who require intubation, endotracheal intubation should be performed. For those with hypoxemic respiratory failure who do not require intubation but who do not improve with conventional oxygen therapies, high flow nasal cannula (HFNC) is recommended over noninvasive positive pressure ventilation (NIPPV) [
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. If HFNC is not available and there is no urgent need for intubation, a trial of NIPPV ventilation is recommended with frequent reassessment, though NIPPV increases the risk of aerosolization [
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. NIPPV may result in patient improvement. The SCCM does not make a clear recommendation for helmet NIPPV compared to mask NIPPV [
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. While most recommend avoiding NIPPV due to the risk of aerosolization, it can be utilized safely if high risk patients are cohorted and clinicians use appropriate PPE [
       <xref ref-type="bibr" rid="bb0405">
        81
       </xref>
       ]. Patients who decline despite use of HFNC or NIPPV should be intubated [
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. If intubation is indicated, airborne precautions should be used with the patient ventilated using tidal volumes of 4–8 mL/kg of predicted body weight and plateau pressures &lt;30 cm H
       <sub>
        2
       </sub>
       O [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. If available, patients with severe ARDS may benefit from prone ventilation &gt;12 h per day [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ].
      </p>
      <p id="p0185">
       Over-resuscitation with intravenous fluids should be avoided, which can potentially worsen oxygenation [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. Even when COVID-19 is suspected as the cause of the patient's symptoms, the WHO recommends administering empiric antibiotics and a neuraminidase inhibitor within 1 h of identifying sepsis [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. Early recognition of septic shock is critical, with management of sepsis focusing on intravenous fluid resuscitation and antibiotics [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. A conservative resuscitation strategy with buffered/balanced crystalloids is recommended for those in shock, and hypotonic crystalloids should be avoided [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. Vasopressors, preferentially norepinephrine, are indicated for persistent shock with a goal MAP of 60–65 mmHg [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. For those with continued shock despite norepinephrine, vasopressin should be added, rather than increasing norepinephrine dose [
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. If cardiac dysfunction is present and there is persistent hypoperfusion, dobutamine is recommended [
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. Systemic steroids (hydrocortisone 200 mg per day) should be considered in those with vasopressor-refractory shock or for those with another indication for steroids such as chronic obstructive pulmonary disease exacerbation [
       <xref ref-type="bibr" rid="bb0110">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0350">
        70
       </xref>
       ]. Without delaying antibiotic administration, bacterial blood cultures should be obtained [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ].
      </p>
      <p id="p0190">
       Clinical trials of investigational drugs and antivirals are underway, although none are currently approved by the U.S. Food and Drug Administration (FDA) (
       <xref ref-type="table" rid="t0020">
        Table 4
       </xref>
       ) [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0230">
        46
       </xref>
       ]. Remdesivir has demonstrated activity against MERS-CoV and SARS-CoV in vitro and animal models [
       <xref ref-type="bibr" rid="bb0410">
        82
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0415">
        83
       </xref>
       ]. An in vitro study found that remdesivir and chloroquine inhibit viral infection, but further study is required [
       <xref ref-type="bibr" rid="bb0420">
        84
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0425">
        85
       </xref>
       ]. Results from a single study of over 100 COVID-19 patients found chloroquine was superior to control in reducing pneumonia exacerbation, improving imaging findings and virus-negative conversion, and shortening the course of the disease [
       <xref ref-type="bibr" rid="bb0430">
        86
       </xref>
       ]. A study evaluating lopinavir-ritonavir found no improvement in patient survival or differences in detectable viral RNA [
       <xref ref-type="bibr" rid="bb0435">
        87
       </xref>
       ]. Hydroxychloroquine and azithromycin are also under study [
       <xref ref-type="bibr" rid="bb0440">
        88
       </xref>
       ]. In a single prospective, observational study of 36 patients with COVID-19, those receiving hydroxychloroquine demonstrated higher rates of viral load reduction/disappearance, though no patient centered outcomes were assessed [
       <xref ref-type="bibr" rid="bb0440">
        88
       </xref>
       ]. Other medications under study include tocilizumab and favipiravir [
       <xref ref-type="bibr" rid="bb0445">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0450">
        90
       </xref>
       ]. There are no clear data supporting harm or benefit with angiotensin converting enzyme inhibitors or ACE receptor blockers (ARBs) [
       <xref ref-type="bibr" rid="bb0455">
        91
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0460">
        92
       </xref>
       ]. Unless authorized through a clinically approved trial or Monitored Emergency Use of Unregistered Interventions Framework (MEURI), unlicensed treatments should not be administered [
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. Continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and immunoglobulin have been utilized for management, but have not been definitively shown to be beneficial [
       <xref ref-type="bibr" rid="bb0200">
        40
       </xref>
       ].
       <table-wrap id="t0020" position="float">
        <label>
         Table 4
        </label>
        <caption>
         <p>
          COVID-19 therapies under study.
         </p>
        </caption>
        <alt-text id="al0045">
         Table 4
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Medication
           </th>
           <th>
            Dosing
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Remdesivir
           </td>
           <td>
            200 mg for 1 day, then 100 mg IV every day for 9 days
           </td>
          </tr>
          <tr>
           <td>
            Lopinavir/Ritonavir
           </td>
           <td>
            400–100 mg PO BID for 14 days
           </td>
          </tr>
          <tr>
           <td>
            Chloroquine
           </td>
           <td>
            500 mg PO BID for 10 days
           </td>
          </tr>
          <tr>
           <td>
            Hydroxychloroquine
           </td>
           <td>
            400 mg PO BID for 1 day, then 200 mg PO BID for 4 days
           </td>
          </tr>
          <tr>
           <td>
            Tocilizumab
           </td>
           <td>
            8 mg/kg in 100 mL of 0.9% NS IV over 60 min
           </td>
          </tr>
          <tr>
           <td>
            Favipiravir
           </td>
           <td>
            1600 mg PO BID for one day, then 600 mg PO BID for 6 days
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           Abbreviations: mg – milligrams, IV -intravenous, BID – twice per day, PO – per os, NS – normal saline, mL – milliliters, kg – kilogram.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="s5060">
      <label>
       2.8
      </label>
      <title>
       Disposition
      </title>
      <p id="p0200">
       Patients with severe symptoms, hypoxemia requiring oxygen supplementation, or high risk for clinical deterioration (i.e. pneumonia on radiograph, severe comorbidities) may require admission for further management and monitoring. Patients with mild symptoms and no significant comorbidities without concern for deterioration of clinical condition may be candidates for discharge, self-quarantine for two weeks, and home monitoring [
       <xref ref-type="bibr" rid="bb0465">
        93
       </xref>
       ]. These patients must have the ability to be safely isolated at home to prevent transmission to others and be carefully monitored [
       <xref ref-type="bibr" rid="bb0110">
        22
       </xref>
       ]. Social distancing is a vital component of reducing the spread of the virus, comprised of limiting events, mass gatherings, and even small group meeting [
       <xref ref-type="bibr" rid="bb0470">
        94
       </xref>
       ]. Individuals should remain 6 ft or 2 meters apart from other individuals. Health departments should be involved early in the care of these patients and can assist with decisions regarding disposition, further surveillance, and testing, especially until confirmatory test results are available [
       <xref ref-type="bibr" rid="bb0285">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. Emergency physicians should counsel these patients to return for worrisome symptoms including new or worsening pulmonary complaints and fever [
       <xref ref-type="bibr" rid="bb0285">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0310">
        62
       </xref>
       ]. Development of a clinical pathway among emergency physicians, infectious disease specialists, and health departments is critical to safely evaluate COVID-19 PUIs in the community.
      </p>
     </sec>
    </sec>
    <sec id="s0065">
     <label>
      3
     </label>
     <title>
      Conclusion
     </title>
     <p id="p0205">
      COVID-19 is a novel coronavirus that has affected an unprecedented number of people to date. Patients typically present with a combination of fever or cough and have a history of exposure to either a close contact with COVID-19 or travel to an affected geographic area. While most patients will have mild disease, some may develop severe complications including ARDS and multi-organ failure, with some succumbing to the disease. Special consideration should be given to those at the extremes of age, the immunocompromised, or pregnant women. No curative treatment is currently approved. Emergency physicians should obtain a detailed travel history from all patients and suspect COVID-19 in patients presenting with symptoms of an acute upper respiratory illness and fever. Early recognition and isolation of a patient with COVID-19 in the ED may help decrease exposure to other patients and healthcare personnel. Future research is necessary to expand our collective knowledge of COVID-19 and optimize patient outcomes.
     </p>
    </sec>
    <sec id="s0070">
     <title>
      Meetings
     </title>
     <p id="p0210">
      None.
     </p>
    </sec>
    <sec id="s0075">
     <title>
      Grants/financial support
     </title>
     <p id="p0215">
      None.
     </p>
    </sec>
    <sec id="s0080">
     <title>
      Author contributions
     </title>
     <p id="p0220">
      SC, SL, AK, and BL conceived the idea for this manuscript and contributed substantially to the writing and editing of the review.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0225">
      None.
     </p>
    </sec>
    <back>
     <ref-list id="bi0005">
      <title>
       References
      </title>
      <ref id="bb0005">
       <label>
        1
       </label>
       <mixed-citation id="or0005" publication-type="other">
        World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).
        <ext-link ext-link-type="uri" id="ir0045" xlink:href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)">
         https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
        </ext-link>
        . Published January 30, 2020. Accessed February 18, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0010">
       <label>
        2
       </label>
       <mixed-citation id="or0010" publication-type="other">
        World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020.
        <ext-link ext-link-type="uri" id="ir0050" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">
         https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
        </ext-link>
        . Published March 11, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0015">
       <label>
        3
       </label>
       <mixed-citation id="or0015" publication-type="other">
        World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020.
        <ext-link ext-link-type="uri" id="ir0055" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020">
         https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
        </ext-link>
        . Published February 11, 2020. Accessed March 08, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0020">
       <label>
        4
       </label>
       <mixed-citation id="or0020" publication-type="other">
        World Health Organization. Q&amp;A on coronaviruses.
        <ext-link ext-link-type="uri" id="ir0060" xlink:href="https://www.who.int/news-room/q-a-detail/q-a-coronaviruses">
         https://www.who.int/news-room/q-a-detail/q-a-coronaviruses
        </ext-link>
        . Published February 11, 2020. Accessed March 08, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0025">
       <label>
        5
       </label>
       <mixed-citation id="or0025" publication-type="other">
        New images of Novel Coronavirus SARS-CoV-2 now available|NIH: National Institute of Allergy and Infectious Diseases.
        <ext-link ext-link-type="uri" id="ir0065" xlink:href="https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images">
         https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images
        </ext-link>
        . Accessed March 18, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0030">
       <label>
        6
       </label>
       <mixed-citation id="or0030" publication-type="other">
        CDC. 2019 ovel Coronavirus (2019-nCoV) frequently asked questions and answers. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0070" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/faq.html">
         https://www.cdc.gov/coronavirus/2019-ncov/faq.html
        </ext-link>
        . Published February 11, 2020. Accessed March 18, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0035">
       <label>
        7
       </label>
       <mixed-citation id="or0035" publication-type="other">
        Naming the coronavirus disease (COVID-2019) and the virus that causes it.
        <ext-link ext-link-type="uri" id="ir0075" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
        </ext-link>
        . Accessed March 12, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0040">
       <label>
        8
       </label>
       <mixed-citation id="or0040" publication-type="other">
        CDC. HAN Archive - 00426|Health Alert Network (HAN).
        <ext-link ext-link-type="uri" id="ir0080" xlink:href="https://emergency.cdc.gov/han/han00426.asp">
         https://emergency.cdc.gov/han/han00426.asp
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0045">
       <label>
        9
       </label>
       <element-citation id="rf0005" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           News Scan for Dec 31
          </surname>
         </name>
        </person-group>
        <article-title>
         CIDRAP
        </article-title>
        <ext-link ext-link-type="uri" id="ir0085" xlink:href="http://www.cidrap.umn.edu/news-perspective/2019/12/news-scan-dec-31-2019">
         http://www.cidrap.umn.edu/news-perspective/2019/12/news-scan-dec-31-2019
        </ext-link>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bb0050">
       <label>
        10
       </label>
       <mixed-citation id="or0045" publication-type="other">
        Taylor DB. A timeline of the coronavirus. The New York Times.
        <ext-link ext-link-type="uri" id="ir0090" xlink:href="https://www.nytimes.com/2020/02/13/world/coronavirus-timeline.html">
         https://www.nytimes.com/2020/02/13/world/coronavirus-timeline.html
        </ext-link>
        . Published February 13, 2020. Accessed March 18, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0055">
       <label>
        11
       </label>
       <element-citation id="rf0010" publication-type="other">
        <article-title>
         CHP closely monitors cluster of pneumonia cases on Mainland
        </article-title>
        <ext-link ext-link-type="uri" id="ir0095" xlink:href="https://www.info.gov.hk/gia/general/201912/31/P2019123100667.htm">
         https://www.info.gov.hk/gia/general/201912/31/P2019123100667.htm
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0060">
       <label>
        12
       </label>
       <mixed-citation id="or0050" publication-type="other">
        Salcedo A, Cherelus G. Coronavirus travel restrictions, across the globe. The New York Times.
        <ext-link ext-link-type="uri" id="ir0100" xlink:href="https://www.nytimes.com/article/coronavirus-travel-restrictions.html">
         https://www.nytimes.com/article/coronavirus-travel-restrictions.html
        </ext-link>
        . Published March 20, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0065">
       <label>
        13
       </label>
       <element-citation id="rf0015" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           CNN JG
          </surname>
         </name>
         <name>
          <surname>
           AW
          </surname>
         </name>
        </person-group>
        <article-title>
         780 million people in China face travel restrictions over coronavirus outbreak. CNN
        </article-title>
        <ext-link ext-link-type="uri" id="ir0105" xlink:href="https://www.cnn.com/2020/02/16/asia/coronavirus-covid-19-death-toll-update-intl-hnk/index.html">
         https://www.cnn.com/2020/02/16/asia/coronavirus-covid-19-death-toll-update-intl-hnk/index.html
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0070">
       <label>
        14
       </label>
       <mixed-citation id="or0055" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) situation summary. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0110" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/summary.html">
         https://www.cdc.gov/coronavirus/2019-ncov/summary.html
        </ext-link>
        . Published February 11, 2020. Accessed March 18, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0075">
       <label>
        15
       </label>
       <mixed-citation id="or0060" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) prevention &amp; treatment. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0115" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html">
         https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0080">
       <label>
        16
       </label>
       <element-citation id="rf0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molinari
          </surname>
          <given-names>
           N.-A.M.
          </given-names>
         </name>
         <name>
          <surname>
           LeBlanc
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of a case of Ebola virus disease on Emergency Department visits in Metropolitan Dallas-Fort Worth, TX, July, 2013–July, 2015: An interrupted time series analysis
        </article-title>
        <source>
         PLoS Curr
        </source>
        <year>
         2018
        </year>
        <fpage>
         10
        </fpage>
       </element-citation>
      </ref>
      <ref id="bb0085">
       <label>
        17
       </label>
       <element-citation id="rf0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hewlett
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Varkey
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ribner
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ebola virus disease: preparedness and infection control lessons learned from two biocontainment units
        </article-title>
        <source>
         Curr Opin Infect Dis
        </source>
        <volume>
         28
        </volume>
        <issue>
         4
        </issue>
        <year>
         2015
        </year>
        <fpage>
         343
        </fpage>
        <lpage>
         348
        </lpage>
        <pub-id pub-id-type="pmid">
         26098504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0090">
       <label>
        18
       </label>
       <mixed-citation id="or0065" publication-type="other">
        Identify, Isolate, Inform: Emergency Department Evaluation and Management for Patients Under Investigation (PUIs) for Ebola Virus Disease (EVD)|Emergency Services|Clinicians|Ebola (Ebola Virus Disease)|CDC.
        <ext-link ext-link-type="uri" id="ir0120" xlink:href="https://www.cdc.gov/vhf/ebola/clinicians/emergency-services/emergency-departments.html">
         https://www.cdc.gov/vhf/ebola/clinicians/emergency-services/emergency-departments.html
        </ext-link>
        . Published August 30, 2019. Accessed February 18, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0095">
       <label>
        19
       </label>
       <mixed-citation id="or0070" publication-type="other">
        Coronavirus|Human Coronavirus Types|CDC.
        <ext-link ext-link-type="uri" id="ir0125" xlink:href="https://www.cdc.gov/coronavirus/types.html">
         https://www.cdc.gov/coronavirus/types.html
        </ext-link>
        . Published February 16, 2020. Accessed March 12, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0100">
       <label>
        20
       </label>
       <element-citation id="rf0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of Novel Coronavirus–infected pneumonia
        </article-title>
        <source>
         N Engl J Med.
        </source>
        <volume>
         0
        </volume>
        <issue>
         0
        </issue>
        <year>
         2020
        </year>
        <comment>
         null
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0105">
       <label>
        21
       </label>
       <mixed-citation id="or0075" publication-type="other">
        CDC. Coronavirus Disease 2019 (COVID-19): animals and Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0130" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/prepare/animals.html">
         https://www.cdc.gov/coronavirus/2019-ncov/prepare/animals.html
        </ext-link>
        . Published March 16, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0110">
       <label>
        22
       </label>
       <element-citation id="rf0035" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Hirsch
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bloom
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <source>
         Coronavirus disease 2019 (COVID-19)
        </source>
        <year>
         February 2020
        </year>
        <publisher-name>
         Date
        </publisher-name>
        <ext-link ext-link-type="uri" id="ir0135" xlink:href="https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19/print">
         https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19/print
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0115">
       <label>
        23
       </label>
       <mixed-citation id="or0080" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) transmission. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0140" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html">
         https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html
        </ext-link>
        . Published February 11, 2020. Accessed March 12, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0120">
       <label>
        24
       </label>
       <element-citation id="rf0040" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           WHO
          </surname>
         </name>
        </person-group>
        <article-title>
         Director-General's remarks at the media briefing on COVID-2019 outbreak on 17 February
        </article-title>
        <ext-link ext-link-type="uri" id="ir0145" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-covid-2019-outbreak-on-17-february-2020">
         https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-covid-2019-outbreak-on-17-february-2020
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0125">
       <label>
        25
       </label>
       <mixed-citation id="or0085" publication-type="other">
        World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – 60.
        <ext-link ext-link-type="uri" id="ir0150" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200320-sitrep-60-covid-19.pdf?sfvrsn=8894045a_2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200320-sitrep-60-covid-19.pdf?sfvrsn=8894045a_2
        </ext-link>
        . Published March 20, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0130">
       <label>
        26
       </label>
       <mixed-citation id="or0090" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) cases in the U.S. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0155" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html">
         https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html
        </ext-link>
        . Published March 20, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0135">
       <label>
        27
       </label>
       <mixed-citation id="or0095" publication-type="other">
        Coronavirus Disease 2019 Transcript for CDC Media Telebriefing. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0160" xlink:href="https://wwwdev.cdc.gov/media/releases/2020/s0215-Diamond-Princess-Repatriation.html">
         https://wwwdev.cdc.gov/media/releases/2020/s0215-Diamond-Princess-Repatriation.html
        </ext-link>
        . Published February 18, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0140">
       <label>
        28
       </label>
       <element-citation id="rf0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ruan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV-2 viral load in upper eespiratory specimens of infected patients
        </article-title>
        <source>
         N Engl J Med.
        </source>
        <volume>
         0
        </volume>
        <issue>
         0
        </issue>
        <year>
         2020
        </year>
        <comment>
         null
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0145">
       <label>
        29
       </label>
       <element-citation id="rf0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presumed asymptomatic carrier transmission of COVID-19
        </article-title>
        <source>
         JAMA.
        </source>
        <year>
         February 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0150">
       <label>
        30
       </label>
       <element-citation id="rf0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wax
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients
        </article-title>
        <source>
         Can J Anesth Can Anesth
        </source>
        <year>
         February 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0155">
       <label>
        31
       </label>
       <element-citation id="rf0060" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           del Rio
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Malani
          </surname>
          <given-names>
           P.N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         COVID-19—new insights on a rapidly changing epidemic
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         JAMA
        </publisher-name>
        <comment>
         February
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0160">
       <label>
        32
       </label>
       <element-citation id="rf0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020
        </article-title>
        <source>
         Eurosurveillance.
        </source>
        <volume>
         25
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020
        </year>
        <fpage>
         2000058
        </fpage>
       </element-citation>
      </ref>
      <ref id="bb0165">
       <label>
        33
       </label>
       <mixed-citation id="or0100" publication-type="other">
        Rettner R. How does the new coronavirus compare with the flu?
        <ext-link ext-link-type="uri" id="ir0165" xlink:href="http://livescience.com">
         livescience.com
        </ext-link>
        .
        <ext-link ext-link-type="uri" id="ir0170" xlink:href="https://www.livescience.com/new-coronavirus-compare-with-flu.html">
         https://www.livescience.com/new-coronavirus-compare-with-flu.html
        </ext-link>
        . Published March 19, 2020. Accessed March 11, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0170">
       <label>
        34
       </label>
       <element-citation id="rf0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020
        </article-title>
        <source>
         China CDC Wkly
        </source>
        <volume>
         2
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0175">
       <label>
        35
       </label>
       <element-citation id="rf0075" publication-type="other">
        <article-title>
         Feb 17 LS|NE|CN|, 2020. More outbreak details emerge as COVID-19 cases top 70,000. CIDRAP
        </article-title>
        <ext-link ext-link-type="uri" id="ir0175" xlink:href="http://www.cidrap.umn.edu/news-perspective/2020/02/more-outbreak-details-emerge-covid-19-cases-top-70000">
         http://www.cidrap.umn.edu/news-perspective/2020/02/more-outbreak-details-emerge-covid-19-cases-top-70000
        </ext-link>
        <comment>
         Accessed March 19, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0180">
       <label>
        36
       </label>
       <element-citation id="rf0080" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Szabo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Facts vs. fears: five things to help weigh your Coronavirus risk. Kais Health News
        </article-title>
        <ext-link ext-link-type="uri" id="ir0180" xlink:href="https://khn.org/news/facts-vs-fears-five-things-to-help-weigh-your-coronavirus-risk/">
         https://khn.org/news/facts-vs-fears-five-things-to-help-weigh-your-coronavirus-risk/
        </ext-link>
        <year>
         February 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0185">
       <label>
        37
       </label>
       <element-citation id="rf0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Dorigatti
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Cori
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Report 2: estimating the potential total number of novel Coronavirus cases in Wuhan City
        </article-title>
        <source>
         China.
        </source>
        <volume>
         6
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0190">
       <label>
        38
       </label>
       <element-citation id="rf0090" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dorigatti
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Okell
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cori
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Report 4: severity of 2019-novel coronavirus (nCoV)
        </article-title>
        <comment>
         Available at
        </comment>
        <ext-link ext-link-type="uri" id="ir0185" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200219-sitrep-30-covid-19.pdf?sfvrsn=3346b04f_2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200219-sitrep-30-covid-19.pdf?sfvrsn=3346b04f_2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0195">
       <label>
        39
       </label>
       <element-citation id="rf0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         The Lancet.
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0200">
       <label>
        40
       </label>
       <element-citation id="rf0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0205">
       <label>
        41
       </label>
       <mixed-citation id="or0105" publication-type="other">
        Parker E, The Vaccine Centre, London School of Hygiene &amp; Tropical Medicine. Covid 2019 tracker.
        <ext-link ext-link-type="uri" id="ir0190" xlink:href="https://vac-lshtm.shinyapps.io/ncov_tracker/">
         https://vac-lshtm.shinyapps.io/ncov_tracker/
        </ext-link>
        . Published 2020. Accessed March 21, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0210">
       <label>
        42
       </label>
       <element-citation id="rf0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Troeger
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Blacker
          </surname>
          <given-names>
           B.F.
          </given-names>
         </name>
         <name>
          <surname>
           Khalil
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         89
        </lpage>
        <pub-id pub-id-type="pmid">
         30553848
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0215">
       <label>
        43
       </label>
       <mixed-citation id="or0110" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) symptoms. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0195" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html">
         https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0220">
       <label>
        44
       </label>
       <element-citation id="rf0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan
        </article-title>
        <source>
         medRxiv
        </source>
        <volume>
         2020
        </volume>
        <year>
         February 2020
        </year>
        <comment>
         (02.12.20022327)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0225">
       <label>
        45
       </label>
       <mixed-citation id="or0115" publication-type="other">
        Shah N. Higher co-infection rates in COVID19. Medium.
        <ext-link ext-link-type="uri" id="ir0200" xlink:href="https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333">
         https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333
        </ext-link>
        . Published March 19, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0230">
       <label>
        46
       </label>
       <mixed-citation id="or0120" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) clinical care. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0205" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0235">
       <label>
        47
       </label>
       <mixed-citation id="or0125" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) pregnant women. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0210" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/pregnancy-faq.html">
         https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/pregnancy-faq.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0240">
       <label>
        48
       </label>
       <element-citation id="rf0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qiao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         What are the risks of COVID-19 infection in pregnant women?
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         0
        </volume>
        <issue>
         0
        </issue>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0245">
       <label>
        49
       </label>
       <mixed-citation id="or0130" publication-type="other">
        CDC - Health Care Workers, Infectious Agents - NIOSH workplace safety and health topic.
        <ext-link ext-link-type="uri" id="ir0215" xlink:href="https://www.cdc.gov/niosh/topics/healthcare/infectious.html">
         https://www.cdc.gov/niosh/topics/healthcare/infectious.html
        </ext-link>
        . Published November 6, 2018. Accessed March 12, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0250">
       <label>
        50
       </label>
       <element-citation id="rf0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           C
          </surname>
          <given-names>
           Km
          </given-names>
         </name>
         <name>
          <surname>
           B
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           C
          </surname>
          <given-names>
           Mg
          </given-names>
         </name>
         <name>
          <surname>
           O
          </surname>
          <given-names>
           Bj
          </given-names>
         </name>
         <name>
          <surname>
           O
          </surname>
          <given-names>
           Ba
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intubation of SARS patients: infection and perspectives of healthcare workers
        </article-title>
        <source>
         Can J Anaesth J Can Anesth
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         122
        </fpage>
        <lpage>
         129
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0255">
       <label>
        51
       </label>
       <element-citation id="rf0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Matukas
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tomlinson
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         JAMA.
        </source>
        <volume>
         289
        </volume>
        <issue>
         21
        </issue>
        <year>
         2003
        </year>
        <fpage>
         2801
        </fpage>
        <lpage>
         2809
        </lpage>
        <pub-id pub-id-type="pmid">
         12734147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0260">
       <label>
        52
       </label>
       <element-citation id="rf0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lietz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Westermann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Nienhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Schablon
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The occupational risk of influenza A (H1N1) infection among healthcare personnel during the 2009 pandemic: a systematic review and meta-analysis of observational studies
        </article-title>
        <source>
         PLoS ONE
        </source>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <year>
         2016
        </year>
       </element-citation>
      </ref>
      <ref id="bb0265">
       <label>
        53
       </label>
       <mixed-citation id="or0135" publication-type="other">
        American College of Emergency Physicians. Two emergency physicians in critical condition. ACEP.
        <ext-link ext-link-type="uri" id="ir0220" xlink:href="https://www.acep.org/corona/covid-19-articles/a-statement-from-acep-president-william-jaquis-md-facep/">
         https://www.acep.org/corona/covid-19-articles/a-statement-from-acep-president-william-jaquis-md-facep/
        </ext-link>
        . Published March 14, 2020. Accessed March 21, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0270">
       <label>
        54
       </label>
       <mixed-citation id="or1005" publication-type="other">
        2 ER doctors at rush Oak Park Hospital test positive for Coronavirus. NBC Chic. March 2020. https://www.nbcchicago.com/news/local/2-doctors-at-rush-oak-park-hospital-test-positive-for-coronavirus/2240158/. Accessed March 21, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0275">
       <label>
        55
       </label>
       <mixed-citation id="or0145" publication-type="other">
        Italy has a world-class health system. The coronavirus has pushed it to the breaking point. NBC News.
        <ext-link ext-link-type="uri" id="ir0225" xlink:href="https://www.nbcnews.com/health/health-news/italy-has-world-class-health-system-coronavirus-has-pushed-it-n1162786">
         https://www.nbcnews.com/health/health-news/italy-has-world-class-health-system-coronavirus-has-pushed-it-n1162786
        </ext-link>
        . Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0280">
       <label>
        56
       </label>
       <element-citation id="rf0135" publication-type="other">
        <article-title>
         Mar 16 MVB|NW|CN|, 2020. Doctors: COVID-19 pushing Italian ICUs toward collapse. CIDRAP
        </article-title>
        <ext-link ext-link-type="uri" id="ir0230" xlink:href="http://www.cidrap.umn.edu/news-perspective/2020/03/doctors-covid-19-pushing-italian-icus-toward-collapse">
         http://www.cidrap.umn.edu/news-perspective/2020/03/doctors-covid-19-pushing-italian-icus-toward-collapse
        </ext-link>
        <comment>
         Accessed March 20, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0285">
       <label>
        57
       </label>
       <mixed-citation id="or0150" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) flowchart for healthcare professionals. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0235" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/identify-assess-flowchart.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/identify-assess-flowchart.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0290">
       <label>
        58
       </label>
       <element-citation id="rf0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K.-H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         The Lancet.
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020
        </year>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0295">
       <label>
        59
       </label>
       <element-citation id="rf0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of Coronavirus Disease 2019 in China
        </article-title>
        <source>
         N Engl J Med.
        </source>
        <volume>
         0
        </volume>
        <issue>
         0
        </issue>
        <year>
         2020
        </year>
        <comment>
         null
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0300">
       <label>
        60
       </label>
       <element-citation id="rf0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA.
        </source>
        <volume>
         323
        </volume>
        <issue>
         11
        </issue>
        <year>
         2020
        </year>
        <fpage>
         1061
        </fpage>
        <lpage>
         1069
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0305">
       <label>
        61
       </label>
       <element-citation id="rf0155" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study
        </article-title>
        <comment>
         Published March 5. Available at
        </comment>
        <ext-link ext-link-type="uri" id="ir0240" xlink:href="https://journals.lww.com/ajg/Documents/COVID_Digestive_Symptoms_AJG_Preproof.pdf">
         https://journals.lww.com/ajg/Documents/COVID_Digestive_Symptoms_AJG_Preproof.pdf
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0310">
       <label>
        62
       </label>
       <mixed-citation id="or0155" publication-type="other">
        World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected.
        <ext-link ext-link-type="uri" id="ir0245" xlink:href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected">
         https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
        </ext-link>
        . Published January 28, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0315">
       <label>
        63
       </label>
       <mixed-citation id="or0160" publication-type="other">
        CDC. Coronavirus Disease 2019 (COVID-19) Interim Infection Prevention and Control Recommendations. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0250" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html">
         https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html
        </ext-link>
        . Published February 11, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0320">
       <label>
        64
       </label>
       <mixed-citation id="or0165" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) healthcare infection prevention and control FAQs for COVID-19. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0255" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-prevention-control-faq.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-prevention-control-faq.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0325">
       <label>
        65
       </label>
       <element-citation id="rf0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heymann
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Shindo
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19: what is next for public health?
        </article-title>
        <source>
         The Lancet.
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020
        </year>
        <fpage>
         542
        </fpage>
        <lpage>
         545
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0330">
       <label>
        66
       </label>
       <mixed-citation id="or0170" publication-type="other">
        CDC. Coronavirus Disease 2019 (COVID-19): evaluating and testing persons for Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0260" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
        </ext-link>
        . Published February 11, 2020. Accessed March 21, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0335">
       <label>
        67
       </label>
       <mixed-citation id="or0175" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) evaluating and reporting PUI. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0265" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0340">
       <label>
        68
       </label>
       <mixed-citation id="or0180" publication-type="other">
        CDC. Coronavirus Disease 2019 (COVID-19) Interim Guidance for Emergency Medical Services (EMS) Systems and 911 Public Safety Answering Points (PSAPs) for COVID-19 in the United States. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0270" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-for-ems.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-for-ems.html
        </ext-link>
        . Published February 11, 2020. Accessed March 14, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0345">
       <label>
        69
       </label>
       <mixed-citation id="or0185" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) infection control. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0275" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0350">
       <label>
        70
       </label>
       <element-citation id="rf0165" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alhazzani
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Møller
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)
        </chapter-title>
        <volume>
         101
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0355">
       <label>
        71
       </label>
       <mixed-citation id="or0190" publication-type="other">
        Public Health Agency of Canada. Infection prevention and control for coronavirus disease (COVID-19): interim guidance for acute healthcare settings. aem.
        <ext-link ext-link-type="uri" id="ir0280" xlink:href="https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/interim-guidance-acute-healthcare-settings.html#a4.18">
         https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/interim-guidance-acute-healthcare-settings.html#a4.18
        </ext-link>
        . Published February 24, 2020. Accessed February 27, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0360">
       <label>
        72
       </label>
       <mixed-citation id="or0195" publication-type="other">
        Anesthesia Patient Safety Foundation. Perioperative considerations for the 2019 Novel Coronavirus (COVID-19). Anesthesia Patient Safety Foundation.
        <ext-link ext-link-type="uri" id="ir0285" xlink:href="https://www.apsf.org/news-updates/perioperative-considerations-for-the-2019-novel-coronavirus-covid-19/">
         https://www.apsf.org/news-updates/perioperative-considerations-for-the-2019-novel-coronavirus-covid-19/
        </ext-link>
        . Published February 12, 2020. Accessed February 24, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0365">
       <label>
        73
       </label>
       <mixed-citation id="or0200" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) Testing. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0290" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html">
         https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0370">
       <label>
        74
       </label>
       <mixed-citation id="or0205" publication-type="other">
        CDC. 2019 Novel Coronavirus (2019-nCoV) information for laboratories COVID-19 requests for diagnostic panels and virus. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0295" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/lab/tool-virus-requests.html">
         https://www.cdc.gov/coronavirus/2019-ncov/lab/tool-virus-requests.html
        </ext-link>
        . Published February 11, 2020. Accessed March 19, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0375">
       <label>
        75
       </label>
       <mixed-citation id="or0210" publication-type="other">
        CDC. Coronavirus Disease 2019 (COVID-19) interim guidelines for collecting, handling, and testing clinical specimens from persons under investigation (PUIs) for Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0300" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html">
         https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html
        </ext-link>
        . Published February 11, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0380">
       <label>
        76
       </label>
       <element-citation id="rf0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of SARS-CoV-2 in different types of clinical specimens
        </article-title>
        <source>
         JAMA.
        </source>
        <year>
         March 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0385">
       <label>
        77
       </label>
       <element-citation id="rf0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of chest CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19) in China: a report of 1014 cases
        </article-title>
        <source>
         Radiology.
        </source>
        <volume>
         26
        </volume>
        <year>
         2020 Feb
        </year>
        <fpage>
         200642
        </fpage>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0390">
       <label>
        78
       </label>
       <mixed-citation id="or1010" publication-type="other">
        Januzzi J. Troponin and BNP use in COVID-19. Latest in cardiology. http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2020%2f03%2f18%2f15%2f25%2ftroponin-and-bnp-use-in-covid19. Published March 18, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0395">
       <label>
        79
       </label>
       <element-citation id="rf0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <year>
         March 2020
        </year>
        <pub-id pub-id-type="doi">
         10.1007/s00134-020-05996-6
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0400">
       <label>
        80
       </label>
       <mixed-citation id="or0220" publication-type="other">
        World Health Organization. DRAFT landscape of COVID-19 candidate vaccines. World Health Organization.
        <ext-link ext-link-type="uri" id="ir0310" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1">
         https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
        </ext-link>
        . Published March 20, 2020. Accessed March 21, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0405">
       <label>
        81
       </label>
       <element-citation id="rf0185" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Episode 38 - COVID-19 Update
          </surname>
         </name>
        </person-group>
        <article-title>
         An interview with Andrea Duca, MD. EBMedicine
        </article-title>
        <comment>
         Published March 19. Available at
        </comment>
        <ext-link ext-link-type="uri" id="ir0315" xlink:href="https://www.ebmedicine.net/topics/infectious-disease/COVID-19/podcast">
         https://www.ebmedicine.net/topics/infectious-disease/COVID-19/podcast
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0410">
       <label>
        82
       </label>
       <element-citation id="rf0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tchesnokov
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gotte
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Biol Chem.
        </source>
        <year>
         February 2020
        </year>
        <comment>
         jbc.AC120.013056
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0415">
       <label>
        83
       </label>
       <element-citation id="rf0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martinez
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compounds with therapeutic potential against novel respiratory 2019 coronavirus
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         March 2020
        </year>
        <comment>
         AAC.00399-20, aac;AAC.00399-20v1
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0420">
       <label>
        84
       </label>
       <element-citation id="rf0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         30
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0425">
       <label>
        85
       </label>
       <element-citation id="rf0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         31996494
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0430">
       <label>
        86
       </label>
       <element-citation id="rf0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020 Mar 16
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="pmid">
         32074550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0435">
       <label>
        87
       </label>
       <element-citation id="rf0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         March 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0440">
       <label>
        88
       </label>
       <element-citation id="rf0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Parola
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         105949
        </volume>
        <year>
         March 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0445">
       <label>
        89
       </label>
       <element-citation id="rf0225" publication-type="other">
        <article-title>
         Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID-19 (TACOS)
        </article-title>
        <ext-link ext-link-type="uri" id="ir0320" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04306705?term=Tocilizumab&amp;cond=COVID19&amp;draw=2">
         https://clinicaltrials.gov/ct2/show/NCT04306705?term=Tocilizumab&amp;cond=COVID19&amp;draw=2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bb0450">
       <label>
        90
       </label>
       <element-citation id="rf0230" publication-type="other">
        <article-title>
         Favipiravir combined with tocilizumab in the treatment of Corona Virus Disease
        </article-title>
        <ext-link ext-link-type="uri" id="ir0325" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04310228?term=favipiravir&amp;cond=covid19&amp;draw=2&amp;rank=2">
         https://clinicaltrials.gov/ct2/show/NCT04310228?term=favipiravir&amp;cond=covid19&amp;draw=2&amp;rank=2
        </ext-link>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bb0455">
       <label>
        91
       </label>
       <element-citation id="rf0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Slutsky
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <year>
         March 2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         5
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0460">
       <label>
        92
       </label>
       <element-citation id="rf0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <volume>
         0
        </volume>
        <issue>
         0
        </issue>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0465">
       <label>
        93
       </label>
       <mixed-citation id="or0225" publication-type="other">
        World Health Organization. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts.
        <ext-link ext-link-type="uri" id="ir0330" xlink:href="https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts">
         https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts
        </ext-link>
        . Published February 4, 2020. Accessed February 24, 2020.
       </mixed-citation>
      </ref>
      <ref id="bb0470">
       <label>
        94
       </label>
       <mixed-citation id="or0230" publication-type="other">
        CDC. Coronavirus Disease 2019 (COVID-19): interim US guidance for risk assessment and public health management of persons with potential Coronavirus Disease 2019 (COVID-19) exposures: geographic risk and contacts of laboratory-confirmed cases. Centers for Disease Control and Prevention.
        <ext-link ext-link-type="uri" id="ir0335" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html">
         https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html
        </ext-link>
        . Published March 7, 2020. Accessed March 20, 2020.
       </mixed-citation>
      </ref>
     </ref-list>
     <ack id="ac0005">
      <title>
       Acknowledgements
      </title>
      <p>
       This manuscript did not utilize any grants, and it has not been presented in abstract form. This clinical review has not been published, it is not under consideration for publication elsewhere, its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. This review does not reflect the views or opinions of the U.S. government, Department of Defense, U.S. Army, U.S. Air Force, Brooke Army Medical Center, or SAUSHEC EM Residency Program.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Saf Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Saf Sci
      </journal-id>
      <journal-title-group>
       <journal-title>
        Safety Science
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0925-7535
      </issn>
      <issn pub-type="epub">
       0925-7535
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32296266
      </article-id>
      <article-id pub-id-type="pmc">
       7158845
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0925-7535(20)30170-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ssci.2020.104773
      </article-id>
      <article-id pub-id-type="publisher-id">
       104773
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au005">
        <name>
         <surname>
          Bruinen de Bruin
         </surname>
         <given-names>
          Yuri
         </given-names>
        </name>
        <email>
         yuri.bruinen-de-bruin@ec.europa.eu
        </email>
        <xref ref-type="aff" rid="af005">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au010">
        <name>
         <surname>
          Lequarre
         </surname>
         <given-names>
          Anne-Sophie
         </given-names>
        </name>
        <xref ref-type="aff" rid="af005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au015">
        <name>
         <surname>
          McCourt
         </surname>
         <given-names>
          Josephine
         </given-names>
        </name>
        <xref ref-type="aff" rid="af005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au020">
        <name>
         <surname>
          Clevestig
         </surname>
         <given-names>
          Peter
         </given-names>
        </name>
        <xref ref-type="aff" rid="af010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au025">
        <name>
         <surname>
          Pigazzani
         </surname>
         <given-names>
          Filippo
         </given-names>
        </name>
        <xref ref-type="aff" rid="af015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au030">
        <name>
         <surname>
          Zare Jeddi
         </surname>
         <given-names>
          Maryam
         </given-names>
        </name>
        <xref ref-type="aff" rid="af020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au035">
        <name>
         <surname>
          Colosio
         </surname>
         <given-names>
          Claudio
         </given-names>
        </name>
        <xref ref-type="aff" rid="af025">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au040">
        <name>
         <surname>
          Goulart
         </surname>
         <given-names>
          Margarida
         </given-names>
        </name>
        <xref ref-type="aff" rid="af005">
         a
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af005">
       <label>
        a
       </label>
       European Commission Joint Research Centre, Belgium, Italy
      </aff>
      <aff id="af010">
       <label>
        b
       </label>
       On-Site Technical Expert to the Regional EU CBRN CoE Secretariat for the Gulf Cooperation Council Countries, Abu Dhabi, United Arab Emirates
      </aff>
      <aff id="af015">
       <label>
        c
       </label>
       Division of Molecular and Clinical Medicine, MEMO Research, University of Dundee, United Kingdom
      </aff>
      <aff id="af020">
       <label>
        d
       </label>
       Unit of Biostatistics, Epidemiology, and Public Health, University of Padua, Padua, Italy
      </aff>
      <aff id="af025">
       <label>
        e
       </label>
       Department of Health Sciences of the University of Milan and Occupational Health Unit of the Saints Paolo and Carlo Hospitals, Milan, Italy
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Corresponding author at: European Commission, Joint Research Centre, Via E. Fermi, 2749, 21027 Ispra, VA, Italy.
        <email>
         yuri.bruinen-de-bruin@ec.europa.eu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        15
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       104773
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         9
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Published by Elsevier Ltd.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="ab005">
       <title>
        Highlights
       </title>
       <p>
        <list id="l0005" list-type="simple">
         <list-item id="o0005">
          <label>
           •
          </label>
          <p id="p0005">
           Timely first response during the COVID-19 pandemic benefits from globally harmonised risk mitigation options.
          </p>
         </list-item>
         <list-item id="o0010">
          <label>
           •
          </label>
          <p id="p0010">
           International, national and local acceptance, preparedness and alignment are key in the early phase of a local outbreak.
          </p>
         </list-item>
         <list-item id="o0015">
          <label>
           •
          </label>
          <p id="p0015">
           Global citizens awareness addressing the role of individuals and groups in controlling an outbreak creates quick obedience of imposed measures.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="ab010">
       <p>
        This paper presents an analysis of risk mitigation measures taken by countries around the world facing the current COVID-19 outbreak. In light of the current pandemic the authors collated and clustered (using harmonised terminology) the risk mitigation measures taken around the globe in the combat to contain, and since March 11 2020, to limit the spread of the SARS-CoV-2 virus known to cause the Coronavirus disease 2019 (COVID-19). This overview gathers lessons learnt, providing an update on the current knowledge for authorities, sectors and first responders on the effectiveness of said measures, and may allow enhanced prevention, preparedness and response for future outbreaks. Various measures such as mobility restrictions, physical distancing, hygienic measures, socio-economic restrictions, communication and international support mechanisms have been clustered and are reviewed in terms of the nature of the actions taken and their qualitative early-perceived impact. At the time of writing, it is still too premature to express the quantitative effectiveness of each risk mitigation cluster, but it seems that the best mitigation results are reported when applying a combination of voluntary and enforceable measures.
       </p>
      </abstract>
      <kwd-group id="kg005">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        risk mitigation measures
       </kwd>
       <kwd>
        Corona virus
       </kwd>
       <kwd>
        public health
       </kwd>
       <kwd>
        mitigation impact
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0020">
      The modern world is fast-evolving, interconnected and highly mobile, making risk governance based on the application of harmonised biorisk mitigation measures a significant challenge. After the two zoonotic coronavirus outbreaks (the severe acute respiratory syndrome coronavirus [SARS-CoV] from 2002 to 2003 and the Middle East respiratory syndrome coronavirus in 2012 [MERS-CoV]), another coronavirus has crossed species to infect human populations, for the third time in the 21st century (
      <xref ref-type="bibr" rid="b0185">
       Perlman 2020
      </xref>
      ). This virus, provisionally named 2019 novel coronavirus (2019-nCoV, further referred to as SARS-CoV-2), was identified in Wuhan, China, in early January 2020 after cell culture and isolation of the viral particle (Zhu et al., 2020; Lee et al., 2020). As for SARS-CoV and MERS-CoV, the primary reservoir of the COVID-19 is probably the bat, based on sequence similarity with bat coronaviruses. Presumably, the intermediate animal hosts of 2019-nCoV should be among the wildlife species sold at the Huanan Seafood Wholesale Market (
      <xref ref-type="bibr" rid="b0240">
       Ye et al., 2020
      </xref>
      ). Despite public health risk mitigation measures and regulation efforts by many countries, regions and sectors, the current COVID-19 outbreak reminds the world about our vulnerability to natural and man-made chemical, biological, radiological and nuclear (CBRN) hazards and on the importance of mitigation actions
      <xref ref-type="fn" rid="fn1">
       1
      </xref>
      .
     </p>
     <p id="p0025">
      Emerging biological hazards may include pathogens in new settings due to climate change influencing the spread of vector-borne diseases arising from the melting arctic ice (Sutherstet al., 2004). Other examples are pathogens with zoonotic potential arising from intensive or inappropriate farming (such as avian or swine flu, MERS) or spill-over of pathogens from wildlife due to the continuous expansion of human territory (such as SARS, Ebola) both bringing humans and potential animal vectors in closer contact with each other (
      <xref ref-type="bibr" rid="b0155">
       Mills, et al.,2010
      </xref>
      ). These new agents may cause significant threats to human health, if they display high infectivity with potentially high morbidity or even lethality.
     </p>
     <p id="p0030">
      On January 30 2020, a panel of experts of the World Health Organisation (WHO) declared the outbreak of SARS-CoV2, causing the Coronavirus disease 2019 (COVID-19), a Public Health Emergency of International Concern (PHEIC) and on March 11 2020, the ongoing COVID-19 outbreak was upscaled by the WHO to its 6
      <sup>
       th
      </sup>
      and highest alert scale as a pandemic (WHO, 2020).
     </p>
     <p id="p0035">
      For many years the risk of emerging infectious diseases with pandemic potential was declared a major threat to global health security and addressed by many stakeholders around the world; namely WHO, global health security initiative (GHSI) 2001, nuclear threat initiative (NTI) who have been very active recently in the bio field, the European Parliament, various national or regional Centre’s of Disease Control, etc. (McCloskey et al., 2014). The degree to which countries translated these warnings and recommendations on prevention, preparedness and response capacity varies. In many countries, priorities were given to other domains and investments into appropriate and effective personal protective equipment (PPE) stocks in healthcare facilities and other first responder institutions were left behind (Papp et al., 2020). According to these authors, there is also a long lasting and ongoing trend in our societies to undermine scientific facts in the domain of public health and healthcare by non-evidence based opinions or purely economic considerations. One recent example is the discussion about the safety of the vaccine against the 2009 swine flu outbreak when a great deal of mistrust and unfounded theories heavily influenced people’s willingness to be vaccinated (
      <xref ref-type="bibr" rid="b0025">
       Cohen and Enserink 2009
      </xref>
      ; Seale et al., 2011). For example in Scandinavia, great scepticism towards vaccines undermined global vaccination campaigns (e.g. the Mumps, Measles, Rubella vaccine for children)
      <xref ref-type="fn" rid="fn2">
       2
      </xref>
      . Due to our increasingly connected world, especially in the last decade, a lot of misinformation spreads through social media and is accessible to all, leading to the politicisation of science (
      <xref ref-type="bibr" rid="b0045">
       Deming, 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="b0090">
       Jasanoff, 2005
      </xref>
      ; Davies, 2019) and the organisation of ignorance (
      <xref ref-type="bibr" rid="b0070">
       Frickel and Vincent, 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="b0105">
       Knowles, 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="b0220">
       Wieland, 2017
      </xref>
      ). This adds complexity to the interface between policy, science and practice and underlines the importance of knowledge management and consistent sharing of best practice in the domain of risk mitigation (Daszak et al., 2020).
     </p>
     <p id="p0040">
      The challenge to achieve sharing of best practices for risk mitigation during the current COVID-19 pandemic is high (Koonin, 2020). It requires mechanisms that build upon knowing how to evaluate, plan, implement and maintain risk mitigation measures, along with appropriately deciding who to involve (
      <xref ref-type="bibr" rid="b0190">
       Renn, 2008
      </xref>
      ; Nucci et al., 2017), making decisions about the chain of command, and channelling communication. Communication and information sharing foster democratic learning across governments and sectors, amongst varied stakeholders (decision-makers, scientists, practitioners and citizens), and between different levels of society (international, national, regional and local) (Tompkins et al. 2008). These mechanisms are especially important when they are able to bring together different regions of the world in discussing and preparing for the different phases of a pandemic, quickly understanding lessons learned and applying them in the regions that are going through the earlier steps of the process. An excellent example of an existing mechanism is the European Union’s Chemical Biological Radiological and Nuclear risk mitigation Centres of Excellence Initiative (EU CBRN CoE), which was launched in 2010 to strengthen and structure the institutional capacity and country mechanisms outside the European Union with regard to prevention, preparedness and response of chemical, biological, radiological and nuclear risks. This initiative addresses risks of criminal origin (e.g. the Sarin attack on the Japanese subway; Okumura et al., 1998), accidentally created (e.g. Bhopal,
      <xref ref-type="bibr" rid="b0010">
       Broughton, 2005
      </xref>
      ) or naturally occurring (e.g. swine flu outbreak, COVID-19 pandemic). The EU CBRN CoE is led, financed and implemented by the European Commission, in close coordination with the European External Action Service (EEAS) and with the support of the United Nations Interregional Crime and Justice Research Institute (UNICRI) and other International Organisations and local experts. The EU CBRN CoE is active in 61 countries in eight regions, each region hosting a Regional Secretariat, and each country with a National Focal Point and a CBRN National Team (see
      <xref ref-type="fig" rid="f0005">
       Figure 1
      </xref>
      ).
      <fig id="f0005">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         The countries that join the initiative work together in eight regions, headed up by a secretariat at regional level.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0045">
      Through activities led by the EU CBRN CoE initiative, many countries have elaborated CBRN national action plans, notably against biological threats, creating awareness and mechanisms
      <xref ref-type="fn" rid="fn3">
       3
      </xref>
      to structure prevention, preparedness and response during disasters. These plans include the establishment of a chain of command, the identification of national stakeholders, decision-making procedures, enhanced inter-agency communication, stockpiles of PPEs, medicines, drills, communication procedures, etc. Over the last ten years, 25 projects (out of a total of 82 to date) have focused on capacity building in the domains of biosafety and biosecurity including the identification of risk mitigation measures for biological disasters
      <xref ref-type="fn" rid="fn4">
       4
      </xref>
      . With the help of the EU CBRN CoE network, the project outcomes are being activated for quick response to the spread of the virus, by quickly compiling the experiences and by keeping in touch through the regional secretariats using virtual meeting tools. Other initiatives could take the same approach, disseminating risk mitigation actions such as the ones compiled in the present paper.
     </p>
     <p id="p0050">
      By studying the literature, media and national information channels, in light of the current pandemic, we have collated and clustered the risk mitigation measures taken around the globe first in the effort to contain and since March 11 2020 to mitigate the risks of COVID-19 by limiting the spread of SARS-CoV-2. The objective is to make this clustering globally available and to harmonise its terminology so that governments and sectors gain valuable time to put adequate measures in place. Furthermore, the intention of this paper is to highlight the importance of building trust, by improving effective communication processes with cross-country and cross-sectoral information sharing, enhancing the learning process (Edelman Trust Barometer, 2020), and in turn enhancing risk governance mechanisms.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      From COVID-19 risk perception to risk mitigation
     </title>
     <p id="p0055">
      Three adult patients with severe pneumonia were admitted to a hospital in Wuhan on December 27 2019, two of whom were linked to the Huanan Seafood Wholesale Market (Zhu et al., 2020). Patients 1 and 3 recovered and were discharged from the hospital on January 16 2020. Patient 2 died on January 9 2020. Evidence for the presence of SARS-CoV-2 was found by the identification in bronchoalveolar-lavage fluid in the three patients by whole-genome sequencing, direct PCR, and culture (Zhu et al., 2020). Before the end of December 2019, still few people knew that this new virus existed.
     </p>
     <p id="p0060">
      As the infection spread within the city of Wuhan local health workers alarmed local authorities and the outbreak got international attention via media coverage. In early January local risk mitigation measures were implemented including the closure of the Huanan Seafood Wholesale Market. At that time for the rest of the world, especially outside Asia, business continued as usual and any risk perception was considered minimal. On January 12 2020 China shared the genetic sequence of SARS-CoV-2
      <xref ref-type="fn" rid="fn5">
       5
      </xref>
      and on January 13 2020 the first case was reported outside China: a patient in Thailand reported to have visited the Huanan Seafood Wholesale Market
      <xref ref-type="fn" rid="fn6">
       6
      </xref>
      . Due to the absence of a cure or a vaccine, controlling the infection to prevent the spread of COVID-19 was correctly seen as the only intervention that could be used (
      <xref ref-type="bibr" rid="b0120">
       Lai et al., 2020
      </xref>
      ). Consequent risk mitigation measures were soon after announced in Wuhan (holiday extension, city lockdown, quarantine requirements) (
      <xref ref-type="bibr" rid="b0140">
       Lin et al., 2020
      </xref>
      ) and in neighbouring cities and regions. Other areas and countries such as Hong Kong, Taiwan, South Korea and Mongolia followed with almost daily announcements of ever more strict risk mitigation measures to limit the spread. These comprised of travel restrictions, isolation of travellers coming from the Wuhan region, closure of schools and universities and the prescription of hygienic measures (see the timeline of the events in
      <xref ref-type="fig" rid="f0010">
       Figure 2
      </xref>
      ). On January 30 2020 the WHO Emergency Committee convened for a second time under the IHR2005 rules (World Health Organisation, 2008) and declared the outbreak as fulfilling the criteria for being a Public Health Emergency of International Concern (PHEIC)
      <xref ref-type="fn" rid="fn7">
       7
      </xref>
      . At this time, related discussions started in European countries but still dramatic measures such as locking down entire cities, regions or countries was not considered (Kervorkian et al., 2020). Concern grew but no real changes occurred, since the perception of the risk was still low and individual and group behaviour was not affected. This status started to change when two regions in Italy (Veneto and Lombardy) faced a rapid growth in the number of infected people, forcing the Italian Authorities to lockdown the most affected villages first, then the entire Northern part of the country and finally the entire country. Other countries followed, albeit with a one to two week delay. At the time of writing, the Italian health care system is still fighting the crisis and remains on the brink of collapse experiencing innumerable numbers of hospitalised patients, a scarcity of intensive care beds, medical staff (over 60 doctors in Italy have died
      <xref ref-type="fn" rid="fn8">
       8
      </xref>
      ), PPEs, ventilators and medicines. Although in different degrees, other countries are also experiencing similar challenges, including Spain and the United States
      <xref ref-type="fn" rid="fn9">
       9
      </xref>
      .
      <fig id="f0010">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Time line of events and application of COVID-19 risk mitigation measures
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0065">
      Looking at what seems to be the critical points in reaching an ‘out-of-control’ situation in Italy, we note that while many Italian first responders did their utmost to contain the virus, many citizens in Italy did not comply with restrictions at first, and it took some time and multiple efforts of the authorities to communicate to the population why compliance with the restrictions was important. It is believed that one of the critical moments of spread was the Champions League football match played in the San Siro stadium in Milan on February 19 2020 where about 40000 football fans from Bergamo – which became the hotspot in the Northern region of Italy in the following weeks - attended and afterwards filled up the bars and restaurants around the stadium
      <xref ref-type="fn" rid="fn10">
       10
      </xref>
      . Most strikingly, while the Northern Regions already had many restrictions being most importantly self-quarantine, social/physical distancing, hygienic measures and a lock down of the Northern region, the weekend of March 7-8 is believed to have caused the collapse of the respective regional health system in the weeks thereafter, by coinciding with the celebration of the International Women’s Day. Following Italy, other European countries were experiencing rapidly increasing numbers of COVID-19 patients in the time after the spring break. It is believed that many people became infected in Alpine ski resorts during the spring break spreading the virus upon their return. Consequently, as another mitigation measure European ski resorts were shut down
      <xref ref-type="fn" rid="fn11">
       11
      </xref>
      .
     </p>
     <p id="p0070">
      Many countries followed Italy implementing risk mitigation measures starting from advisory, to recommendable and finally enforceable measures. Interestingly though, and similarly to the experience in Italy, the process of risk perception and the translation to compliance and trust in taking risk mitigation measures also took time in other countries (Edelman Trust Barometer, 2020), at the likely cost of additional spread and contamination. As health is a national responsibility in the EU (not regulated by the European Union), many countries have applied different levels of risk mitigation measures and followed different communication strategies. These ranged from the acceptance of a propagation in view of promoting group immunity (mainly in the United Kingdom, the Netherlands and Sweden
      <xref ref-type="fn" rid="fn12">
       12
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="fn" rid="fn13">
       13
      </xref>
      ) to strategies to fully protecting all individuals, mainly to prevent overwhelming the healthcare systems but also in the interest of awaiting the results from ongoing medical trials on treatments and studies about individual and group immunity (
      <xref ref-type="bibr" rid="b0115">
       Kwok et al., 2020
      </xref>
      ). In an attempt to understand these fundamental differences, the authors believe that this is related to the differences of the societal structure as seen in Northern regions in Europe and many parts of the US (Northern structure) versus the Southern European, Arab, Asian and Latin world (Southern structure). The Northern structure is based on elderly people living in retirement homes (similar to parts of the US) and elderly living alone. The Southern structure is based on large(r) families living under the same roof and across multiple generations. Because inside retirement homes disease can rapidly spread due to the higher risk group, leading to segmented, high mortality numbers
      <xref ref-type="fn" rid="fn14">
       14
      </xref>
      , retirement homes were locked down and the assumption may have been made that the elderly living alone may stand a better chance of not contracting the disease at all.
     </p>
    </sec>
    <sec id="s0015">
     <label>
      3
     </label>
     <title>
      Clusters of COVID-19 risk mitigation measures
     </title>
     <p id="p0075">
      Risk mitigation is an interdisciplinary decision-making process based on information from risk and exposure assessment (Bruinen de Bruin, 2007). It entails consideration of political, socioeconomic, epidemiological, (mental) health and engineering data to compile regulatory options and select the appropriate regulatory, societal, sector or company response to COVID-19. At the time of writing many countries have taken risk mitigation measures and are trying to prepare for the future by looking at countries that are ahead in the course of the pandemic and learning from their experiences (
      <xref ref-type="bibr" rid="b0235">
       Wu and McGoogan, 2020
      </xref>
      ).
     </p>
     <p id="p0080">
      To better understand the underlying differences and to harmonise terminology, the risk mitigation measures were clustered into various categories. The categorisation along with the timeline of events are illustrated in
      <xref ref-type="fig" rid="f0010">
       Figure 2
      </xref>
      .
     </p>
     <p id="p0085">
      Reviewing the risk mitigation measures implemented by numerous countries the measures were clustered according to the following categories:
      <list id="l0010" list-type="simple">
       <list-item id="o0020">
        <label>
         1.
        </label>
        <p id="p0090">
         <italic>
          Mobility Restrictions.
         </italic>
         These aim to limit the movement of people in order to contain or to slow down the spread of the virus. It reduces the number of people who can be infected by both symptomatic and non-symptomatic uncontained cases (Gostic et al., 2020; Hellewell, 2020). Restrictions comprise active zoning, closing/limiting public transportation, air traffic restrictions or even temporary closure, limiting use of private cars, bicycles, and outdoor activities such as walking (some countries only allowed walking outside with a dog) and running, particularly in groups of more than two people;
        </p>
       </list-item>
       <list-item id="o0025">
        <label>
         2.
        </label>
        <p id="p0095">
         <italic>
          Socio-economic restrictions.
         </italic>
         These target social and economic activities where people gather for educational, recreational, sportive, or work-related purposes. Restrictions comprise the closure or limiting of schools/nurseries/child-care and homes for the elderly, closure of museums, swimming pools, bars and restaurants, indoor and outdoor sport facilities and hotels. Suspension of retail trade, save for essential goods (including food, medicines and their supply chains) with banking, financial and insurance services also belonging to this cluster. Additional examples are the promotion/obligation of teleworking, limiting/cancellation of production in factories;
        </p>
       </list-item>
       <list-item id="o0030">
        <label>
         3.
        </label>
        <p id="p0100">
         <italic>
          Physical Distancing;
         </italic>
         These measures have also been referred to as social distancing. In fact, physical distancing is regarded as a more appropriate term to avoid social isolation especially of fragile groups such as the elderly, given that with a proper distance (currently defined between 1.5-2m) it is still possible to be social; it also embraces virtual social connections. Other examples entail the prohibition of groups larger than 2-3 persons, closing public outdoor spaces (parks, benches, beaches, etc.) and imposing regulations in terms of entrances and number of people present per square meter, required distance between humans/occupants in indoor spaces comprising offices, meeting places and commercial spaces;
        </p>
       </list-item>
       <list-item id="o0035">
        <label>
         4.
        </label>
        <p id="p0105">
         <italic>
          Hygiene Measures;
         </italic>
         These aim to limit the risk of spreading the virus and direct or indirect contamination of others. Recommendations comprise washing hands for at least 20 seconds, sneezing in elbow, avoiding touching surfaces, contactless payments (avoid exchanging money), wearing PPEs such as masks, eye and hand protections, household waste disposal instructions preventing contact with contaminated infectious materials by waste collectors and waste processing operators, worker protection in the places where physical distancing is not feasible (e.g. placement of protective glass in supermarkets between cashier and customer), precautionary and sickness driven quarantine (family vs. individual), targeted symptomatic screening upon arrival or entrance such as obliged temperature check or (large scale) testing;
        </p>
       </list-item>
       <list-item id="o0040">
        <label>
         5.
        </label>
        <p id="p0110">
         <italic>
          Communication
         </italic>
         ; This cluster is, in the authors view, the most essential part of risk mitigation measures since it drives the public understanding, trust, acceptance and compliance with the measures. Especially in societies where large-scale disasters were absent for decades, as is the case in many countries since WWII, where mistrust in authorities prevail and/or where individual freedom became the norm, above caring for the group, the communication of risk mitigation measures during a major crisis situation adds significant challenges. In March 2020 a WHO ‘WhatsApp’ group was set up, providing information and risk mitigation instructions related to categories 1-4. Countries also launched national communication measures structured in news and information websites/platforms jointly combatting fake news, aiming to encourage awareness, understanding and compliance towards restrictions;
        </p>
       </list-item>
       <list-item id="o0045">
        <label>
         6.
        </label>
        <p id="p0115">
         <italic>
          International support mechanisms;
         </italic>
         As the world is fighting the same threat, and many countries are limited in their capacity and resources, the importance of acting internationally is acknowledged, as exemplified by the following actions: countries, sectors and companies increased global production and international exchange of PPE’s, raw materials for pharmaceuticals, pharmaceutical formulations, basic medical drugs, and ventilators. Existing risk mitigation networks were quickly activated, and new transnational platforms are being set up for knowledge exchange on clinical trials, treatments, lessons learned and publications
         <xref ref-type="fn" rid="fn15">
          15
         </xref>
         .
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="s0020">
     <label>
      4
     </label>
     <title>
      Early signs of effectiveness
     </title>
     <p id="p0120">
      At the time of writing, increasing information is being generated about the experiences in mitigating COVID-19. Although it is difficult to precisely understand the effectiveness of each category of risk mitigation measure the currently available literature has been studied.
     </p>
     <p id="p0125">
      <italic>
       Mobility Restrictions.
      </italic>
      Early analysis of the Wuhan COVID-19 outbreak suggest that the effects of travel limitations are important for national and international agencies dealing with public health response planning.
      <xref ref-type="bibr" rid="b0020">
       Chinazzi et al. (2020)
      </xref>
      showed that by January 23 2020 the epidemic had already spread to other cities within China and therefore the travel quarantine around Wuhan had only modestly delayed the epidemic spread to other areas of China. The Wuhan travel ban was initially effective at reducing international case exportations but not to limit the already ongoing spread outside China. Most importantly, this study showed that additional travel limitations up to 90% of the traffic has a modest effect unless paired with public health interventions and behavioural changes that achieve a considerable reduction in the disease transmissibility in the communities, as also confirmed during the SARS outbreak in Singapore (Drake et al., 2003). These findings underline the importance of quick response based on proper early detection and epidemiological risk analysis, in combination with the application of additional risk mitigation measures. In addition, disease experts estimate that each COVID-19 patient/carrier infects between two to three others
      <xref ref-type="fn" rid="fn16">
       16
      </xref>
      . Each risk mitigation measure contributes to a decrease in new infections (
      <xref ref-type="bibr" rid="b0005">
       Anderson et al., 2020
      </xref>
      ). In order for these restrictions to be effective it is believed that testing, registering number of hospitalisations and deaths in the weeks after the restrictions are key to tracking the effectiveness of the measures. At present, the effectiveness of each measure cannot be quantitatively assessed. However, the authors of this paper believe in the application of the precautionary principle meaning that application of a combination of mitigation measures – even those without current clear scientific evidence such as school closures (
      <xref ref-type="bibr" rid="b0005">
       Anderson et al., 2020
      </xref>
      ) – is the best practice to gain most time in decreasing the rate of new infections (
      <xref ref-type="bibr" rid="b0085">
       Hellewell et al., 2020
      </xref>
      ).
     </p>
     <p id="p0130">
      Socio-economic restrictions.
     </p>
     <p id="p0135">
      The implementation of socio-economic restrictions occurred gradually within most countries and even up to date there are major differences between countries in terms of the closing down of public places. The most plausible reason is that these restrictions are expected to impose a major impact on the functioning of the current economy and way of life. A recent analysis of smartphone location data by the U.S. search engine giant Google showed that visits to shops, parks or railway stations fell steeply in most European countries between February 16 and March 29 2020 as governments sought to slow the explosive spread of the COVID-19 disease
      <xref ref-type="fn" rid="fn17">
       17
      </xref>
      . Reuters reported that in Italy and Spain, retail and recreational trips were down by 94%. Physical presence in workplaces also decreased by over 60% in respective countries. Both Italy and Spain, along with France imposed near lockdown of their states, and, by the time of writing, the restrictions they have imposed are, with a time lag, starting to ‘flatten the curve’ of new infections at least in some countries (Financial Times, April 4, 2020). These latest findings add to the suggestion that the combination of different categories of risk mitigation measures contribute most successfully to the fastest decrease of new infections, given the geographic scale and severity of COVID-19.
     </p>
     <p id="p0140">
      <italic>
       Physical Distancing.
      </italic>
      Individual behaviour is crucial in controlling the spread of COVID-19. In early March 2020
      <xref ref-type="bibr" rid="b0005">
       Anderson et al. (2020)
      </xref>
      described that in Western democracies personal action, rather than government action, might be the most important issue comprising of early self-isolation (within one day from symptom onset), seeking medical advice remotely unless symptoms are severe, and physical distancing. The same authors described the importance of the application of a combination of mitigation measures such as physical distancing in combination with the ban of mass gatherings, good diagnostic facilities and remotely accessed health advice, together with specialised treatment for people with severe COVID-19 infections. A combination of these measures was suggested to lead to a 60% reduction in transmission. At the time of writing, many Western democracies also experienced the effects of the lack of awareness of a significant portion of the population leading to non-compliance with the recommended or obligatory restrictions. As a result, in the course of days, governments increasingly implemented a combination of communication strategies (outdoor signs, use of social media, drones informing the public) in combination with enforcement strategies giving increasing fines to groups that were violating the ever more stringent restriction measures. Germany established on March 22 2020 a fine of up to 25000 euro for gathering in groups of more than 3 persons
      <xref ref-type="fn" rid="fn18">
       18
      </xref>
      . The Netherlands reported on March 27 2020 the arrest of an individual coughing in the face of a police officer while claiming to be infected with COVID-19
      <xref ref-type="fn" rid="fn19">
       19
      </xref>
      .
     </p>
     <p id="p0145">
      Niu et al. (2020) reported that transmission by people with mild or no symptoms can undermine the effectiveness of the isolation strategy because of reduced likelihood of isolating all cases and tracing all contacts. The identification and testing of potential cases needs therefore to be as extensive as is permitted by healthcare and diagnostic testing capacity—including the identification, testing, and isolation of suspected cases with no or mild disease (e.g., influenza-like illness). In the fight against COVID-19, early control measures such as isolation and contact tracing could gain more power, thanks to modern technology. The authors believe that detection combined with contact tracing should continue to be an important measure to control the outbreak.
     </p>
     <p id="p0150">
      <italic>
       Hygiene Measures.
      </italic>
      Wild animals were slaughtered in the Wuhan market, increasing the risk of human exposure to blood and to other animal fluids with high risk of being exposed to wild animal viruses. ’Wet’ markets such as these are poorly viewed by many countries in the world who are now combatting the consequences of the outbreak. However, it should be borne in mind that similar ‘wet’ markets exist in several other places around the world such as in Africa, Asia and South America, with cultural habits and behaviour being hard to change. The authors believe the solution lies with the avoidance of mixing wild and domestic animals in indoor and outdoor spaces, and prohibition of on-the-spot slaughtering of animals in markets due to very weak hygienic measures. For many years already, Western countries have enforced the systematic use of slaughterhouses with very strict hygienic measures and authority control. In a recent announcement, Chinese authorities (temporarily) prohibited these wild life markets as of March 2020
      <xref ref-type="fn" rid="fn20">
       20
      </xref>
      adding to the long list of risk mitigation measures currently being taken.
     </p>
     <p id="p0155">
      WHO, CDC, ECDC and other international/European organisations have been drawing attention to the importance of hand hygiene for many years. The WHO began drawing up guidelines in 2004 and have produced specific guidelines for ‘Hand Hygiene in Health Care’ in 2009
      <xref ref-type="fn" rid="fn21">
       21
      </xref>
      and in general
      <xref ref-type="fn" rid="fn22">
       22
      </xref>
      . Apart from the six languages on the WHO site, most countries have this information available in their official language(s).
     </p>
     <p id="p0160">
      The message regarding use, or not, of face masks has been very unclear, also internationally. This lack of clarity has been compounded by the lack of suitable masks, such as those meeting the technical specifications of FFP2 and FFP3, covered by Regulation (EU) 2016/425 on Personal Protective Equipment. Moreover, surgical masks, which seem effective in clinical settings at reducing the risk of infection for professionals, do not provide adequate protection during Aerosol Generating Procedures (AGPs). Therefore, masks need to be used in combination with other PPE measures
      <xref ref-type="fn" rid="fn23">
       23
      </xref>
      (
      <xref ref-type="bibr" rid="b0210">
       Smith et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="b0145">
       Long et al., 2020
      </xref>
      ). For the ECDC the use of face masks is of highest priority in healthcare workers but also in symptomatic confirmed/suspected cases of COVID-19 and those caring for them. Instead, WHO and others health authorities do not recommend the use of face mask for the general public
      <xref ref-type="fn" rid="fn24">
       24
      </xref>
      . Whether the recommendation by Western countries (US, UK, and the majority of EU) that the public should not wear face masks, is or not motivated by the need to preserve limited supplies for professional use in health-care settings is unclear. In parts of Asia (China, Japan, South Korea, Singapore) and recently in some EU countries (Czech Republic and Austria), all citizens have been encouraged to wear face masks in public, regardless of whether they have symptoms. Austria and Italy have joined a small but growing number of European countries making the wearing of face masks outside the home compulsory amid shifting debate over the medical gear’s protective utility
      <xref ref-type="fn" rid="fn25">
       25
      </xref>
      . Authorities started distributing millions of free face masks at the entrances to all supermarkets from April 01 2020 in Austria. Shoppers will only be permitted inside supermarkets and other open stores, such as pharmacies, if they are wearing masks. Italy made the outdoor wearing of masks or scarfs obligatory as of April 04 2020 (Ordinanza N.521
      <xref ref-type="fn" rid="fn26">
       26
      </xref>
      ). According to research on the SARS epidemic, face masks (surgical and FFP2/N95) were an effective intervention for reducing the contraction and spread of the virus (Jefferson et al., 2011). As evidence suggests that nearly half of SARS-CoV-2 transmissions occur before the infected person becomes symptomatic, a consistent and proper use of face masks by the general population could offer a partial additional benefit to the other essential mitigation measures such as hand hygiene and isolation of infected people. Moreover, universal use of face masks could prevent discrimination of individuals who wear masks when unwell because everybody is wearing a mask (
      <xref ref-type="bibr" rid="b0055">
       Feng et al., 2020
      </xref>
      ; Leung et al., 2020). Hence, there is some rationale for mask-wearing in the general population, even if there is evidence disputing this. However, during a pandemic from a new respiratory virus such as SARS-CoV-2, in the absence of specific and well-tested pharmaceutical interventions, masks might well play a role in reducing transmission, in particular when physical distancing is not possible. This is probably why in the U.S., the CDC is reportedly contemplating a change in guidance.
     </p>
     <p id="p0165">
      A recent EC communication (Commission Recommendation EU 2020 403 13 March 2020
      <xref ref-type="fn" rid="fn27">
       27
      </xref>
      ) clarifies many questions including for e.g. those of critical service providers (who will not be able to avail of government supplies destined for health workers), under what conditions they may provide their employees with non-CE labelled masks, assuming they can import their own supply. Also at European level, one of the risk mitigation measures taken was the creation of a strategic rescEU stockpile of medical equipment such as ventilators and protective masks to help EU countries in the context of the COVID-19 pandemic
      <xref ref-type="fn" rid="fn28">
       28
      </xref>
      . Part of the stockpile will include items such as: i) intensive care medical equipment such as ventilators, ii) personal protective equipment such as reusable masks, iii) vaccines and therapeutics and iv) laboratory supplies. It remains to be seen how quickly the European Member States will be able to avail of this stockpile.
     </p>
     <p id="p0170">
      <italic>
       Communication
      </italic>
      ; During the outbreak crisis it is key to have trustworthy and well-coordinated communication channels to create community trust and compliance. Hong Kong, Singapore, Japan and South Korea are among those that stabilised the cumulative number of cases within two to three weeks after the 100
      <sup>
       th
      </sup>
      case (FT Analysis of John Hopkins University, CSSE, March 14 2020). These countries quickly applied a combination of risk mitigation measures such as school closures, strict quarantine and isolation measures and contact tracing. Moreover, data studied at the time of March 16, 2020 suggests that a strong community response to the risk mitigation measures communicated by the authorities is key to stabilising the cumulative increase of the spread of COVID-19. This demonstrates the importance of citizen awareness, social trust in authorities and well-coordinated risk mitigation communication.
     </p>
     <p id="p0175">
      <italic>
       International support mechanism;
      </italic>
      Avoiding an uncontrollable world pandemic requires the implementation of a global mechanism, built and empowered to act at an unprecedented speed (Niud, Y. and Xu, F., 2020). As
      <xref ref-type="bibr" rid="b0085">
       Hellewell et al. (2020)
      </xref>
      described, the time window of early response is potentially extremely short, signifying that, once the number of initial cases increases to a few tenths (40 cases seems to be a critical number), the probability of failure to control is high, i.e. at 80% even if 80% of contacts are traced and isolated. In this context, global coordination is mandatory and help should be quickly directed to the focal points of viral spread. Some effective measures include the pharmaceutical industry, factories, retailers (of medicines, PPE, etc.) are collaborating better and re-directing their production lines to COVID-19 related products. For example, high-level fashion brands such as Armani, Gucci, and others are producing masks and protective garments for healthcare workers, and alcoholic beverage brands are directing their production to disinfectant gel. In addition, solidarity is removing some commercial confidentiality barriers, forming novel supply chains, or easing trade restrictions under certain circumstances, while increasing them on others. For example, the EU introduced a temporary (6 weeks) export ban on certain medical/protective equipment to destinations outside the EU (Commission Implementing Regulation 2020/402, 14 March 2020
      <xref ref-type="fn" rid="fn29">
       29
      </xref>
      ).
     </p>
    </sec>
    <sec id="s0025">
     <label>
      5
     </label>
     <title>
      Conclusions and recommendations
     </title>
     <p id="p0180">
      The general lack of understanding of this new virus led to confusion and mixed advice from professionals and authorities. The global community (political, medical and international organisations) were taken by complete surprise in its rapid spread from China and establishment of community spread in Italy, Iran, Spain and at present in the US. At the time of writing the world is overwhelmed with COVID-19 patients and countries are applying risk mitigation measures at an unprecedented level with almost daily updates. In Europe, in the current major hotspots in Italy and Spain, and recently in the US, in New York, hospitals are being overwhelmed and responders are combatting the pandemic by all possible means. Since the rules and policies adopted by many countries differ as well as societal and population structure, and healthcare systems, the mitigation measures will likely lead to various results. It will be interesting to see the exact impact of the different strategies but unfortunately it is still too early, and it is not yet possible to give quantitative advice. The intention of this paper is to highlight the importance of building trust, improving effective communication processes with cross-country and cross-sectoral information sharing, enhancing the learning process, and in turn enhancing risk governance mechanisms. The conceptual analysis in this paper aimed to provide a structure in the countless risk mitigation measures taken around the world knowing it is a snapshot in time and lots of effort is currently being undertaken. The authors collated and clustered risk mitigation measures, using a harmonisation of the taxonomical approach, available for countries combatting the COVID-19 pandemic and investing in the limitation of the spread of the virus. Our work mainly focusses on the limitation of the spread of the SARS-CoV-2 virus causing COVID-19. Current knowledge reveals that:
      <list id="l0015" list-type="simple">
       <list-item id="o0050">
        <label>
         •
        </label>
        <p id="p0185">
         The information published on risk mitigation measures and their effectiveness is difficult to find and more and more papers are being published every day;
        </p>
       </list-item>
       <list-item id="o0055">
        <label>
         •
        </label>
        <p id="p0190">
         COVID-19 demonstrates the weaknesses of the current systems; the world was insufficiently prepared, scientific warnings were not picked up quickly enough, there were confusing messages and trust building took too much time. Specifically, many countries started with processes such as understanding the problem from the beginning and not building upon existing knowledge and best practices of other countries. This lead to similar outcomes such as disbelief, underestimation of the scale and potential danger and losing valuable time in jointly implementing the best risk mitigation practices. Besides the differences between countries in terms of cultures or economic prosperity, this pandemic demonstrates the unpreparedness of many health systems lacking mechanisms and materials to adequately respond to a quickly spreading infection, relying on societal and economic improvisation;
        </p>
       </list-item>
       <list-item id="o0060">
        <label>
         •
        </label>
        <p id="p0195">
         It is suggested that countries where the elderly live among the general population, impose more strict restrictive mitigation measures than countries where the elderly are separated from the general population;
        </p>
       </list-item>
       <list-item id="o0065">
        <label>
         •
        </label>
        <p id="p0200">
         Several restrictions have proven effective in slowing down the spread of COVID-19, but the highest effect is obtained by applying a combination of measures representing different aims. In this regard:
         <list id="l0020" list-type="simple">
          <list-item id="o0070">
           <label>
            o
           </label>
           <p id="p0205">
            It is recommended for all countries to invest in preventive risk mitigation resources limiting the spread of SARS-CoV-2 comprising physical distancing measures and hygienic measures; this is particularly important for countries with fewer resources.
           </p>
          </list-item>
          <list-item id="o0075">
           <label>
            o
           </label>
           <p id="p0210">
            It is recommended to impose a combination of mitigation measures limiting the spread by individuals who become ill after being missed by a screening programme. To this end screening programmes need to be improved and applied on a large(r) scale, along with registering the number of hospitalisations and deaths. Contact tracing is important even if many countries are now believed to have passed this phase due to too high number of infections. New technologies could be applied in this respect.
           </p>
          </list-item>
          <list-item id="o0080">
           <label>
            o
           </label>
           <p id="p0215">
            It is believed that correctly wearing appropriate face masks is beneficial when physical distancing is not possible to ensure all the time. The spread of small drops containing SARS-CoV-2 is difficult to predict (think of air currents, convections and air humidity), and it is more likely that individuals will touch their face (mouth/nose) less frequently than without a mask. It seems that countries who have more effectively curtailed an expanding propagation are countries whose population used masks extensively;
           </p>
          </list-item>
         </list>
        </p>
       </list-item>
       <list-item id="o0085">
        <label>
         •
        </label>
        <p id="p0220">
         A clear and coordinated communication strategy on effective risk mitigation is crucial in building trust with the citizens in a quickly evolving situation, using all possible channels and combatting fake news.
        </p>
       </list-item>
       <list-item id="o0090">
        <label>
         •
        </label>
        <p id="p0225">
         Existing global mechanisms need strengthened benefiting from interlinked national health mechanisms. Being part of a network of first responders, practitioners or risk mitigation stakeholders is an added value in this scenario; for example, several partner countries of the EU CBRN CoE are reporting to have greatly benefited from the structures that were put in place thanks to the Initiative and, at least in some countries, this mechanism has been found very useful to mobilise a coordinated response;
        </p>
       </list-item>
       <list-item id="o0095">
        <label>
         •
        </label>
        <p id="p0230">
         Citizens’ trust related to the degree of risk mitigation measures in place and parties involved in the communication is highly variable across countries. This is expected to influence citizens’ behaviour and respective implementation and obedience of the imposed risk mitigation measures. Some countries are also creating child-friendly Covid 19 communication material such as comics
         <xref ref-type="fn" rid="fn30">
          30
         </xref>
         , TV and online broadcasted news
         <xref ref-type="fn" rid="fn31">
          31
         </xref>
         . In countries and cultures with a higher degree of trust in science, authorities, and with adequate science based communication, faster changes are expected;
        </p>
       </list-item>
       <list-item id="o0100">
        <label>
         •
        </label>
        <p id="p0235">
         The delay in imposing risk mitigation measures is crucial and can make the difference between a local outbreak with few cases to a pandemic with countless sick and deceased citizens. The window of opportunity for full containment is believed to be limited to a situation with a very low number of infected people (maximum 40 cases);
        </p>
       </list-item>
       <list-item id="o0105">
        <label>
         •
        </label>
        <p id="p0240">
         Proper early detection based on early warnings would lower the intervention time. Such a mechanism should be based on a response time of hours, rather than days.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="s0030">
     <title>
      Uncited references
     </title>
     <p id="p0245">
      <xref ref-type="bibr" rid="b0015">
       Bruinen de Bruin et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="b0030">
       Daszak et al., 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0035">
       Drake et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="b0040">
       Davies, 2019
      </xref>
      ,
      <xref ref-type="bibr" rid="b0050">
       Di Nucci et al., 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="b0060">
       Financial Times, 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0065">
       Fox-Skelly, 2017
      </xref>
      ,
      <xref ref-type="bibr" rid="b0075">
       Gostic et al., 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0080">
       Jefferson et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="b0095">
       Kevorkian et al., 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0100">
       Keping, 2018
      </xref>
      ,
      <xref ref-type="bibr" rid="b0110">
       Koonin, 2020 Jan 1
      </xref>
      ,
      <xref ref-type="bibr" rid="b0125">
       Lee and Hsueh, 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0130">
       Leung et al., 2020 Mar 21
      </xref>
      ,
      <xref ref-type="bibr" rid="b0135">
       Li et al., 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0150">
       McCloskey et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="b0160">
       Nicholson et al., 2019
      </xref>
      ,
      <xref ref-type="bibr" rid="b0165">
       Niud and Xu, 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0170">
       Okumura et al., 1998a
      </xref>
      ,
      <xref ref-type="bibr" rid="b0175">
       Okumura et al., 1998b
      </xref>
      ,
      <xref ref-type="bibr" rid="b0180">
       Papp et al., 2020 Feb 1
      </xref>
      ,
      <xref ref-type="bibr" rid="b0195">
       Seale et al., 2011 Feb 11
      </xref>
      ,
      <xref ref-type="bibr" rid="b0200">
       Semple and Cherrie, 2020
      </xref>
      ,
      <xref ref-type="bibr" rid="b0205">
       Smith et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="b0215">
       Sutherst, 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="b0225">
       World Health Organization, 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="b0230">
       World Health Organization
      </xref>
      ,
      <xref ref-type="bibr" rid="b0245">
       Zhu et al., 2020
      </xref>
      .
     </p>
    </sec>
    <back>
     <ref-list id="bi005">
      <title>
       References
      </title>
      <ref id="b0005">
       <element-citation id="h0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Heesterbeek
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Klinkenberg
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hollingsworth
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         How will country-based mitigation measures influence the course of the COVID-19 epidemic?
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10228
        </issue>
        <year>
         2020
        </year>
        <fpage>
         931
        </fpage>
        <lpage>
         934
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0010">
       <element-citation id="h0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Broughton
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Bhopal disaster and its aftermath: a review
        </article-title>
        <source>
         Environ. Health
        </source>
        <volume>
         4
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         6
        </fpage>
        <pub-id pub-id-type="pmid">
         15882472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0015">
       <element-citation id="h0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bruinen de Bruin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lahaniatis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Papameletiou
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Del Pozo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Reina
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Van Engelen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Heinemeyer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Viso
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jantunen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk management measures for chemicals in consumer products: documentation, assessment, and communication across the supply chain
        </article-title>
        <source>
         J. Eposure Sci. Environ. Epidemiol.
        </source>
        <volume>
         17
        </volume>
        <issue>
         1
        </issue>
        <year>
         2007
        </year>
        <fpage>
         S55
        </fpage>
        <lpage>
         S66
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0020">
       <mixed-citation id="h0020" publication-type="other">
        Chinazzi, M., Davis, J.T., Ajelli, M., Gioannini, C., Litvinova, M., Merler, S., y Piontti, A.P., Rossi, L., Sun, K., Viboud, C., Xiong, X., 2020. The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak. medRxiv.
       </mixed-citation>
      </ref>
      <ref id="b0025">
       <element-citation id="h0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Enserink
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         As swine flu circles globe, scientists grapple with basic questions
        </article-title>
        <source>
         Science
        </source>
        <volume>
         324
        </volume>
        <issue>
         5927
        </issue>
        <year>
         2009
        </year>
        <fpage>
         572
        </fpage>
        <lpage>
         573
        </lpage>
        <pub-id pub-id-type="pmid">
         19407164
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0030">
       <mixed-citation id="h0030" publication-type="other">
        Daszak, Peter, Olival, Kevin J., Li, Hongying, 2020. A strategy to prevent future pandemics similar to the 2019-nCoV outbreak.
       </mixed-citation>
      </ref>
      <ref id="b0035">
       <element-citation id="h0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drake
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chew
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Societal learning in epidemics: intervention effectiveness during the 2003 SARS outbreak in Singapore
        </article-title>
        <source>
         PLoS ONE
        </source>
        <volume>
         1
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <object-id pub-id-type="publisher-id">
         e20
        </object-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0000020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0040">
       <mixed-citation id="h0040" publication-type="other">
        Davies, 2019. Green Populism?—Action and mortality in the Anthropocene, Centre for the Understanding of Sustainable Prosperity (CUSP), July 2019. https://www.cusp.ac.uk/wp-content/uploads/12-Will-Davies-online.pdf.
       </mixed-citation>
      </ref>
      <ref id="b0045">
       <element-citation id="h0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Global warming, the politicization of science, and Michael Crichton's state of fear
        </article-title>
        <source>
         J. Sci. Exploration
        </source>
        <volume>
         19
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         247
        </fpage>
        <lpage>
         256
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0050">
       <element-citation id="h0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Di Nucci
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Brunnengräber
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Isodoro Losada
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         From the “right to know” to the “right to object” and “decide”. A comparative perspective on participation in siting procedures for high level radioactive waste repositories
        </article-title>
        <source>
         Prog. Nucl. Energy
        </source>
        <volume>
         100
        </volume>
        <issue>
         2017
        </issue>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="b0055">
       <element-citation id="h0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Shuo
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Chen
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Nan
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Wei
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           Mengzhen
          </given-names>
         </name>
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           Benjamin J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rational use of face masks in the COVID-19 pandemic
        </article-title>
        <source>
         The Lancet Respiratory Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30134-X
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0060">
       <mixed-citation id="h0060" publication-type="other">
        Financial Times (April 4 2020). Coronavirus tracked: the latest figures as the pandemic spreads, https://www.ft.com/coronavirus-latest.
       </mixed-citation>
      </ref>
      <ref id="b0065">
       <mixed-citation id="h0065" publication-type="other">
        Fox-Skelly, J., 2017. There are diseases hidden in ice, and they are waking up. BBC News. Available at: http://www. bbc. com/earth/story/20170504-there-are-diseases-hidden-in-ice-and-they-are-waking-up (accessed 14 October 2019).
       </mixed-citation>
      </ref>
      <ref id="b0070">
       <element-citation id="h0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frickel
          </surname>
          <given-names>
           Scott
          </given-names>
         </name>
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M. Bess
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hurricane Katrina, contamination, and the unintended organization of ignorance
        </article-title>
        <source>
         Technol. Soc.
        </source>
        <volume>
         29
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         181
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.techsoc.2007.01.007
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0075">
       <element-citation id="h0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gostic
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gomez
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mummah
          </surname>
          <given-names>
           R.O.
          </given-names>
         </name>
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lloyd-Smith
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19
        </article-title>
        <source>
         Elife
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="b0080">
       <element-citation id="h0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jefferson
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Del Mar
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Dooley
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ferroni
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ansary
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bawazeer
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Driel
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nair
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Thorning
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Conly
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses
        </article-title>
        <source>
         Cochrane Database Syst. Rev.
        </source>
        <volume>
         2011
        </volume>
        <year>
         2011
        </year>
        <fpage>
         7
        </fpage>
        <comment>
         Art. No.: CD006207. DOI: 10.1002/14651858.CD006207.pub4
        </comment>
       </element-citation>
      </ref>
      <ref id="b0085">
       <element-citation id="h0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hellewell
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Abbott
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gimma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosse
          </surname>
          <given-names>
           N.I.
          </given-names>
         </name>
         <name>
          <surname>
           Jarvis
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
         <name>
          <surname>
           Munday
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Edmunds
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Flasche
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts
        </article-title>
        <source>
         The Lancet Global Health
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="b0090">
       <element-citation id="h0090" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jasanoff
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Judgment under siege: The three-body problem of expert legitimacy
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Weingart
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Maasen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <source>
         Democratization of Expertise? Exploring Novel Forms of Scientific Advice in Political Decision-Making
        </source>
        <year>
         2005
        </year>
        <publisher-name>
         Kluwer
        </publisher-name>
        <publisher-loc>
         Dordrecht
        </publisher-loc>
        <fpage>
         209
        </fpage>
        <lpage>
         224
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0095">
       <mixed-citation id="h0095" publication-type="other">
        Kevorkian, A., Grenet, T., Gallee, H., 2020. Tracking the Covid-19 pandemic: Simple visualization of the epidemic states and trajectories of select European countries &amp; assessing the effects of delays in official response. medRxiv.
       </mixed-citation>
      </ref>
      <ref id="b0100">
       <element-citation id="h0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keping
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Governance and good governance: a new framework for political analysis
        </article-title>
        <source>
         Fudan J. Humanities Social Sci.
        </source>
        <volume>
         11
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
        <ext-link ext-link-type="uri" id="ir005" xlink:href="https://link.springer.com/content/pdf/10.1007/s40647-017-0197-4.pdf">
         https://link.springer.com/content/pdf/10.1007/s40647-017-0197-4.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="b0105">
       <element-citation id="h0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knowles
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engineering risk and disaster: disaster-STS and the American history of technology
        </article-title>
        <source>
         J. Eng. Stud.
        </source>
        <volume>
         6
        </volume>
        <issue>
         3
        </issue>
        <year>
         2014
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         248
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0110">
       <element-citation id="h0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koonin
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus disease (COVID-19) outbreak: Now is the time to refresh pandemic plans
        </article-title>
        <source>
         J. Business Continuity Emergency Planning
        </source>
        <volume>
         13
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Jan 1
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         5
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0115">
       <element-citation id="h0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwok
          </surname>
          <given-names>
           K.O.
          </given-names>
         </name>
         <name>
          <surname>
           Florence
          </surname>
          <given-names>
           L.A.I.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Julian
          </surname>
          <given-names>
           T.A.N.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Herd immunity–estimating the level required to halt the COVID-19 epidemics in affected countries
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="b0120">
       <element-citation id="h0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Shih
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID- 19): the epidemic and the challenges
        </article-title>
        <source>
         Int. J. Antimicrobial Agents
        </source>
        <year>
         2020
        </year>
        <comment>
         105924
        </comment>
       </element-citation>
      </ref>
      <ref id="b0125">
       <element-citation id="h0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           P.I.
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV
        </article-title>
        <source>
         J. Microbiol. Immunol. Infect.
        </source>
        <volume>
         Feb
        </volume>
        <year>
         2020
        </year>
        <fpage>
         4
        </fpage>
       </element-citation>
      </ref>
      <ref id="b0130">
       <element-citation id="h0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mass masking in the COVID-19 epidemic: people need guidance
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10228
        </issue>
        <year>
         2020 Mar 21
        </year>
        <fpage>
         945
        </fpage>
       </element-citation>
      </ref>
      <ref id="b0135">
       <element-citation id="h0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="b0140">
       <element-citation id="h0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Musa
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A conceptual model for the outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan, China with individual reaction and governmental action
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="b0145">
       <element-citation id="h0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta-analysis
        </article-title>
        <source>
         J. Evidence-Based Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="b0150">
       <element-citation id="h0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCloskey
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Dar
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Heymann
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread
        </article-title>
        <source>
         Lancet. Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <issue>
         10
        </issue>
        <year>
         2014 Oct 1
        </year>
        <fpage>
         1001
        </fpage>
        <lpage>
         1010
        </lpage>
        <pub-id pub-id-type="pmid">
         25189351
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0155">
       <element-citation id="h0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mills
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Gage
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential influence of climate change on vector-borne and zoonotic diseases: a review and proposed research plan
        </article-title>
        <source>
         Environ. Health Perspect.
        </source>
        <volume>
         118
        </volume>
        <issue>
         11
        </issue>
        <year>
         2010
        </year>
        <fpage>
         1507
        </fpage>
        <lpage>
         1514
        </lpage>
        <pub-id pub-id-type="pmid">
         20576580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0160">
       <element-citation id="h0160" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nicholson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ogawa
          </surname>
          <given-names>
           V.A.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         National Academies of Sciences, Engineering, and Medicine. Reflections on a Century of Infectious Disease Outbreaks and Pandemics
        </chapter-title>
        <source>
         Exploring Lessons Learned from a Century of Outbreaks: Readiness for 2030: Proceedings of a Workshop 2019 May 8
        </source>
        <year>
         2019
        </year>
        <publisher-name>
         National Academies Press
        </publisher-name>
        <publisher-loc>
         US
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="b0165">
       <element-citation id="h0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niud
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deciphering the power of isolation in controlling COVID-19 outbreaks
        </article-title>
        <source>
         The Lancet Global Health
        </source>
        <volume>
         8
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020
        </year>
        <fpage>
         e452
        </fpage>
        <lpage>
         e453
        </lpage>
        <pub-id pub-id-type="pmid">
         32199105
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0170">
       <element-citation id="h0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Fukuda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kohama
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Takasu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ishimatsu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hinohara
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Tokyo subway sarin attack: disaster management, Part 1: Community emergency response
        </article-title>
        <source>
         Acad. Emerg. Med.
        </source>
        <volume>
         5
        </volume>
        <issue>
         6
        </issue>
        <year>
         1998
        </year>
        <fpage>
         613
        </fpage>
        <lpage>
         617
        </lpage>
        <pub-id pub-id-type="pmid">
         9660289
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0175">
       <element-citation id="h0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Fukuda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kohama
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Takasu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ishimatsu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hinohara
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Tokyo subway sarin attack: disaster management, part 2: hospital response
        </article-title>
        <source>
         Acad. Emerg. Med.
        </source>
        <volume>
         5
        </volume>
        <issue>
         6
        </issue>
        <year>
         1998
        </year>
        <fpage>
         618
        </fpage>
        <lpage>
         624
        </lpage>
        <pub-id pub-id-type="pmid">
         9660290
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0180">
       <element-citation id="h0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Papp
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kimmerl
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gatz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Laue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Grunow
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kaspari
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of sporicidal disinfectants for the disinfection of personal protective equipment during biological hazards
        </article-title>
        <source>
         Health Security
        </source>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020 Feb 1
        </year>
        <fpage>
         36
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="pmid">
         32078425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0185">
       <mixed-citation id="h0185" publication-type="other">
        Perlman, Stanley, 2020. Another decade, another coronavirus, pp. 760–762.
       </mixed-citation>
      </ref>
      <ref id="b0190">
       <element-citation id="h0190" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Renn
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Risk Governance: Coping with Uncertainty in a Complex World
        </chapter-title>
        <year>
         2008
        </year>
        <publisher-name>
         Earthscan
        </publisher-name>
        <publisher-loc>
         Oxon, UK/New York
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="b0195">
       <element-citation id="h0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kaur
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           MacIntyre
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         29
        </volume>
        <issue>
         8
        </issue>
        <year>
         2011 Feb 11
        </year>
        <fpage>
         1605
        </fpage>
        <lpage>
         1610
        </lpage>
        <pub-id pub-id-type="pmid">
         21211593
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0200">
       <mixed-citation id="h0200" publication-type="other">
        Semple, Sean, Cherrie, John W., 2020. Covid-19: Protecting Worker Health, Annals of Work Exposures and Health, wxaa033, https://doi.org/10.1093/annweh/wxaa033.
       </mixed-citation>
      </ref>
      <ref id="b0205">
       <element-citation id="h0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           A.W.
          </given-names>
         </name>
         <name>
          <surname>
           Skilling
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Castello
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           S.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ice as a reservoir for pathogenic human viruses: specifically, caliciviruses, influenza viruses, and enteroviruses
        </article-title>
        <source>
         Med. Hypotheses
        </source>
        <volume>
         63
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         560
        </fpage>
        <lpage>
         566
        </lpage>
        <pub-id pub-id-type="pmid">
         15324997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0210">
       <element-citation id="h0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           MacDougall
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Johnstone
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Copes
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Garber
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis
        </article-title>
        <source>
         CMAJ
        </source>
        <volume>
         188
        </volume>
        <issue>
         8
        </issue>
        <year>
         2016
        </year>
        <fpage>
         567
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         26952529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0215">
       <element-citation id="h0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sutherst
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Global change and human vulnerability to vector-borne diseases
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         17
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         136
        </fpage>
        <lpage>
         173
        </lpage>
        <pub-id pub-id-type="pmid">
         14726459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0220">
       <element-citation id="h0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wieland
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Responsibility for strategic ignorance
        </article-title>
        <source>
         Synthese
        </source>
        <volume>
         194
        </volume>
        <year>
         2017
        </year>
        <fpage>
         4477
        </fpage>
        <lpage>
         4497
        </lpage>
       </element-citation>
      </ref>
      <ref id="b0225">
       <mixed-citation id="h0225" publication-type="other">
        World Health Organization, 2008. International health regulations (2005). World Health Organization.
       </mixed-citation>
      </ref>
      <ref id="b0230">
       <mixed-citation id="h0230" publication-type="other">
        World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March. Available from URL: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed March 2020).
       </mixed-citation>
      </ref>
      <ref id="b0235">
       <mixed-citation id="h0235" publication-type="other">
        Wu, Z., McGoogan, J.M., 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama.
       </mixed-citation>
      </ref>
      <ref id="b0240">
       <element-citation id="h0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           Z.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zoonotic origins of human coronaviruses
        </article-title>
        <source>
         Int. J. Biol. Sci.
        </source>
        <volume>
         16
        </volume>
        <issue>
         10
        </issue>
        <year>
         2020
        </year>
        <fpage>
         1686
        </fpage>
        <lpage>
         1697
        </lpage>
        <pub-id pub-id-type="pmid">
         32226286
        </pub-id>
       </element-citation>
      </ref>
      <ref id="b0245">
       <element-citation id="h0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020 Jan 24
        </year>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ak005">
      <title>
       Acknowledgements
      </title>
      <p>
       The authors would like to thank Marian de Bruijn from the United Nations Interregional Crime and Justice Research Institute (UNICRI), in Turin, Italy, for the fruitful brainstorming discussions on the shaping of this paper’s structure and content.
      </p>
     </ack>
     <fn-group>
      <fn id="fn1">
       <label>
        1
       </label>
       <p id="np005">
        <underline>
         https://europa.eu/cbrn-risk-mitigation/
        </underline>
       </p>
      </fn>
      <fn id="fn2">
       <label>
        2
       </label>
       <p id="np010">
        <underline>
         https://www.who.int/vaccine_safety/committee/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/
        </underline>
       </p>
      </fn>
      <fn id="fn3">
       <label>
        3
       </label>
       <p id="np015">
        https://ec.europa.eu/fpi/sites/fpi/files/documents/icsp-strategy-paper-mip-20140812_en.pdf
       </p>
      </fn>
      <fn id="fn4">
       <label>
        4
       </label>
       <p id="np020">
        <underline>
         https://europa.eu/cbrn-risk-mitigation/projects_en
        </underline>
       </p>
      </fn>
      <fn id="fn5">
       <label>
        5
       </label>
       <p id="np025">
        <underline>
         https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
        </underline>
       </p>
      </fn>
      <fn id="fn6">
       <label>
        6
       </label>
       <p id="np030">
        <underline>
         https://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand-ex-china/en/
        </underline>
       </p>
      </fn>
      <fn id="fn7">
       <label>
        7
       </label>
       <p id="np035">
        <underline>
         https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
        </underline>
       </p>
      </fn>
      <fn id="fn8">
       <label>
        8
       </label>
       <p id="np040">
        <underline>
         https://www.independent.co.uk/news/world/europe/coronavirus-italy-doctor-death-toll-gp-a9438896.html
        </underline>
       </p>
      </fn>
      <fn id="fn9">
       <label>
        9
       </label>
       <p id="np045">
        <underline>
         https://www.theguardian.com/us-news/2020/apr/03/de-blasio-new-york-coronavirus
        </underline>
       </p>
      </fn>
      <fn id="fn10">
       <label>
        10
       </label>
       <p id="np050">
        <underline>
         https://www.theguardian.com/world/2020/mar/24/bergamo-mayor-says-football-match-escalated-coronavirus-infections-italian-provinceMany
        </underline>
       </p>
      </fn>
      <fn id="fn11">
       <label>
        11
       </label>
       <p id="np055">
        <underline>
         https://news.sky.com/story/coronavirus-european-ski-resorts-close-early-to-stop-covid-19-spread-11957732
        </underline>
       </p>
      </fn>
      <fn id="fn12">
       <label>
        12
       </label>
       <p id="np060">
        <underline>
         https://www.bbc.com/news/world-europe-52135814
        </underline>
       </p>
      </fn>
      <fn id="fn13">
       <label>
        13
       </label>
       <p id="np065">
        <underline>
         https://www.bbc.com/news/world-europe-52076293
        </underline>
       </p>
      </fn>
      <fn id="fn14">
       <label>
        14
       </label>
       <p id="np070">
        <underline>
         https://nos.nl/artikel/2329504-kerkdienst-in-verpleeghuis-lijkt-coronahaard-nooit-gedacht-aan-heftige-gevolgen.html
        </underline>
       </p>
      </fn>
      <fn id="fn16">
       <label>
        16
       </label>
       <p id="np080">
        https://www.sciencealert.com/the-new-coronavirus-isn-t-like-the-flu-but-they-have-one-big-thing-in-common
       </p>
      </fn>
      <fn id="fn17">
       <label>
        17
       </label>
       <p id="np085">
        <underline>
         https://www.reuters.com/article/us-health-coronavirus-google-europe/europes-north-south-lockdown-divide-revealed-by-google-data-idUSKBN21L1US; https://www.google.com/covid19/mobility/
        </underline>
       </p>
      </fn>
      <fn id="fn18">
       <label>
        18
       </label>
       <p id="np090">
        https://www.nu.nl/coronavirus/6039503/duitsland-verbiedt-samenscholing-van-meer-dan-twee-personen.htm
       </p>
      </fn>
      <fn id="fn19">
       <label>
        19
       </label>
       <p id="np095">
        <underline>
         https://www.at5.nl/artikelen/200958/man-hoest-agent-in-gezicht-na-arrestatie-ik-heb-corona
        </underline>
       </p>
      </fn>
      <fn id="fn20">
       <label>
        20
       </label>
       <p id="np100">
        <underline>
         https://edition.cnn.com/2020/03/05/asia/china-coronavirus-wildlife-consumption-ban-intl-hnk/index.html
        </underline>
       </p>
      </fn>
      <fn id="fn21">
       <label>
        21
       </label>
       <p id="np105">
        https://apps.who.int/iris/bitstream/handle/10665/44102/9789241597906_eng.pdf;jsessionid=41E5DD6BBC1CE944DDB5F1EEF9FF7C23?sequence=1
       </p>
      </fn>
      <fn id="fn22">
       <label>
        22
       </label>
       <p id="np110">
        <underline>
         https://www.who.int/gpsc/clean_hands_protection/en/
        </underline>
       </p>
      </fn>
      <fn id="fn23">
       <label>
        23
       </label>
       <p id="np115">
        https://www.cebm.net/wp-content/uploads/2020/03/COVID-CAT-PPE-MASKS-9-REVISED-002.pdf
       </p>
      </fn>
      <fn id="fn24">
       <label>
        24
       </label>
       <p id="np120">
        <underline>
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks
        </underline>
       </p>
      </fn>
      <fn id="fn25">
       <label>
        25
       </label>
       <p id="np125">
        <underline>
         https://www.ft.com/content/f68f3063-5024-4654-9389-bcc7ee1efd8e
        </underline>
       </p>
      </fn>
      <fn id="fn26">
       <label>
        26
       </label>
       <p id="np130">
        <underline>
         https://www.regione.lombardia.it/wps/portal/istituzionale/HP/DettaglioRedazionale/servizi-e-informazioni/cittadini/salute-e-prevenzione/Prevenzione-e-benessere/red-coronavirusnuoviaggiornamenti
        </underline>
       </p>
      </fn>
      <fn id="fn27">
       <label>
        27
       </label>
       <p id="np135">
        <underline>
         https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32020H0403
        </underline>
        )
       </p>
      </fn>
      <fn id="fn28">
       <label>
        28
       </label>
       <p id="np140">
        <underline>
         https://ec.europa.eu/commission/presscorner/detail/en/ip_20_476
        </underline>
       </p>
      </fn>
      <fn id="fn29">
       <label>
        29
       </label>
       <p id="np145">
        <underline>
         https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX:32020R0402
        </underline>
        )
       </p>
      </fn>
     </fn-group>
     <fn-group>
      <fn id="fn15">
       <label>
        15
       </label>
       <p id="np075">
        https://www.who.int/thailand/news/detail/20-03-2020-thailand-joins-the-who-solidarity-trial-global-testing-of-effective-treatments-of-covid-19-across-8-countries-an-aggressive-effort-to-save-lives-from-the-pandemic
        <underline>
         https://presse.inserm.fr/lancement-dun-essai-clinique-europeen-contre-le-covid-19/38737/https://www.elsevier.com/connect/coronavirus-information-center
        </underline>
       </p>
      </fn>
      <fn id="fn30">
       <label>
        30
       </label>
       <p id="np150">
        https://www.hse.ie/eng/services/news/newsfeatures/covid19-updates/partner-resources/
       </p>
      </fn>
      <fn id="fn31">
       <label>
        31
       </label>
       <p id="np155">
        https://jeugdjournaal.nl/
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>